0000318154-24-00004410-Q AMGEN INC 20241030202410301843201843201843200 0000318154-24-000044 10-Q 83 20240930 20241031 20241030 AMGEN INC 0000318154 2836 953540776 DE 1231 10-Q 34 001-37702 241411854 ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000 ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 AMGEN 19870305 10-Q 1 amgn-20240930.htm 10-Q amgn-20240930000031815 4false2024Q312/31http://fasb.org/srt/2024#PartnershipInterestMemberhttp://fasb.org/srt/2024#PartnershipInterestMemberxbrli:sharesiso4217:USDiso4217:USDxbrli:shares01-012024-09-300000318154us-gaap:CommonStockMember2024-01-012024-09-300000318154amgn:A2.00SeniorNotesDue2026Member2024-01-012024-09-3000003181542024-10-250000318154us-gaap:ProductMember2024-07-012024-09-300000318154us-gaap:ProductMember2023-07-012023-09-300000318154us-gaap:ProductMember2024-01-012024-09-300000318154us-gaap:ProductMember2023-01-012023-09-300000318154us-gaap:ProductAndServiceOtherMember2024-07-012024-09-300000318154us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300000318154us-gaap:ProductAndServiceOtherMember2024-01-012024-09-300000318154us-gaap:ProductAndServiceOtherMember2023-01-012023-09-3000003181542024-07-012024-09-3000003181542023-07-012023-09-3000003181542023-01-012023-09-3000003181542024-09-3000003181542023-12-310000318154us-gaap:CommonStockMember2023-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-12-310000318154us-gaap:RetainedEarningsMember2023-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000318154us-gaap:RetainedEarningsMember2024-01-012024-03-3100003181542024-01-012024-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000318154us-gaap:CommonStockMember2024-01-012024-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-01-012024-03-310000318154us-gaap:CommonStockMember2024-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-03-310000318154us-gaap:RetainedEarningsMember2024-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100003181542024-03-310000318154us-gaap:RetainedEarningsMember2024-04-012024-06-3000003181542024-04-012024-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000318154us-gaap:CommonStockMember2024-04-012024-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-04-012024-06-300000318154us-gaap:CommonStockMember2024-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-06-300000318154us-gaap:RetainedEarningsMember2024-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000318154us-gaap:RetainedEarningsMember2024-07-012024-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000318154us-gaap:CommonStockMember2024-07-012024-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-07-012024-09-300000318154us-gaap:CommonStockMember2024-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-09-300000318154us-gaap:RetainedEarningsMember2024-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000318154us-gaap:CommonStockMember2022-12-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2022-12-310000318154us-gaap:RetainedEarningsMember2022-12-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000318154us-gaap:RetainedEarningsMember2023-01-012023-03-3100003181542023-01-012023-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000318154us-gaap:CommonStockMember2023-01-012023-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-01-012023-03-310000318154us-gaap:CommonStockMember2023-03-310000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-03-310000318154us-gaap:RetainedEarningsMember2023-03-310000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-3100003181542023-03-310000318154us-gaap:RetainedEarningsMember2023-04-012023-06-3000003181542023-04-012023-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000318154us-gaap:CommonStockMember2023-04-012023-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-04-012023-06-300000318154us-gaap:CommonStockMember2023-06-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-06-300000318154us-gaap:RetainedEarningsMember2023-06-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000003181542023-06-300000318154us-gaap:RetainedEarningsMember2023-07-012023-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000318154us-gaap:CommonStockMember2023-07-012023-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-07-012023-09-300000318154us-gaap:CommonStockMember2023-09-300000318154us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-09-300000318154us-gaap:RetainedEarningsMember2023-09-300000318154us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000003181542023-09-300000318154amgn:HorizonTherapeuticsMember2023-10-060000318154amgn:HorizonTherapeuticsMember2023-10-062023-10-060000318154amgn:HorizonTherapeuticsMember2024-01-012024-09-300000318154amgn:HorizonTherapeuticsMemberus-gaap:DevelopedTechnologyRightsMember2023-10-060000318154amgn:HorizonTherapeuticsMemberus-gaap:DevelopedTechnologyRightsMember2023-10-062023-10-060000318154amgn:HorizonTherapeuticsMember2023-07-012023-09-300000318154amgn:HorizonTherapeuticsMember2023-01-012023-09-300000318154country:USamgn:ProliaMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:ProliaMember2024-07-012024-09-300000318154amgn:ProliaMember2024-07-012024-09-300000318154country:USamgn:ProliaMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:ProliaMember2023-07-012023-09-300000318154amgn:ProliaMember2023-07-012023-09-300000318154country:USamgn:EnbrelMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2024-07-012024-09-300000318154amgn:EnbrelMember2024-07-012024-09-300000318154country:USamgn:EnbrelMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2023-07-012023-09-300000318154amgn:EnbrelMember2023-07-012023-09-300000318154country:USamgn:XgevaMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2024-07-012024-09-300000318154amgn:XgevaMember2024-07-012024-09-300000318154country:USamgn:XgevaMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2023-07-012023-09-300000318154amgn:XgevaMember2023-07-012023-09-300000318154country:USamgn:RepathaevolocumabMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2024-07-012024-09-300000318154amgn:RepathaevolocumabMember2024-07-012024-09-300000318154country:USamgn:RepathaevolocumabMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2023-07-012023-09-300000318154amgn:RepathaevolocumabMember2023-07-012023-09-300000318154country:USamgn:OtezlaMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:OtezlaMember2024-07-012024-09-300000318154amgn:OtezlaMember2024-07-012024-09-300000318154country:USamgn:OtezlaMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:OtezlaMember2023-07-012023-09-300000318154amgn:OtezlaMember2023-07-012023-09-300000318154country:USamgn:TEPEZZAMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:TEPEZZAMember2024-07-012024-09-300000318154amgn:TEPEZZAMember2024-07-012024-09-300000318154country:USamgn:TEPEZZAMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:TEPEZZAMember2023-07-012023-09-300000318154amgn:TEPEZZAMember2023-07-012023-09-300000318154country:USamgn:EVENITYMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:EVENITYMember2024-07-012024-09-300000318154amgn:EVENITYMember2024-07-012024-09-300000318154country:USamgn:EVENITYMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:EVENITYMember2023-07-012023-09-300000318154amgn:EVENITYMember2023-07-012023-09-300000318154country:USamgn:KyprolisMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2024-07-012024-09-300000318154amgn:KyprolisMember2024-07-012024-09-300000318154country:USamgn:KyprolisMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2023-07-012023-09-300000318154amgn:KyprolisMember2023-07-012023-09-300000318154country:USamgn:NplateMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2024-07-012024-09-300000318154amgn:NplateMember2024-07-012024-09-300000318154country:USamgn:NplateMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2023-07-012023-09-300000318154amgn:NplateMember2023-07-012023-09-300000318154country:USamgn:AranespMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2024-07-012024-09-300000318154amgn:AranespMember2024-07-012024-09-300000318154country:USamgn:AranespMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2023-07-012023-09-300000318154amgn:AranespMember2023-07-012023-09-300000318154country:USamgn:KRYSTEXXAMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:KRYSTEXXAMember2024-07-012024-09-300000318154amgn:KRYSTEXXAMember2024-07-012024-09-300000318154country:USamgn:KRYSTEXXAMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:KRYSTEXXAMember2023-07-012023-09-300000318154amgn:KRYSTEXXAMember2023-07-012023-09-300000318154country:USamgn:BLINCYTOMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:BLINCYTOMember2024-07-012024-09-300000318154amgn:BLINCYTOMember2024-07-012024-09-300000318154country:USamgn:BLINCYTOMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:BLINCYTOMember2023-07-012023-09-300000318154amgn:BLINCYTOMember2023-07-012023-09-300000318154country:USamgn:VectibixMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:VectibixMember2024-07-012024-09-300000318154amgn:VectibixMember2024-07-012024-09-300000318154country:USamgn:VectibixMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:VectibixMember2023-07-012023-09-300000318154amgn:VectibixMember2023-07-012023-09-300000318154country:USamgn:TEZSPIREMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:TEZSPIREMember2024-07-012024-09-300000318154amgn:TEZSPIREMember2024-07-012024-09-300000318154country:USamgn:TEZSPIREMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:TEZSPIREMember2023-07-012023-09-300000318154amgn:TEZSPIREMember2023-07-012023-09-300000318154country:USamgn:OtherProductsMember2024-07-012024-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2024-07-012024-09-300000318154amgn:OtherProductsMember2024-07-012024-09-300000318154country:USamgn:OtherProductsMember2023-07-012023-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2023-07-012023-09-300000318154amgn:OtherProductsMember2023-07-012023-09-300000318154country:USus-gaap:ProductMember2024-07-012024-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2024-07-012024-09-300000318154country:USus-gaap:ProductMember2023-07-012023-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2023-07-012023-09-300000318154country:USamgn:ProliaMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:ProliaMember2024-01-012024-09-300000318154amgn:ProliaMember2024-01-012024-09-300000318154country:USamgn:ProliaMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:ProliaMember2023-01-012023-09-300000318154amgn:ProliaMember2023-01-012023-09-300000318154country:USamgn:EnbrelMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2024-01-012024-09-300000318154amgn:EnbrelMember2024-01-012024-09-300000318154country:USamgn:EnbrelMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:EnbrelMember2023-01-012023-09-300000318154amgn:EnbrelMember2023-01-012023-09-300000318154country:USamgn:XgevaMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2024-01-012024-09-300000318154amgn:XgevaMember2024-01-012024-09-300000318154country:USamgn:XgevaMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:XgevaMember2023-01-012023-09-300000318154amgn:XgevaMember2023-01-012023-09-300000318154country:USamgn:RepathaevolocumabMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2024-01-012024-09-300000318154amgn:RepathaevolocumabMember2024-01-012024-09-300000318154country:USamgn:RepathaevolocumabMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:RepathaevolocumabMember2023-01-012023-09-300000318154amgn:RepathaevolocumabMember2023-01-012023-09-300000318154country:USamgn:OtezlaMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:OtezlaMember2024-01-012024-09-300000318154amgn:OtezlaMember2024-01-012024-09-300000318154country:USamgn:OtezlaMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:OtezlaMember2023-01-012023-09-300000318154amgn:OtezlaMember2023-01-012023-09-300000318154country:USamgn:TEPEZZAMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:TEPEZZAMember2024-01-012024-09-300000318154amgn:TEPEZZAMember2024-01-012024-09-300000318154country:USamgn:TEPEZZAMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:TEPEZZAMember2023-01-012023-09-300000318154amgn:TEPEZZAMember2023-01-012023-09-300000318154country:USamgn:EVENITYMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:EVENITYMember2024-01-012024-09-300000318154amgn:EVENITYMember2024-01-012024-09-300000318154country:USamgn:EVENITYMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:EVENITYMember2023-01-012023-09-300000318154amgn:EVENITYMember2023-01-012023-09-300000318154country:USamgn:KyprolisMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2024-01-012024-09-300000318154amgn:KyprolisMember2024-01-012024-09-300000318154country:USamgn:KyprolisMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:KyprolisMember2023-01-012023-09-300000318154amgn:KyprolisMember2023-01-012023-09-300000318154country:USamgn:NplateMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2024-01-012024-09-300000318154amgn:NplateMember2024-01-012024-09-300000318154country:USamgn:NplateMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:NplateMember2023-01-012023-09-300000318154amgn:NplateMember2023-01-012023-09-300000318154country:USamgn:AranespMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2024-01-012024-09-300000318154amgn:AranespMember2024-01-012024-09-300000318154country:USamgn:AranespMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:AranespMember2023-01-012023-09-300000318154amgn:AranespMember2023-01-012023-09-300000318154country:USamgn:KRYSTEXXAMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:KRYSTEXXAMember2024-01-012024-09-300000318154amgn:KRYSTEXXAMember2024-01-012024-09-300000318154country:USamgn:KRYSTEXXAMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:KRYSTEXXAMember2023-01-012023-09-300000318154amgn:KRYSTEXXAMember2023-01-012023-09-300000318154country:USamgn:BLINCYTOMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:BLINCYTOMember2024-01-012024-09-300000318154amgn:BLINCYTOMember2024-01-012024-09-300000318154country:USamgn:BLINCYTOMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:BLINCYTOMember2023-01-012023-09-300000318154amgn:BLINCYTOMember2023-01-012023-09-300000318154country:USamgn:VectibixMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:VectibixMember2024-01-012024-09-300000318154amgn:VectibixMember2024-01-012024-09-300000318154country:USamgn:VectibixMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:VectibixMember2023-01-012023-09-300000318154amgn:VectibixMember2023-01-012023-09-300000318154country:USamgn:TEZSPIREMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:TEZSPIREMember2024-01-012024-09-300000318154amgn:TEZSPIREMember2024-01-012024-09-300000318154country:USamgn:TEZSPIREMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:TEZSPIREMember2023-01-012023-09-300000318154amgn:TEZSPIREMember2023-01-012023-09-300000318154country:USamgn:OtherProductsMember2024-01-012024-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2024-01-012024-09-300000318154amgn:OtherProductsMember2024-01-012024-09-300000318154country:USamgn:OtherProductsMember2023-01-012023-09-300000318154us-gaap:NonUsMemberamgn:OtherProductsMember2023-01-012023-09-

300000318154amgn:OtherProductsMember2023-01-012023-09-300000318154country:USus-gaap:ProductMember2024-01-012024-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2024-01-012024-09-300000318154country:USus-gaap:ProductMember2023-01-012023-09-300000318154us-gaap:NonUsMemberus-gaap:ProductMember2023-01-012023-09-300000318154us-gaap:DomesticCountryMember2021-05-310000318154amgn:TaxYears20102012Memberus-gap:DomesticCountryMember2021-05-310000318154amgn:TaxYears20132015Memberus-gaap:DomesticCountryMember2022-04-280000318154us-gaap:DomesticCountryMember2022-12-190000318154us-gaap:USTreasuryBillSecuritiesMember2024-09-300000318154us-gaap:MoneyMarketFundsMember2024-09-300000318154amgn:OtherShortTermInterestBearingSecuritiesMember2024-09-300000318154us-gaap:USTreasuryBillSecuritiesMember2023-12-310000318154us-gaap:MoneyMarketFundsMember2023-12-310000318154amgn:OtherShortTermInterestBearingSecuritiesMember2023-12-310000318154amgn:AvailableForSalesInvestmentsMember2024-09-300000318154amgn:AvailableForSalesInvestmentsMember2023-12-310000318154amgn:BeiGeneMember2024-09-300000318154amgn:BeiGeneMember2023-12-310000318154amgn:BeiGeneMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300000318154amgn:BeiGeneMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310000318154amgn:BeiGeneMember2024-07-012024-09-300000318154amgn:BeiGeneMember2023-07-012023-09-300000318154amgn:BeiGeneMember2024-01-012024-09-300000318154amgn:BeiGeneMember2023-01-012023-09-300000318154amgn:BeiGeneMembersrt:MaximumMember2023-09-300000318154amgn:BeiGeneMembersrt:MaximumMember2024-09-300000318154us-gaap:OtherNoncurrentAssetsMember2024-09-300000318154us-gaap:OtherNoncurrentAssetsMember2023-12-310000318154amgn:NeumoraTherapeuticsIncMember2024-09-300000318154amgn:NeumoraTherapeuticsIncMember2023-12-310000318154amgn:NeumoraTherapeuticsIncMember2024-07-012024-09-300000318154amgn:NeumoraTherapeuticsIncMember2023-07-012023-09-300000318154amgn:NeumoraTherapeuticsIncMember2024-01-012024-09-300000318154amgn:NeumoraTherapeuticsIncMember2023-01-012023-09-300000318154amgn:NeumoraTherapeuticsIncMembersrt:MaximumMember2023-09-300000318154amgn:NeumoraTherapeuticsIncMembersrt:MinimumMember2023-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-01-012024-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-01-012023-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-07-012023-09-300000318154us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-07-012024-09-300000318154us-gaap:DevelopedTechnologyRightsMember2024-09-300000318154us-gaap:DevelopedTechnologyRightsMember2023-12-310000318154us-gaap:LicensingAgreementsMember2024-09-300000318154us-gaap:LicensingAgreementsMember2023-12-310000318154us-gaap:MarketingRelatedIntangibleAssetsMember2024-09-300000318154us-gaap:MarketingRelatedIntangibleAssetsMember2023-12-310000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2024-09-300000318154amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember2023-12-310000318154us-gaap:InProcessResearchAndDevelopmentMember2024-09-300000318154us-gaap:InProcessResearchAndDevelopmentMember2023-12-310000318154amgn:A3.625NotesDueIn2024Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A3.625NotesDueIn2024Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A1.90NotesDue2025Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A1.90NotesDue2025Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A525NotesDue2025Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A525NotesDue2025Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TermLoanDueApril2025Memberus-gaap:SecuredDebtMember2024-09-300000318154amgn:TermLoanDueApril2025Memberus-gaap:SecuredDebtMember2023-12-310000318154amgn:A3.125NotesDue2025Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A3.125NotesDue2025Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A2.00NotesDue2026Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A2.00NotesDue2026Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A5507NotesDue2026Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A5507NotesDue2026Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TermLoanDueOctober2026Memberus-gaap:SecuredDebtMember2024-09-300000318154amgn:TermLoanDueOctober2026Memberus-gaap:SecuredDebtMember2023-12-310000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:ThreePointTwoZeroNotesDue2027Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:ThreePointTwoZeroNotesDue2027Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A515NotesDue2028Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A515NotesDue2028Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:OnePointSixFivePercent2028NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:OnePointSixFivePercent2028NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A3002029NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A3002029NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A525NotesDue2030Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A525NotesDue2030Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointZeroPercent2032NotesMemberMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointZeroPercent2032NotesMemberMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A3352032NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A3352032NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A525NotesDue2033Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A525NotesDue2033Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:ThreePointOneFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:ThreePointOneFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointEightZeroPercent2041NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointEightZeroPercent2041NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FivePointSixFivePercentNotesDue2042Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FivePointSixFivePercentNotesDue2042Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A560NotesDue2043Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A560NotesDue2043Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:ThreePointThreeSevenFivePercentNotesDue2050Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:ThreePointThreeSevenFivePercentNotesDue2050Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A300NotesDue20523002052NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A300NotesDue20523002052NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A48752053NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A48752053NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A565NotesDue2053Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A565NotesDue2053Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A4402062NotesMemberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A4402062NotesMemberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:A575NotesDue2063Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:A575NotesDue2063Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154amgn:OtherNotesDue2097Memberus-gaap:NotesPayableToBanksMember2024-09-300000318154amgn:OtherNotesDue2097Memberus-gaap:NotesPayableToBanksMember2023-12-310000318154us-gaap:NotesPayableToBanksMember2024-01-012024-09-300000318154amgn:TermLoanDueApril2025Memberus-gaap:NotesPayableToBanksMember2024-01-012024-09-300000318154amgn:TermLoanDueOctober2026Memberus-gaap:NotesPayableToBanksMember2024-01-012024-09-300000318154amgn:A3.625NotesDueIn2024Memberus-gaap:NotesPayableToBanksMember2024-01-012024-09-300000318154542023-10-012023-12-310000318154us-gaap:SubsequentEventMember2024-10-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2023-12-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2024-01-012024-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2024-03-310000318154us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2024-04-012024-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2024-06-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-07-012024-09-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2024-07-012024-09-300000318154us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000318154amgn:AccumulatedOtherAdjustmentAttributabletoParentMember2024-09-300000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000318154us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000318154us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-09-

300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2024-09-300000318154us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember2024-09-300000318154us-gaap:FairValueInputsLevel3Memberamgn:OtherShortTermInterestBearingSecuritiesMember2024-09-300000318154us-gaap:FairValueInputsLevel1Member2024-09-300000318154us-gaap:FairValueInputsLevel2Member2024-09-300000318154us-gaap:FairValueInputsLevel3Member2024-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2024-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2024-09-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2024-09-300000318154us-gaap:ForeignExchangeContractMember2024-09-300000318154us-gaap:FairValueInputsLevel1Memberamgn:CrossCurrencySwapContractsMember2024-09-300000318154us-gaap:FairValueInputsLevel2Memberamgn:CrossCurrencySwapContractsMember2024-09-300000318154us-gaap:FairValueInputsLevel3Memberamgn:CrossCurrencySwapContractsMember2024-09-300000318154amgn:CrossCurrencySwapContractsMember2024-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2024-09-300000318154us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2024-09-300000318154us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2024-09-300000318154us-gaap:InterestRateSwapMember2024-09-300000318154us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember2023-12-310000318154us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember2023-12-310000318154us-gaap:FairValueInputsLevel3Memberamgn:OtherShortTermInterestBearingSecuritiesMember2023-12-310000318154us-gaap:FairValueInputsLevel1Member2023-12-310000318154us-gaap:FairValueInputsLevel2Member2023-12-310000318154us-gaap:FairValueInputsLevel3Member2023-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2023-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2023-12-310000318154us-gaap:ForeignExchangeContractMember2023-12-310000318154us-gaap:FairValueInputsLevel1Memberamgn:CrossCurrencySwapContractsMember2023-12-310000318154us-gaap:FairValueInputsLevel2Memberamgn:CrossCurrencySwapContractsMember2023-12-310000318154us-gaap:FairValueInputsLevel3Memberamgn:CrossCurrencySwapContractsMember2023-12-310000318154amgn:CrossCurrencySwapContractsMember2023-12-310000318154us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2023-12-310000318154us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2023-12-310000318154us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMember2023-12-310000318154us-gaap:InterestRateSwapMember2023-12-310000318154us-gaap:NotesPayableToBanksMember2024-09-300000318154us-gaap:NotesPayableToBanksMember2023-12-310000318154us-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000318154us-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000318154amgn:A2.00NotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2024-09-300000318154amgn:A2.00NotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:EUR2024-09-300000318154amgn:A2.00NotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:USD2024-09-300000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2024-09-300000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:GBP2024-09-300000318154amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:USD2024-09-300000318154amgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2024-09-300000318154amgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:GBP2024-09-300000318154amgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMembercurrency:USD2024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember2023-01-012023-09-300000318154amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000318154amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember2023-07-012023-09-300000318154amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000318154us-gaap:CashFlowHedgingMember2024-07-012024-09-300000318154us-gaap:CashFlowHedgingMember2023-07-012023-09-300000318154us-gaap:CashFlowHedgingMember2024-01-012024-09-300000318154us-gaap:CashFlowHedgingMember2023-01-012023-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000318154amgn:A3.625NotesDueIn2024Memberus-gaap:InterestRateSwapMember2024-09-300000318154amgn:A525NotesDue2033Memberus-gaap:InterestRateSwapMember2024-09-300000318154amgn:LongTermDebtCurrentMaturitiesMember2024-09-300000318154amgn:LongTermDebtCurrentMaturitiesMember2023-12-310000318154us-gaap:LongTermDebtMember2024-09-300000318154us-gaap:LongTermDebtMember2023-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000318154us-gaap:InterestRateSwapMember2024-07-012024-09-300000318154us-gaap:InterestRateSwapMember2024-01-012024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000318154us-gaap:InterestRateSwapMember2023-07-012023-09-300000318154us-gaap:InterestRateSwapMember2023-01-012023-09-300000318154us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2024-09-300000318154us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember2023-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2024-09-300000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2024-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2024-09-300000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2024-09-300000318154us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000318154us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2023-12-310000318154us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2023-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2023-12-310000318154amgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2023-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:OtherCurrentNoncurrentAssetsMember2023-12-310000318154us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMemberamgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMember2023-12-310000318154us-gaap:DesignatedAsHedgingInstrumentMember2023-12-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORMÂ 10-Q(Mark One)â˜'QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024orâ˜TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter)DelawareÂ 95-3540776(State or other jurisdiction ofincorporation or organization)Â (I.R.S. EmployerIdentification No.)One Amgen Center DriveÂ 91320-1799Thousand OaksCalifornia(Address of principal executive offices)Â (Zip Code)(805) 447-1000 (Registrantâ€™s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon stock, $0.0001 par valueAMGNThe Nasdaq Stock Market LLC2.00% Senior Notes due 2026AMGN26The Nasdaq Stock Market LLCIndicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)Â has been subject to such filing requirements for the past 90 days.Â YesÂ â˜'Â NoÂ â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â YesÂ â˜'Â NoÂ â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.Large accelerated filerâ˜'Accelerated filerâ˜Non-accelerated filerâ˜SmallerÂ reportingÂ companyâ˜EmergingÂ growthÂ companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act).Yes â˜ NoÂ â˜'As of OctoberÂ 25, 2024, the registrant had 537,532,723 shares of common stock, $0.0001 par value, outstanding.AMGEN INC.INDEXÂ Â PageÂ No.DEFINED TERMS AND PRODUCTSiiPART Iâ€”FINANCIAL INFORMATION1ItemÂ 1.FINANCIAL STATEMENTS1CONDENSED CONSOLIDATED STATEMENTS OF INCOME1CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME2CONDENSED CONSOLIDATED BALANCE SHEETS3CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY4CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS6NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS7ItemÂ 2.MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS30ItemÂ 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK44ItemÂ 4.CONTROLS AND PROCEDURES45PART IIâ€”OTHER INFORMATION46ItemÂ 1.LEGAL PROCEEDINGS46ItemÂ 1A.RISK FACTORS46ItemÂ 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS53Item 5.OTHER INFORMATION53ItemÂ 6.EXHIBITS53INDEX TO EXHIBITS54SIGNATURES60iDefined Terms and Products Defined termsWe use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related as well as names of other companies, which are given below.TermDescriptionAOCIaccumulated other comprehensive income (loss)AstraZenecaAstraZeneca plcBeiGeneBeiGene, Ltd.CMSCenters for Medicare & Medicaid ServicesEMAEuropean Medicines AgencyEPSearnings per shareEUEuropean UnionFDAU.S. Food and Drug AdministrationFitchFitch Ratings, Inc.FTCFederal Trade CommissionGAAPU.S. generally accepted accounting principlesHHSU.S. Department of Health and Human ServicesHorizonHorizon Therapeutics plcIPR&Din-process research and developmentIRAInflation Reduction Act of 2022IRSInternal Revenue ServiceMD&Amanagementâ€™s discussion and analysisMoodyâ€™sMoodyâ€™s Investors Service, Inc.NeumoraNeumora Therapeutics, Inc.OECDOrganisation for Economic Co-operation and DevelopmentPBMpharmacy benefit managerPDABPrescription Drug Affordability BoardR&Dresearch and developmentRANKLreceptor activator of nuclear factor kappa-B ligandRARRevenue Agent ReportROWrest of worldS&PStandard & Poorâ€™s Financial Services LLCSECU.S. Securities and Exchange CommissionSG&Aselling, general and administrativeSOFRSecured Overnight Financing RateU.S. TreasuryU.S. Department of TreasuryUTBunrecognized tax benefitiiProductsThe brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.TermDescriptionACTIMMUNEACTIMMUNEÂ® (interferon gamma-1b)(1)AimovigAimovigÂ® (erenumab-aooe)AMJEVITA/AMGEVITAAMJEVITAÂ® (adalimumab-atto)/AMGEVITAâ„¢ (adalimumab)AranespAranespÂ® (darbepoetin alfa)AVSOLAAVSOLAÂ® (infliximab-axxq)BEKEMVBEKEMVâ„¢ (eculizumab)BLINCYTOBLINCYTOÂ® (blinatumomab)BUPHENYLBUPHENYLÂ® (sodium phenylbutyrate)(1)CorlanorCorlanorÂ® (ivabradine)DUEXISDUEXISÂ® (ibuprofen and famotidine)(1)ENBRELEnbrelÂ® (etanercept)EPOGENEPOGENÂ® (epoetin alfa)EVENITYEVENITYÂ® (romosozumab-aqqg)IMDELLTRAIMDELLTRAâ„¢ (tarlatamab-dlle)IMLYGICIMLYGICÂ® (talimogene laherparepvec)KANJINTIKANJINTIÂ® (trastuzumab-anns)KRYSTEXXAKRYSTEXXAÂ® (pegloticase)(1)KYPROLISKYPROLISÂ® (carfilzomib)LUMAKRAS/LUMYKRASLUMAKRASÂ®/LUMYKRASâ„¢ (sotorasib)MVASIMVASIÂ® (bevacizumab-awwb)NeulastaNeulastaÂ® (pegfilgrastim)NEUPOGENNEUPOGENÂ® (filgrastim)NplateNplateÂ® (romiplostim)OtezlaOtezlaÂ® (apremilast)ParsabivParsabivÂ® (etelcalcetide)PENNSAIDPENNSAIDÂ® (diclofenac sodium topical solution) 2% (1)PROCYSBIPROCYSBIÂ® (cysteamine bitartrate)(1)ProliaProliaÂ® (denosumab)QUINSAIRQUINSAIRÂ® (levofloxacin)(1)RAVICTIRAVICTIÂ® (glycerol phenylbutyrate)(1)RAYOSRAYOSÂ® (prednisone)(1)RepathaRepathaÂ® (evolocumab)RIABNIRIABNIÂ® (rituximab-arrx)Sensipar/MimparaSensiparÂ®/Mimparaâ„¢ (cinacalcet)TAVNEOSTAVNEOSÂ® (avacopan)TEPEZZATEPEZZAÂ® (teprotumumab-trbw)(1)TEZSPIRETEZSPIREÂ® (tezepelumab-ekko)UPLIZNAUPLIZNAÂ® (inebilizumab-cdon)(1)VectibixVectibixÂ® (panitumumab)WEZLANA/WEZENLAWEZLANAâ„¢ (ustekinumab-auub)/WEZENLAâ„¢ (ustekinumab)XGEVAXGEVAÂ® (denosumab)_____(1)Â Â Â Â Products were acquired from our Horizon acquisition on October 6, 2023.iiiPART Iâ€”FINANCIAL INFORMATIONÂ ItemÂ 1.FINANCIAL STATEMENTSAMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF

INCOME(In millions, except per-share data)(Unaudited)Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023202420232023Revenues:Product sales$8,151Â $6,548Â $23,310Â $19,077Â Other revenues352Â 355Â 1,028Â 917Â Total revenues8,503Â 6,903Â 24,338Â 19,994Â Operating expenses:Cost of sales3,310Â 1,806Â 9,746Â 5,339Â Research and development1,450Â 1,079Â 4,240Â 3,250Â Selling, general and administrative1,625Â 1,353Â 5,218Â 3,905Â Other71Â 644Â 187Â 874Â Total operating expenses6,456Â 4,882Â 19,391Â 13,368Â Operating income2,047Â 2,021Â 4,947Â 6,626Â Other income (expense):Interest expense, net(776)(759)(2,408)(2,054)Other income, net1,830Â 685Â 1,288Â 2,431Â Income before income taxes3,101Â 1,947Â 3,827Â 7,003Â Provision for income taxes271Â 217Â 364Â 1,053Â Net income$2,830Â $1,730Â $3,463Â $5,950Â Earnings per share:Basic$5.27Â $3.23Â $6.45Â $11.12Â Diluted$5.22Â $3.22Â $6.40Â $11.06Â Weighted-average shares used in calculation of earnings per share:Basic537Â 535Â 537Â 535Â Diluted542Â 538Â 541Â 538Â See accompanying notes.1AMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In millions)(Unaudited)Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023202420232023Net income$2,830Â $1,730Â $3,463Â $5,950Â Other comprehensive (loss) income, net of reclassification adjustments and taxes:Foreign currency translation adjustments71Â (44)32Â (5)Cash flow hedges(253)181Â (76)73Â Other1Â 17Â (3)37Â Other comprehensive (loss) income, net of reclassification adjustments and taxes(181)154Â (47)105Â Comprehensive income$2,649Â $1,884Â $3,416Â $6,055Â See accompanying notes.2AMGEN INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In millions, except per-share data)September 30, 2024December 31, 2023(Unaudited)ASSETSCurrent assets:Cash and cash equivalents$9,011Â $10,944Â Trade receivables, net7,317Â 7,268Â Inventories7,362Â 9,518Â Other current assets3,076Â 2,602Â Total current assets26,766Â 30,332Â Property, plant and equipment, net6,156Â 5,941Â Intangible assets, net28,920Â 32,641Â Goodwill18,658Â 18,629Â Other noncurrent assets10,383Â 9,611Â Total assets$90,883Â $97,154Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITYCurrent liabilities:Accounts payable$2,147Â $1,590Â Accrued liabilities14,621Â 15,359Â Current portion of long-term debt3,544Â 1,443Â Total current liabilities20,312Â 18,392Â Long-term debt56,854Â 63,170Â Long-term deferred tax liabilities1,711Â 2,354Â Long-term tax liabilities2,280Â 4,680Â Other noncurrent liabilities2,199Â 2,326Â Contingencies and commitments (see Note 13)Stockholdersâ€™ equity:Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstandingâ€”537.5 shares in 2024 and 535.4 shares in 202333,393Â 33,070Â Accumulated deficit(25,530)(26,549)Accumulated other comprehensive loss(336)(289)Total stockholdersâ€™ equity7,527Â 6,232Â Total liabilities and stockholdersâ€™ equity$90,883Â $97,154Â See accompanying notes.3AMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY(In millions, except per-share data)(Unaudited)NumberofÂ sharesofÂ commonstockCommonstock andadditionalpaid-inÂ capitalAccumulateddeficitAccumulatedothercomprehensivelossTotalBalance as of December 31, 2023535.4Â $33,070Â $(26,549)$(289)$6,232Â Net lossâ€”Â â€”Â (113)â€”Â (113)Other comprehensive income, net of taxesâ€”Â â€”Â â€”Â 99Â 99Â Dividends declared on common stock ($2.25 per share)â€”Â â€”Â (1,208)â€”Â (1,208)Issuance of common stock in connection with equity award programs1.0Â 34Â â€”Â â€”Â 34Â Stock-based compensation expenseâ€”Â 103Â â€”Â â€”Â 103Â Tax impact related to employee stock-based compensation expenseâ€”Â (125)â€”Â â€”Â (125)Balance as of March 31, 2024536.4Â 33,082Â (27,870)(190)5,022Â Net incomeâ€”Â â€”Â 746Â â€”Â 746Â Other comprehensive income, net of taxesâ€”Â â€”Â â€”Â 35Â 35Â Issuance of common stock in connection with equity award programs0.8Â 65Â â€”Â â€”Â 65Â Stock-based compensation expenseâ€”Â 157Â â€”Â â€”Â 157Â Tax impact related to employee stock-based compensation expenseâ€”Â (100)â€”Â â€”Â (100)Balance as of June 30, 2024537.2Â 33,204Â (27,124)(155)5,925Â Net incomeâ€”Â â€”Â 2,830Â â€”Â 2,830Â Other comprehensive loss, net of taxesâ€”Â â€”Â â€”Â (181)(181)Dividends declared on common stock ($2.25 per share)â€”Â â€”Â (1,236)â€”Â (1,236)Issuance of common stock in connection with equity award programs0.3Â 67Â â€”Â â€”Â 67Â Stock-based compensation expenseâ€”Â 136Â â€”Â â€”Â 136Â Tax impact related to employee stock-based compensation expenseâ€”Â (14)â€”Â â€”Â (14)Balance as of September 30, 2024537.5Â $33,393Â $(25,530)$(336)$7,527Â Â Â Â Â 4AMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (continued)(In millions, except per-share data)(Unaudited)NumberofÂ sharesofÂ commonstockCommonstock andadditionalpaid-inÂ capitalAccumulateddeficitAccumulatedothercomprehensivelossTotalBalance as of December 31, 2022534.0Â $32,514Â $(28,622)$(231)$3,661Â Net incomeâ€”Â â€”Â 2,841Â â€”Â 2,841Â Other comprehensive loss, net of taxesâ€”Â â€”Â â€”Â (37)(37)Dividends declared on common stock ($2.13 per share)â€”Â â€”Â (1,138)â€”Â (1,138)Issuance of common stock in connection with equity award programs0.3Â 11Â â€”Â â€”Â 11Â Stock-based compensation expenseâ€”Â 47Â â€”Â â€”Â 47Â Tax impact related to employee stock-based compensation expenseâ€”Â (37)â€”Â â€”Â (37)Balance as of March 31, 2023534.3Â 32,535Â (26,919)(268)5,348Â Net incomeâ€”Â â€”Â 1,379Â â€”Â 1,379Â Other comprehensive loss, net of taxesâ€”Â â€”Â â€”Â (12)(12)Issuance of common stock in connection with equity award programs0.6Â 16Â â€”Â â€”Â 16Â Stock-based compensation expenseâ€”Â 119Â â€”Â â€”Â 119Â Tax impact related to employee stock-based compensation expenseâ€”Â (69)â€”Â â€”Â (69)Balance as of June 30, 2023534.9Â 32,601Â (25,540)(280)6,781Â Net incomeâ€”Â â€”Â 1,730Â â€”Â 1,730Â Other comprehensive income, net of taxesâ€”Â â€”Â â€”Â 154Â 154Â Dividends declared on common stock ($2.13 per share)â€”Â â€”Â (1,161)â€”Â (1,161)Issuance of common stock in connection with equity award programs0.2Â 33Â â€”Â â€”Â 33Â Stock-based compensation expenseâ€”Â 124Â â€”Â â€”Â 124Â Tax impact related to employee stock-based compensation expenseâ€”Â (5)â€”Â â€”Â (5)Balance as of September 30, 2023535.1Â $32,753Â $(24,971)$(126)$7,656Â See accompanying notes.5AMGEN INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In millions)(Unaudited)Â Nine months endedSeptember 30,Â 20242023Cash flows from operating activities:Net income$3,463Â $5,950Â Noncash adjustments to reconcile net income to net cash provided by operating activities:Depreciation, amortization and other4,195Â 2,691Â Stock-based compensation expense396Â 270Â Deferred income taxes(894)(650)Adjustments for equity method investments(11)(17)Gains on equity securities(717)(1,304)Other items, net1Â 579Â Changes in operating assets and liabilities, net of acquisitions:Trade receivables, net(32)(582)Inventories2,209Â (82)Other assets(638)(332)Accounts payable544Â (215)Accrued income taxes, net(1,064)998Â Long-term tax liabilities(561)293Â Accrued liabilities(636)69Â Accrued sales incentives and allowance536Â 415Â Other liabilities(72)(150)Net cash provided by operating activities6,719Â 7,933Â Cash flows from investing activities:Proceeds from sales of marketable securitiesâ€”Â 1,125Â Proceeds from maturities of marketable securitiesâ€”Â 550Â Purchases of property, plant and equipment(725)(863)Other81Â 73Â Net cash (used in) provided by investing activities(644)885Â Cash flows from financing activities:Net proceeds from issuance of debtâ€”Â 23,781Â Extinguishment of debt(659)(550)Repayment of debt(3,600)(1,454)Dividends paid(3,627)(3,416)Other(122)(67)Net cash (used in) provided by financing activities(8,008)18,294Â (Decrease) increase in cash and cash equivalents(1,933)27,112Â Cash and cash equivalents at beginning of period10,944Â 7,629Â Cash and cash equivalents at end of period$9,011Â $34,741Â See accompanying notes.6AMGEN INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSSeptember 30, 2024 (Unaudited)1. Summary of significant accounting policiesBusinessAmgen Inc. (including its consolidated subsidiaries, referred to as â€œAmgen,â€ â€œthe Company,â€ â€œwe,â€ â€œourâ€ or â€œusâ€) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.Â We operate in one business segment: human therapeutics.Basis of presentationThe interim unaudited financial information for the three and nine months ended September 30, 2024 and 2023, has been prepared in accordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) that Amgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024.Principles of consolidationThe condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entityâ€™s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with the current presentation.Use of estimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.Property, plant and equipment, netProperty, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $10.3Â billion and $9.8 billion as of September 30, 2024 and December 31, 2023, respectively.Recent accounting pronouncementsIn December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or may elect retrospective application. We are currently evaluating the impact of adopting this new standard on our related disclosures.In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted, and the standard requires retrospective application to all prior 7periods presented. We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements.2. AcquisitionsAcquisition of Horizon Therapeutics plcOn October 6, 2023, Amgen completed its acquisition of Horizon by acquiring all of the outstanding shares of Horizon for $116.50 per share in cash, representing a total consideration of approximately $27.8Â billion. Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs of patients impacted by rare, autoimmune and severe inflammatory diseases. The acquisition, which was accounted for as a business combination, aligns with Amgenâ€™s core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases and strengthens Amgenâ€™s leading rare disease portfolio by adding first-in-class, early-in-lifecycle medicines, including TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout and UPLIZNA for neuromyelitis optica spectrum disorder. Upon its acquisition, Horizon became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.During the nine months ended September 30, 2024, the purchase price allocation of the acquisition was completed and measurement period adjustments were finalized, which included changes to the purchase price allocation that resulted in a net increase of approximately $25Â million to goodwill. The measurement period adjustments resulted primarily from adjustments to acquired assets and liabilities, including deferred tax attributes, based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. The adjustments did not have a significant impact on Amgenâ€™s results of operations during the nine months ended September 30, 2024, and would not have had a significant impact on prior period results if the adjustments had been made as of the acquisition date.The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):Cash and cash equivalents$681Â Inventories5,014Â Property, plant and equipment, net318Â Finite-lived intangible assets â€“ developed-product-technology rights19,590Â IPR&D1,060Â Goodwill3,136Â Deferred tax asset795Â Deferred tax liability(2,488)Other assets and liabilities, net(273)Total assets acquired, net of liabilities assumed$27,833Â The $27.8Â billion total consideration for this transaction consisted of (i) cash consideration transferred to common shareholders of $26.7Â billion; (ii) cash consideration transferred to vested and outstanding stock options, outstanding restricted stock unit (RSU) awards and outstanding performance stock unit (PSU) awards of $523Â million; (iii) the fair value of Amgen replacement awards (based on conversion of outstanding employee RSU awards) of $180Â million representing noncash consideration; and (iv) a portion of Horizonâ€™s debt, settled by Amgen on the acquisition closing date, of $382Â million. Amgen issued 1.7Â million replacement equity awards with the original vesting conditions, the fair value of which was determined based on the acquisition date fair value based on the conversion calculation.The estimated fair values of $20.7Â billion for the developed-product-technology rights and IPR&D intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 10 years from the acquisition date using the straight-line methodology.8The estimated fair value of the acquired inventory of $5.0Â billion was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyerâ€™s effort are applied. The inventory fair value adjustment is being amortized using a weighted-average inventory turnover, which we estimate to approximate 27 months from the acquisition date.A deferred tax liability of $2.5Â billion was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired, as well as an associated deferred tax asset for anticipatory foreign tax credits of $795Â million.The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $3.1Â billion was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from the marketed products acquired and other benefits.Supplemental Pro Forma Financial InformationThe following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the three and nine months ended September 30, 2023, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions):Three months ended September 30, 2023Nine months ended September 30, 2023Total revenues$7,854Â $22,728Â Net income$902Â $3,518Â The unaudited supplemental pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Amgen and Horizon. In order to reflect the occurrence of the acquisition on JanuaryÂ 1, 2022, the unaudited supplemental pro forma financial information includes adjustments to reflect the following: (i) incremental amortization expense based on the fair values of the identifiable intangible assets and inventory step-up; (ii) the additional interest expense associated with the issuance of debt to finance the acquisition; and (iii) the income tax impact using an estimated effective tax rate applied to the combined entity. The unaudited supplemental pro forma financial information is not necessarily indicative of what the condensed consolidated results of operations would have been had the acquisition been completed on JanuaryÂ 1, 2022. In addition, the unaudited supplemental pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition.93. RevenuesWe operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customersâ€™ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.Revenues were as follows (in millions):Three months ended September 30,20242023U.S.ROWTotalU.S.ROWTotalProlia$683Â $362Â $1,045Â $673Â $313Â $986Â ENBREL817Â 8Â 825Â 1,026Â 9Â 1,035Â XGEVA373Â 168Â 541Â 374Â 145Â 519Â Repatha281Â 286Â products(3)958Â 405Â 1,363Â 675Â 329Â 1,004Â Total product sales(4)$5,979Â $2,172Â 8,151Â $4,691Â $1,857Â 6,548Â Other revenues352Â 355Â Total revenues$8,503Â $6,903Â 10Nine months ended September 30,20242023U.S.ROWTotalU.S.ROWTotalProlia$2,110Â $1,099Â $3,209Â $1,987Â $954Â $2,941Â ENBREL2,280212,301Â 2,645372,682Â XGEVA1,1385261,664Â 1,1454401,585Â Repatha8247 products(3)2,858Â 1,2044,062Â 2,271Â 1,0493,320Â Total product sales(4)$16,792Â $6,518Â 23,310Â $13,402Â $5,675Â 19,077Â Other revenues1,028Â 917Â Total revenues$24,338Â $19,994Â

(1)Â Â Â Â TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.(2)Â Â Â Â TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.(3)Â Â Â Â Consists of product sales of our non-principal products.
(4)Â Â Â Â Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2024 and 2023.114. Income taxes The effective tax rates for the three and nine months ended September 30, 2024, were 8.7% and 9.5%, respectively, compared with 11.1% and 15.0%, respectively, for the corresponding periods in the prior

year.The decrease in our effective tax rate for the three months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets), partially offset by the quarter-to-date unrealized gains on our strategic equity investments (primarily BeiGene). See Note 6, Investmentsâ€”BeiGene, Ltd. The decrease in our effective tax rate for the nine months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets). The effective tax rates differ from the federal statutory rate primarily due to the impact of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from locations where the Company has significant manufacturing operations, including Singapore, Ireland and Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to a tax incentive grant through 2050. Additionally, the Companyâ€™s operations conducted in Singapore are subject to a tax incentive grant through 2036. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. Additionally, effective January 1, 2024, selected individual countries, including the United Kingdom and EU member countries, have enacted the global minimum tax agreement. Our legal entities in such countries, along with their direct and indirect subsidiaries, are now subject to a 15% minimum tax rate on adjusted financial statement income.Beginning on January 1, 2023, we were no longer subject to a 4% excise tax in the U.S. territory of Puerto Rico on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We qualify for and are subject to the alternative income tax rate on industrial development income of our Puerto Rico affiliate. In the United States, this income tax qualifies for foreign tax credits. Both this income tax and the associated foreign tax credits are generally recognized in our provision for income taxes. We accounted for the 2022 excise tax that was capitalized in Inventories as an expense in Cost of sales when the related products were sold in the first half of 2023, and a foreign tax credit was not recognized with respect to the excise tax expense in 2023. We do not have this excise tax exposure in 2024.One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.In 2017, we received an RAR and a modified RAR from the IRS for the years 2010â€“2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010â€“2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010â€“2012 by an amount that would result in additional federal tax of approximately $3.6Â billion, plus interest. Any additional tax that could be imposed for the years 2010â€“2012 would be reduced by up to approximately $900Â million of repatriation tax previously accrued on our foreign earnings.In 2020, we received an RAR and a modified RAR from the IRS for the years 2013â€“2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010â€“2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013â€“2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013â€“2015 by an amount that would result in additional federal tax of approximately $5.1Â billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0Â billion. Any additional tax that could be imposed for the years 2013â€“2015 would be reduced by up to approximately $2.2Â billion of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS positions set forth in the 2010â€“2012 and 2013â€“2015 Notices are without merit. We are contesting the 2010â€“2012 and 2013â€“2015 Notices through the judicial process. The two cases were consolidated in the U.S. Tax Court on December 19, 2022. The trial is currently scheduled to begin on November 4, 2024.We are currently under examination by the IRS for the years 2016â€“2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.12Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three and nine months ended September 30, 2024, the gross amounts of our UTBs increased by $40 million and $120Â million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of September 30, 2024, if recognized, would affect our effective tax rate.5. Earnings per shareThe computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.The computations for basic and diluted EPS were as follows (in millions, except per-share data):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 2024202320242023Income (Numerator):Net income for basic and diluted EPS$2,830Â $1,730Â $3,463Â $5,950Â Shares (Denominator):Weighted-average shares for basic EPS537Â 535Â 537Â 535Â Effect of dilutive securities5Â 3Â 4Â 3Â Weighted-average shares for diluted EPS542Â 538Â 541Â 538Â Basic EPS$5.27Â $3.23Â $6.45Â $11.12Â Diluted EPS$5.22Â $3.22Â $6.40Â $11.06Â For the three and nine months ended September 30, 2024 and 2023, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant.136. InvestmentsAvailable-for-sale investmentsThe amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):Types of securities as of September 30, 2024AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvaluesU.S. Treasury bills$996Â $â€”Â $â€”Â $996Â Money market mutual funds7,437Â â€”Â â€”Â 7,437Â Other short-term interest-bearing securities143Â â€”Â â€”Â 143Â Total interest-bearing securities$8,576Â $â€”Â $â€”Â $8,576Â Types of securities as of December 31, 2023AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvaluesU.S. Treasury bills$â€”Â $â€”Â $â€”Â $â€”Â Money market mutual funds10,266Â â€”Â â€”Â 10,266Â Other short-term interest-bearing securities138Â â€”Â â€”Â 138Â Total interest-bearing securities$10,404Â $â€”Â $â€”Â $10,404Â The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):Condensed Consolidated Balance Sheets locationsSeptember 30, 2024December 31, 2023Cash and cash equivalents$8,576Â $10,404Â Total interest-bearing securities$8,576Â $10,404Â Cash and cash equivalents in the above table excludes bank account cash of $435 million and $540Â million as of September 30, 2024 and December 31, 2023, respectively.All interest-bearing securities as of September 30, 2024 and December 31, 2023, mature in one year or less.For the three and nine months ended September 30, 2024 and 2023, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.Equity securitiesBeiGene, Ltd.Our ownership interest in BeiGene was approximately 18% as of both September 30, 2024 and December 31, 2023, and the fair values of our investment were $4.3Â billion and $3.4Â billion, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. In the first quarter of 2023, we began to account for our ownership interest as an equity security with a readily determinable fair value, with changes in fair value recorded in Other income, net, in our Condensed Consolidated Statements of Income. See Note 11, Fair value measurement. During the three months ended September 30, 2024 and 2023, we recognized unrealized gains of $1.6Â billion and $30Â million, respectively, recorded in Other income, net, in our Condensed Consolidated Statements of Income. During the nine months ended September 30, 2024 and 2023, we recognized unrealized gains of $836Â million and $1.2Â billion, respectively, recorded in Other income, net, in our Condensed Consolidated Statements of Income.14Subject to certain exceptions or otherwise agreed to by BeiGene, while Amgen holds at least 5.0% of BeiGeneâ€™s outstanding common stock, (A) we may only sell our BeiGene equity investment via: (i) a registered public offering, (ii) a sale under Rule 144 of the Securities Act of 1933 (the â€œSecurities Actâ€) or (iii) a private sale exempt from registration requirements under the Securities Act, and (B) we may not sell more than 5.0% of BeiGeneâ€™s outstanding common stock in any rolling 12-month period.Other equity securities Excluding our equity investments in BeiGene (discussed above) and Neumora (discussed below), we held investments in other equity securities with readily determinable fair values (publicly traded securities) of $336 million and $494 million as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and nine months ended September 30, 2024 and 2023, net unrealized gains and losses on these publicly traded securities were not material. Additionally, net realized gains and losses on sales of publicly traded securities for the three and nine months ended September 30, 2024 and 2023, were not material.We held investments of $318 million and $309 million in equity securities without readily determinable fair values as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and nine months ended September 30, 2024 and 2023, upward and downward adjustments on these securities were not material. Adjustments were based on observable price transactions. Net realized gains and losses on sales of securities without readily determinable fair values for the three and nine months ended September 30, 2024 and 2023, were not material.Equity method investmentsNeumora Therapeutics, Inc.As of September 30, 2024 and December 31, 2023, our ownership interests in Neumora were approximately 22.1% and 23.2%, respectively, and the fair values of our investment were $467 million and $603 million, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. Although our equity investment qualifies us for the equity method of accounting, we have elected the fair value option to account for our investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings in Other income, net, in our Condensed Consolidated Statements of Income each reporting period. See Note 11, Fair value measurement. We believe the fair value option best reflects the economics of the underlying transaction. During the three months ended September 30, 2024 and 2023, we recognized unrealized gains of $119Â million and $153Â million, respectively, and during the nine months ended September 30, 2024 and 2023, we recognized $136Â million of unrealized losses and $134Â million of unrealized gains, respectively. We are contractually restricted from selling more than 5.0% of Neumoraâ€™s outstanding common stock in any rolling 12-month period for as long as we hold at least 10.0% of their outstanding common stock, subject to certain exceptions or otherwise agreed to by Neumora.Limited partnershipsWe held limited partnership investments of $272 million and $251 million as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of September 30, 2024, unfunded additional commitments to be made for these investments during the next several years amounted to $139Â million. For the three and nine months ended September 30, 2024 and 2023, net unrealized gains and losses from our limited partnership investments were not material.7. InventoriesInventories consisted of the following (in millions):September 30, 2024December 31, 2023Raw materials$788Â $993Â Work in process4,339Â 5,747Â Finished goods2,235Â 2,778Â Total inventories$7,362Â $9,518Â 158. Goodwill and other intangible assetsGoodwillThe change in the carrying amount of goodwill was as follows (in millions):Balance at January 1, 2024$18,629Â Adjustments to goodwill resulting from acquisitions (1)25Â Foreign currency translation adjustments4Â Balance at September 30, 2024$18,658Â _____(1) Â Â Â Â For the nine months ended September 30, 2024, adjustments to goodwill consisted of measurement period adjustments related to our Horizon acquisition. See Note 2, Acquisitions.Other intangible assetsOther intangible assets consisted of the following (in millions):Â September 30, 2024December 31, 2023Â GrosscarryingamountsAccumulatedamortizationOther intangibleassets, netGrosscarryingamountsAccumulatedamortizationOther intangibleassets, netFinite-lived intangible assets:Developed-product-technology rights$48,636Â $(21,472)$27,164Â $48,631Â $(18,049)$30,582Â Licensing rights3,864Â (3,360)504Â 3,865Â (3,265)600Â Marketing-related rights1,203Â (1,188)15Â 1,339Â (1,264)75Â Research and development technology rights1,400Â (1,253)147Â 1,394Â (1,228)166Â Total finite-lived intangible assets55,103Â (27,273)27,830Â 55,229Â (23,806)31,423Â Indefinite-lived intangible assets:In-process research and development1,090Â â€”Â 1,090Â 1,218Â â€”Â 1,218Â Total other intangible assets$56,193Â $(27,273)$28,920Â $56,447Â $(23,806)$32,641Â Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertain to technologies used in R&D that have alternative future uses.IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.During the three months ended September 30, 2024 and 2023, we recognized amortization associated with our finite-lived intangible assets of $1.2Â billion and $693 million, respectively. During the nine months ended September 30, 2024 and 2023, we recognized amortization associated with our finite-lived intangible assets of $3.6Â billion and $2.1Â billion, respectively. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. As of September 30, 2024, the total estimated amortization of our finite-lived intangible assets for the remaining three months ending December 31, 2024, and the years ending December 31, 2025, 2026, 2027, 2028 and 2029, are $1.2 billion, $4.5 billion, $3.9 billion, $3.9 billion, $2.9 billion and $2.2 billion, respectively.169. Financing arrangementsOur borrowings consisted of the following (in millions):Â September 30, 2024December 31, 20233.625% notes due 2024 (3.625% 2024 Notes)$â€”Â $1,400Â 1.90% notes due 2025 (1.90% 2025 Notes)500Â 500Â 5.25% notes due 2025 (5.25% 2025 Notes)2,000Â 2,000Â Term loan due April 2025â€”Â 2,000Â 3.125% notes due 2025 (3.125% 2025 Notes)1,000Â 1,000Â 2.00% â‚¬750 million notes due 2026 (2.00% 2026 euro Notes)835Â 828Â 5.507% notes due 2026 (5.507% 2026 Notes)1,500Â 1,500Â 2.60% notes due 2026 (2.60% 2026 Notes)1,250Â 1,250Â Term loan due October 20261,800Â 2,000Â 5.50% Â£475 million notes due 2026 (5.50% 2026 pound sterling Notes)635Â 605Â 2.20% notes due 2027 (2.20% 2027 Notes)1,724Â 1,724Â 3.20% notes due 2027 (3.20% 2027 Notes)1,000Â 1,000Â 5.15% notes due 2028 (5.15% 2028 Notes)3,750Â 3,750Â 1.65% notes due 2028 (1.65% 2028 Notes)1,234Â 1,234Â 3.00% notes due 2029 (3.00% 2029 Notes)750Â 750Â 4.05% notes due 2029 (4.05% 2029 Notes)1,250Â 1,250Â 4.00% Â£700 million notes due 2029 (4.00% 2029 pound sterling Notes)936Â 892Â 2.45% notes due 2030 (2.45% 2030 Notes)1,250Â 1,250Â 5.25% notes due 2030 (5.25% 2030 Notes)2,750Â 2,750Â 2.30% notes due 2031 (2.30% 2031 Notes)1,250Â 1,250Â 2.00% notes due 2032 (2.00% 2032 Notes)1,001Â 1,001Â 3.35% notes due 2032 (3.35% 2032 Notes)1,000Â 1,000Â 4.20% notes due 2033 (4.20% 2033 Notes)750Â 750Â 5.25% notes due 2033 (5.25% 2033 Notes)4,250Â 4,250Â 6.375% notes due 2037 (6.375% 2037 Notes)478Â 478Â 6.90% notes due 2038 (6.90% 2038 Notes)254Â 254Â 6.40% notes due 2039 (6.40% 2039 Notes)333Â 333Â 3.15% notes due 2040 (3.15% 2040 Notes)1,668Â 1,803Â 5.75% notes due 2040 (5.75% 2040 Notes)373Â 373Â 2.80% notes due 2041 (2.80% 2041 Notes)776Â 949Â 4.95% notes due 2041 (4.95% 2041 Notes)600Â 600Â 5.15% notes due 2041 (5.15% 2041 Notes)729Â 729Â 5.65% notes due 2042 (5.65% 2042 Notes)415Â 415Â 5.60% notes due 2043 (5.60% 2043 Notes)2,750Â 2,750Â 5.375% notes due 2043 (5.375% 2043 Notes)185Â 185Â 4.40% notes due 2045 (4.40% 2045 Notes)2,250Â 2,250Â 4.563% notes due 2048 (4.563% 2048 Notes)1,415Â 1,415Â 3.375% notes due 2050 (3.375% 2050 Notes)1,764Â 2,132Â 4.663% notes due 2051 (4.663% 2051 Notes)3,541Â 3,541Â 3.00% notes due 2052 (3.00% 2052 Notes)890Â 999Â 4.20% notes due 2052 (4.20% 2052 Notes)895Â 950Â 4.875% notes due 2053 (4.875% 2053 Notes)1,000Â 1,000Â 5.65% notes due 2053 (5.65% 2053 Notes)4,250Â 4,250Â 2.77% notes due 2053 (2.77% 2053 Notes)940Â 940Â 4.40% notes due 2062 (4.40% 2062 Notes)1,165Â 1,200Â 17Â September 30, 2024December 31, 20235.75% notes due 2063 (5.75% 2063 Notes)2,750Â 2,750Â Other notes due 2097100Â 100Â Unamortized bond discounts, premiums and issuance costs, net(1,373)(1,420)Fair value adjustments(192)(314)Other27Â 17Â Total carrying value of debt60,398Â 64,613Â Less current portion(3,544)(1,443)Total long-term debt$56,854Â $63,170Â There are no material differences between the effective interest rates and coupon rates of our notes except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6%

and 5.2%, respectively.The Term loans have an interest rate of three-month SOFR plus 1.225%.Debt repaymentsDuring the nine months ended September 30, 2024, we repaid the $2.0Â billion aggregate principal amount on the Term loan due April 2025, $200Â million aggregate principal amount of the Term loan due October 2026 and the $1.4Â billion aggregate principal amount of the 3.625% 2024 Notes.Debt extinguishmentDuring the nine months ended September 30, 2024, we repurchased an aggregate principal amount of our debt of $875Â million, including portions of the 3.15% 2040 Notes, 2.80% 2041 Notes, 3.375% 2050 Notes, 3.00% 2052 Notes, 4.20% 2052 Notes and 4.40% 2062 Notes, for an aggregate cost of $659Â million, which resulted in the recognition of a $215Â million gain on extinguishment of debt recorded in Other income, net, in the Condensed Consolidated Statements of Income.Interest rate swap contractsSee Note 12, Derivative instruments, for a discussion of interest rate swap contracts related to certain of our notes. 10. Stockholdersâ€™ equityStock repurchase programDuring the nine months ended September 30, 2024 and 2023, we did not repurchase shares under our stock repurchase program. As of September 30, 2024, $7.0 billion of authorization remained available under our stock repurchase program.DividendsIn August 2024, March 2024 and December 2023, our Board of Directors declared quarterly cash dividends of $2.25 per share, which were paid in September 2024, June 2024 and March 2024, respectively. In October 2024, our Board of Directors declared a quarterly cash dividend of $2.25 per share that will be paid in December 2024.18Accumulated other comprehensive income (loss)The components of AOCI were as follows (in millions):Foreigncurrencytranslation adjustmentsCashÂ flowhedgesOtherAOCIBalance as of December 31, 2023(298)(22)$31Â $(289)Foreign currency translation adjustments(24)â€”Â â€”Â (24)Unrealized gainsâ€”Â 178Â â€”Â 178Â Reclassification adjustments into earningsâ€”Â (20)â€”Â (20)Otherâ€”Â â€”Â (3)(3)Income taxesâ€”Â (32)â€”Â (32)Balance as of March 31, 2024(322)104Â 28Â (190)Foreign currency translation adjustments(15)â€”Â â€”Â (15)Unrealized gainsâ€”Â 117Â â€”Â 117Â Reclassification adjustments into earningsâ€”Â (52)â€”Â (52)Otherâ€”Â â€”Â (1)(1)Income taxesâ€”Â (14)â€”Â (14)Balance as of June 30, 2024(337)155Â 27Â (155)Foreign currency translation adjustments71Â â€”Â â€”Â 71Â Unrealized lossesâ€”Â (158)â€”Â (158)Reclassification adjustments into earningsâ€”Â (166)â€”Â (166)Otherâ€”Â â€”Â 1Â 1Â Income taxesâ€”Â 71Â â€”Â 71Â Balance as of September 30, 2024(266)(98)$28Â $(336)Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):Three months ended September 30,Components of AOCI20242023Condensed ConsolidatedStatements of Income locationsCash flow hedges:Foreign currency contract gains$45Â $33Â Product salesCross-currency swap contract gains (losses)121Â (86)Other income, net166Â (53)Income before income taxes(36)11Â Provision for income taxes$130Â $(42)Net incomeNine months ended September 30,Components of AOCI20242023Condensed ConsolidatedStatements of Income locationsCash flow hedges:Foreign currency contract gains$151Â $121Â Product salesCross-currency swap contract gains (losses)87Â (57)Other income, net238Â 64Â Income before income taxes(51)(14)Provision for income taxes$187Â $50Â Net income1911. Fair value measurementTo estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the sources of inputs as follows:LevelÂ 1â€”Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to accessLevelÂ 2â€”Valuations for which all significant inputs are observable either directly or indirectlyâ€”other than Level 1 inputsLevelÂ 3â€”Valuations based on inputs that are unobservable and significant to the overall fair value measurementThe availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.The fair values of each major class of the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):QuotedÂ prices in activeÂ marketsÂ for identical assets(Level 1)SignificantotherÂ observableinputs(Level 2)Significantunobservableinputs(Level 3)Fair value measurement as of September 30, 2024, using:TotalAssets:Available-for-sale securities:U.S. Treasury billsâ€”Â $996Â â€”Â $996Â Money market mutual funds7,437Â â€”Â â€”Â 7,437Â Other short-term interest-bearing securitiesâ€”Â 143Â â€”Â 143Â Equity securities5,057Â â€”Â â€”Â 5,057Â Derivatives:Foreign currency forward contractsâ€”Â 99Â â€”Â 99Â Cross-currency swap contractsâ€”Â 4Â â€”Â 4Â Interest rate swap contractsâ€”Â 9Â â€”Â 9Â Total assets$12,494Â $1,251Â $â€”Â $13,745Â Liabilities:Derivatives:Foreign currency forward contracts$â€”Â $121Â $â€”Â $121Â Cross-currency swap contractsâ€”Â 361Â â€”Â 361Â Interest rate swap contractsâ€”Â 404Â â€”Â 404Â Contingent consideration obligationsâ€”Â â€”Â 112Â 112Â Total liabilities$â€”Â $886Â $112Â $998Â 20QuotedÂ prices in activeÂ marketsÂ for identical assets(Level 1)Significantother observableinputs(Level 2)Significantunobservableinputs(Level 3)Fair value measurement as of December 31, 2023, using:TotalAssets:Available-for-sale securities:U.S. Treasury billsâ€”Â $â€”Â $â€”Â $â€”Â Money market mutual funds10,266Â â€”Â â€”Â 10,266Â Other short-term interest-bearing securitiesâ€”Â 138Â â€”Â 138Â Equity securities4,514Â â€”Â â€”Â 4,514Â Derivatives:Foreign currency forward contractsâ€”Â 145Â â€”Â 145Â Cross-currency swap contractsâ€”Â â€”Â â€”Â â€”Â Interest rate swap contractsâ€”Â â€”Â â€”Â â€”Â Total assets$14,780Â $283Â $â€”Â $15,063Â Liabilities:Derivatives:Foreign currency forward contracts$â€”Â $116Â $â€”Â $116Â Cross-currency swap contractsâ€”Â 405Â â€”Â 405Â Interest rate swap contractsâ€”Â 571Â â€”Â 571Â Contingent consideration obligationsâ€”Â â€”Â 96Â 96Â Total liabilities$â€”Â $1,092Â $96Â $1,188Â Interest-bearing and equity securitiesThe fair values of our money market mutual funds and equity investments in publicly traded securities, including our equity investments in BeiGene and Neumora, as of September 30, 2024 and December 31, 2023, are based on quoted market prices in active markets, with no valuation adjustment.DerivativesAll of our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of Aâ€“ or equivalent by S&P, Moodyâ€™s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, SOFR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.Contingent consideration obligationsAs a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.21Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):Three months endedSeptember 30,Nine months endedSeptember 30,20242023Beginning balance$107Â $248Â $96Â $270Â Payments(2)(3)(6)(7)Net changes in valuations7Â (147)22Â (165)Ending balance$112Â $98Â $112Â $98Â As of September 30, 2024 and December 31, 2023, our contingent consideration obligations are primarily the result of our acquisition of Teneobio, Inc. in October 2021, which obligates us to pay the former shareholders payments upon achieving separate development and regulatory milestones with regard to various R&D programs.Summary of the fair values of other financial instrumentsCash equivalentsThe fair values of cash equivalents are approximated at their carrying values due to the short-term nature of such financial instruments.BorrowingsWe estimate the fair values of our fixed-rate notes by using Level 2 inputs. As of September 30, 2024 and December 31, 2023, the aggregate fair values of our fixed-rate notes were $58.0 billion and $59.2 billion, respectively, and the carrying values of this debt were $58.6 billion and $60.6 billion, respectively. The estimate of the fair values of our Term loans is approximated as the carrying values as of September 30, 2024 and December 31, 2023 as these debt instruments bear interest at floating rates.During the nine months ended September 30, 2024 and 2023, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis.2212. Derivative instrumentsThe Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes.Cash flow hedgesWe are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales is partially offset by corresponding cash outflows from our international operating expenses. To further reduce our exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.As of September 30, 2024 and December 31, 2023, we had outstanding foreign currency forward contracts with aggregate notional amounts of $7.1 billion and $6.6 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros and pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the terms of the contracts by paying U.S. dollars and receiving euros and pounds sterling. In addition, we will pay U.S. dollars to and receive euros and pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros and pounds sterling to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.The notional amounts and interest rates of our cross-currency swaps as of September 30, 2024, were as follows (notional amounts in millions):Foreign currencyU.S. dollarsHedged notesNotional amountsInterest ratesNotional amountsInterest rates2.00% 2026 euro Notesâ‚¬750Â 2.0Â %$833Â 3.9Â %5.50% 2026 pound sterling NotesÂ£475Â 5.5Â %$747Â 6.0Â %4.00% 2029 pound sterling NotesÂ£700Â 4.0Â %$1,111Â 4.6Â %In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the terms of the associated debt issuances. Amounts recognized in connection with forward interest rate contracts during the nine months ended September 30, 2024, and amounts expected to be recognized during the subsequent 12 months are not material.23Unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Derivatives in cash flow hedging relationships20242023020242023Foreign currency forward contracts(238)198Â $87Â $222Â Cross-currency swap contracts80Â (22)50Â (36)Forward interest rate contractsâ€”Â â€”Â â€”Â (31)Total unrealized (losses) gains(158)176Â $137Â $155Â Fair value hedgesTo achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate coupons over the terms of the related hedge contracts. As of both September 30, 2024 and December 31, 2023, we had interest rate swap contracts with aggregate notional amounts of $6.7Â billion, that hedge certain portions of our long-term debt issuances. During the nine months ended September 30, 2024, interest rate swaps with an aggregate notional amount of $1.4Â billion matured in connection with the repayment of the 3.625% 2024 Notes. In addition, we entered into new interest rate swaps with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4Â billion at an interest rate of SOFR plus 1.8%.For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining term of the previously hedged debt.The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):Carrying amounts of hedged liabilities(1)Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)Condensed Consolidated Balance Sheets locationsSeptember 30, 2024December 31, 2023September 30, 2024December 31, 2023Current portion of long-term debt$1,039Â $1,441Â $39Â $41Â Long-term debt$5,307Â $4,788Â (231)(355)_____(1) Â Â Â Â Current portion of long-term debt includes $58 million and $69 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $245 million and $288 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively.(2)Â Â Â Â Current portion of long-term debt includes $58 million and $69 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $145 million and $188 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively.24Impact of hedging transactionsThe following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):Three months ended September 30, 2024Nine months ended September 30, 2024Product salesOther income, netInterest expense, netProduct salesOther income, netInterest expense, netTotal amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$8,151Â $1,830Â (776)23,310Â $1,288Â $(2,408)The effects of cash flow and fair value hedging:Gains on cash flow hedging relationships reclassified out of AOCI:Foreign currency forward contracts$45Â $â€”Â $â€”Â $151Â $â€”Â $â€”Â Cross-currency swap contracts$â€”Â $121Â $â€”Â $87Â $â€”Â (Losses) gains on fair value hedging relationshipsâ€”interest rate swap agreements:Hedged items(1)$â€”Â $â€”Â (153)â€”Â $â€”Â $(122)Derivatives designated as hedging instruments$â€”Â $â€”Â $168Â $â€”Â $â€”Â $176Â Three months ended September 30, 2023Nine months ended September 30, 2023Product salesOther income, netInterest expense, netProduct salesOther income, netInterest expense, netTotal amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,548Â $685Â (759)19,077Â $2,431Â $(2,054)The effects of cash flow and fair value hedging:Gains (losses) on cash flow hedging relationships reclassified out of AOCI:Foreign currency forward contracts$33Â $â€”Â $â€”Â $121Â $â€”Â $â€”Â Cross-currency swap contracts$â€”Â (86)â€”Â $â€”Â (57)â€”Â Gains (losses) on fair value hedging relationshipsâ€”interest rate swap agreements:Hedged items(1)$â€”Â $â€”Â $58Â $â€”Â $â€”Â $63Â Derivatives designated as hedging instruments$â€”Â $â€”Â (37)â€”Â $â€”Â $5Â _____(1)Â Â Â Â Gains (losses) on hedged items do not exactly offset losses (gains) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of September 30, 2024, amounts expected to be recognized into earnings during the subsequent 12 months on our foreign currency and cross-currency swap contracts are not

material.Derivatives not designated as hedgesTo reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of September 30, 2024 and December 31, 2023, the total notional amounts of these foreign currency forward contracts were $82 million and $457 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and nine months ended September 30, 2024 and 2023.25Fair values of derivativesThe fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):Â Derivative assetsDerivative liabilitiesSeptember 30, 2024Condensed ConsolidatedBalance Sheets locationsFairÂ valuesCondensed ConsolidatedBalance Sheets locationsFairÂ valuesDerivatives designated as hedgingÂ instruments:Foreign currency forward contractsOther current assets/ Other noncurrent assets$99Â Accrued liabilities/ OtherÂ noncurrent liabilities$121Â Cross-currency swap contractsOther current assets/ Other noncurrent assets4Â Accrued liabilities/ OtherÂ noncurrent liabilities361Â Interest rate swap contractsOther current assets/ Other noncurrent assets9Â Accrued liabilities/ OtherÂ noncurrent liabilities404Â Total derivatives designated as hedging instruments112Â 886Â Total derivatives$112Â $886Â Â Derivative assetsDerivative liabilitiesDecember 31, 2023Condensed ConsolidatedBalance Sheets locationsFairÂ valuesCondensed ConsolidatedBalance Sheets locationsFairÂ valuesDerivatives designated as hedging instruments:Foreign currency forward contractsOther current assets/ Other noncurrent assets$145Â Accrued liabilities/ Other noncurrent liabilities$116Â Cross-currency swap contractsOther current assets/ Other noncurrent assetsâ€”Â Accrued liabilities/ Other noncurrent liabilities405Â Interest rate swap contractsOther current assets/ Other noncurrent assetsâ€”Â Accrued liabilities/ Other noncurrent liabilities571Â Total derivatives designated as hedging instruments145Â 1,092Â Total derivatives$145Â $1,092Â For additional information, see Note 11, Fair value measurement.Our derivative contracts that were in liability positions as of September 30, 2024, contain certain credit-risk-related contingent provisions that would be triggered if (i)Â we were to undergo a change-in-control and (ii)Â our or the surviving entityâ€™s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash (used in) provided by financing activities.2613. Contingencies and commitmentsContingenciesIn the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1A. Risk Factorsâ€”Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024.We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended MarchÂ 31, 2024 and JuneÂ 30, 2024, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended MarchÂ 31, 2024 and JuneÂ 30, 2024, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.Certain recent developments concerning our legal proceedings and other matters are discussed below.Repatha Patent LitigationPatent Disputes in the International RegionGermanyOn October 17, 2024 in Sanofi-Aventis Deutschland GmbH (Sanofi-Aventis) and Regeneron Pharmaceuticals, Inc.â€™s (Regeneron) actions seeking damages arising from the provisional enforcement of an injunction against PRALUENTÂ®, the Munich Regional Court scheduled a hearing for February 26, 2025.Unified Patent Court of the European UnionAmgen filed a Statement of Appeal on September 13, 2024, asking the Court of Appeals to the Unified Patent Court (UPC) to set aside the decision of the UPC Central Division revoking Amgenâ€™s European Patent No. 3,666,797 (EP â€˜797).On September 25, 2024, Sanofi Biotechnologies SAS and Regeneron filed a brief seeking to expand the ongoing UPC action, alleging that Amgenâ€™s Repatha infringes a newly-issued patent, European Patent No. 4,252,857, seeking an injunction against the marketing, use, or importation of Repatha in 18 countries (Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Sweden) and damages for past infringement.European Patent OfficeThe European Patent Office (EPO) Opposition Division will hear argument on Sanofi-Aventis and Regeneronâ€™s opposition against Amgenâ€™s EP â€˜797 from March 31 to April 4, 2025.In Amgenâ€™s opposition before the EPO against Regeneronâ€™s European Patent No. 3,536,712, the Opposition Division will hear argument on March 11 and 12, 2025.27JapanOn September 16, 2024, Amgen filed an appeal brief with the Japanese Intellectual Property High Court, seeking to overturn the Japanese Patent Officeâ€™s decision to reject Amgenâ€™s amended patent claims following a remand of the case to the Japanese Patent Office from the Japanese Intellectual Property High Court.Prolia/XGEVA Biologics Price Competition and Innovation Act (BPCIA) LitigationAmgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al.On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgenâ€™s Prolia and XGEVA products. The complaint asserts infringement of the following 34 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,058,418; 8,247,210; 8,460,896; 8,680,248; 9,012,178; 9,320,816; 9,328,134; 9,359,435; 9,481,901; 10,106,829; 10,167,492; 10,227,627; 10,421,987; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 10,907,186; 11,098,079; 11,130,980; 11,254,963; 11,292,829; 11,299,760; 11,384,378; 11,427,848; 11,434,514; 11,634,476; 11,685,772; 11,744,950; and 11,946,085 (collectively, the Asserted Patents). Amgen seeks a judgment from the New Jersey District Court that Samsung has infringed or will infringe one or more claims of each of the Asserted Patents and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Samsungâ€™s proposed denosumab biosimilar before expiration of each of the Asserted Patents found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Bioepis filed its Answer and Counterclaims in response to the Complaint on October 1, 2024. Biologicâ€™s response to the Complaint is due on October 28, 2024.Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al.On October 4, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the Northern District of Illinois (Northern Illinois District Court) against Fresenius Kabi USA, LLC, Fresenius SwissBiosim GmbH, Fresenius Kabi Deutschland, GmbH, and Fresenius Kabi Austria GmbH (collectively, Fresenius) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgenâ€™s Prolia and XGEVA products. The complaint asserts infringement of the following 33 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,053,236; 8,058,418; 8,460,896; 8,680,248; 9,012,178; 9,228,168; 9,320,816; 9,328,134; 9,359,435; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,744,950; 11,786,866; 11,946,085; 11,952,605; and 12,084,686 (collectively, the Asserted Patents). Amgen seeks a judgment from the Northern Illinois District Court that Fresenius has infringed or will infringe one or more claims of each of the Asserted Patents and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Freseniusâ€™s proposed denosumab biosimilar before expiration of each of the Asserted Patents found infringed. Amgen also seeks monetary remedies for any past acts of infringement.PAVBLUâ„¢ (formerly ABP 938 (aflibercept-ayyh)) Patent LitigationOn September 23, 2024, the U.S. District Court for the Northern District of West Virginia denied Regeneronâ€™s motion for a preliminary injunction, and Regeneron filed a notice of appeal, a motion to expedite the appeal, and an emergency motion for an injunction pending resolution of the appeal and for an administrative stay with the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On September 25, 2024, the Federal Circuit Court issued an order temporarily enjoining the launch of PAVBLU on an administrative basis while it considered Regeneronâ€™s motion for an injunction pending appeal. On October 22, 2024, the Federal Circuit Court denied Regeneronâ€™s motion for an injunction pending appeal and lifted the temporary injunction that was entered on September 25, 2024. Amgenâ€™s response brief to the appeal is due on November 4, 2024, Regeneronâ€™s reply brief is due on November 13, 2024 and oral arguments for the appeal will be scheduled for January 2025.Antitrust Class ActionsSensipar Antitrust Class ActionsOn September 13, 2024, the putative class of direct purchasers of Sensipar (Sensipar Plaintiffs) filed their opening brief in its appeal of the dismissal of its claims by the U.S. District Court for the District of Delaware (Delaware District Court). Amgen has obtained an extension until November 14, 2024 to file its opposing brief. The Sensipar Plaintiffsâ€™ reply is due December 5, 2024.28Regeneron Pharmaceuticals, Inc. Antitrust ActionThe trial before the Delaware District Court that had been set to begin on November 12, 2024 was taken off calendar. A new date for the trial has not yet been set. The Delaware District Court set a hearing on November 20, 2024 to hear Amgenâ€™s motion for summary judgment and the partiesâ€™ motions to exclude expert testimony.CareFirst of Maryland Antitrust Class ActionOn August 6, 2024, CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., and CareFirst BlueChoice, Inc. (collectively, CareFirst), filed a class action antitrust lawsuit against Amgen Inc., Amgen Manufacturing, Limited (corrected to Amgen Manufacturing Limited LLC in CareFirstâ€™s amended complaint on October 11, 2024), and Immunex Corporation in the U.S. District Court for the Eastern District of Virginia, alleging federal and state antitrust claims and state consumer protection claims. The plaintiffs allege that, in 2004, Amgen entered into an anticompetitive agreement with certain F. Hoffman-La Roche AG entities (Roche) and other parties that provided Amgen with rights to Rocheâ€™s patents in a manner that enabled Amgen to allegedly unlawfully extend the life of patents applicable to ENBREL and, thereby, delay biosimilar entry. Amgenâ€™s response to the complaint is due on November 4, 2024.U.S. Tax Litigation and Related MattersAmgen Inc. & Subsidiaries v. Commissioner of Internal RevenueSee Note 4, Income taxes, for discussion of the IRS tax dispute and the Companyâ€™s petitions in the U.S. Tax Court.Securities Class Action Litigation (Roofers Local No. 149 Pension Fund)On September 30, 2024, the U.S. District Court for the Southern District of New York denied Amgenâ€™s motion to dismiss. Amgen's response to the complaint is due on November 20, 2024.Shareholder Derivative Litigation (Hamilton)On October 16, 2024, David Hamilton filed a derivative action captioned David Hamilton v. Robert A. Bradway, et al., No. 2024-1063 (Del. Chan. Ct. Oct. 16, 2024), purportedly on behalf of Amgen, against Amgen, Robert Bradway, Peter Griffith and Amgenâ€™s Board members during the relevant time period. The action was filed in the Delaware Chancery Court. The complaint in this matter alleges claims for breach of fiduciary duty and unjust enrichment. The factual allegations that form the basis for these claims are fundamentally the same as those asserted by the Roofers Local No. 149 Pension Fund on March 13, 2023 (alleging false and misleading statements and omissions made from July 29, 2020 through April 27, 2022 relating to Amgenâ€™s tax liabilities, business and finances, and the adequacy and maintenance of its internal controls).ChemoCentryx, Inc. Securities MattersOn September 10, 2024, the U.S. District Court for the Northern District of California granted an administrative motion to extend certain case schedule deadlines, including setting the expert discovery cutoff to December 20, 2024 and setting the deadlines for summary judgment motions on April 4, 2025, summary judgment oppositions on April 25, 2025, and summary judgment replies on May 9, 2025. Trial is set for September 2025.29ItemÂ 2.MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following MD&A is intended to assist the reader in understanding Amgenâ€™s business. MD&A is provided as a supplement to and should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2023, and our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024. Our results of operations discussed in MD&A are presented in conformity with GAAP. Amgen operates in one business segment: human therapeutics. Therefore, our results of operations are discussed on a consolidated basis.Forward-looking statementsThis report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our managementâ€™s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases, written statements or our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls and conference calls. Such words as â€œexpect,â€ â€œanticipate,â€ â€œoutlook,â€ â€œcould,â€ â€œtarget,â€ â€œproject,â€ â€œintend,â€ â€œplan,â€ â€œbelieve,â€ â€œseek,â€ â€œestimate,â€ â€œshould,â€ â€œmay,â€ â€œassumeâ€ and â€œcontinueâ€ as well as variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. We describe our respective risks, uncertainties and assumptions that could affect the outcome or results of operations in Item 1A. Risk Factors in Part II herein and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2023, and in Part II, Item 1A. Risk Factors of our Quarterly Reports on Form 10-Q for the periods ended MarchÂ 31, 2024 and June 30, 2024. We have based our forward-looking statements on our managementâ€™s beliefs and assumptions based on information available to our management at the time the statements are made. We caution you that actual outcomes and results may differ materially from what is expressed, implied or forecasted by our forward-looking statements. Reference is made in particular to forward-looking statements regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses, EPS, liquidity and capital resources, trends, planned dividends, stock repurchases, and collaborations. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements after the distribution of this report, whether as a result of new information, future events, changes in assumptions or otherwise.OverviewAmgen Inc. (including its subsidiaries, referred to as â€œAmgen,â€ â€œthe Company,â€ â€œwe,â€ â€œourâ€ or â€œusâ€) discovers, develops, manufactures and delivers innovative medicines to fight some of the worldâ€™s toughest diseases. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that dramatically improve peopleâ€™s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 40 years ago and have grown to be one of the worldâ€™s leading independent biotechnology companies. Our robust pipeline includes potential first-in-class medicines at all stages of development.Our principal products are Prolia, ENBREL, XGEVA, Repatha, Otezla, TEPEZZA, EVENITY, KYPROLIS, Nplate, Aranesp, KRYSTEXXA, BLINCYTO, Vectibix and TEZSPIRE. We also market a number of other products, including but not limited to MVASI, AMJEVITA/AMGEVITA, Neulasta, RAVICTI, Parsabiv, UPLIZNA, LUMAKRAS/LUMYKRAS, Aimovig, TAVNEOS, PROCYSBI, EPOGEN and IMDELLTRA.Macroeconomic and other challengesUncertain macroeconomic conditions, including the risk of inflation, higher interest rates and instability in the financial system, as well as rising healthcare costs continue to pose challenges to our business. Further, ongoing geopolitical conflicts continue to create additional uncertainty in global macroeconomic conditions. Additionally, with public and private healthcare-provider focus, the industry continues to be subject to cost containment measures and significant pricing pressures, resulting in net price declines. Moreover, provisions of the IRA, as well as the 340B Drug Pricing Program, have affected, and are likely to continue to affect, our business. Finally, wholesale and end-user buying patterns can affect our product sales. These buying patterns can cause fluctuations in quarterly product sales but have generally not been significant to date when comparing full-year product performance to the prior year. See Part II, Item 1A. Risk Factors, of this Quarterly Report on Form 10-Q.30Significant developmentsFollowing is a summary of selected significant developments affecting our business that occurred since the filing of our Quarterly Report on Form 10-Q for the period ended June 30, 2024. For additional developments, see our Annual Report on Form 10-K for the year ended December 31, 2023, and our Quarterly Reports

on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024.Products/PipelineTEPEZZAIn September 2024, we announced TEPEZZA was approved for the treatment of active or high clinical activity score (CAS) thyroid eye disease (TED) in Japan.UPLIZNAIn September 2024, we announced top-line results of the Phase 3 MINT trial of UPLIZNA, an anti-CD19 humanized monoclonal antibody. MINT is a Phase 3, randomized, placebo-controlled, double-blind trial assessing the efficacy and safety of UPLIZNA in patients with generalized myasthenia gravis (gMG). The trial met its primary endpoint, with a statistically significant change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score for UPLIZNA compared with placebo at week 26 of the combined patient population. UPLIZNA demonstrated a statistically significant and clinically meaningful change from baseline compared to placebo for four out of five key secondary endpoints. The overall safety results during the placebo-controlled period of the trial were consistent with the known safety profile of UPLIZNA.RocatinlimabIn September 2024, we announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor. ROCKET HORIZON is a Phase 3, randomized, placebo-controlled, double-blind trial assessing the efficacy, safety and tolerability of rocatinlimab monotherapy in adults with moderate to severe atopic dermatitis. The study met its co-primary endpoints and reached statistically significant difference from placebo for all key secondary endpoints. Overall safety findings in the study were comparable to those seen in the Phase 2b study.Selected financial informationThe following is an overview of our results of operations (in millions, except percentages and per-share data):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeProduct salesU.S.$5,979Â $4,691Â 27Â %$16,792Â $13,402Â 25Â %ROW2,172Â 1,857Â 17Â %6,518Â 5,675Â 15Â %Total product sales8,151Â 6,548Â 24Â %23,310Â 19,077Â 22Â %Other revenues352Â 355Â (1)%1,028Â 917Â 12Â %Total revenues$8,503Â $6,903Â 23Â %$24,338Â $19,994Â 22Â %Operating expenses$6,456Â $4,882Â 32Â %$19,391Â $13,368Â 45Â %Operating income$2,047Â $2,021Â 1Â %$4,947Â $6,626Â (25)%Net income$2,830Â $1,730Â 64Â %$3,463Â $5,950Â (42)%Diluted EPS$5.22Â $3.22Â 62Â %$6.40Â $11.06Â (42)%Diluted shares542Â 538Â 1Â %541Â 538Â 1Â %In the following discussion of changes in product sales, any reference to unit demand growth or decline refers to changes in purchases of our products by healthcare providers (such as physicians or their clinics), dialysis centers, hospitals and pharmacies. In addition, any reference to increases or decreases in inventory refers to changes in inventory held by wholesaler customers and end users (such as pharmacies) as may be noted.Total product sales increased 24% and 22% for the three and nine months ended September 30, 2024, respectively, primarily driven by volume growth of 29% and 27%, respectively, partially offset by declines in net selling price of 2% and 3%, respectively.31For the three months ended September 30, 2024, U.S. volume grew 34% and ROW volume grew 18%. Product sales from acquired Horizon products contributed $1.1 billion, with volume growth of 12% from our other brands, including Repatha, TEZSPIRE, EVENITY, BLINCYTO and Prolia.For the nine months ended September 30, 2024, U.S. volume grew 31% and ROW volume grew 17%. Product sales from acquired Horizon products contributed $3.1 billion, with volume growth of 10% from our other brands, including Repatha, TEZSPIRE, EVENITY, Prolia and BLINCYTO.For the remainder of 2024, we expect product sales growth from acquired Horizon products and volume growth from our other brands to be partially offset by net selling price declines on a year-over-year basis at a portfolio level.Uncertain macroeconomic conditions, changes in the healthcare ecosystem and geopolitical conflicts have the potential to introduce variability into product sales. Furthermore, product sales continue to be impacted by actions from governments and other entities to curb high inflation, provisions of the IRA, the 340B Drug Pricing Program and growth in numbers of Medicaid enrollees and uninsured individuals. See Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, and Part II, Item 1A. Risk Factors, of our Quarterly Reports on Form 10-Q for the periods ended MarchÂ 31, 2024, June 30, 2024 and September 30, 2024.Other revenues remained relatively unchanged for the three months ended September 30, 2024. Other revenues increased for the nine months ended September 30, 2024, driven by higher royalty income and corporate partner revenue from licensed products.Operating expenses increased for the three and nine months ended September 30, 2024, primarily driven by higher amortization expense from Horizon acquisition-related assets and expenses from the acquired Horizon business.32Results of operationsProduct salesWorldwide product sales were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeProliaÂ $1,045Â $986Â 6Â %$3,209Â $2,941Â 9Â %ENBREL825Â 1,035Â (20)%2,301Â 2,682Â (14)%XGEVA541Â 519Â 4Â %1,664Â 1,585Â 5Â %Repatha567Â 406Â 40Â %1,616Â 1,218Â 33Â %Evenity399Â 307Â 30Â %1,132Â 842Â 34Â %Other products(3)1,363Â 1,004Â 36Â %4,062Â 3,320Â 22Â %Total product sales$8,151Â $6,548Â 24Â %$23,310Â $19,077Â 22Â %N/A = not applicable_____(1)Â Â Â Â Â TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on OctoberÂ 6, 2023, and include product sales in the periods after the acquisition date.(2)Â Â Â Â Â TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.(3)Â Â Â Â Â Consists of product sales of our non-principal products.Future sales of our products will depend in part on the factors discussed below and in the following sections of this report: (i) Part I, Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Overview, and Selected financial information; and (ii) Part II, Item 1A. Risk Factors, and in the following sections of our Annual Report on Form 10-K for the year ended December 31, 2023: (i) Part I, Item 1. Businessâ€”Marketing, Distribution and Selected Marketed Products; (ii) Part I, Item 1A. Risk Factors; and (iii) Part II, ItemÂ 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Overview, and Results of operationsâ€”Product sales, as well as in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024: (i) Part I, Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Results of operationsâ€”Product sales; and (ii) Part II, Item 1A. Risk Factors.ProliaTotal Prolia sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeProlia â€” U.S.$683Â $673Â 1Â %$2,110Â $1,987Â 6Â %Prolia â€” ROW362Â 313Â 16Â %1,099Â 954Â 15Â %Total Prolia$1,045Â $986Â 6Â %$3,209Â $2,941Â 9Â %The increase in global Prolia sales for the three months ended September 30, 2024 was driven by volume growth of 9%, 33partially offset by lower inventory.The increase in global Prolia sales for the nine months ended September 30, 2024 was driven by volume growth.As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1. Businessâ€”Marketing, Distribution and Selected Marketed Productsâ€”Patents, our U.S. patent for RANKL antibodies (including sequences) for Prolia and XGEVA expires in February 2025. For information about our settlement with Sandoz Inc., see Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended MarchÂ 31, 2024.For a discussion of litigation related to Prolia, see Part IVâ€”Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024 and September 30, 2024.ENBRELTotal ENBREL sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeENBREL â€” U.S.$817Â $1,026Â (20)%$2,280Â $2,645Â (14)%ENBREL â€” Canada8Â 9Â (11)%21Â 37Â (43)%Total ENBREL$825Â $1,035Â (20)%$2,301Â $2,682Â (14)%The decrease in ENBREL sales for the three months ended September 30, 2024 was primarily driven by unfavorable changes to estimated sales deductions of 13% and lower net selling price of 12%.The decrease in ENBREL sales for the nine months ended September 30, 2024 was driven by lower net selling price. Going forward, we expect relatively flat volumes with continued declines in net selling price, including the impact from the IRA Medicare Part D price set by CMS beginning in 2026.XGEVATotal XGEVA sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeXGEVAÂ â€”Â U.S.$373Â $374Â 0Â %$1,138Â $1,145Â (1)%XGEVAÂ â€”Â ROW168Â 145Â 16Â %526Â 440Â 20Â %Total XGEVA$541Â $519Â 4Â %$1,664Â $1,585Â 5Â %The increase in global XGEVA sales for the three and nine months ended September 30, 2024 was driven by higher net selling price.As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1. Businessâ€”Marketing, Distribution and Selected Marketed Productsâ€”Patents, our U.S. patent for RANKL antibodies (including sequences) for Prolia and XGEVA expires in February 2025. For information about our settlement with Sandoz Inc., see Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Report on Form 10-Q for the period ended March 31, 2024.For a discussion of litigation related to XGEVA, see Part IVâ€”Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024 and September 30, 2024.34RepathaTotal Repatha sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeRepatha â€” U.S.$281Â $183Â 54Â %$824Â $592Â 39Â %Repatha â€” ROW286Â 223Â 28Â %792Â 626Â 27Â %Total Repatha$567Â $406Â 40Â %1,616Â $1,218Â 33Â %The increase in global Repatha sales for the three months ended September 30, 2024 was driven by volume growth of 41% and favorable changes to estimated sales deductions of 8%, partially offset by lower net selling price of 10%. The increase in global Repatha sales for the nine months ended September 30, 2024 was driven by volume growth of 44%, partially offset by lower net selling price of 13%.For a discussion of ongoing litigation related to Repatha, see Part IVâ€”Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023, and Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024 and September 30, 2024.Otezla Total Otezla sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeOtezlaÂ â€”Â U.S.$460Â $462Â 0Â %$1,185Â $1,251Â (5)%OtezlaÂ â€”Â ROW104Â 105Â (1)%317Â 308Â 3Â %Total Otezla$564Â $567Â (1)%$1,502Â $1,559Â (4)%The decrease in global Otezla sales for the three months ended September 30, 2024 was primarily driven by lower net selling price of 7%, partially offset by volume growth of 5%.The decrease in global Otezla sales for the nine months ended September 30, 2024 was driven by lower net selling price of 8%, partially offset by higher inventory of 3% and volume growth of 2%.TEPEZZATotal TEPEZZA sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeTEPEZZAÂ â€”Â U.S.$482Â $â€”Â N/A$1,379Â $â€”Â N/ATEPEZZAÂ â€”Â ROW6Â â€”Â N/A12Â â€”Â N/ATotal TEPEZZA$488Â $â€”Â N/A$1,391Â $â€”Â N/AN/A = not applicableTEPEZZA was acquired on October 6, 2023 from our Horizon acquisition and generated $488 million and $1.4 billion in product sales for the three and nine months ended September 30, 2024, respectively. As TEPEZZA was acquired on October 6, 2023, there were no recorded product sales for the comparative prior periods.35EVENITYTotal EVENITY sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeEVENITYÂ â€”Â U.S.$289Â $214Â 35Â %$806Â $570Â 41Â %EVENITYÂ â€” ROW110Â 93Â 18Â %326Â 272Â 20Â %Total EVENITY$399Â $307Â 30Â %$1,132Â $842Â 34Â %The increase in global EVENITY sales for the three and nine months ended September 30, 2024 was driven by volume growth.KYPROLISTotal KYPROLIS sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeKYPROLIS â€” U.S.$238Â $231Â 3Â %$712Â $699Â 2Â %KYPROLIS â€” ROW140Â 118Â 19Â %419Â 354Â 18Â %Total KYPROLIS$378Â $349Â 8Â %$1,131Â $1,053Â 7Â %The increase in global KYPROLIS sales for the three and nine months ended September 30, 2024 was primarily driven by volume growth outside the United States.NplateTotal Nplate sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeNplateÂ â€”Â U.S.$345Â $322Â 7Â %$749Â $744Â 1Â %NplateÂ â€” ROW111Â 97Â 14Â %370Â 347Â 7Â %Total Nplate$456Â $419Â 9Â %$1,119Â $1,091Â 3Â %Global Nplate sales for the three months ended September 30, 2024 increased 9% and included U.S. government orders of $128Â million and $142Â million for the three months ended September 30, 2024 and 2023, respectively. Excluding the U.S. government orders from this comparison, global Nplate sales increased 18% for the three months ended September 30, 2024, driven by volume growth of 14% and higher net selling price.Global Nplate sales for the nine months ended September 30, 2024 increased 3% and included U.S. government orders of $128Â million and $224Â million for the nine months ended September 30, 2024 and 2023, respectively. Excluding the U.S. government orders from this comparison, global Nplate sales increased 14% for the nine months ended September 30, 2024, driven by volume growth of 9% and higher net selling price.36AranespTotal Aranesp sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeAranesp â€” U.S.$105Â $107Â (2)%$296Â $345Â (14)%Aranesp â€” ROW232Â 216Â 7Â %738Â 698Â 6Â %Total Aranesp$337Â $323Â 4Â %$1,034Â $1,043Â (1)%The increase in global Aranesp sales for the three months ended September 30, 2024 was driven by volume growth outside the United States.The decrease in global Aranesp sales for the nine months ended September 30, 2024 was driven by unfavorable changes to estimated sales deductions and unfavorable changes to foreign currency exchange rates, partially offset by volume growth outside the United States.KRYSTEXXATotal KRYSTEXXA sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeKRYSTEXXAÂ â€”Â U.S.$310Â $â€”Â N/A$839Â $â€”Â N/AKRYSTEXXAÂ â€” ROWâ€”Â â€”Â N/Aâ€”Â â€”Â N/ATotal KRYSTEXXA$310Â $â€”Â N/A$839Â $â€”Â N/AN/A = not applicableKRYSTEXXA was acquired on OctoberÂ 6, 2023 from our Horizon acquisition and generated $310 million and $839 million in product sales for the three and nine months ended September 30, 2024, respectively. As KRYSTEXXA was acquired on October 6, 2023, there were no recorded product sales for the comparative prior periods.BLINCYTOTotal BLINCYTO sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeBLINCYTOÂ â€”Â U.S.$237Â $147Â 61Â %$555Â $418Â 33Â %BLINCYTOÂ â€” ROW90Â 73Â 23Â %280Â 202Â 39Â %Total BLINCYTO$327Â $220Â 49Â %$835Â $620Â 35Â %The increase in global BLINCYTO sales for the three and nine months ended September 30, 2024 was primarily driven by volume growth.37VectibixTotal Vectibix sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeVectibixÂ â€”Â U.S.$132Â $116Â 14Â %$385Â $345Â 12Â %VectibixÂ â€” ROW150Â 136Â 10Â %414Â 388Â 7Â %Total Vectibix$282Â $252Â 12Â %$799Â $733Â 9Â %The increase in global Vectibix sales for the three and nine months ended September 30, 2024 was primarily driven by volume growth.TEZSPIRETotal TEZSPIRE sales by geographic region were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeTEZSPIREÂ â€”Â U.S.$269Â $161Â 67Â %$676Â $390Â 73Â %The increase in TEZSPIRE sales for the three and nine months ended September 30, 2024 was primarily driven by volume growth.38Other productsOther product sales by geographic region were as follows (dollar amounts in millions):Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeMVASI â€” U.S.$136Â $140Â (3)%$341Â $384Â (11)%MVASI â€” ROW59Â 73Â (19)%213Â 228Â (7)%AMJEVITA â€” U.S.28Â 23Â 22Â %49Â 93Â (47)%AMGEVITA â€” ROW138Â 129Â 7Â %418Â 373Â 12Â %Neulasta â€” U.S.84Â 92Â (9)%246Â 502Â (51)%Neulasta â€” ROW26Â 32Â (19)%87Â 107Â (19)%RAVICTI â€” U.S.(1)98Â â€”Â N/A286Â â€”Â N/ARAVICTI â€” ROW(1)9Â â€”Â N/A12Â â€”Â N/AParsabiv â€” U.S.32Â 59Â (46)%164Â 171Â (4)%Parsabiv â€” ROW38Â 36Â 6Â %117Â 102Â 15Â %UPLIZNA â€” U.S.(1)74Â â€”Â N/A221Â â€”Â N/AUPLIZNA â€” ROW(1)32Â â€”Â N/A57Â â€”Â N/ALUMAKRAS â€” U.S.53Â 48Â 10Â %161Â 146Â 10Â %LUMYKRAS â€” ROW45Â 4Â *104Â 57Â 82Â %Aimovig â€” U.S.77Â 88Â (13)%222Â 230Â (3)%Aimovig â€” ROW5Â 6Â (17)%15Â 15Â â€”Â %TAVNEOS â€” U.S.74Â 32Â *180Â 84Â *TAVNEOS â€” ROW6Â 5Â 20Â %22Â 6Â *PROCYSBI â€” U.S.(1)57Â â€”Â N/A160Â â€”Â N/APROCYSBI â€” ROW(1)1Â â€”Â N/A6Â â€”Â N/AEPOGEN â€” U.S.33Â 50Â (34)%106Â 171Â (38)%IMDELLTRA â€” U.S.36Â â€”Â N/A48Â â€”Â N/AOther â€” U.S.(2)176Â 143Â 23Â %674Â 490Â 38Â %Other â€” ROW(2)46Â 44Â 5Â %153Â 161Â (5)%Total other products$1,363Â $1,004Â 36Â %$4,062Â $3,320Â 22Â %Total U.S. â€” other products$958Â $675Â 42Â %$2,858Â $2,271Â 26Â %Total ROW â€” other products405Â 329Â 23Â %1,204Â 1,049Â 15Â %Total other products$1,363Â $1,004Â 36Â %$4,062Â $3,320Â 22Â %N/A = not applicable* Change in excess of 100%_____(1)Â Â Â Â Â RAVICTI, UPLIZNA and PROCYSBI were acquired from our Horizon acquisition on October 6, 2023, and include product sales in the periods after the acquisition date.(2)Â Â Â Â Â Consists of product sales from (i) KANJINTI, RIABNI, Corlanor, AVSOLA, NEUPOGEN, IMLYGIC, BEKEMV, WEZLANA/WEZENLA and Sensipar/Mimpara; and (ii) ACTIMMUNE, RAYOS, BUPHENYL, QUINSAIR, PENNSAID and DUEXIS in the periods after our Horizon acquisition on OctoberÂ 6, 2023.39Operating expensesOperating expenses were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Change20242023ChangeOperating expenses:Cost of sales$3,310Â $1,806Â 83Â %$9,746Â $5,339Â 83Â %% of product sales40.6Â %27.6Â %41.8Â %28.0Â %% of total revenues38.9Â %26.2Â %40.0Â %26.7Â %Research and development$1,450Â $1,079Â 34Â %$4,240Â $3,250Â 30Â %% of product sales17.8Â %16.5Â %18.2Â %17.0Â %% of total revenues17.1Â %15.6Â %17.4Â %16.3Â %Selling, general and

administrative$1,625Â $1,353Â 20Â %$5,218Â $3,905Â 34Â %% of product sales19.9Â %20.7Â %22.4Â %20.5Â %% of total revenues19.1Â %19.6Â %21.4Â %19.5Â %Other$71Â $644Â (89)%$187Â $874Â (79)%Total operating expenses$6,456Â $4,882Â 32Â %$19,391Â $13,368Â 45Â %Cost of salesCost of sales increased to 38.9% and 40.0% of total revenues for the three and nine months ended September 30, 2024, respectively, driven by higher amortization expense from Horizon acquisition-related assets and, to a lesser extent, higher royalty and profit share expense. The increase for the nine months ended September 30, 2024 was partially offset by the prior year impact of the 2022 Puerto Rico tax law change, which replaced an excise tax with an income tax beginning in 2023. See Note 4, Income taxes, to the condensed consolidated financial statements.Research and developmentThe increase in R&D expense for the three and nine months ended September 30, 2024, was driven by higher spend in later-stage clinical programs, marketed product support and research and early pipeline, including Horizon-acquired programs. We expect to continue to grow our spend on later-stage clinical programs as we advance our pipeline.Selling, general and administrativeThe increase in SG&A expense for the three months ended September 30, 2024, was primarily driven by commercial expenses related to Horizon-acquired products.The increase in SG&A expense for the nine months ended September 30, 2024, was driven by expenses from the acquired Horizon business and other commercial expenses.OtherOther operating expenses for the three and nine months ended September 30, 2024, consisted primarily of impairment charges associated with IPR&D assets and changes in the fair values of contingent consideration liabilities, both related to our Teneobio, Inc. acquisition from 2021.Other operating expenses for the three and nine months ended September 30, 2023, consisted of a net impairment charge resulting from the termination of AMG 340 and expenses related to our restructuring plan initiated in the first quarter of 2023.40Nonoperating expense/income and income taxesNonoperating expense/income and income taxes were as follows (dollar amounts in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023202420Interest expense, net(776)(759)$(2,408)$(2,054)Other income, net$1,830Â $685Â $1,288Â $2,431Â Provision for income taxes$271Â $217Â $364Â $1,053Â Effective tax rate8.7Â %11.1Â %9.5Â %15.0Â %Interest expense, netInterest expense, net, remained relatively unchanged for the three months ended September 30, 2024. The increase in Interest expense, net, for the nine months ended September 30, 2024, was primarily due to higher average debt outstanding and higher weighted-average fixed and floating interest rates on the debt. Other income, netThe increase in Other income, net, for the three months ended September 30, 2024, was primarily due to higher unrealized gains on our strategic equity investments, primarily BeiGene, partially offset by reduced interest income as a result of lower average cash balances.The decrease in Other income, net, for the nine months ended September 30, 2024, was primarily due to lower current year net unrealized gains on our strategic equity investments, primarily BeiGene, and reduced interest income as a result of lower average cash balances. Prior period net gains on our strategic equity investments were principally composed of amounts recognized on our BeiGene investment in the first quarter of 2023 as a result of a change from the equity method of accounting to recording this investment at fair value with changes in fair value recognized in earnings. See Note 6, Investments, to the condensed consolidated financial statements.Income taxesThe decrease in our effective tax rate for the three months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets), partially offset by the quarter-to-date unrealized gains on our strategic equity investments (primarily BeiGene). See Note 6, Investmentsâ€”BeiGene, Ltd., to the condensed consolidated financial statements. The decrease in our effective tax rate for the nine months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets).As previously reported, the OECD reached an agreement to align countries on a minimum corporate tax rate and an expansion of the taxing rights of market countries. Effective January 1, 2024, selected individual countries, including the United Kingdom and EU member countries, have enacted the global minimum tax agreement. Our legal entities in the countries that have enacted the agreement, along with their direct and indirect subsidiaries, are now subject to a 15% minimum tax rate on adjusted financial statement income. Other countries, including the United States and the U.S. territory of Puerto Rico, have not yet enacted the OECD agreement, and implementation remains highly uncertain. The continued enactment of the agreement, either by all OECD participants or unilaterally by individual countries, could result in tax increases or double taxation in the United States or foreign jurisdictions.As of January 1, 2023, we are no longer subject to a 4% excise tax in the U.S. territory of Puerto Rico on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We qualify for and are subject to the alternative income tax rate on industrial development income of our Puerto Rico affiliate. In the United States, this income tax qualifies for foreign tax credits under the U.S. Treasury final foreign tax credit regulations. See Note 4, Income taxes, to the condensed consolidated financial statements.41In 2017, we received an RAR and a modified RAR from the IRS for the years 2010â€“2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010â€“2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010â€“2012 by an amount that would result in additional federal tax of approximately $3.6Â billion, plus interest. Any additional tax that could be imposed for the years 2010â€“2012 would be reduced by up to approximately $900Â million of repatriation tax previously accrued on our foreign earnings.In 2020, we received an RAR and a modified RAR from the IRS for the years 2013â€“2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010â€“2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013â€“2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013â€“2015 by an amount that would result in additional federal tax of approximately $5.1Â billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0Â billion. Any additional tax that could be imposed for the years 2013â€“2015 would be reduced by up to approximately $2.2Â billion of repatriation tax previously accrued on our foreign earnings.We firmly believe that the IRS positions set forth in the 2010â€“2012 and 2013â€“2015 Notices are without merit. We are contesting the 2010â€“2012 and 2013â€“2015 Notices through the judicial process. The two cases were consolidated in the U.S. Tax Court on December 19, 2022. The trial is currently scheduled to begin on November 4, 2024.We are currently under examination by the IRS for the years 2016â€“2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.See our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1A, Risk Factorsâ€”We could be subject to additional tax liabilities, including from an adverse outcome in our ongoing tax dispute with the IRS and other tax examinations, enactment of the OECD minimum corporate tax rate agreement and the adoption and interpretation of new tax legislation, and we anticipate additional tax liabilities from certain provisions of the 2017 Tax Act that will go into effect in 2026; such tax liabilities could adversely affect our profitability and results of operations, and Note 4, Income taxes, to the condensed consolidated financial statements in this filing for further discussion.Financial condition, liquidity and capital resourcesSelected financial data were as follows (in millions):September 30, 2024December 31, 2023Cash and cash equivalents$9,011Â $10,944Â Total assets$90,883Â $97,154Â Current portion of long-term debt$3,544Â $1,443Â Long-term debt$56,854Â $63,170Â Stockholdersâ€™ equity$7,527Â $6,232Â Cash and cash equivalentsOur balance of cash and cash equivalents was $9.0 billion as of September 30, 2024. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.42Capital allocationConsistent with the objective to optimize our capital structure, we deploy our accumulated cash balances in a strategic manner and consider a number of alternatives, including investments in innovation both internally and externally (including investments that expand our portfolio of products in areas of therapeutic interest), capital expenditures, repayment of debt, payment of dividends and stock repurchases.We intend to continue investing in our business while reducing our debt and returning capital to stockholders through the payment of cash dividends and stock repurchases. This reflects our desire to optimize our cost of capital and our confidence in the future cash flows of our business. The timing and amount of future dividends and stock repurchases will vary based on a number of factors, including future capital requirements for strategic transactions, debt levels and debt service requirements, our credit rating, availability of financing on acceptable terms, changes to applicable tax laws or corporate laws, changes to our business model and periodic determination by our Board of Directors that cash dividends and/or stock repurchases are in the best interests of stockholders and are in compliance with applicable laws and the Companyâ€™s agreements. In addition, the timing and amount of stock repurchases may also be affected by our overall level of cash, stock price and blackout periods, during which we are restricted from repurchasing stock. The manner of stock repurchases may include block purchases, tender offers, accelerated share repurchases and market transactions.In August 2024, March 2024 and December 2023, our Board of Directors declared quarterly cash dividends of $2.25 per share of common stock, which were paid in September 2024, June 2024 and March 2024, respectively, and was an increase of 6% over the quarterly cash dividends paid each quarter in 2023. In October 2024, our Board of Directors declared a quarterly cash dividend of $2.25 per share of common stock that will be paid in December 2024.During the nine months ended September 30, 2024, we did not repurchase any of our common stock under our stock repurchase program. As of September 30, 2024, $7.0 billion of authorization remained available under our stock repurchase program.As a result of stock repurchases and quarterly dividend payments, we have an accumulated deficit as of September 30, 2024 and December 31, 2023. Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our strong financial position.During the nine months ended September 30, 2024 and 2023, debt repayments totaled $3.6Â billion and $1.5Â billion, respectively. In addition, we opportunistically repurchase our debt when market conditions are favorable. During the nine months ended September 30, 2024 and 2023, we paid $659Â million and $550Â million, respectively, to extinguish principal amounts of debt of $875Â million and $739Â million, respectively.We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, as well as our plans to reduce debt, pay dividends and repurchase stock, and other business initiatives we plan to strategically pursue, including acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a variety of sources, including cash provided by operating activities, sales of marketable securities, borrowings through commercial paper and/or syndicated credit facilities and access to other domestic and foreign debt markets and equity markets. See our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1A. Risk Factorsâ€”Global economic conditions may negatively affect us and may magnify certain risks that affect our business.Certain of our financing arrangements contain nonfinancial covenants. In addition, our revolving credit agreement and term loan credit agreement include a financial covenant that requires us to maintain a specified minimum interest coverage ratio of (i) the sum of consolidated net income, interest expense, provision for income taxes, depreciation expense, amortization expense, unusual or nonrecurring charges and other noncash items (consolidated earnings before interest, taxes, depreciation and amortization) to (ii) Consolidated Interest Expense, each as defined and described in the respective agreements. We were in compliance with all applicable covenants under these arrangements as of September 30, 2024.43Cash flowsOur summarized cash flow activity was as follows (in millions):Â Nine months endedSeptember 30,Â 20242023Net cash provided by operating activities$6,719Â $7,933Â Net cash (used in) provided by investing activities(644)885Â Net cash (used in) provided by financing activities$(8,008)$18,294Â OperatingCash provided by operating activities has been and is expected to continue to be our primary recurring source of funds. Cash provided by operating activities during the nine months ended September 30, 2024, decreased compared with the prior year period due to the timing of repatriation and income tax payments to the IRS, partially offset byÂ higher net income after adjustments for noncash items and timing of working capital.InvestingCash used in investing activities during the nine months ended September 30, 2024, was primarily due to capital expenditures of $725 million, including construction costs of new plants in North Carolina and Ohio. Cash provided by investing activities during the nine months ended September 30, 2023, was primarily due to net cash inflows from sales and maturities of marketable securities of $1.7Â billion, partially offset by capital expenditures of $863Â million, including construction costs of new plants in North Carolina and Ohio. We currently estimate full year 2024 spending on capital projects to be approximately $1.3Â billion.FinancingCash used in financing activities during the nine months ended September 30, 2024, was primarily due to the payment of dividends of $3.6 billion and the repayment and extinguishment of debt of $3.6 billion and $659Â million, respectively. Cash provided by financing activities during the nine months ended SeptemberÂ 30, 2023, was primarily due to proceeds from the issuance of debt of $23.8Â billion, partially offset by the payment of dividends of $3.4Â billion, as well as the repayment and extinguishment of debt of $1.5 billion and $550Â million, respectively. See Note 9, Financing arrangements, and Note 10, Stockholdersâ€™ equity, to the condensed consolidated financial statements for further discussion.Critical Accounting Policies and EstimatesThe preparation of our condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes to the financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions. A summary of our critical accounting policies and estimates is presented in Part II, ItemÂ 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2023.ItemÂ 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKInformation about our market risk is disclosed in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2023, and is incorporated herein by reference. There were no material changes during the nine months ended September 30, 2024, to the information provided in Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2023.44ItemÂ 4.CONTROLS AND PROCEDURESWe maintain â€œdisclosure controls and procedures,â€ as such term is defined under the Securities Exchange Act Rule 13a-15(e) that are designed to ensure that information required to be disclosed in Amgenâ€™s Exchange Act reports gets recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms and that such information gets accumulated and communicated to Amgenâ€™s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to facilitate timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, Amgenâ€™s management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, Amgenâ€™s management necessarily was required to apply its judgment in evaluating the costâ€“benefit relationship of possible controls and procedures. We carried out an evaluation under the supervision and with the participation of our management, including Amgenâ€™s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of Amgenâ€™s disclosure controls and procedures. Based on their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024.Management determined that as of September 30, 2024, no changes in our internal control over financial reporting had occurred during the fiscal quarter then ended that materially affected or are reasonably likely to materially affect our internal control over financial reporting.45PART II â€“ OTHER INFORMATIONItemÂ 1.LEGAL PROCEEDINGSSee Part Iâ€“Note 13, Contingencies and commitments, to the condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024, June 30, 2024 and September 30, 2024, for discussions that are limited to certain recent developments concerning our legal proceedings. Those discussions should be read in conjunction with Part IVâ€“Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023.ItemÂ 1A.RISK FACTORS This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our managementâ€™s assumptions. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties our business faces. The risks described below are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employment relations, general economic conditions, geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. Below we provide in supplemental form the material changes to our risk factors that occurred during the past quarter. Our risk factors

disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2023, provide additional disclosure for these supplemental risks and are incorporated herein by reference.Our sales depend on coverage and reimbursement from government and commercial third-party payers, and pricing and reimbursement pressures have affected, and are likely to continue to affect, our profitability.Sales of our products depend on the availability and extent of coverage and reimbursement from third-party payers, including government healthcare programs and private insurance plans. Governments and private payers continue to pursue initiatives to manage drug utilization and contain costs. Further, pressures on healthcare budgets from the economic downturn and inflation continue and are likely to increase across the markets we serve. Payers are increasingly focused on costs, which have resulted, and are expected to continue to result, in lower reimbursement rates for our products or narrower populations for which payers will reimburse. Continued intense public scrutiny of the price of drugs and other healthcare costs, together with payer dynamics, have limited, and are likely to continue to limit, our ability to set or adjust the price of our products based on their value, which can have a material adverse effect on our business. In the United States, particularly over the past few years, a number of legislative and regulatory proposals have been introduced and/or signed into law that attempt to lower drug prices. These include the IRA law that enables the U.S. government to set prices for certain drugs in Medicare, redesigns Medicare Part D benefits to shift a greater portion of the costs to manufacturers and enables the U.S. government to impose penalties if drug prices are increased at a rate faster than inflation (IRA Inflation Penalties). Additional proposals focused on drug pricing continue to be debated, and additional executive orders or regulatory initiatives focused on drug pricing and competition are likely to be adopted and implemented in some form. In March 2024, the Administration released its budget plan for fiscal year 2025 that included proposals to expand the IRAâ€™s drug price setting to more drugs and sooner after launch and making IRA Inflation Penalties applicable to commercial health insurance. Government actions or ballot initiatives at the state level also represent a highly active area of policymaking and experimentation, including proposals that limit drug reimbursement under state run Medicaid programs based on decisions of drug affordability boards, use of reference prices, or permitting importation of drugs from Canada. Such state policies may also eventually be adopted at the federal level.We are unable to predict which or how many policy, regulatory, administrative or legislative changes may ultimately be, or effectively estimate the consequences to our business if, enacted and implemented. However, to the extent that payer actions further decrease or modify the coverage or reimbursement available for our products, require that we pay increased rebates or shift other costs to us, limit or affect our decisions regarding the pricing of or otherwise reduce the use of our products, such actions could have a material adverse effect on our business and results of operations.46â€”Changing U.S. federal coverage and reimbursement policies and practices have affected and are likely to continue to affect access to, pricing of and sales of our productsA substantial portion of our U.S. business relies on reimbursement from federal government healthcare programs and commercial insurance plans regulated by federal and state governments. See Part I, Item 1. Businessâ€”Reimbursement, of our Annual Report on Form 10-K for the year ended December 31, 2023. Our business has been and will continue to be affected by legislative actions changing U.S. federal reimbursement policy. For example, in 2022, the IRA was enacted and includes provisions requiring that beginning in 2026, mandatory price setting be introduced in Medicare for certain drugs paid for under Parts B and D, whereby manufacturers must accept a price established by the government or face penalties on all U.S. sales (starting with 10 drugs in 2026, adding 15 in 2027 and 2028, and adding 20 in 2029 and subsequent years such that by 2031 approximately 100 drugs could be subject to such set prices). The Medicare price setting process began in August 2023 when CMS announced the first 10 drugs for Medicare price setting, which includes ENBREL, currently a product that generates considerable revenue. Effective July 30, 2024, CMS set a price for ENBREL in Medicare Part D, applicable beginning on January 1, 2026, which we expect will negatively impact its profitability. See Part I, Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€”Results of operationsâ€”Product salesâ€”ENBREL. Depending on the growth and success of our medicines, other of our medicines may also be subject to selection by CMS in the next, or in a future, cycle of mandatory Medicare price setting. If other of our medicines are selected by CMS for mandatory Medicare price setting, we may be required to accept a price set by the government for Medicare similar to the process that was applied to ENBREL. Also under the IRA, starting on January 1, 2024, Medicare Part D was redesigned to cap beneficiary out-of-pocket costs and, beginning January 1, 2025, Federal reinsurance will be reduced in the catastrophic phase (resulting in a shift and increase of such costs to Part D plans and manufacturers, including by requiring manufacturer discounts on certain drugs). Further, the IRA created a mechanism for CMS to collect rebates from manufacturers if price increases outpace inflation. Rebate obligations began to accrue October 1, 2022 for Medicare Part D and January 1, 2023 for Medicare Part B, but CMS has not yet issued invoices and has some discretion as to when to issue such invoices to manufacturers. We expect that several of our products will be subject to these inflation rebates, and several of our products have been on lists that are issued and updated on a quarterly basis by CMS under a related program under which Medicare beneficiaries are charged reduced coinsurance if price increases exceed inflation. The IRAâ€™s drug pricing controls and Medicare redesign are likely to have a material adverse effect on our sales, our business and our results of operations, and such impact is expected to increase through the end of the decade and will depend on factors including the extent of our portfolioâ€™s exposure to Medicare reimbursement, the rate of inflation over time, the number of our products selected for mandatory price setting and the timing of market entry of generic or biosimilar competition. Further, following the passage of the IRA, the environment remains dynamic and U.S. policymakers continue to demonstrate interest in health care and drug pricing changes. For example, in April 2024, CMS finalized policy changes that will give Part D plans more flexibility to substitute biosimilars for reference products on formularies in 2025. In early 2023, the HHS selected new healthcare payment and delivery models for testing, in response to an October 2022 Executive Order on Lowering Prescription Drug Costs for Americans, including the Accelerating Clinical Evidence Model, which could introduce new payment methods that reduce reimbursement for drugs approved under accelerated approval. That Executive Order followed a 2021 Executive Order designed to increase competition in the healthcare sector, including by calling for the FDA to work with states that seek to develop prescription drug importation programs and the FTC to apply greater scrutiny of anticompetitive activity and responses to which include actions from the HHS (which released a report with drug pricing proposals that seek to promote competition) and from the U.S. Patent and Trademark Office (which has taken steps to strengthen coordination with the FDA to address perceived impediments to generic drug and biosimilar competition). Other CMS policy changes and demonstration projects to test new care, delivery and payment models can also significantly affect how drugs, including our products, are covered and reimbursed. In the fourth quarter of 2021, HHS released a plan to address drug pricing that included potential future mandatory models that link payment for prescription drugs and biologics to certain factors, including the overall cost of care. In March 2024, the Administration released its budget plan for fiscal year 2025 that included proposals to expand the number of drugs subject to mandatory Medicare price setting under the IRA, imposing such price setting activity earlier, and extending to commercial health insurance the requirement that drug manufacturers pay rebates if price increases outpace inflation. While those proposed expansions of the IRAâ€™s drug pricing controls have not been enacted, the proposals demonstrate that this area continues to be a focus of the Administration.We also face risks related to the reporting of pricing data that affects reimbursement of and discounts provided for our products. U.S. government price reporting regulations are complex and may require biopharmaceutical manufacturers to update certain previously submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other government enforcement actions, which could have a material adverse effect on our business and results of operations. In addition, as a result of restating previously reported price data, we may be required to pay additional rebates and provide additional discounts.47â€”Changing reimbursement and pricing actions in various states have negatively affected and may continue to negatively affect access to, and have affected and may continue to affect sales of, our productsAt the state level, legislation, government actions, and ballot initiatives can also affect how our products are covered and reimbursed and/or create additional pressure on our pricing decisions. Existing and proposed state pricing laws have added complexity to the pricing of drugs and may already be affecting industry pricing decisions. A number of states have adopted, and many other states are considering, PDABs, drug importation programs, reference pricing schemes, and other pricing actions, including proposals designed to require biopharmaceutical manufacturers to report to the state proprietary pricing information or provide advance notice of certain price increases.States are also enacting laws referencing the IRA and seeking to regulate the 340B Drug Pricing Program. For example, following the passage of the IRA, bills have been proposed in multiple states that would apply the drug price caps set by HHS for Medicare to drug prices in an individual state, and such references to IRA price caps have also been included in PDAB legislation. For Medicaid patients, states have established a Medicaid drug spending cap (New York) and implemented a new review and supplemental rebate negotiation process (Massachusetts). Eight states (Colorado, Maine, New Hampshire, New Jersey, Maryland, Minnesota, Oregon and Washington) have enacted laws that establish PDABs to identify drugs that pose affordability challenges, and four such states include authority for the state PDAB to set upper payment limits on certain drugs for in-state patients, payers and providers. In 2024, no fewer than 17 states introduced PDAB legislation. The eight states with enacted PDAB laws are in various phases of implementation, with Coloradoâ€™s PDAB being the furthest along. In August 2023, the Colorado PDAB announced the first five drugs to undergo an affordability review, three of which, including ENBREL, have since been deemed â€œunaffordableâ€ and will be subject to rulemaking to establish an Upper Payment Limit (UPL). For ENBREL, a UPL could be effective as soon as the third quarter of 2025. Further, Louisiana, Arkansas, West Virginia, Minnesota, Kansas, Mississippi, Missouri and Maryland have enacted laws with mandates on manufacturers participating in the 340B drug pricing program, and, thus far in 2024, no fewer than 25 states have considered similar legislation. These bills vary, but include provisions on restricting a manufacturerâ€™s ability to direct drugs in 340B channels, recognizing 340B contract pharmacies and a prohibition on requiring the inclusion of 340B claims modifiers. In March 2024, the U.S. Court of Appeals for the 8th Circuit ruled that Arkansasâ€™ Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute. The decision could increase the number of states that will consider similar legislation. In July 2024, the U.S. District Court for the Southern District of Mississippi denied motions for a preliminary injunction in two cases challenging a similar law in Mississippi, finding that neither plaintiff had demonstrated a substantial likelihood of success on the merits. These orders are being appealed at the U.S. Court of Appeals for the 5th Circuit. In September 2024, the U.S. District Court for the Western District of Louisiana dismissed a lawsuit challenging Louisianaâ€™s 340B contract pharmacy mandate law, and the U.S. District Court for the District of Maryland denied a motion for preliminary injunction challenging a similar law in Maryland. These lawsuits challenging states on their 340B contract pharmacy laws are subsequent to Genesis Health Care, Inc. v. Becerra, where the U.S. District Court for the District of South Carolina issued an order in November 2023 that enjoins the Health Resources and Services Administration from enforcing its more restrictive interpretation of what is considered a patient under the 340B program, to the potential benefit of healthcare systems seeking to expand the application of 340B discounts.Additionally, on January 5, 2024, the FDA authorized Florida to move forward with its importation program proposal. Colorado, Maine, New Hampshire, New Mexico, Texas and Vermont have also enacted state importation laws, and some have submitted plans for approval to the FDA. Other states could adopt similar approaches or could pursue different policy changes in a continuing effort to reduce their costs.Ultimately, as with U.S. federal government actions, existing or future state government actions or ballot initiatives may also have a material adverse effect on our product sales, business and results of operations.â€”U.S. commercial payer actions have affected and may continue to affect access to and sales of our products Payers, including healthcare insurers, PBMs, integrated healthcare delivery systems (vertically-integrated organizations built from consolidations of healthcare insurers and PBMs) and group purchasing organizations, increasingly seek ways to reduce their costs. With increasing frequency, payers are adopting benefit plan changes that shift a greater proportion of drug costs to patients. Such measures include more limited benefit plan designs, high deductible plans, higher patient co-pay or coinsurance obligations and more significant limitations on patientsâ€™ use of manufacturer commercial co-pay assistance programs. Further, government regulation of payers may affect these trends. For example, CMS finalized a policy for plan years starting on or after January 1, 2021 that has caused commercial payers to more widely adopt co-pay accumulator adjustment programs. While the U.S. District Court for the District of Columbia struck down this policy in September 2023 and further clarified in December 2023 that its ruling had the effect of reinstating the co-pay accumulator adjustment policy from 2020, CMS and HHS have signaled that they do not intend to enforce certain restrictions from the 2020 policy that would reduce the adoption of co-pay accumulator adjustment programs, and CMS has indicated that the issue will be addressed in future rulemaking. Payers, including PBMs, have sought, and continue to seek, price discounts or rebates in connection with the 48placement of our products on their formularies or those they manage, and to also impose restrictions on access to or usage of our products (such as Step Therapy), require that patients receive the payerâ€™s prior authorization before covering the product, and/or chosen to exclude certain indications for which our products are approved. For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit and may continue to limit patient access to Repatha treatment. In an effort to reduce barriers to access, we reduced the net price of Repatha by providing greater discounts and rebates to payers (including PBMs that administer Medicare Part D prescription drug plans), and in response to a very high percentage of Medicare patients abandoning their Repatha prescriptions rather than paying their co-pay, we introduced a set of new National Drug Codes to make Repatha available at a lower list price. However, affordability of patient out-of-pocket co-pay cost has limited and may continue to limit patient use. Further, despite these net and list price reductions, some payers have restricted, and may continue to restrict, patient access and may seek further discounts or rebates or take other actions, such as changing formulary coverage for Repatha, that could reduce our sales of Repatha. These factors have limited, and may continue to limit, patient affordability and use, negatively affecting Repatha sales.Further, significant consolidation in the health insurance industry has resulted in a few large insurers and PBMs, which places greater pressure on pricing and usage negotiations with biopharmaceutical manufacturers, significantly increasing discount and rebate requirements and limiting patient access and usage. For example, in the United States, as of the beginning of 2024, the top five integrated health plans and PBMs controlled about 92% of all pharmacy prescriptions. This high degree of consolidation among insurers, PBMs and other payers, including integrated healthcare delivery systems and/or with specialty or mail-order pharmacies and pharmacy retailers, has increased the negotiating leverage such entities have over us and other biopharmaceutical manufacturers and has resulted in greater price discounts, rebates and service fees realized by those payers from our business. Each of CVS, Express Scripts and United Health Group (among the top five integrated health plans and PBMs) have Rebate Management Organizations that further increase their leverage to negotiate deeper discounts. Ultimately, additional discounts, rebates, fees, coverage changes, plan changes, restrictions or exclusions imposed by these commercial payers could have a material adverse effect on our product sales, business and results of operations. Policy reforms advanced by Congress or the Administration that refine the role of PBMs in the U.S. marketplace could have downstream implications or consequences for our business and how we interact with these entities. For example, in June 2022, the FTC launched an inquiry into the business practices of PBMs and subsequently expanded the investigation to the three rebate management organizations owned by the three largest PBMs, and in September 2024, the FTC brought action against the three largest PBMs alleging anticompetitive and unfair rebating practices. In addition, multiple Congressional Committees are investigating PBM practices and have also proposed legislation that could increase transparency and reporting of these practices and/or impact rebates and service fees. The results of such inquiries could have an effect on manufacturer interactions with PBMs, resulting in changes to access for certain medicines. See our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1A. Risk Factorsâ€”Concentration of sales at certain of our wholesaler distributors, and consolidation of private payers, such as insurers, and PBMs has negatively affected, and may continue to negatively affect, our business.Our business is also affected by policies implemented by private healthcare entities that process Medicare claims, including Medicare Administrative Contractors. For example, in the second quarter of 2022, several Medicare Administrative Contractors issued notice that TEZSPIRE would be added to their â€œself-administered drugâ€ exclusion lists. Although the Medicare Administrative Contractors subsequently removed TEZSPIRE from their exclusion lists, these exclusions, if reintroduced and/or implemented, would result in Medicare beneficiaries with severe asthma losing access to TEZSPIRE coverage under Medicare Part B and potentially also under Medicare Advantage.â€”Government and commercial payer actions outside the United States have affected and will continue to affect access to and sales of our productsOutside the United States, we expect countries will also continue to take actions to reduce their drug expenditures and to reduce intellectual property protections. See Part I, Item 1. Businessâ€”Reimbursement, of our Annual Report on Form 10-K for the year ended December 31, 2023. Pressures to decrease drug expenditures may intensify as governments take actions to address budgets strained by high inflation, expenditures to respond to the COVID-19 pandemic and weak economic conditions, including in Europe where the effects of the Russiaâ€“Ukraine conflict have challenged the economies in that region. Further, the EU is currently undergoing a review and revision of its pharmaceutical legislation that, while full implementation is not expected before 2027, has led to proposals that would reduce intellectual property protection for new products (including potentially shortening the duration of regulatory data exclusivity and orphan drug exclusivity protections), as well as change the reimbursement and regulatory landscape. International reference pricing has been widely used by many countries outside the United States to control costs based on an external benchmark of a productâ€™s price in other countries. International

reference pricing policies can change quickly and frequently and may not reflect differences in the burden of disease, indications, market structures or affordability differences across countries or regions. Other expenditure control practices, including but not limited to the use of revenue clawbacks, rebates and caps on product sales, are used in various foreign jurisdictions as well. In addition, countries may refuse to reimburse or may restrict the reimbursed population for a product when their national health technology 49assessments do not consider a medicine to demonstrate sufficient clinical benefit beyond existing therapies or to meet certain cost effectiveness thresholds. For example, despite the EMAâ€™s approval of Repatha for the treatment of patients with established atherosclerotic disease, prior to 2020, the reimbursement of Repatha in France was limited to a narrower patient population (such as those with homozygous familial hypercholesterolemia (HoFH)) following a national health technology assessment. Many countries decide on reimbursement between potentially competing products through national or regional tenders that often result in one product receiving most or all of the sales in that country or region. Failure to obtain coverage and reimbursement for our products, a deterioration in their existing coverage and reimbursement or a decline in the timeliness or certainty of payment by payers to hospitals and other providers has negatively affected, and may further negatively affect, the ability or willingness of healthcare providers to prescribe our products for their patients and otherwise negatively affect the use of our products or the prices we realize for them. Such changes have had, and could in the future have, a material adverse effect on our product sales, business and results of operations.A breakdown of our information technology systems, cyberattack or information security breach could significantly compromise the confidentiality, integrity and availability of our information technology systems, network-connected control systems and/or our data, interrupt the operation of our business and/or affect our reputation.To achieve our business objectives, we rely on sophisticated information technology systems, including hardware, software, technology infrastructure, online sites and networks for both internal and external operations, mobile applications, cloud services and network-connected control systems, some of which are managed, hosted, provided or serviced by third parties. Internal or external events that compromise the confidentiality, integrity and availability of our systems and data may significantly interrupt the operation of our business, result in significant costs and/or adversely affect our reputation.Our information technology systems are highly integrated into our business, including our R&D efforts, our clinical and commercial manufacturing processes and our product sales and distribution processes. Further, as the majority of our employees work remotely for some portion of their jobs in our hybrid work environment, our reliance on our and third-party information technology systems has increased substantially and is expected to continue to increase. Remote and hybrid working arrangements, including those of many third-party providers, can increase cybersecurity risks due to the challenges associated with managing remote computing assets and security vulnerabilities that are present in many non-corporate and home networks. The complexity and interconnected nature of software, hardware and our systems make them vulnerable to breakdown or other service interruptions, and to software errors or defects, misconfiguration and other security vulnerabilities. For example, in July 2024, businesses worldwide were affected by an information technology outage due to a faulty software update issued by a cybersecurity firm. Although our systems and operations were temporarily affected by the outage, the impact of this firmâ€™s faulty update on the Company was immaterial to our business operations. However, there can be no assurance that a future similar incident would not result in a material adverse effect on our business or results of operations. Upgrades or changes to our systems or the software that we use have resulted and we expect, in the future, will result in the introduction of new cybersecurity vulnerabilities and risks. In 2022, we identified a number of security vulnerabilities introduced into our information systems as a result of flaws that we subsequently identified in software that we had purchased and installed, and these flaws required that we apply emergency patches to certain of our systems. While we did not experience any significant adverse effects as a result of these vulnerabilities, there can be no assurance that we will timely identify and address future vulnerabilities. Our systems are also subject to frequent perimeter network reconnaissance and scanning, phishing and other cyberattacks. For example, as a result of our cybersecurity monitoring of the Horizon legacy information systems, we detected phishing activity in the accounts of two Horizon executives. These accounts were de-activated, the incidents were investigated and the determination was made separately by both our internal cybersecurity team and our external digital forensics and incident response supplier that no confidential information had been exfiltrated. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect and increasingly sophisticated in using techniques and toolsâ€”including artificial intelligenceâ€”that circumvent security controls, evade detection and remove forensic evidence. Such attacks could include the use of harmful and virulent malware, including ransomware or other denials of service, which can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering/phishing.50We have also experienced denial of service attacks against our network, and, although such attacks did not succeed, there can be no assurance that our efforts to guard against the wide and growing variety of potential attack techniques will be successful in the future. Attacks such as those experienced by government entities (including those that approve and/or regulate our products, such as the EMA) and other multi-national companies, including some of our peers, could leave us unable to utilize key business systems or access or protect important data, and could have a material adverse effect on our ability to operate our business, including developing, gaining regulatory approval for, manufacturing, selling and/or distributing our products. For example, in 2017, a pharmaceutical company experienced a cyberattack involving virulent malware that significantly disrupted its operations, including its research and sales operations and the production of some of its medicines and vaccines. As a result of the cyberattack, its orders and sales for certain products were negatively affected. In late 2020, SolarWinds Corporation, a leading provider of software for monitoring and managing information technology infrastructure, disclosed that it had suffered a cybersecurity incident whereby attackers had inserted malicious code into legitimate software updates for its products that were installed by myriad private and government customers, enabling the attackers to access a backdoor to such systems. In 2022, Okta, Inc., a provider of software that helps companies manage user authentication, disclosed that several hundred of its corporate customers were vulnerable to a security breach that allowed attackers to access Oktaâ€™s internal network. Although this breach did not have a significant effect on our business, there can be no assurance that a similar future breach would not result in a material adverse effect on our business or results of operations.Our systems also contain and use a high volume of sensitive data, including intellectual property, trade secrets and other proprietary business information, financial information, regulatory information, strategic plans, sales trends and forecasts, litigation materials and/or personal identifiable information belonging to us, our staff, our patients, customers and/or other parties. In some cases, we utilize third-party service providers to collect, process, store, manage or transmit such data, which have increased our risk. Intentional or inadvertent data privacy or security breaches (including cyberattacks) resulting from attacks or lapses by employees, service providers (including providers of information technology-specific services), business partners, nation states (including groups associated with or supported by foreign intelligence agencies), organized crime organizations, â€œhacktivistsâ€ or others, create risks that our sensitive data may be exposed to unauthorized persons, our competitors or the public. Malicious actors, including those working under state-sponsored campaigns, have sought employment, often in remote information technology roles, as a means to gain inside access at targeted companies. In the third quarter of 2024, an individual used fraudulent identification in connection with their hiring by the Company. While the individual was detected and terminated before any data was extracted or malware installed, there can be no assurance that future attempts by similar actors will be unsuccessful. System vulnerabilities and/or cybersecurity breaches experienced by our third-party service providers have constituted a substantial share of the information security risks that have affected us. For example, in the first half of 2021, a supplier experienced a data breach in which an unauthorized third party acquired access to certain information provided to the supplier in the course of its provision of services to us, including business documents and certain personally identifiable patient information (not including social security or other financial or health insurance information). As required, we promptly notified the applicable state attorneys general and the individuals whose personally identifiable information was affected of this data breach at the supplier. In the third quarter of 2022, another service provider experienced a similar cybersecurity breach in which an attacker exfiltrated certain data (including non-significant Amgen data) from the service providerâ€™s systems. Additionally, in April 2024, one of our former vendors notified us that its subsidiary that had provided us with certain patient support services until mid-2022, experienced a cybersecurity incident that it discovered in February 2024 and that data containing individually identifiable health information of over 1.7 million Amgen patients (that was retained as required by FDA regulations) was involved in the incident. Pursuant to the Health Breach Notification Rule requirements, we notified the FTC of this incident. Although these supplier data breaches have not resulted in material adverse effects on our business, there can be no assurance that a similar future cybersecurity incident would not result in a material adverse effect on our business or results of operations. Further, the timeliness of our awareness of a cybersecurity incident affects our ability to respond to and work to mitigate the severity of such events. For example, in 2020 and 2022, two of our vendors experienced cyberattacks and each initially reported to us that neither event involved our data. However, upon further investigation, they each subsequently informed us that the attackers had accessed limited, non-significant Amgen information. Although neither of these breaches had a significant adverse effect on our business, in the future we may again not receive timely reporting of cybersecurity events and such events could have a material adverse effect on our business.Cyberattackers are also increasingly exploiting vulnerabilities in commercially available software from shared or open-source code. We rely on third party commercial software that have had and may have such vulnerabilities, but as use of open-source code is frequently not disclosed, our ability to fully assess this risk to our systems is limited. For example, in December 2021, a remote code execution vulnerability was discovered in a software library that is widely used in a variety of commercially available software and services. Although this vulnerability has not resulted in any significant adverse effects on us, there can be no assurances that a similar future vulnerability in the software and services that we use would not result in a material adverse effect on our business or results of operations.51Domestic and global government regulators, our business partners, suppliers with whom we do business, companies that provide us or our partners with business services and companies we have acquired or may acquire face similar risks. Security breaches of their systems or service outages have adversely affected systems and could, in the future, affect our systems and security, leave us without access to important systems, products, raw materials, components, services or information, or expose our confidential data or sensitive personal information. For example, in 2019, two vendors that perform testing and analytical services that we use in developing and manufacturing our products experienced cyberattacks, and in April and September of 2020, vendors that provide us with information technology services and clinical data services, respectively, each experienced ransomware attacks. Although there was no breach of our systems, each of these incidents required us to disconnect our systems from those vendorsâ€™ systems. While we were able to reconnect our systems following restoration of these vendorsâ€™ capabilities without significantly affecting product availability, a more extended service outage affecting these or other vendors, particularly where such vendor is the single source from which we obtain the services, could have a material adverse effect on our business or results of operations. In February 2024, Change Healthcare, a large U.S. insurance claim and co-pay card processing clearinghouse, experienced a ransomware attack that has caused significant disruptions to healthcare provider and pharmacy operations. While Change Healthcare does not directly provide us with services, disruptions to co-pay card support, insurance billing and Medicaid rebate processing led to lost sales and required us to take action to help patients access their medications and to provide extended payment terms to certain customers. Although services have been rerouted and restored, and the impact on our business has been immaterial, similar disruptions may occur in the future stemming from the interconnectedness of the U.S. healthcare ecosystem and industry reliance on centralized claims processing systems and networks, and such future disruptions may have a material adverse effect on our business or results of operations. In addition, we distribute our products in the United States primarily through three pharmaceutical wholesalers, and a security breach that impairs the distribution operations of our wholesalers could significantly impair our ability to deliver our products to healthcare providers and patients. There can be no assurance that our cybersecurity risk management program and processes, including our policies, controls, or procedures, will be fully implemented, complied with or effective in protecting our information technology systems and sensitive data.Although we have experienced system breakdowns, attacks and information security breaches, we do not believe such breakdowns, attacks and breaches have had a material adverse effect on our business or results of operations. We will continue to experience varying degrees of cyberattacks and other incidents in the future. Even though we continue to invest in the monitoring, protection and resilience of our critical and/or sensitive data and systems, there can be no assurances that our efforts will detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks and/or breaches of our systems that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in material financial, legal business or reputational harm to us or negatively affect our stock price. While we maintain cyber-liability insurance, our insurance is not sufficient to cover us against all losses that could potentially result from a service interruption, breach of our systems or loss of our critical or sensitive data.We are also subject to various laws and regulations globally regarding cybersecurity, privacy and data protection, including laws and regulations relating to the collection, storage, handling, use, disclosure, transfer and security of personal data. The legislative and regulatory environment regarding privacy and data protection is continuously evolving and developing and the subject of significant attention globally. For example, we are subject to the EUâ€™s General Data Protection Regulation (GDPR), which became effective in May 2018, and the California Consumer Privacy Act (CCPA), which became effective in January 2020, both of which provide for substantial penalties for noncompliance. The CCPA was amended in late 2020, to create the California Privacy Rights Act to create opt in requirements for the use of sensitive personal data and the formation of a new dedicated agency for the enforcement of the law, the California Privacy Protection Agency. Similar consumer privacy laws went into effect in nine other states, have been enacted (but not yet in effect) in in 11 other states, and have been proposed in six additional states. Outside the United States, other jurisdictions where we operate have passed, or continue to propose, data privacy or cybersecurity legislation and/or regulations. For example, in China, the Personal Information Protection Law and the Data Security Law, which regulate data processing activities associated with personal and nonpersonal data, are in effect and build upon the existing Cybersecurity Law. Further, in March 2024, the European Parliament adopted the Artificial Intelligence Act that provides for EU-wide rules on data quality, transparency, human oversight and accountability with respect to the use of artificial intelligence. In April 2024, the EU also revised its Cybersecurity Directive NIS2 rules that create new cybersecurity risk management and reporting obligations. Failure to comply with these current and future laws could result in significant penalties and reputational harm and could have a material adverse effect on our business and results of operations.52ItemÂ 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSDuring the three months ended September 30, 2024, we had one outstanding stock repurchase program, under which we had no repurchase activity.PeriodTotal numberof sharespurchasedAverageprice paidper shareTotal numberof shares purchasedas part of publicly announced programMaximum dollarvalue that mayyet be purchasedunder the programJuly 1â€”31â€”Â â€”Â $6,979,263,848Â August 1â€”31(1)(1)â€”Â $6,979,263,848Â September 1â€”30â€”Â â€”Â $6,979,263,848Â Totalâ€”Â â€”Â (1)Â Â Â Â In August 2024, the Company purchased 913 shares at an average price paid of $328.80 per share from a staff member to satisfy federal law compliance obligations. These shares were not repurchased under our stock repurchase program.ItemÂ 5.Â OTHER INFORMATION Trading ArrangementsDuring the three months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any â€œRule 10b5-1 trading arrangementâ€ or â€œnon-Rule 10b5-1 trading arrangement,â€ as each term is defined in Item 408 of Regulation S-K.ItemÂ 6.Â EXHIBITS Reference is made to the Index to Exhibits included herein.53INDEX TO EXHIBITSExhibitÂ No.Description2.1Agreement and Plan of Merger, dated July 27, 2021, by and among Amgen Inc., Teneobio, Inc., Tuxedo Merger Sub, Inc., and Fortis Advisors LLC. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential)(Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2021 on November 3, 2021 and incorporated herein by reference.)2.2Agreement and Plan of Merger, dated as of August 3, 2022, among ChemoCentryx, Inc., Amgen Inc. and Carnation Merger Sub, Inc. (Filed as an exhibit to Form 8-K on August 4, 2022 and incorporated herein by reference.)2.3Transaction Agreement, dated as of December 11, 2022, by and among Amgen Inc., Pillartree Limited and Horizon Therapeutics plc. (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)2.4Appendix 3 to the Rule 2.7 Announcement, dated as of December 12, 2022 (Conditions Appendix). (Filed as an exhibit to Form 8-K on December 12, 2022 and incorporated herein by reference.)3.1Restated Certificate of Incorporation of Amgen Inc. (As Restated March 6, 2013.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2013 on May 3, 2013 and incorporated herein by reference.)3.2Amended and Restated Bylaws of Amgen Inc. (As Amended and Restated February 15, 2016.) (Filed as an exhibit to Form 8-K on February 17, 2016 and incorporated herein by reference.)4.1Form of stock certificate for the common stock, par value $.0001 of the Company. (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 1997 on May 14, 1997 and incorporated herein by reference.)4.2Form of Indenture, dated January 1, 1992. (Filed as an exhibit to Form S-3 Registration Statement filed on December 19, 1991 and incorporated herein by reference.)4.3Agreement of Resignation, Appointment and Acceptance dated February 15, 2008. (Filed as an exhibit to Form 10-K for the year ended December 31, 2007 on February 28, 2008 and incorporated herein by reference.)4.4First Supplemental Indenture, dated February 26, 1997. (Filed as an exhibit to Form 8-K on March 14, 1997 and incorporated herein by reference.)4.58-1/8% Debentures due April 1, 2097. (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)4.6Officerâ€™s

Certificate of Amgen Inc., dated April 8, 1997, establishing a series of securities entitled â€œ8 1/8% Debentures due April 1, 2097.â€ (Filed as an exhibit to Form 8-K on April 8, 1997 and incorporated herein by reference.)4.7Indenture, dated August 4, 2003. (Filed as an exhibit to Form S-3 Registration Statement on August 4, 2003 and incorporated herein by reference.)4.8Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede & Co., as Nominee of The Depository Trust Company, and Citibank, N.A., as Paying Agent. (Filed as an exhibit to Form 10-Q for the quarter ended MarchÂ 31, 1998 on MayÂ 13, 1998 and incorporated herein by reference.)4.9Officersâ€™ Certificate of Amgen Inc., dated May 30, 2007, including form of the Companyâ€™s 6.375% Senior Notes due 2037. (Filed as an exhibit to Form 8-K on May 30, 2007 and incorporated herein by reference.)4.10Officersâ€™ Certificate of Amgen Inc., dated May 23, 2008, including form of the Companyâ€™s 6.90% Senior Notes due 2038. (Filed as exhibit to Form 8-K on May 23, 2008 and incorporated herein by reference.)4.11Officersâ€™ Certificate of Amgen Inc., dated January 16, 2009, including form of the Companyâ€™s 6.40% Senior Notes due 2039. (Filed as exhibit to Form 8-K on January 16, 2009 and incorporated herein by reference.)4.12Officersâ€™ Certificate of Amgen Inc., dated March 12, 2010, including form of the Companyâ€™s 5.75% Senior Notes due 2040. (Filed as exhibit to Form 8-K on March 12, 2010 and incorporated herein by reference.)544.13Officersâ€™ Certificate of Amgen Inc., dated September 16, 2010, including form of the Companyâ€™s 4.95% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on September 17, 2010 and incorporated herein by reference.)4.14Officersâ€™ Certificate of Amgen Inc., dated June 30, 2011, including form of the Companyâ€™s 5.65% Senior Notes due 2042. (Filed as an exhibit to Form 8-K on June 30, 2011 and incorporated herein by reference.)4.15Officersâ€™ Certificate of Amgen Inc., dated November 10, 2011, including form of the Companyâ€™s 5.15% Senior Notes due 2041. (Filed as an exhibit to Form 8-K on November 10, 2011 and incorporated herein by reference.)4.16Officersâ€™ Certificate of Amgen Inc., dated December 5, 2011, including form of the Companyâ€™s 5.50% Senior Notes due 2026. (Filed as an exhibit to Form 8-K on December 5, 2011 and incorporated herein by reference.)4.17Officersâ€™ Certificate of Amgen Inc., dated May 15, 2012, including form of the Companyâ€™s 5.375% Senior Notes due 2043. (Filed as an exhibit to Form 8-K on May 15, 2012 and incorporated herein by reference.)4.18Officersâ€™ Certificate of Amgen Inc., dated September 13, 2012, including form of the Companyâ€™s 4.000% Senior Notes due 2029. (Filed as an exhibit to Form 8-K on September 13, 2012 and incorporated herein by reference.)4.19Indenture, dated May 22, 2014, between Amgen Inc. and The Bank of New York Mellon Trust Company, N.A., as Trustee. (Filed as an exhibit to Form 8-K on May 22, 2014 and incorporated herein by reference.)4.20Officerâ€™s Certificate of Amgen Inc., dated May 1, 2015, including forms of the Companyâ€™s 3.125% Senior Notes due 2025 and 4.400% Senior Notes due 2045. (Filed as an exhibit on Form 8-K on May 1, 2015 and incorporated herein by reference.)4.21Officerâ€™s Certificate of Amgen Inc., dated as of February 25, 2016, including form of the Companyâ€™s 2.000% Senior Notes due 2026. (Filed as an exhibit on Form 8-K on February 26, 2016 and incorporated herein by reference.)4.22Officerâ€™s Certificate of Amgen Inc., dated as of June 14, 2016, including forms of the Companyâ€™s 4.563% Senior Notes due 2048 and 4.663% Senior Notes due 2051. (Filed as an exhibit to Form 8-K on June 14, 2016 and incorporated herein by reference.)4.23Officerâ€™s Certificate of Amgen Inc., dated as of August 19, 2016, including forms of the Companyâ€™s 2.600% Senior Notes due 2026. (Filed as an exhibit to Form 8-K on August 19, 2016 and incorporated herein by reference.)4.24Officerâ€™s Certificate of Amgen Inc., dated as of November 2, 2017, including in the form of the Companyâ€™s 3.200% Senior Notes due 2027. (Filed as an exhibit to Form 8-K on November 2, 2017 and incorporated herein by reference.)4.25Officerâ€™s Certificate of Amgen Inc., dated as of February 21, 2020, including forms of the Companyâ€™s 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes due 2030, 3.150% Senior Notes due 2040 and 3.375% Senior Notes due 2050. (Filed as an exhibit to Form 8-K on February 21, 2020 and incorporated herein by reference.)4.26Officerâ€™s Certificate of Amgen Inc., dated as of May 6, 2020, including form of the Companyâ€™s 2.300% Senior Notes due 2031. (Filed as an exhibit to Form 8-K on May 6, 2020 and incorporated herein by reference.)4.27Officerâ€™s Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Companyâ€™s 2.770% Senior Notes due 2053. (Filed as an exhibit to Form 8-K on August 18, 2020 and incorporated herein by reference.) 4.28Officerâ€™s Certificate of Amgen Inc., dated as of August 9, 2021, including forms of the Companyâ€™s 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes due 2041 and 3.000% Senior Notes due 2052. (Filed as an exhibit to Form 8-K on August 9, 2021 and incorporated herein by reference.)554.29Officerâ€™s Certificate of Amgen Inc., dated as of February 22, 2022, including forms of the Companyâ€™s 3.000% Senior Notes due 2029, 3.350% Senior Notes due 2032, 4.200% Senior Notes due 2052 and 4.400% Senior Notes due 2062. (Filed as an exhibit to Form 8-K on February 22, 2022 and incorporated herein by reference.)4.30Officerâ€™s Certificate of Amgen Inc., dated as of August 18, 2022, including forms of the Companyâ€™s 4.050% Senior Notes due 2029, 4.200% Senior Notes due 2033 and 4.875% Senior Notes due 2053. (Filed as an exhibit to Form 8-K on August 18, 2022 and incorporated herein by reference.)4.31Officerâ€™s Certificate of the Company, dated as of March 2, 2023, including forms of the Companyâ€™s 5.250% Senior Notes due 2025, 5.507% Senior Notes due 2026, 5.150% Senior Notes due 2028, 5.250% Senior Notes due 2030, 5.250% Senior Notes due 2033, 5.600% Senior Notes due 2043, 5.650% Senior Notes due 2053 and 5.750% Senior Notes due 2063. (Filed as an exhibit to Form 8-K on March 2, 2023 and incorporated herein by reference.)4.32Description of Amgen Inc.â€™s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934. (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)10.1+Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. (Filed as Appendix C to the Definitive Proxy Statement on Schedule 14A on April 17, 2024 and incorporated herein by reference.)10.2+Form of Grant of Stock Option Agreement for the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.3+Form of Restricted Stock Unit Agreement for the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.4+Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.5+Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.6+Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.7+Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.8+Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended and Restated on May 31, 2024.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2024 on August 7, 2024 and incorporated herein by reference.)10.9+Amgen Inc. Supplemental Retirement Plan. (As Amended and Restated effective October 16, 2013.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)10.9.1+First Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 14, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)10.9.2+Second Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 23, 2019. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)10.9.3+Third Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2021. (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)5610.9.4+Fourth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective October 20, 2022. (Filed as an exhibit to Form 10-K for the year ended December 31, 2022 on February 9, 2023 and incorporated herein by reference.)10.9.5+Fifth Amendment to the Amgen Inc. Supplemental Retirement Plan, effective January 1, 2024. (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)10.10+Amended and Restated Amgen Change of Control Severance Plan. (As Amended and Restated effective December 9, 2010 and subsequently amended effective March 2, 2011.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2011 on May 10, 2011 and incorporated herein by reference.)10.11+Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January 1, 2022.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2022 on April 28, 2022 and incorporated herein by reference.)10.12+Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated effective October 16, 2013.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2013 on February 24, 2014 and incorporated herein by reference.)10.12.1+First Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective October 14, 2016. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2016 on October 28, 2016 and incorporated herein by reference.)10.12.2+Second Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2020. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)10.12.3+Third Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2022. (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)10.12.4+Fourth Amendment to the Amgen Nonqualified Deferred Compensation Plan, effective January 1, 2024. (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)10.13+Aircraft Time Sharing Agreement, dated December 3, 2021, by and between Amgen Inc. and Robert A. Bradway. (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)10.14+Agreement between Amgen Inc. and James Bradner, dated December 13, 2023. (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)10.15Term Loan Credit Agreement, dated as of December 22, 2022, by and among Amgen Inc., Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents, and the other banks party thereto. (Filed as an exhibit to Form 8-K on December 22, 2022 and incorporated herein by reference.)10.16Third Amended and Restated Credit Agreement, dated as of March 9, 2023, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase Bank, N.A., as Syndication Agent. (Filed as an exhibit to Form 8-K on March 9, 2023 and incorporated herein by reference.)10.17Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited dated May 10, 2002 (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) and Amendment No. 1, effective June 9, 2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)5710.17.1Amendment No. 2 to Collaboration and License Agreement, effective November 14, 2016, between Amgen Inc. and Celltech R&D Limited. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)10.18Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2019 on July 31, 2019 and incorporated herein by reference.)10.19Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)10.19.1First Amendment to Collaboration Agreement, dated April 20, 2022, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)10.19.2Second Amendment to Collaboration Agreement, entered into as of February 26, 2023, by and between Amgen Inc. and BeiGene Switzerland GmbH, and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2023 on April 28, 2023 and incorporated herein by reference.)10.20Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-K for the year ended December 31, 2019 on February 12, 2020 and incorporated herein by reference.)10.21Share Purchase Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene, Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed). (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)10.21.1Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Schedule 13D on January 8, 2020 and incorporated herein by reference.)10.21.2Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 10-Q for the quarter ended September 30, 2020 on October 29, 2020 and incorporated herein by reference.)10.21.3Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and among BeiGene, Ltd. and Amgen Inc. (Filed as an exhibit to Form 8-K on January 31, 2023 and incorporated herein by reference.)10.22Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)10.22.1Amendment No. 1 to the Collaboration Agreement, dated October 1, 2014, by and among Amgen Inc., AstraZeneca Collaboration Ventures, LLC and AstraZeneca Pharmaceuticals LP (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2022 on August 5, 2022 and incorporated herein by reference.)10.22.2Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016, January 31, 2018, and May 15, 2020, respectively (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2020 on July 29, 2020 and incorporated herein by reference.)5810.22.3Amendment No. 7 to the Collaboration Agreement, dated December 17, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2020 on February 9, 2021 and incorporated herein by reference.)10.22.4Amendment No. 8 to the Collaboration Agreement, dated November 19, 2021, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2021 on February 16, 2022 and incorporated herein by reference.)10.22.5Letter Agreement Regarding the Collaboration Agreement, dated as of December 1, 2023, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)10.23License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc. and Kyowa Kirin Co., Ltd. (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential). (Filed as an exhibit to Form 10-Q for the quarter ended June 30, 2021 on August 4, 2021 and incorporated herein by reference.)31*Rule 13a-14(a) Certifications.32**Section 1350 Certifications.101.INSInline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.101.SCH*Inline XBRL Taxonomy Extension Schema Document.101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)._____(* = filed herewith)(** = furnished herewith and not â€œfiledâ€ for purposes of SectionÂ 18 of the Securities Exchange Act of 1934, as amended)(+ = management contract or compensatory plan or arrangement)59SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.Amgen Inc.(Registrant)Date:October 30, 2024By:/S/Â Â PETER H. GRIFFITHPeter H. GriffithExecutive Vice President and Chief Financial Officer(Principal Financial Officer)60 EX-31 2 amgn-ex31_20240930x10xq.htm RULE 13A-14(A) CERTIFICATIONS DocumentExhibit 31CERTIFICATIONSI, Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President of Amgen Inc., certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.;2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material

fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and(d)Disclosed in this quarterly report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.October 30, 2024/s/ ROBERT A. BRADWAYRobert A. BradwayChairman of the Board,Chief Executive Officer and President1CERTIFICATIONSI, Peter H. Griffith, Executive Vice President and Chief Financial Officer of Amgen Inc., certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Amgen Inc.;2.Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and(d)Disclosed in this quarterly report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.October 30, 2024/s/ PETER H. GRIFFITHPeter H. GriffithExecutive Vice President and Chief Financial Officer2 EX-32 3 amgn-ex32_20240930x10xq.htm SECTION 1350 CERTIFICATIONS DocumentExhibit 32Certification of Chief Executive OfficerPursuant to 18 U.S.C. Â§ 1350, as created by SectionÂ 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the â€œCompanyâ€) hereby certifies that:(i)the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and(ii)information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.October 30, 2024/s/ ROBERT A. BRADWAYRobert A. BradwayChairman of the Board,Chief Executive Officer and PresidentA signed original of this written statement required by SectionÂ 906 of the Sarbanes-Oxley Act of 2002 (â€œSection 906â€), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by SectionÂ 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.1Certification of Chief Financial OfficerPursuant to 18 U.S.C. Â§ 1350, as created by SectionÂ 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the â€œCompanyâ€) hereby certifies that:(i)the accompanying Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of SectionÂ 13(a) or SectionÂ 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and(ii)information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.October 30, 2024/s/ PETER H. GRIFFITHPeter H. GriffithExecutive Vice President and Chief Financial OfficerA signed original of this written statement required by SectionÂ 906 of the Sarbanes-Oxley Act of 2002 (â€œSection 906â€), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by SectionÂ 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.2 EX-101.SCH 4 amgn-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Earnings per share link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Goodwill and other intangible assets link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Financing arrangements link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Stockholders' equity link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Fair value measurement link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Derivative instruments link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Contingencies and commitments link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Earnings per share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Goodwill and other intangible assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Financing arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stockholders' equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Fair value measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Derivative instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Acquisitions - Acquisition of Horizon Therapeutics plc (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Acquisitions - Supplemental Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Revenues - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Revenues - Disaggregation of Revenue by Product and by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Earnings per share - Computation for Basic and Diluted EPS (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Investments - Schedule of Available-For-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Investments - Schedule of Fair Values by Classification (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Investments - Available-For-Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Investments - BeiGene, Ltd. (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Investments - Other Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Investments - Limited Partnership (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Goodwill and other intangible assets - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Goodwill and other intangible assets - Schedule of Identifiable Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Goodwill and other intangible assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Financing arrangements - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Financing arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stockholders' equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stockholders' equity - Components of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Stockholders' equity - Reclassifications Out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Fair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Fair value measurement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Derivative instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Derivative instruments - Schedule of Cross-Currency Swaps (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Derivative instruments - Summary of Unrealized Gains and Losses Recognized in AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Derivative instruments - Hedged Liabilities and Cumulative Amount (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Derivative instruments - Summary of Income and Expense Line Items (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Derivative instruments - Fair Value of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 amgn-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 amgn-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 amgn-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Noncash adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Repayment of debt Repayments of debt Repayments of Long-Term Debt Amount available for stock repurchases under a board approved stock repurchase plan Share Repurchase Program, Remaining Authorized, Amount Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax 4.875% notes due 2053 (4.875% 2053 Notes) 4.875% 2053 Notes [Member] 4.875% 2053 Notes Derivatives Fair Value [Line Items] Derivatives, Fair Value [Line Items] Cover [Abstract] Cover [Abstract] Hedged Liabilities and Cumulative Amount Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] (Decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect In-process research and development In Process Research and Development [Member] Ownership percentage Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Income Tax Authority [Domain] Income Tax Jurisdiction [Domain] Gains (losses) on fair value hedging relationships, hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Trading Symbol Trading Symbol Ownership percentage Equity Method Investment, Ownership Percentage Current portion of long-term debt Long-Term Debt, Current Maturities [Member] Long-Term Debt, Current Maturities [Member] 3.375% notes due 2050 (3.375% 2050 Notes) Three Point Three Seven Five Percent Notes Due 2050 [Member] Three Point Three Seven Five Percent Notes Due 2050 [Member] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Derivative assets Derivative Asset, Subject to Master Netting Arrangement, before Offset 3.625% notes due 2024 (3.625% 2024 Notes) 3.625% Notes Due In 2024 [Member] Three Point Six Two Five Percent Notes Due 2024 [Member] Non-NEOs Non-NEOs [Member] Computation for Basic and Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Long-term debt Long-Term Debt [Member] Common stock, dividends declared per share (in usd per share) Dividends declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Interest rate swap contracts Interest Rate Fair Value Hedge Liability at Fair Value Other Other General Expense (Income), Other Adjustments Other General Expense (Income), Other Adjustments Adjustments to goodwill resulting from acquisition Goodwill, Measurement Period Adjustment Pay vs Performance Disclosure [Line Items] Carrying value with discontinued hedging relationships Hedged Liability, Discontinued Fair Value Hedge Hedged Liability, Discontinued Fair Value Hedge Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Income Tax Examination [Line Items] Income Tax Examination [Line Items] Unfunded additional commitments Investment Company, Financial Support to Investee Contractually Required, Amount Trade receivables, net Increase (Decrease) in Accounts Receivable Derivative [Table] Derivative [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value of Derivatives Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Fair value measurement Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Identifiable intangible assets Identifiable Intangible Assets Gross Identifiable intangible assets gross. Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount

Total estimated amortization of finite-lived intangible assets for 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Common stock and additional paid-in capital, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding 5.65% notes due 2042 (5.65% 2042 Notes) Five Point Six Five Percent Notes Due 2042 [Member] Five Point Six Five Percent Notes Due 2042 [Member] 4.95% notes due 2041 (4.95% 2041 Notes) Four Point Nine Five Percent Notes Due 2041 [Member] Four Point Nine Five Percent Notes Due 2041 [Member] Cash flow hedges Cash flow hedge Cash Flow Hedging [Member] Other revenues Product and Service, Other [Member] TEZSPIRE TEZSPIRE [Member] TEZSPIRE Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] U.S. UNITED STATES Tax Years 2010-2012 Tax Years 2010-2012 [Member] Tax Years 2010-2012 Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Gross carrying amounts Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Schedule of Borrowings Schedule of Long-Term Debt Instruments [Table Text Block] 5.50% Â£475 million notes due 2026 (5.50% 2026 pound sterling Notes) 5.50% 2026 pound sterling Notes Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member] Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member] 6.90% notes due 2038 (6.90% 2038 Notes) Six Point Nine Zero Percent Notes Due 2038 [Member] Six Point Nine Zero Percent Notes Due 2038 [Member] Money market mutual funds Money Market Funds [Member] XGEVA XGEVA [Member] XGEVA. Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Components of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Secured Debt Secured Debt [Member] Equity Components [Axis] Equity Components [Axis] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair values Total interest-bearing securities Available-for-sale securities: Debt Securities, Available-for-Sale Net income Business Acquisition, Pro Forma Net Income (Loss) Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstandingâ€”537.5 shares in 2024 and 535.4 shares in 2023 Common Stocks, Including Additional Paid in Capital Insider Trading Policies and Procedures [Line Items] Use of estimates Use of Estimates, Policy [Policy Text Block] Total operating expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Reclassification adjustments into earnings Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Developed-product-technology rights Developed Technology Rights [Member] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Proceeds from maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Tabular List, Table Tabular List [Table Text Block] Total unrealized (losses) gains Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Derivative assets Foreign Currency Contract, Asset, Fair Value Disclosure Cross-currency swap contract gains (losses) Cross-currency swap contracts Cross-currency swap contracts Cross Currency Swap Contracts [Member] Cross currency swap contracts. Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Accrued liabilities Accrued Liabilities, Current 2.00% Senior Notes due 2026 2.00% Senior Notes Due 2026 [Member] 2.00% Senior Notes Due 2026 [Member] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Balance at January 1, 2024 Balance at September 30, 2024 Goodwill Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] 4.20% notes due 2052 (4.20% 2052 Notes) 4.20% 2052 Notes [Member] 4.20% 2052 Notes Inventories Inventory Disclosure [Text Block] 2.00% notes due 2032 (2.00% 2032 Notes) Two point zero percent 2032 Notes Member [Member] Two point zero percent 2032 Notes Member Marketing-related rights Marketing-Related Intangible Assets [Member] Repatha Repatha (evolocumab) [Member] Repatha (evolocumab) [Member] Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Term loan due October 2026 Term Loan Due October 2026 [Member] Term Loan Due October 2026 Tax Year 2013-2015 Tax Years 2013-2015 [Member] Tax Years 2013-2015 Schedule of Cross-Currency Swaps Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block] Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps Product and Service [Domain] Product and Service [Domain] Entity Information [Line Items] Entity Information [Line Items] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] 2.30% notes due 2031 (2.30% 2031 Notes) Two Point Three Zero Percent Notes Due 2031 [Member] Two Point Three Zero Percent Notes Due 2031 Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other Proceeds from (Payments for) Other Financing Activities Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Security Exchange Name Security Exchange Name Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate 2.00% â‚¬750 million notes due 2026 (2.00% 2026 euro Notes) 2.00% 2026 euro Notes 2.00% Notes Due 2026 [Member] 2.00% Notes Due 2026 Award Type Award Type [Axis] Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Number of notices consolidated Number Of Notices Consolidated Number Of Notices Consolidated Work in process Inventory, Work in Process, Net of Reserves Property, plant and equipment, net Property, Plant and Equipment, Net Consideration transferred for replacement awards Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Value Of Acquirer Replacement Awards Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Value Of Acquirer Replacement Awards Derivative liabilities Foreign Currency Contracts, Liability, Fair Value Disclosure Common stock and additional paid-in capital, par value (in usd per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Available-For-Sale Investments Debt Securities, Available-for-Sale [Table Text Block] Weighted average period of amortization Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Investment, Type [Extensible Enumeration] Investment, Type [Extensible Enumeration] Expiration Date Trading Arrangement Expiration Date Available-for-sale investments Available For Sales Investments [Member] Available for sales investments. Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Long-term tax liabilities Increase (Decrease) In Noncurrent Tax Liability Increase (Decrease) In Noncurrent Tax Liability Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Income taxes Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Total Shareholder Return Amount Total Shareholder Return Amount Business Nature Of Operations [Policy Text Block] Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description". Accrued income taxes, net Increase (Decrease) in Income Taxes Payable Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash Cash Accumulated depreciation and amortization on property, plant and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Unrealized gains (losses) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock and additional paid-in capital, shares authorized (in shares) Common Stock, Shares Authorized Diluted (in shares) Weighted-average shares for diluted EPS (in shares) Weighted Average Number of Shares Outstanding, Diluted Number of notices on proposed additional tax Number of notices on proposed additional tax Number of notices on proposed additional tax Other comprehensive (loss) income, net of reclassification adjustments and taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Total estimated amortization of finite-lived intangible assets for the remainder of the year Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year 4.40% notes due 2045 (4.40% 2045 Notes) Four Point Four Zero Percent Notes Due Two Zero Four Five [Member] Four Point Four Zero Percent Notes Due Two Zero Four Five [Member] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Hedging Designation [Domain] Hedging Designation [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Business Acquisition, Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Selling, general and administrative Selling, General and Administrative Expense Other comprehensive (loss) income, net of reclassification adjustments and taxes Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Product sales Product [Member] Other liabilities Increase (Decrease) in Other Operating Liabilities Total carrying value of debt Carrying value of long-term debt, including current portion Long-Term Debt 4.20% notes due 2033 (4.20% 2033 Notes) 4.20% 2033 Notes [Member] 4.20% 2033 Notes Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Acquisition price per share (in dollars per share) Business Acquisition, Share Price Total estimated amortization of finite-lived intangible assets for 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Investment Income [Table] Investment Income [Table] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] 3.35% notes due 2032 (3.35% 2032 Notes) 3.35% 2032 Notes [Member] 3.35% 2032 Notes Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] 6.40% notes due 2039 (6.40% 2039 Notes) Six Point Four Zero Percent Notes Due 2039 [Member] Six Point Four Zero Percent Notes Due 2039 [Member] Other income (expense): Other Income and Expenses [Abstract] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Dividends payable per share (in usd per share) Dividends Payable, Amount Per Share Indefinite-lived intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization charges associated with finite-lived intangible assets Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Other intangible assets, net Finite-Lived Intangible Assets, Net Contingent Consideration Obligations Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] ROW Non-US [Member] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Other Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent Revenues: Revenues [Abstract] 2.77% notes due 2053 (2.77% 2053 Notes) Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member] Two Point Seven Seven Percent Notes Due Two Zero Five Three BLINCYTO BLINCYTO [Member] BLINCYTO 5.25% notes due 2030 (5.25% 2030 Notes) 5.25% Notes Due 2030 [Member] 5.25% Notes Due 2030 Acquisitions Business Combination Disclosure [Text Block] Document Fiscal Period Focus Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Licensing rights Licensing Agreements [Member] Issuance of common stock in connection with equity award programs (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture EVENITY EVENITY [Member] EVENITY Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Accrued sales incentives and allowance Increase (Decrease) In Sales Incentives And Allowance Increase (Decrease) In Sales Incentives And Allowance Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends paid Payments of Ordinary Dividends, Common Stock Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Deferred tax liability Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in usd per share) Diluted EPS (in usd per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Goodwill increase Goodwill, Period Increase (Decrease) Derivative, basis spread on variable rate Derivative, Basis Spread on Variable Rate Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Number of operating segments Number of Operating Segments Fair Value of Financial Assets and Liabilities on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] U.S. Treasury bills US Treasury Bill Securities [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense 3.125% notes due 2025 (3.125% 2025 Notes) 3.125% Notes Due 2025 [Member] 3.125% Notes Due 2025 Fair Value Measured at Net Asset Value Per Share Fair Value Measured at Net Asset Value Per Share [Member] ENBREL ENBREL [Member] ENBREL. Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 5.15% notes due 2041 (5.15% 2041 Notes) Five Point One Five Percent Notes Due 2041 [Member] Five Point One Five Percent Notes Due 2041 [Member] Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Notional amounts Derivative, Notional Amount Total revenues Product sales Revenue from Contract with Customer, Excluding Assessed Tax Other income, net Nonoperating Income (Expense) Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other Other Long-Term Debt Other Other Comprehensive Income (Loss), Other Adjustment, Before Tax Other Comprehensive Income (Loss), Other Adjustment, Before Tax Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Deferred tax asset Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating income Operating Income (Loss) Income Tax Authority [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and stockholdersâ€™ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Hedging Designation [Axis] Hedging Designation [Axis] Derivative instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Carrying amounts of hedged liabilities Hedged Liability, Fair Value Hedge Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] 3.20% notes due 2027 (3.20% 2027 Notes) Three Point Two Zero Notes Due 2027 [Member] Three Point Two Zero Notes Due 2027 [Member] BeiGene BeiGene [Member] BeiGene [Member] Underlying Security Market Price Change Underlying Security Market Price

Change, Percent Repatriation tax on proposed additional tax Repatriation Tax On Proposed Additional Tax Repatriation Tax On Proposed Additional Tax Individual: Individual [Axis] Tax impact related to employee stock-based compensation expense Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated other comprehensive loss AOCI AOCI Attributable to Parent [Member] 2.20% notes due 2027 (2.20% 2027 Notes) Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member] Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member] Liabilities incurred Business Combination, Consideration Transferred, Liabilities Incurred CashÂ flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories Total inventories Inventory, Net Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] 2.80% notes due 2041 (2.80% 2041 Notes) Two point eight zero percent 2041 Notes [Member] Two point eight zero percent 2041 Notes Accumulated amortization Identifiable Intangible Assets Accumulated Amortization Identifiable intangible assets accumulated amortization. Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Consideration transferred Business Combination, Consideration Transferred LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Alternative investments Alternative Investment Unamortized bond discounts, premiums and issuance costs, net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Interest rates Derivative, Fixed Interest Rate Minimum Minimum [Member] Aranesp Aranesp [Member] Aranesp. Restatement Determination Date Restatement Determination Date Aggregate fair value of long-term debt, including current portion Notes Payable, Fair Value Disclosure Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Other notes due 2097 Other Notes Due 2097 [Member] Other Notes Due 2097 [Member] 4.05% notes due 2029 (4.05% 2029 Notes) 4.05% 2029 Notes [Member] 4.05% 2029 Notes Schedule of Identifiable Intangible Assets Schedule Of Intangible Assets [Table Text Block] Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets. Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Term loan due April 2025 Term Loan Due April 2025 [Member] Term Loan Due April 2025 Currency [Axis] Currency [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] 1.90% notes due 2025 (1.90% 2025 Notes) 1.90% Notes Due 2025 [Member] One Point Nine Zero Percent Notes Due Two Zero Two Five [Member] Tax Period [Axis] Tax Period [Axis] Total revenues Business Acquisition, Pro Forma Revenue Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Long-Term Debt, Gross 4.40% notes due 2062 (4.40% 2062 Notes) 4.40% 2062 Notes [Member] 4.40% 2062 Notes 6.375% notes due 2037 (6.375% 2037 Notes) Six Point Three Seven Five Percent Notes Due 2037 [Member] Six Point Three Seven Five Percent Notes Due 2037 [Member] Exercise Price Award Exercise Price Earnings per share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Summary of Unrealized Gains and Losses Recognized in AOCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Subsequent Event Subsequent Event [Member] Operating expenses: Costs and Expenses [Abstract] Goodwill and other intangible assets Goodwill and Intangible Assets Disclosure [Text Block] Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Schedule of Available-for-sale Securities [Table] Marketable Securities [Table] Domestic Tax Authority Domestic Tax Jurisdiction [Member] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Basis of presentation Basis Of Presentation [Policy Text Block] Shows the basis of presentation of financial information for interim periods. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Total estimated amortization of finite-lived intangible assets for 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] 4.663% notes due 2051 (4.663% 2051 Notes) Four Point Six Six Three Percent Notes Due Two Zero Five One [Member] Four Point Six Six Three Percent Notes Due Two Zero Five One [Member] Other products Other Products [Member] Other Products [Member] Sale of unrealized gains (losses) on equity securities Sale of Equity Securities, FV-NI, Unrealized Gain (Loss) Sale of Equity Securities, FV-NI, Unrealized Gain (Loss) Increase and decrease in equity securities without readily determinable fair value, amount Increase and Decrease in Equity Securities without Readily Determinable Fair Value, Amount Increase and Decrease in Equity Securities without Readily Determinable Fair Value, Amount PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Name Trading Arrangement, Individual Name Prolia Prolia [Member] Prolia. Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax 5.375% notes due 2043 (5.375% 2043 Notes) Five Point Three Seven Five Percent Notes Due 2043 [Member] Five Point Three Seven Five Percent Notes Due 2043 [Member] 5.60% notes due 2043 (5.60% 2043 Notes) 5.60% Notes Due 2043 [Member] 5.60% Notes Due 2043 Adjustments for equity method investments Income (Loss) from Equity Method Investments 4.00% Â£700 million notes due 2029 (4.00% 2029 pound sterling Notes) 4.00% 2029 pound sterling Notes Four Percent Pound Sterling Notes Due 2029 [Member] Four Percent Pound Sterling Notes Due 2029 [Member] Income before income taxes Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities) Fair value adjustments Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Assets: Assets, Fair Value Disclosure [Abstract] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure 5.25% notes due 2025 (5.25% 2025 Notes) 5.25% Notes Due 2025 [Member] 5.25% Notes Due 2025 Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Schedule of Fair Values by Classification Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block] Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets. Local Phone Number Local Phone Number Liability Class [Axis] Liability Class [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Long-term deferred tax liabilities Deferred Income Tax Liabilities, Net Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Gains on equity securities Unrealized Gain (Loss) on Investments 3.00% notes due 2052 (3.00% 2052 Notes) 3.00% notes due 2052 (3.00% 2052 Notes) [Member] 3.00% notes due 2052 (3.00% 2052 Notes) Other assets Increase (Decrease) in Other Operating Assets Changes in operating assets and liabilities, net of acquisitions: Increase (Decrease) in Operating Capital [Abstract] Length of time hedged in foreign currency contracts (or less) Maximum Length of Time, Foreign Currency Cash Flow Hedge PEO Total Compensation Amount PEO Total Compensation Amount Finite-lived intangible assets â€“ developed-product-technology rights Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Consideration transferred for vested and outstanding awards Business Combination, Payments To Acquire Business, Vested And Outstanding Awards Business Combination, Payments To Acquire Business, Vested And Outstanding Awards Derivative liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset Other current assets/ Other noncurrent assets Other Current Noncurrent Assets [Member] Other current assets/other non-current assets. Replacement equity awards issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares KRYSTEXXA KRYSTEXXA [Member] KRYSTEXXA Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Number ofÂ shares ofÂ common stock Common Stock [Member] Measure: Measure [Axis] Issuance of common stock in connection with equity award programs Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Increase in unrecognized tax benefits resulting from tax positions taken during the current period Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total liabilities Liabilities, Fair Value Disclosure Income Tax Examination [Table] Income Tax, Examination [Table] Entity Central Index Key Entity Central Index Key Inventories Schedule of Inventory, Current [Table Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Net gains (losses) from limited partnership investments Alternative Investment, Net Gain (Loss) Alternative Investment, Net Gain (Loss) Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount United States of America, Dollars United States of America, Dollars Stockholders' equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Current portion of long-term debt Less current portion Long-Term Debt, Current Maturities Interest rate swap contracts Interest Rate Fair Value Hedge Asset at Fair Value Summary of Income and Expense Line Items Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Business Combination, Contingent Consideration [Roll Forward] Business Combination, Contingent Consideration [Roll Forward] Business Combination, Contingent Consideration [Roll Forward] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Net changes in valuations Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Indefinite-lived intangible assets: Intangible Assets, Net (Excluding Goodwill) [Abstract] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] 4.563% notes due 2048 (4.563% 2048 Notes) Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member] Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member] Interest expense, net Interest Expense, Debt Summary of significant accounting policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Contingent consideration obligations Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Common stock and additional paid-inÂ capital Common Stock Including Additional Paid in Capital [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2.45% notes due 2030 (2.45% 2030 Notes) Two Point Four Five Percent Notes Due 2030 [Member] Two Point Four Five Percent Notes Due 2030 [Member] Accrued liabilities Increase (Decrease) in Accrued Liabilities Tax Period [Domain] Tax Period [Domain] 5.75% notes due 2040 (5.75% 2040 Notes) Five Point Seven Five Percent Notes Due 2040 [Member] Five Point Seven Five Percent Notes Due 2040 [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] KYPROLIS Kyprolis [Member] Kyprolis [Member] Long-term debt Total long-term debt Long-Term Debt, Excluding Current Maturities 5.25% notes due 2033 (5.25% 2033 Notes) 5.25% Notes Due 2033 [Member] 5.25% Notes Due 2033 Estimated fair value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Euro Member Countries, Euro Euro Member Countries, Euro Income taxes Income Tax Disclosure [Text Block] Long-term tax liabilities Liability for Uncertainty in Income Taxes, Noncurrent Earnings per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income (Numerator): Net Income (Loss) Attributable to Parent [Abstract] Equity [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) 5.15% notes due 2028 (5.15% 2028 Notes) 5.15% Notes Due 2028 [Member] 5.15% Notes Due 2028 Reclassifications Out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories Net Investment Income [Line Items] Net Investment Income [Line Items] Net unrealized gains Unrealized gains (losses) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Deferred income taxes Deferred Income Taxes and Tax Credits 3.00% notes due 2029 (3.00% 2029 Notes) 3.00% 2029 Notes [Member] 3.00% 2029 Notes Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Sale of securities without readily determinable fair value Sale of Securities without Readily Determinable Fair Value, Amount Sale of Securities without Readily Determinable Fair Value, Amount TEPEZZA TEPEZZA [Member] TEPEZZA Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Extinguishment of debt Payment for Debt Extinguishment or Debt Prepayment Cost Dividends declared on common stock Dividends, Common Stock, Cash Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Cash purchase price Payments to Acquire Businesses, Gross Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation, amortization and other Depreciation, Depletion and Amortization Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] United Kingdom, Pounds United Kingdom, Pounds Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value as of Grant Date Award Grant Date Fair Value Total assets acquired, net of liabilities assumed Business Acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Business Acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Significant otherÂ observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Financing arrangements Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Face amount Debt Instrument, Face Amount Disaggregation of Revenue by Product and by Geographic Area Disaggregation of Revenue [Table Text Block] 1.65% notes due 2028 (1.65% 2028 Notes) One point six five percent 2028 Notes [Member] One point six five percent 2028 Notes Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of consolidation Consolidation, Policy [Policy Text Block] Interest rate swap contracts Interest Rate Swap Interest rate swap agreements Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Proposed additional income tax Proposed Additional Income Tax Proposed Additional Income Tax 2.60% notes due 2026 (2.60% 2026 Notes) Two Point Six Zero Notes Due Two Zero Two Six [Member] Two Point Six Zero Notes Due Two Zero Two Six [Member] 5.507% notes due 2026 (5.507% 2026 Notes) 5.507% Notes Due 2026 [Member] 5.507% Notes Due 2026 Derivatives: Derivative Assets Fair Value Disclosure [Abstract] Derivative assets. Other Accumulated Other Adjustment Attributable to Parent [Member] Accumulated Other Adjustment Attributable to Parent [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value 5.75% notes due 2063 (5.75% 2063 Notes) 5.75% Notes Due 2063 [Member] 5.75% Notes Due 2063 Other Payments for (Proceeds from) Other Investing Activities Equity securities Equity Securities, FV-NI, Noncurrent Other Noncurrent Assets Other Noncurrent Assets [Member] Otezla Otezla [Member] Otezla [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] All Currencies [Domain] All Currencies [Domain] Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Derivatives: Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract] Derivative financial instruments liabilities fair value disclosure. Penalties on proposed additional income tax Penalties On Proposed Additional Income Tax Penalties On Proposed Additional Income Tax Foreign currency forward contracts Forward Contracts [Member] Basic (in usd per share) Basic EPS (in usd per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Forward interest rate contracts Forward Interest Rate Contracts [Member] Forward Interest Rate Contracts Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Aggregate Pension Adjustments

Service Cost Aggregate Pension Adjustments Service Cost [Member] Designated as Hedging Instrument Derivatives designated as hedging instrument Designated as Hedging Instrument [Member] Property, plant and equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Finite-lived intangible assets: Finite-Lived Intangible Assets, Net [Abstract] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted-average shares used in calculation of earnings per share: Shares (Denominator): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Total estimated amortization of finite-lived intangible assets for 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of sales Cost of Goods and Services Sold Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Research and development technology rights Acquired Research And Development Technology Rights [Member] Acquired research and development technology rights. Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Contingencies and commitments (see Note 13) Commitments and Contingencies 5.65% notes due 2053 (5.65% 2053 Notes) 5.65% Notes Due 2053 [Member] 5.65% Notes Due 2053 Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Notes Fixed-rate notes Notes Payable to Banks [Member] Derivatives not designated as hedging instrument Not Designated as Hedging Instrument [Member] Entity Address, City or Town Entity Address, City or Town Net proceeds from issuance of debt Proceeds from Issuance of Long-Term Debt Neumora Therapeutics, Inc. Neumora Therapeutics, Inc. [Member] Neumora Therapeutics, Inc. Debt Instrument [Axis] Debt Instrument [Axis] Net income Net income Net income (loss) Net income for basic and diluted EPS Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Hedging adjustments on discontinued hedging relationships Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) Entity File Number Entity File Number Liabilities: Liabilities, Fair Value Disclosure [Abstract] Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Revenue from External Customers by Products and Services [Table] Segment Reporting, Revenue from External Customer, Product and Service [Table] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Extinguishment of debt Extinguishment of Debt, Amount Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Other short-term interest-bearing securities Other Short Term Interest Bearing Securities [Member] Other short-term interest bearing securities. Total assets Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name 3.15% notes due 2040 (3.15% 2040 Notes) Three Point One Five Percent Notes Due 2040 [Member] Three Point One Five Percent Notes Due 2040 [Member] Total estimated amortization of finite-lived intangible assets for 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Finished goods Inventory, Finished Goods, Net of Reserves Nplate Nplate [Member] Nplate Other items, net Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Payments Business Combination, Contingent Consideration Arrangements, Payments Business Combination, Contingent Consideration Arrangements, Payments Insider Trading Arrangements [Line Items] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Adjustment to Compensation: Adjustment to Compensation [Axis] Accrued liabilities/ OtherÂ noncurrent liabilities Accrued Liabilities Other Non Current Liabilities [Member] Accrued liabilities/other non-current liabilities. Foreign currency contract gains Foreign currency forward contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Horizon Therapeutics Horizon Therapeutics [Member] Horizon Therapeutics Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Vectibix Vectibix [Member] Vectibix Computation of basic and diluted earnings per share Basic And Diluted Earning Per Share [Abstract] Basic and diluted earning per share. Basic (in shares) Weighted-average shares for basic EPS (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Marketable Securities [Line Items] Marketable Securities [Line Items] IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business combination, turnover period of inventory acquired Business combination, turnover period of inventory acquired Business combination, turnover period of inventory acquired Property, plant and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in AOCI [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name Partnership Interest [Member] EX-101.PRE 8 amgn-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover Page - shares 9 Months Ended Sep. 30, 2024 Oct. 25, 2024 Entity Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-37702 Â Entity Registrant Name Amgen Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 95-3540776 Â Entity Address, Address Line One One Amgen Center Drive Â Entity Address, City or Town Thousand Oaks Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 91320-1799 Â City Area Code 805 Â Local Phone Number 447-1000 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 537,532,723 Entity Central Index Key 0000318154 Â Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Document Fiscal Period Focus --12-31 Â Common Stock Â Â Entity Information [Line Items] Â Â Title of 12(b) Security Common stock, $0.0001 par value Â Trading Symbol AMGN Â Security Exchange Name NASDAQ Â 2.00% Senior Notes due 2026 Â Â Entity Information [Line Items] Â Â Title of 12(b) Security 2.00% Senior Notes due 2026 Â Trading Symbol AMGN26 Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Total revenues $ 8,503 $ 6,903 $ 24,338 $ 19,994 Operating expenses: Â Â Â Â Cost of sales 3,310 1,806 9,746 5,339 Research and development 1,450 1,079 4,240 3,250 Selling, general and administrative 1,625 1,353 5,218 3,905 Other 71 644 187 874 Total operating expenses 6,456 4,882 19,391 13,368 Operating income 2,047 2,021 4,947 6,626 Income before income taxes 3,101 1,947 3,827 7,003 Other income (expense): Â Â Â Â Interest expense, net (776) (759) (2,408) (2,054) Other income, net 1,830 685 1,288 2,431 Provision for income taxes 271 217 364 1,053 Net income $ 2,830 $ 1,730 $ 3,463 $ 5,950 Earnings per share: Â Â Â Â Basic (in usd per share) $ 5.27 $ 3.23 $ 6.45 $ 11.12 Diluted (in usd per share) $ 5.22 $ 3.22

$ 6.40 $ 11.06 Weighted-average shares used in calculation of earnings per share: Â Â Â Â Basic (in shares) 537 535 537 535 Diluted (in shares) 542 538 541 538 Product sales Â Â Â Â Revenues: Â Â Â Â Total revenues $ 8,151 $ 6,548 $ 23,310 $ 19,077 Other revenues Â Â Â Â Revenues: Â Â Â Â Total revenues $ 352 $ 355 $ 1,028 $ 917 X - DefinitionOther General Expense (Income), Other Adjustments + ReferencesNo definition available. + Details Name: amgn_OtherGeneralExpenseIncomeOtherAdjustments Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-

S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net income $ 2,830 $ 1,730 $ 3,463 $ 5,950 Other comprehensive (loss) income, net of reclassification adjustments and taxes: Â Â Â Â Foreign currency translation adjustments 71 (44) 32 (5) Cash flow hedges (253) 181 (76) 73 Other 1 17 (3) 37 Other comprehensive (loss) income, net of reclassification adjustments and taxes (181) 154 (47) 105 Comprehensive income $ 2,649 $ 1,884 $ 3,416 $ 6,055 X - DefinitionOther Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent + ReferencesNo definition available. + Details Name: amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 9,011 $ 10,944 Trade receivables, net 7,317 7,268 Inventories 7,362 9,518 Other current assets 3,076 2,602 Total current assets 26,766 30,332 Property, plant and equipment, net 6,156 5,941 Intangible assets, net 28,920 32,641 Goodwill 18,658 18,629 Other noncurrent assets 10,383 9,611 Total assets 90,883 97,154 Current liabilities: Â Â Accounts payable 2,147 1,590 Accrued liabilities 14,621 15,359 Current portion of long-term debt 3,544 1,443 Total current liabilities 20,312 18,392 Long-term debt 56,854 63,170 Long-term deferred tax liabilities 1,711 2,354 Long-term tax liabilities 2,280 4,680 Other noncurrent liabilities 2,199 2,326 Contingencies and commitments (see Note 13) Stockholdersâ€™ equity: Â Â Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstandingâ€”537.5 shares in 2024 and 535.4 shares in 2023 33,393 33,070 Accumulated deficit (25,530) (26,549) Accumulated other comprehensive loss (336) (289) Total stockholdersâ€™ equity 7,527 6,232 Total liabilities and stockholdersâ€™ equity $ 90,883 $ 97,154 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of par value plus amounts in excess of par value or issuance value for common stock issued. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStocksIncludingAdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1:

http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount recognized for uncertainty in income taxes classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilityForUncertainTaxPositionsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Millions Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Common stock and additional paid-in capital, par value (in usd per share) $ 0.0001 $ 0.0001 Common stock and additional paid-in capital, shares authorized (in shares) 2,750.0 2,750.0 Common stock and additional paid-in capital, shares outstanding (in shares) 537.5 535.4 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946

-SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY - USD ($) shares in Millions, $ in Millions Total Number ofÂ shares ofÂ common stock Common stock and additional paid-inÂ capital Accumulated deficit Accumulated other comprehensive loss Beginning balance (in shares) at Dec. 31, 2022 Â 534.0 Â Â Â Beginning balance at Dec. 31, 2022 $ 3,661 Â $ 32,514 $ (28,622) $ (231) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 2,841 Â Â 2,841 Â Other comprehensive income (loss), net of taxes (37) Â Â Â (37) Dividends declared on common stock (1,138) Â Â (1,138) Â Issuance of common stock in connection with equity award programs (in shares) Â 0.3 Â Â Â Issuance of common stock in connection with equity award programs 11 Â 11 Â Â Stock-based compensation expense 47 Â 47 Â Â Tax impact related to employee stock-based compensation expense (37) Â (37) Â Â Ending balance (in shares) at Mar. 31, 2023 Â 534.3 Â Â Â Ending balance at Mar. 31, 2023 5,348 Â 32,535 (26,919) (268) Beginning balance (in shares) at Dec. 31, 2022 Â 534.0 Â Â Â Beginning balance at Dec. 31, 2022 3,661 Â 32,514 (28,622) (231) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 5,950 Â Â Â Â Other comprehensive income (loss), net of taxes 105 Â Â Â Â Ending balance (in shares) at Sep. 30, 2023 Â 535.1 Â Â Â Ending balance at Sep. 30, 2023 7,656 Â 32,753 (24,971) (126) Beginning balance (in shares) at Mar. 31, 2023 Â 534.3 Â Â Â Beginning balance at Mar. 31, 2023 5,348 Â 32,535 (26,919) (268) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 1,379 Â Â 1,379 Â Other comprehensive income (loss), net of taxes (12) Â Â Â (12) Issuance of common stock in connection with equity award programs (in shares) Â 0.6 Â Â Â Issuance of common stock in connection with equity award programs 16 Â 16 Â Â Stock-based compensation expense 119 Â 119 Â Â Tax impact related to employee stock-based compensation expense (69) Â (69) Â Â Ending balance (in shares) at Jun. 30, 2023 Â 534.9 Â Â Â Ending balance at Jun. 30, 2023 6,781 Â 32,601 (25,540) (280) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 1,730 Â Â 1,730 Â Other comprehensive income (loss), net of taxes 154 Â Â Â 154 Dividends declared on common stock (1,161) Â Â (1,161) Â Issuance of common stock in connection with equity award programs (in shares) Â 0.2 Â Â Â Issuance of common stock in connection with equity award programs 33 Â 33 Â Â Stock-based compensation expense 124 Â 124 Â Â Tax impact related to employee stock-based compensation expense (5) Â (5) Â Â Ending balance (in shares) at Sep. 30, 2023 Â 535.1 Â Â Â Ending balance at Sep. 30, 2023 $ 7,656 Â 32,753 (24,971) (126) Beginning balance (in shares) at Dec. 31, 2023 535.4 535.4 Â Â Â Beginning balance at Dec. 31, 2023 $ 6,232 Â 33,070 (26,549) (289) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) (113) Â Â (113) Â Other comprehensive income (loss), net of taxes 99 Â Â Â 99 Dividends declared on common stock (1,208) Â Â (1,208) Â Issuance of common stock in connection with equity award programs (in shares) Â 1.0 Â Â Â Issuance of common stock in connection with equity award programs 34 Â 34 Â Â Stock-based compensation expense 103 Â 103 Â Â Tax impact related to employee stock-based compensation expense (125) Â (125) Â Â Ending balance (in shares) at Mar. 31, 2024 Â 536.4 Â Â Â Ending balance at Mar. 31, 2024 $ 5,022 Â 33,082 (27,870) (190) Beginning balance (in shares) at Dec. 31, 2023 535.4 535.4 Â Â Â Beginning balance at Dec. 31, 2023 $ 6,232 Â 33,070 (26,549) (289) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 3,463 Â Â Â Â Other comprehensive income (loss), net of taxes $ (47) Â Â Â Â Ending balance (in shares) at Sep. 30, 2024 537.5 537.5 Â Â Â Ending balance at Sep. 30, 2024 $ 7,527 Â 33,393 (25,530) (336) Beginning balance (in shares) at Mar. 31, 2024 Â 536.4 Â Â Â Beginning balance at Mar. 31, 2024 5,022 Â 33,082 (27,870) (190) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 746 Â Â 746 Â Other comprehensive income (loss), net of taxes 35 Â Â Â 35 Issuance of common stock in connection with equity award programs (in shares) Â 0.8 Â Â Â Issuance of common stock in connection with equity award programs 65 Â 65 Â Â Stock-based compensation expense 157 Â 157 Â Â Tax impact related to employee stock-based compensation expense (100) Â (100) Â Â Ending balance (in shares) at Jun. 30, 2024 Â 537.2 Â Â Â Ending balance at Jun. 30, 2024 5,925 Â 33,204 (27,124) (155) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net income (loss) 2,830 Â Â 2,830 Â Other comprehensive income (loss), net of taxes (181) Â Â Â (181) Dividends declared on common stock (1,236) Â Â (1,236) Â Issuance of common stock in connection with equity award programs (in shares) Â 0.3 Â Â Â Issuance of common stock in connection with equity award programs 67 Â 67 Â Â Stock-based compensation expense 136 Â 136 Â Â Tax impact related to employee stock-based compensation expense $ (14) Â (14) Â Â Ending balance (in shares) at Sep. 30, 2024 537.5 537.5 Â Â Â Ending balance at Sep. 30, 2024 $ 7,527 Â $ 33,393 $ (25,530) $ (336) X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_DividendsCommonStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (Parenthetical) - $ / shares 3 Months Ended Sep. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Mar. 31, 2023 Statement of Stockholders' Equity [Abstract] Â Â Â Â Â Common stock, dividends declared per share (in usd per share) $ 2.25 $ 2.25 $ 2.25 $ 2.13 $ 2.13 X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net income (loss) $ 3,463 $ 5,950 Noncash adjustments to reconcile net income to net cash provided by operating activities: Â Â Depreciation, amortization and other 4,195 2,691 Stock-based compensation expense 396 270 Deferred income taxes (894) (650) Adjustments for equity method investments (11) (17) Gains on equity securities (717) (1,304) Other items, net 1 579 Changes in operating assets and liabilities, net of acquisitions: Â Â Trade receivables, net (32) (582) Inventories 2,209 (82) Other assets (638) (332) Accounts payable 544 (215) Accrued income taxes, net (1,064) 998 Long-term tax liabilities (561) 293 Accrued liabilities (636) 69 Accrued sales incentives and allowance 536 415 Other liabilities (72) (150) Net cash provided by operating activities 6,719 7,933 Cash flows from investing activities: Â Â Proceeds from sales of marketable securities 0 1,125 Proceeds from maturities of marketable securities 0 550 Purchases of property, plant and equipment (725) (863) Other 81 73 Net cash (used in) provided by investing activities (644) 885 Cash flows from financing activities: Â Â Net proceeds from issuance of debt 0 23,781 Extinguishment of debt (659) (550) Repayment of debt (3,600) (1,454) Dividends paid (3,627) (3,416) Other (122) (67) Net cash (used in) provided by financing activities (8,008) 18,294 (Decrease) increase in cash and cash equivalents (1,933) 27,112 Cash and cash equivalents at beginning of period 10,944 7,629 Cash and cash equivalents at end of period $ 9,011 $ 34,741 X - DefinitionIncrease (Decrease) In Noncurrent Tax Liability + ReferencesNo definition available. + Details Name: amgn_IncreaseDecreaseInNoncurrentTaxLiability Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) In Sales Incentives And Allowance + ReferencesNo definition available. + Details Name: amgn_IncreaseDecreaseInSalesIncentivesAndAllowance Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtExtinguishmentCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_UnrealizedGainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of significant accounting policies Summary of significant accounting policiesBusinessAmgen Inc. (including its consolidated subsidiaries, referred to as â€œAmgen,â€ â€œthe Company,â€ â€œwe,â€ â€œourâ€ or â€œusâ€) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.Â We operate in one business segment: human therapeutics.Basis of presentationThe interim unaudited financial information for the three and nine months ended September 30, 2024 and 2023, has been prepared in accordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) that Amgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024.Principles of consolidationThe condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entityâ€™s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with the current presentation.Use of estimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates.Property, plant and equipment, netProperty, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $10.3Â billion and $9.8 billion as of September 30, 2024 and December 31, 2023, respectively.Recent accounting pronouncementsIn December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or may elect retrospective application. We are currently evaluating the impact of adopting this new standard on our related disclosures.In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted, and the standard requires retrospective application to all prior periods presented. We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â AcquisitionsAcquisition of Horizon Therapeutics plcOn October 6, 2023, Amgen completed its acquisition of Horizon by acquiring all of the outstanding shares of Horizon for $116.50 per share in cash, representing a total consideration of approximately $27.8Â billion. Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs of patients impacted by rare, autoimmune and severe inflammatory diseases. The acquisition, which was accounted for as a business combination, aligns with Amgenâ€™s core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases and strengthens Amgenâ€™s leading rare disease portfolio by adding first-in-class, early-in-lifecycle medicines, including TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout and UPLIZNA for neuromyelitis optica spectrum disorder. Upon its acquisition, Horizon became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date.During the nine months ended September 30, 2024, the purchase price allocation of the acquisition was completed and measurement period adjustments were finalized, which included changes to the purchase price allocation that resulted in a net increase of approximately $25Â million to goodwill. The measurement period adjustments resulted primarily from adjustments to acquired assets and liabilities, including deferred tax attributes, based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. The adjustments did not have a significant impact on Amgenâ€™s results of operations during the nine months ended September 30, 2024, and would not have had a significant impact on prior period results if the adjustments had been made as of the acquisition date.The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):Cash and cash equivalents$681Â Inventories5,014Â Property, plant and equipment, net318Â Finite-lived intangible assets â€“ developed-product-technology rights19,590Â IPR&D1,060Â Goodwill3,136Â Deferred tax asset795Â Deferred tax liability(2,488)Other assets and liabilities, net(273)Total assets acquired, net of liabilities assumed$27,833Â The $27.8Â billion total consideration for this transaction consisted of (i) cash consideration transferred to common shareholders of $26.7Â billion; (ii) cash consideration transferred to vested and outstanding stock options, outstanding restricted stock unit (RSU) awards and outstanding performance stock unit (PSU) awards of $523Â million; (iii) the fair value of Amgen replacement awards (based on conversion of outstanding employee RSU awards) of $180Â million representing noncash consideration; and (iv) a portion of Horizonâ€™s debt, settled by Amgen on the acquisition closing date, of $382Â million. Amgen issued 1.7Â million replacement equity awards with the original vesting conditions, the fair value of which was determined based on the acquisition date fair value based on the conversion calculation.The estimated fair values of $20.7Â billion for the developed-product-technology rights and IPR&D intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 10 years from the acquisition date using the straight-line methodology.The estimated fair value of the acquired inventory of $5.0Â billion was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyerâ€™s effort are applied. The inventory fair value adjustment is being amortized using a weighted-average inventory turnover, which we estimate to approximate 27 months from the acquisition date.A deferred tax liability of $2.5Â billion was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired, as well as an associated deferred tax asset for anticipatory foreign tax credits of $795Â million.The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $3.1Â billion was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from the marketed products acquired and other benefits.Supplemental Pro Forma Financial InformationThe following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the three and nine months ended September 30, 2023, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions):Three months ended September 30, 2023Nine months ended September 30, 2023Total revenues$7,854Â $22,728Â Net income$902Â $3,518Â The unaudited supplemental pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Amgen and Horizon. In order to reflect the occurrence of the acquisition on JanuaryÂ 1, 2022, the unaudited supplemental pro forma financial information includes adjustments to reflect the following: (i) incremental amortization expense based on the fair values of the identifiable intangible assets and inventory step-up; (ii) the additional interest expense associated with the issuance of debt to finance the acquisition; and (iii) the income tax impact using an estimated effective tax rate applied to the combined entity. The unaudited supplemental pro forma financial information is not necessarily indicative of what the condensed consolidated results of operations would have been had the acquisition been completed on JanuaryÂ 1, 2022. In addition, the unaudited supplemental pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenues RevenuesWe operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customersâ€™ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.Revenues were as follows (in millions):Three months ended September 30,20242023U.S.ROWTotalU.S.ROWTotalProlia$683Â $362Â $1,045Â $673Â $313Â $986Â ENBREL817Â 8Â 825Â 1,026Â 9Â 1,035Â XGEVA373Â 168Â 541Â 374Â 145Â 519Â Repatha281Â 286Â products(3)958Â 405Â 1,363Â 675Â 329Â 1,004Â Total product sales(4)$5,979Â $2,172Â 8,151Â $4,691Â $1,857Â 6,548Â Other revenues352Â 355Â Total revenues$8,503Â $6,903Â Nine months ended September 30,20242023U.S.ROWTotalU.S.ROWTotalProlia$2,110Â $1,099Â $3,209Â $1,987Â $954Â $2,941Â ENBREL2,280212,301Â 2,645372,682Â XGEVA1,1385261,664Â 1,1454401,585Â Repatha824[9] products(3)2,858Â 1,2044,062Â 2,271Â 1,0493,320Â Total product sales(4)$16,792Â $6,518Â 23,310Â $13,402Â $5,675Â 19,077Â Other revenues1,028Â 917Â Total revenues$24,338Â $19,994Â _____(1)Â Â Â Â TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.(2)Â Â Â Â TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.(3)Â Â Â Â Consists of product sales of our non-principal products. (4)Â Â Â Â Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2024 and 2023. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Income taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income taxes Income taxes The effective tax rates for the three and nine months ended September 30, 2024, were 8.7% and 9.5%, respectively, compared with 11.1% and 15.0%, respectively, for the corresponding periods in the prior year.The decrease in our effective tax rate for the three months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets), partially offset by the quarter-to-date unrealized gains on our strategic equity investments (primarily BeiGene). See Note 6, Investmentsâ€”BeiGene, Ltd. The decrease in our effective tax rate for the nine months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets). The effective tax rates differ from the federal statutory rate primarily due to the impact of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from locations where the Company has significant manufacturing operations, including Singapore, Ireland and Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to a tax incentive grant through 2050. Additionally, the Companyâ€™s operations conducted in Singapore are subject to a tax incentive grant through 2036. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. Additionally, effective January 1, 2024, selected individual countries, including the United Kingdom and EU member countries, have enacted the global minimum tax agreement. Our legal entities in such countries, along with their direct and indirect subsidiaries, are now subject to a 15% minimum tax rate on adjusted financial statement income.Beginning on January 1, 2023, we were no longer subject to a 4% excise tax in the U.S. territory of Puerto Rico on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We qualify for and are subject to the alternative income tax rate on industrial development income of our Puerto Rico affiliate. In the United States, this income tax qualifies for foreign tax credits. Both this income tax and the associated foreign tax credits are generally recognized in our provision for income taxes. We accounted for the 2022 excise tax that was capitalized in Inventories as an expense in Cost of sales when the related products were sold in the first half of 2023, and a foreign tax credit was not recognized with respect to the excise

tax expense in 2023. We do not have this excise tax exposure in 2024.One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters.In 2017, we received an RAR and a modified RAR from the IRS for the years 2010â€“2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010â€“2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010â€“2012 by an amount that would result in additional federal tax of approximately $3.6Â billion, plus interest. Any additional tax that could be imposed for the years 2010â€“2012 would be reduced by up to approximately $900Â million of repatriation tax previously accrued on our foreign earnings.In 2020, we received an RAR and a modified RAR from the IRS for the years 2013â€“2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010â€“2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013â€“2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013â€“2015 by an amount that would result in additional federal tax of approximately $5.1Â billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0Â billion. Any additional tax that could be imposed for the years 2013â€“2015 would be reduced by up to approximately $2.2Â billion of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS positions set forth in the 2010â€“2012 and 2013â€“2015 Notices are without merit. We are contesting the 2010â€“2012 and 2013â€“2015 Notices through the judicial process. The two cases were consolidated in the U.S. Tax Court on December 19, 2022. The trial is currently scheduled to begin on November 4, 2024.We are currently under examination by the IRS for the years 2016â€“2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions.Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed consolidated financial statements.During the three and nine months ended September 30, 2024, the gross amounts of our UTBs increased by $40 million and $120Â million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of September 30, 2024, if recognized, would affect our effective tax rate. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings per share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Earnings per share Earnings per shareThe computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.The computations for basic and diluted EPS were as follows (in millions, except per-share data):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023Income (Numerator):Net income for basic and diluted EPS$2,830Â $1,730Â $3,463Â $5,950Â Shares (Denominator):Weighted-average shares for basic EPS537Â 535Â 537Â 535Â Effect of dilutive securities5Â 3Â 4Â 3Â Weighted-average shares for diluted EPS542Â 538Â 541Â 538Â Basic EPS$5.27Â $3.23Â $6.45Â $11.12Â Diluted EPS$5.22Â $3.22Â $6.40Â $11.06Â For the three and nine months ended September 30, 2024 and 2023, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Investments 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Investments InvestmentsAvailable-for-sale investmentsThe amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):Types of securities as of September 30, 2024AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvaluesU.S. Treasury bills$996Â $â€”Â $â€”Â $996Â Money market mutual funds7,437Â â€”Â â€”Â 7,437Â Other short-term interest-bearing securities143Â â€”Â â€”Â 143Â Total interest-bearing securities$8,576Â $â€”Â $â€”Â $8,576Â Types of securities as of December 31, 2023AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvaluesU.S. Treasury billsâ€”Â $â€”Â $â€”Â $â€”Â Money market mutual funds10,266Â â€”Â â€”Â 10,266Â Other short-term interest-bearing securities138Â â€”Â â€”Â 138Â Total interest-bearing securities$10,404Â $â€”Â $â€”Â $10,404Â The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):Condensed Consolidated Balance Sheets locationsSeptember 30, 2024December 31, 2023Cash and cash equivalents$8,576Â $10,404Â Total interest-bearing securities$8,576Â $10,404Â Cash and cash equivalents in the above table excludes bank account cash of $435 million and $540Â million as of September 30, 2024 and December 31, 2023, respectively.All interest-bearing securities as of September 30, 2024 and December 31, 2023, mature in one year or less.For the three and nine months ended September 30, 2024 and 2023, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method.The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer.Equity securitiesBeiGene, Ltd.Our ownership interest in BeiGene was approximately 18% as of both September 30, 2024 and December 31, 2023, and the fair values of our investment were $4.3Â billion and $3.4Â billion, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. In the first quarter of 2023, we began to account for our ownership interest as an equity security with a readily determinable fair value, with changes in fair value recorded in Other income, net, in our Condensed Consolidated Statements of Income. See Note 11, Fair value measurement. During the three months ended September 30, 2024 and 2023, we recognized unrealized gains of $1.6Â billion and $30Â million, respectively, recorded in Other income, net, in our Condensed Consolidated Statements of Income. During the nine months ended September 30, 2024 and 2023, we recognized unrealized gains of $836Â million and $1.2Â billion, respectively, recorded in Other income, net, in our Condensed Consolidated Statements of Income.Subject to certain exceptions or otherwise agreed to by BeiGene, while Amgen holds at least 5.0% of BeiGeneâ€™s outstanding common stock, (A) we may only sell our BeiGene equity investment via: (i) a registered public offering, (ii) a sale under Rule 144 of the Securities Act of 1933 (the â€œSecurities Actâ€) or (iii) a private sale exempt from registration requirements under the Securities Act, and (B) we may not sell more than 5.0% of BeiGeneâ€™s outstanding common stock in any rolling 12-month period.Other equity securities Excluding our equity investments in BeiGene (discussed above) and Neumora (discussed below), we held investments in other equity securities with readily determinable fair values (publicly traded securities) of $336 million and $494 million as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and nine months ended September 30, 2024 and 2023, net unrealized gains and losses on these publicly traded securities were not material. Additionally, net realized gains and losses on sales of publicly traded securities for the three and nine months ended September 30, 2024 and 2023, were not material.We held investments of $318 million and $309 million in equity securities without readily determinable fair values as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and nine months ended September 30, 2024 and 2023, upward and downward adjustments on these securities were not material. Adjustments were based on observable price transactions. Net realized gains and losses on sales of securities without readily determinable fair values for the three and nine months ended September 30, 2024 and 2023, were not material.Equity method investmentsNeumora Therapeutics, Inc.As of September 30, 2024 and December 31, 2023, our ownership interests in Neumora were approximately 22.1% and 23.2%, respectively, and the fair values of our investment were $467 million and $603 million, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. Although our equity investment qualifies us for the equity method of accounting, we have elected the fair value option to account for our investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings in Other income, net, in our Condensed Consolidated Statements of Income each reporting period. See Note 11, Fair value measurement. We believe the fair value option best reflects the economics of the underlying transaction. During the three months ended September 30, 2024 and 2023, we recognized unrealized gains of $119Â million and $153Â million, respectively, and during the nine months ended September 30, 2024 and 2023, we recognized $136Â million of unrealized losses and $134Â million of unrealized gains, respectively. We are contractually restricted from selling more than 5.0% of Neumoraâ€™s outstanding common stock in any rolling 12-month period for as long as we hold at least 10.0% of their outstanding common stock, subject to certain exceptions or otherwise agreed to by Neumora.Limited partnershipsWe held limited partnership investments of $272 million and $251 million as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of September 30, 2024, unfunded additional commitments to be made for these investments during the next several years amounted to $139Â million. For the three and nine months ended September 30, 2024 and 2023, net unrealized gains and losses from our limited partnership investments were not material. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Inventories InventoriesInventories consisted of the following (in millions):September 30, 2024December 31, 2023Raw materials$788Â $993Â Work in process4,339Â 5,747Â Finished goods2,235Â 2,778Â Total inventories$7,362Â $9,518Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and other intangible assets 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and other intangible assets Goodwill and other intangible assetsGoodwillThe change in the carrying amount of goodwill was as follows (in millions):Balance at January 1, 2024$18,629Â Adjustments to goodwill resulting from acquisitions (1)25Â Foreign currency translation adjustments4Â Balance at September 30, 2024$18,658Â _____(1) Â Â Â Â For the nine months ended September 30, 2024, adjustments to goodwill

consisted of measurement period adjustments related to our Horizon acquisition. See Note 2, Acquisitions.Other intangible assetsOther intangible assets consisted of the following (in millions):Â September 30, 2024December 31, 2023Â GrosscarryingamountsAccumulatedamortizationOther intangibleassets, netGrosscarryingamountsAccumulatedamortizationOther intangibleassets, netFinite-lived intangible assets:Developed-product-technology rights$48,636Â $(21,472)$27,164Â $48,631Â $(18,049)$30,582Â Licensing rights3,864Â (3,360)504Â 3,865Â (3,265)600Â Marketing-related rights1,203Â (1,188)15Â 1,339Â (1,264)75Â Research and development technology rights1,400Â (1,253)147Â 1,394Â (1,228)166Â Total finite-lived intangible assets55,103Â (27,273)27,830Â 55,229Â (23,806)31,423Â Indefinite-lived intangible assets:In-process research and development1,090Â â€”Â 1,090Â 1,218Â â€”Â 1,218Â Total other intangible assets$56,193Â $(27,273)$28,920Â $56,447Â $(23,806)$32,641Â Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertain to technologies used in R&D that have alternative future uses.IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval.During the three months ended September 30, 2024 and 2023, we recognized amortization associated with our finite-lived intangible assets of $1.2Â billion and $693 million, respectively. During the nine months ended September 30, 2024 and 2023, we recognized amortization associated with our finite-lived intangible assets of $3.6Â billion and $2.1Â billion, respectively. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. As of September 30, 2024, the total estimated amortization of our finite-lived intangible assets for the remaining three months ending December 31, 2024, and the years ending December 31, 2025, 2026, 2027, 2028 and 2029, are $1.2 billion, $4.5 billion, $3.9 billion, $3.9 billion, $2.9 billion and $2.2 billion, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Financing arrangements 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Financing arrangements Financing arrangementsOur borrowings consisted of the following (in millions):Â September 30, 2024December 31, 20233.625% notes due 2024 (3.625% 2024 Notes)$â€”Â $1,400Â 1.90% notes due 2025 (1.90% 2025 Notes)500Â 500Â 5.25% notes due 2025 (5.25% 2025 Notes)2,000Â 2,000Â Term loan due April 2025â€”Â 2,000Â 3.125% notes due 2025 (3.125% 2025 Notes)1,000Â 1,000Â 2.00% â‚¬750 million notes due 2026 (2.00% 2026 euro Notes)835Â 828Â 5.507% notes due 2026 (5.507% 2026 Notes)1,500Â 1,500Â 2.60% notes due 2026 (2.60% 2026 Notes)1,250Â 1,250Â Term loan due October 20261,800Â 2,000Â 5.50% Â£475 million notes due 2026 (5.50% 2026 pound sterling Notes)635Â 605Â 2.20% notes due 2027 (2.20% 2027 Notes)1,724Â 1,724Â 3.20% notes due 2027 (3.20% 2027 Notes)1,000Â 1,000Â 5.15% notes due 2028 (5.15% 2028 Notes)3,750Â 3,750Â 1.65% notes due 2028 (1.65% 2028 Notes)1,234Â 1,234Â 3.00% notes due 2029 (3.00% 2029 Notes)750Â 750Â 4.05% notes due 2029 (4.05% 2029 Notes)1,250Â 1,250Â 4.00% Â£700 million notes due 2029 (4.00% 2029 pound sterling Notes)936Â 892Â 2.45% notes due 2030 (2.45% 2030 Notes)1,250Â 1,250Â 5.25% notes due 2030 (5.25% 2030 Notes)2,750Â 2,750Â 2.30% notes due 2031 (2.30% 2031 Notes)1,250Â 1,250Â 2.00% notes due 2032 (2.00% 2032 Notes)1,001Â 1,001Â 3.35% notes due 2032 (3.35% 2032 Notes)1,000Â 1,000Â 4.20% notes due 2033 (4.20% 2033 Notes)750Â 750Â 5.25% notes due 2033 (5.25% 2033 Notes)4,250Â 4,250Â 6.375% notes due 2037 (6.375% 2037 Notes)478Â 478Â 6.90% notes due 2038 (6.90% 2038 Notes)254Â 254Â 6.40% notes due 2039 (6.40% 2039 Notes)333Â 333Â 3.15% notes due 2040 (3.15% 2040 Notes)1,668Â 1,803Â 5.75% notes due 2040 (5.75% 2040 Notes)373Â 373Â 2.80% notes due 2041 (2.80% 2041 Notes)776Â 949Â 4.95% notes due 2041 (4.95% 2041 Notes)600Â 600Â 5.15% notes due 2041 (5.15% 2041 Notes)729Â 729Â 5.65% notes due 2042 (5.65% 2042 Notes)415Â 415Â 5.60% notes due 2043 (5.60% 2043 Notes)2,750Â 2,750Â 5.375% notes due 2043 (5.375% 2043 Notes)185Â 185Â 4.40% notes due 2045 (4.40% 2045 Notes)2,250Â 2,250Â 4.563% notes due 2048 (4.563% 2048 Notes)1,415Â 1,415Â 3.375% notes due 2050 (3.375% 2050 Notes)1,764Â 2,132Â 4.663% notes due 2051 (4.663% 2051 Notes)3,541Â 3,541Â 3.00% notes due 2052 (3.00% 2052 Notes)890Â 999Â 4.20% notes due 2052 (4.20% 2052 Notes)895Â 950Â 4.875% notes due 2053 (4.875% 2053 Notes)1,000Â 1,000Â 5.65% notes due 2053 (5.65% 2053 Notes)4,250Â 4,250Â 2.77% notes due 2053 (2.77% 2053 Notes)940Â 940Â 4.40% notes due 2062 (4.40% 2062 Notes)1,165Â 1,200Â Â September 30, 2024December 31, 20235.75% notes due 2063 (5.75% 2063 Notes)2,750Â 2,750Â Other notes due 2097100Â 100Â Unamortized bond discounts, premiums and issuance costs, net(1,373)(1,420)Fair value adjustments(192)(314)Other27Â 17Â Total carrying value of debt60,398Â 64,613Â Less current portion(3,544)(1,443)Total long-term debt$56,854Â $63,170Â There are no material differences between the effective interest rates and coupon rates of our notes except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.The Term loans have an interest rate of three-month SOFR plus 1.225%.Debt repaymentsDuring the nine months ended September 30, 2024, we repaid the $2.0Â billion aggregate principal amount on the Term loan due April 2025, $200Â million aggregate principal amount of the Term loan due October 2026 and the $1.4Â billion aggregate principal amount of the 3.625% 2024 Notes.Debt extinguishmentDuring the nine months ended September 30, 2024, we repurchased an aggregate principal amount of our debt of $875Â million, including portions of the 3.15% 2040 Notes, 2.80% 2041 Notes, 3.375% 2050 Notes, 3.00% 2052 Notes, 4.20% 2052 Notes and 4.40% 2062 Notes, for an aggregate cost of $659Â million, which resulted in the recognition of a $215Â million gain on extinguishment of debt recorded in Other income, net, in the Condensed Consolidated Statements of Income.Interest rate swap contractsSee Note 12, Derivative instruments, for a discussion of interest rate swap contracts related to certain of our notes. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' equity Stockholdersâ€™ equityStock repurchase programDuring the nine months ended September 30, 2024 and 2023, we did not repurchase shares under our stock repurchase program. As of September 30, 2024, $7.0 billion of authorization remained available under our stock repurchase program.DividendsIn August 2024, March 2024 and December 2023, our Board of Directors declared quarterly cash dividends of $2.25 per share, which were paid in September 2024, June 2024 and March 2024, respectively. In October 2024, our Board of Directors declared a quarterly cash dividend of $2.25 per share that will be paid in December 2024.Accumulated other comprehensive income (loss)The components of AOCI were as follows (in millions):Foreigncurrencytranslation adjustmentsCashÂ flowhedgesOtherAOCIBalance as of December 31, 2023(298)(22)$31Â $(289)Foreign currency translation adjustments(24)â€”Â â€”Â (24)Unrealized gainsâ€”Â 178Â â€”Â 178Â Reclassification adjustments into earningsâ€”Â (20)â€”Â (20)Otherâ€”Â â€”Â (3)(3)Income taxesâ€”Â (32)â€”Â (32)Balance as of March 31, 2024(322)104Â 28Â (190)Foreign currency translation adjustments(15)â€”Â â€”Â (15)Unrealized gainsâ€”Â 117Â â€”Â 117Â Reclassification adjustments into earningsâ€”Â (52)â€”Â (52)Otherâ€”Â â€”Â (1)(1)Income taxesâ€”Â (14)â€”Â (14)Balance as of June 30, 2024(337)155Â 27Â (155)Foreign currency translation adjustments71Â â€”Â â€”Â 71Â Unrealized lossesâ€”Â (158)â€”Â (158)Reclassification adjustments into earningsâ€”Â (166)â€”Â (166)Otherâ€”Â â€”Â 1Â 1Â Income taxesâ€”Â 71Â â€”Â 71Â Balance as of September 30, 2024(266)(98)$28Â $(336)Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):Three months ended September 30,Components of AOCI20242023Condensed ConsolidatedStatements of Income locationsCash flow hedges:Foreign currency contract gains$45Â $33Â Product salesCross-currency swap contract gains (losses)121Â (86)Other income, net166Â (53)Income before income taxes(36)11Â Provision for income taxes$130Â $(42)Net incomeNine months ended September 30,Components of AOCI20242023Condensed ConsolidatedStatements of Income locationsCash flow hedges:Foreign currency contract gains$151Â $121Â Product salesCross-currency swap contract gains (losses)87Â (57)Other income, net238Â 64Â Income before income taxes(51)(14)Provision for income taxes$187Â $50Â Net income X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement 9 Months Ended Sep. 30, 2024 Fair Value

Disclosures [Abstract] Â Fair value measurement Fair value measurementTo estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the sources of inputs as follows:LevelÂ 1â€”Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to accessLevelÂ 2â€”Valuations for which all significant inputs are observable either directly or indirectlyâ€”other than Level 1 inputsLevelÂ 3â€”Valuations based on inputs that are unobservable and significant to the overall fair value measurementThe availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement.The fair values of each major class of the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):QuotedÂ prices in activeÂ marketsÂ for identical assets(Level 1)SignificantotherÂ observableinputs(Level 2)Significantunobservableinputs(Level 3)Fair value measurement as of September 30, 2024, using:TotalAssets:Available-for-sale securities:U.S. Treasury bills$â€”Â $996Â $â€”Â $996Â Money market mutual funds7,437Â â€”Â â€”Â 7,437Â Other short-term interest-bearing securitiesâ€”Â 143Â â€”Â 143Â Equity securities5,057Â â€”Â â€”Â 5,057Â Derivatives:Foreign currency forward contractsâ€”Â 99Â â€”Â 99Â Cross-currency swap contractsâ€”Â 4Â â€”Â 4Â Interest rate swap contractsâ€”Â 9Â â€”Â 9Â Total assets$12,494Â $1,251Â $â€”Â $13,745Â Liabilities:Derivatives:Foreign currency forward contracts$â€”Â $121Â $â€”Â $121Â Cross-currency swap contractsâ€”Â 361Â â€”Â 361Â Interest rate swap contractsâ€”Â 404Â â€”Â 404Â Contingent consideration obligationsâ€”Â â€”Â 112Â 112Â Total liabilities$â€”Â $886Â $112Â $998Â QuotedÂ prices in activeÂ marketsÂ for identical assets(Level 1)Significantother observableinputs(Level 2)Significantunobservableinputs(Level 3)Fair value measurement as of December 31, 2023, using:TotalAssets:Available-for-sale securities:U.S. Treasury bills$â€”Â $â€”Â $â€”Â Money market mutual funds10,266Â â€”Â â€”Â 10,266Â Other short-term interest-bearing securitiesâ€”Â 138Â â€”Â 138Â Equity securities4,514Â â€”Â â€”Â 4,514Â Derivatives:Foreign currency forward contractsâ€”Â 145Â â€”Â 145Â Cross-currency swap contractsâ€”Â â€”Â â€”Â â€”Â Interest rate swap contractsâ€”Â â€”Â â€”Â â€”Â Total assets$14,780Â $283Â $â€”Â $15,063Â Liabilities:Derivatives:Foreign currency forward contracts$â€”Â $116Â $â€”Â $116Â Cross-currency swap contractsâ€”Â 405Â â€”Â 405Â Interest rate swap contractsâ€”Â 571Â â€”Â 571Â Contingent consideration obligationsâ€”Â â€”Â 96Â 96Â Total liabilities$â€”Â $1,092Â $96Â $1,188Â Interest-bearing and equity securitiesThe fair values of our money market mutual funds and equity investments in publicly traded securities, including our equity investments in BeiGene and Neumora, as of September 30, 2024 and December 31, 2023, are based on quoted market prices in active markets, with no valuation adjustment.DerivativesAll of our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of Aâ€“ or equivalent by S&P, Moodyâ€™s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, SOFR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments.Contingent consideration obligationsAs a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income.Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):Three months endedSeptember 30,Nine months endedSeptember 30,20242023Beginning balance$107Â $248Â $96Â $270Â Payments(2)(3)(6)(7)Net changes in valuations7Â (147)22Â (165)Ending balance$112Â $98Â $112Â $98Â As of September 30, 2024 and December 31, 2023, our contingent consideration obligations are primarily the result of our acquisition of Teneobio, Inc. in October 2021, which obligates us to pay the former shareholders payments upon achieving separate development and regulatory milestones with regard to various R&D programs.Summary of the fair values of other financial instrumentsCash equivalentsThe fair values of cash equivalents are approximated at their carrying values due to the short-term nature of such financial instruments.BorrowingsWe estimate the fair values of our fixed-rate notes by using Level 2 inputs. As of September 30, 2024 and December 31, 2023, the aggregate fair values of our fixed-rate notes were $58.0 billion and $59.2 billion, respectively, and the carrying values of this debt were $58.6 billion and $60.6 billion, respectively. The estimate of the fair values of our Term loans is approximated as the carrying values as of September 30, 2024 and December 31, 2023 as these debt instruments bear interest at floating rates.During the nine months ended September 30, 2024 and 2023, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Derivative instruments Derivative instrumentsThe Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes.Cash flow hedgesWe are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales is partially offset by corresponding cash outflows from our international operating expenses. To further reduce our exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods.As of September 30, 2024 and December 31, 2023, we had outstanding foreign currency forward contracts with aggregate notional amounts of $7.1 billion and $6.6 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros and pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the terms of the contracts by paying U.S. dollars and receiving euros and pounds sterling. In addition, we will pay U.S. dollars to and receive euros and pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros and pounds sterling to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.The notional amounts and interest rates of our cross-currency swaps as of September 30, 2024, were as follows (notional amounts in millions):Foreign currencyU.S. dollarsHedged notesNotional amountsInterest ratesNotional amountsInterest rates2.00% 2026 euro Notesâ‚¬750Â 2.0Â %$833Â 3.9Â %5.50% 2026 pound sterling NotesÂ£475Â 5.5Â %$747Â 6.0Â %4.00% 2029 pound sterling NotesÂ£700Â 4.0Â %$1,111Â 4.6Â %In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the terms of the associated debt issuances. Amounts recognized in connection with forward interest rate contracts during the nine months ended September 30, 2024, and amounts expected to be recognized during the subsequent 12 months are not material.Unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Derivatives in cash flow hedging relationships20242023202420232Foreign currency forward contracts(238)198Â $87Â $222Â Cross-currency swap contracts80Â (22)50Â (36)Forward interest rate contractsâ€”Â â€”Â â€”Â (31)Total unrealized (losses) gains(158)176Â $137Â $155Â Fair value hedgesTo achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate coupons over the terms of the related hedge contracts. As of both September 30, 2024 and December 31, 2023, we had interest rate swap contracts with aggregate notional amounts of $6.7Â billion, that hedge certain portions of our long-term debt issuances. During the nine months ended September 30, 2024, interest rate swaps with an aggregate notional amount of $1.4Â billion matured in connection with the repayment of the 3.625% 2024 Notes. In addition, we entered into new interest rate swaps with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4Â billion at an interest rate of SOFR plus 1.8%.For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining term of the previously hedged debt.The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):Carrying amounts of hedged liabilities(1)Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)Condensed Consolidated Balance Sheets locationsSeptember 30, 2024December 31, 2023September 30, 2024December 31, 2023Current portion of long-term debt$1,039Â $1,441Â $39Â $41Â Long-term debt$5,307Â $4,788Â (231)(355)_____(1) Â Â Â Â Current portion of long-term debt includes $58 million and $69 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $245 million and $288 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively.(2)Â Â Â Â Current portion of long-term debt includes $58 million and $69 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $145 million and $188 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively.Impact of hedging transactionsThe following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):Three months ended September 30, 2024Nine months ended September 30, 2024Product salesOther income, netInterest expense, netProduct salesOther income, netInterest expense, netTotal amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$8,151Â $1,830Â (776)23,310Â $1,288Â $(2,408)The effects of cash flow and fair value hedging:Gains on cash flow hedging relationships reclassified out of AOCI:Foreign currency forward contracts$45Â $â€”Â $â€”Â $151Â $â€”Â $â€”Â Cross-currency swap contracts$â€”Â $121Â $â€”Â $â€”Â $87Â $â€”Â (Losses) gains on fair

value hedging relationshipsâ€”interest rate swap agreements:Hedged items(1)$â€”Â $â€”Â (153)â€”Â $â€”Â $(122)Derivatives designated as hedging instruments$â€”Â $â€”Â $168Â $â€”Â $â€”Â $176Â Three months ended September 30, 2023Nine months ended September 30, 2023Product salesOther income, netInterest expense, netProduct salesOther income, netInterest expense, netTotal amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,548Â $685Â (759)19,077Â $2,431Â $(2,054)The effects of cash flow and fair value hedging:Gains (losses) on cash flow hedging relationships reclassified out of AOCI:Foreign currency forward contracts$33Â $â€”Â $â€”Â $121Â $â€”Â $â€”Â Cross-currency swap contracts$â€”Â (86)â€”Â $â€”Â (57)â€”Â Gains (losses) on fair value hedging relationshipsâ€”interest rate swap agreements:Hedged items(1)$â€”Â $â€”Â $58Â $â€”Â $â€”Â $63Â Derivatives designated as hedging instruments$â€”Â $â€”Â (37)â€”Â $â€”Â $5Â _____(1)Â Â Â Â Gains (losses) on hedged items do not exactly offset losses (gains) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period.No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of September 30, 2024, amounts expected to be recognized into earnings during the subsequent 12 months on our foreign currency and cross-currency swap contracts are not material.Derivatives not designated as hedgesTo reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of September 30, 2024 and December 31, 2023, the total notional amounts of these foreign currency forward contracts were $82 million and $457 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and nine months ended September 30, 2024 and 2023.Fair values of derivativesThe fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):Â Derivative assetsDerivative liabilitiesSeptember 30, 2024Condensed ConsolidatedBalance Sheets locationsFairÂ valuesCondensed ConsolidatedBalance Sheets locationsFairÂ valuesDerivatives designated as hedgingÂ instruments:Foreign currency forward contractsOther current assets/ Other noncurrent assets$99Â Accrued liabilities/ OtherÂ noncurrent liabilities$121Â Cross-currency swap contractsOther current assets/ Other noncurrent assets4Â Accrued liabilities/ OtherÂ noncurrent liabilities361Â Interest rate swap contractsOther current assets/ Other noncurrent assets9Â Accrued liabilities/ OtherÂ noncurrent liabilities404Â Total derivatives designated as hedging instruments112Â 886Â Total derivatives$112Â $886Â Â Derivative assetsDerivative liabilitiesDecember 31, 2023Condensed ConsolidatedBalance Sheets locationsFairÂ valuesCondensed ConsolidatedBalance Sheets locationsFairÂ valuesDerivatives designated as hedging instruments:Foreign currency forward contractsOther current assets/ Other noncurrent assets$145Â Accrued liabilities/ Other noncurrent liabilities$116Â Cross-currency swap contractsOther current assets/ Other noncurrent assetsâ€”Â Accrued liabilities/ Other noncurrent liabilities405Â Interest rate swap contractsOther current assets/ Other noncurrent assetsâ€”Â Accrued liabilities/ Other noncurrent liabilities571Â Total derivatives designated as hedging instruments145Â 1,092Â Total derivatives$145Â $1,092Â For additional information, see Note 11, Fair value measurement.Our derivative contracts that were in liability positions as of September 30, 2024, contain certain credit-risk-related contingent provisions that would be triggered if (i)Â we were to undergo a change-in-control and (ii)Â our or the surviving entityâ€™s creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur.The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash (used in) provided by financing activities. X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Contingencies and commitments 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Contingencies and commitments Contingencies and commitmentsContingenciesIn the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1A. Risk Factorsâ€”Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024.We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously.Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended MarchÂ 31, 2024 and JuneÂ 30, 2024, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended MarchÂ 31, 2024 and JuneÂ 30, 2024, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows.Certain recent developments concerning our legal proceedings and other matters are discussed below.Repatha Patent LitigationPatent Disputes in the International RegionGermanyOn October 17, 2024 in Sanofi-Aventis Deutschland GmbH (Sanofi-Aventis) and Regeneron Pharmaceuticals, Inc.â€™s (Regeneron) actions seeking damages arising from the provisional enforcement of an injunction against PRALUENTÂ®, the Munich Regional Court scheduled a hearing for February 26, 2025.Unified Patent Court of the European UnionAmgen filed a Statement of Appeal on September 13, 2024, asking the Court of Appeals to the Unified Patent Court (UPC) to set aside the decision of the UPC Central Division revoking Amgenâ€™s European Patent No. 3,666,797 (EP â€˜797).On September 25, 2024, Sanofi Biotechnologies SAS and Regeneron filed a brief seeking to expand the ongoing UPC action, alleging that Amgenâ€™s Repatha infringes a newly-issued patent, European Patent No. 4,252,857, seeking an injunction against the marketing, use, or importation of Repatha in 18 countries (Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Sweden) and damages for past infringement.European Patent OfficeThe European Patent Office (EPO) Opposition Division will hear argument on Sanofi-Aventis and Regeneronâ€™s opposition against Amgenâ€™s EP â€˜797 from March 31 to April 4, 2025.In Amgenâ€™s opposition before the EPO against Regeneronâ€™s European Patent No. 3,536,712, the Opposition Division will hear argument on March 11 and 12, 2025.JapanOn September 16, 2024, Amgen filed an appeal brief with the Japanese Intellectual Property High Court, seeking to overturn the Japanese Patent Officeâ€™s decision to reject Amgenâ€™s amended patent claims following a remand of the case to the Japanese Patent Office from the Japanese Intellectual Property High Court.Prolia/XGEVA Biologics Price Competition and Innovation Act (BPCIA) LitigationAmgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al.On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgenâ€™s Prolia and XGEVA products. The complaint asserts infringement of the following 34 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,058,418; 8,247,210; 8,460,896; 8,680,248; 9,012,178; 9,320,816; 9,328,134; 9,359,435; 9,481,901; 10,106,829; 10,167,492; 10,227,627; 10,421,987; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 10,907,186; 11,098,079; 11,130,980; 11,254,963; 11,292,829; 11,299,760; 11,384,378; 11,427,848; 11,434,514; 11,634,476; 11,685,772; 11,744,950; and 11,946,085 (collectively, the Asserted Patents). Amgen seeks a judgment from the New Jersey District Court that Samsung has infringed or will infringe one or more claims of each of the Asserted Patents and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Samsungâ€™s proposed denosumab biosimilar before expiration of each of the Asserted Patents found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Bioepis filed its Answer and Counterclaims in response to the Complaint on October 1, 2024. Biologicâ€™s response to the Complaint is due on October 28, 2024.Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al.On October 4, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the Northern District of Illinois (Northern Illinois District Court) against Fresenius Kabi USA, LLC, Fresenius SwissBiosim GmbH, Fresenius Kabi Deutschland, GmbH, and Fresenius Kabi Austria GmbH (collectively, Fresenius) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgenâ€™s Prolia and XGEVA products. The complaint asserts infringement of the following 33 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,053,236; 8,058,418; 8,460,896; 8,680,248; 9,012,178; 9,228,168; 9,320,816; 9,328,134; 9,359,435; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,744,950; 11,786,866; 11,946,085; 11,952,605; and 12,084,686 (collectively, the Asserted Patents). Amgen seeks a judgment from the Northern Illinois District Court that Fresenius has infringed or will infringe one or more claims of each of the Asserted Patents and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Freseniusâ€™s proposed denosumab biosimilar before expiration of each of the Asserted Patents found infringed. Amgen also seeks monetary remedies for any past acts of infringement.PAVBLUâ„¢ (formerly ABP 938 (aflibercept-ayyh)) Patent LitigationOn September 23, 2024, the U.S. District Court for the Northern District of West Virginia denied Regeneronâ€™s motion for a preliminary injunction, and Regeneron filed a notice of appeal, a motion to expedite the appeal, and an emergency motion for an injunction pending resolution of the appeal and for an administrative stay with the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On September 25, 2024, the Federal Circuit Court issued an order temporarily enjoining the launch of PAVBLU on an administrative basis while it considered Regeneronâ€™s motion for an injunction pending appeal. On October 22, 2024, the Federal Circuit Court denied Regeneronâ€™s motion for an injunction pending appeal and lifted the temporary injunction that was entered on September 25, 2024. Amgenâ€™s response brief to the appeal is due on November 4, 2024, Regeneronâ€™s reply brief is due on November 13, 2024 and oral arguments for the appeal will be scheduled for January 2025.Antitrust Class ActionsSensipar Antitrust Class ActionsOn September 13, 2024, the putative class of direct purchasers of Sensipar (Sensipar Plaintiffs) filed their opening brief in its appeal of the dismissal of its claims by the U.S. District Court for the District of Delaware (Delaware District Court). Amgen has obtained an extension until November 14, 2024 to file its opposing brief. The Sensipar Plaintiffsâ€™ reply is due December 5, 2024.Regeneron Pharmaceuticals, Inc. Antitrust ActionThe trial before the Delaware District Court that had been set to begin on November 12, 2024 was taken off calendar. A new date for the trial has not yet been set. The Delaware District Court set a hearing on November 20, 2024 to hear Amgenâ€™s motion for summary judgment and the partiesâ€™ motions to exclude expert testimony.CareFirst of Maryland Antitrust Class ActionOn August 6, 2024, CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., and CareFirst BlueChoice, Inc. (collectively, CareFirst), filed a class action antitrust lawsuit against Amgen Inc., Amgen Manufacturing, Limited (corrected to Amgen Manufacturing Limited LLC in CareFirstâ€™s amended complaint on October 11, 2024), and Immunex Corporation in the U.S. District Court for the Eastern District of Virginia, alleging federal and state antitrust claims and state consumer protection claims. The plaintiffs allege that, in 2004, Amgen entered into an anticompetitive agreement with certain F. Hoffman-La Roche AG entities (Roche) and other parties that provided Amgen with rights to Rocheâ€™s patents in a manner that enabled Amgen to allegedly unlawfully extend the life of patents applicable to ENBREL and, thereby, delay biosimilar entry. Amgenâ€™s response to the complaint is due on November 4, 2024.U.S. Tax Litigation and Related MattersAmgen Inc. & Subsidiaries v. Commissioner of Internal RevenueSee Note 4, Income taxes, for discussion of the IRS tax dispute and the Companyâ€™s petitions in the U.S. Tax Court.Securities Class Action Litigation (Roofers Local No. 149 Pension Fund)On September 30, 2024, the U.S. District Court for the Southern District of New York denied Amgenâ€™s motion to dismiss. Amgen's response to the complaint is due on November 20, 2024.Shareholder Derivative Litigation (Hamilton)On October 16, 2024, David Hamilton filed a derivative action captioned David Hamilton v. Robert A. Bradway, et al., No. 2024-1063 (Del. Chan. Ct. Oct. 16, 2024), purportedly on behalf of Amgen, against Amgen, Robert Bradway, Peter Griffith and Amgenâ€™s Board members during the relevant time period. The action was filed in the Delaware Chancery Court. The complaint in this matter alleges claims for breach of fiduciary duty and unjust enrichment. The factual allegations that form the basis for these claims are fundamentally the same as those asserted by the Roofers Local No. 149 Pension Fund on March 13, 2023 (alleging false and misleading statements and omissions made from July 29, 2020 through April 27, 2022 relating to Amgenâ€™s tax liabilities, business and finances, and the adequacy and maintenance of its internal controls).ChemoCentryx, Inc. Securities MattersOn September 10, 2024, the U.S. District Court for the Northern District of California granted an administrative motion to extend certain case schedule deadlines, including setting the expert discovery cutoff to December 20, 2024 and setting the deadlines for summary judgment motions on April 4, 2025, summary judgment oppositions on April 25, 2025, and summary judgment replies on May 9, 2025. Trial is set for September 2025. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar.

31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Net income for basic and diluted EPS $ 2,830 $ 746 $ (113) $ 1,730 $ 1,379 $ 2,841 $ 3,463 $ 5,950 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Business BusinessAmgen Inc. (including its consolidated subsidiaries, referred to as â€œAmgen,â€ â€œthe Company,â€ â€œwe,â€ â€œourâ€ or â€œusâ€) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics.Â We operate in one business segment: human therapeutics. Basis of presentation Basis of presentationThe interim unaudited financial information for the three and nine months ended September 30, 2024 and 2023, has been prepared in accordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) that Amgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024. Principles of consolidation Principles of consolidationThe condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entityâ€™s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with the current presentation. Use of estimates Use of estimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment, netProperty, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $10.3Â billion and $9.8 billion as of September 30, 2024 and December 31, 2023, respectively. Recent accounting pronouncements Recent accounting pronouncementsIn December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or may elect retrospective application. We are currently evaluating the impact of adopting this new standard on our related disclosures.In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted, and the standard requires retrospective application to all prior periods presented. We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements. X - DefinitionShows the basis of presentation of financial information for interim periods. + ReferencesNo definition available. + Details Name: amgn_BasisOfPresentationPolicyTextBlock Namespace Prefix: amgn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDescribes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description". + ReferencesNo definition available. + Details Name: amgn_NatureOfOperationsPolicyTextBlock Namespace Prefix: amgn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -

Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions (Tables) 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Schedule of Business Acquisitions, by Acquisition The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):Cash and cash equivalents$681Â Inventories5,014Â Property, plant and equipment, net318Â Finite-lived intangible assets â€“ developed-product-technology rights19,590Â IPR&D1,060Â Goodwill3,136Â Deferred tax asset795Â Deferred tax liability(2,488)Other assets and liabilities, net(273)Total assets acquired, net of liabilities assumed$27,833Â Business Acquisition, Pro Forma Information The following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the three and nine months ended September 30, 2023, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions):Three months ended September 30, 2023Nine months ended September 30, 2023Total revenues$7,854Â $22,728Â Net income$902Â $3,518Â X - DefinitionTabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Disaggregation of Revenue by Product and by Geographic Area Revenues were as follows (in millions):Three months ended September 30,20242023U.S.ROWTotalU.S.ROWTotalProlia$683Â $362Â $1,045Â $673Â $313Â $986Â ENBREL817Â 8Â 825Â 1,026Â 9Â 1,035Â XGEVA373Â 168Â 541Â 374Â 145Â 519Â Repatha281Â 286Â products(3)958Â 405Â 1,363Â 675Â 329Â 1,004Â Total product sales(4)$5,979Â $2,172Â 8,151Â $4,691Â $1,857Â 6,548Â Other revenues352Â 355Â Total revenues$8,503Â $6,903Â Nine months ended September 30,20242023U.S.ROWTotalU.S.ROWTotalProlia$2,110Â $1,099Â $3,209Â $1,987Â $954Â $2,941Â ENBREL2,280212,301Â 2,645372,682Â XGEVA1,1385261,664Â 1,1454401,585Â Repatha824?9 products(3)2,858Â 1,2044,062Â 2,271Â 1,0493,320Â Total product sales(4)$16,792Â $6,518Â 23,310Â $13,402Â $5,675Â 19,077Â Other revenues1,028Â 917Â Total revenues$24,338Â $19,994Â _____(1)Â Â Â Â TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.(2)Â Â Â Â TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.(3)Â Â Â Â Consists of product sales of our non-principal products. (4)Â Â Â Â Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2024 and 2023. X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings per share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Computation for Basic and Diluted EPS The computations for basic and diluted EPS were as follows (in millions, except per-share data):Â Three months endedSeptember 30,Nine months endedSeptember 30,Â 20242023202420232023Income (Numerator):Net income for basic and diluted EPS$2,830Â $1,730Â $3,463Â $5,950Â Shares (Denominator):Weighted-average shares for basic EPS537Â 535Â 537Â 535Â Effect of dilutive securities5Â 3Â 4Â 3Â Weighted-average shares for diluted EPS542Â 538Â 541Â 538Â Basic EPS$5.27Â $3.23Â $6.45Â $11.12Â Diluted EPS$5.22Â $3.22Â $6.40Â $11.06Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Investments (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of Available-For-Sale Investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):Types of securities as of September 30, 2024AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvaluesU.S. Treasury bills$996Â $â€”Â $â€”Â $996Â Money market mutual funds7,437Â â€”Â â€”Â 7,437Â Other short-term interest-bearing securities143Â â€”Â â€”Â 143Â Total interest-bearing securities$8,576Â $â€”Â $â€”Â $8,576Â Types of securities as of December 31, 2023AmortizedcostGrossunrealizedgainsGrossunrealizedlossesFairvaluesU.S. Treasury bills$â€”Â $â€”Â $â€”Â $â€”Â Money market mutual funds10,266Â â€”Â â€”Â 10,266Â Other short-term interest-bearing securities138Â â€”Â â€”Â 138Â Total interest-bearing securities$10,404Â $â€”Â $â€”Â $10,404Â Schedule of Fair Values by Classification The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions):Condensed Consolidated Balance Sheets locationsSeptember 30, 2024December 31, 2023Cash and cash equivalents$8,576Â $10,404Â Total interest-bearing securities$8,576Â $10,404Â X - DefinitionTabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets. + ReferencesNo definition available. + Details Name: amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock Namespace Prefix: amgn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Â Inventories Inventories consisted of the following (in millions):September 30, 2024December 31, 2023Raw materials$788Â $993Â Work in process4,339Â 5,747Â Finished goods2,235Â 2,778Â Total inventories$7,362Â $9,518Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and other intangible assets (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Goodwill The change in the carrying amount of goodwill was as follows (in millions):Balance at January 1, 2024$18,629Â Adjustments to goodwill resulting from acquisitions (1)25Â Foreign currency translation adjustments4Â Balance at September 30, 2024$18,658Â _____(1)Â Â Â Â For the nine months ended September 30, 2024, adjustments to goodwill consisted of measurement period adjustments related to our Horizon acquisition. See Note 2, Acquisitions. Schedule of Identifiable Intangible Assets Other intangible assets consisted of the following (in millions):Â September 30, 2024December 31, 2023Â GrosscarryingamountsAccumulatedamortizationOther intangibleassets, netGrosscarryingamountsAccumulatedamortizationOther intangibleassets, netFinite-lived intangible assets:Developed-product-technology rights$48,636Â $(21,472)$27,164Â $48,631Â $(18,049)$30,582Â Licensing rights3,864Â (3,360)504Â 3,865Â (3,265)600Â Marketing-related rights1,203Â (1,188)15Â 1,339Â (1,264)75Â Research and development technology rights1,400Â (1,253)147Â 1,394Â (1,228)166Â Total finite-lived intangible assets55,103Â (27,273)27,830Â 55,229Â (23,806)31,423Â Indefinite-lived intangible assets:In-process research and development1,090Â â€”Â 1,090Â 1,218Â â€”Â 1,218Â Total other intangible assets$56,193Â $(27,273)$28,920Â $56,447Â $(23,806)$32,641Â X - DefinitionTabular disclosure of finite-lived and indefinite-lived identifiable intangible assets. + ReferencesNo definition available. + Details Name: amgn_ScheduleOfIntangibleAssetsTableTextBlock Namespace Prefix: amgn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Financing arrangements (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Borrowings Our borrowings consisted of the following (in millions):Â September 30, 2024December 31, 20233.625% notes due 2024 (3.625% 2024 Notes)$â€”Â $1,400Â 1.90% notes due 2025 (1.90% 2025 Notes)500Â 500Â 5.25% notes due 2025 (5.25% 2025 Notes)2,000Â 2,000Â Term loan due April 2025â€”Â 2,000Â 3.125% notes due 2025 (3.125% 2025 Notes)1,000Â 1,000Â 2.00% â,¬750 million notes due 2026 (2.00% 2026 euro Notes)835Â 828Â 5.507% notes due 2026 (5.507% 2026 Notes)1,500Â 1,500Â 2.60% notes due 2026 (2.60% 2026 Notes)1,250Â 1,250Â Term loan due October 20261,800Â 2,000Â 5.50% Â£475 million notes due 2026 (5.50% 2026 pound sterling Notes)635Â 605Â 2.20% notes due 2027 (2.20% 2027

Notes)1,724Â 1,724Â 3.20% notes due 2027 (3.20% 2027 Notes)1,000Â 1,000Â 5.15% notes due 2028 (5.15% 2028 Notes)3,750Â 3,750Â 1.65% notes due 2028 (1.65% 2028 Notes)1,234Â 1,234Â 3.00% notes due 2029 (3.00% 2029 Notes)750Â 750Â 4.05% notes due 2029 (4.05% 2029 Notes)1,250Â 1,250Â 4.00% Â£700 million notes due 2029 (4.00% 2029 pound sterling Notes)936Â 892Â 2.45% notes due 2030 (2.45% 2030 Notes)1,250Â 1,250Â 5.25% notes due 2030 (5.25% 2030 Notes)2,750Â 2,750Â 2.30% notes due 2031 (2.30% 2031 Notes)1,250Â 1,250Â 2.00% notes due 2032 (2.00% 2032 Notes)1,001Â 1,001Â 3.35% notes due 2032 (3.35% 2032 Notes)1,000Â 1,000Â 4.20% notes due 2033 (4.20% 2033 Notes)750Â 750Â 5.25% notes due 2033 (5.25% 2033 Notes)4,250Â 4,250Â 6.375% notes due 2037 (6.375% 2037 Notes)478Â 478Â 6.90% notes due 2038 (6.90% 2038 Notes)254Â 254Â 6.40% notes due 2039 (6.40% 2039 Notes)333Â 333Â 3.15% notes due 2040 (3.15% 2040 Notes)1,668Â 1,803Â 5.75% notes due 2040 (5.75% 2040 Notes)373Â 373Â 2.80% notes due 2041 (2.80% 2041 Notes)776Â 949Â 4.95% notes due 2041 (4.95% 2041 Notes)600Â 600Â 5.15% notes due 2041 (5.15% 2041 Notes)729Â 729Â 5.65% notes due 2042 (5.65% 2042 Notes)415Â 415Â 5.60% notes due 2043 (5.60% 2043 Notes)2,750Â 2,750Â 5.375% notes due 2043 (5.375% 2043 Notes)185Â 185Â 4.40% notes due 2045 (4.40% 2045 Notes)2,250Â 2,250Â 4.563% notes due 2048 (4.563% 2048 Notes)1,415Â 1,415Â 3.375% notes due 2050 (3.375% 2050 Notes)1,764Â 2,132Â 4.663% notes due 2051 (4.663% 2051 Notes)3,541Â 3,541Â 3.00% notes due 2052 (3.00% 2052 Notes)890Â 999Â 4.20% notes due 2052 (4.20% 2052 Notes)895Â 950Â 4.875% notes due 2053 (4.875% 2053 Notes)1,000Â 1,000Â 5.65% notes due 2053 (5.65% 2053 Notes)4,250Â 4,250Â 2.77% notes due 2053 (2.77% 2053 Notes)940Â 940Â 4.40% notes due 2062 (4.40% 2062 Notes)1,165Â 1,200Â Â September 30, 2024December 31, 20235.75% notes due 2063 (5.75% 2063 Notes)2,750Â 2,750Â Other notes due 2097100Â 100Â Unamortized bond discounts, premiums and issuance costs, net(1,373)(1,420)Fair value adjustments(192)(314)Other27Â 17Â Total carrying value of debt60,398Â 64,613Â Less current portion(3,544)(1,443)Total long-term debt$56,854Â $63,170Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Components of Accumulated Other Comprehensive Income The components of AOCI were as follows (in millions):Foreigncurrencytranslation adjustmentsCashÂ flowhedgesOtherAOCIBalance as of December 31, 2023(298)(22)$31Â $(289)Foreign currency translation adjustments(24)â€”Â â€”Â (24)Unrealized gainsâ€”Â 178Â â€”Â 178Â Reclassification adjustments into earningsâ€”Â (20)â€”Â (20)Otherâ€”Â â€”Â (3)(3)Income taxesâ€”Â (32)â€”Â (32)Balance as of March 31, 2024(322)104Â 28Â (190)Foreign currency translation adjustments(15)â€”Â â€”Â (15)Unrealized gainsâ€”Â 117Â â€”Â 117Â Reclassification adjustments into earningsâ€”Â (52)â€”Â (52)Otherâ€”Â â€”Â (1)(1)Income taxesâ€”Â (14)â€”Â (14)Balance as of June 30, 2024(337)155Â 27Â (155)Foreign currency translation adjustments71Â â€”Â â€”Â 71Â Unrealized lossesâ€”Â (158)â€”Â (158)Reclassification adjustments into earningsâ€”Â (166)â€”Â (166)Otherâ€”Â â€”Â 1Â 1Â Income taxesâ€”Â 71Â â€”Â 71Â Balance as of September 30, 2024(266)(98)$28Â $(336) Reclassifications Out of Accumulated Other Comprehensive Income Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions):Three months ended September 30,Components of AOCI20242023Condensed ConsolidatedStatements of Income locationsCash flow hedges:Foreign currency contract gains$45Â $33Â Product salesCross-currency swap contract gains (losses)121Â (86)Other income, net166Â (53)Income before income taxes(36)11Â Provision for income taxes$130Â $(42)Net incomeNine months ended September 30,Components of AOCI20242023Condensed ConsolidatedStatements of Income locationsCash flow hedges:Foreign currency contract gains$151Â $121Â Product salesCross-currency swap contract gains (losses)87Â (57)Other income, net238Â 64Â Income before income taxes(51)(14)Provision for income taxes$187Â $50Â Net income X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss). + ReferencesNo definition available. + Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value of Financial Assets and Liabilities on Recurring Basis The fair values of each major class of the Companyâ€™s financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions):QuotedÂ prices in activeÂ marketsÂ for identical assets(Level 1)SignificantotherÂ observableinputs(Level 2)Significantunobservableinputs(Level 3)Fair value measurement as of September 30, 2024, using:TotalAssets:Available-for-sale securities:U.S. Treasury bills$â€”Â $996Â $â€”Â $996Â Money market mutual funds7,437Â â€”Â â€”Â 7,437Â Other short-term interest-bearing securitiesâ€”Â 143Â â€”Â 143Â Equity securities5,057Â â€”Â â€”Â 5,057Â Derivatives:Foreign currency forward contractsâ€”Â 99Â â€”Â 99Â Cross-currency swap contractsâ€”Â 4Â â€”Â 4Â Interest rate swap contractsâ€”Â 9Â â€”Â 9Â Total assets$12,494Â $1,251Â $â€”Â $13,745Â Liabilities:Derivatives:Foreign currency forward contracts$â€”Â $121Â $â€”Â $121Â Cross-currency swap contractsâ€”Â 361Â â€”Â 361Â Interest rate swap contractsâ€”Â 404Â â€”Â 404Â Contingent consideration obligationsâ€”Â â€”Â 112Â 112Â Total liabilities$â€”Â $886Â $112Â $998Â QuotedÂ prices in activeÂ marketsÂ for identical assets(Level 1)Significantother observableinputs(Level 2)Significantunobservableinputs(Level 3)Fair value measurement as of December 31, 2023, using:TotalAssets:Available-for-sale securities:U.S. Treasury bills$â€”Â $â€”Â $â€”Â $â€”Â Money market mutual funds10,266Â â€”Â â€”Â 10,266Â Other short-term interest-bearing securitiesâ€”Â 138Â â€”Â 138Â Equity securities4,514Â â€”Â â€”Â 4,514Â Derivatives:Foreign currency forward contractsâ€”Â 145Â â€”Â 145Â Cross-currency swap contractsâ€”Â â€”Â â€”Â â€”Â Interest rate swap contractsâ€”Â â€”Â â€”Â â€”Â Total assets$14,780Â $283Â â€”Â $15,063Â Liabilities:Derivatives:Foreign currency forward contracts$â€”Â $116Â $â€”Â $116Â Cross-currency swap contractsâ€”Â 405Â â€”Â 405Â Interest rate swap contractsâ€”Â 571Â â€”Â 571Â Contingent consideration obligationsâ€”Â â€”Â 96Â 96Â Total liabilities$â€”Â $1,092Â $96Â $1,188Â Contingent Consideration Obligations Changes in the carrying amounts of contingent consideration obligations were as follows (in millions):Three months endedSeptember 30,Nine months endedSeptember 30,20242023202420232023Beginning balance$107Â $248Â $96Â $270Â Payments(2)(3)(6)(7)Net changes in valuations7Â (147)22Â (165)Ending balance$112Â $98Â $112Â $98Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments (Tables) 9 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Schedule of Cross-Currency Swaps The notional amounts and interest rates of our cross-currency swaps as of September 30, 2024, were as follows (notional amounts in millions):Foreign currencyU.S. dollarsHedged notesNotional amountsInterest ratesNotional amountsInterest rates2.00% 2026 euro Notesâ‚¬750Â 2.0Â %$833Â 3.9Â %5.50% 2026 pound sterling NotesÂ£475Â 5.5Â %$747Â 6.0Â %4.00% 2029 pound sterling NotesÂ£700Â 4.0Â %$1,111Â 4.6Â % Summary of Unrealized Gains and Losses Recognized in AOCI Unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions):Â Three months endedSeptember 30,Nine months endedSeptember 30,Derivatives in cash flow hedging relationships20242023202420232023Foreign currency forward contracts(238)198Â $87Â $222Â Cross-currency swap contracts80Â (22)50Â (36)Forward interest rate contractsâ€”Â â€”Â â€”Â (31)Total unrealized (losses) gains(158)176Â $137Â $155Â Hedged Liabilities and Cumulative Amount The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):Carrying amounts of hedged liabilities(1)Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)Condensed Consolidated Balance Sheets locationsSeptember 30, 2024December 31, 2023September 30, 2024December 31, 2023Current portion of long-term debt$1,039Â $1,441Â $39Â $41Â Long-term debt$5,307Â $4,788Â (231)(355)_____(1) Â Â Â Â Current portion of long-term debt includes $58 million and $69 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $245 million and $288 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. (2)Â Â Â Â Current portion of long-term debt includes $58 million and $69 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $145 million and $188 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Summary of Income and Expense Line Items The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):Three months ended September 30, 2024Nine months ended September 30, 2024Product salesOther income, netInterest expense, netProduct salesOther income, netInterest expense, netTotal amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$8,151Â $1,830Â (776)23,310Â $1,288Â $(2,408)The effects of cash flow and fair value hedging:Gains on cash flow hedging relationships reclassified out of AOCI:Foreign currency forward contracts$45Â $â€”Â $â€”Â $151Â $â€”Â $â€”Â Cross-currency swap contracts$â€”Â $121Â $â€”Â $â€”Â $87Â $â€”Â (Losses) gains on fair value hedging relationships$â€”interest rate swap agreements:Hedged items(1)$â€”Â $â€”Â (153)â€”Â $â€”Â $(122)Derivatives designated as hedging instruments$â€”Â $â€”Â $168Â $â€”Â $â€”Â $176Â Three months ended September 30, 2023Nine months ended September 30, 2023Product salesOther income, netInterest expense, netProduct salesOther income, netInterest expense, netTotal amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income$6,548Â $685Â (759)19,077Â $2,431Â $(2,054)The effects of cash flow and fair value hedging:Gains (losses) on cash flow hedging relationships reclassified out of AOCI:Foreign currency forward contracts$33Â $â€”Â $â€”Â $121Â $â€”Â $â€”Â Cross-currency swap contracts$â€”Â (86)â€”Â $â€”Â (57)â€”Â Gains (losses) on fair value hedging relationships$â€”interest rate swap agreements:Hedged items(1)$â€”Â $â€”Â $58Â $â€”Â $â€”Â $63Â Derivatives designated as hedging instruments$â€”Â $â€”Â (37)â€”Â $â€”Â $5Â _____(1)Â Â Â Â Gains (losses) on hedged items do not exactly offset losses (gains) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. Fair Value of Derivatives The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions):Â Derivative assetsDerivative liabilitiesSeptember 30, 2024Condensed ConsolidatedBalance Sheets locationsFairÂ valuesCondensed ConsolidatedBalance Sheets locationsFairÂ valuesDerivatives designated as hedgingÂ instruments:Foreign currency forward contractsOther current assets/ Other noncurrent assets$99Â Accrued liabilities/ OtherÂ noncurrent liabilities$121Â Cross-currency swap contractsOther current assets/ Other noncurrent assets4Â Accrued liabilities/ OtherÂ noncurrent liabilities361Â Interest rate swap contractsOther current assets/ Other noncurrent assets9Â Accrued liabilities/ OtherÂ noncurrent liabilities404Â Total derivatives designated as hedging instruments112Â 886Â Total derivatives$112Â $886Â Â Derivative assetsDerivative liabilitiesDecember 31, 2023Condensed ConsolidatedBalance Sheets locationsFairÂ valuesCondensed ConsolidatedBalance Sheets locationsFairÂ valuesDerivatives designated as hedging instruments:Foreign currency forward contractsOther current assets/ Other noncurrent assets$145Â Accrued liabilities/ Other noncurrent liabilities$116Â Cross-currency swap contractsOther current assets/ Other noncurrent assetsâ€”Â Accrued liabilities/ Other noncurrent liabilities405Â Interest rate swap contractsOther current assets/ Other noncurrent assetsâ€”Â Accrued liabilities/ Other noncurrent liabilities571Â Total derivatives designated as hedging instruments145Â 1,092Â Total derivatives$145Â $1,092Â X - DefinitionSchedule of Notional Amounts and Interest Rates for Cross-Currency Swaps + ReferencesNo definition available. + Details Name: amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock Namespace Prefix: amgn_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:

na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies (Details) $ in Billions 9 Months Ended Sep. 30, 2024 USD ($) segment Sep. 30, 2024 USD ($) Segment Dec. 31, 2023 USD ($) Accounting Policies [Abstract] Â Â Â Number of operating segments 1 1 Â Accumulated depreciation and amortization on property, plant and equipment $ 10.3 $ 10.3 $ 9.8 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions - Acquisition of Horizon Therapeutics plc (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions 9 Months Ended Oct. 06, 2023 Sep. 30, 2024 Dec. 31, 2023 Business Acquisition [Line Items] Â Â Â Goodwill Â $ 18,658 $ 18,629 Horizon Therapeutics Â Â Â Business Acquisition [Line Items] Â Â Â Acquisition price per share (in dollars per share) $ 116.50 Â Â Consideration transferred $ 27,800 Â Â Goodwill increase Â $ 25 Â Cash purchase price 26,700 Â Â Consideration transferred for vested and outstanding awards 523 Â Â Consideration transferred for replacement awards 180 Â Â Liabilities incurred $ 382 Â Â Replacement equity awards issued (in shares) 1.7 Â Â Inventories $ 5,014 Â Â Business combination, turnover period of inventory acquired 27 months Â Â Deferred tax liability $ 2,488 Â Â Deferred tax asset 795 Â Â Goodwill 3,136 Â Â Horizon Therapeutics | Developed-product-technology rights Â Â Â Business Acquisition [Line Items] Â Â Â Estimated fair value $ 20,700 Â Â Weighted average period of amortization 10 years Â Â X - DefinitionBusiness Combination, Consideration Transferred, Equity Interests Issued And Issuable, Value Of Acquirer Replacement Awards + ReferencesNo definition available. + Details Name: amgn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableValueOfAcquirerReplacementAwards Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionBusiness Combination, Payments To Acquire Business, Vested And Outstanding Awards + ReferencesNo definition available. + Details Name: amgn_BusinessCombinationPaymentsToAcquireBusinessVestedAndOutstandingAwards Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionBusiness combination, turnover period of inventory acquired + ReferencesNo definition available. + Details Name: amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired Namespace Prefix: amgn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + ReferencesNo definition available. + Details Name: us-gaap_BusinessAcquisitionSharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of inventory recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Oct. 06, 2023 Business Acquisition [Line Items] Â Â Â Goodwill $ 18,658 $ 18,629 Â Horizon Therapeutics Â Â Â Business Acquisition [Line Items] Â Â Â Cash and cash equivalents Â Â $ 681 Inventories Â Â 5,014 Property, plant and equipment, net Â Â 318 IPR&D Â Â 1,060 Goodwill Â Â 3,136 Deferred tax asset Â Â 795 Deferred tax liability Â Â (2,488) Other assets and liabilities, net Â Â (273) Total assets acquired, net of liabilities assumed Â Â 27,833 Horizon Therapeutics | Developed-product-technology rights Â Â Â Business Acquisition [Line Items] Â Â Â Finite-lived intangible assets â€“ developed-product-technology rights Â Â $ 19,590 X - DefinitionBusiness Acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net + ReferencesNo definition available. + Details Name: amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionBusiness Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities) + ReferencesNo definition available. + Details Name: amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of inventory recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of property, plant, and equipment recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Acquisitions - Supplemental Pro Forma Financial Information (Details) - Horizon Therapeutics - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2023 Sep. 30, 2023 Business Acquisition [Line Items] Â Â Total revenues $ 7,854 $ 22,728 Net income $ 902 $ 3,518 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2 + Details Name: us-gaap_BusinessAcquisitionsProFormaRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=amgn_HorizonTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Narrative (Details) - 9 months ended Sep. 30, 2024 segment Segment Revenue from Contract with Customer [Abstract] Â Â Number of operating segments 1 1 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Disaggregation of Revenue by Product and by Geographic Area (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue from External Customer [Line Items] Â Â Â Â Â Total revenues $ 8,503 $ 6,903 $ 24,338 $ 19,994 Product sales Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 8,151 6,548 23,310 19,077 Product sales | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 5,979 4,691 16,792 13,402 Product sales | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 2,172 1,857 6,518 5,675 Prolia Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 1,045 986 3,209 2,941 Prolia | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 683 673 2,110 1,987 Prolia | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 362 313 1,099 954 ENBREL Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 825 1,035 2,301 2,682 ENBREL | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 817 1,026 2,280 2,645 ENBREL | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 8 9 21 37 XGEVA Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 541 519 1,664 1,585 XGEVA | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 373 374 1,138 1,145 XGEVA | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 168 145 526 440 Repatha Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 567 406 1,616 1,218 Repatha | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 281 183 824 592 Repatha | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 286 223 792 626 Otezla Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 564 567 1,502 1,559 Otezla | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 460 462 1,185 1,251 Otezla | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 104 105 317 308 TEPEZZA Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 488 0 1,391 0 TEPEZZA | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 482 0 1,379 0 TEPEZZA | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 6 0 12 0 EVENITY Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 399 307 1,132 842 EVENITY | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 289 214 806 570 EVENITY | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 110 93 326 272 KYPROLIS Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 378 349 1,131 1,053 KYPROLIS | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 238 231 712 699 KYPROLIS | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 140 118 419 354 Nplate Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 456 419 1,119 1,091 Nplate | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 345 322 749 744 Nplate | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 111 97 370 347 Aranesp Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 337 323 1,034 1,043 Aranesp | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 105 107 296 345 Aranesp | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 232 216 738 698 KRYSTEXXA Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 310 0 839 0 KRYSTEXXA | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 310 0 839 0 KRYSTEXXA | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 0 0 0 0 BLINCYTO Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 327 220 835 620 BLINCYTO | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 237 147 555 418 BLINCYTO | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 90 73 280 202 Vectibix Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 282 252 799 733 Vectibix | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 132 116 385 345 Vectibix | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 150 136 414 388 TEZSPIRE Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 269 161 676 390 TEZSPIRE | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 269 161 676 390 TEZSPIRE | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 0 0 0 0 Other products Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 1,363 1,004 4,062 3,320 Other products | U.S. Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 958 675 2,858 2,271 Other products | ROW Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues 405 329 1,204 1,049 Other revenues Â Â Â Â Revenue from External Customer [Line Items] Â Â Â Â Total revenues $ 352 $ 355 $ 1,028 $ 917 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_ProliaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_EnbrelMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_XgevaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_OtezlaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_TEPEZZAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_EVENITYMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_KyprolisMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_NplateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_AranespMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_KRYSTEXXAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_BLINCYTOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_VectibixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_TEZSPIREMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=amgn_OtherProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Income taxes (Details) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 Sep. 30, 2024 USD ($) Sep. 30, 2023 Dec. 19, 2022 case Apr. 28, 2022 USD ($) May 31, 2021 USD ($) notice Income Tax Examination [Line Items] Â Â Â Â Â Â Â Â Â Effective income tax rate 8.70% 11.10% 9.50% 15.00% Â Â Â Increase in unrecognized tax benefits resulting from tax positions taken during the current period $ 40 Â $ 120 Â Â Â Â Domestic Tax Authority Â Â Â Â Â Â Â Income Tax Examination [Line Items] Â Â Â Â Â Â Â Number of notices on proposed additional tax | notice Â Â Â Â Â Â 2 Number of notices consolidated | case Â Â Â Â 2 Â Â Domestic Tax Authority | Tax Years 2010-2012 Â Â Â Â Â Â Â Income Tax Examination [Line Items] Â Â Â Â Â Â Â Proposed additional income tax Â Â Â Â Â Â $ 3,600 Repatriation tax on proposed additional tax Â Â Â Â Â Â $ 900 Domestic Tax Authority | Tax Year 2013-2015 Â Â Â Â Â Â Â Income Tax Examination [Line Items] Â Â Â Â Â Â Â Proposed additional income tax Â Â Â Â Â $ 5,100 Â Repatriation tax on proposed additional tax Â Â Â Â Â 2,200 Â Penalties on proposed additional income tax Â Â Â Â Â $ 2,000 Â X - DefinitionNumber Of Notices Consolidated + ReferencesNo definition available. + Details Name: amgn_NumberOfNoticesConsolidated Namespace Prefix: amgn_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of notices on proposed additional tax + ReferencesNo definition available. + Details Name: amgn_NumberOfNoticesOnProposedAdditionalTax Namespace Prefix: amgn_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionPenalties On Proposed Additional Income Tax + ReferencesNo definition available. + Details Name: amgn_PenaltiesOnProposedAdditionalIncomeTax Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionProposed Additional Income Tax + ReferencesNo definition available. + Details Name: amgn_ProposedAdditionalIncomeTax Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepatriation Tax On Proposed Additional Tax + ReferencesNo definition available. + Details Name: amgn_RepatriationTaxOnProposedAdditionalTax Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_IncomeTaxExaminationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A + Details Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TaxPeriodAxis=amgn_TaxYears20102012Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TaxPeriodAxis=amgn_TaxYears20132015Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings per share - Computation for Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Income (Numerator): Â Â Â Â Â Â Â Â Net income for basic and diluted EPS $ 2,830 $ 746 $ (113) $ 1,730 $ 1,379 $ 2,841 $ 3,463 $ 5,950 Shares (Denominator): Â Â Â Â Â Â Â Â Weighted-average shares for basic EPS (in shares) 537 Â Â 535 Â Â 537 535 Effect of dilutive securities (in shares) 5 Â Â 3 Â Â 4 3 Weighted-average shares for diluted EPS (in shares) 542 Â Â 538 Â Â 541 538 Basic EPS (in usd per share) $ 5.27 Â Â $ 3.23 Â Â $ 6.45 $ 11.12 Diluted EPS (in usd per share) $ 5.22 Â Â $ 3.22 Â Â $ 6.40 $ 11.06 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 52 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Available-For-Sale Investments (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Marketable Securities [Line Items] Â Â Amortized cost $ 8,576 $ 10,404 Gross unrealized gains 0 0 Gross unrealized losses 0 0 Fair values 8,576 10,404 U.S. Treasury bills Â Â Marketable Securities [Line Items] Â Â Amortized cost 996 0 Gross unrealized gains 0 0 Gross unrealized losses 0 0 Fair values 996 0 Money market mutual funds Â Â Marketable Securities [Line Items] Â Â Amortized cost 7,437 10,266 Gross unrealized gains 0 0 Gross unrealized losses 0 0 Fair values 7,437 10,266 Other short-term interest-bearing securities Â Â Marketable Securities [Line Items] Â Â Amortized cost 143 138 Gross unrealized gains 0 0 Gross unrealized losses 0 0 Fair values $ 143 $ 138 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Fair Values by Classification (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Marketable Securities [Line Items] Â Â Total interest-bearing securities $ 8,576 $ 10,404 Available-for-sale investments Â Â Marketable Securities [Line Items] Â Â Cash and cash equivalents 8,576 10,404 Total interest-bearing securities $ 8,576 $ 10,404 X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-

gaap_FinancialInstrumentAxis=amgn_AvailableForSalesInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Available-For-Sale (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Investments, Debt and Equity Securities [Abstract] Â Â Cash $ 435 $ 540 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - BeiGene, Ltd. (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Equity securities $ 5,057 Â $ 5,057 Â $ 4,514 Net unrealized gains 0 $ 0 0 $ 0 Â Other Noncurrent Assets Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Equity securities 336 Â 336 Â 494 BeiGene Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Net unrealized gains 1,600 $ 30 836 $ 1,200 Â BeiGene | Other Noncurrent Assets Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Equity securities $ 4,300 Â $ 4,300 Â $ 3,400 BeiGene Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Ownership percentage 18.00% Â 18.00% Â 18.00% BeiGene | Maximum Â Â Â Â Â Debt Securities, Available-for-sale [Line Items] Â Â Â Â Â Ownership percentage 5.00% 5.00% 5.00% Â X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-1 + Details Name: us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=amgn_BeiGeneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_BeiGeneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Other Equity Securities (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Â Â Â Equity securities $ 5,057,000,000 Â $ 5,057,000,000 Â $ 4,514,000,000 Unrealized gains (losses) on equity securities 0 $ 0 0 $ 0 Â Sale of unrealized gains (losses) on equity securities 0 0 0 0 Â Increase and decrease in equity securities without readily determinable fair value, amount 0 0 0 0 Â Sale of securities without readily determinable fair value 0 $ 0 0 $ 0 Â Other Noncurrent Assets Â Â Â Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Â Â Â Equity securities 336,000,000 Â 336,000,000 Â 494,000,000 Equity securities without readily determinable fair value $ 318,000,000 Â $ 318,000,000 Â $ 309,000,000 X - DefinitionIncrease and Decrease in Equity Securities without Readily Determinable Fair Value, Amount + ReferencesNo definition available. + Details Name: amgn_IncreaseAndDecreaseInEquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSale of Equity Securities, FV-NI, Unrealized Gain (Loss) + ReferencesNo definition available. + Details Name: amgn_SaleOfEquitySecuritiesFVNIUnrealizedGainLoss Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSale of Securities without Readily Determinable Fair Value, Amount + ReferencesNo definition available. + Details Name: amgn_SaleOfSecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Neumora Therapeutics, Inc. (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Schedule of Equity Method Investments [Line Items] Â Â Â Â Â Equity securities $ 5,057 Â $ 5,057 Â $ 4,514 Unrealized gains (losses) on equity securities $ 0 $ 0 $ 0 $ 0 Â Neumora Therapeutics, Inc. Â Â Â Â Â Schedule of Equity Method Investments [Line Items] Â Â Â Â Â Ownership percentage 22.10% Â 22.10% Â 23.20% Equity securities $ 467 Â $ 467 Â $ 603 Unrealized gains (losses) on equity securities $ 119 $ 153 $ (136) $ 134 Â Neumora Therapeutics, Inc. | Maximum Â Â Â Â Â Schedule of Equity Method Investments [Line Items] Â Â Â Â Â Ownership percentage Â 5.00% Â 5.00% Â Neumora Therapeutics, Inc. | Minimum Â Â Â Â Â Schedule of Equity Method Investments [Line Items] Â Â Â Â Â Ownership percentage Â 10.00% Â 10.00% Â X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_ScheduleOfEquityMethodInvestmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=amgn_NeumoraTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Limited Partnership (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Net Investment Income [Line Items] Â Â Â Â Â Investment, Type [Extensible Enumeration] Partnership Interest [Member] Â Partnership Interest [Member] Â Partnership Interest [Member] Fair Value Measured at Net Asset Value Per Share Â Â Â Â Â Net Investment Income [Line Items] Â Â Â Â Â Alternative investments $ 272 Â $ 272 Â $ 251 Unfunded additional commitments 139 Â 139 Â Â Net gains (losses) from limited partnership investments $ 0 $ 0 $ 0 $ 0 Â X - DefinitionAlternative Investment, Net Gain (Loss) + ReferencesNo definition available. + Details Name: amgn_AlternativeInvestmentNetGainLoss Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 54B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482134/820-10-35-54BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A + Details Name: us-gaap_AlternativeInvestment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of financial support committed by investment company to investee that is contractually required. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-15 + Details Name: us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIndicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2 + Details Name: us-gaap_InvestmentTypeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Inventory Disclosure [Abstract] Â Â Raw materials $ 788 $ 993 Work in process 4,339 5,747 Finished goods 2,235 2,778 Total inventories $ 7,362 $ 9,518 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 60 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and other intangible assets - Schedule of Goodwill (Details) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Goodwill [Roll Forward] Â Balance at January 1, 2024 $ 18,629 Adjustments to goodwill resulting from acquisition 25 Foreign currency translation adjustments 4 Balance at September 30, 2024 $ 18,658 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 61 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and other intangible assets - Schedule of Identifiable Intangible Assets (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Finite-lived intangible assets: Â Â Gross carrying amounts $ 55,103 $ 55,229 Accumulated amortization (27,273) (23,806) Other intangible assets, net 27,830 31,423 Indefinite-lived intangible assets: Â Â Identifiable intangible assets 56,193 56,447 Accumulated amortization (27,273) (23,806) Intangible assets, net 28,920 32,641 In-process research and development Â Â Indefinite-lived intangible assets: Â Â Indefinite-lived intangible assets 1,090 1,218 Developed-product-technology rights Â Â Finite-lived intangible assets: Â Â Gross carrying amounts 48,636 48,631 Accumulated amortization (21,472) (18,049) Other intangible assets, net 27,164 30,582 Licensing rights Â Â Finite-lived intangible assets: Â Â Gross carrying amounts 3,864 3,865 Accumulated amortization (3,360) (3,265) Other intangible assets, net 504 600 Marketing-related rights Â Â Finite-lived intangible assets: Â Â Gross carrying amounts 1,203 1,339 Accumulated amortization (1,188) (1,264) Other intangible assets, net 15 75 Research and development technology rights Â Â Finite-lived intangible assets: Â Â Gross carrying amounts 1,400 1,394 Accumulated amortization (1,253) (1,228) Other intangible assets, net $ 147 $ 166 X - DefinitionIdentifiable intangible assets accumulated amortization. + ReferencesNo definition available. + Details Name: amgn_IdentifiableIntangibleAssetsAccumulatedAmortization Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIdentifiable intangible assets gross. + ReferencesNo definition available. + Details Name: amgn_IdentifiableIntangibleAssetsGross Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -

Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and other intangible assets - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Amortization charges associated with finite-lived intangible assets $ 1,200 $ 693 $ 3,600 $ 2,100 Total estimated amortization of finite-lived intangible assets for the remainder of the year 1,200 Â 1,200 Â Total estimated amortization of finite-lived intangible assets for 2025 4,500 Â 4,500 Â Total estimated amortization of finite-lived intangible assets for 2026 3,900 Â 3,900 Â Total estimated amortization of finite-lived intangible assets for 2027 3,900 Â 3,900 Â Total estimated amortization of finite-lived intangible assets for 2028 2,900 Â 2,900 Â Total estimated amortization of finite-lived intangible assets for 2029 $ 2,200 Â $ 2,200 Â X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 63 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Financing arrangements - Schedule of Borrowings (Details) $ in Millions Sep. 30, 2024 USD ($) Sep. 30, 2024 EUR (â‚¬) Sep. 30, 2024 GBP (Â£) Dec. 31, 2023 USD ($) Debt Instrument [Line Items] Â Â Â Â Unamortized bond discounts, premiums and issuance costs, net $ (1,373) Â Â $ (1,420) Fair value adjustments (192) Â Â (314) Other 27 Â Â 17 Total carrying value of debt 60,398 Â Â 64,613 Less current portion (3,544) Â Â (1,443) Total long-term debt 56,854 Â Â 63,170 Notes Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Total carrying value of debt $ 58,600 Â Â 60,600 Notes | 3.625% notes due 2024 (3.625% 2024 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.625% 3.625% 3.625% Â Long-term debt, gross $ 0 Â Â 1,400 Notes | 1.90% notes due 2025 (1.90% 2025 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 1.90% 1.90% 1.90% Â Long-term debt, gross $ 500 Â Â 500 Notes | 5.25% notes due 2025 (5.25% 2025 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.25% 5.25% 5.25% Â Long-term debt, gross $ 2,000 Â Â 2,000 Notes | 3.125% notes due 2025 (3.125% 2025 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.125% 3.125% 3.125% Â Long-term debt, gross $ 1,000 Â Â 1,000 Notes | 2.00% â‚¬750 million notes due 2026 (2.00% 2026 euro Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.00% 2.00% 2.00% Â Face amount | â‚¬ Â â‚¬ 750,000,000 Â Â Long-term debt, gross $ 835 Â Â 828 Notes | 5.507% notes due 2026 (5.507% 2026 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.507% 5.507% 5.507% Â Long-term debt, gross $ 1,500 Â Â 1,500 Notes | 2.60% notes due 2026 (2.60% 2026 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.60% 2.60% 2.60% Â Long-term debt, gross $ 1,250 Â Â 1,250 Notes | 5.50% Â£475 million notes due 2026 (5.50% 2026 pound sterling Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.50% 5.50% 5.50% Â Face amount | Â£ Â Â Â£ 475,000,000 Â Long-term debt, gross $ 635 Â Â 605 Notes | 2.20% notes due 2027 (2.20% 2027 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.20% 2.20% 2.20% Â Long-term debt, gross $ 1,724 Â Â 1,724 Notes | 3.20% notes due 2027 (3.20% 2027 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.20% 3.20% 3.20% Â Long-term debt, gross $ 1,000 Â Â 1,000 Notes | 5.15% notes due 2028 (5.15% 2028 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.15% 5.15% 5.15% Â Long-term debt, gross $ 3,750 Â Â 3,750 Notes | 1.65% notes due 2028 (1.65% 2028 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 1.65% 1.65% 1.65% Â Long-term debt, gross $ 1,234 Â Â 1,234 Notes | 3.00% notes due 2029 (3.00% 2029 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.00% 3.00% 3.00% Â Long-term debt, gross $ 750 Â Â 750 Notes | 4.05% notes due 2029 (4.05% 2029 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.05% 4.05% 4.05% Â Long-term debt, gross $ 1,250 Â Â 1,250 Notes | 4.00% Â£700 million notes due 2029 (4.00% 2029 pound sterling Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.00% 4.00% 4.00% Â Face amount | Â£ Â Â Â£ 700,000,000 Â Long-term debt, gross $ 936 Â Â 892 Notes | 2.45% notes due 2030 (2.45% 2030 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.45% 2.45% 2.45% Â Long-term debt, gross $ 1,250 Â Â 1,250 Notes | 5.25% notes due 2030 (5.25% 2030 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.25% 5.25% 5.25% Â Long-term debt, gross $ 2,750 Â Â 2,750 Notes | 2.30% notes due 2031 (2.30% 2031 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.30% 2.30% 2.30% Â Long-term debt, gross $ 1,250 Â Â 1,250 Notes | 2.00% notes due 2032 (2.00% 2032 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.00% 2.00% 2.00% Â Long-term debt, gross $ 1,001 Â Â 1,001 Notes | 3.35% notes due 2032 (3.35% 2032 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.35% 3.35% 3.35% Â Long-term debt, gross $ 1,000 Â Â 1,000 Notes | 4.20% notes due 2033 (4.20% 2033 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.20% 4.20% 4.20% Â Long-term debt, gross $ 750 Â Â 750 Notes | 5.25% notes due 2033 (5.25% 2033 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.25% 5.25% 5.25% Â Long-term debt, gross $ 4,250 Â Â 4,250 Notes | 6.375% notes due 2037 (6.375% 2037 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 6.375% 6.375% 6.375% Â Long-term debt, gross $ 478 Â Â 478 Notes | 6.90% notes due 2038 (6.90% 2038 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 6.90% 6.90% 6.90% Â Long-term debt, gross $ 254 Â Â 254 Notes | 6.40% notes due 2039 (6.40% 2039 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 6.40% 6.40% 6.40% Â Long-term debt, gross $ 333 Â Â 333 Notes | 3.15% notes due 2040 (3.15% 2040 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.15% 3.15% 3.15% Â Long-term debt, gross $ 1,668 Â Â 1,803 Notes | 5.75% notes due 2040 (5.75% 2040 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.75% 5.75% 5.75% Â Long-term debt, gross $ 373 Â Â 373 Notes | 2.80% notes due 2041 (2.80% 2041 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.80% 2.80% 2.80% Â Long-term debt, gross $ 776 Â Â 949 Notes | 4.95% notes due 2041 (4.95% 2041 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.95% 4.95% 4.95% Â Long-term debt, gross $ 600 Â Â 600 Notes | 5.15% notes due 2041 (5.15% 2041 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.15% 5.15% 5.15% Â Long-term debt, gross $ 729 Â Â 729 Notes | 5.65% notes due 2042 (5.65% 2042 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.65% 5.65% 5.65% Â Long-term debt, gross $ 415 Â Â 415 Notes | 5.60% notes due 2043 (5.60% 2043 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.60% 5.60% 5.60% Â Long-term debt, gross $ 2,750 Â Â 2,750 Notes | 5.375% notes due 2043 (5.375% 2043 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.375% 5.375% 5.375% Â Long-term debt, gross $ 185 Â Â 185 Notes | 4.40% notes due 2045 (4.40% 2045 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.40% 4.40% 4.40% Â Long-term debt, gross $ 2,250 Â Â 2,250 Notes | 4.563% notes due 2048 (4.563% 2048 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.563% 4.563% 4.563% Â Long-term debt, gross $ 1,415 Â Â 1,415 Notes | 3.375% notes due 2050 (3.375% 2050 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.375% 3.375% 3.375% Â Long-term debt, gross $ 1,764 Â Â 2,132 Notes | 4.663% notes due 2051 (4.663% 2051 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.663% 4.663% 4.663% Â Long-term debt, gross $ 3,541 Â Â 3,541 Notes | 3.00% notes due 2052 (3.00% 2052 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 3.00% 3.00% 3.00% Â Long-term debt, gross $ 890 Â Â 999 Notes | 4.20% notes due 2052 (4.20% 2052 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.20% 4.20% 4.20% Â Long-term debt, gross $ 895 Â Â 950 Notes | 4.875% notes due 2053 (4.875% 2053 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.875% 4.875% 4.875% Â Long-term debt, gross $ 1,000 Â Â 1,000 Notes | 5.65% notes due 2053 (5.65% 2053 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.65% 5.65% 5.65% Â Long-term debt, gross $ 4,250 Â Â 4,250 Notes | 2.77% notes due 2053 (2.77% 2053 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 2.77% 2.77% 2.77% Â Long-term debt, gross $ 940 Â Â 940 Notes | 4.40% notes due 2062 (4.40% 2062 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 4.40% 4.40% 4.40% Â Long-term debt, gross $ 1,165 Â Â 1,200 Notes | 5.75% notes due 2063 (5.75% 2063 Notes) Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate, stated percentage 5.75% 5.75% 5.75% Â Long-term debt, gross $ 2,750 Â Â 2,750 Notes | Other notes due 2097 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Long-term debt, gross 100 Â Â 100 Secured Debt | Term loan due April 2025 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Long-term debt, gross 0 Â Â 2,000

Secured Debt | Term loan due October 2026 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Long-term debt, gross $ 1,800 Â Â $ 2,000 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4EE -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE + Details Name: us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_OtherLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A3.625NotesDueIn2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A1.90NotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A525NotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A3.125NotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A2.00NotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A5507NotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_ThreePointTwoZeroNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A515NotesDue2028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_OnePointSixFivePercent2028NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A3002029NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A4052029NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointFourFivePercentNotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A525NotesDue2030Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointThreeZeroPercentNotesDue2031Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointZeroPercent2032NotesMemberMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A3352032NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_DebtInstrumentAxis=amgn_A4202033NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A525NotesDue2033Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_SixPointThreeSevenFivePercentNotesDue2037Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_SixPointNineZeroPercentNotesDue2038Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_SixPointFourZeroPercentNotesDue2039Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FivePointSevenFivePercentNotesDue2040Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPointNineFivePercentNotesDue2041Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FivePointOneFivePercentNotesDue2041Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FivePointSixFivePercentNotesDue2042Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A560NotesDue2043Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FivePointThreeSevenFivePercentNotesDue2043Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A48752053NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A565NotesDue2053Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A4402062NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A575NotesDue2063Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_OtherNotesDue2097Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TermLoanDueApril2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TermLoanDueOctober2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Financing arrangements - Narrative (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Debt Instrument [Line Items] Â Â Repayments of debt $ 3,600 $ 1,454 Extinguishment of debt 659 Â Gain on extinguishment of debt $ 215 Â Notes Â Â Debt Instrument [Line Items] Â Â Basis spread on variable rate 1.225% Â Repayments of debt $ 875 Â 4.563% notes due 2048 (4.563% 2048 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 4.563% Â Effective interest rate 6.30% Â 4.663% notes due 2051 (4.663% 2051 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 4.663% Â Effective interest rate 5.60% Â 2.77% notes due 2053 (2.77% 2053 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 2.77% Â Effective interest rate 5.20% Â 3.15% notes due 2040 (3.15% 2040 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 3.15% Â 2.80% notes due 2041 (2.80% 2041 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 2.80% Â 3.375% notes due 2050 (3.375% 2050 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 3.375% Â 3.00% notes due 2052 (3.00% 2052 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 3.00% Â 4.20% notes due 2052 (4.20% 2052 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 4.20% Â 4.40% notes due 2062 (4.40% 2062 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 4.40% Â 3.625% notes due 2024 (3.625% 2024 Notes) | Notes Â Â Debt Instrument [Line Items] Â Â Interest rate, stated percentage 3.625% Â Repayments of debt $ 1,400 Â Term loan due April 2025 | Notes Â Â Debt Instrument [Line Items] Â Â Repayments of debt 2,000 Â Term loan due October 2026 | Notes Â Â Debt Instrument [Line Items] Â Â Repayments of debt $ 200 Â X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGross amount of debt extinguished. + ReferencesNo definition available. + Details Name: us-gaap_ExtinguishmentOfDebtAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_ThreePointOneFivePercentNotesDue2040Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TwoPointEightZeroPercent2041NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_ThreePointThreeSevenFivePercentNotesDue2050Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A300NotesDue20523002052NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A4202052NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A4402062NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A3.625NotesDueIn2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TermLoanDueApril2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_TermLoanDueOctober2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' equity - Narrative (Details) - USD ($) $ / shares in Units, $ in Billions 3 Months Ended Sep. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Mar. 31, 2023 Oct. 31, 2024 Class of Stock [Line Items] Â Â Â Â Â Â Amount available for stock repurchases under a board approved stock repurchase plan $ 7.0 Â Â Â Â Â Dividends declared per share (in usd per share) $ 2.25 $ 2.25 $ 2.25 $ 2.13 $ 2.13 Â Subsequent Event Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Dividends payable per share (in usd per share) Â Â Â Â Â $ 2.25 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph

(d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe per share amount of a dividend declared, but not paid, as of the financial reporting date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details Name: us-gaap_DividendsPayableAmountPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' equity - Components of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions 3 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Increase (Decrease) in AOCI [Roll Forward] Â Â Â Beginning balance $ 5,925 $ 5,022 $ 6,232 Ending balance 7,527 5,925 5,022 Foreign currency translation adjustments Â Â Â Increase (Decrease) in AOCI [Roll Forward] Â Â Â Beginning balance (337) (322) (298) Foreign currency translation adjustments 71 (15) (24) Unrealized gains (losses) 0 0 0 Reclassification adjustments into earnings 0 0 0 Other 0 0 0 Income taxes 0 0 0 Ending balance (266) (337) (322) CashÂ flow hedges Â Â Â Increase (Decrease) in AOCI [Roll Forward] Â Â Â Beginning balance 155 104 (22) Foreign currency translation adjustments 0 0 0 Unrealized gains (losses) (158) 117 178 Reclassification adjustments into earnings (166) (52) (20) Other 0 0 0 Income taxes 71 (14) (32) Ending balance (98) 155 104 Other Â Â Â Increase (Decrease) in AOCI [Roll Forward] Â Â Â Beginning balance 27 28 31 Foreign currency translation adjustments 0 0 0 Unrealized gains (losses) 0 0 0 Reclassification adjustments into earnings 0 0 0 Other 1 (1) (3) Income taxes 0 0 0 Ending balance 28 27 28 AOCI Â Â Â Increase (Decrease) in AOCI [Roll Forward] Â Â Â Beginning balance (155) (190) (289) Foreign currency translation adjustments 71 (15) (24) Unrealized gains (losses) (158) 117 178 Reclassification adjustments into earnings (166) (52) (20) Other 1 (1) (3) Income taxes 71 (14) (32) Ending balance $ (336) $ (155) $ (190) X - DefinitionOther Comprehensive Income (Loss), Other Adjustment, Before Tax + ReferencesNo definition available. + Details Name: amgn_OtherComprehensiveIncomeLossOtherAdjustmentBeforeTax Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=amgn_AccumulatedOtherAdjustmentAttributabletoParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' equity - Reclassifications Out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Product sales $ 8,503 Â Â $ 6,903 Â Â $ 24,338 $ 19,994 Other income, net 1,830 Â Â 685 Â Â 1,288 2,431 Income before income taxes 3,101 Â Â 1,947 Â Â 3,827 7,003 Provision for income taxes (271) Â Â (217) Â Â (364) (1,053) Net income 2,830 $ 746 $ (113) 1,730 $ 1,379 $ 2,841 3,463 5,950 Product sales Â Â Â Â Â Â Â Â Â Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Product sales 8,151 Â Â 6,548 Â Â 23,310 19,077 Reclassification out of Accumulated Other Comprehensive Income | CashÂ flow hedges Â Â Â Â Â Â Â Â Â Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Income before income taxes 166 Â Â (53) Â Â 238 64 Provision for income taxes (36) Â Â 11 Â Â (51) (14) Net income 130 Â Â (42) Â Â 187 50 Reclassification out of Accumulated Other Comprehensive Income | Foreign currency contract gains | CashÂ flow hedges | Product sales Â Â Â Â Â Â Â Â Â Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Product sales 45 Â Â 33 Â Â 151 121 Reclassification out of Accumulated Other Comprehensive Income | Cross-currency swap contract gains (losses) | CashÂ flow hedges Â Â Â Â Â Â Â Â Â Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Other income, net 121 Â Â (86) Â Â 87 (57) Reclassification out of Accumulated Other Comprehensive Income | Cash flow hedges | Foreign currency contract gains | CashÂ flow hedges | Product sales Â Â Â Â Â Â Â Â Â Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Product sales 45 Â Â 33 Â Â 151 121 Reclassification out of Accumulated Other Comprehensive Income | Cash flow hedges | Cross-currency swap contract gains (losses) | CashÂ flow hedges Â Â Â Â Â Â Â Â Â Reclassification out of Accumulated Other Comprehensive Income [Line Items] Â Â Â Â Â Â Â Â Â Other income, net $ 121 Â Â $ (86) Â Â $ 87 $ (57) X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-

32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Millions Sep. 30, 2024 Jun. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Dec. 31, 2022 Assets: Â Â Â Â Â Â Available-for-sale securities: $ 8,576 Â $ 10,404 Â Â Â Equity securities 5,057 Â 4,514 Â Â Â Derivatives: Â Â Â Â Â Â Total assets 13,745 Â 15,063 Â Â Â Derivatives: Â Â Â Â Â Â Contingent consideration obligations 112 $ 107 96 $ 98 $ 248 $ 270 Total liabilities 998 Â 1,188 Â Â Â Foreign currency forward contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 99 Â 145 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 121 Â 116 Â Â Â Cross-currency swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 4 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 361 Â 405 Â Â Â Interest rate swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 9 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 404 Â 571 Â Â Â QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Equity securities 5,057 Â 4,514 Â Â Â Derivatives: Â Â Â Â Â Â Total assets 12,494 Â 14,780 Â Â Â Derivatives: Â Â Â Â Â Â Contingent consideration obligations 0 Â 0 Â Â Â Total liabilities 0 Â 0 Â Â Â QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) | Foreign currency forward contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 0 Â 0 Â Â Â QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) | Cross-currency swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 0 Â 0 Â

Â Â QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) | Interest rate swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 0 Â 0 Â Â Â Significant otherÂ observable inputs (Level 2) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Equity securities 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Total assets 1,251 Â 283 Â Â Â Derivatives: Â Â Â Â Â Â Contingent consideration obligations 0 Â 0 Â Â Â Total liabilities 886 Â 1,092 Â Â Â Significant otherÂ observable inputs (Level 2) | Foreign currency forward contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 99 Â 145 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 121 Â 116 Â Â Â Significant otherÂ observable inputs (Level 2) | Cross-currency swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 4 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 361 Â 405 Â Â Â Significant otherÂ observable inputs (Level 2) | Interest rate swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 9 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 404 Â 571 Â Â Â Significant unobservable inputs (Level 3) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Equity securities 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Total assets 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Contingent consideration obligations 112 Â 96 Â Â Â Total liabilities 112 Â 96 Â Â Â Significant unobservable inputs (Level 3) | Foreign currency forward contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 0 Â 0 Â Â Â Significant unobservable inputs (Level 3) | Cross-currency swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Derivative assets 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Derivative liabilities 0 Â 0 Â Â Â Significant unobservable inputs (Level 3) | Interest rate swap contracts Â Â Â Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 0 Â 0 Â Â Â Derivatives: Â Â Â Â Â Â Interest rate swap contracts 0 Â 0 Â Â Â U.S. Treasury bills Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 996 Â 0 Â Â Â U.S. Treasury bills | QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 0 Â 0 Â Â Â U.S. Treasury bills | Significant otherÂ observable inputs (Level 2) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 996 Â 0 Â Â Â U.S. Treasury bills | Significant unobservable inputs (Level 3) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 0 Â 0 Â Â Â Money market mutual funds Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 7,437 Â 10,266 Â Â Â Money market mutual funds | QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 7,437 Â 10,266 Â Â Â Money market mutual funds | Significant otherÂ observable inputs (Level 2) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 0 Â 0 Â Â Â Money market mutual funds | Significant unobservable inputs (Level 3) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 0 Â 0 Â Â Â Other short-term interest-bearing securities Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 143 Â 138 Â Â Â Other short-term interest-bearing securities | QuotedÂ prices in activeÂ marketsÂ for identical assets (Level 1) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 0 Â 0 Â Â Â Other short-term interest-bearing securities | Significant otherÂ observable inputs (Level 2) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: 143 Â 138 Â Â Â Other short-term interest-bearing securities | Significant unobservable inputs (Level 3) Â Â Â Â Â Â Assets: Â Â Â Â Â Â Available-for-sale securities: $ 0 Â $ 0 Â Â Â X - DefinitionDerivative assets. + ReferencesNo definition available. + Details Name: amgn_DerivativeAssetsFairValueDisclosureAbstract Namespace Prefix: amgn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDerivative financial instruments liabilities fair value disclosure. + ReferencesNo definition available. + Details Name: amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract Namespace Prefix: amgn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_InterestRateFairValueHedgeAssetAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=amgn_OtherShortTermInterestBearingSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement - Contingent Consideration Obligations (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Business Combination, Contingent Consideration [Roll Forward] Â Â Â Â Beginning balance $ 107 $ 248 $ 96 $ 270 Payments (2) (3) (6) (7) Net changes in valuations 7 (147) 22 (165) Ending balance $ 112 $ 98 $ 112 $ 98 X - DefinitionBusiness Combination, Contingent Consideration Arrangements, Payments + ReferencesNo definition available. + Details Name: amgn_BusinessCombinationContingentConsiderationArrangementsPayments Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionBusiness Combination, Contingent Consideration [Roll Forward] + ReferencesNo definition available. + Details Name: amgn_BusinessCombinationContingentConsiderationRollForward Namespace Prefix: amgn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 70 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurement - Narrative (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Carrying value of long-term debt, including current portion $ 60,398 $ 64,613 Fixed-rate notes Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Aggregate fair value of long-term debt, including current portion 58,000 59,200 Carrying value of long-term debt, including current portion $ 58,600 $ 60,600 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration

X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of notes payable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments - Narrative (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Derivative [Line Items] Â Â Length of time hedged in foreign currency contracts (or less) 3 years Â Notes | 3.625% notes due 2024 (3.625% 2024 Notes) Â Â Derivative [Line Items] Â Â Interest rate, stated percentage 3.625% Â Notes | 5.25% notes due 2033 (5.25% 2033 Notes) Â Â Derivative [Line Items] Â Â Interest rate, stated percentage 5.25% Â Foreign currency forward contracts | Designated as Hedging Instrument Â Â Derivative [Line Items] Â Â Notional amounts $ 7,100 $ 6,600 Foreign currency forward contracts | Derivatives not designated as hedging instrument Â Â Derivative [Line Items] Â Â Notional amounts 82 457 Interest Rate Swap | 3.625% notes due 2024 (3.625% 2024 Notes) Â Â Derivative [Line Items] Â Â Notional amounts 1,400 Â Interest Rate Swap | 5.25% notes due 2033 (5.25% 2033 Notes) Â Â Derivative [Line Items] Â Â Notional amounts $ 1,400 Â Derivative, basis spread on variable rate 1.80% Â Interest Rate Swap | Designated as Hedging Instrument Â Â Derivative [Line Items] Â Â Notional amounts $ 6,700 $ 6,700 X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe percentage points added to the reference rate to compute the variable rate on the interest rate derivative. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeBasisSpreadOnVariableRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionMaximum period of hedging exposure to variability in future cash flows for forecasted transaction of foreign currency cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 30 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1 + Details Name: us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A3.625NotesDueIn2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A525NotesDue2033Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments - Schedule of Cross-Currency Swaps (Details) â,¬ in Millions, Â£ in Millions, $ in Millions Sep. 30, 2024 USD ($) Sep. 30, 2024 EUR (â,¬) Sep. 30, 2024 GBP (Â£) 2.00% 2026 euro Notes | Notes Â Â Â Derivative [Line Items] Â Â Â Interest rate, stated percentage 2.00% 2.00% 2.00% 5.50% 2026 pound sterling Notes | Notes Â Â Â Derivative [Line Items] Â Â Â Interest rate, stated percentage 5.50% 5.50% 5.50% 4.00% 2029 pound sterling Notes | Notes Â Â Â Derivative [Line Items] Â Â Â Interest rate, stated percentage 4.00% 4.00% 4.00% Cash flow hedge | Cross-currency swap contracts | 2.00% 2026 euro Notes Â Â Â Derivative [Line Items] Â Â Â Notional amounts $ 833 â,¬ 750 Â Cash flow hedge | Cross-currency swap contracts | 5.50% 2026 pound sterling Notes Â Â Â Derivative [Line Items] Â Â Â Notional amounts 747 Â Â£ 475 Cash flow hedge | Cross-currency swap contracts | 4.00% 2029 pound sterling Notes Â Â Â Derivative [Line Items] Â Â Â Notional amounts $ 1,111 Â Â£ 700 Cash flow hedge | Cross-currency swap contracts | Euro Member Countries, Euro | 2.00% 2026 euro Notes Â Â Â Derivative [Line Items] Â Â Â Interest rates 2.00% 2.00% 2.00% Cash flow hedge | Cross-currency swap contracts | United Kingdom, Pounds | 5.50% 2026 pound sterling Notes Â Â Â Derivative [Line Items] Â Â Â Interest rates 5.50% 5.50% 5.50% Cash flow hedge | Cross-currency swap contracts | United Kingdom, Pounds | 4.00% 2029 pound sterling Notes Â Â Â Derivative [Line Items] Â Â Â Interest rates 4.00% 4.00% 4.00% Cash flow hedge | Cross-currency swap contracts | United States of America, Dollars | 2.00% 2026 euro Notes Â Â Â Derivative [Line Items] Â Â Â Interest rates 3.90% 3.90% 3.90% Cash flow hedge | Cross-currency swap contracts | United States of America, Dollars | 5.50% 2026 pound sterling Notes Â Â Â Derivative [Line Items] Â Â Â Interest rates 6.00% 6.00% 6.00% Cash flow hedge | Cross-currency swap contracts | United States of America, Dollars | 4.00% 2029 pound sterling Notes Â Â Â Derivative [Line Items] Â Â Â Interest rates 4.60% 4.60% 4.60% X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFixed interest rate related to the interest rate derivative. + ReferencesNo definition available. + Details Name: us-gaap_DerivativeFixedInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=amgn_A2.00NotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=amgn_FourPercentPoundSterlingNotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_EUR Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_GBP Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_USD Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments - Summary of Unrealized Gains and Losses Recognized in AOCI (Details) - Cash flow hedge - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Total unrealized (losses) gains $ (158) $ 176 $ 137 $ 155 Foreign currency forward contracts Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Total unrealized (losses) gains (238) 198 87 222 Cross-currency swap contracts Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Total unrealized (losses) gains 80 (22) 50 (36) Forward interest rate contracts Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Total unrealized (losses) gains $ 0 $ 0 $ 0 $ (31) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_ForwardInterestRateContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments - Hedged Liabilities and Cumulative Amount (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Derivative [Line Items] Â Â Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities $ (192) $ (314) Current portion of long-term debt Â Â Derivative [Line Items] Â Â Carrying amounts of hedged liabilities 1,039 1,441 Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities 39 41 Carrying value with discontinued hedging relationships 58 69 Hedging adjustments on discontinued hedging relationships 58 69 Long-term debt Â Â Derivative [Line Items] Â Â Carrying amounts of hedged liabilities 5,307 4,788 Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities (231) (355) Carrying value with discontinued hedging relationships 245 288 Hedging adjustments on discontinued hedging relationships $ 145 $ 188 X - DefinitionHedged Liability, Discontinued Fair Value Hedge + ReferencesNo definition available. + Details Name: amgn_HedgedLiabilityDiscontinuedFairValueHedge Namespace Prefix: amgn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4EE -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE + Details Name: us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability hedged in fair value hedging relationship. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4EE -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE + Details Name: us-gaap_HedgedLiabilityFairValueHedge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk. + ReferencesReference

1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4EE -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE + Details Name: us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=amgn_LongTermDebtCurrentMaturitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_LongTermDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments - Summary of Income and Expense Line Items (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Product sales $ 8,503 $ 6,903 $ 24,338 $ 19,994 Other income, net 1,830 685 1,288 2,431 Interest expense, net (776) (759) (2,408) (2,054) Interest rate swap agreements Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Gains (losses) on fair value hedging relationships, hedged items (153) 58 (122) 63 Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments 168 (37) 176 5 Reclassification out of Accumulated Other Comprehensive Income | CashÂ flow hedges | Cross-currency swap contracts Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Other income, net 121 (86) 87 (57) Product sales Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Product sales 8,151 6,548 23,310 19,077 Product sales | Reclassification out of Accumulated Other Comprehensive Income | CashÂ flow hedges | Foreign currency forward contracts Â Â Â Â Derivative Instruments, Gain (Loss) [Line Items] Â Â Â Â Product sales $ 45 $ 33 $ 151 $ 121 X - DefinitionAmount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 25 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480238/815-25-50-1 + Details Name: us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 25 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480238/815-25-50-1 + Details Name: us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Derivative instruments - Fair Value of Derivatives (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Derivatives Fair Value [Line Items] Â Â Derivative assets $ 112 $ 145 Derivative liabilities 886 1,092 Derivatives designated as hedging instrument Â Â Derivatives Fair Value [Line Items] Â Â Derivative assets 112 145 Derivative liabilities 886 1,092 Derivatives designated as hedging instrument | Foreign currency forward contracts | Other current assets/ Other noncurrent assets Â Â Derivatives Fair Value [Line Items] Â Â Derivative assets 99 145 Derivatives designated as hedging instrument | Foreign currency forward contracts | Accrued liabilities/ OtherÂ noncurrent liabilities Â Â Derivatives Fair Value [Line Items] Â Â Derivative liabilities 121 116 Derivatives designated as hedging instrument | Cross-currency swap contracts | Other current assets/ Other noncurrent assets Â Â Derivatives Fair Value [Line Items] Â Â Derivative assets 4 0 Derivatives designated as hedging instrument | Cross-currency swap contracts | Accrued liabilities/ OtherÂ noncurrent liabilities Â Â Derivatives Fair Value [Line Items] Â Â Derivative liabilities 361 405 Derivatives designated as hedging instrument | Interest rate swap contracts | Other current assets/ Other noncurrent assets Â Â Derivatives Fair Value [Line Items] Â Â Derivative assets 9 0 Derivatives designated as hedging instrument | Interest rate swap contracts | Accrued liabilities/ OtherÂ noncurrent liabilities Â Â Derivatives Fair Value [Line Items] Â Â Derivative liabilities $ 404 $ 571 X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=amgn_OtherCurrentNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=amgn_CrossCurrencySwapContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (&>57ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !GE5Y9501$$>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9? 17)O)TT7#Z';B^))07!!\1:2V=U@DX9DI-VW-XV[740?P&-F_GSS M#4ŘG@]1CQ.\4:O^/ 9AP(S&G! AYX2-'4#K%\F MAM,\=' %+##*Z-)W 8<&WIX>7\JZE?6) ME->8? R4KZ11PRRZ37]N[^]T#ZP47FZKA5621A'^_1S80RY8-[9)-NILˆ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l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{}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

NXHD.,";HJ%MT M7Z<<4M2 LV05"P-_6AT+9";3GA:X+Q-D*-*!#E5MXAG"Z,+3PB0<$"=62\(Y M*7Y!<*[68HFH.XCJ3"

K*J(%?H MWYM&6=AYI1,S1B91S%9SP*(O[RKMJ4 \Q]DOI1<:_Z/4/"<&,JT? _=!QK;V; M7$_8Y[JQM>&8_0OQV-A'M=HS0("J,(LL/B!<%#S)PG !E4_ARRTY"QHQ3;Y$ ME1Y/)^(B377(%5%8+T@,E,?/77^Y!)S6)&0X%NX"\K7+'IX&*/^[DC_3(PIF^ MLBX&"!P!!>MC>2X"1'@V!6EO.[&IE]^05\QE8M9B,.Q.;'^J;W3:H$03TU3> M:C7(=B]U_\!UBH*B;/_T3I0!YSVII<12JI*LF 3SPBRX]BM=-F6P/@=W$P,% MUPN5XP6*CX<*BJ9KDF5?J2P,S."V Y7: J*60D)6D/%\@3@YG6H911"^"LUY MD(K9\<.!(2%RX(;T T8Q&)SI2E:)CF!G&R-<)Z#37%<58Z+:"N8AM<_002LC MR%AEARL?/036$^U4+(<04TYG'R3]^C7AI=P:1T'!>TE$+!"0+(F=04$)ISXW MU%4I'#2QX&;$/3'&!L\P:HB1B7C/;:?0V9I!QD >%C!S:H'5*\EEI+LAI L? M4H#P60I;JM#^3=T+')E'9@R@F66ZT)">H!W=90:"GG;]E8*-.HXW+5;H"?H4 MRAUD<&FX.H9RY \[X)Q)-+/,#F%V.0?/6B9?5),!'7X.R";;:VMNM&N92/?& M, (Z@3+A6@W)>#S4Q[R> (J,?(@$B5Q)>Q/+9(/4Q+#6%^JW< M #EM7^ZWBK&X 0&8QH57&,6#%P)*$M0B1JJ=W28VEAV+4YF MSWF#I2)NI7@ M$H2+QC>JM<8ODON:+TQQ0TQ MD':N4=3C:AR'?#&])%!L1H3=(PKIA/8V MO*1@&->%2F34'B8H-I1X"QLIO]%-DH5<.=HQY$TA-UE!9:L;"@W1%:+U=NC M=DMZ=74=>!XK&W:="TKF:"_.$5>U=,83=X*U;$$\AWTWTF9BG\'6'S8ZIJ+Y M=/:8N1QH4-! 8XVXNKB*\"E-2BR4\JUN/H0=''?!I+^-(S91'AMES_)R/":O M)G8G[1"VPFC.#/$9J0,(- _P;YL="B"4992WA?(KA5IIBSDBJ=](PY=+2/N M[3T!TMIQHTZ[QAO=H*CT+&<\R2(9I!(M"A5**04Q-6QYIX7B)>L:>QNJAXQ: MV*+Q@<::2BX*]AM#8;+LR7-^?FL0&W#(C)-$)$%IJ97GB6? #E0\+Q /9C#, M:G >/U<&TWI=(/Z([G4WT&-SQ$T387B):3O1JDK6XH=X^]'^]6Y87=&)O?)+53&JD\%MK!NA#@3K\^LB5*;/8>-R MPY5*"3NM:@]RIJP[2C&I+!B^EWS'"[(R>JT5)DP. M+_Y- >.A>Q,/GPF>F]YQR7^".5-/1Y30"'9[@L+"]\< >5EEZ1/VTHJ\6U$Z MSG>*ND:_< :&[Z#E7U!+ P04 " !GE5Y995L6.A,) "]'@ &0 'AL M+W=O\ZG1LG(J,VT@7(D?/1)N,.[R::<<61O#$3\I4I]_M MGG0R+O/6U85O^VBN+G3IE,S%1\-LF6770]IO! PEQ0SVWAF9,E8ZUMZ^9!< MMKJDD% B=B2!X^=.O!%*D2"H\:V2V;J7I(G-YX7T]]YVV#+F5KS1ZJM,7'K9 M.FNQ1$QXJ=PG/?M55/8XP5X] (ZG563\9[)//SR^PJ'QH2S M[HX)_6I"W^L=%O):ON6.7U8]+B8+M9%/;0+Q)T7W8P%BWW8>B#[0T MMHA0I$I24?SW'9**8G<3MP7Z8/,V<^8,YT+-.Z4?3(5HX:D6TBRBRMKF.DE, M46'-S$@U*.EDIW3- +"WU/C&-1E9ZI5HD69K.DIIQ&2WG?F^MEW/56L$EKC68 MMJZ9/JQ0J&X1C:/GC2]\7UFWD2SG#=OC!NVOS5K3*AE02EZC-%Q)T+A;1#?C MZ]7$R7N!WSAVYF@.SI.M4@]N\:E<1*DCA (+ZQ 8#8_X$85P0$3CSQXS&DPZ MQ>/Y,_I/WG?R9F1C47(:1/?7W<*1P]99"UBMDGG,LN6_D].KLG)C7,2?K_9 M&JLI)_YXS=\ -WD=SM7)M6E8@8N("L&@?L1H^<-WXUGZXQFRDX'LY!SZOXS(M?\6 7RJ$0M5-:YDO!{5SVH#7.07<[EMJL:?6A-UFCK53YS1T;(!)],(=KZ>^[0PH]W;FZ87=*

M.VZWN94L]^R91*-WM6;"4L%V8$/$HW99#;QG8CCJ32XF-.B-3H<=^P_'O?/) MJ?AE \S+)ZO9H3<:[CP_3N'QV; S?I32D\&D,[[%"KB>
<(W%#H>RK3/L+-.+ M^NS:=NYP..*_8+4X1F--IE-"+JTCU$Z_1]"]44D=&AV.O>&@ M-SH[VS56F/ZVZ!M/.^/=Z)OT3H>3'9YA]ENC;PA\Q^/'P?'0YZ-
@>>AS.RXG MO?/I (/1=-R-&N2;L_%WC,KAV<[S(]/0X+0S?I3ZI^?#SOB;HA(' _X]')/# MWN""XY%#LS><3EL!6QS2N:MV@+;G9*>V-S\8#A$97<
'GN*8FX&R@A8)BFM8 M@3J3#1XG"Q#T\MSRA^(D)ZZSK+T9^"KT>B)Y$%ND@GX(1Z0,RY:8BM9Q M7]KT4$M)*M#U0)6#D4HU$X&-
V637C([A2RK"R=[0C7 W6XN['V5>OGS?0\XS MZ:90P[JWVB?+OOA+';H5::H\-,,;*4'2RT_D6RZLN\B^W[1*W89?@HZVZ3'I MM(XL3\T"_!1T1-
U*9B+XF%P=!\>B<8-O[/]8^N24++[9S;W)]^T.N?IU3;O% MB)1E":33U@;9:A<.ZDN"5G*AV+/8=_?[VP^]X.%ZAJ.>ZN?@O/H:-5K""-G" M4"B$>4U]
]T7MW4WU(@8+G@B(4E?24DG1V!#P3HP&'PP'DC<*25^PR352!'B ML02FKCA&^X_+7]>."W='JM2A,J/3G'I#F0")3O-"OCEC$,.$I%V(G*_2EX[;
MK,H1%F9TH1[ZD\=MMM16)L:FH>& WX'M&.! ,]<>2!=F5C?>Q^T-"'F6$RI M%5R*.;4A/?;3BBB'"B=$2,R7NR6K2I0)3!L&-
BF:8Z\S#C&K,NEC"R04YVR= MF5)T\^],=J_2G3NAJ)B*@G-;Y38CQK&P[QJQD0-Q#/#0:P=(:^E2/X 11DFK MQ-.E0ZK3@-&$NW1"T\;10-
JL;NIK\T"P=6W^>ZU6?)N$T%<6<)S145/(1=WA M%@R:#YRFWH08 '"5#T7?;X#Z9K5.%7298Y %7&F*-!PF8;>+ M2;G=.Y3VYB$"_9;WD;EJ\^[?_:34
9_]$] >:G]3JG#L(N.7B)@-%Z3+E"92 M&B%^.6!2<==<%S'O=WRT[4B82&O77+;EE&\>+^97KD@^\DUQ'EY3T3T[:BV$
M;'>&"RRJIZ+1C5KHH@A7,1G=3U.E.3BGHGTR;4K/T?E O)?KH-SST0OQ?(R_ M,_R=OT!-
MX&Y[E0&Y^+Y<((5HQ$&9Z:JED.K/@XBTXQFOJ(HM7,M.F1+_L,C,0;X@V^PUY=B=0,%-U24A"5,I"F MMP'<08+KTF00R-
%WP815R>]LVWRD4"U1518%.&L;Q7B4@KATQ%=4(GFJ;G'H M@'F36)%,%E;FE(C"R^C=*]#0#S#,-_=X44D@;ND0W)27>_N)9'L-5R/TDNQ+
MDQ6:@[A%?;T[I<,T7%%&+3;.%;IA!6G.0'LEZXL;9!.SXG+X*P5M>,_W1:7' M;-S"^+@.:-Y"A/.E_V38\;N-Q8+0\X!_'FD/XV>FT/^!+#.Y'0/O9Z45_U,Q0 M7J?
CB8JT;-T>L3L69)?2ZR(U\QO"9UW"9X/-3)=P.%I;XQT ")3X2(|)C$3X M:+?E7;=7LJ=U=C45IX?C,0:IP=WT472+##DX(7,1C0:NLLT)6>SDN@,"M+ZC
M%HS^0WN(?J=PNW Y7UXU=!Z*Z)-IK*$85H9E70U^KPIDJ 7_:L2%5C3\M**=;7^8+)4>L,M?-6K:Y-KP1.:M$FOAX/!]'K# M97;V\CG]]E&_?*X*F\I,?
-3,%)L-U[O7(E7;%V?16?G#SW*UMOC#]K%*#?W/MF[L% ;'A;%]JXR<#!QN9N;_\J]=# M,&$^.#!AZ"<,B6^W$''YAEO^\KE66Z9Q-
%###R0JS0;F9(:;\LEJ>"IAGGWY M1FAYQU$S3&;&Z@(4;LWS:PNT<<1U[.F\=G2&!^C&_35+1%*??PT\ M58P-2\9>#X\2_"3R/AL->FPX&
(Z/T!M5@HZ(WNA^0=_M!64\2]@/(EG);,5> M(4*DE<*P-]+$J3*%%NSOKQ8P'-#SCRZMN$7'W8NB13TU.8_%BS,P&2/TG3A[M^=U?
HNG@V1&1QI5(XV/4'[!WCZ'#/J\%NU6;G&<[)@T37W-E1,*L8N + .T9 MX%-KD<4[>!:O>;823',K2*B(('^HC# B#$,/ R, M ALU??99P;"DB 53A6[/,T6\=IS
UI@>VPI6&!BKV9K?T>>$Q4);\$9@FUUB M]>!+G!8);GA+#OAARW72:S]1.3+88[%6QEQ5/YLMSWOEM(;0;37@:!:#G2"< M0-A?A6,
[$086(QE+YM62%+"7 :!J6,S-FBW!D1+Q)9>:W?&T #(86&>H3YX M:E1)=C\Y4S9;"; "'XQ# ?V(- *9X#+0L,.Z= 02_;)X@0205(=GJ TA0KE MB $"!^.
!4W*\. &L7Z#X'Q+G MT_ZT_*&'UI0+2HW27:=' MV:#JBW> $1UA*\,]K_WM#0]"AM J=:8.0^UC?^Z-4/UGX MX\(FJ/Q=%JN-**
<8OJEPP9)"X]8Z5>'3$DJ:9X93I@IR+I>P)0P0F<%@9Y3. MAD);;"$28_QL>YQZB$E5MG*P3\0"@T3H)L+2!]T Q?0$1'#&/<+Z$N3I+@& MJ8>">(@;4
^7"6'%;7(.Z 5E&9B2HKKP-]@A 2A-V"_]3WT(66F*YH\Q"HFW MD,\=AB#8B[QT.OA#M:[S% 3-/9J:9)RPI4ZK:)[SG4\?+5O*KT#!!1AUUY2U
MMB2Z:9B*$M6$V(M'OOB0&OH +,:31+I4!#C;@A4CQ3HY=)=[A1U1*X4%QV&! MHE%8$97NH.8!M-(O+4F\WHV'=U-O+CZ&6JB9ZCY6,>^]RQS/FP-
"L8#;!H31Y-IZQ*1$:EPO>')T\&PQP*$V.>E$4P;*%(@ON;IC%2V,* A[LQC[,D,.\HOCDS!P&(H'9("@J;C5]$YWDJ8XY5"NWO9S!(B+ [
MM]I"V*T0;B2FD(WXU[+/+-D/#5T; 5X:THI(^NQ[SMK6?H_ 89)5+ ^>:CJ;G M'46L5AGYELI5L(?Z"B0$H 6GZ^B T!5V?>'P>)?
1'3*#G,6KS2$)_:!QSOE2AUD!G$.M>]$MB]ZO0OV/W,.[6&P.UGLUQ3+3=7!W;?::ZJJ:*3RWEO DZ
M!*%QT1HH/.$=*:XE^&*J>;#$"3ZUO&J[L#EG%\/1_!)]SLT\)*!M[P832]QI:,P / MHXGC<3;%_T?(9#29L+?-S@QF\#Q>2W&'=3#N$A37H/JO"/C
(5);)U54E#=< M)+F:A'J?->|ER=IAK8CKJCZN*GY+X;A_IM%[EQVX;1OWI5H8%O7G3_IH]B>;
MR*XRD'90;=F';U%XMXQ*_7:1L*,6P,8V^IQ|\5)Y_487E*JSLDH-^0XBDLO(MJ0^S%5 X5,Q!HTD5?G3@@($B3
MWPICR50\TS'7FHIY)ZE7DJMK7+9P0LI4.4,M\ R5=(7NPU/+M;B3JC#@:H.Z MR95)_H?4Y[I4N5-IYQQI7&Q\Y_YJ 0/IPF7:IB!\VN MN-2*2:<-
NJ7$QH:M\D9(P2IL,+JAO^-Q!'_I"WSZL3EPTAL-,"49]V;SN4NI M(DQ7+D:3R27[9_#/*_J^M=W1&2CI?#(O=]/WE&^]WBD4[<,B@6)-&AI,BM\
MD&_GBH?J]D-!OMZ[_O$0K\/QI,[L<#[_T[DEF'TSA7>9 #SY\W0>-74>U77^ M9S'\;I.CJP\XJ'7>W:D>>BQZA""*^ LK&.^I- WJS](CNKX9<>"].\-#=HJ4
M^XZ \,TN:FMBK8^!,_!C.*Y53H7GU2=HY_Z*KD-S[2*O8U#].*35+ ^R.;X^< MY2JO>S1]X:=S64_8]E8[J_L*YUJ%5!6$66P
=3/>F+*#Y295#4J\7GCX*D[OA(8^E>[EZ>2][7W4& C1NI5! MF=WQH^+6P<";$V[O-:Y+'KT9$MQ&8>9N-J]I,R):*-V-_()!H>95A?./5?
675%'QBU.QY^!8M:TA3ZNEK!I]Z# M(:5ZZO#CIC,[K>RSRE6<)W98SOX)81XAU '& @E/&'(@Z+: M29F$RJQBWR]P8EW[7S.5U1]
X+NYP7LFNJCWMCIFA/IP6/!V.? R8/RDP@BP7P^[9A[3L_.Z>G)^.SH#OZ/P!.[0X_" M9S3]IO@L,\7'0&3R+5'Z>$8FL^AQ6(4MB']#FV$W6JE]X)
[C85IY_@<#9>9> M!:- 9B!BX%$>[$PO//7>T 4:*A3Z[$,]9C7R ?+FX,'3ZLH.1'GI+\(>S-R0 M" ^RF!C2(&FO\ #IJCH
H81W11U6K>ZD(9IN456D":9Z5LO5RIUF+B&07-*M M2N%2] *OKJ[P[KD[V;J2V14QKU)7 4L8CP'9!U"0^,Y?X82%[8XV=?;,>.:V
MD.JNW1LOB<#8]^CB5WFE1QH&K I-5Z 2L821;O.X(RD)!=P38_[B/DE#]](Q M9Y89;)\[HUIIGM"+,;R*]$!W*_@7A&63(;ZT_ABJ)2J=Q_D$[&Z?0H!^5 R
M['5=('7JI2N35%'@JW$]MH#R&3,/.G12/3J8G3.$97AVRB3(^AOOC-'YWCJPQVE],)XX;C M+3WLTM#V0_&'VX7LUZ\H8=GI(8,[I5W!Q$.M[+R&ZUK?
!:W:A2]].55_H!H' MOJ/$JYN?M354!K #V^*9@X]+ >FM2;*;_<;2P;0'?J\.,G?>N:\-@Z;/044^ MI %%[S&]I622DS?:IZ7O00NT,,$.?USL@A=G>/7.8
^+4_!453Y=1U972=%U M>36\X=?)QP6]Y":SRQI'H#7 ?IVC?M<[AM?!NZ(;<&_T1JQQ>^9>&ZU^K5ZZ M?>7>-=T/=V_L_L3U"BN75"QAZJ
_FYPY4R^_6)73FZ<+9:W:T,>U +>D<0 | M7RH('?X++E"]BOSRWU!+ P04 " !GE5Y9,E^X0X<3 ":. &0 'AL
M+W=OS4JH2#UF:FU='JZI:_WQZ:N*5RJ1I%6N5XY=%46:RPF.Y/#7K4LF$ M%V7I:;?='IYF4N='KU_RN]OR]7U;XNDT0$ETIG*CBUR4:O'J:-
KY^;Q/\WG"KUK=F\98 M$"7SHOA"#]?)JZ,V(:12%5<$0>+?1EVH-"5 0.,/!_,H;$D+FV,/_8II:RUS M:=1%D?
ZFDVKUZFA\)!*UD'5:W17W;Y6C9T#PXB(U_%?25SI\!<&7$FSQ1R?[Z4Z 6\.MZ_,Z[7P4X4^N6Z+4CT6UW^U^!UPOT]AA>[UEZ M W5,
[3[]E]K$:6'J4HG_G,Y-54)I_NL0%^PF_<.;D"']-8R5J^.8"E&E1MU M]/JGOW2&[;.OD- /)/2_!OW'1?8/@'O$G^M<5"LEBC+1.4P8, ^O2X'DAYK4!
M7&,B<:^$!/]TOBG2C4HP$!M9ZJ(V(E5+F8IU6<1* <(2LY?%1I4Y[44KE*GT M4I*Y6DP*[%9"W:M*E09;RXIA |%UJAX(="XKDA9-7LD-
4*DK_*H:DQ.]6.@8 M1BJJ GMCX[AJB9FBN:68YGD-G.[4NB@K 3=!MBXZ[1=_%?!X3.U6R5(HTF=Q
MJ6*5S8%2K\,:V8O$K<2ZZTA<5PKKIBUQI\T7<07%*4KSTU_&W4[W3'S$3IY# M(&AEKL$,"C^ 7X)8HY+OQ_1O-62ORG3K MD#5-
;/\6L%TK:']B',+O91FO/+9]1N==G:O@XUC$)610)@A9<0E>& 8%OV0(MMP8M#G7U4)&J>'%B3IS6"4P0DC.D&W,Y3Y53
^B:G&LHW!8&8R!ME8.>N"YA M&8P-091949..+/BI5"GSPF(@<|>) "FR %W*T@_,YK J*N-3&L\1<0,*?X(M/$+LU&!W DU+BW5@Y'2]XO
M)#M[!=GY\D]K_=^SUHB@6ZG>>P?*UM0TM(CW+];K(F>$C%)?2(7EO8210XH2 MJE"]V*KJ!I/Y?Z746[. MNZ 2\B/D#8U)5P:Z*7D@"@B(22D5J%-4.F(
MC3D!3XP*BRVD)-2<(UM6E.K)2L'1FMGK3=D*AR4A Q4!NN)4DU2"=&5/J:S- MV5 &[;#Q)VKH&@AG=T+8Q-*LQ)U/"SV0D%4F@KSF,2W%]8I
T$"2XA];XYJ M,W6#BI=4:$[-@A;ILH2?0X[-"<[-+DMV;U"OK>M*&1_XKW, LTQDNUW2W%_ M64A=?,S%1V3E9*&=D=-YK)O)O%CH%U,2&
(1]J>K*Q*N44/PEF[\5Q_L33AAY M@%:Y*@F3E03X&*N0*Z=@W74>MSCO'YT9<1PFGG #@H([N7]BC7?K2!<,/2_* M(K-66A8;;2P-BBP@5MY$./'YOZ0/
MT''+!8"Z@"PJ06V=I$XIP(@5G!?O#-E>]3ER3=AG=|B\&;3$Y]Q&(L=LN][Y MY3=U"7T!.I@$3*89R"27S'!GWC_1[.D:\U)2/M3RE?60Y NMAY&&>4$@
WR[M(J2W!]$X_GQ[<4(SC$)2:W2BG$>)F7,>3W@J<.S_!XTB)UVA'4'7B"K+:()$O"WI+9%CUB6R>:'F&B+U/@C<8^$T2 M+"F7R-
5]NGW!/A.Y+I,6':2U'W4'W6@\@&UX; ZKFXW+Y1=%L2R"]U7L49W[MKAS[=[B(SI@<^*1 G#B>U@8C&8ESE2YUG6%0ITO)KRY53I'!H*F*G-
Y>L+,CQ3_E/C4 M-)/]GZ!,'T_$QW5PKD$W[W6:LEW"+2QK:T-/?-2>(@7A%SMP7E*/%+RIP=;= M^!2]&ZZ+G4*+7#6?YT_6MZ
/U<+"DSL"&X_ANV>XG38I@8]V%2G:Z7R_5RP MR'8Z3#\MMXB^D["7?7/L#+TY[CDF,,8Z(VMS]] 81H$A4("E^)%2PY@B]RVA
M7J*0>ZN1P+#;B9IV2NE,59?Y/H@]00<^!+^$=:7ZG:+Q/G-E9G,R:Z"N<(3" MI0B$;(E8EG'8M(XMIG+7.^_BR7>3UZ*7R.Q.__V7-[].R8>1]XH-7A/
M"R3[L/F0C5WGJ&"MO4]!T/'Y[<7U]*09IBWW*2(*W%P$YYK* M>U/KRN<'GUNS%B4-|#^QCR0^-PZOP>$/ZEZ|H]1I*XX;X_V5)T'OGZ,(++%O
MK!MI3'-\Q<3(T7X 6!2QQ62QD\KU[P%WRAL&U5R#;/SIEZ_=YK?ZSNC M,#];^057 H"CJ#?L1Z/>| S#\7@<==H=&DZZXZC;'IR)<=0>C*-9TS#;G\4
M=3MM&O:'[6@\&=)P.&[C%TR81&TH7&?$PQ[JR3%<)0\!M]?GX6 2]7L#&O;' MG6A"NW7:V'48C;L3.QZ.HOZDR^-N=Q0-NR,>][N8/[;C 1*@$16(-!
[WHM[$ MOA\.!E%G,.3QN-N-AKVV'4_ZT61D84[:HZ@SICF=J#T!?:,)CSLHVR;C-H^[M |P?]NQXTG6XT7@2C89V3F_#S,D:+RD_U\F2)1_|
MU;,69U,>;T;4R/.JDU "PE'#O]FKH)P[A6XU&V>/41.<9S2,"IMY[*B;LN;, MPW;E0U($Y5[IN:Y\%DL%O2JY=,J">U(^2T(A5MJL-4UM&2I14Y)Y>P^5LP_C
M#-H\SJI@-,6A60O/DV"#P I1%5.0PQ2FSN2\:;HN?"/1U&7U([*F072MV3' M;2]#9.F%$V0&?E=4/R!.H1? D1:.T\VUT[_0"3YY?#@R26C6AP.
(=F(,A[(H[N+HV MXJ]RKL7GV33BL+,+8!Y0__\N@'V GB"_S? *[7WG$:;^0)R[F?X_CF.]?S2. M]:)N;_@HI'TSCG4I> V_)Z1]9QS[^V,7XM4(,-
O]'XA=C7C5F42#X=,8U0?^ M@\E@/R[1> Q:AC9VN?ADQRARA|125T6T$0>'X^$_*W9]P|IL5-F9P9]!;!?$ M E?^U<+8[?
37\YO/5%SWQU#T8VI:GXK)KVQ.):+5",_,-%(S.]69O=FQ4X[H MF;Y5CJ5\LN.*:E(N!\XVL<"^RO8(PH2]GNM)M_7AD84:5TU M.GJN@I?
N'(E[Z,"92)=DNW0XLMV5]LRX)YU%S[HKE? IU(4N8XJRQX=>VNCX M;,/OV27"]=PD]^%SKV]I1*$L]HZ5>(*^S%E?().!S+V M9(+Z^!IPORG8@YRU?-
S+5;K=;]/T79KTE0WM,8Y>D%72+IXG38US-QDDG5-5 M3%]QB/6M1_$ZY'>VN^.\C-MVE^)]*#863DC-GA)3C7=6& X!U;Z]K4]QR F
M^3;53K7VTKLL808?.7*AN|%L5G--U1Z6SS40;2LWL"_K9A:SY]H>Z+YBV=]SF+NZ^ MH39VR7VF/?!WFZB"$.,X6/?(M_"S0/)*UT:5J+W M ,N'>(>-
I]%D#+WB@^NM]%##E$6]%F\+L]:53/5_[PZEW],1,#@X4^4&$='X M%5S#!I#G::TN5H6F(PS6AT?Y9IAY$H40:VU7NM.70(>O"?>Z_&[3 W5E% I+
M;%F6]M(A]?N_48)"M0)23_K4|<':VQ7?)Y;XZRRK<_4 =2G)Q_NC[6^Y@C=(MM!ZG,SZ3:1Q_+5Q\XJJNXG/_P"'G=W8_4:R$@RXIHZSKX.EB[W<#>
MEN,+$-UV.Y3O/AYQ#BNM3&+?%:>S]V6I;/G'"4CLSLBO6E"Z* MF'+37PB:KOA(C%^=-([%G?I;L^?S8&*Z18)!EW3;G.V!U^XR9I?IZIPO N2Y
M1U^VR<#M==GO9A'@?IEM683_*AF3#;Q-1>3GSO M+A(T^BP_R6Q0]F;U'&F2EGSXN*%D,'/] WLSRMT9H.L"&Y77BJ\&\XV=/ELJ M7=VKY /9-
6FHNZ30R$BO[V8T@7ZARPC!A5%_"87#3C3N[,3L&0&1Y Y?9BJ& M%;+<]UQ5@V)H2K$@,F|*;]G=K*B?UA'4 MB_V/HOSB$[^#GAR"=*'?R?K??
E#*W7#Y=8;8J59%2OGRI2KUQF8Q31:|E5"N MBFY4-&]T!"]^*6$LPD|*OC39 7,.-99K^D|WM_:70$GN""@|:TN_X&Q^)P^M0.TI,"$PIS;5 M-'@4E
*M"KHN[/L +A']MA$UCIMM6@U)[R(/DCIKYE#Y5$DN;QIW\MB-.Q]# M?$K<6>R[&MAU)PRO'6[&V6/WKKV1U+67K=T)\[ZHR:W-'>O6-[8TNY
MTT.N0!+U1RUCRW;Z/@M^G*;XY%Q[QT>7RLLBI?;6Q4IE!5^8V3ZX/*7AE;R/ MW:|
[OMO!'&Q47""9P@3J4BQ+Z*L[I]^O?)M]!0Y0/K+R,;BOK6#C,J'/6^BF M']^!9|&H*O2U7,ZXNXP8UQ7EQP <$OJ0O-IV\6YQ@'XX<_4I*AU[-V]21$^G
M[FY2-*:[LG9@!?AD#54?) -6S*V8^-L/GSA[UX;3<4*L42C3A$,?')TVOA?C M7@Q]%6?L'1W[Z5AX&SZ\F]KOS7;3[5=[,!+8!'W:L|#2=FLT.+*YB7^HBC5_
M?38OJJK(>(B2 -Z8)N!W^J;$/] &X7/$U_\#4$L#!!0 (&>57EFL>(-J M[@(%0+ 9 >&PO=V]R:W-H965TEO&G\4*0**7-
*&B;ZVD7'=M6T0K2+&X86N@ZLF"\11+->5+6ZPYX-A M:6)[CM.T4TRH%?;,VHR'/9;)A%"8<22R-,7\]182MNU;KK5;>"#+E=0+=MA; MXR7,03ZN9US-
[%(E)BE001A%'!9]ZX?;G0;:WAC\)K 5>V.D,WEB[%E/IG'? M%F]O.&Q_=,RI7 M @UI#'$%/SG/=\[PMDJYS-O;Y7WKG164!'/W7G\9T;/XH/S M^#WF"G??
Q8?U@_L<01]2YT] O@&K/#S)[?I?*^JLDN*#2XI-KRDV.B28N-+BDTN M*3:]D-A!'0=E'0?GU,-?JB\B-&
(I(%7(N@$@$<(T1C%),@DQ&L[F5>6O=DOTU.C5M \M!F /T_D< MK=^ZW;%;L3Y1+6/>X;W)Y_VF^M\N"14H@85RY=RT5"O!\QXNGTBV-@?!$Y.J
M73##E6I[@6L#]7S!F-Q-M(.RD0[_ 5!+ P04 " !GE5Y9 ']/]T," "* M!@ &0 'AL+W=O M=@,A7VT*2,FV57/8*DJV|=G! UAK;&J;L/OO:QM"TRIAI5S -
C//;XP8HD;(M9U4 :/12,JYBK]"Z6O]^2@LHL1J)"KAYD@E98FVF,O=5)0$3EU0R/PR"N5]B MRKTDOV6-O%|?*)_=;6;6@Y8P8-@ORC11>Q]!'"!#-=,
[T3S#;IZ M9I:7"J;<%35M[.2CA)::5%VR<:@I+R]XY?N',X2#.=R0M@EA,Z[W!>ZA&:!+

TX80>:DQNU1U"YU>AMKO9JDJG$+LF0]#@3R" ME[Q_-YX'GP:4I[WR=(B>[&H&:!P<9O?CK?%S0KGG_6'*

M$F3NNJ!"J:BY;EM%O]HWVE7;7_Z&MUWZ$62;]5!JU M" +Q@ !D !X;"]W;W)K&ULO5EM<]LV$OXK
M&+73B6<429;M^"6V9^2DN+?7GVV05[O;+NLR^4"N)+51I_,RA"J*_&8Y\5JI)^9&ME\&9A M724#?KKEV-
=.R9PW5>5X.IF\&E=2F\'M-:_=N]MKVX12&W7OA&^J2KKUG2KM MZF9P/&@7/NAE$6AA2'M=RZ5Z4.&QOG?X-
>ZTY+I2QFMKA%.+F\'L^.KNDN19 MX!]:K?S&LR!/YM9^IA_O\YO!A Q2IJ+(D13#CMZ1ST!U)&S>? M6^WOV'?
X,I=>O;'EKSH/Q,]&6V]/Q?L8JR9Z<# MD34^V"IMA@65-O&O_)+BL+'A8K)GPS1MF++=\2"V\JT,\O;:V95P) UM],"N
M\FX8IPTEY2$XO-78%VX?8C*$70BOET8O="9-0+ RVYB@S5+4MM295EZ\N$]/ M1]?C@*-)P3A+Q]S%8Z9[CKD4/UD3"B]^-
+G*M_>/87)G][2U^VYZ4.&#JD?B M9#(4T\GT]("^DRX.)ZSO9(^^6>]PZZ;XYVSN@P-N_K7+X:CO=+<^JJ4K7\M,
MW0Q0+%ZY)S6X_>&[XU>3UP>L/>VL/3VD_?:N\5CQ?I==7[=3S*JE,N*]R4;B MA399V>3DNPY>9-9XA""70>4HUKG7N98.
1E2%2KGL!RLD%[\\-W%=#IYS:J& M_./X=;L8"B7>V*J69OW\U4HJ7[&-:U>L:Q<;G]:.A/9"BF5IY[(4L\. M)TEZ>(R29.B8((G
=N7Z=Z@1'POR)RBG*]$8B;Q3GA?:2)-IQ%>;2/4DBR=R M#O\ZI3AX!F>(*M:RHEH6J,2@JCERT)8C"^+A9"@*H&2N
#284$M"CC9,+B[' M<0ID%PKQE]GLGO=$'%*:RE+(_!/HC\(,ZB%,:L_E"7^L*=?"D)4E83)KG*,W
MFSL:4U*B+*5FI3VYG(/:X.I1QK/^O-"0Q&9=A 5$A.2[&0VFT%;LBFPS#$ M!L%#I/"R1G,!QF!3JIP<_0I>;M40Y- C.!,14-
#F4VPM3,.:MCD0]SZEI=V M@,'-T-FFX7;R@T +?:UDFZA% P,7* .8MU;2C3C=>^SJ<^[AHHJ!\X5MRAQ) M$]3CR6?
L^=28V$0Y7ZC6KU!$"263X R2GE08 WL"Q@5(A!(T/+R[YU3Y$@"VUM$(F+M>)@@1N=LFO75GGZE@;\TTB$M"'VTT6\:
M^4MG9$IBLO,GZ;*B-3(6Q-\:5$Y;(H=8XE7'$J\.EO<]0)_I&C@G)/3^[N&* MWZWLFR&4RIC#D@8)UAI+#HRP4E3?
GFNFDI^LTV']TJ[,LWY#!0&V1O Q^%"! MKPI%:<)^+@T.. ^J%BG:NC,+LHM,L(\435,AYF;A.^8#,!)PSI-UMV6]J+"1*
M:@["B'KMBKJ*14\!P80X/>J@8WQ((JJ+9%)9Z-^8GZA.T?JPKY>D9G9_AH(MP>FVTAE!AJF6B+
%HYV7>AG#3CUV[JV;B])Z'P].8',T:Y(;%-$!=%](@)G MJ_\R+^.2KH%S+(+"*%Q;XQXTL6#*1$O]P0[16M5 M:!3#X:2-
Q&R36EE/%L<'@1G,>)E%VJ1 80R@H/F4,^HOZ.D "6,R4E:/WY%X MHQS5-$6KE-ZS&U%;KZ"2A%A+MB'(;35K;N[?
3"N$>K:=4)OXA:F%\AW9BM6B M<6'/5ILYQ SG'3.<'RSF1_- 7G0%-&=8^*W:6 .B#T\@C.2Q#=00NL]@;+O M^D[]UF@:S% %N
.2,$6JDI_5QN$<4H][8QVSQEB5BX5*!2:KR#&."3I"X,]) M&V")R3'V>FZTE5R#$G"T:TN-.GAGZJ'L7739N_@?5$Q3
C%57?)=#)91F&HR M=(AA(.S*YQ_5*0Z*T 2.ZL'8AO@A^ 6&,= VC1D9N"]J(-[-LJ9J2@YSK@ 8 MA#G>OBF\%;*C_YVF*4A_?
SP9G6"@+\M6Y/O+T46_P.RQ9[[<,0FD>0Q\6*X/ M)>*R2\3EP:!]P!'/[L(.U(U9*&)F5QK^F$9J>)UCT2G"\;L.L!O7U(> ,$@'
MDKJS^"->O)L]W-%5R3<(_D[!QYH*0+R8/3P>B9_MB(]X.;D3HROQOH*)3\D\E&8O*=YBSD1KHHO5D%[I*$K]GT0"1/).I"WU
MJ&B^3K_)0,!"49^7NN3:[>\?^,?C(N>X(^Q0BG-]@]XB:>XJ*$90MW$FS>7= M/GA62YTS>OK#
(2V72Z>6':]Q]V1RT=O.\%60J@#GE#KU%B)&GR),5=+OI,FP M;M#/L_[BV+5%OF3$T;?M-
7.UQ(V4+S(+=+|>",=G:6@4/TJ:0V5NF0CIN)J& MHX!RBX-PIY]X2M9UN69W.@.1H+Y&:)H@.?Y$!L="_Y+WIB[)XP"U[M2NL%$]
MR;*1C"Y2GV8=JG\VC9P!Z [/#\|;B#V M? A:X"MX&LKIR 3;Z44/6U]. CR=M'OV =?UHNF&OQ? N!';9EDDV&W[@['- M-
EOS8*=.?:FI(:5VD^/NC0"W\PYN?JV57ED&V :6+P0 &D) 9 M>&PO=V]R:W-H965TU"!) B63)3IS$ M-N"DZYH"
[8(DZSX,^T!+)XLK1:HD9SR:JL8)+O=-@FJIB>G.#0JVGP2#8'CSP96G=032;U&R)CVC_K.\U M[:(>)><52L.5!(W%-
)@/KFY&3MX+?.&X-CMK<)$LE/KJ-G?Y-(B=0R@PLPZ! MT=|*;U$(!T1N?.LP@]ZD4]Q=;]'?
^]@IE@4S>*O$7SRWY308!Y!CP1IA']3Z M W;Q> 0-<:JJE,F#RHNVW_VW.7A-0I)IY!XOUM#WLMWS++9 M1*LU:"=-:&
[A0_7:Y!R7KBB/5M,M)ST[FV??&FZXRY"!XR>V$&A.)I$E:"<0 M91W,30N3_ +F$CXI:4L#O\D<|Y?
Z$;G4^Y5L_;I)#@(^8GT&:1Q"$B?# WAI M'V?J\=)?X-TTADZ,@5M5+;AD+N 0YL80[W=R$ *3.7Q47%KX@M(V&J&MOJ/0
MW_.%L9J(], ^^#+4.#/<[X)KKRM0LPVE W6-0KS"8';T9G,?7!\(;]N$-#Z'/ M'JE9\T8@J
+Z4'=K&\)BLWNP+X"#)O8'|%0B%$I0:W.Y!.OHT_4W_XX&K+NF M;
NPRM)O1I[P"6;3I=J1KH9LTBK'\Y!3B=0,*YAQ41#0!06<[4RK9AV\J0M M.%MP03HD0O=-
A7D(7&:"4K#RR:B0&2HBC1$+-6JN2#'_E_K*G1#CN:2N$L*E MZ.0*;IDI/7#F%DB6R+X7? OGXP'RIQ:R42JCE!K0;, 8&E^'H,H:
[^X9F\#QTDX'(]/X \JF.XS_3+!;3#'R45Z D^^FC]5 MI!6@G.^I"N4ON0C':0H'R#[JR3XZ2/9]!]=)=I6I2H5VY;=1_.#X*^GN;]U MU'
D;R1K$&$FG.JR6V M3?&!&/:=VH! 7'4(P1NQI4;T I(4H&HG+KJ)"S0O+58+JEXW-%,:909XX35W M>XL|V.*7+
>598UG!.T_,MG0RTR,<@C)S]WQY.W_CUGX_ K?.@)IHKMT[?T6 MB!RCH6-)$EXD8_A,3*(^5A72V669#OW*FGD:C
M93N4:9H/EW73#8X.XMZE.SJPZ] VG;ETY-?+9>W^/#&MO3TS)Q)&-K M/_'B;'HX2-DATYI)8(0:M_FU+0M \&-/S:8@]V1;'A?
WJ+_&&-'+./:FU/; M_MI,P^)P4 YH:F;UN@U7]O:UV<23,=[$MCY>Z;;7S=,!3=8^V.7&&!XLFZZ_
MUU|V>;AG4'[-0&X,9/2[/RAZ^4,=ZJ,#9V_)L3;06(BA1FLXUW17M[4X];XO8-A "P_'XV"<]A/P*1$6_V"XL/(VZJ9D^M!_"
MG9U/KB5[JQH6X?+Q% V]3T@O)2X:IRB:M(4IWQ7A'W!%^K,J?1^JPJ$F6 O\Y97E! M H=*^*C3G"Z"^:NM2>BCW2I:0C\
[.8##H)S(B55522%IDHA.P7]_.'RZN+-V35)5<)!/"]*R *Z M)2E=T?FJK8.!B!B%()WEI*2DJB"-4(Y=W1F_BKY))4DIA)8*5A-T<]7'ZYO
M1N_?]]XJG+_UZ[[|\^'[RYNS\],/-!2 +JN"3!*HNJ. 'UY=C6BEW*/9%[M@%D6N=BM6;X("S!EU=,7]%)[5&4E M"L%%5;E"[3-
X$$N+:O1DV:B3KUM^8^D]\")+JJ+"72:BD%0F(A-8Z22O1&12 MF164)YDN-T>Z+<,57%99MH'>;;|
1I8RX_*DPOT<'?)_)3H<11$BR2MV7"4R MK>*Z*@LF>J:C5@7^;@@O$UDBW^!MHE*^YN %B@0!->AI+Q(!+F5H!Y'DX"[6 M4-
+@EDBR,MO1OX2[1259"[7+(.711HIRVP(PA8%"E\$T956)I*JTY'56/6@% M% OI%ZRD*O&O_5"FS- |>BLI*Q 55TW+NY8H
,8D9Q5!.7*D,@XGS=2V+0IT MB"HX,@'%0FLT2A$3*G:](:LK/"F*)1ZV'"%YD>^@65;5O3:%_$2'2+"98Y#H
M")VD>#N!&86(4>&D1,&)KW>*R!,N/!,[8Z^AWQ-1)3J5L96XZ425I$7QN%OX M35M2!4[|HU^D3A02_8(MJTK3[_U?
S.V6*OQ]NLMZ_W&9_+%N'/HI?I9Q6K_C MF^UG[K5US5\L=G0Q"98;+H_]II*(UW23=CTUCV+%=XJQ5L8U=NJIG@78/4:?
M@D7[L0J[DC0>8Y7[9(*)7U*[=H39JJW'UM7!.CKF|>"CZ-0,03QT#AL,W-GNNY6#_|WJKE9LC#J]-M-YT\UICH':
MQSA;Z[WQ"=WBL[Z@&JG;1,XI>'A TJ>VLP'!(/ &|!CYG&L]DC8N@O][+G;W4WNQ_W >J?>C_V_U&[.D;9F!M-T
MO\@&Y/I1NE\$NXKCZ]@&C&I17.#7AW&L@.66=[4O#V @ K08 !D !X;"]W;W)K&ULA57?;]HP$/Y7K&R:6HF2D!] &40J+=/ZT
J5;GV8]F"2"[&:V)GME.Z_ MWJF&E$J4/21G7^Z^^\Z^NTRW0CZK$D"3U[KB:N:56C<3WU=9"355?=$ QR^%
MD#75N)4;7S42:&Z=ZLH/@V#HUY1Q+YU:W5*F4]'JBG%82J+:NJ;R[QPJL9UY M V^O>&";4AN%GTX;NH$5Z!_-4N+.[U!R5@-73'
BH9AY5X/)/#;VUN G@ZTZ M6!.3R5J(9[.YS6=>8 A!!9DV"!3%"UQ*51D@I/%GA^EU(8WCX7J/_LWFCKFL MJ8)K43VQ7)*+'@.
M^7M_'XEU[,()NWEX$G %39]$08^$01B?P(NZ;".+%_TOVR5FN[+9_KI:*RVQ M.'X?R]?!QXCB-K(QZ\3!"F?0ND\!= M/]*_
2ZPL7;03[:-(;^@+QAN ZXG#L_#8"?1")^DDXNBP"E#1.$8X)PA"K)6 M,LW0-R$1B?
$YA7W(/(E#1!VC'%@Y[^(B]WXX,JGT0Y/)L!\G)L%!?Q >5H4S M#)UAZ P#9Q@,R;':]]&"!
[TQ@Y*A371D&XYNHT5C!]):::!QO=EGB_P2D,<#OA1!ZOS$!NC]4^@]02P,$ M% @ 9Y5>6:7-Z2&T P %0H !D !X;"]W;W)K&ULE5;?
C]HX$/Y71FE5724@(?Q8=@M(L-OV^E#=JM#>P^D>G&1"K'5B M:CM0[J^_L1-2*B#=?4GL\N9EQFSO?%_'&>9,
M]^06"UI)I\|.93)WM4\ZDLC> %/BK099XS M=5BBD/N9U_>.@B]\DQDK\.?3+=O@"LW7[:.BF=^@)#S'0G-9@,)TYBWZ=\N1
MU7<*WSCN]XWI-2ZMX>GX MB/[!<2%?:4[(H]QJ8W, M:V.:Y[RH_NQ'G8<3@TEPQ2"L#4(7=^7(1?G
#)M/E=R#LMJ$9@>.JK.FX'AA M-V5E%*URLC/S3\4.M:$L&PU_K%DD4+^=^H:0[;H?URC+"B6\@G(+GV5A,@WO
MBP237^U]BJ@)*SR&M0Q; 5>X[<$@Z$ 8A,,6O$%#<^#P!K^GV8$'C RP(H'W MWTMN#K#"N%3<<-3PSR+21M%1^?=2$BH?
P\L^;/G91?6A4._3F;U[U MQ\&[%@;#AL&P#7V^HG),2H$@4UCL&!=VK[IT,KLK1M(3@I9\ 4DC^J^X0T$V -6^I!74UL.Q
=P!RV+AFU_0'VI U, M0RH%M1HZSKR@BA&"BE^_O8,UZ>L3 [O=S GHL!G,(U3-B8-%0_RCHU9]/U@J M7WNK'JR)J2[5
2)RH.$UW-Z.Z?OFU23LA^]^&=D5J@X\4-FJ)VJS>6E*)B M MBT3#36ECOH#P=G,%:VEH:O(>,*YSUW>Y&[P|=Y?3+Y&\8
M#*^PJ!=;&L&H:02C9S<"E]1O56U12=P+IC5/>I#[1"7^\#SZ]A&X:0 M50"D!Y1\N)=T*Q2:#@2-M!0\888F2R98$2.L[.6E?
U>^SP,YNM:7BOK\J-XS MG;DF%=L!TG5)-U=^+,HZIU[21VU;+9_1;5 M5?]3O7HP?69J0]T7!*9D&O1N:'-5]0BI)D9NW<4?
24//"#?,Z-V&RBK0>BJE M.4ZL@^8E./\?4$L#!!0 (&>57EDB6@6F?@(&|% 9 >&PO=V]R M:W-H965T
MTQNV=,#]^8[]NNV=>MDP@Y=*//',EBMOYD&&.=L*>Z^:[]CW,W%\J1*F':'I M:J/0@W1KK*IZ,"FHN.R^[+7_#WN 6? !
(.P!8:N[VZA5><4L2Y9:-:!=-;&Y M2=MJBR9Q7+I#>;":5CGA;'(C7U!:I3D:.'ED&X'F=.E;8G;K?MJSK#N6\ .6
M.=PJ:4L#WV2&V;]XGQ0-LL*=K'5XE/ !ZS.(@A&$01@?X8N&-J.6+_I/FV]P MQ4TJE-EJA%\7&V,UW8O?ASKN"./#A,XK"U.S%%
<>F<&@?D$O^?)I?!Y\/2(W M'N3&Q]CW3^60M*/@P]+VSSE5Y"EC,0.5@RT1KA+. *TSXS;C,1W+.&;J1%S9DP\!FFLQF-
\WD$3V1((,9:JQ2-@7@4 M17.8C*;Q%*ZYY'1M,RB4R@R$HS":T#B=SN!1628(]ZZ82$?1>>AH1Y/Q# []
M8G_/!!7JHK6Z:W8K;>>'(3N\)A>=B=[+NZ?HENF"2P,"6VBA+!FVG);V(J%T!K>=*V5W@-AC>V.0O4$L#!!0 (&>57EGSQ=50
M800 #D* 9 >&PO=V]R:W-H965TLVAANQ MSHTU#.?3FJ_Q%LUO];6BT7"'DHD2*RUD!0I7,V?A3RXBN[Y=\+O C=[[!LMD
M*>6]'5QE,\>S"6&!J;$(G'X>\",6A06B-+[WF,XNI'7<_]ZB?VJY$Y7>!VBPON>'SJ9(;4'8UH=F/EFKK3/8*
M_!B^R^P\IU5V^;)OO!3L*>(OU.02>"\QCX1&\8,<_:/&"M_"_ M>F*^Z)A?"IT64C<*X<_%4AM%*OKK4!FZ*.'A*+:S)KKF*^V#$[
M3]R8C6&1_4/RIOZF,AOYA$SUH8ZR85=*EM2VWQNAA6UA"N,/@$5 _4C=5E%_ M*(55^@BT+Y4N>-?G>[CA?

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|P_<7IK;!,X(M'%',SAMGX#>-$_1)V;Q$:[AY_'#_I0"$|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|YQ+=< M)T):T!K^O!YIHZA(_MJ%N7 9[79IB=/7'O-<#EA.XXQG+LX7&N-1@/+QO ;9R,NN.$$A$K] 9-<*9Y-X89IKG/?)KQ"4\8%75=WE/WS$&@DC.8CE!5==>$7%,$?7B2IDI]'ZY?&!>6 M*6?4'L\T$PC:1NM]>'K^>,Y/"GG? PD$5FAX"RXKP05)O5YG:TSLP27E5#U3 M1TYSD]-RDSP;:^@VH[!;::^>Q>P7RCJUVIE4YLR@2H%G]$!MSD;(7.[6<56F M? A1NR.^_Y]PLZYKMIM?>7K*8O47%7YCMJ824.B3UOPSL3F&6+&ESU(*I,234 M#"RKUJOV>G5QJ*369Y697K#Y#INH)GTLD8%B!O<9U-8HMZPLO+?@!|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|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

MG*I+44)A[BR$S*DVIW(9JE("S2I1SL,XBI(PIZP(9I/JVIV<3<1:=4/GT$+K;3 ?/%^[9D2'D!_+^^D.0L;EXSE4"@F"B1A,0T^
MX"N"AU90M?B#P5:UCI$=RER('_;D-IL&D>T1<$BUM:#F:P,WP+EU,OWX69L& MS6]:8?OXV?U3-7@SF#E5<"/XGRS3JVDP"E &"
[KF^EYL/T,]H('U2P57U2?: MUFVC *5KI45>BTT/F_4WQ\(>O?V/7J+6(&^,,ZM8A)]
MTT_[:V%:]^GCKD_QD3X]0'F)>M$YBJ.XWR&_<U:<*5*FL(T,)-= M@=Q ,#M[@Y/HN@N73S/BR>P
9:]!V7.YSWX3(MN:LNHBME,FE=(N=IL9'B6# MT23O'&._&6/?.<;/0K)_3(5|6X&D):PU2SNGD-/EU KQ M:48|F1W0&S3T!OXGV|
G2I]FQ)/9 P &YX9R*'1G M-3JM3D7HTXPD+V9|,L+-?#\@,VS(#)UD;HN-X6#F*72R<(I/9>'3C.S,!BT6
M@PCWNV&,&A@C)XP[:3*HU$_GJ.2TT%7%V&(I33C4YZ@ W<7(Z7DJ(Y]F9/2" M40^/NA&-&T1C=[WLD1'*WXC9TX""Q
2LB0IH^(*M4]7=PF)X/QZ49JMS:8X7AP MA,L^-&-GD#SDPAF=,\[T4R<;KUG9JQNIW=IL+N+^Z,AZ@OCGK'P.UC-
'9&R\ZW$/0O(K !;I[WV44I M1;9.]86&=%4(+I9/2-HMEN[7?:|)VZL;|>5V"'H?LG'B_X4%>XW;7MV(+[=#
MGOMHCMW9_!,KF(8+SC;FV<$*38LEFW-X7@/.WHQBC*]1]LI"]IKMO;J1VNU@ M;V,|&/_L(6MO4*[L_N%RB4K%.*P,+KH$* M:
;2-C#W%T+HYQ.[(]EL6<_^ U!+ P04 " !GE5Y9'(T#$Y4" "=!@ M&0 'AL+W=O|[NS]1RO MI'K0.8 A3P47>N3EQI2GOJ_3' JJ#V4) E?
F4A74X%0M?%TJH)D#%=P/@^#(M+R@37A*[V%0EL:P,9P*FBNBJ**AZ'@.7JY'7\]:!&[;(C0WX25S2!)O"1/@W!*AC,>&TVNWM,#-
|9K]PM6.M=Q3#1/)O[/,Y"/OV",9S&G%S8U< M74)3CQ.82J[=EZR:W, C::6-+!HP*BB8J/_TJ>G#!@!YN@%A PC_%A U@,@5
M6BMS99U30Y-8R151-AO9[,#UQJ&Q&B;L*I+FD*(P_M08-:@I>\?]<["CYUU?N? MR+:J[[?5]W>Q)[?2WE8%2Q 5=-ZN&G_D|-
;7ELGP>-"/_>5F";^3PG 8'K=9 M6]H&K;;!3FU?T8B92&4!7;H&K[8\"<(7LE[G1(/>2U7^A@,4H!;,)925,
M;09MM/7>,V57ED:NTDQ)0(P% 9 M>&PO=V]R:W-H965T_9,TBO]:&H M2YY$(TT:U-:V:TI-7H-@9J%:D+A3*BV815-
7U+0:6.%!HJ%1&*ZH8%P&6>)] M6YTEJK,-E[#5Q'1",/W[%AK51\$R.#EVO*JM<] L:5D%>[!?VZU&BTXL!1<@
M#5>2:"C3X&:YWL0NW@=\X]";LS5Q2@Y*/3KCODB#T"4$#>36,3#\'6$#3>.(M,(U?(VF Y^L3^R>O';4.#IEY67?,
MLBS1JB?:12.;6_C:>#2JX=+=XMYJW.6(L]D.CB [,.0M>6!:,U=4\NH.+..- M>8W>#T0H:6M#0!90D#VT"Q*';T@41E<)M9B"(Z+Y>-
SM<%STS'$&*GP"=@:X MN0SMO&[D5Q?^5@;LH6J"-AX]YI8F!1&2W0?<1./LN^D&Q)[:PLN1*2K(M^L=7
MDB61O+Q#>SIGONS&]N'/'EWZ6F=XAGSQ>;GZ=7W;MIOLM[OY8OWR[':SN7]^ M?KZ^NFWOINMGR_MVL?W*A^7J;KK9?
KBZ.5_?K]KI]7[0W?Q=+YNNOKWZW:^_/SR3)P=/W$YN[G=[#YQ?O'B M?GK3OFLWW]^_76T_.C]1KF=W[6(]6RZR5?
OAY=DK\=R*8C]B+_EAUGY>>__. M=M?R?KG\=??!F^N79_GN1VKG[=5FQYAN__>IG;3S^0ZU_4'^=:">G;[I;J#_ M[R/]K_NKWU[-
^^FZG2SG/\ZN-[-=+>?K M_7^SSP=M?I9=?5QOEG>'P=N?X&ZV>/C_]+?#*^$-V'+X ?(P0-(!NF. .@Q0 M3_T.^C!/_4[%
(IL.VYS<=E^:A__O[.U] M>?WQ:I--%]>[#[]LES>KZ?WM["I[M9V@V1],NYG.YNL_;CG?OS/9'[IX8_9% M-
EMD7_F\RUM_>)\L_UI=]_S_.KPD[U^^,EDQT^FLJ^7B\WM.K.+Z_::&6_2 MXYO$^//MJW1ZJ>3QI7HMD\!W[?VS3.5_RF0N-
?/S3)X^7'&7,^R[V__[NP9_6W3KA;3>3;93]AVE?WCJZT^>[-I[];_Y$K_ -<\ M?-<=GZ_OIU?MR[-M^UNWJT_MV<7O?R?
_"_:\#"^W(_?_47Y=%$7^79R?/)?W%A4-E1D8I'42M6ARL8JT32- M/JF"RRQ.EUDD+_/8F-;3.7^5R>%]IQH29I P"X(%-2A/-2C';
8ELD)(F$'" M+ @65*@Z5:@:V P>QA=^,]B^_R/-(!:5A2:_YB862:5$3H!K!)-7E5\,ZA/ MEUD_O1ED_\V^?_;N&7>Q24K?
&8>$&23,@F!!*9I3*9HQ>T*#K! 29I P"X(% M%1*Y>^^?#^P*!X#_:UHT54/: J/294.:AV%4HJP:21H#)U,ZEWQG$)[1$;UZ
MP^6W/[)7G*3TG7E0FH'2+(H6UD.Z>L@Q&\2!CJH3DF:@-(NBA75R1D\D7!\,B(IHIL-C$HT M=%]9QR49]
TBZ*%A7#>3HHQ.X.$>CXHS4!I%D4+ MZ^0\GTQZE2=TA@,@^%-?4BO!B03M#(Q(Y U]T\"HF]C24(ZSR33GLE^_K2 M?
L5>'W3E"THS4)I%T<(2."\G]:@M 6KXH#0#I5D4+:R3,WPRO7[WA)90Q$L3
MDOH(1B1R5=">$*NDR@7M"8RJK#MN0$IGF63:,CTTA8212(_O/>>@*V%0FD71
MPDHX2R>K47L#U/!!.09*LRA:6"=G^&1Z.>\)O:%FEBTKVAMBD<@EO_QUG !*V!- 9&0OR!8222OE]@-*KCWH)R5DFEK=)/7]H?
M7K'7!5WX@M(,E&91M+ "7L)QW(@C-N.(#3EB4XYC.#WEG)X:&G0\ (+E0DVS
M39Q(1.T@%HFRU+0A,*JB[GB3H)Q54FFKM&\)"?^0'MY[QD$7OZ-TBZ*%A7!. M3HV:=U10GP>E&2C-HFAAG9S/4T-3CRJ.
(2JZQC!A19IV!B;0**((-*OJL@_* M&265-DK'SM#A'M*C>T\XZ,H7E&91M+ .SL:I44./"NKRH#0#I5D4+7PRPKD\
M/33XJ+FP(O4/G(@F' PC*NC-!\N(M,[YMJ"=2=)IDW39WD\WMVR@*3VR[U2# MT@R49E&TL ;.Q^E18XX:ZO:@- .E610MK)-
S>WIHS%&SH4/:$F*1SNFM1D8D M2A'U!$8EO2AD>*'>8V%INW1H"@D?D0;TGG/0M2\HS:)H82F->FHH7X/2C-
0FD71PCHYOZ>')ATUDT^D M^>8)))Y)18XA%\<-3C*CTS$;XA+6S2T7:+GV[:?\S9VU$>F#OIZNAZUU0FD71 MPA(X*U>,FG
LH'8/2C-0FD71PCHYNU<,33@6<>*PH"L($U9$GY5B1*+(:4M@ M5473T1.<7RK2?NFA)R1<1'I\[RD'7?^"TBR*%E;"&;IBU*1C
75[4)J!TBR* M%M;)VZAD:-*QB(.'NLQI:^!$DK8&)@XIZH*V!D8EBXXGI@IGEXJT73JUA@X; MD1[>>\9!U[^@-(NBA85PA]X8-
>=80.T>E&:@-(NBA75R=]\8FG,LN*:! M$]'E"$:D:&+2ZIBN4C(B\GS",1"BZ>8M-@L)K M=%ZI?,0K/?2#A(=(WI/-
^CJ%Y1F4,2P%,[-E:-F'4NHUX/2#)1F4,2P3L[K ME4.SCF6=VD*'?TB/[SW;H.M> M4)I%T<)*>-
LZCKNO(W9C1^S.CMBM':7S>>70G&/)[-Q(>T(LB7H"DUZD MMQN3F/#ZG#\]T_[(_F"_>?/=S^R%09>ZH#0#I5D4+:R!,V_EJ-
'&$FKPH#0# MI5D4+=SGU1F\:FBTL8JSAHKNBS#A1#E=@&!$0BC:$1A5K3O""I4S2%7:(!UZ M0L(\I %]IQR49] TBZ*%I7
^KAHUXEA!31Z49J TBZ*%=7(FKQH:<:R8G1SK MJ#5PVSW2QR$844USD)81%57'NX7*>:0J[9%
<9^CP#^GQO2<<=,4+2K,H6E@) MY^2J4?.-%=3G06D&2K,H6E@GY_.JH?G&BHDNTEW6)HRHH2DF1J.BIR$8D:RZ
MWC%X6^"G7=+??W%[^>U7;]ZQUP==ZH+2#)1F4;2P",[*5:,F&RNHW8/2#)1F
M4;2P3L[N54.3C54<-50577_@1)H^5,V(MC:"KD!PJKQ0?%>HG5^JTW[IV!52 MIT5 %[V@-.E610MK(7S=/6H(<<:;OB@-
.E610MK),S?/70D&,=APXE?1AZ MPHKHJ1&,J(IN.C*BLNF(.-;.+]5IO^2UA@XGD0;TGG'0=2\HS:)H82F;EKT\Z)H7E&:@-
(NBA25P;JX>-=M80PT?E&:@-(NBA77R3F0; MFFVLX["A+NCJ)">*=F=B1$+$+8&+238=J>?:..8Z[9@>>D+*1D"7P* T Z59
M%"T\>,Y9NF;4C&,#M7M0FH'2+(H6ULG9O69HQK%A=E:,CI#A1)(^$,&(*GHC MPK*BCC<+C7-
+3=HMG1I#AXE(#^\]WZ#K7U":1='"0C@_UXP:^H#0#I5D4+:R!\W'-J ''!FKVH#0#I5D4+:R3,WO-T(!CP^S1J.CF
M3)PHVF>!$8E.=7 MCWN -?8$:^P1UM@SK,=80W$&B[,P'*F6 M=Y9U/O@PZYR)-
]),\X15T1T<#:>JHCVA.579=#QMO7V3X5ULVD?]_?+G=]_9 MGWYBG[A^9'#_B0==%,/B+ Q':N$=:YV/&H4\XF'5@GI"+,["
<*1:WN'6^>#3 MK7,FR!@E(CD5?:B*T]0J.MPZ22(7ZIUMG3^2B3RVB-3YUFE&_[F'/>$:BK,P
M'"F)=\AU/NXIUSGVF&LHSF!Q%H8CU?*.NLX'GW6=,QE(IE/$JKA3Q!JN4Z1(MX84*SV2)1W*27J?
H^1.C)B:/>%BUL/80BK,P'*F69P_%T-SDD1 N7M 5#DXE9=PA8E5- M#\NVG*J4G5W"(L#$>JY9E$.31C>20$.:G(M=S
B>DZFX42RCJP'I\H[GNX6TG-8,NVP?FBO-K/WL]_XB\0NLT%Q!HNS,!PI MA><#Y:A)RR,>5BVL583B+ Q'JN5913DT;WDDA+_9T:
(HIRIH$IM3573_*^2DC/:"576&K:3GM&3::7G-HLM\I G] M9Q]VN0V^LS <*8CG!N6HH591#0YF*B9R643N@U.I
MJ%9J;!F$8HS6)R%X4BU/+.H M!BC1U.7F"QCQ!8].:\"*UY['T M8V=SWVYGWOUJ>?WQ:L-?9)K0>]9!<0:+LS <*8CG_6XL4R-
M8I0G,'B+_Q' MJN5913TXEJF9 [15J6B;X&0Y/:/3<#*=T_-[+2=3JC-\I3VW1\[M]OO%RD;
MD@;UGXC813@HSL)PI"Z>,=3CYC4UUC1"<0:+LS_"*7?!VC<:L*KHG<8C$KD,G]'P<@:0;?"_U_?MNW&3#?3BQ?;F773
M3MKY?)U=+3\N-KOIZ7UV>X$?=B_&\U?R[#SZ_&OQ?"*8SQOQW.X_?^[P%R_N MIS?
MU]/5S6RQSN;MA^VWRI_M#E9:S6YN3Q]LEO?;.IQE[Y>;[;3?__.VG5ZW MJYU@^_4/R^7F^,'N&WQ>KG[=7\[%_P!02P,$% @
9Y5>66";%!N7!0 M:"T !D !X;"]W;W)K&ULM9IM;^HV%,>_BL6N MIGNEC<3AH= !4FF>*JU3U>YNFJ:]
<(F!J$F<:YO23OOPLY,T$!I\R[VG?0$X M\?D=N_['/O'Q9,OX@UA3*M%3FF1BVEE+F9];EEBL:4I$E^4T4W>6C*=$JB)?
M62+GE$2%49I8CFT/K93$663J;JSLY.PJ6["4(DF>]$?72I)G(A/Z .*,W0=)XG2EYA84GG2]:U% M19V75.<(M8>N62;7
GE91*,6>]=L/S;86ZJ'=3>=EV[.'2/PCN9=L-_0H[M M]-'G.Q=]_/"II5V7;\?TVKH%TPKO^UKAF\U=NN@B/"[,';10#WX+(S_S+G+>
M1_5VNX5])Y9V[^3)^0]$??PD&*Z M_/M750]=29J*?]JD74+[[5"]EIR+G"SHM*,6"T'Y(^W,?OP!#^U?VO0$"7,A M81XDS(>$!9"P$
C6$&"_%F#?1)}JYRR4MUF8UF[Y,LX@3V?; S4L4+B=J'7(\ MSNRN/1J.&W\3ZW%?7JU&&.-F-;>=/1XTJWE5-
:=).ZCE&_M\ZEA#PD(@6&.L M!_58#XQCK28;%3L*/=1HDW&Z8*LL_I=&Q9C?TXPN8RE4M"=44!5G*[3D+"WN MY4S$>EX2JO1
,Q1MN+XOUU2M_YS33**<\IBU+:/SLDW#O0'KVP<2,3;[U!GH MM3_L'#CT(!WZD+
$A8"P1IB&]9B&QK%YJK)1*A5LEC;+C9RS7@LG]L$8N2< MNIA!PEQ(F <)\R%A 20L!((U-'=6:^[L/:*I,T@!0L)<2)@'"?,A80$D+ 2"
M-00XJ@4X,DYZOVW2>\H16U9O" (1^>6),R'A 60L+"$#?9"$J<.2!HZ&]$;4I1NOP7)5P@ MQ\;VS^K#:=UT,^)/51@HS06E>:
T'Y06@-)'"*%I3DGO;O_@]HK]*"J5$2)H+ M2O-.:3XH+0"EA5"TIA*=G1(=X^1XTQ+)[;-6D5H!)XL0DB:"TKS0&D^*"T
MI845;7^J3>T[?:(#N\R =BXSSN[I3F1/"XG-_U^'U=(0W:!4:Y'[X)2C-!:5YH#0? ME!:_TD(H6E.1N[P$'KQ+A >Y67X)2G-
!:1XHS0>E!:"T$(K65.(N:8'-68MO MB/! TQ>@-!>4YH'2?%!:4-'V5\H!M@_2?B&4SZ:X=MD);-Q[_NX(#S1/ 4IS
M06D>*,T'I045K;$=Z+Q6VGMD(? N#8'->8@;JG0DX^/YAZ_,::#I!U":"TKS
M0&D^*"VH:/MSFA+:*Z4!^2R59NT=TTPI7Q5'=G5V89/)\E1;?;4^%GQ1'(8] MN#['YY>XY;J+S[WRT.\.7YY!OB9\%6<")72I7-
G=,_6(\?)8;UF0+"\.B=XS M*5E:_%Q3$E&N*ZC[2\;D2T$[J]7S_X'4$L#!!0 (&>57EE'^I>S@P0 M % 9 9 >&PO=V]R:W-
H965T0AA((*W54#>K.9Y<8L":)6=LIL_]^G4<#25POG?47B)U[SCUV M3JX39W(B] <[(,3!SS3)V-0X<'Z\-TVV/:

4L@$YHDR*&!YFD+ZSQPEY#0U;..MXQO>'WC1 M81P-J'D!&@1+=B*@]).!)5I<.S M$-(,9WL&CDC< @=
($;@##R0]YAR6;A3W$YA#AK< 9C%8X"3G* ;ATP9\6B . M<<)N!>)YLP"?;F[!#3 K%@9P!IXSS-*
GGBXY'G"2"5/3=7#8G)A=#*029VUKV MO)+MO"/;!8\DXP<&PBQ&L00?J?%C!=X44JC,H_,VCW-'2;A!QP%PK<_L1Q/ MHN=!#?*
\SSY3PA1K^"*F V^_"P^O%NQ+X\GKQ,OCJ>O$R>/3_9G[]RV-O&<%M M;BBWY'/?X5MG6Y(B\.EKGB(*.;&W]S)[5R2>G*18X>*
[9$6[1U!!+&$/T%1FS MWW^S?>L/F;=TDBUTDH4ZR98ZR58ZR2*=9&M-9"WW>HU[/17[[*MXO,*5@XO" M_]*
(4_OA<^&5VKEC]DK5XOGJ=.2/7FIBOES;M!P6>WXY9]&/N;-MM!X7](#OH M9EM*@MQ@W*
Y:R71[=CLHZ@>YGM_1M.X'#4&GLX136ZED]&C4]&OUQ?XLLW5;5C1GW'*
M>$[',THA'_6,3K)0HMX==5RC,^%*)UDDF_O.\]=:/<*6<\:-<\9*Y\Q;JT_.*
MXO/^A]0B%5MP*6'@=%D0G6=B7[PZ<;FG1F7&EDRSJR_<'7J>JK_M! MMCVP';E/;.N\/V8IG;+HU)'_]DI-*
V#%+MZ"HTW[4+5K90LD(W-X(EEISKK2R M19(1",MT"",)$I:Q_(YES(O=U131?;DUS\"6Y!FO]H6:WF;[_TNYZ=WIG]OW*
M*UO2'Q6?"\K=W#-]]:WA$=(]SAA(T$ZDL@:!*(*TVKZO&IPGSL? M]S S.0CYI+8*
FGR/>*RFUE;KW95MJ^46(J;Z8@*;:6#U_H7]2Y8\)K-@"FX$_S-< MZ>W4&EED!6N6C@BB,CU?V/>^(M2@#U3P2X>8#[U@*
O#_"R1(_*LK1NF6:SB10'(E,TL]4W6=]DT9A-&*?#.-<2 MWX88IV=W\1Z4QG'1BO3('&?)*N% Q)I<[UG(V8)##_NK-V?XM K^> L:*
>H3 MACW.;\G'#Y_(!Q+&Y#[D' =(36R-^M*OV,MC%O>$ECGL^L1S?B*NX_HM MX3?F\%M88CC-PKUZN(V]4G2-6W2-*
F_%Y)_CNF7S"'+$'R!R6B0QU"(K\]2O" MR)V&2/W=EN*1TV_G3!?EE=JQ)4PM7'4*Y!ZLV8_T,#YN2WACLAJZ7M%^IZ) M?*
78=";G#?V%%ED+IME2/\4$6GY:+_6PT& 83>U]-H0FBCN_X!;JFS2^T^49M M7Z50BB0Q%BZ>2=Q@P6J=<4>>0>7SSBN!)D1-*
W* 0-[A,',M"L*&M]K&=,FR#"FPT+8T"CLL3_OD]^QTU0BG\D"JTBK M0"/)I>NK(]):OJ,BW]$[E)=1E^EW1%9+?URD/_Z?*
Y67N9V,2<6![4 M*0W1Z:BVY$2FY6N$U 56')MV55]R)J-"$Z2NL#1.:C2F"1*=,(X62?QJEVED>O2I=856SWSTB^I_P[%AAI=^.(N*
MZ(BMW@6E*U.S+9\O.+1IMD/?&[Z>F$T4==P@.#$Y2U^F9F.^H.XT_;>QJDV0*
MNL#2GZG9H"^I.\/S"DV0NL+24:G1L<[6G=&;QK>),HUOZ7?4;'B_Z2W@_GF+ ML["G04:X5\(+[J=Z"V*
RC#=$%2NS5;V1_N+%V!%;?6=5FJSKO,?>RNC<%V^N M.F*K=T%IXZ[9QL_7([=IS=3W7DW7-I W:I^L;F7K:W;PMQH9XI1'AV8!*
[<%U!A3[..#2UVV8'00F@MHNQV"VP%,@7@^[40^J61GC$59XJS_P!0 M2P,$% @ 9Y5>64R"5?NT @ A @ !D*
!X;"]W;W)K&ULM59A;YLP$/TK%JNF5EH*(22I.H+4)JH6:96]9NT^3/O@D"_8 M-9C:)FG__X_W[LZ8<"ODDTH!-*
'G)>*XF3JIU<>FZ*DXA MH^I<%)#CDT3(C&]#*7LFVCO4<$I=* MBZP&HX*,Y=6=OM1YV 'T@P, OP;X'P4,:L#*
&JV465LSJFD42K$ETD0CFQG8 MW%@TNF&YJ>)"2WS*$*>C>;X!I;$L6I$>66"3K$H.1"3DAC))'BDO09'E*YER*
MJA1+6$QM^D]GH"GCZ@Q1#XL9.3TY(R>$Y>26<8X!*G0URC,O<>-:RG4EQ3\@ M90'%.1EX7XCO^4$+?-H-*
GT&,\+Z%#_;A+B:ER8S?9,:W?(,#?+=4/J")69C M 7$IF6:8B5_?,8S,-63J=YO%BC-HYS1;\E(5-(:)@WM.@=R $WW^U!]Y7]L,*
M'XELS_Z@L3_H8H]^"$TY%E0#$JAD^9JH)A5M[BO*D:4TWX]-=#$HIBU=C?UF[3VLGWKY4Z$MF> M]6%C??@?*
&G5X3/M'(MNS/VKLCSHK/Z4J)31?D=@,X+ED&ZS^@:)75,/N!GT? MU-&@XT;F^/C[.?R1_?0^]$VNNW-&F/,9NV;-6:.?=7LV M @*
#04 !D !X;"]W;W)K&ULK53!;MLP#/T5 M02N&%F@CQT[2(7,,M,F&]5 @:-#M,.R@.$PL5+9-.[4IT&^(+*WE M!A:]_7L*O^N-*
IXOV#PW<%>W>P9KZ2I3$/WKA937CD M$P(-.7H&2;\=3$%K3T1I/+:_N -0-P"*
MXG\%)"T@*">:S$)9,XDR2ZW9,^N]B+&3L].6,G3%7L5FE-%^%2@92' M9Q-Y&_.ZB1F_$7,!=8\ET3F+HWAP!#Y]'SZ#G.#]*
$]>PP55WTD0=Q+$@2_Y MNP3G; 9+9+):L2^/6X7/; 'YUBI4X-C/JZ5#2^_NU[&2FQB#XS%\+XY=+7.8*
M<&HV!W8'//OXH3^*/A\3X#^1O9(CZ>1(WF//IM(5QPIL4*. \K-AEPV282IV MAWG_Z3,<1)U/DXXX>*Q^4-*
Q*NU&58QK6A(IZET/,;--\C8&F#N]W:9"Z(2P+ MFE=@O0.=KXW!%\.W1#6>JAJTC.! ^R, !D M*
!X;"]W;W)K&ULM9I9;]LX$,>_"J$M%BV01*(. MQ\G:!I)(V@W0M$&#[CXL]D&Q)[90'2Y)V^EB/_Q21W198>1F\I+HX/S^Y PU MHL:*
<[%+VC:\ !'F,HX1/M940ZW-=Y_,5Q $_2=>0R#L/*8L#(4_94N=K!L$B M-XHCW32,D1X'8:+-*
)OFU6S:,I!L1A0G<,L(W<1RP'Y<0I;NI1K6G"U_"Y4ID*
M%_399!TLX0[$U_4MDV=Z15F$,20\3!/"X&&J7=!SWS0R@[S%GR'L>..89$.Y M3]-OV9IQ/._9%>T'9D:F6^X2./26/8@ M#I/B?*
_!8.J)A(#G]!F9I8'8-[&<,K-+ &JI@EP;V4 6G-'"&&HQ*@U'N^\)9 MN:?=0*
2S"4MWA&6M)2T[R,.56TL'ATDVL^X$DW=#:2=FU\D6N)!317!R3"XA M_!T2."(?Q>*$O'=!!&'$/\@[7^]<\O[=!_*.A FY":-*
(3@L^T87L0@;2YZ7< M92%G/B-GD9LT$2M.O&0!BQY[5VU_IK#7Y="K\9M/X[\TE< [6)\0RS@BIF': M/?*
VY&FYN]0WG=>K>Z]1]M;D+I)O,H:![8% M;?;K+W1D_.87.TR8BPGS,&$^$JP5<[N*N:VBS[SOFU#\(+R*>E]0"\0H1V2O*
MNNW,,9S3B;YM!DNI[SHMW!<9WHL,7SF:GYR(H\I7(Z6O/HL5,/(I M3>1$9/)U1BXX!]'K+B7HT!R#"7,Q81XFS$>"M4)[6H7V],W?*
Z>8,<>$N9@P M#Q/F(\%:,1]7,1^__KTRWLM9EC7J9#ZES&Q&B#H80KZ^X+VV3,OE;/*LV=* MSY9K_#Y_*@T/?*
4@P82XFS,.$^4BP5BBI47^]&6^>&DL)I+"CTEQ4FH=*\[%H M[= W/MPIRN*PQ#1SB.Q#=X%8MFJN[JSN$K&'--Y+?*
ST@:G;E?/78?M9W9NT[M:@T'XO6CG5=E*!O7Y6@J&4)5)]+2O-0:3X6 MK1WZNC9!$8H3M.?+W=K/CZCEB4&:'JJFWZ-IV0W-*
MH_K$@55UR@4RTFUY<%/ M#2;-1:5YJ#0?B}:.:%U(H:.W3YBH-194FHM*\U!I/A:M'?JZT$*5W_2SS[L$ M&%^%:[(&-I?*
+H6#9_V07&&HVBX$G=-Q-FJB%DF&B'JJH_Z)HV]-U>8.JZQOU M"O0F> SC3=SK9LQ:PA4JS46E>:@T'XO6CFU=8*%G;Y]*
46LQJ#07E>:ATGPL M6OO'Y+H>8RH_^@ZD*]L3^,N$^%2./\< 7! EC60-Y_2%/Q=)(5/M]9O\#4$1# M!!0 (&>57EGOJ=CV&P0*
(P5 9 >&PO=V]R:W-H965T8A%>N8<\LQX..)X1]D7O@$0Z%L<)7RB;81(1[K. MPPW$F%_3%!+YS8JR& LY9&N=IPSP,G>*
(]TRC)X>8Y)HTW$^=\>F8YJ)B"1P MQQ#/XABSQQE$=#?13.UIXB-9;X2:T*?C%*]A >(^O6-RI%;F9!\QA3J/_R%)L)MI*
0TM8X2P2'^GN'R@WY"J\D$8\ M_X]VI:VAH3#C@L:ELUQ!3)+B$W\KA=ASD#CU#E;I8!T[."\XV*6#?2J#4SHX MIS*XI8-*
[*D.O=.CEVA=BY4I[6.#IF-$=8LI:HJF'/%RYMQ28)"JS%H+);XGT M$]/;9 MHULXPI9AN74K&=^NKM=MYW+V/W+V(-*
F=P]"Z6[6N1]H:5=Y9.=X]@MX 28, M?<)1!E=HAB.6G\F]$L)]:=7]7?$4QS"1),%E@/;@C;]XS>S9_Q5%]@NP;PNP?PNP8*. MP*
X2PJD2PFE"GY9%A%=%I"ZH!40OAU!GX';J&F[?R/_&^G8_9(ULYX;L=%Z_ M2]*
[@9U['-9TCW@.YW4INMU'N^T3V%1'Y#DNTEOV$+-D1Y1QDQ9;'-YP2BP+? MW5O;<0C:81(_26@"3 M[0Y^D %9J;-*
E6YPM.*99(NH4[[!HJ@NH"=_@!02P,$% @ 9Y5>63Z158IJ! M/QT !D !X;"]W;W)K&ULO5E=P01!"*G\.7/!BXABG(FV8]O%:E6:^;*
_>M'=J\8O!S, MO<_ADD9_D5"LY]J9AD)8^EDDOM#MKU -R,[Y AKQXB_:EFTGMH:"C L:5V#9 M@Y@DY:__4 5B#X /*
(Y:TE6WY1V%6@98!)DL^L6\'D6R)Q8G&5;(+.54$1Q_19\AB MRGSTQQJ8GT(F2,_H*LD.$4G#@B?*
1/R];'9WZZ"3=^_1.T02=$VB2,X1/M.% M[$_.J@>5]D6I;1[0MM U3<2:(S<)(>S ._WX:0]>EW&H@V$^!N/"["6\A?04*
M6<8'9!KFJ*,_E\/A5M=P7J?NOD[=ZX<[($VV\$4NKGEA6P6<=ZH[,@6$6 M :)+Y'[+B/B.KD&L:8CVI]S?*
OTD8NA(0\W^Z)E"I,>K6R+/N.4_] .::3*L< MV :TQ<_X;'Q2Y=[*LD?M)KXQ6V)]MX3S;PGVVA=<[SA=.T7$=Q7%O M%*
_7N*Z(]7(=FX!4DCDJR5R59)XBLH:[D]K=R1N4G8E*UU62.2K)7)5DGB*R MANMGM>MGO?_3OV\38'Q-*
4I0""Z3%EU:UIF=_V9UE&>OKZX3Y\6OG&[MO?*'!O? 8*N2D'OJ>#8L+HCBXW=,LSX MGVM[);#?+XRGK/^H59 >\M;O$+:SWZ*
M#UW[#R3.XLY8]M(>6P"4LCE*V5RE;)XJMJ;=YLYN\PV*?R6BRGR5;(Y2-E*K6G^;K\!]RYL!W\#]-,<;6_)ALU&J37L=DI5NETP3-*
13)=HT9+<5@/OW M OJ3+TD.)E^5"_%+I6R.4C97*9NGBJUI]VYS MMOD7P5;0U4YJMDRJX?U-E6.?/VT/NW[5)QQM9Y?X/-+W/'*

=N>9:WHR^/%J]]MLJ7(Q$LI91Q MFI_%L2*TKKP1-"U.E^ZI$#0N+M?@A\#R!O+]DE+Q>),+U&>FBQ]02P,$% M @ 9Y5>6;*
[">0RX P KQ$!D !X;"]W;W)K&ULM5A=C]HX%/TK5K;JIE)W0A+(#!209DBBCE16J.QT'ZH^&'*!J$Z)YD49D,&5/<%XH]S[O4]_KH>*
[KGX+C< BCRE+),C:Z-4/K!MN=Q 2N4U MSR'#EA47*558%&M;Y@)H7(!29KN=CF^G-,FL\;"HFXGQD&\52S*8"2*W:4K%*
MCWM@?#^R'.NYXG.RWBA=88^'.5W#'-1C/A-8LFN6.$DADPG/B(#5R+IS!E%? M]R\Z?$E@+P^^B1[)@O/ONO*
0CZR.=@@8+)5FH/BW@PDPIHG0C7\K3JLVJ8&'MW_L43%V',N"2IAP]D\2]\W(NK5(#"NZ9>HSWW^$:CP]S;?D3!:_9%_V];'S MI*
F6?E/GZHX' "\S@F 6P'<%P"G>P+@50#O7 O="M]UT*O O3. MM>!7 +^(?1FL(M(!570\%'Q/A.Z-;/JCD*M*
8X"33$^LN1+8FB!.C1^R'4B% M,T5)\B?YE*2)@IC,J% 9"+E)D*LW[\@;DF1DFC"&DT,. M;86.:#I[61F]+XVZ)XQZ9,HSM9$DS&*
(&_!!.[[?@K"4_45[!YYW@^PMW MPY^S"C^7/ 7R]1-V(P*4OFM:<*4G-UF3KV[#F1.ES"RK^3$G_+MAD(,M]0 4W*MUJX=)F;)*
M,DH4FR2)# M9$>:^[7F_F_8S'V3*ILD"TR2A2;)(D-D1RK?U"K?M*[L.X;[14;U'1\O=O6% ML$G:DL@OB'32LAN[-*
^[0WAT]UFKL4L7.,!B:-!@U&.PYM<&C^-[6\;UMC>]C MMMKJFRJA<9SH4Y$R@@L)[]HGXUP2]@Z*
<+S^BSBW&KTTSF<8#$T:C R1'0G2 MKP7IMPJBM[4U9MV27#&.9Q)-;%ZF_Q#F[S529"=2U]>O"79%4OZB_=P83IZ$^< 9A*
M^7CPD[Y\RIA2L=;",%BAJ<[U#4Y)43X/E 7%\R*=77"%R7'QN0$:@] =L'W% MN7HN: /U&\WX/U!+ P04 " !GE5Y9^%&&/(0" ##!@*
&0 'AL+W=O M!?[]K)T2E#=T>]I+XXY[C[!66EDR9V[%ZF MB=AHSDJXET1MBH+*URO@HIXX*
^=MX(&MUMH,N&E2T17,03J6]Q)[,L>2LP)* MQ41))"PGSN7@8AJ;>!OP@T&M=MK$.%D(\6PZM_G$\8P@X)!IPT#QMX4I<&Z(*
M4,;OEM/IEC3 W?8;^[7UCEX65,%4\">6Z_7$&3DDAR7=9S/ MR.G)&3DAK"1WC'/<O\#^CE4YR3POA#?\|,>^/0X? 89*
MP@<6'KR'NVBT<^MW;GW+%_S%[2N9,95QH382R,_+A=(2[].O/G\-8=A/:'+L M0E4T@XF#2:1 ;L%)/W\:Q-ZW/K?*

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{ :B:-8&V+>(;NHXG^ MHAGUPTPZF,G_GA/=6(O%BLIO=VW["'"9]1S4^^X/"WVL'!>JL:7H&$E5)VW:& MSMKUUMTVNG9B5=DTEY6RU*J:84[_!M1N M 7U?*V5W$[=!]{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

(787XW&^W/(XR)UTQQ/YEW6:Q8&0I]EF MG.\R'JQTIS@:$]?UQW$0)J/Y3+?=9?-9NA=1F/"[#.7[. ZR[U<|2A|O1WCT MU/
*IW&R%:AC/9[M@P^^Y^+R[R^39N%)9A3%/\C!-4,;7EZ.W^.+:(I&C MG]%'=:ZF&)W=B],,:+,NI5 M$94\$_4;%P1J^*
*]WSF(NF\0<0GK&,_U|=VI M93BTFE6]J>@S>C=\(=!MDHMLK^83_?.[O #=*A[G_W;-5J'&NM54)5_DNV#) M+T>R5',>/?#1_* ?1*
*M?>^\,4)KK)X3[5=.?*N37^43&LG'(#_;D=^:3X*]AB-KS)Z.)I6CB=71QU3P MSD>)M=NIQ0$D5G,XK1Q.09*4TCC0&*
(UX^>5\7/KK;T\C!'!6>HI'T(LC!8 M1!S);QC>Y;R0P_0@65W'Q80T$]8:MZ*'%;>=-(T8H_4U\D!*
M!6"K$^9X/OT1):H&T6K/Y14=^LUUS\>),,>V.ST5"AA7/?4=F2-V->1H1ILQQKF^,WJ M];"J7K^H7GER1/4"X4PY(T/
$39TA'W8Z@4BG]+\$!R%#4AA.TGUJMY)=_7Z M[5P? J&P82AL)963JG?:6;V>WW0T!!MA T?83D?$F4P:Q4O16=&JCX^H72 .
*M*N=C'"HBAJJ("UJ[! B=RH6"(4",&! C=A#K4[NE9#//R6322'1[[++[>#%(1 M*[6<4KJE4]MT2=/1$)Q$#"'<1.R=1!WL-*
:G;16=&JCU\N77N$D[-W"+0B!JT(M@RU=(&XJS0]!8<10&+%36*_2]3KSG+969NRQ^WHS/$7LRTW$F;J-1,?J.TJU
*MZN,C$AT4L:#4ZO-A$(M,8!,==!$+2]UNWB 8L2-8KT3O9C$R,>;Y$"Q&#(L1 M.XM1ATX:3W1//]%ULSXY(M-!:0Q*K?XBP]*
8A:4Q"DIC4&IU\X;&#R-E9+- M7U*4MM;|*
],'[FC,X1NTX1AVW\4SWB$IU5S_3Y?'+F6Z/KDZ1AJ9WDSS(;",&BRC+RV.D8XT+UJ/37/0I3$H MM?I\&)2CL$MC%)3;H-3JY@VW4?
*BEL5*RB2ZL^5O4'KJO-4-EU$YES&&-//=U MGC.=Y_Y1>0[ZQA%*K3X?!N7H.6R>@U(;E%I]%X:A-F9_,]DGSTO)5IZSYL:,*
M(9B,&29C=B:CCD\;B$Z8XA;=K$]>SG1[C%-O-I1:?48,R#'85Y4,E-J@U.KF M#;4Q^%>5K/M5)?5;^POLP?N:.]A-!;=JFNK5'L_U1*
*8Q@R&,3N&_M4E#N@E*K3X#A+@;+70R4NZ#4ZN8-=S$[=QV9R)/6KCOB MMA-Y",YBAK.8G;/JB?S'4J0+GJE4]]VI#*
*(I64&KU*3!HQ6#1BH&B%91:?0>I M02L/8M.7U]!T15J9;(TJI/QP2[PF&<;O3D^1\MTGXAB)W756FW ?ZN'WG3?: MK_#%=;&-*
WL@4N_H_!-DF3'(4\;64=)V)+-6LV"A?G(ATI_>:+U(ATE@?;GFP
MXIFZ0/Y]G982HX'N:9'+N1$KEMZXK@PA3)F]XCAD]V7&1,D5%L7=E+I'"%1I0F MKM?KC=V4Q9FSF)FZ1[&8\4(E<8:/
*F21IDR|W&/"CW.G[[Q6?(WWD=(5[F*6 MLSUN4#WECX)*;DT)XQ0S&?,,,!.[FSEW_=CW5\2;@CQB/\N0>=$NVG#_KPN=P*
*M[O1T0IA@H#2!T>6 #Y@D&D1I?*N83OU*+3R]?Z6O3-NI+5LF\8$G?\;ABN;.*
*MU($0=ZQ(U%=^_(15>T::%_!$FE\X5K$]!X)"*IY68LH@C;/RRKY7_7 B($ZS MP*L$WEO!\()@4*
*D&707#2C#L*AA5@E%7P;@2C+L*)I5@8@:K[%TS-#Y3;#$3 M_ A"1Q--WYCQ-6H:D3C33MPH04]CTJG%1O'@.>))B$+^!/BMB-4+_*
R_,2&8 M-@E<^:A8G,AKJGW:^'#UX1H^@ LR8@(EQ!D\9;&2'ZF2[N_C)"&'R9FK#G] M"C>HKDO_$N)#**
*+SQ3D81E%F)XKG>I477+O->6W7NMP WF-S#H?02OYPT; M\GEHEW]A@N3]BW*_7>YC4,L'#?)E]^2;Y*ONR3?)U^WRWP-*
U]>UG0S&H338P MO,$%WD/"I 2^ ^,V^.M7>@Z?%:;R[R:CE+!A,TQ/S;[\TC;)-F&\3MK0)6]F$K2W!SKPRK+TR;,O[E)>9*
K8@28=MDT0:+4% M:7PC,"]$$-'"(Z&@64(@RUG(@26YX(?,/Q/(.0)RYH\5B8Q-DGHU?JPF,S< MPZEQ6M-
\KW%LPI8V82N;L+4EV)EQ1K5Q1JW&\>-#'&(62OH2"1):G$+(R2)F MG8(K6IL*>5)SW62*\@63$U-X-]HC2^Z!/E=@I9-0?
W!>="J2]"ZM6?^9[^/ MZWX?M_:[IMA^FY ^M,N#_3;U+&MA/?.Z#9AODW8TB9L91.VM@0[,\BD-LC$*
MYNH_L>D5FS#?)FQI$[:R"5M;@IUY95I[9=IQ$L_9BUG^WSN'M_+?:Q^;,-\F
M;&D3MK()6T_:E[[2%N]CC5%L3>'$1("_>U7;O'JVQ]\X\YL\]_4W_=O5^6Q MQ;^8\A'"%]D#
*[.)0X(Z0O9L)+9*B/)@H"XKG9E^\Y8IVV>8V0D:?E3J GN\X M5Z\%_8+Z=&CQ#U!+ P04 " !GE5Y9=,L'75D& "V)P &0 'AL+W=O*
ML M X(6";]&/9"E6A;JR2Z(AVW^_2C'F*:(D4EB/PFL>3_G>Y.XO%G4HL#R[_P M+:4"?$N3C%\/MD+LKD8C'FYI&O!+MJ.9_&;-*
*\C00\C#?C/@NIT%4&J7)"'G> M9)0&<398+LISG_+E@NU%$F?T4P[X/DV#_/LM3=CA>@ 'SR?NX\U6%"=&R\4N MV- '*AYWGW)Y-*
*#IZB>*49CQF&N GGT&1RF?&OA0' M'Z+K@5=$1!,:BL)%(/\]T15-DL*3C.-K[71PO&9A>/KYV?MO9?(RF<\!IRN6 M_!5'8GL]F U 1-*
*?!/A'W]/ [K1,:%_Y"EO#R+SC46F\ PCT7+*V-901IG%7_ M@V]U(4X,I! ^[:H-4-/ ;S' M0%^]8%?&_AE9:I4RCJ00 3+1Q^*
*Z&8,72'M]\7'T ?]^S) %R: MT_R)#I8__@ GWB^VNO7IC/3D3*NI?ZRI[_*^O*6;.,OB;"/[21)D(;65KG(Q M*5T4K?*
5I.9ZC\6+T=%H2B\A#2!<14S1\6(FT%,:'%,:.%.1@Z8B_LA^?7'4Z M1M-&_;(3))81*=):O%/CO%/G/'+AU;VZTSVOSRG6?*
@=B#S(N.P_Y4P1_2O; M8EKT)EMF3L^O?:C[=$9ZSMC6)F M#(\AQLV!9A,9C<(B0O.9?:#-CRG,SS;0YF8+@8V\3,D0-ON'15-
,C;:LH>@ MQG/F]9C)9SR)_Y.\LI'LR\'[A'%. ^8650#PC!*^12+>$."5Z&B=L:IU!W-,P M"3B/UW%HW!(Y? 4#-,B+)]!.5K [KTX)*
<4KTO)#'"SGS*AG2&C+]J#KE30IP2 M/60%6M#)',L:<47PC=]+C;LC[Y00IT2/7.$,=/-,-PS4#O0Q.)DTP[>HC%9& MK*HV'H*
**:*";.%8!WU:->RU_J8(MC38M]\'IY[5S5;_>2%_>]!HJJ(*3,S(M[!6L>O5&^O*F%U:Q%71BQLM H/9Q.C#@N/F+P2;R_.80,T7#UA&F8*
:Z:>8M M !--C&:7Z>$."5Z5HIOH!MP7@<"5EZ9-3,Q51 :;= BFK; &E)8@]Q8\S8> M0":A#*'1YFVJ<9-%;2+40FF2XL0":*
M&)1LT0QA<]#;1&W+!$A1#7)333<;0-(AO/FD+"(C-Y&;'"*OA?21HAODIIOV M9\9I]JKY[E=OI"]O>LT43*'Q&4$]4I8O7HC?
7G3"ZL("[G7K5X$ K6/TW%@ MK+S9-+/F>#(U&+8,)X4RRC(R;Z$ 9')T:4I)<0IT;-2,(/<;/,J"D#=,-,M*
*M(4Z)GH:"&>2&F3=._R;2&'EU2HA3HN]A**S!;JQI[>'8Q(SFY&F1#!L;8M/@ ME] 5K& WK'3-*
_+B;6;HEQ"G1(U?,@MW,TCWI8Q,VFNUG9=,T=CM1P__9,O+ MS2S%-&4-NM_MK'[WL\ZQH845)&'_G-N$O9)4K]Y(7]*
[TPBJ2PNYEJ1=-^-C< M(AN:/_VMJKG1#RPJ-)NWC"D%+OA\&V[8Y!#C)XY%8^XV1M6P%8$0UV$\VK MYGYL65HQ5P
*L*G,%P"9J6P' BF2PFV3>A@#8LH=DK@#85,8*@$W4M@* %>%@ M-^&TDX!E/:49MFWUIAFU1=-" K["%]^-+UTDX)OX80P0B\9<*
[")VM8 ? 4R MOAMDNG&@=C#1KHN;CXU-9:X"6%7SYH,S.GFA:7YIGPQC(.0[3-1O>MS/'M\ M^>RF?.6J?626'4@V*Y\;>HS*
*M$X*EY<5@R?GZ?#@LYDNVBHHWV9JEXI/: M+%]%7+S-[X;%.F?1H@I:)4-=TZSA*HK3P?2BVG:53R^R#4_BE%WEI-BL5E'^*
*M[1U+LH?+ 1U\W_QOEORK&.[M@UXY_65[EX-]Q1%O&*I46#*
*MM_0\U.TRH!KQ9\P>BKW7I)S*399]+M^$B\N!5E;$$C;G)2(2O^[9C"5)21)U M?*FA@UW.,G#_]7>Z5TU>3.8F*M@L2_Z*%WQY.;*
'9,%NHTW"/V8/ :LG-"IY M\RPIJI_DH1ZK#+"E9QNOT=?:UWQ%Z X,@#]#I [P;8!P,.L X M-L"L \QC T9UP.C8 *L.L(X-*
&-9LF"Y<4OA'W9Q/P; M.2,?V3R)BB^C>=1*D1WSQAB3<.[YX6;A_?/&R\.!I>S[\WW-O"<'8 M'4-*
&Q3,.\+H'"\E..E;^_EWP2,C9JOA'=EALDYORY.7%\+Q81W-V.1#H@N7W M;##]^2=J:;_-(F$.4B8BX1Y2)B/A 5(6*
B"M51O[E1OJNC3JSQ;;..:<%%'" MI?S;;A5A9=KKONI/=+$\7:_KT=ECE/UB(2Y_?*M2;=\#YG11*"?OFZ:1AV MN_ZP/XI.)A-S-ZJEC-*
%.&2.E,K;GNK@ZN[TF>,R=6P1H_W,MJ%UU*',6 M;(EDO!/)^+$KRWUX_3'G%': M60:X_6QTW,WF]4G4&$_:@_S^(-*
TV.VH.^ND,T^K4%/8'C28C3;[/)[M]/GG: MFD\9?NJ]"A+F(&NN8A83X2%B!A(0C6TBW5&IM+>\Y[]#H[2/A0F@.EN5";
*M!Z7Y4%H I84H6EO_>S8O?=J9NX[?OU[8=-1=1ZFSG*Q,),V5S, :F9V[&@^: MTX?2 LD,=$/<\G2N[))A=**-*
*Q_)K.]4;C>A*C3SQ'/DOF47%5":#Z4%4%J(HK4/A<;1I\]JZ5.HIP^E.5":"Z5Y M4)H/I0506HBBM?7?>/M4;>Z?YM/5L-*
*8%R;*Z2P>HU0^EN9()G(VZ7C\TI0^E M!9()Z#VS7S+(.F#UT\;KIVJS_S2SCO9-Y3.CIQ2H[0^EN9()4-H5"M3XA](" MV1?*
07>6'LD'TD%(;ZY^JO7^U84)HV"+6?]59%V84Y6?](MF@.EN5":!Z7Y4%H I84H6EO_34N/K$G5TU06FNI'ZC=V\"*
M;2)!:8&D_IZQ',H&Z0?^V$1ONCZZTE4'.)IY5A1GNV5%\1"MNVN+EXD8PHI7 MI_B?ZK)//:E":0Z4YD)I'I3F0VD!E!:B:.T#IVD7Z?
0Y%Q4ZLFTR@\(<,V% MTCPHS8?2 B@M1-':^F]:8;JZ%7;4G[#6C$/7K%JTRLE;2_B![H8ZMF?=<&:[+:,H#0'2G.A_]*\Z&T*
*$H+4;2V_ILVFOYH M&^V1,WB_)]-S,=0Y3M8EM'$FJ;_G8D S^E!:(*F_[V+(!AUT,9K&F;YNG/V(MM<:/,C:0':D9E.9*
*,2Z4YD%I/I060&DABM8^EII6HSY^UG4&M%L(I3E0F@NE M>5":#Z4%4%J(HK7UWW0+=?5_31UG;$C^5:EO;$!;>5":*YF Q-B*
=NB@M$ R M@;ZQ(9EDS]@8[CT:9L7RN^]Y0H6XU&]2OGW"Q6[K[ME%;ZLG]G2VOZ/G/I5L M#^AYN'TR48/?/BCI?93?E>N(A-
*V*5-J;L5@6Y=MG#VW?\&Q=/9CF)N,\6U4O MERQ:L+P<(#Z_S3+^_4V98/<$J.E_4$L#!!0 (&>57EGQ-Z(D^1$!(/ M 0 9*
>&PO=V]R:W-H965THKVVT@,:MJ9Y!@,NG)[#/;IFTBLN0A:7L:F!_E"R[6"3[DB6=R4MB MMU7GTKZ75:6C2_+#|
[;XO;S+LBKXY_UZ4WX\NZNJA^_/S\NKN^P^+=]O'[)- M_9.;;7&?5O6WQ>UY^5!DZ?5^T/WZ/)LYN?W:;XYN_BP_[=?
BHL/V\=JG6^R M7XJ@?+R_3XLO/V:K[?/'L_#L]1]^S6_OJMT_G%]\>$AOLT]9]=O#+T7]W?D;
MY3J_SS9EOMT$17;S\>R'\'L31JO=B/U+_IYGSV7CZV#WNWS>;G_???.GZX]G MD]TA9>OLJMHQTOI_3]EEME[O4/6!_.-
/7L+NAO8_/J5KO>_??W;?$[+['[M_O_\NKK[>+8\"ZZSF_1Q7?VZ??Z_[/ ;S7:\]^VZW/\W>#Z\=G(67#V6U?;^*
M,+@^@OM_+_])^'OT1C0!A_94!T&!"-'3]#)B.'1 ?!L1C!\P. V9C!\P/ M ^9C!RP. Q;[9+W\=?>I2=(JO?A0;) ^+#8O?]FK;[8I_?
_>@Z(_EF5XN?]J+^ M:5Z/JRYTFA?!4[I^S(+[+"T?BZPNM"IX%^Q_\/?]#[8W@8J3]?!#V69 M5660;JZ#G_+T<[I.JSPK@[JJ?
LVN'HLBW]P&/Z9E7@;?)EF5YNORNYKVVZBN<:,^;?H7W4@??]^7P96#S>O8LL^(1.[OX[_ MYY/_[*'I_J<3S^OLW?U0OFN3-*
=94.XF MAOTTT5LN+[SYGK=;.I\NEK/%_/Y4[,,Q"^9="-&$[B2>R&5&1(3<(,!'/R M&[_E-Q;S]_[QF%=?&CGM2^D+8M;X*
\\FLT4KI6(>>\"Z>+>-8ZU<48OEGO"3F;S>MW^R]XY8-D](<.H-0,L>[9EY*
MS6+R]AKGC[=Z^^.M1DR4;_N6N.\OM>K^ANWCOQ3#^)XUW8!AN&Q%5&1$3<(,M!',2&DZL&IF(=7;(LMO-*
\%.:V2;JR]!_8[F.2VN=V='5:17_2NB#/6=0U%: M@M(42M,HS5 TMW0:5BT\:9T]#>*A*0E*$VA-(W2#$5SB\0:M% 4,8TB$3;8 M!X:*
*[9K26##F.=_Z[$H M=N*+VL[[Q"=I"4I3*$VC-$/1W"*Q>C&4_:+'AK$K_:;SSH81U8P](>-)YRTC MZAE1F]%H;BN-*
*-8V1;!K_M*FRFEL%15IE(_:+,LZ[Q09UC"A-H32-T@Q%VE@XYHGL*E^^V7V2'>37V:;*K][:NX)O?\]>LG40?M=;%*BB1&D)2E,H3:,TM0]'<,K.*,I(5I=3TC]I)E):@-(72-$HS%,VM#VLG(]E.CFH.C[JRL*<[7(ID M70$]1K3;'X[&U"C-4#0WL]911JB"_*
M_KE$U-..&,6KSM82=9-]0>/%LO,F$[63,U0-/>"+FLGIY.3SOTI:B-16H+2 M%$K3*,U0-+=(K(V11S&.Z?#$A$-*

J%&:H6AN3AM7[,J7[++R(/A7<%SCO'R4WLL(>|4P MZBI1FD9IAJ*YM6A=Y30^;:]!6KM+E):@-(72-$HS%,TM$FL[I[+M'-4$=6"(
MBQ!J(8<#*C2@1FF&HKDYM6IQ>EKWXQ3UBR@M06D*I6F49BB:6R36+TY'=S\. M;4$',Q(OY5C>-3#< HD&U"C-
4#0WL58O3N5+C_$MJ'<+OGR WO,+*C!1FD)I M&J49BN:6H168T]5IBQ"I]2Y16H+2%$K3*,U0-/?^1U:'QC*SYJC=YX$AK3]R M&-
_T#P=4:$"-T@Q%=?'S>TPNJ/E&:0FD:I1F* MYE9AX\:*IZG/&%6?*"U!:0JE:91F*)L;)%9]QK+Z])Y9ABVH'-&[$H8M*!I0
MHS1#T=ST6@L:GV9!8]2"HK0$I2F4IE&:H6AND5@+&LL6U'L.&':A:H?OW9L,J4P_BF?SB@0@-
JE&8HFIM3JS)GIZG,&:HR45]"TA1* MTRC-4#2W2*S*G(UIX_SZQQ>SGGM 1K/V343D(-[)[\:,ENW;NJ,A-4HS%,W-
MJ;68L].N!9^ADA&E)2A-H32-T@Q%.;M,_8,5-_&H4AP,J-*!& M:8:BN6EN/-)%UH2CVO1G756W7+8?O"0'\LYJ-V0X647MQ++/8F$?
QO*?$(0S M*PAG\O-8_.7 T?WX\I%XKQ>H:T1I"J5IE&8HFEMOUC7.3GM@S Q]8@Q*2U":
M0FD:I1F*YA:)-98SV5B.ZHB:]3S>I7UK*3F.=_Y[']DS3N9$]&E*C-$/1W+1: M>S@[K1MRABI$E):@-(72-$HS%,U]/)Q5B//1W9
#V\UY5^MU;V0O1_.M@KZ0 MG1O9HR$U2C,4S4VN=8ES^:+NHW:;WJWW\D'XSB,H+4%I"J5IE&8HFEMJUDC.
MY>=)#RTV<_2ITB@M06D*I6F49BB:6R16<<[E1LU1&\T#0[K[O1S&._W=@&U5 MA0;4*,U0-#>GUDC.3VM[G*-
MCR@M06D*I6F49BB:6R369\Y'7_$]M,OL&L;N MW>_E:-Y5T W9O?L]&E*C-$/1W.0V'C']'W":ODUP\C%X3R/L$ZU1FXG2-$HS
M%,VM-&LSYZ?9S#EJ,U%:@M(42M,HS5 TMTBLS9S+-M-[9ND1F^WU!O6:/0$[M^TW4:J(T0]'<]%JK.3_-
:LY1JXG2$I2F4)I&:8:B.46RL%9SP3Z09]$5C=U; MYLLQ?6NA)V3WEOEH2(W2#$5S4VS=YF*\VWSWMKI?9OI,$2DM0FD)I
M&J49BN96D%66"UE9"MWU"]16HK0$I2F4IE&:H6AN?5A;N9!MY:CN^L6@/+R4 MPWBG?]A6H@$U2C,4SR'QS56[_H
MZ3WLIA75@CTANVE%O2!*,Q3-3;OU@@OYX36C?<#1#?7R 7BO$ZA91&D*I6F4 M9BB:4V9+:Q:7ISU,9XD^3 >E)2A-H32-
T@Q%T,TH$9IAJ*YB;7><"DJ)Z_=I7<#O1S;>^I I2-*4RA-HS1# MT=P*L])Q.3MM?4$?
X(W2$I2F4)I&:8:BN45B5>92;K4A+M([=ZGO;K;%NS*M MWZ[:+OG^LNDJPE6[N^E2CNI=#<-6$@VH49JA:&Z*K95
M;Z&@MA.E)2A-H32-T@Q%5IBM9 MFAZQ_JR&WZR@?G,XH$(#:I1F*)J3X'!BK>7N:__UAWFVUD!LWTF$Q24L3K$X MS>
(,AFL56M@H-/EY.\):\SH4JQ-4B;(XQ>(TBS,8KE4G4:-.Y$?N^*\YKT3Y M3<] 7/^J&'Z4.!M2LSB#X5JIGC92+9O0X;7'^X83
R']IQ+4K+(XQ>(TBS,8 MKE5?<:,.^XN.7'-2_LKB$Q2D6IUF;[$OPHLZ"^\?J,5T'-X^;Z]Y/: 9@_E,$:EU9 MG&)QFL49#-
>JG$6CJDV6C3N3^T6.6DFY? MYR*>+CJK":I0^Z+6;PCF[0OAV;":Q1D,U\KWJI%OV9!^=47Y0S[$&3@Z_ZD' M5;,L3K$XS>(,AG-
+,6R8W%!N0)66J) 5L2@N87&*Q6D69S!U"/ M6*+";E=HWQ(E!_8OBV[4WB4*#:M9G,%PK7PWA&HH"U5IB8(^YY&/P'\Z84TM
MBE,L3K,X@^%:Y=:0NJ'\>'5Q&6+E+(I+6)QB<9K%&0S7JI.&G U%K7?4,A0/ M2S4;SX]+CNLR$5Q"8M3+$ZS.(/A6G72$+FAW&]
[S++3O0]H=]EAI>UP M2,6&U"S.8+A6HALF-I1-[%]V;V>"\FY;5.^JK+BOEY27ZZ[>?<[2(M_<#MQP M?H#O/VNP_A;%*1:G69S!
<*UB:FC>4'X8DKBZL X6Q24L3K$XS>(,AG/K)&HX
MV$CNICUB=8EZGKT>3]OKBQS7NRKZ@DZ7[14&#:I9G,%PK60W1&HDBU2?%>:/ M^3A(/F#OJ0C%)2Q.L3C-
X@R&:U5G0_M&1S]UZ74H5B>LKT5QBL5I%F!V*U0GK?E&<8G&:Q1D,UZJ3AON-Z)L@O!+GXALDUO,. MAU1L2,WB#(9[2?
1Y>9=E59)6Z<6'A_0V^SDM;O--&:RSFQH_>;]![5F:1W]Z] M?5-M'^JZ. L^;ZMJ>[__\BY+K[-B]X+ZYS?:,;?7ZS7G-?]X6O^]C7/P;4$L#
M!!0 (_&>57EE#K.E")P, *_* 9 >&PO=V]R:W-H965T$]N ACRL^1"#X.E,:NK,-3Y$DJJ M+_^0*!#Z92U52@UNU"/5*
2TKJ6+Y=AAF8#);=$66MDLPL7?8?&>#%AZ^3>*'S*$&>RMY0HJ%\#:0$]M<*L @, M.2=C*0P3"[O!68%*.J2^W'&V<(M-
3F;@*&,ZY<(^'0_(6?/7Y+GA ERPSBW M%H/0X"6MJS"O+S2]+A0?N5!";M#S4I.I**#PX">G\9"D33EDCB^Y C?:*WQ1&NLB7+&
MA"N#5\=KY>N=Y)S@&[VEJOCF*X;*7>IW9YODE5[1'(8!=D$-:@-!]N)9IQ>] M\67B*M]FQVTCLGI1X2W_9MN5M-Q6RN^/N
M/&X)\Y@D+5T>D[8NCTG?+ZO7R.J=E/4!YX1\2?'-TK:IVC9=-5Z?SMZ!^W;^ M#BW..VG+:')H%+?"-?7Q]+I^J?U&:O^D5.S6?
ZG0_F&%=M])/+2Y;!?H(VBF M)VDJ>>').)[<$M7"SCB:Y7 M3M=/FM!FGKMT4T3H?=:[&'<_Y!,>O:EKZ0U_- M;C=4X0NM"8=\W+?
Q9< 3@Y5>&Q.K9";ELYU<)R/'LP4!A]A8!HI_2Q@#YY8(R_A> MGJ6+Y9E-B48U3-A=G!J%3QGB3'1%F2)+R@L@&5!=*,
M,N2$W%&EJ+68 M'$[4,;U$:X^3B?D\."('! FR"WC'+="#UV#E5@^-ZZS7E99_7>R3B$_)8%W M3'S/[!;_Q[OA$X@1WBGAP2;<1?V-
"7YC@E_R!;M,>+(F'),+K<%H0D5";AB= M,3 U]"4[T\4,G]#ZU6;4GL@WC@L:X8!=[-,8F>;6ZJPZ2<*E M2$\,J
S/TLP<8YOOALB+7(ME8NE3W ;;Y4R<(RF7W]+*/0"\X&0W>Y+K@E
MJAMV@B9J0TFW4=+=J>2*O4!R@AT/1$@#K3V]D^%/MVU/9!MB>XW8WG_5[[U] M&K77*2I@M0VR?SG>_-ON[Y*V5OKY][\{Q?
NKXEZLQ?B]K0 MTV_T]/_E^>UOG(-Q2LAT5>N&6$G?M3K/?$[=4I4QHPF&... ^TCU:HZHZN M)D;FY34WDP8OS7*XP,\:4#8
G\\EGNMZ8F_.YD,I^@%02P,$% @ 9Y5> M6=$[=6RH! BQH !D !X;"]W;W)K&ULM5E= M;]LV%/TKA-8-"9!:(N6O9+::!)E[1
$T1)&CW,.R!L6A;J"1Z)&TW0'_\+BE% M'[;"V@GS8HL4[[D\EX?2D33:;9'+L+95:7?B^G"U92F6'KU@&
M9^9)A[ZKB+%TNE._S):$47[)ZIKZM; 2V_1(GBE&4RYAD2;#[V/N"+*]+7 M 6;$MYAM9>T8:2H/G'_7C>MH[
5Z1BQA,Z4A*/QMV!5+HT_BO /7*G#]P M?OR$_M&0!S(/5+(KGOP=1VHY]H8>BMB?6$&HI_%F/)'F%VV+L8&'
M9FNI>%H$PPS2.,O_Z8^B$+4 P&D/($4 V0WH/A,0%@&A(9K/S-":4D4G(\&W M2.C1@*8/3&U,-+"),[V,]TK
V1CBU&3*1+RANI0HSJ02:U@B)=%[](4*D?>? M3)FB<2)/H??K_12=O#M%[V TNHF3!)9"CGP%,]%X_JS(>IEG)<]D/49,_?L/]X,\V
MEH[&IR[)>>N#7WRF64+M41\CA3L<[1DT8)%6B9PK8'-E(&:A6#9[!'-8.T% M[%^)3KA
"9/RM*TR]G0A>F14M&GORAKXPBKTRBKTK-/ZPA63Z"<*,WW2^QUE MIAFMF1$F.BFZ3<,,;65N37&L)AR!-:K1+ZO1=
[4/^BXY.P)K5G(,;+V9&[*JKQ%EX-5V8-]YS)V:DIT?)EH/"!#NH.I(GNMW3U6D-M3WCTXKV%"\.5#<-
#9Z)U:KA:FB%,WY0JMR;MR4^3U;JJ :-C^P?[6_<6H?()^[75_RL3"? 61X/0A>?[F MO^PMO[1\,-\7_&IX_IGFA@I0J40)FT-HT!E
)47^Y2-O*+XR'P|>N%(\-8=+ MV,Q,Z %P?L[AME0T=(+R^]/D?U!+ P04_" !GE5Y9>ZOP]P% "&+P M&0 'AL+W=O
MWF.=*W%Z8/R+V%(JT=15(?\L2]V MG$;K?%":]+'G#?MI%&>]^30_=\OG4[:729S16X[$/DTC_NV*)NPPZ_F]YQ-W
M\>-6ZA/]^707/=(EE?>[6ZZ.^D>4=9S23,0L0YQN9KU/_B4)1GI 'O%G3_^B M\A[I5!X8^Z(/KM>SGJ=G1!.ZDAHB4B]/=$&31".I>?
Q;@O:.WZD'5M_H_^< M)Z^2>8@$7;#DKW@MM[/>N(?6=!/M$WG'#K_2,J&!QENQ1.3_T:&,]7IHM1>2
MI>5@-8,TSHK7Z&M)1&4 QB\,P.4 W'9 4 X(V@X(RP%ASDR12LX#B60TGW)V M0%Q'*S3])BQ&B?GA/+X*=+U\ L
MNL!\OK]#9V4&=6"D"]@O5[<;3&=^@M57ZW)<"Q<')R#AR^ XPO/^U$C#Q'= M?$T[_A%R*7;2BLY[ZC1"4/]'>7,_6^UC'(B08
0*S; R. M_8Y>M!BKS]/Q;5C^VRMT])#H M2. (7&8%HN_;TA@,3G36+HPTAEEYC8]YC9UYA<^7L4EGI3F!NQ8*)!@! K,(MG1P)G4
L;0))("08 0*S"/0]8WL]<*V5D*?7H?!$;^W"2&.8G5G%T/O.S!;1 MV**-
ZN>0,O"/5*FKL.^K9_LNE'U'*Y9)KIHNK;Y:FUE+@/.;NU83*!J!0K-9 M-
T[=QU"2]$%=.B@:@4*S631&W7?:V+FJ/-4:1@F*4G6AD/5%6$,*[(9!\&I M!HL@/ZQ$C0;>J03?PE3[QE7[;EO=7:D-
GK66+N<<.E<;)!J!0K/Y-PV /P#3 M+*CE!T4C4&@VB\;U^TY/W$ZS!<2@JL9P=*I94"-?HOG5[PQ'+SA9WUATW^W1 MNVNVP?
W6TN6<0^=J@T0C4&@V_Z:5\,=@F@5M'D#1"!2:S:+I'WRGNVZGV4W%>G.Y@ MF-WSZGQ#%A*-0*'9:V+:%.Q#"1F#MAV@:
0*S6:Q\H#_83 :F/K2Q"WNA'; M+HPTAMEY&../W<;_NT+OLUAW[+^I"^F:I>?H5E],7^F1W9/K7&"@|_VAT.R%
M,3T*#L%D"MII@*(1*#2;1=-I8/>SAA8R';2[D=LRCC3'V:D8NX_==A]0J.]P MQN])=:XQT(X#"LU>&-.9X!&84D'["U-T
H5FLVCZ"^Q^5M%"J>-6=X';A9'& M,#L/X_"QV^&_6J9+?2=&"[$4#;!U T H5FLVC:A\#]E*-9IR7 Z14PF)P(M64<:8ZS4S$>/G![
M^+>1ZBMLL'N>GYZ=:PWTL004FKU&ID\)P'8C!:!- M!2@:@4*S631-1=!A2U)]"=;O&0J_DVR[.-(<5Z32K^QYUCO4;R+ ^&&
<")72C MQGD7(U5^O-CT71Q(MLNW03\P*5F:O]W2:$VY#E"?;YA267F@=U8?M]I/_P=0 M2P,$% @ 9Y5>6:41D1GV P R!0 !D
!X;"]W;W)K&ULM9AM;]LV$,>_"J$510+4T9/EA]06D%C:&J#!@GC97@Q]P4AG
M6ZA$>B1MM_WT(RE%MFQ523KF32)1=S_R>*>_S)OL*/O"5P "?2URPJ?62HCU MI6WS9
4%YA=T#40^65!68"%OV=+F:P8XU4Y%;GN.,[+G!$KG.BQ.Q9.Z$;D M&8$[AOBF*##[=@TYW4TMUWH:N,^6*Z$&
[""RQDN8@WA8WS%Y9]>4-"N \(P2 MQ& QM:[_%=2JYU2.A]=/|%]U\#*81\QA1O._LE2LIM;(0BDL\"87]W3W":J L5+ M:,
[U7[2K;!T+)1LN:%$YRQ44&2G_XZ_51APX2$Z[@U,<._1\X^)6#_](9 M^I5#_Z4S!)6##MTN8]<;%V&!PPFC.\24M:2I"
[W[VEON5T94H8I.@SY1PXNH>$ M+HE^EA%T]?OL!IU%("6\W-)F6&^0@M9C6@%Z1+DR,,\0F?OSM$[97^;Y;DL
M%SZQA8Q%K-O+: MZP3.87V!?.<#\AROW[*>VY?JO/T5*]YVU9*8$##50?H6W8 M[O:ID3L<-&VB%AM_V+2)6VR"H+9IA!S4(0>=
(?RP9IT;N^,@F.K49'2O&J8GG>>V*,:HC'G5& M/&,RP%ZM%WR'U]UBT8E[;16:A$4F8;$A6",GXSHGXS<7B[')-)F$129AL2%8
M(TVNLS]=.*;EHB(V7G/G2"U:;'H'[WEU #@U"HY <1O('[0+AGMPIC*?^Y&A M?U-D1(#<58$8%M
M&MW$UY:C45IDE!:;HC5SX^USX[VY=%13F$J625IDE!:; MHC63M3]&NIW'GY^2#__DT'"B'L^:1,^;Q"TF/=\]D@[[H#-3
%OJEAB74K A MHCQ.UZ-UV^U*-YN.QJ_=RYG:,AZI-IWN!.WQ98_O%K.E;M;DL)!3.1=#*7*L M;)N5-X*N=5_HD0I!"WVY
IP"4P;R^8)2\72C)JB;E^%_4$L#!!0 (&>5 M7EFWVS]'F0, ,&PO=V]R:W-H965T.1N3BP/A7D0)("VCN5A:J93%G6V+.(4,BUM60*[N
M;!G/L%2G?&>+@@-.3%)&;<]Q)G:&26Y%"W/MD4<+5DI*5H1T AEEH"J[\]K(!2K:1_%.+6LTS=6+[^%G]
M#P.O8#98P(K1+R21Z=*:62B!+2ZI_,@.]U #&8,QH\+\HD,=ZU@H+H5D69VL
M'&0DK_[QMWH@6@EN<"'!JQ.\ER;X=8)O0"MG!FN-)8X6G!T0U]%*31^8L3'9 MBH;D>AJ?)%=WB$^AOJQ(*]VP57^NX\]/BK0G*
C<_B*=-I:G/_G[.3VC.@,_#[F$/6NP M9R^;J0KR0&2*$B)BEDN2E\KT,[9!U5^?E!2]]F=GWL+9B?WSD,F\W_Z\L3\?

MM'_?,RFJP_PW@OEU@O.02P2N2:W+?5SSN(/+B__1$VOA3F'ZSO2D-'NB@NEL=J$ZC\L6]V=?M]0&VV W MGN^>XO=$^6%X ? ^X='&OK%U&ZX_U@]H&O2 \I>@)NCB'QQ6(._BQ'[=+UL^;
M=+Z^9QP]06<<=FN7I;>X'S!7%@2BL%59SNU4B?!JUUB=2%;8C=>&2;6 .,X>I MVFD#UP'J_I8Q^7RB]W+-WCWZ%U!+ P04 "
!GE5Y9,!.5,B@% ";'-M&0 'AL+W=O M64AW5TH6KHUT4:-$UWZH^L$![X(.\-;V[N:D_OC:0& !+TEZSI<$O#//>%YX MF,'S R;?:(H0
T]%7M*%EC*VO=1U&J>H@/0";U')?UEC4D#&;\E&IUN"8%(I M%;EN&8:G%S KM>6\6KLCRSG>L3PKT1T!=%
<4D'R_1CD^+#13>UZXSS8I$POZ M%W>HN29 4J:89+0-!ZH5V9EY$9"(5*XH\,'>C1-1"N/&+\ M3=S<) O-
$#M".8J9@(#\WQZM4)X+)+Z/?QI0K;4I%(^OG]$_5\YS9QXA12N< M_YDE+%UHO@82M(;[G-WCPV^H<<@5>#'.:?47'!I90P/QCC)
<-,I\!T56UO_A M4Q.((P6.(U>P&@5KJ."<4+ ;!?NU%IQ&P7FM!;=1J%S7;]^KP(60P>6KVZ+7/GQZQ'_]MZ+QAV6S)VA6>_7#
(W7Y6Z>)_LE[YK\ +9'\=V+.0% M0Z%P+&0YMNWWI:*QE!D$@=-*J;QT6R_=22]_9RDBG&T$0YV!$C&9IS6$>VS9
MMXV!IV,ASW<'CDJ +'_HYUB(1\.4N^FU;GJ3;MZ4#/$280#5!'S256]D_'PV M\P:NRH3<8."K1,ARC*&S,BG#/9'46>OM['7>$L@0H
>X!7!#$*J(1N;U)-Q; MZ40E6*@2+%($ULN)W^;$?W?6]U6F2258J!(L4@362U/0IBF8?'1$.GA/EO-\ M(X1WHJO84;
'N8[!%*4;+)RPQO\'(HVG:,9EJ=0+*,$9")OLK0%XV?<=(GJG?+!@V:,DG-1 B!M%8[Z96F+ M:XQ?%MX@)"N)T+D]&\1-
AC3D]$@BY)Z(V]%L8$[&[1[%..0T6V=Q%1K)TTQ M$%S%\.[8Y55 ZA?P"A>\F%,Q0%8$40T,_X(5I&E=VFL^D=:%1L4ZX:DXCW>$
MH#+^7C-\S%MVPN=&>3 G-_I6ZE"*%BI%BU2A]5-N=2FWWIWF&Q.JDJ42+52* M%JE"ZR>K&\3,R0'B=
M&E]^;,;CFV^Z(W(82WFN,^SN)%*6;9O&D"#&8F9@S$Y11#J&57-Z6GV9H(+11T/''=+36,8>?J&4R(QX+I()6<,/=_K164N!
MR*8ZY*+\X=^5K/Z&WJZV!VE7U?'18/W:O%R9DO50'+Q59SL=?'UJ=PO)1@RR M.5IS4\;%C),HJ0_"ZAN&MI5)SR-F#!?
598I@@H@0X+^O,6;/-\) >QRY_]0 M2P,$% @ 9Y5>6>$0>)-,! ,AL !D !X;"]W;W)K&ULM5E=C]HX%/TK5K;J6FD[B9T08
I(+:CJ2*UVU%&[#U4?/,$" M5I.8M0VT4G_\VB&3#P@I49V7(1_W'NX]N0>?<28'+K[+#8!"/Y(XE5-GH]3V MUG5EM(&$RAN^A53?
67&14*5/Q=J56P%TF24EL4L\+W03RE)G-LFNW8O9A.]4 MS%*X%TCNDH2*GV\AYH>I@YVG"Y_8>J/,!7H3/[R'O*&!
MP8MX++._Z)#'>@Z*=E+Q)$_6%20L/7[2'SD1E00<7$@@>0*Y-L'/$_RLT6-E M65L+JNAL(O@!"1.MTD>90%]HO /$5Z@,D^C%
A1EL7RIHSX_+-"+9R_1,YV-/K(XUH]&3ERE M*S/X;I17\?98!;E0Q0-L;Y#O_8V(1X*&]'E[^@(BG8ZS=+^>[FH^"E)(00K) M\/S?
DB*K/'S]H./0G8)$?FOJ\0@:-(,:/=[*+8U@ZFC!21![<&;/_*A]]JI M8TM@M?[]HG^_#;TZ%%1*4(U/]
@19A#FQV(_PYA,W'VUB8:88%#$U&H+BMJ" M:VN+&7UD,5,,&@L\X@PJ7SX:A2<%GL=@;TR:*QP4%0ZNK%#J'Q3)UBE5L-1,
MH@TLURQ=5Y365'M*#'[SP]!>?,=)Z,/PX-+Q8+\7-;0:J]]G@4KXJ%"$/=&MW16@OM_,$].'7<&G8<"^.#5NU;+;0 MZAR4I@U;
<&WXW)(%I^-_'N)=&/[2M.%K79N5X;>X%K36W7D"+*'562Z-)Q[W MH@*KYM 66GT#I'2'I-5Y=5@+T;N=:^726'NU2! MYDHAH<-
Z6 K;J^V\ 60)KH_7MP.OWG M(1>6 E*:-7*M6;,Q^_96@O:R.P^);0ZR:79)(->1$]I"JW-0>D+2ZK>Z MK 3AV79OX)W:HH:@P1"?
J,&MO- P;Y,^4J%'6J(85CK+NQEJ2L3Q!6U2O":;_0]02P,$% @ 9Y5>6>6J ML,EV P !Q< T
!X;"]S='EL97,N>&ULW5A+;MLP$+V*H#1% A21;#6R MU=@&6@,:"K1%@&3174!;E$V ^I2B4SO+7J7;GJ)'Z4G*$?6SPS&<+)JH-
F*1 M_3>/))#?3+*Y8;3ZR6ETEK'/,G'JE+*[)WCY/,EC4E^EF8T44B4BIA(U14+ M)\\$)6$.I)@[?=?
UG9BPQ)Z,DE5\&K1([MGEO'+'WX&*JH_J:VM-XT M#>G8OCUY_6V5RHM7ECX>O3DZNAIX9N'?/Q'=&FC).N7&F(RB-&GVAV?
K@,1+8FK=$3ZVIX2S MF6# BDC,^$;'^Q"8ISP5EE0;4QGI022_UW!//V#/ECHQ2U)1Y-89], ^L/'T' MJ'I@D"%>&^S;.C
9941**I)+U2E.+H(/(*MLWVPRY7 AR*;7/[<;0G%026:I M'*EHKA-V%9J,.(W CF"+)1QEFCD
2IG&JA$RLD@34GBH&&5#RLT424SWX@Q-.1J3B6#L?T%WD-XD]2:K1B7+"E[2Q:&-'GP^*KD)9FIM_PM?75^2",R
MXO*F!L=VT_Y,0[:*@_JL*YB(\JRF_0F&IYZ%JY<3E8LE(5W3<%IVQ6)6-"W5 M4%G+#Q!VD-V $@7FUL3S
P%8!JQW(;\X#-67F>!ZL*N8-MV\$X$@08 K5HKE'?1V;'AZ]Y?;!=XGE!8$8 ,SOP/ R!W8@CF /P@"&>5]P' M=^Y'3G6?-
/Æ_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 (&>57ED,;=WY3P4 #XL M /
>&PO=V]R:V)O;VLN>&ULQ9K?;^(X$(#_%8N7VY.N"^37]E:E$BVT M1>(H*E5?3VXR@-7$YFR';O>O7R>(JU/"Z%ZF/$&
<$+Y,XOG&=BY>E7YY5NJ% M_2QR:0:=M;6;\V[7I&LHN/FJ-B#=GJ72!;=N4Z^Z9J.!9V8-8(N\&_1Z2;?@
M0G8N+_;GFNNNOZ$LI%8HZ1JKABJ>T^*6DY?DBU2K/!YW^;L<3;"O2@^9%!?G(GTW=8OGS W<@ M@T[2<0NW6I4;(5?
5:=Q5=+W+J..P M_]P%\5S_GS"JY5*D,%)I68"TNSAJR"M
:=9B8SI,\@(&G6NU!$C#W([PCD=UK(15D47+\QM61&K*1P/^/2NA2>JE);X4'^0"!_MT$(.TW]+]Y]UNY^Y>UCJ[M$R/< 69 D-
'E0EQ"Z9R%05X,S\L\F$F:-/K(XQ MU]*YWK"-TZY9<]WP+J:+/K$O)G(+QE8'-8*%R:%/;(<*25I7EC7O'Z:"/K$+
M;I7*7D6>,RXSINS:W47A2D:Y]C@8]S$QG?2);7 C))>I>] 8U]K1P<%]Q2S0 M)]; PJKT9:WR#+3Y@X'+9/;-9\.2?Y\X^]]PH=F6YR6P
K@I=1TZGP[+^GWB MM#\"+;:\&DNXQ\Y877Z\KP$F@(!8 -=N].2>.7!/'IBZA[@$7(B#I\)@5@B(MK3#G;YQKV!QT_7.9
AL)D^;JNM<^)#K (-;$1!KA>@=[U#RK>O&PO1<'F# " M8F&@=5*C=@\PB03$$O$K)?;%#<%S,'_Z<)A. F*=[$NF5C!,(&Q0
[KE%9$ MS"(!L46\@J65#;-(0&P1KW)I9<,<$A [!"UAFK,7F$Q"8IFTES!MT0PQG83$
M.FFK95HA,9V$Q#II+VI:,=$9*V*CM%#0LPM(;%;&N([M8]YF17[G8V*F"8E-\P%SX4Z9E6XLY1BO2N-
/MX28;4)BVWS$+#>;O.Y%/&=S MK7Q,3#PAL7C^*RC.V*S*FW5G^C("RT7>[$&8@D)B!7F4KO;FJY6&%=_F0]^
M%1YA"HJ(%>1/(+4&,<+,$Q&;IZ5$.V/7JMB4MCK8Q\3<Y/9=[+M&;W'FY= M/'U,S#W1YTU_?<"LY>ECHNLEGS
E]HY91["2X]F-TF<+WH@FYIZ(V#U-S"L0 MMR#A+S:UV=>J(_F8F'LB8Q_K6GB*^$6D)8^)N:>Z!-',BZO0UDHS=FC
MH^4;*/W)J0AS3_0)@YYWS*DHA(6,S;FVTA7';Q\3DT[$+)_&V*PEJ<>8"#,[^VC#'WQ,3NP3']U<88Q;-==1S7?
YF)B%$F(+'<6\@VP%F8^) M62@AMA :S<8L>X*^-49LH:.8!WDSP2R4U!;]U@>;RXL,ED)"-G-_85Q[RO-T MKEGUL7L!)X]K5?
1EF>?7KNU>3A7/]J^_[E_=O?P-4$L#!!0 (&>57EG(M7,%2((- G ; >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VCMN MVT
4A>&M"%R 1_0"^D0*=(8/!4Q)'CY M5Q^((9]^E4,[[KM3W>W[NO@X'DYUU>S&L?^14EWORK&M=UU?
3N]IV5,C:+UW;8EG'5I(_#]71-EX/W53.\O$F3Y@Y2"-+Y@PR";/X@ MAR"?/R@@*.8/RA"4YP^ZAZ#[^8,>(.AA_J!'"'J"8
N!V()D"X'9@F@+@=J"; N!VX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK
M@=XZ>=DFT%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET%M1;R70VU!O M(J#;4&\CT-
M0;R/0VR:,)01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ M;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'K[9+.,0&]'O9U
,T>]G4!O1[V=0&]' MO9U ;T>]G4#O0+V#0.] O8-[T"]@T#O0+V#0.] O8-[YA\K"30.U#O(-[M4.\@T#M0[R#0.U#O(-
[H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.^,>F<" MO?/D9Q,"O3/JG;]3[SI^'DJ]]GRM\?G?2?5XOK=<'W]9?IV_M4$L#!!0 (
&>57EGB(3)"\0$!DG-3 6T-O;G1E;G1?5'EP97-= M+GAM:,W:RT[#,.! %T%^ILD6-ZR7M+2;-DVNMOGGV+A^7@1J8S&YV&T$,I\
<]\15X^-1WE"P+Q.&F>\#7L_=/%((34V36QO2 MM>WR+K9M64S/+<5R?XDO>G3+95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T
M^^0'YX]E]@7FG;?!^9@G%NCW<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S M_4^N; >YQ'9^#C\CC_.^+W^+_L0('U(D#X42!\:I
\#TL60=!36*! L0 ! M (! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 " !GE5Y9501$$>X M K @ $0 @ &O
9&]C4')O<',O8V]R92YX;6Q02P$" M% ,4 " !GE5Y9F5R<(Q & "<)P $P @ ', 0 >&PO M=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (
&>57EE&BM8Q708 '0E 8 M " @0T(!X;"]W;W)K&PO M=V]R:W-H965T&UL4$L! A0#% @ 9Y5>6;B,]*3/ P M:@X !@ ("!2Q4
'AL+W=O57EF^ CL>GP4 /46 8 " @5 9 M !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 9Y5>68#-#.5 M7EF;06V+Y (*8(8 "
@6HO !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ 9Y5>682'O,]:" JQ4 !@ ("!I#D 'AL+W=O&PO=V]R:W-H965T57EF1D
4[X@, !,) 9 " M@:U@ !X;"]W;W)K&UL4$L! A0#% @ 9Y5> M665;%CH3"0 O1X !D ("!QF0 'AL+W=O&PO=V]R:W-H965T57ED+5-
@UN08 #(1 9 " @;YP !X;"]W;W)K M&UL4$L! A0#% @ 9Y5>69(?^9 1!P &Q0 M !D ("!KG< 'AL+W=O&PO=V]R:W-
H965T57ED3HA#" MN L +HC 9 " @9.$!X;"]W;W)K&UL4$L! A0#% @ 9Y5>67P%P-0K$ ECP !D M ("!@I 'AL+W=O&PO=V]R:W-
H965T M57EFL>(-J[@(%0+ 9 M " @:*T !X;"]W;W)K&UL4$L! A0# M% @ 9Y5>60!ZCZM# @ B@8 !D ("!Q[< 'AL+W=O
M&PO=V]R:W-H965T57ED&V :6+P0 &D) 9 " @2W# M !X;"]W;W)K&UL4$L! A0#% @ 9Y5>6>2? M-VX&!@ VPP !D ("!D\<
'AL+W=O&PO=V]R:W-H965T57EFES>DAM , !4* 9 " @?W0 !X;"]W;W)K&UL4$L! A0#% @ 9Y5>62):!:9^ @ ;P4 !D M ("!Z-0
'AL+W=O&PO M=V]R:W-H965T57EF66%R8P04 M *T/ 9 " @37< !X;"]W;W)K&UL4$L! A0#% @ 9Y5>6:R:S(=8! B@P !D ("! M+>(
'AL+W=O&PO=V]R:W-H965T57EDK=<'9^ < %4? 9 M " @&UL4$L! A0#% M @ 9Y5>636/"L;- @ [P< !D ("!JO,
'AL+W=O&PO=V]R:W-H965T57EG/,<[)1P0 +X6 9 " @9/\ !X M;"]W;W)K&UL4$L! A0#% @ 9Y5>61R- Q.5 M @ G08 !D ("!0!
'AL+W=O&PO=V]R:W-H965T5 M7ED0/-H%?Q$ +[1 9 " @3D& 0!X;"]W;W)K&UL4$L! A0#% @ 9Y5>66";%!N7!0 :"T !D M ("!
IQ&PO=V]R M;W-H965T57EE6R^9+&@0 %\4 M 9 " @7&UL M4$L! A0#% @ 9Y5>64R"5?NT @ A @ !D ("!R"8! M 'AL+W=OS8" -
!0 &0 @(&S*0$ >&PO=V]R:W-H965T57EGJH:M(S@0 /LC 9 M " @2 L 0!X;"]W;W)K&UL4$L! A0#% @ M9Y5>6>^IV/8;! C!4 !D
("!)3$! 'AL+W=O&PO=V]R:W-H965T57EF^PGD,N , *\1 9 " @1@Z 0!X;"]W M;W)K&UL4$L! A0#% @ 9Y5>6?A1ACR$ @ MPP8 !D
("!!SX! 'AL+W=O&PO=V]R:W-H965T57EF> MRA1O 4 #\< 9 " @:M# 0!X;"]W;W)K&UL4$L! A0#% @ 9Y5>65S9*7>? P SQ !D M
("!XD@! 'AL+W=O&PO=V]R:W-H M965T57EG_LWQ;=P8 +HP 9 M " @6)D 0!X;"]W;W)K&UL4$L! M A0#% @ 9Y5>6 P *1(!D
("!$&L! 'AL M+W=O&PO=V]R:W-H965T57ED/1?8Y@0< U* 9 " M@75U 0!X;"]W;W)K&UL4$L! A0#% @ 9Y5> M6?$WHB3Y$0

$@\! !D ("!+7T! 'AL+W=O&PO=V]R:W-H965T57ED<)>9NX@(#0) 9 " @;N2 0!X;"]W;W)K M&UL4$L! A0#% @ 9Y5>6=$[=6RH! BQH M !D ("!U)4! 'AL+W=OZOP]P% "&+P &0 @(&SF@$ M>&PO=V]R:W-H965T57EFE$9$9 M]@, ,@4 9 " @<:@ 0!X;"]W;W)K&UL4$L! A0#% @ 9Y5>6;?;/T>9 P QP\ !D M ("!\Z0! 'AL+W=O&PO=V]R:W-H965T M57EGA$'B33 0 #(; 9 M " @2*N 0!X;"]W;W)K&UL4$L! A0# M% @ 9Y5>6>6JL,EV P !Q< T (!I;(! 'AL+W-T M>6QE&PO=V]R;V)O;VLN>&UL4$L! A0#% M @ 9Y5>66>(A,D+Q 0 &2< M !, (! [\! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& / $L 2P"$%)<$! end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none') {d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html5722621false1170false10 falsefalseR1.htm0000001 - Document - Cover PageSheethttp://www.amgen.com/role/CoverPageCover PageCover1 falsefalseR2.htm9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOMESheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMECONDENSED CONSOLIDATED STATEMENTS OF INCOMEStatements2 falsefalseR3.htm9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMESheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMECONDENSE CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEStatements3 falsefalseR4.htm9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSCONDENSED CONSOLIDATED BALANCE SHEETSStatements4 falsefalseR5.htm9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements5 falsefalseR6.htm9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITYSheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITYStatements6 falsefalseR7.htm9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)Sheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthl CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY (Parenthetical)Statements7 falsefalseR8.htm9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements8 falsefalseR9.htm9952158 - Disclosure - Summary of significant accounting policiesSheethttp://www.amgen.com/role/SummaryofsignificantaccountingpoliciesSummary of significant accounting policiesNotes9 falsefalseR10.htm9952159 - Disclosure - AcquisitionsSheethttp://www.amgen.com/role/AcquisitionsAcquisitionsNotes10 falsefalseR11.htm9952160 - Disclosure - RevenuesSheethttp://www.amgen.com/role/RevenuesRevenuesNotes11 falsefalseR12.htm9952161 - Disclosure - Income taxesSheethttp://www.amgen.com/role/IncometaxesIncome taxesNotes12 falsefalseR13.htm9952162 - Disclosure - Earnings per shareSheethttp://www.amgen.com/role/EarningspershareEarnings per shareNotes13 falsefalseR14.htm9952163 - Disclosure - InvestmentsSheethttp://www.amgen.com/role/InvestmentsInvestmentsNotes14 falsefalseR15.htm9952164 - Disclosure - InventoriesSheethttp://www.amgen.com/role/InventoriesInventoriesNotes15 falsefalseR16.htm9952165 - Disclosure - Goodwill and other intangible assetsSheethttp://www.amgen.com/role/GoodwillandotherintangibleassetsGoodwill and other intangible assetsNotes16 falsefalseR17.htm9952166 - Disclosure - Financing arrangementsSheethttp://www.amgen.com/role/FinancingarrangementsFinancing arrangementsNotes17 falsefalseR18.htm9952167 - Disclosure - Stockholders' equitySheethttp://www.amgen.com/role/StockholdersequityStockholders' equityNotes18 falsefalseR19.htm9952168 - Disclosure - Fair value measurementSheethttp://www.amgen.com/role/FairvaluemeasurementFair value measurementNotes19 falsefalseR20.htm9952169 - Disclosure - Derivative instrumentsSheethttp://www.amgen.com/role/DerivativeinstrumentsDerivative instrumentsNotes20 falsefalseR21.htm9952170 - Disclosure - Contingencies and commitmentsSheethttp://www.amgen.com/role/ContingenciesandcommitmentsContingencies and commitmentsNotes21 falsefalseR22.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes22 falsefalseR23.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes23 falsefalseR24.htm9954471 - Disclosure - Summary of significant accounting policies (Policies)Sheethttp://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPoliciesSummary of significant accounting policies (Policies)Policies24 falsefalseR25.htm9954472 - Disclosure - Acquisitions (Tables)Sheethttp://www.amgen.com/role/AcquisitionsTablesAcquisitions (Tables)Tableshttp://www.amgen.com/role/Acquisitions25 falsefalseR26.htm9954473 - Disclosure - Revenues (Tables)Sheethttp://www.amgen.com/role/RevenuesTablesRevenues (Tables)Tableshttp://www.amgen.com/role/Revenues26 falsefalseR27.htm9954474 - Disclosure - Earnings per share*

(Tables)Sheethttp://www.amgen.com/role/EarningspershareTablesEarnings per share
(Tables)Tableshttp://www.amgen.com/role/Earningspershare27 falsefalseR28.htm9954475 - Disclosure - Investments
(Tables)Sheethttp://www.amgen.com/role/InvestmentsTablesInvestments
(Tables)Tableshttp://www.amgen.com/role/Investments28 falsefalseR29.htm9954476 - Disclosure - Inventories
(Tables)Sheethttp://www.amgen.com/role/InventoriesTablesInventories
(Tables)Tableshttp://www.amgen.com/role/Inventories29 falsefalseR30.htm9954477 - Disclosure - Goodwill and other intangible assets (Tables)Sheethttp://www.amgen.com/role/GoodwillandotherintangibleassetsTablesGoodwill and other intangible assets (Tables)Tableshttp://www.amgen.com/role/Goodwillandotherintangibleassets30 falsefalseR31.htm9954478 - Disclosure - Financing arrangements (Tables)Sheethttp://www.amgen.com/role/FinancingarrangementsTablesFinancing arrangements (Tables)Tableshttp://www.amgen.com/role/Financingarrangements31 falsefalseR32.htm9954479 - Disclosure - Stockholders' equity (Tables)Sheethttp://www.amgen.com/role/StockholdersequityTablesStockholders' equity
(Tables)Tableshttp://www.amgen.com/role/Stockholdersequity32 falsefalseR33.htm9954480 - Disclosure - Fair value measurement (Tables)Sheethttp://www.amgen.com/role/FairvaluemeasurementTablesFair value measurement
(Tables)Tableshttp://www.amgen.com/role/Fairvaluemeasurement33 falsefalseR34.htm9954481 - Disclosure - Derivative instruments (Tables)Sheethttp://www.amgen.com/role/DerivativeinstrumentsTablesDerivative instruments
(Tables)Tableshttp://www.amgen.com/role/Derivativeinstruments34 falsefalseR35.htm9954482 - Disclosure - Summary of significant accounting policies
(Details)Sheethttp://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetailsSummary of significant accounting policies (Details)Detailshttp://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies35 falsefalseR36.htm9954483 - Disclosure - Acquisitions - Acquisition of Horizon Therapeutics plc
(Details)Sheethttp://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetailsAcquisitions - Acquisition of Horizon Therapeutics plc (Details)Details36 falsefalseR37.htm9954484 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition
(Details)Sheethttp://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetailsAcquisitions - Schedule of Business Acquisitions, by Acquisition (Details)Details37 falsefalseR38.htm9954485 - Disclosure - Acquisitions - Supplemental Pro Forma Financial Information
(Details)Sheethttp://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetailsAcquisitions - Supplemental Pro Forma Financial Information (Details)Details38 falsefalseR39.htm9954486 - Disclosure - Revenues - Narrative (Details)Sheethttp://www.amgen.com/role/RevenuesNarrativeDetailsRevenues - Narrative (Details)Details39 falsefalseR40.htm9954487 - Disclosure - Revenues - Disaggregation of Revenue by Product and by Geographic Area
(Details)Sheethttp://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetailsRevenues - Disaggregation of Revenue by Product and by Geographic Area (Details)Details40 falsefalseR41.htm9954488 - Disclosure - Income taxes (Details)Sheethttp://www.amgen.com/role/IncometaxesDetailsIncome taxes
(Details)Detailshttp://www.amgen.com/role/Incometaxes41 falsefalseR42.htm9954489 - Disclosure - Earnings per share - Computation for Basic and Diluted EPS
(Details)Sheethttp://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetailsEarnings per share - Computation for Basic and Diluted EPS (Details)Details42 falsefalseR43.htm9954490 - Disclosure - Investments - Schedule of Available-For-Sale Investments
(Details)Sheethttp://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetailsInvestments - Schedule of Available-For-Sale Investments (Details)Details43 falsefalseR44.htm9954491 - Disclosure - Investments - Schedule of Fair Values by Classification
(Details)Sheethttp://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetailsInvestments - Schedule of Fair Values by Classification (Details)Details44 falsefalseR45.htm9954492 - Disclosure - Investments - Available-For-Sale
(Details)Sheethttp://www.amgen.com/role/InvestmentsAvailableForSaleDetailsInvestments - Available-For-Sale (Details)Details45 falsefalseR46.htm9954493 - Disclosure - Investments - BeiGene, Ltd.
(Details)Sheethttp://www.amgen.com/role/InvestmentsBeiGeneLtdDetailsInvestments - BeiGene, Ltd. (Details)Details46 falsefalseR47.htm9954494 - Disclosure - Investments - Other Equity Securities
(Details)Sheethttp://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetailsInvestments - Other Equity Securities (Details)Details47 falsefalseR48.htm9954495 - Disclosure - Investments - Neumora Therapeutics, Inc.
(Details)Sheethttp://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetailsInvestments - Neumora Therapeutics, Inc. (Details)Details48 falsefalseR49.htm9954496 - Disclosure - Investments - Limited Partnership
(Details)Sheethttp://www.amgen.com/role/InvestmentsLimitedPartnershipDetailsInvestments - Limited Partnership (Details)Details49 falsefalseR50.htm9954497 - Disclosure - Inventories
(Details)Sheethttp://www.amgen.com/role/InventoriesDetailsInventories
(Details)Detailshttp://www.amgen.com/role/InventoriesTables50 falsefalseR51.htm9954498 - Disclosure - Goodwill and other intangible assets - Schedule of Goodwill
(Details)Sheethttp://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetailsGoodwill and other intangible assets - Schedule of Goodwill (Details)Details51 falsefalseR52.htm9954499 - Disclosure - Goodwill and other intangible assets - Schedule of Identifiable Intangible Assets
(Details)Sheethttp://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetailsGoodwill and other intangible assets - Schedule of Identifiable Intangible Assets (Details)Details52 falsefalseR53.htm9954500 - Disclosure - Goodwill and other intangible assets - Narrative
(Details)Sheethttp://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetailsGoodwill and other intangible assets - Narrative (Details)Details53 falsefalseR54.htm9954501 - Disclosure - Financing arrangements - Schedule of Borrowings (Details)Sheethttp://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetailsFinancing arrangements - Schedule of Borrowings (Details)Details54 falsefalseR55.htm9954502 - Disclosure - Financing arrangements - Narrative (Details)Sheethttp://www.amgen.com/role/FinancingarrangementsNarrativeDetailsFinancing arrangements - Narrative (Details)Details55 falsefalseR56.htm9954503 - Disclosure - Stockholders' equity - Narrative
(Details)Sheethttp://www.amgen.com/role/StockholdersequityNarrativeDetailsStockholders' equity - Narrative (Details)Details56 falsefalseR57.htm9954504 - Disclosure - Stockholders' equity - Components of Accumulated Other Comprehensive Income
(Details)Sheethttp://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetailsStockholders' equity - Components of Accumulated Other Comprehensive Income (Details)Details57 falsefalseR58.htm9954505 - Disclosure - Stockholders' equity - Reclassifications Out of Accumulated Other Comprehensive Income
(Details)Sheethttp://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetailsStockholders' equity - Reclassifications Out of Accumulated Other Comprehensive Income (Details)Details58 falsefalseR59.htm9954506 - Disclosure - Fair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis
(Details)Sheethttp://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetailsFair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis (Details)Details59 falsefalseR60.htm9954507 - Disclosure - Fair value measurement - Contingent Consideration Obligations
(Details)Sheethttp://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetailsFair value measurement - Contingent Consideration Obligations (Details)Details60 falsefalseR61.htm9954508 - Disclosure - Fair value measurement - Narrative (Details)Sheethttp://www.amgen.com/role/FairvaluemeasurementNarrativeDetailsFair value measurement - Narrative (Details)Details61 falsefalseR62.htm9954509 - Disclosure - Derivative instruments - Narrative

(Details)Sheethttp://www.amgen.com/role/DerivativeinstrumentsNarrativeDetailsDerivative instruments - Narrative (Details)Details62 falsefalseR63.htm9954510 - Disclosure - Derivative instruments - Schedule of Cross-Currency Swaps (Details)Sheethttp://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetailsDerivative instruments - Schedule of Cross-Currency Swaps (Details)Details63 falsefalseR64.htm9954511 - Disclosure - Derivative instruments - Summary of Unrealized Gains and Losses Recognized in AOCI (Details)Sheethttp://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails instruments - Summary of Unrealized Gains and Losses Recognized in AOCI (Details)Details64 falsefalseR65.htm9954512 - Disclosure - Derivative instruments - Hedged Liabilities and Cumulative Amount (Details)Sheethttp://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetailsDerivative instruments - Hedged Liabilities and Cumulative Amount (Details)Details65 falsefalseR66.htm9954513 - Disclosure - Derivative instruments - Summary of Income and Expense Line Items (Details)Sheethttp://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetailsDerivative instruments - Summary of Income and Expense Line Items (Details)Details66 falsefalseR67.htm9954514 - Disclosure - Derivative instruments - Fair Value of Derivatives (Details)Sheethttp://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetailsDerivative instruments - Fair Value of Derivatives (Details)Details67 falsefalseAll ReportsBookAll Reports amgn-20240930.htmamgn-20240930.xsdamgn-20240930_cal.xmlamgn-20240930_def.xmlamgn-20240930_lab.xmlamgn-20240930_pre.xml http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "amgn-20240930.htm": { "nsprefix": "amgn", "nsuri": "http://www.amgen.com/20240930", "dts": { "inline": { "local": ["amgn-20240930.htm"] }, "schema": { "local": ["amgn-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["amgn-20240930_cal.xml"] }, "definitionLink": { "local": ["amgn-20240930_def.xml"] }, "labelLink": { "local": ["amgn-20240930_lab.xml"] }, "presentationLink": { "local": ["amgn-20240930_pre.xml"] } }, "keyStandard": 234, "keyCustom": 28, "axisStandard": 23, "axisCustom": 0, "memberStandard": 38, "memberCustom": 77, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 572, "entityCount": 1, "segmentCount": 117, "elementCount": 610, "unitCount": 10, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1268, "http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.amgen.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R3": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R4": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement",

"subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-50", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-55", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R7": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R9": { "role": "http://www.amgen.com/role/Summaryofsignificantaccountingpolicies", "longName": "9952158 - Disclosure - Summary of significant accounting policies", "shortName": "Summary of significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.amgen.com/role/Acquisitions", "longName": "9952159 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.amgen.com/role/Revenues", "longName": "9952160 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.amgen.com/role/Incometaxes", "longName": "9952161 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.amgen.com/role/Earningspershare", "longName": "9952162 - Disclosure - Earnings per share", "shortName": "Earnings per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.amgen.com/role/Investments", "longName": "9952163 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.amgen.com/role/Inventories", "longName": "9952164 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.amgen.com/role/Goodwillandotherintangibleassets", "longName": "9952165 - Disclosure - Goodwill and other intangible assets", "shortName": "Goodwill and other intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.amgen.com/role/Financingarrangements", "longName": "9952166 - Disclosure - Financing arrangements", "shortName": "Financing arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":

null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.amgen.com/role/Stockholdersequity", "longName": "9952167 - Disclosure - Stockholders' equity", "shortName": "Stockholders' equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.amgen.com/role/Fairvaluemeasurement", "longName": "9952168 - Disclosure - Fair value measurement", "shortName": "Fair value measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.amgen.com/role/Derivativeinstruments", "longName": "9952169 - Disclosure - Derivative instruments", "shortName": "Derivative instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.amgen.com/role/Contingenciesandcommitments", "longName": "9952170 - Disclosure - Contingencies and commitments", "shortName": "Contingencies and commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-13", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies", "longName": "9954471 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "amgn:NatureOfOperationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "amgn:NatureOfOperationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.amgen.com/role/AcquisitionsTables", "longName": "9954472 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.amgen.com/role/RevenuesTables", "longName": "9954473 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.amgen.com/role/EarningspershareTables", "longName": "9954474 - Disclosure - Earnings per share (Tables)", "shortName": "Earnings per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.amgen.com/role/InvestmentsTables", "longName": "9954475 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.amgen.com/role/InventoriesTables", "longName": "9954476 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null,

"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsTables", "longName": "9954477 - Disclosure - Goodwill and other intangible assets (Tables)", "shortName": "Goodwill and other intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.amgen.com/role/FinancingarrangementsTables", "longName": "9954478 - Disclosure - Financing arrangements (Tables)", "shortName": "Financing arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.amgen.com/role/StockholdersequityTables", "longName": "9954479 - Disclosure - Stockholders' equity (Tables)", "shortName": "Stockholders' equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.amgen.com/role/FairvaluemeasurementTables", "longName": "9954480 - Disclosure - Fair value measurement (Tables)", "shortName": "Fair value measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.amgen.com/role/DerivativeinstrumentsTables", "longName": "9954481 - Disclosure - Derivative instruments (Tables)", "shortName": "Derivative instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails", "longName": "9954482 - Disclosure - Summary of significant accounting policies (Details)", "shortName": "Summary of significant accounting policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "amgn:NatureOfOperationsPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-17", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R36": { "role": "http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "longName": "9954483 - Disclosure - Acquisitions - Acquisition of Horizon Therapeutics plc (Details)", "shortName": "Acquisitions - Acquisition of Horizon Therapeutics plc (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:BusinessAcquisitionSharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R37": { "role": "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "longName": "9954484 - Disclosure - Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)", "shortName": "Acquisitions - Schedule of Business Acquisitions, by Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R38": { "role": "http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails", "longName": "9954485 - Disclosure - Acquisitions - Supplemental Pro Forma Financial Information (Details)", "shortName": "Acquisitions - Supplemental Pro Forma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.amgen.com/role/RevenuesNarrativeDetails", "longName": "9954486 - Disclosure - Revenues - Narrative (Details)", "shortName": "Revenues - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-

gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "amgn:NatureOfOperationsPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails", "longName": "9954487 - Disclosure - Revenues - Disaggregation of Revenue by Product and by Geographic Area (Details)", "shortName": "Revenues - Disaggregation of Revenue by Product and by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-181", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R41": { "role": "http://www.amgen.com/role/IncometaxesDetails", "longName": "9954488 - Disclosure - Income taxes (Details)", "shortName": "Income taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails", "longName": "9954489 - Disclosure - Earnings per share - Computation for Basic and Diluted EPS (Details)", "shortName": "Earnings per share - Computation for Basic and Diluted EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R43": { "role": "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails", "longName": "9954490 - Disclosure - Investments - Schedule of Available-For-Sale Investments (Details)", "shortName": "Investments - Schedule of Available-For-Sale Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails", "longName": "9954491 - Disclosure - Investments - Schedule of Fair Values by Classification (Details)", "shortName": "Investments - Schedule of Fair Values by Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-289", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "amgn:FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R45": { "role": "http://www.amgen.com/role/InvestmentsAvailableForSaleDetails", "longName": "9954492 - Disclosure - Investments - Available-For-Sale (Details)", "shortName": "Investments - Available-For-Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:Cash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "longName": "9954493 - Disclosure - Investments - BeiGene, Ltd. (Details)", "shortName": "Investments - BeiGene, Ltd. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-295", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R47": { "role": "http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails", "longName": "9954494 - Disclosure - Investments - Other Equity Securities (Details)", "shortName": "Investments - Other Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "amgn:SaleOfEquitySecuritiesFVNIUnrealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["amgn:SaleOfEquitySecuritiesFVNIUnrealizedGainLoss", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R48": { "role": "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails", "longName": "9954495 - Disclosure - Investments - Neumora Therapeutics, Inc. (Details)", "shortName": "Investments - Neumora Therapeutics, Inc. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"],

"reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-304", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true }], "R49": { "role": "http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails", "longName": "9954496 - Disclosure - Investments - Limited Partnership (Details)", "shortName": "Investments - Limited Partnership (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-311", "name": "us-gaap:AlternativeInvestment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-312", "name": "us-gaap:AlternativeInvestment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true }], "R50": { "role": "http://www.amgen.com/role/InventoriesDetails", "longName": "9954497 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails", "longName": "9954498 - Disclosure - Goodwill and other intangible assets - Schedule of Goodwill (Details)", "shortName": "Goodwill and other intangible assets - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R52": { "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails", "longName": "9954499 - Disclosure - Goodwill and other intangible assets - Schedule of Identifiable Intangible Assets (Details)", "shortName": "Goodwill and other intangible assets - Schedule of Identifiable Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "amgn:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "amgn:ScheduleOfIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails", "longName": "9954500 - Disclosure - Goodwill and other intangible assets - Narrative (Details)", "shortName": "Goodwill and other intangible assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails", "longName": "9954501 - Disclosure - Financing arrangements - Schedule of Borrowings (Details)", "shortName": "Financing arrangements - Schedule of Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "longName": "9954502 - Disclosure - Financing arrangements - Narrative (Details)", "shortName": "Financing arrangements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfLongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ExtinguishmentOfDebtAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R56": { "role": "http://www.amgen.com/role/StockholdersequityNarrativeDetails", "longName": "9954503 - Disclosure - Stockholders' equity - Narrative (Details)", "shortName": "Stockholders' equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954504 - Disclosure - Stockholders' equity - Components of Accumulated Other Comprehensive Income (Details)", "shortName": "Stockholders' equity - Components of Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-41", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-427", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R58": { "role": "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954505 - Disclosure - Stockholders' equity - Reclassifications Out of Accumulated Other Comprehensive Income

(Details)", "shortName": "Stockholders' equity - Reclassifications Out of Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-452", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R59": { "role": "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "longName": "9954506 - Disclosure - Fair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis (Details)", "shortName": "Fair value measurement - Fair Value of Financial Assets and Liabilities on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R60": { "role": "http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails", "longName": "9954507 - Disclosure - Fair value measurement - Contingent Consideration Obligations (Details)", "shortName": "Fair value measurement - Contingent Consideration Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-41", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "amgn:BusinessCombinationContingentConsiderationArrangementsPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R61": { "role": "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails", "longName": "9954508 - Disclosure - Fair value measurement - Narrative (Details)", "shortName": "Fair value measurement - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-508", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R62": { "role": "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "longName": "9954509 - Disclosure - Derivative instruments - Narrative (Details)", "shortName": "Derivative instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "longName": "9954510 - Disclosure - Derivative instruments - Schedule of Cross-Currency Swaps (Details)", "shortName": "Derivative instruments - Schedule of Cross-Currency Swaps (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-337", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-512", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "amgn:ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R64": { "role": "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "longName": "9954511 - Disclosure - Derivative instruments - Summary of Unrealized Gains and Losses Recognized in AOCI (Details)", "shortName": "Derivative instruments - Summary of Unrealized Gains and Losses Recognized in AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-533", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-533", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails", "longName": "9954512 - Disclosure - Derivative instruments - Hedged Liabilities and Cumulative Amount (Details)", "shortName": "Derivative instruments - Hedged Liabilities and Cumulative Amount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-541", "name": "us-gaap:HedgedLiabilityFairValueHedge", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true } }, "R66": { "role":

"http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "longName": "9954513 - Disclosure - Derivative instruments - Summary of Income and Expense Line Items (Details)", "shortName": "Derivative instruments - Summary of Income and Expense Line Items (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-549", "name": "us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "unique": true }], "R67": { "role": "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "longName": "9954514 - Disclosure - Derivative instruments - Fair Value of Derivatives (Details)", "shortName": "Derivative instruments - Fair Value of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-16", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-16", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "amgn-20240930.htm", "first": true, "unique": true } } }, "tag": { "amgn_A1.90NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A1.90NotesDue2025Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "1.90% notes due 2025 (1.90% 2025 Notes)", "label": "1.90% Notes Due 2025 [Member]", "documentation": "One Point Nine Zero Percent Notes Due Two Zero Two Five [Member]" } } }, "auth_ref": [] }, "amgn_A2.00NotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A2.00NotesDue2026Member", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2.00% \u20ac750 million notes due 2026 (2.00% 2026 euro Notes)", "verboseLabel": "2.00% 2026 euro Notes", "label": "2.00% Notes Due 2026 [Member]", "documentation": "2.00% Notes Due 2026" } } }, "auth_ref": [] }, "amgn_A2.00SeniorNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A2.00SeniorNotesDue2026Member", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "2.00% Senior Notes due 2026", "label": "2.00% Senior Notes Due 2026 [Member]", "documentation": "2.00% Senior Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "amgn_A3.125NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A3.125NotesDue2025Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.125% notes due 2025 (3.125% 2025 Notes)", "label": "3.125% Notes Due 2025 [Member]", "documentation": "3.125% Notes Due 2025" } } }, "auth_ref": [] }, "amgn_A3.625NotesDueIn2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A3.625NotesDueIn2024Member", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.625% notes due 2024 (3.625% 2024 Notes)", "label": "3.625% Notes Due In 2024 [Member]", "documentation": "Three Point Six Two Five Percent Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "amgn_A3002029NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A3002029NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.00% notes due 2029 (3.00% 2029 Notes)", "label": "3.00% 2029 Notes [Member]", "documentation": "3.00% 2029 Notes" } } }, "auth_ref": [] }, "amgn_A300NotesDue20523002052NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A300NotesDue20523002052NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.00% notes due 2052 (3.00% 2052 Notes)", "label": "3.00% notes due 2052 (3.00% 2052 Notes) [Member]", "documentation": "3.00% notes due 2052 (3.00% 2052 Notes)" } } }, "auth_ref": [] }, "amgn_A3352032NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A3352032NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "3.35% notes due 2032 (3.35% 2032 Notes)", "label": "3.35% 2032 Notes [Member]", "documentation": "3.35% 2032 Notes" } } }, "auth_ref": [] }, "amgn_A4052029NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A4052029NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.05% notes due 2029 (4.05% 2029 Notes)", "label": "4.05% 2029 Notes [Member]", "documentation": "4.05% 2029 Notes" } } }, "auth_ref": [] }, "amgn_A4202033NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A4202033NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.20% notes due 2033 (4.20% 2033 Notes)", "label": "4.20% 2033 Notes [Member]", "documentation": "4.20% 2033 Notes" } } }, "auth_ref": [] }, "amgn_A4202052NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A4202052NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.20% notes due 2052 (4.20% 2052 Notes)", "label": "4.20% 2052 Notes [Member]", "documentation": "4.20% 2052 Notes" } } }, "auth_ref": [] }, "amgn_A4402062NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A4402062NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.40% notes due 2062 (4.40% 2062 Notes)", "label": "4.40% 2062 Notes [Member]", "documentation": "4.40% 2062 Notes" } } }, "auth_ref": [] }, "amgn_A48752053NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A48752053NotesMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.875% notes due 2053 (4.875% 2053 Notes)", "label": "4.875% 2053 Notes [Member]", "documentation": "4.875% 2053 Notes" } } }, "auth_ref": [] }, "amgn_A515NotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A515NotesDue2028Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.15% notes due 2028 (5.15% 2028 Notes)", "label": "5.15% Notes Due 2028 [Member]", "documentation": "5.15% Notes Due

2028" } } }, "auth_ref": [] }, "amgn_A525NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A525NotesDue2025Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.25% notes due 2025 (5.25% 2025 Notes)", "label": "5.25% Notes Due 2025 [Member]", "documentation": "5.25% Notes Due 2025" } } }, "auth_ref": [] }, "amgn_A525NotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A525NotesDue2030Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.25% notes due 2030 (5.25% 2030 Notes)", "label": "5.25% Notes Due 2030 [Member]", "documentation": "5.25% Notes Due 2030" } } }, "auth_ref": [] }, "amgn_A525NotesDue2033Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A525NotesDue2033Member", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.25% notes due 2033 (5.25% 2033 Notes)", "label": "5.25% Notes Due 2033 [Member]", "documentation": "5.25% Notes Due 2033" } } }, "auth_ref": [] }, "amgn_A5507NotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A5507NotesDue2026Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.507% notes due 2026 (5.507% 2026 Notes)", "label": "5.507% Notes Due 2026 [Member]", "documentation": "5.507% Notes Due 2026" } } }, "auth_ref": [] }, "amgn_A560NotesDue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A560NotesDue2043Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.60% notes due 2043 (5.60% 2043 Notes)", "label": "5.60% Notes Due 2043 [Member]", "documentation": "5.60% Notes Due 2043" } } }, "auth_ref": [] }, "amgn_A565NotesDue2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A565NotesDue2053Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.65% notes due 2053 (5.65% 2053 Notes)", "label": "5.65% Notes Due 2053 [Member]", "documentation": "5.65% Notes Due 2053" } } }, "auth_ref": [] }, "amgn_A575NotesDue2063Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "A575NotesDue2063Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.75% notes due 2063 (5.75% 2063 Notes)", "label": "5.75% Notes Due 2063 [Member]", "documentation": "5.75% Notes Due 2063" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r73", "r811"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Trade receivables, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r964"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r75"] }, "amgn_AccruedLiabilitiesOtherNonCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "AccruedLiabilitiesOtherNonCurrentLiabilitiesMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities/ Other\u00a0noncurrent liabilities", "label": "Accrued Liabilities Other Non Current Liabilities [Member]", "documentation": "Accrued liabilities/other non-current liabilities." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated depreciation and amortization on property, plant and equipment", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r32", "r160", "r620"] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Cash\u00a0flow hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r177", "r184", "r185", "r473", "r773", "r942"] }, "amgn_AccumulatedOtherAdjustmentAttributabletoParentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "AccumulatedOtherAdjustmentAttributabletoParentMember", "presentation": ["http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Accumulated Other Adjustment Attributable to Parent [Member]", "documentation": "Accumulated Other Adjustment Attributable to Parent [Member]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r183", "r184", "r525", "r526", "r527", "r528", "r529", "r530"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r20", "r21", "r93", "r170", "r616", "r645", "r646"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r183", "r184", "r525", "r526", "r527", "r528", "r529", "r530"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "verboseLabel": "AOCI", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r4", "r13", "r21", "r485", "r488", "r538", "r641", "r642", "r942", "r943", "r944", "r952", "r953", "r954", "r955"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r5", "r13", "r21", "r91", "r92", "r184", "r185", "r526", "r527", "r528", "r529", "r530", "r942"] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period of amortization", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r303", "r763"] }, "amgn_AcquiredResearchAndDevelopmentTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "AcquiredResearchAndDevelopmentTechnologyRightsMember", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development technology rights", "label": "Acquired Research And Development Technology Rights [Member]", "documentation": "Acquired research and development technology rights." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r875"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r888"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r888"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r888"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r888"] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tax impact related to employee stock-based compensation expense", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r43", "r44", "r405"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": {

"terseLabel": "Noncash adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r921"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r847", "r857", "r867", "r899"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r850", "r860", "r870", "r902"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r922"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r888"] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r895"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r851", "r861", "r871", "r895", "r903", "r907", "r915"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r913"] }, "us-gaap_AlternativeInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AlternativeInvestment", "crdr": "debit", "presentation": ["http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Alternative investments", "label": "Alternative Investment", "documentation": "Fair value of investment other than investment in equity security, investment in debt security and equity method investment. Includes, but is not limited to, investment in certain entities that calculate net asset value per share. Example includes, but is not limited to, investment in hedge fund, venture capital fund, private equity fund, and real estate partnership or fund." } } }, "auth_ref": ["r495", "r512", "r800", "r803", "r804", "r1034", "r1036", "r1037", "r1038"] }, "amgn_AlternativeInvestmentNetGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "AlternativeInvestmentNetGainLoss", "crdr": "credit", "presentation": ["http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net gains (losses) from limited partnership investments", "label": "Alternative Investment, Net Gain (Loss)", "documentation": "Alternative Investment, Net Gain (Loss)" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amortization charges associated with finite-lived intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r9", "r300", "r307", "r782"] }, "amgn_AranespMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "AranespMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aranesp", "label": "Aranesp [Member]", "documentation": "Aranesp." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r131", "r142", "r164", "r196", "r226", "r230", "r237", "r238", "r283", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r471", "r474", "r521", "r612", "r698", "r777", "r778", "r811", "r838", "r1015", "r1016", "r1055"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r157", "r173", "r196", "r283", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r471", "r474", "r521", "r811", "r1015", "r1016", "r1055"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": {

{"http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r496", "r497", "r800"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r251"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r252"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r248", "r291", "r611"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails", "http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair values", "totalLabel": "Total interest-bearing securities", "verboseLabel": "Available-for-sale securities:", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r249", "r291", "r496", "r607", "r800", "r803", "r965", "r1036", "r1037", "r1038"] }, "amgn_AvailableForSalesInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "AvailableForSalesInvestmentsMember", "presentation": ["http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Available-for-sale investments", "label": "Available For Sales Investments [Member]", "documentation": "Available for sales investments." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r910"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r911"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r906"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r906"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r906"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r906"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r906"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r906"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421",

"r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r909"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r908"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r907"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r907"] }, "amgn_BLINCYTOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BLINCYTOMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "BLINCYTO", "label": "BLINCYTO [Member]", "documentation": "BLINCYTO" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r319", "r1067", "r1068"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r59", "r62", "r319", "r1067", "r1068"] }, "amgn_BasicAndDilutedEarningPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BasicAndDilutedEarningPerShareAbstract", "presentation": ["http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Computation of basic and diluted earnings per share", "label": "Basic And Diluted Earning Per Share [Abstract]", "documentation": "Basic and diluted earning per share." } } }, "auth_ref": [] }, "amgn_BasisOfPresentationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BasisOfPresentationPolicyTextBlock", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Basis of presentation", "label": "Basis Of Presentation [Policy Text Block]", "documentation": "Shows the basis of presentation of financial information for interim periods." } } }, "auth_ref": [] }, "amgn_BeiGeneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BeiGeneMember", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails"], "lang": { "en-us": { "role": { "terseLabel": "BeiGene", "label": "BeiGene [Member]", "documentation": "BeiGene [Member]" } } }, "auth_ref": [] }, "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total assets acquired, net of liabilities assumed", "label": "Business Acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "documentation": "Business Acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails", "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r301", "r302", "r303", "r304", "r305", "r463", "r794", "r795"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails", "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r45", "r46", "r301", "r302", "r303", "r304", "r305", "r463", "r794", "r795"] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Replacement equity awards issued (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": ["r123"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items

represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r463"] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": ["http://www.amgen.com/role/AcquisitionsTables"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Information", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": ["r932", "r933"] }, "us-gaap_BusinessAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionSharePrice", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Acquisition price per share (in dollars per share)", "label": "Business Acquisition, Share Price", "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": ["r461", "r462"] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": ["http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": ["r461", "r462"] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r1", "r2", "r11"] }, "amgn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableValueOfAcquirerReplacementAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableValueOfAcquirerReplacementAwards", "crdr": "credit", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred for replacement awards", "label": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Value Of Acquirer Replacement Awards", "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Value Of Acquirer Replacement Awards" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities incurred", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination." } } }, "auth_ref": ["r1", "r2", "r50", "r466"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net changes in valuations", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r468", "r947"] }, "amgn_BusinessCombinationContingentConsiderationArrangementsPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessCombinationContingentConsiderationArrangementsPayments", "crdr": "debit", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments", "label": "Business Combination, Contingent Consideration Arrangements, Payments", "documentation": "Business Combination, Contingent Consideration Arrangements, Payments" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails", "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration obligations", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r51", "r122", "r467", "r498", "r499", "r500"] }, "amgn_BusinessCombinationContingentConsiderationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessCombinationContingentConsiderationRollForward", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementContingentConsiderationObligationsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Contingent Consideration [Roll Forward]", "label": "Business Combination, Contingent Consideration [Roll Forward]", "documentation": "Business Combination, Contingent Consideration [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Acquisitions"], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r120", "r464"] }, "amgn_BusinessCombinationPaymentsToAcquireBusinessVestedAndOutstandingAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessCombinationPaymentsToAcquireBusinessVestedAndOutstandingAwards", "crdr": "credit", "presentation": [

"http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred for vested and outstanding awards", "label": "Business Combination, Payments To Acquire Business, Vested And Outstanding Awards", "documentation": "Business Combination, Payments To Acquire Business, Vested And Outstanding Awards" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } }, "auth_ref": ["r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "negatedTerseLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": ["r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": ["r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets \u2013 developed-product-technology rights", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": ["r47", "r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": ["r47", "r48"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r47", "r48"] }, "amgn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssetsLiabilities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag":

"amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other assets and liabilities, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets (Liabilities)" } } }, "auth_ref": [] }, "amgn_BusinessCombinationTurnoverPeriodOfInventoryAcquired": { "xbrltype": "durationItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "BusinessCombinationTurnoverPeriodOfInventoryAcquired", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business combination, turnover period of inventory acquired", "label": "Business combination, turnover period of inventory acquired", "documentation": "Business combination, turnover period of inventory acquired" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://www.amgen.com/role/InvestmentsAvailableForSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r144", "r615", "r668", "r693", "r811", "r838", "r941"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r26", "r159", "r767"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1034", "r1035"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r26", "r107", "r192"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "(Decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r3", "r107"] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Cash flow hedges", "terseLabel": "Cash flow hedge", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": ["r56"] }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) on fair value hedging relationships, Derivatives designated as hedging instruments", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement." } } }, "auth_ref": ["r130"] }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) on fair value hedging relationships, hedged items", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement." } } }, "auth_ref": ["r130"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r886"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":

{"http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r883"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r881"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r153", "r167", "r168", "r169", "r196", "r216", "r217", "r219", "r221", "r228", "r229", "r283", "r328", "r330", "r331", "r332", "r335", "r336", "r370", "r371", "r374", "r377", "r384", "r521", "r649", "r650", "r651", "r652", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r669", "r685", "r707", "r724", "r744", "r745", "r746", "r747", "r748", "r925", "r948", "r956"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.amgen.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r167", "r168", "r169", "r228", "r370", "r371", "r372", "r374", "r377", "r382", "r384", "r649", "r650", "r651", "r652", "r788", "r925", "r948"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r887"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r887"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Contingencies and commitments (see Note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r79", "r134", "r614", "r684"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Contingenciesandcommitments"], "lang": { "en-us": { "role": { "verboseLabel": "Contingencies and commitments", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r113", "r320", "r321", "r751", "r1007", "r1012"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "http://www.amgen.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, dividends declared per share (in usd per share)", "verboseLabel": "Dividends declared per share (in usd per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r119"] }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockIncludingAdditionalPaidInCapitalMember", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Common stock and additional paid-in\u00a0capital", "label": "Common Stock Including Additional Paid in Capital [Member]", "documentation": "Common stock held by shareholders with par value plus amounts in excess of par value or issuance value (in cases of no-par value stock)." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Number of\u00a0shares of\u00a0common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r827", "r828", "r829", "r831", "r832", "r833", "r836", "r952", "r953", "r955", "r1032", "r1097", "r1098"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock and additional paid-in capital, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r81"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock and additional paid-in capital, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r81", "r685"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock and additional paid-in capital, shares outstanding (in shares)", "periodStartLabel":

"Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r81", "r685", "r704", "r1098", "r1099"] }, "us-gaap_CommonStocksIncludingAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStocksIncludingAdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding\u2014537.5 shares in 2024 and 535.4 shares in 2023", "label": "Common Stocks, Including Additional Paid in Capital", "documentation": "Amount of par value plus amounts in excess of par value or issuance value for common stock issued." } } }, "auth_ref": ["r81", "r82", "r119"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r892"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r891"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r893"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r890"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r22", "r180", "r182", "r186", "r608", "r626", "r627"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r52", "r774"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r95", "r96", "r572"] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r103"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "amgn_CrossCurrencySwapContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "CrossCurrencySwapContractsMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "netLabel": "Cross-currency swap contract gains (losses)", "terseLabel": "Cross-currency swap contracts", "verboseLabel": "Cross-currency swap contracts", "label": "Cross Currency Swap Contracts [Member]", "documentation": "Cross currency swap contracts." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": ["r1052"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt

Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Financingarrangements"], "lang": { "en-us": { "role": { "verboseLabel": "Financing arrangements", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r114", "r194", "r314", "r315", "r316", "r317", "r318", "r326", "r327", "r337", "r343", "r344", "r345", "r346", "r347", "r348", "r353", "r360", "r361", "r363", "r533"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r18", "r74", "r75", "r132", "r133", "r198", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r783", "r784", "r785", "r786", "r787", "r810", "r949", "r1008", "r1009", "r1010", "r1053", "r1054"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r18", "r133", "r364"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r338", "r533", "r534", "r784", "r785", "r810"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r77", "r367", "r533", "r534", "r810"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate, stated percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r77", "r339"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r198", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r783", "r784", "r785", "r786", "r787", "r810", "r949", "r1053", "r1054"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r18", "r198", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r783", "r784", "r785", "r786", "r787", "r810", "r949", "r1008", "r1009", "r1010", "r1053", "r1054"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r18", "r38", "r41", "r72", "r117", "r118", "r198", "r338", "r339", "r340", "r341", "r342", "r344", "r349", "r350", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r362", "r783", "r784", "r785", "r786", "r787", "r810", "r949", "r1053", "r1054"] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Unamortized bond discounts, premiums and issuance costs, net", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r349", "r365", "r532", "r533", "r534", "r784", "r785", "r810"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information

about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.amgen.com/role/InvestmentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-For-Sale Investments", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r435", "r436", "r613"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r109"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation, amortization and other", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r9", "r226", "r233", "r238", "r777", "r778"] }, "amgn_DerivativeAssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "DerivativeAssetsFairValueDisclosureAbstract", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Derivatives:", "label": "Derivative Assets Fair Value Disclosure [Abstract]", "documentation": "Derivative assets." } } }, "auth_ref": [] }, "us-gaap_DerivativeBasisSpreadOnVariableRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeBasisSpreadOnVariableRate", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative, basis spread on variable rate", "label": "Derivative, Basis Spread on Variable Rate", "documentation": "The percentage points added to the reference rate to compute the variable rate on the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r675", "r677", "r690", "r691", "r692", "r694", "r695", "r696", "r697", "r699", "r700", "r701", "r702", "r712", "r713", "r714", "r715", "r718", "r719", "r720", "r721", "r738", "r739", "r740", "r741", "r827", "r829", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1046", "r1047"] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": ["r16", "r90", "r126", "r127", "r174", "r772"] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": ["r16", "r90", "r126", "r127", "r174", "r772"] }, "amgn_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Derivatives:", "label": "Derivative Financial Instruments Liabilities Fair Value Disclosure [Abstract]", "documentation": "Derivative financial instruments liabilities fair value disclosure." } } }, "auth_ref": [] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFixedInterestRate", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Interest rates", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails",

"http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r60", "r63", "r65", "r128", "r675", "r677", "r690", "r691", "r692", "r694", "r695", "r696", "r697", "r699", "r700", "r701", "r702", "r712", "r713", "r714", "r715", "r718", "r719", "r720", "r721", "r738", "r739", "r740", "r741", "r772", "r827", "r829", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1046", "r1047"] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Derivativeinstruments"], "lang": { "en-us": { "role": { "verboseLabel": "Derivative instruments", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": ["r125", "r482", "r490"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": ["r15", "r60", "r63"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r15", "r60", "r63", "r65", "r68", "r69", "r478"] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r478"] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r490"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notional amounts", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1029", "r1030"] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": ["r15", "r53", "r54", "r55", "r57", "r61", "r63", "r66", "r67", "r69", "r490"] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivatives Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "verboseLabel": "Derivatives designated as hedging instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r15"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Developed-product-technology rights", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r121", "r997", "r998", "r999", "r1000", "r1002", "r1003", "r1005", "r1006"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [

"http://www.amgen.com/role/RevenuesTables"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue by Product and by Geographic Area", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1018"] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends declared on common stock", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": ["r119"] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableAmountPerShare", "presentation": ["http://www.amgen.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable per share (in usd per share)", "label": "Dividends Payable, Amount Per Share", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": ["r27"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r842"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r874"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Domestic Tax Authority", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r438"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r885"] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "EUR", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Euro Member Countries, Euro", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "amgn_EVENITYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "EVENITYMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "EVENITY", "label": "EVENITY [Member]", "documentation": "EVENITY" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per share:", "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in usd per share)", "terseLabel": "Basic EPS (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r187", "r204", "r205", "r206", "r207", "r208", "r209", "r214", "r216", "r219", "r220", "r221", "r225", "r459", "r470", "r493", "r494", "r609", "r628", "r775"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in usd per share)", "terseLabel": "Diluted EPS (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r187", "r204", "r205", "r206", "r207", "r208", "r209", "r216", "r219", "r220", "r221", "r225", "r459", "r470", "r493", "r494", "r609", "r628", "r775"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.amgen.com/role/Earningspershare"], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r213", "r222", "r223", "r224"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate",

"label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r438", "r798"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "amgn_EnbrelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "EnbrelMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "ENBREL", "label": "ENBREL [Member]", "documentation": "ENBREL." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r840"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r840"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r840"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r924"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r840"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r840"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [

"http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r840"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r840"] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r879"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r920"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r920"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r920"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r14", "r155", "r183", "r184", "r185", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r227", "r284", "r285", "r313", "r385", "r448", "r449", "r456", "r457", "r458", "r460", "r469", "r470", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r525", "r526", "r527", "r528", "r529", "r530", "r535", "r536", "r538", "r624", "r641", "r642", "r643", "r657", "r724"] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": ["r280", "r281", "r282", "r455", "r926", "r927", "r928", "r1025", "r1026", "r1027", "r1028"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r280"] }, "us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails"], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage", "documentation": "Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee." } } }, "auth_ref": ["r931"] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails", "http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity securities", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": ["r520"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails", "http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gains", "verboseLabel": "Unrealized gains (losses) on equity securities", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r629", "r982"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity securities without readily determinable fair value", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r278"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {

"en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r889"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r847", "r857", "r867", "r899"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r844", "r854", "r864", "r896"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r895"] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment of debt", "label": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r496", "r497", "r510", "r800"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r496", "r497", "r510", "r800"] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": ["http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r70", "r71"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r351", "r398", "r399", "r400", "r401", "r402", "r403", "r495", "r497", "r498", "r499", "r500", "r509", "r510", "r512", "r543", "r544", "r545", "r784", "r785", "r791", "r792", "r793", "r800", "r803"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r501", "r502", "r503", "r504", "r505", "r506", "r511"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.amgen.com/role/Fairvaluemeasurement"], "lang": { "en-us": { "role": { "verboseLabel": "Fair value measurement", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r505", "r507", "r508", "r509", "r512", "r513", "r514", "r515", "r516", "r605", "r800", "r804"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Quoted\u00a0prices in active\u00a0markets\u00a0for identical assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or

liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r351", "r398", "r403", "r497", "r510", "r543", "r791", "r792", "r793", "r800"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Significant other\u00a0observable inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r351", "r398", "r403", "r497", "r498", "r510", "r544", "r784", "r785", "r791", "r792", "r793", "r800"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Significant unobservable inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r351", "r398", "r399", "r400", "r401", "r402", "r403", "r497", "r498", "r499", "r500", "r510", "r545", "r784", "r785", "r791", "r792", "r793", "r800", "r803"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r501", "r502", "r503", "r504", "r505", "r506", "r511"] }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "presentation": ["http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measured at Net Asset Value Per Share", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "documentation": "Fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r398", "r495", "r512", "r800"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r351", "r398", "r399", "r400", "r401", "r402", "r403", "r495", "r497", "r498", "r499", "r500", "r509", "r510", "r512", "r543", "r544", "r545", "r784", "r785", "r791", "r792", "r793", "r800", "r803"] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives Balance Sheet Location By Derivative Contract Type By Hedging Designation [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": ["r59", "r61", "r68"] }, "amgn_FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FairValuesOfAvailableForSaleInvestmentsByClassificationInConsolidatedBalanceSheetsTableTextBlock", "presentation": ["http://www.amgen.com/role/InvestmentsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Fair Values by Classification", "label": "Fair Values of Available for Sale Investments By Classification In Consolidated Balance Sheets [Table Text Block]", "documentation": "Tabular disclosure of fair values of available-for-sale investments by classification in the consolidated balance sheets." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails", "http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r294", "r362", "r382", "r490", "r517", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r625", "r780", "r800", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r812", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r978", "r979", "r980", "r981", "r1033", "r1036", "r1037", "r1038", "r1045", "r1048"] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r162", "r296", "r306", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r308", "r763", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total estimated amortization of finite-lived intangible assets for the remainder of the year", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization

for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r1104"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r308", "r763", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r308", "r763", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r308", "r763", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total estimated amortization of finite-lived intangible assets for 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r308", "r763", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r299", "r301", "r302", "r303", "r305", "r306", "r310", "r311", "r573", "r574", "r763"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Gross carrying amounts", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r296", "r306", "r574", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r299", "r306", "r310", "r311", "r312", "r573", "r763", "r782"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r299", "r301", "r302", "r303", "r305", "r306", "r310", "r311", "r763"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Other intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r573", "r1003"] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Finite-lived intangible assets:", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "amgn_FivePointFiveZeroPercentPoundSterlingNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FivePointFiveZeroPercentPoundSterlingNotesDue2026Member", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.50% \u00a3475 million notes due 2026 (5.50% 2026 pound sterling Notes)", "verboseLabel": "5.50% 2026 pound sterling Notes", "label": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]", "documentation": "Five Point Five Zero Percent Pound Sterling Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "amgn_FivePointOneFivePercentNotesDue2041Member": { "xbrltype": "domainItemType", "nsuri":

"http://www.amgen.com/20240930", "localname": "FivePointOneFivePercentNotesDue2041Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.15% notes due 2041 (5.15% 2041 Notes)", "label": "Five Point One Five Percent Notes Due 2041 [Member]", "documentation": "Five Point One Five Percent Notes Due 2041 [Member]" } } }, "auth_ref": [] }, "amgn_FivePointSevenFivePercentNotesDue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FivePointSevenFivePercentNotesDue2040Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.75% notes due 2040 (5.75% 2040 Notes)", "label": "Five Point Seven Five Percent Notes Due 2040 [Member]", "documentation": "Five Point Seven Five Percent Notes Due 2040 [Member]" } } }, "auth_ref": [] }, "amgn_FivePointSixFivePercentNotesDue2042Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FivePointSixFivePercentNotesDue2042Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.65% notes due 2042 (5.65% 2042 Notes)", "label": "Five Point Six Five Percent Notes Due 2042 [Member]", "documentation": "Five Point Six Five Percent Notes Due 2042 [Member]" } } }, "auth_ref": [] }, "amgn_FivePointThreeSevenFivePercentNotesDue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FivePointThreeSevenFivePercentNotesDue2043Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "5.375% notes due 2043 (5.375% 2043 Notes)", "label": "Five Point Three Seven Five Percent Notes Due 2043 [Member]", "documentation": "Five Point Three Seven Five Percent Notes Due 2043 [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Derivative assets", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": ["r496", "r497"] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Derivative liabilities", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": ["r496", "r497"] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency contract gains", "verboseLabel": "Foreign currency forward contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": ["r772", "r791", "r799", "r800"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r851", "r861", "r871", "r903"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r851", "r861", "r871", "r903"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r851", "r861", "r871", "r903"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r851", "r861", "r871", "r903"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r851", "r861", "r871", "r903"] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForwardContractsMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency forward contracts", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": ["r1031"] }, "amgn_ForwardInterestRateContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ForwardInterestRateContractsMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forward interest rate contracts", "label": "Forward Interest Rate Contracts [Member]", "documentation": "Forward Interest Rate Contracts" } } }, "auth_ref": [] }, "amgn_FourPercentPoundSterlingNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FourPercentPoundSterlingNotesDue2029Member", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.00% \u00a3700 million notes due 2029 (4.00% 2029 pound sterling Notes)", "verboseLabel": "4.00% 2029 pound sterling Notes", "label": "Four Percent Pound Sterling Notes Due 2029 [Member]", "documentation": "Four Percent Pound Sterling Notes Due 2029 [Member]" } } }, "auth_ref": [] }, "amgn_FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember":

{ "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.563% notes due 2048 (4.563% 2048 Notes)", "label": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]", "documentation": "Four Point Five Six Three Percent Notes Due Two Zero Four Eight [Member]" } } }, "auth_ref": [] }, "amgn_FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FourPointFourZeroPercentNotesDueTwoZeroFourFiveMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.40% notes due 2045 (4.40% 2045 Notes)", "label": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]", "documentation": "Four Point Four Zero Percent Notes Due Two Zero Four Five [Member]" } } }, "auth_ref": [] }, "amgn_FourPointNineFivePercentNotesDue2041Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FourPointNineFivePercentNotesDue2041Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.95% notes due 2041 (4.95% 2041 Notes)", "label": "Four Point Nine Five Percent Notes Due 2041 [Member]", "documentation": "Four Point Nine Five Percent Notes Due 2041 [Member]" } } }, "auth_ref": [] }, "amgn_FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "4.663% notes due 2051 (4.663% 2051 Notes)", "label": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]", "documentation": "Four Point Six Six Three Percent Notes Due Two Zero Five One [Member]" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r884"] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "GBP", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails"], "lang": { "en-us": { "role": { "terseLabel": "United Kingdom, Pounds", "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://www.amgen.com/role/FinancingarrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r9", "r34", "r35"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails": { "parentTag": "amgn_BusinessAcquiredAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Balance at January 1, 2024", "periodEndLabel": "Balance at September 30, 2024", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r161", "r297", "r606", "r778", "r781", "r801", "r811", "r986", "r993"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Goodwillandotherintangibleassets"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and other intangible assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r984", "r996"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r298"] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill increase", "label": "Goodwill, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r985"] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to goodwill resulting from acquisition", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r0", "r992"] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "amgn_HedgedLiabilityDiscontinuedFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "HedgedLiabilityDiscontinuedFairValueHedge", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang":

{ "en-us": { "role": { "terseLabel": "Carrying value with discontinued hedging relationships", "label": "Hedged Liability, Discontinued Fair Value Hedge", "documentation": "Hedged Liability, Discontinued Fair Value Hedge" } } }, "auth_ref": [] }, "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging adjustments on discontinued hedging relationships", "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge." } } }, "auth_ref": ["r481"] }, "us-gaap_HedgedLiabilityFairValueHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedge", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang": { "en-us": { "role": { "terseLabel": "Carrying amounts of hedged liabilities", "label": "Hedged Liability, Fair Value Hedge", "documentation": "Amount of liability hedged in fair value hedging relationship." } } }, "auth_ref": ["r479"] }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "crdr": "credit", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Fair value adjustments", "terseLabel": "Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk." } } }, "auth_ref": ["r480"] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r15", "r478"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r15"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": ["r15"] }, "amgn_HorizonTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "HorizonTherapeuticsMember", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Horizon Therapeutics", "label": "Horizon Therapeutics [Member]", "documentation": "Horizon Therapeutics" } } }, "auth_ref": [] }, "amgn_IdentifiableIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "IdentifiableIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Identifiable Intangible Assets Accumulated Amortization", "documentation": "Identifiable intangible assets accumulated amortization." } } }, "auth_ref": [] }, "amgn_IdentifiableIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "IdentifiableIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Identifiable intangible assets", "label": "Identifiable Intangible Assets Gross", "documentation": "Identifiable intangible assets gross." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": ["r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": ["r141", "r630", "r776", "r958", "r960", "r961", "r962", "r963"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Adjustments for equity method investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } },

"auth_ref": ["r9", "r94", "r136", "r226", "r234", "r238", "r279", "r622"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": ["r191", "r438", "r439", "r443", "r447", "r798", "r1024"] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": ["r191", "r438", "r439", "r443", "r447", "r798", "r1024"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Incometaxes"], "lang": { "en-us": { "role": { "verboseLabel": "Income taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r197", "r434", "r438", "r440", "r441", "r442", "r445", "r446", "r450", "r452", "r453", "r454", "r654", "r798"] }, "us-gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationLineItems", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Line Items]", "label": "Income Tax Examination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r443"] }, "us-gaap_IncomeTaxExaminationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationTable", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Table]", "label": "Income Tax, Examination [Table]", "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued." } } }, "auth_ref": ["r1023"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Provision for income taxes", "negatedTerseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r143", "r151", "r211", "r212", "r226", "r235", "r238", "r437", "r438", "r451", "r631", "r798"] }, "amgn_IncreaseAndDecreaseInEquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "IncreaseAndDecreaseInEquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase and decrease in equity securities without readily determinable fair value, amount", "label": "Increase and Decrease in Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Increase and Decrease in Equity Securities without Readily Determinable Fair Value, Amount" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Trade receivables, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued income taxes, net", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r8"] },

"amgn_IncreaseDecreaseInNoncurrentTaxLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "IncreaseDecreaseInNoncurrentTaxLiability", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Long-term tax liabilities", "label": "Increase (Decrease) In Noncurrent Tax Liability", "documentation": "Increase (Decrease) In Noncurrent Tax Liability" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Changes in operating assets and liabilities, net of acquisitions:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r8"] }, "amgn_IncreaseDecreaseInSalesIncentivesAndAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "IncreaseDecreaseInSalesIncentivesAndAllowance", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued sales incentives and allowance", "label": "Increase (Decrease) In Sales Incentives And Allowance", "documentation": "Increase (Decrease) In Sales Incentives And Allowance" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Increase (Decrease) in AOCI [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r299", "r304", "r309", "r782"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": "amgn_IdentifiableIntangibleAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Indefinite-lived intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r296", "r309", "r782"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r299", "r304", "r309", "r782"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r851", "r861", "r871", "r895", "r903", "r907", "r915"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r913"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r843", "r919"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r843", "r919"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r843", "r919"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",

"http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r299", "r1003", "r1004"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets:", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense, net", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r102", "r357", "r368", "r786", "r787"] }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateFairValueHedgeAssetAtFairValue", "crdr": "debit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap contracts", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments." } } }, "auth_ref": ["r128"] }, "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateFairValueHedgeLiabilityAtFairValue", "crdr": "credit", "calculation": { "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap contracts", "label": "Interest Rate Fair Value Hedge Liability at Fair Value", "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments." } } }, "auth_ref": ["r128"] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails", "http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate swap contracts", "terseLabel": "Interest Rate Swap", "netLabel": "Interest rate swap agreements", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": ["r764", "r834", "r835"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.amgen.com/role/Inventories"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r295"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/InventoriesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r112", "r769"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.amgen.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.amgen.com/role/InventoriesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r171", "r768", "r811"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/InventoriesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r112", "r771"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.amgen.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/InventoriesDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r112", "r770"] }, "us-gaap_InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyFinancialSupportToInvesteeContractuallyRequiredAmount", "crdr": "credit", "presentation": ["http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unfunded additional commitments", "label": "Investment Company, Financial Support to Investee Contractually Required, Amount", "documentation": "Amount of financial support committed by investment company to investee that is contractually required." }

```
} ], "auth_ref": [ "r655", "r656" ] }, "us-gaap_InvestmentTypeExtensibleEnumeration": { "xbrltype":
"enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeExtensibleEnumeration",
"presentation": [ "http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Investment, Type [Extensible Enumeration]", "label": "Investment, Type [Extensible Enumeration]",
"documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible
security, fixed income security, government security, option purchased, warrant, loan participation and assignment,
commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other
investment company." } } }, "auth_ref": [ "r670", "r673", "r729", "r731", "r732", "r733", "r734", "r737", "r742", "r743" ] }, "us-
gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and
Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://www.amgen.com/role/Investments" ], "lang": { "en-us": { "role": { "verboseLabel": "Investments", "label": "Investments
in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire
disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r138", "r154", "r244", "r246", "r518",
"r519", "r1063" ] }, "amgn_KRYSTEXXAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930",
"localname": "KRYSTEXXAMember", "presentation": [
"http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "KRYSTEXXA", "label": "KRYSTEXXA [Member]", "documentation": "KRYSTEXXA" } } }, "auth_ref": [] },
"amgn_KyprolisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname":
"KyprolisMember", "presentation": [
"http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "KYPROLIS", "label": "Kyprolis [Member]", "documentation": "Kyprolis [Member]" } } }, "auth_ref": [] },
"us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order":
null, "root": true } }, "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang":
{ "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity",
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling
interests, if any." } } }, "auth_ref": [ "r86", "r135", "r618", "r811", "r950", "r983", "r1049" ] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel":
"LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel":
"Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal
operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } },
"auth_ref": [ "r76", "r158", "r196", "r283", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r472", "r474",
"r475", "r521", "r811", "r1015", "r1055", "r1056" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel":
"Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr":
"credit", "calculation": {
"http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" ],
"lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair
value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r497", "r1034" ] }, "us-
gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [
"http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails" ],
"lang": { "en-us": { "role": { "verboseLabel": "Liabilities:", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } },
"auth_ref": [] }, "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilityForUncertainTaxPositionsNoncurrent", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-
gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Long-term tax liabilities", "label": "Liability for Uncertainty in Income Taxes, Noncurrent", "documentation": "Amount
recognized for uncertainty in income taxes classified as noncurrent." } } }, "auth_ref": [ "r78" ] }, "us-
gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LicensingAgreementsMember", "presentation": [
"http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Licensing rights", "label": "Licensing Agreements [Member]", "documentation": "Rights,
generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or
processes in a specified territory)." } } }, "auth_ref": [ "r49", "r433", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003",
"r1004", "r1005", "r1006", "r1022" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.amgen.com/role/CoverPage" ],
"lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local
phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "totalLabel":
"Total carrying value of debt", "terseLabel": "Carrying value of long-term debt, including current portion", "label": "Long-Term
Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term
debt. Excludes lease obligation." } } }, "auth_ref": [ "r18", "r133", "r350", "r366", "r784", "r785", "r810", "r1065" ] }, "us-
gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"LongTermDebtCurrent", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedLabel": "Less current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r165"] },
"amgn_LongTermDebtCurrentMaturitiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.amgen.com/20240930", "localname": "LongTermDebtCurrentMaturitiesMember", "presentation": [
"http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities [Member]",
"documentation": "Long-Term Debt, Current Maturities [Member]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": [
"http://www.amgen.com/role/DerivativeinstrumentsHedgedLiabilitiesandCumulativeAmountDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtNoncurrent", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 },
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": {
"verboseLabel": "Long-term debt", "terseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r166"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
"http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails",
"http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
"http://www.amgen.com/role/FinancingarrangementsNarrativeDetails",
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r18", "r1008", "r1009", "r1010"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails",
"http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails",
"http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails",
"http://www.amgen.com/role/FinancingarrangementsNarrativeDetails",
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r18", "r33", "r1008", "r1009", "r1010"] }, "us-gaap_MarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MarketableSecuritiesLineItems", "presentation": [
"http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails",
"http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Marketable Securities [Line Items]", "label": "Marketable Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable",
"presentation": ["http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails",
"http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Available-for-sale Securities [Table]", "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MarketingRelatedIntangibleAssetsMember", "presentation": [
"http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketing-related rights", "label": "Marketing-Related Intangible Assets [Member]",
"documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark." } } }, "auth_ref": ["r17", "r997", "r998", "r999", "r1000", "r1002", "r1003", "r1005", "r1006"] }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "presentation": [
"http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Length of time hedged in foreign currency contracts (or less)", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
"documentation": "Maximum period of hedging exposure to variability in future cash flows for forecasted transaction of foreign currency cash flow hedge, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transaction for payment of variable interest on existing financial instrument." } } }, "auth_ref": ["r12"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails",
"http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Maximum", "label": "Maximum [Member]" } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r404", "r432", "r500", "r571", "r639", "r640", "r647", "r676", "r677", "r730", "r732", "r735", "r736", "r742", "r761", "r762", "r779", "r788", "r796", "r803", "r804", "r808", "r809", "r822", "r1017", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062"] }, "ecd_MeasureAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" }
} }, "auth_ref": ["r887"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r887"] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember",

"presentation": ["http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r404", "r432", "r500", "r571", "r639", "r640", "r647", "r676", "r677", "r730", "r732", "r735", "r736", "r742", "r761", "r762", "r779", "r788", "r796", "r803", "r804", "r808", "r822", "r1017", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r906"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Money market mutual funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1020"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r914"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r888"] }, "amgn_NatureOfOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "NatureOfOperationsPolicyTextBlock", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Business", "label": "Nature Of Operations [Policy Text Block]", "documentation": "Describes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as \"predominately\", \"about equally\", or \"major and other\". This element is also referred to as \"Business Description\"." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r190"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r190"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r107", "r108", "r109"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME",

"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "netLabel": "Net income", "verboseLabel": "Net income (loss)", "terseLabel": "Net income for basic and diluted EPS", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r97", "r109", "r137", "r156", "r178", "r181", "r185", "r196", "r202", "r204", "r205", "r206", "r207", "r208", "r211", "r212", "r218", "r283", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r459", "r470", "r494", "r521", "r623", "r706", "r722", "r723", "r837", "r1015"] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAbstract", "presentation": ["http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Income (Numerator):", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "amgn_NeumoraTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "NeumoraTherapeuticsIncMember", "presentation": ["http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Neumora Therapeutics, Inc.", "label": "Neumora Therapeutics, Inc. [Member]", "documentation": "Neumora Therapeutics, Inc." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r887"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r851", "r861", "r871", "r895", "r903"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r878"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r877"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r895"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r914"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r914"] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "ROW", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": ["r1100", "r1101", "r1102", "r1103"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r15"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r101"] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate fair value of long-term debt, including current portion", "label": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": ["r18", "r74", "r75", "r1035", "r1045"] }, "us-gaap_NotesPayableToBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableToBanksMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsNarrativeDetails", "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails", "http://www.amgen.com/role/FairvaluemeasurementNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Notes", "verboseLabel": "Fixed-rate notes", "label": "Notes Payable to Banks [Member]", "documentation": "A written promise to pay a note to a bank." } } }, "auth_ref": [] }, "amgn_NplateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "NplateMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Nplate", "label": "Nplate [Member]", "documentation": "Nplate" } } }, "auth_ref": [] }, "amgn_NumberOfNoticesConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "NumberOfNoticesConsolidated", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of notices consolidated", "label": "Number Of Notices Consolidated",

"documentation": "Number Of Notices Consolidated" } } }, "auth_ref": [] },
"amgn_NumberOfNoticesOnProposedAdditionalTax": { "xbrltype": "integerItemType", "nsuri":
"http://www.amgen.com/20240930", "localname": "NumberOfNoticesOnProposedAdditionalTax", "presentation": [
"http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of notices on proposed additional tax", "label": "Number of notices on proposed additional tax", "documentation": "Number of notices on proposed additional tax" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [
"http://www.amgen.com/role/RevenuesNarrativeDetails",
"http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r778", "r959"] },
"amgn_OnePointSixFivePercent2028NotesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.amgen.com/20240930", "localname": "OnePointSixFivePercent2028NotesMember", "presentation": [
"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "1.65% notes due 2028 (1.65% 2028 Notes)", "label": "One point six five percent 2028 Notes [Member]", "documentation": "One point six five percent 2028 Notes" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
"weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": {
"totalLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r141", "r776", "r958", "r960", "r961", "r962", "r963"] }, "amgn_OtezlaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname":
"OtezlaMember", "presentation": [
"http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Otezla", "label": "Otezla [Member]", "documentation": "Otezla [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
], "lang": { "en-us": { "role": { "verboseLabel": "Other current assets", "label": "Other Assets, Current", "documentation":
"Amount of current assets classified as other." } } }, "auth_ref": ["r172", "r811"] }, "us-gaap_OtherAssetsNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr":
"debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel":
"Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r163"] }, "us-
gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": {
"role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r7", "r13", "r124"] }, "us-
gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax", "crdr":
"credit", "presentation": [
"http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax", "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": ["r5", "r93", "r522", "r523", "r524"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation":
{ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": {
"role": { "terseLabel": "Cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r176"] }, "us-
gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax", "crdr": "credit", "presentation": [
"http://www.amgen.com/role/DerivativeinstrumentsSummaryofUnrealizedGainsandLossesRecognizedinAOCIDetails"], "lang": {
"en-us": { "role": { "verboseLabel": "Total unrealized (losses) gains", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." }

```
} ], "auth_ref": [ "r175", "r176", "r624" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r175", "r176", "r476", "r477", "r483" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive (loss) income, net of reclassification adjustments and taxes", "terseLabel": "Other comprehensive income (loss), net of taxes", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r13", "r124", "r179", "r182", "r208" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive (loss) income, net of reclassification adjustments and taxes:", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "amgn_OtherComprehensiveIncomeLossOtherAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherComprehensiveIncomeLossOtherAdjustmentBeforeTax", "crdr": "credit", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Comprehensive Income (Loss), Other Adjustment, Before Tax", "documentation": "Other Comprehensive Income (Loss), Other Adjustment, Before Tax" } } }, "auth_ref": [] }, "amgn_OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherComprehensiveIncomeLossOtherGainsLossesNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent", "documentation": "Other Comprehensive Income (Loss), Other Gains (Losses), Net of Tax, Portion Attributable to Parent" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "presentation": [ "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income taxes", "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r13", "r124" ] }, "amgn_OtherCurrentNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherCurrentNoncurrentAssetsMember", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets/ Other noncurrent assets", "label": "Other Current Noncurrent Assets [Member]", "documentation": "Other current assets/other non-current assets." } } }, "auth_ref": [] }, "amgn_OtherGeneralExpenseIncomeOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherGeneralExpenseIncomeOtherAdjustments", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other General Expense (Income), Other Adjustments", "documentation": "Other General Expense (Income), Other Adjustments" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r78" ] }, "us-gaap_OtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebt", "crdr": "credit", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Long-Term Debt", "documentation": "Amount of long-term debt classified as other." } } }, "auth_ref": [ "r18", "r133", "r1065" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other items, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r109" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "amgn_OtherNotesDue2097Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherNotesDue2097Member", "presentation": [
```

"http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other notes due 2097", "label": "Other Notes Due 2097 [Member]", "documentation": "Other Notes Due 2097 [Member]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r887"] }, "amgn_OtherProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherProductsMember", "presentation": [
"http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other products", "label": "Other Products [Member]", "documentation": "Other Products [Member]" } } }, "auth_ref": [] }, "amgn_OtherShortTermInterestBearingSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "OtherShortTermInterestBearingSecuritiesMember", "presentation": [
"http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other short-term interest-bearing securities", "label": "Other Short Term Interest Bearing Securities [Member]", "documentation": "Other short-term interest bearing securities." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r849", "r859", "r869", "r901"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r852", "r862", "r872", "r904"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r852", "r862", "r872", "r904"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r876"] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": ["r929", "r945"] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "calculation": {
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Extinguishment of debt", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": ["r6"] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": ["r105"] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [
"http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash purchase price", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": ["r24", "r465"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r104"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r886"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r886"] }, "amgn_PenaltiesOnProposedAdditionalIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "PenaltiesOnProposedAdditionalIncomeTax", "crdr": "credit", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Penalties on proposed additional income tax", "label": "Penalties On Proposed Additional Income Tax", "documentation": "Penalties On Proposed Additional Income Tax" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r878"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r895"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r888"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r877"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r879"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r923"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r878"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance of debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r25", "r649"] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from maturities of marketable securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r188", "r189", "r966"] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": ["r930", "r946"] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from sales of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r23", "r188", "r245", "r277"] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductAndServiceOtherMember", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other revenues", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": ["r1019"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product sales", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r789"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r239", "r572", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r765", "r789", "r821", "r822", "r823", "r825", "r826", "r1013", "r1014", "r1018", "r1066", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1092", "r1093", "r1094", "r1095", "r1096"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r239", "r572", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r765", "r789", "r821", "r822", "r823", "r825", "r826", "r1013", "r1014", "r1018", "r1066", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096"] }, "amgn_ProliaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ProliaMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prolia", "label": "Prolia [Member]", "documentation": "Prolia." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net",

"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r537", "r610", "r621", "r811"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r10", "r147", "r150", "r619"] }, "amgn_ProposedAdditionalIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ProposedAdditionalIncomeTax", "crdr": "credit", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Proposed additional income tax", "label": "Proposed Additional Income Tax", "documentation": "Proposed Additional Income Tax" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r876"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r876"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r397", "r404", "r428", "r429", "r430", "r432", "r500", "r546", "r555", "r571", "r639", "r640", "r647", "r676", "r677", "r730", "r732", "r735", "r736", "r742", "r761", "r762", "r779", "r788", "r796", "r803", "r804", "r808", "r809", "r822", "r829", "r1011", "r1017", "r1037", "r1058", "r1059", "r1060", "r1061", "r1062"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r322", "r323", "r324", "r325", "r397", "r404", "r428", "r429", "r430", "r432", "r500", "r546", "r555", "r571", "r639", "r640", "r647", "r676", "r677", "r730", "r732", "r735", "r736", "r742", "r761", "r762", "r779", "r788", "r796", "r803", "r804", "r808", "r809", "r822", "r829", "r1011", "r1017", "r1037", "r1058", "r1059", "r1060", "r1061", "r1062"] }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "presentation": ["http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r185"] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr": "debit", "presentation": ["http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustments into earnings", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r21"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r185"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r185"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r185"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "presentation": ["http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r185"] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": ["http://www.amgen.com/role/StockholdersequityTables"], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications Out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": {

{"en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r844", "r854", "r864", "r896"] }, "amgn_RepathaevolocumabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "RepathaevolocumabMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Repatha", "label": "Repatha (evolocumab) [Member]", "documentation": "Repatha (evolocumab) [Member]" } } }, "auth_ref": [] }, "amgn_RepatriationTaxOnProposedAdditionalTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "RepatriationTaxOnProposedAdditionalTax", "crdr": "credit", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Repatriation tax on proposed additional tax", "label": "Repatriation Tax On Proposed Additional Tax", "documentation": "Repatriation Tax On Proposed Additional Tax" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of debt", "verboseLabel": "Repayments of debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r106", "r652"] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r1021"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r845", "r855", "r865", "r897"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r846", "r856", "r866", "r898"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r853", "r863", "r873", "r905"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r83", "r119", "r617", "r644", "r646", "r653", "r686", "r811"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r155", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r284", "r285", "r313", "r448", "r449", "r456", "r457", "r458", "r460", "r469", "r470", "r484", "r486", "r487", "r489", "r492", "r535", "r536", "r641", "r643", "r657", "r1098"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "verboseLabel": "Product sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r139", "r140", "r226", "r231", "r232", "r236", "r238", "r239", "r240", "r242", "r394", "r395", "r572"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.amgen.com/role/Revenues"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r152", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r396"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "verboseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r914"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":

"Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r914"] }, "amgn_SaleOfEquitySecuritiesFVNIUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "SaleOfEquitySecuritiesFVNIUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of unrealized gains (losses) on equity securities", "label": "Sale of Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Sale of Equity Securities, FV-NI, Unrealized Gain (Loss)" } } }, "auth_ref": [] }, "amgn_SaleOfSecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "SaleOfSecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.amgen.com/role/InvestmentsOtherEquitySecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of securities without readily determinable fair value", "label": "Sale of Securities without Readily Determinable Fair Value, Amount", "documentation": "Sale of Securities without Readily Determinable Fair Value, Amount" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.amgen.com/role/StockholdersequityTables"], "lang": { "en-us": { "role": { "terseLabel": "Components of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r21", "r1050", "r1051"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementTables"], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Obligations", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.amgen.com/role/AcquisitionsAcquisitionofHorizonTherapeuticsplcDetails", "http://www.amgen.com/role/AcquisitionsScheduleofBusinessAcquisitionsbyAcquisitionDetails", "http://www.amgen.com/role/AcquisitionsSupplementalProFormaFinancialInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": ["r45", "r46", "r463"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": ["http://www.amgen.com/role/AcquisitionsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": ["r45", "r46"] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Unrealized Gains and Losses Recognized in AOCI", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": ["r129"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.amgen.com/role/FinancingarrangementsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Borrowings", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r18", "r38", "r41", "r72", "r117", "r118", "r784", "r786", "r951", "r1053"] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value of Derivatives", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": ["r61"] }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Income and Expense Line Items", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": ["r58"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.amgen.com/role/EarningspershareTables"], "lang": { "en-us": { "role": { "verboseLabel": "Computation for Basic

and Diluted EPS", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r957"] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Segment Reporting, Revenue from External Customer, Product and Service [Table]", "documentation": "Disclosure of information about revenue from external customer by product and service when not provided as part of reportable operating segment information." } } }, "auth_ref": ["r31"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.amgen.com/role/InvestmentsBeiGeneLtdDetails", "http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r280", "r281", "r282", "r455", "r926", "r927", "r928", "r1025", "r1026", "r1027", "r1028"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": ["http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r196", "r280", "r281", "r282", "r283", "r521"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": ["http://www.amgen.com/role/InvestmentsNeumoraTherapeuticsIncDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": ["r156", "r196", "r280", "r281", "r282", "r283", "r521"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementTables"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Assets and Liabilities on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1034", "r1035"] }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Hedged Liabilities and Cumulative Amount", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": ["r64"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsScheduleofIdentifiableIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": ["r299", "r306", "r310", "r311", "r312", "r573", "r763", "r782"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r781", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995"] }, "amgn_ScheduleOfIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ScheduleOfIntangibleAssetsTableTextBlock", "presentation": ["http://www.amgen.com/role/GoodwillandotherintangibleassetsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Identifiable Intangible Assets", "label": "Schedule Of Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of finite-lived and indefinite-lived identifiable intangible assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": ["http://www.amgen.com/role/InventoriesTables"], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r19", "r87", "r88", "r89"] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "presentation": ["http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Income [Line Items]", "label": "Net Investment Income [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r625"] }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "presentation": ["http://www.amgen.com/role/InvestmentsLimitedPartnershipDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investment Income [Table]", "label": "Investment Income [Table]", "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments." } } }, "auth_ref": ["r99", "r100", "r102", "r625"] }, "amgn_ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.amgen.com/20240930", "localname":

"ScheduleOfNotionalAmountsAndInterestRatesForCrossCurrencySwapsTableTextBlock", "presentation": ["http://www.amgen.com/role/DerivativeinstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cross-Currency Swaps", "label": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps [Table Text Block]", "documentation": "Schedule of Notional Amounts and Interest Rates for Cross-Currency Swaps" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.amgen.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r36", "r37", "r38", "r39", "r40", "r41", "r115", "r117", "r118", "r119", "r167", "r168", "r169", "r228", "r370", "r371", "r372", "r374", "r377", "r382", "r384", "r649", "r650", "r651", "r652", "r788", "r925", "r948"] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r839"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r841"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r240", "r241", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r671", "r672", "r674", "r731", "r733", "r737", "r743", "r750", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r766", "r790", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r824", "r829", "r1018", "r1066", "r1069", "r1070", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME"], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r98"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r8"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Summary of significant accounting policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r110", "r193"] }, "amgn_SixPointFourZeroPercentNotesDue2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "SixPointFourZeroPercentNotesDue2039Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "6.40% notes due 2039 (6.40% 2039 Notes)", "label": "Six Point Four Zero Percent Notes Due 2039 [Member]", "documentation": "Six Point Four Zero Percent Notes Due 2039 [Member]" } } }, "auth_ref": [] }, "amgn_SixPointNineZeroPercentNotesDue2038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "SixPointNineZeroPercentNotesDue2038Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "6.90% notes due 2038 (6.90% 2038 Notes)", "label": "Six Point Nine Zero Percent Notes Due 2038 [Member]", "documentation": "Six Point Nine Zero Percent Notes Due 2038 [Member]" } } }, "auth_ref": [] }, "amgn_SixPointThreeSevenFivePercentNotesDue2037Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "SixPointThreeSevenFivePercentNotesDue2037Member", "presentation": ["http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails"], "lang": { "en-us": { "role": { "terseLabel": "6.375% notes due 2037 (6.375% 2037 Notes)", "label": "Six Point Three Seven Five Percent Notes Due 2037 [Member]", "documentation": "Six Point Three Seven Five Percent Notes Due 2037 [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.amgen.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r153", "r167", "r168", "r169", "r196", "r216", "r217", "r219", "r221", "r228", "r229", "r283", "r328", "r330", "r331", "r332", "r335", "r336", "r370", "r371", "r374", "r377", "r384", "r521", "r649", "r650", "r651", "r652", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r669", "r685", "r707", "r724", "r744", "r745", "r746", "r747", "r748", "r925", "r948", "r956"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [

"http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/DerivativeinstrumentsSummaryofIncomeandExpenseLineItemsDetails", "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.amgen.com/role/StockholdersequityReclassificationsOutofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r81", "r84", "r85", "r155", "r183", "r184", "r185", "r199", "r200", "r201", "r203", "r208", "r210", "r212", "r227", "r284", "r285", "r313", "r385", "r448", "r449", "r456", "r457", "r458", "r460", "r469", "r470", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r525", "r526", "r527", "r528", "r529", "r530", "r535", "r536", "r538", "r624", "r641", "r642", "r643", "r657", "r724"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": ["r240", "r241", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r671", "r672", "r674", "r731", "r733", "r737", "r743", "r750", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r766", "r790", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r824", "r829", "r1018", "r1066", "r1069", "r1070", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r199", "r200", "r201", "r227", "r536", "r572", "r648", "r669", "r678", "r679", "r680", "r681", "r682", "r683", "r685", "r688", "r689", "r690", "r691", "r692", "r694", "r695", "r696", "r697", "r699", "r700", "r701", "r702", "r703", "r705", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r724", "r830"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r199", "r200", "r201", "r227", "r243", "r536", "r572", "r648", "r669", "r678", "r679", "r680", "r681", "r682", "r683", "r685", "r688", "r689", "r690", "r691", "r692", "r694", "r695", "r696", "r697", "r699", "r700", "r701", "r702", "r703", "r705", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r724", "r830"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r848", "r858", "r868", "r900"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock in connection with equity award programs (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r14", "r80", "r81", "r119"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in connection with equity award programs", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r42", "r80", "r81", "r119"] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": ["http://www.amgen.com/role/StockholdersequityNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Amount available for stock repurchases under a board approved stock repurchase plan", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.amgen.com/role/StockholdersequityComponentsofAccumulatedOtherComprehensiveIncomeDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r81",

```
"r84", "r85", "r111", "r687", "r704", "r725", "r726", "r811", "r838", "r950", "r983", "r1049", "r1098" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.amgen.com/role/Stockholdersequity" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r116", "r195", "r369", "r371", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r385", "r491", "r727", "r728", "r749" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.amgen.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r531", "r539" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.amgen.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r531", "r539" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.amgen.com/role/StockholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r531", "r539" ] }, "amgn_TEPEZZAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TEPEZZAMember", "presentation": [ "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TEPEZZA", "label": "TEPEZZA [Member]", "documentation": "TEPEZZA" } } }, "auth_ref": [] }, "amgn_TEZSPIREMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TEZSPIREMember", "presentation": [ "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TEZSPIRE", "label": "TEZSPIRE [Member]", "documentation": "TEZSPIRE" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r894" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Period [Axis]", "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Period [Domain]", "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r1023" ] }, "amgn_TaxYears20102012Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TaxYears20102012Member", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Years 2010-2012", "label": "Tax Years 2010-2012 [Member]", "documentation": "Tax Years 2010-2012" } } }, "auth_ref": [] }, "amgn_TaxYears20132015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TaxYears20132015Member", "presentation": [ "http://www.amgen.com/role/IncometaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2013-2015", "label": "Tax Years 2013-2015 [Member]", "documentation": "Tax Years 2013-2015" } } }, "auth_ref": [] }, "amgn_TermLoanDueApril2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TermLoanDueApril2025Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan due April 2025", "label": "Term Loan Due April 2025 [Member]", "documentation": "Term Loan Due April 2025" } } }, "auth_ref": [] }, "amgn_TermLoanDueOctober2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TermLoanDueOctober2026Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan due October 2026", "label": "Term Loan Due October 2026 [Member]", "documentation": "Term Loan Due October 2026" } } }, "auth_ref": [] }, "amgn_ThreePointOneFivePercentNotesDue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ThreePointOneFivePercentNotesDue2040Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.15% notes due 2040 (3.15% 2040 Notes)", "label": "Three Point One Five Percent Notes Due 2040 [Member]", "documentation": "Three Point One Five Percent Notes Due 2040 [Member]" } } }, "auth_ref": [] }, "amgn_ThreePointThreeSevenFivePercentNotesDue2050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ThreePointThreeSevenFivePercentNotesDue2050Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.375% notes due 2050 (3.375% 2050 Notes)", "label": "Three Point Three Seven Five Percent Notes Due 2050 [Member]", "documentation": "Three Point Three Seven Five Percent Notes Due 2050 [Member]" } } }, "auth_ref": [] }, "amgn_ThreePointTwoZeroNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "ThreePointTwoZeroNotesDue2027Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.20% notes due 2027 (3.20% 2027 Notes)", "label": "Three Point Two Zero Notes Due 2027 [Member]", "documentation": "Three Point Two Zero Notes Due 2027 [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r886" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r893" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r913" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r915" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.amgen.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails", "http://www.amgen.com/role/InvestmentsScheduleofFairValuesbyClassificationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r362", "r382", "r490", "r517", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r625", "r800", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r812", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r978", "r979", "r980", "r981", "r1033", "r1036", "r1037", "r1038", "r1045", "r1048" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r916" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r917" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r917" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r915" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r915" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r916" ] }, "amgn_TwoPointEightZeroPercent2041NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointEightZeroPercent2041NotesMember", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.80% notes due 2041 (2.80% 2041 Notes)", "label": "Two point eight zero percent 2041 Notes [Member]", "documentation": "Two point eight zero percent 2041 Notes" } } }, "auth_ref": [] }, "amgn_TwoPointFourFivePercentNotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointFourFivePercentNotesDue2030Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.45% notes due 2030 (2.45% 2030 Notes)", "label": "Two Point Four Five Percent Notes Due 2030 [Member]", "documentation": "Two Point Four Five Percent Notes Due 2030 [Member]" } } }, "auth_ref": [] }, "amgn_TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMember", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsNarrativeDetails", "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.77% notes due 2053 (2.77% 2053 Notes)", "label": "Two Point Seven Seven Percent Notes Due Two Zero Five Three [Member]", "documentation": "Two Point Seven Seven Percent Notes Due Two Zero Five Three" } } }, "auth_ref": [] }, "amgn_TwoPointSixZeroNotesDueTwoZeroTwoSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointSixZeroNotesDueTwoZeroTwoSixMember", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.60% notes due 2026 (2.60% 2026 Notes)", "label": "Two Point Six Zero Notes Due Two Zero Two Six [Member]", "documentation": "Two Point Six Zero Notes Due Two Zero Two Six [Member]" } } }, "auth_ref": [] }, "amgn_TwoPointThreeZeroPercentNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointThreeZeroPercentNotesDue2031Member", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.30% notes due 2031 (2.30% 2031 Notes)", "label": "Two Point Three Zero Percent Notes Due 2031 [Member]", "documentation": "Two Point Three Zero Percent Notes Due 2031" } } }, "auth_ref": [] }, "amgn_TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMember", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.20% notes due 2027 (2.20% 2027 Notes)", "label": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]", "documentation": "Two Point Two Zero Percent Notes Due Two Zero Two Seven [Member]" } } }, "auth_ref": [] }, "amgn_TwoPointZeroPercent2032NotesMemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "TwoPointZeroPercent2032NotesMemberMember", "presentation": [ "http://www.amgen.com/role/FinancingarrangementsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2.00% notes due 2032 (2.00% 2032 Notes)", "label": "Two point zero percent 2032 Notes Member [Member]", "documentation": "Two point zero percent 2032 Notes Member" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": [ "http://www.amgen.com/role/DerivativeinstrumentsScheduleofCrossCurrencySwapsDetails" ], "lang": { "en-us": { "role": {
```

"terseLabel": "United States of America, Dollars", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasuryBillSecuritiesMember", "presentation": ["http://www.amgen.com/role/FairvaluemeasurementFairValueofFinancialAssetsandLiabilitiesonRecurringBasisDetails", "http://www.amgen.com/role/InvestmentsScheduleofAvailableForSaleInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": ["r1064"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r912"] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gains on equity securities", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": ["r9"] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": ["http://www.amgen.com/role/IncometaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in unrecognized tax benefits resulting from tax positions taken during the current period", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": ["r444", "r797"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.amgen.com/role/SummaryofsignificantaccountingpoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r28", "r29", "r30", "r145", "r146", "r148", "r149"] }, "amgn_VectibixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "VectibixMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vectibix", "label": "Vectibix [Member]", "documentation": "Vectibix" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r882"] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": ["r957"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average shares for diluted EPS (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r215", "r221"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares used in calculation of earnings per share:", "terseLabel": "Shares (Denominator):", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.amgen.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.amgen.com/role/EarningspershareComputationforBasicandDilutedEPSDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted-average shares for basic EPS (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r214", "r221"] }, "amgn_XgevaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.amgen.com/20240930", "localname": "XgevaMember", "presentation": ["http://www.amgen.com/role/RevenuesDisaggregationofRevenuebyProductandbyGeographicAreaDetails"], "lang": { "en-us": { "role": { "terseLabel": "XGEVA", "label": "XGEVA [Member]", "documentation": "XGEVA." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r880"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" },

"r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"

}, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" },

"r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r109": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "25", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",

"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification",

"Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",

"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",

"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r658": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting

Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" },

"r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",

"Subparagraph": "1", "Sentence": "iii" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":

"408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r925": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r926": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r927": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r928": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1071": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 84 0000318154-24-000044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000318154-24-000044-xbrl.zip M4$L#!!0 (&>57EEY;2,-A?D! 'RL(P 1 86UG;BTR,#(T,#DS,"YH M=&WLO6MWXCC6-
OS]_A5^F;EG]M8"XB.'5#7/H@BIXNX$,H'JZ>HOLX0M@]>, M3=LFA_[UKV2;A&/ (+ D:U9/*@$?).UK'W1I:^OS_WN>.-(C] /;?
_:_S/Y_^O5/K]R_V-=.69LPET0ZGE0Q!"2W]R MP[$4C]'T;__:3\"Z>7S;_U+^4Z '*M M7BW5H5$IZ99NE89UPRJ-;J8R5*N&5:VHQ8?
+D06&0!N!DE;7ZB7=)42J(!A M24:WZ<.*#JKU2M&ZK &]KHT471O5@:X.*\#2H#$$%6C6E:$FP^B]XQ#U&?7; M#2[!Y,']I3
.P^GEQ<73TU,9?0#=LNE-+G!SY;HF%^)+EZYZTLJ>_W"AU.OU MBV?!\N.2B2PO:KQ<^#WVG'$"S_.]7J OHB?.+W1L]^?2(Z.K\4-
56=8N\-=# M$,#YY?9SN/EJVT670BR;B] ';H""'H1(F/AMW?$5\QOF 6E!P"FZR.8?+$T)-"T-@\@ M^F)E[,(2^FZI&?-
KWY.M8I3D6DE37KL?V)N&%'5$N?C]]J9OCN$$E%8'P?1F M;NAODW7\Y5MS+QV K${!NJ7O_4+C\Q@"J_%Y D,@X=M+\,^9_?
A+H>6Y(;(0 MI<'+%+W'C/_ZI1#"Y_ B4I6+QO_\S_]\#NW0@0VL?Z6YIGV^B#_\?!$_>NA9 M+XW/EOTH!>&+ W\I6'8P=
<#+I>NY$#7 ?K[$%T(__M6V+.A&OZ+ON\A,^;89 MO_\YO(>C7PIF"0V7"R;X2="^;+OH=2\MU#H?.!W7@L^_PI>"9"/)C4IJK="0
MT?\TI:88^N>+I:>F>$D364L+6\QK!SP4I%B$OQ20V"]']C-$=@XX6,V3M]8+ MC>B#PU\XM]#7=F_YP<$_C7Z))B_
=FS!AYO4B^X0Y=[UO(KE$+C7]KA+VA% M-F:A VW7ND+.9GGT+/1):8*>,BY9X%5LFEIH*.J%IJ1[?77^_D27+SON(PQ"
MW$T,X_8SPG!@#QW8=O$#(B6TGRSL";^=%?D;V_G+EV&'4S& /T96'^^02"
M8.;#1OQ7_.7GB^7OYG_C9ZP],X;:L/JPQ"%&DW%ISG'_C:M?OQAU?0J2:VN^FQ^P[-TB,NEEQ_7J\#^(#AN3:*6-:7R9>I
MAC&Y1]W\Q/X!3T2Z@H"^!313]&NZIWFA;<+-K8N_2_4X$X=_&Q^&OTGU*#A; M[^0<5>WO]ZF>]3"
<;GW6UR]W^SPKL6UQ+Y'MGW\.(X<_PL!#/T]LJ$O188$ M;HR16IU?EQWUZLVO+5A^^C3R6_:_ 4%3DA]C'1+ZQ)"OHQ_E],]^]-
M-:N+1> MPH'+\C?SO^_8^/C7D7AM!1NRT1B4 M360IFFI9EOO0M3V_ZX4PN)I!-#(5+H6D4V!'XOE5&/=,D4NJ\?J@Y)M#>F:0
M!C\4/%[>^9XU,\.>WX?^(_)MRQ8A^?;T0*N>'V@5(8[-XM#V%X=&3AQ5(0Z: MS'!-
B&.K=NPK#H+:46=6'$W72K[NA6/H<^E*%%F(AV+7HIQ\;LJ)>+)Q-0IU M?![+B%Z4-
(5(UZB;V*R1@.T_9WA!VYM,/1?]&9R1I#W1F%,W>SE\S#NNZ33T!XM!PT"(ZZE3^:8DX:!$3=6B!+ 2H-_J1N]9 F#5LF"312P1-',^E,
M9W4D9<+Z3/NLLS]"_Z^Q/IW.>E9'4A8TI**>J&MBPIHV&M'WCT8JI/),:9RP M9C$.8L+**(#%A)5R
8D)*^,"%!/6O8.G"]%5;4U,6.F3B9BP9C/PNIBPTB,+ M^B:LQ+HF)JQIHY$,4AMU^G=&4F@,:!_A4NG'.D>3XZPG:L1DPOKD^=P3-
6(#S_H,F8*)&BE9&*Q/FL_E#%1R.;H& MZ_G2M#@#DC(1L_J,!EY,U.F1!0W[04_4-=9GK6=F[=)M0'65]&K0L &5AG%@
M?;J8/7N9D>!8GU.>C[W,2$"LSSWI82^S$6!%3%CW"YXTP=/1')TJV+"2I],Q(0UHX7U9Z9$'?A)58U\2$-6TTDL69)*PG
M_U(Q4.ATBE']7 M'?05?(2.-X76)ICUW.\AY=[^VOVU,CV:.O M'!MP62"F3AT/L4/<N[WH_UJCN5.7:) CF5!'4F3$Y.;401$'4&4-Y.;
MD=RI(YYR+ OJ2*;L36[;'?J0SS*(=>JH)(I,+L]RIXX,RJ\L%)DZYB45V%02?1D:W5_?X"/?%))BLP:EW1.H\NSW*DDE7(J M"RJ)'OY-
;E8>EC4NB3>3FY7;$WN/9R"< S@H^=XYFP"AGQZ M6X4U6NF3"\67E:UE@E M_@QO5I*GDE_*K32H)'TRWF?Q6[O;&?
S@U-.R1BR==:,%UY*GDF+*JS0T*GF? M/!C>C#RMQAJWQ)_AS4KR5)),N94&E<1/MH;WUY MSD5/)14&E;1/ME:W
MZ0,7!E-.W2QKQ-(YS2[?D]>28,JM-*CD?/)@>+/RM*RQ2OP9WHPD;U#)+^56 M&E22/AFOK-W_Z
_:O__Z9X9@S5JZ:Q+:YS+GDJ:*IPZ7-:(IG-:7\Y%3R7EE%MQ5*CD M@7)A>S/RMA76N"8.;6]6HJ>2<\JO.*BD@;*UO;!!,
[2']C.GWI8UHNF6#6F"=>37%&\J]1 MR4/E7"94$D29F>*YQB??\NE^:ZRQ4&>RP_D0/FN$%$*GY61IY*)RIO"9R5\
MP7NM!79WN%;M&4X_5](P\(+PRJG@66.ZN!:&H+BRD;>VO[R)>EG!;>53\'76
M2"VNA2'8K/4#R=RA#QT^O6Q=,%DY%3R5+%9>A<$:O<2+U5F&-D^+.ZF8E>"H9J;P*@TIJ*.M:>G?M
M/_XXPSF1F;A9UCBG\Y;2XUGR5%).N94&E>1/'@QO5IZ6-5:)/\.;D>15*OFE MW$J#2M(GXWT6O[6[G<$//CVMRAJQ=-:-
%EQ+GDJ**;?2H)+WR8/AS']]66**WB2I(IK*@DO;)UNHV?>#"8,JGF]59 M(Y;.:7;YECR5!%-NI4$EYY,'PYN1I]598Y7X,[Q929Y*?
BFWT]"2],EX9>W^ M1W_0_OUW3O?,Z*Q12V==6N-<]E323#F6!Y7L3S[,;U8>ES6.B4?SFY'L#2KI
MIAS+@TH2*%OS^^6FTVW]&/3X=+@&:T33.:TOYZ*GDG+*KSBHY(%R87NS\K:L M<4TW^#9F@/[6=.O2UK1-
,Y;2_GHJ>2<,JM."I4 M=L*:RP3A[8W*]%323?E5QQ44D!9EXO\HW_7N6]SZFU98YG.6R^2 M:]%323?
E5QQ44D"YL+U9>5O66"8.;6]6HJ>2;LJO.*BD@+*UO;UP#/WD>T[+
M)E59HYK.>S@0__*GDGC*N4RH9(3R8XHS\L:5UI@G7DUQ5O*GDH?*N4RH)(@R M,\5SC4^^Y=3]LL9"G2B8J;PJ?
E?"IX[WFP]YQ36\" M!^"Y.0O'GH^:MBR6*_1M$-IF*[8 Y,5CNT@(Z%HTXD@R1DE[%<[\FX-&O$8= MY30?4336=U%/%EE?\/P#
C]0945&_U>/53?NI4L=H;2G=#7T?X-'Z:HE64=R M(2-=ZJ@I.D=<0?_5R8PX=:S0?$2O:1>XI@V<#NJ?/\-W+P_Y[_[AR"8^2]? M;,?
I0W.&Q&+#$U_%"V._,ADX;NRI8V3V'OM;SX4OM\#_">WP<.##KN(Q($OHH=HU^G=FI.Z>"3 M1'Z=NIES1$.B-UHS!_9&
[3]GJ%&W$$VOK+?Q7?\4PBZ8+&V4AO97Z)Z@'ORI MM("Z22Y#@B"J$=3.?;_.MN%0= TT:@'R,-
Z;NIQWO]EP$&V#_;'$(8WG@G> MWC:_(@H"NIZ+O+V/+6,00):\#K73[-R+F:@V4SNS)R'F8Y>_D$)5,UCOKE,[MS:=!*-
K^0B&Y)EFG=OY/@U-RR@RI4TL0T""4C%;OZ]2Q!6<-U?=JS3UP'Y)' MXS]OP:,]F4U.'#80BPXUF3I.0HB8[1
DZEC/FB.R8F./'54:\TC3W VI,G4 M<1N$S%H7SB:>#P9(.& *9Z%M!AW79$?_V&G@A\<_QR Q_ARFZUUXMNH^1,:#7#+HRG
M[="'=SB/#?C,Y(EH"K7D"9.B(3E;5*AC5]@3#0UAJD(=&\.X'#.*5!7JV!OV MY9C%W%^ACL!A7(X9$7$*=1S.0J*W'<(;^Q&BJ0(* !
/LH0/CM9TO+[?@OY[? MH[W\')O/XP96HA3J._C&!0(T0B2.F[E*('(HU*KT4 \LB(JI%U+(' M'=>"HT,L7,>]\ST3!L%F4;&C/=02
DR*AJC64#O'OX+#UU-Y[[$$)_@E\^>)FNU#B,WGD'7O F\H'W!;@_&?)@U'('0M!D M-9I;3F*[H)5R79[+&0T'L0[=$F9I#IKU-
(=>9#/9_ J9 MJ"I32\OD7,A$-9E:CF>KD'&IL!L/N$C&S;EO.^<3=%21#%KX2W:TF%J&*,<" M)JK!U/)+
[TV@E#P8:J)Z3"U7E7LQ$]5F!GDOM2POSI\J?$J9J#(S2'KE0\I$ M=9E!QLLPY"K_4B:IRSJ#C%<^I$Q2EW7V&*_!DW?
GV6[8MY__@+XWES?Z&/^) M_D%?\"EXHNK-'@N67\$3U7BFF;&>&7KH]O,9=Q:Y,9UI;HQ;$1/58O;8L6O[M$4;V&_^"+?
8=]$UTR9TWR6 M8&!#1 JW>Q1:?D5/%&-9X]AFPM^0>9(UNH"'<.GV(GJ.WNT6U[% M3E3;V>/BFIIFK,B9-
PF35.PJ>Z1;#B1,4H>K[+%K31V-@:QI'$N8J ZSQZ/E M0,)$=9AYQDSC4\A$U9AYQHQ3(1/59/88L[[I_$:<1%M\-J]\<+HK@*B*LT>;
MY5SZ1'6?/>YL+OVN[6[A3#G=04!4Z]DCSW(K=Z+ZSAY[-I<[SF_8+'=.\YE(-MZGN-
/4XMMW{GJ>\U]IBVMUV^/1=N#.QT3M,@B"H\>P1:_IL MG\OQ*GFB*L\>69=CR1/5>?88O'DJ1!N?6KJ4#Z$K'*_
$-5W]IB[G$]=J*ZS MQ]A%6Y+FU,UF(\]IFB-1=6>/LLNOX(EJ/'N [DJEX%3]1'6>/D,N[^(EJ/\/,W)8DBZ3.]KRT")\8
M(&H"&";I\HP!HG: 0;[N%0-(PF@N%Z=B:,5!M'S#)Q (&@-=9I# $T @;Q%T MF3U&;^&LC?]_ ^PQ?*^. #F!'7X H:+G/58P?
P(GJN'L\8!Q[1.N)4Q4 MI=EC^7(@8:(ZS!Z'U]1K50.)F.<"1B256&&/G[]8T*@OEBPQ. MEUV)ZC%[Y%H^A$Q4D]ECT.9[G2+J-
/JQG3F)B!4^44!4U=ECT 0*R-L"!ADT M74>SKPK/LR^B>LX@9<:_A(GJ,(,DS3^N\L""">GE@314)];,B:I)+X"V[WQ@J +
MPQ8(QM>.]_0-6@_P#OA,B81:)F6'2&+/_2:/:.,]IA/-,/3MX2S$GC7T&!.* M1BWQ0:W%.B+(T4CY=HU:)H-
^\T:%_*@E.EBPA51(D%I2@EK#NA52:1HZ1VQ%MJ$>.9&PRD108=Y.)116Z05Z0KUJ!DN7.D>< M0M:A7B;R8Y6)H,
(64B%!5HD+6D(]8AFY.D=L1;:A'CF1L,I$4&'>3B44ZNB% MP \O[WS/FIEAS^]#_]$V5])[DF[));Y=H?%Z1';N$;[EW-
W;P<_EEUY[/K0? MW/:S.0;N VRA8?3!:1L1S!7_RPO6=]M]N(>Q00[&]G2Y>8N& 5U(JEEG-E9[MM^L>F@X(
@0Q,QJ0WBSLC595%+?6AV-\+QY6TYNL .G0IW :O%#'4PE3($Q! MODV!MK\IT B: H-:HO1]#8TBM9:/,-
>;^0ADYDQ_"4SG"DILX[G04*&A&3MK M@UK>7&BHT%"J-#0K'\K1(HI (;-^0JP)"11F;PNI6]D2U((B_)M"C+:7VU0 MMT0J3($P!?
DV!=K^IH!H5$#M&KW@,(2&4]6A63EK:E,VA(8*#:5*0[/RH=3E M[P@4YM!/4)N9:# & NA5(-ET"NP"@;MV)35?
+@"H76U@PP6\G1K2'WM^B$O4=]_^S (-MOT#@V^X#BW$!M00W&VZ!3U!0RZFRX2KX! 6U%.38WR3-F:]125U1YXQP @6L.C?-L

M;J) X)H_XS2;FR@ N.;,.,WF)@H :GDRMEP!LP"H"Z.CQQ-HJ 0O)T Q1HH M!(TG0+$&"FI9/?*
JSN8G@6N2[!39W$3EP#7'=MIL;J)RX)KBRD$V-U$P<$US MY2";FR@8N*:\L[F)HH!K;HOG;&ZB*.":6>,YFYLH"JBEU'@?*
>&KJQO/24"# M.KF"PW#P,EVIL-[U0AC<@1!&9Q4LOW?^!;2:07+M6S.9T3B%6BI(2/\,ND\M]X/M M[.\GJ9:EN7(WE[-
*(!J."@L$SU&-.-WY7!29(8IY)P'$[^*PR?>SOL;Q\A, M_KIL?[]G >#4$GL"X)0#_'O_B@6 4\M9;@7X-1+^G6>[(?IE#^A[=] WT25W*
*MWLRU^FBVYR#!"@7@+=2@EE850*4 J,=8ZJ]?]EA0 (H99:$ 3"L (Z$*MLQ&0]!2O0 G,LX9Y-F(0E?UUMP/V0U *MMP-@L71Z/*
)&=<_3XUJ=P%!#&G[8T@CB2&*%]X$AM+;(24+ M.T3QVI; 4'H[M"^&B-HABI>/*(P! C\1#%ZPL" M0XS$0Q2O*
^S$4)*4O;CU)^O=HD,X8T1EG%_$J?Y$Y]C6(^<-O^4:U<48UY1F3'Q?IPGIS(3&H/D=1U MG6+>;INTC3=9J[+&B0#O@+\[QM_9
M+KS7Y,[WK)D9]OP^]!]MK.P-UKH;G2T'1X6 M'X[QO5A:IC=9:=2A3^&3>-:9HKZ$S@F=8Y]NUAGE\^4!T>;SN5%%3)Q/XR2*
*MMT(5N%:%3+P"Q4PV'50C#0;+H)B!IE-*6>B202U[+&8U8E;#9PZ40>UJ@=_Y MH7-\9CX9U*X.B>E3CE4A$_=#*
[9=4(4J[UFF#,3-Z/P>AR1'ZD33+?R&"<<3\Q8W'*#01[-^(+ M<(!KPOX8PO#&,Q>:$07.<6*
*79W^80>7C*ZBG&E*S0(N^;"/C*XL"!QR;A\99=]9WGDJ M#.,B !GEO 4 >;6(U#+/]Z&)SK^C'/*8B:9G6,BR:Q5V&?+\XY#:OP345PR*
MRN^+F21G]I'1E0>!0[!M8Y7QE8@\3RBY,(Q51I<ET;;HVJ@-=':5: I4%C""K0 MK"M#38;_P5;D[9X@?'&0>":V6QJC:=TXO-*
35;"L<7RJR_+^%Y4N! MC\:K-/3"T)MXD_LETLRDM5+:/GH8<$4^ V/@_] M"]2 ^/>X'6NM67@@/BT9^LG-\^]-S_'\R[_)T?|^C=
@E49@8CLOE_\<(# $ M4A<^2??>!+C_+ ; #4H!&M91?&%@_P4O%=SLZ,^GN--5]!S'=N%\$.)N?^]V M!NTKJ3]H#MK]Y393V-
*I^N_7]OC/HM/M2LWLEM7]O?6MVO[:E5N_VMM/O=WI= MZKOP;Q",D2Z&GEN4KLJMLJ3*AEZGOMG7O?O;?_Q-JG-+;V/U'%*
MT)M>UI?U\#3#L=]H?+@%_D^IY/NQI^@ T)P="!\\<,/1^9P!+JEP.F ;R< M__+)LH.I UZ0>8V:%]WT;?FEV,0]0C^T3>*
D+XY>&'^=6+]ZO5PS-&P 0V1I M0VO^XL0VEE%W+]8_UY$!K6S\1BXK&S_?]J2Z5I9U_=U'740MBUN'^H\'_)>" M5IA?/
*66A33]4IT^2\KR.#MPM#8$<>_WQTW3MX$C?7=MT[.@=-O?ID?]"G+T MC'TFP- M\-=*7=.7ABV"XD6D;&EU/K97V\,&[FER4 M\-*
+8(5Y"HW;4(Z1Z_IX>8XO"8\A/;.>,M'K[/QE'"[RQ@!)WCU&7KB,_0\ M^8S!?;/;[V#/0(73P+9+I]MVM;S)Q XP#2%=V\C@()*
*@:WV9PE6T(P8!WQS? M.P>@@5D2I;15J[*Z"D'IX+G!&49.U?<:N;0C=_\?["!$:AQVT3?S4:H4&LW) M*
*W2ECFN6]Q\F*A"U9MNB&.1#^QF88=1]R1M)_FNW)1!(P12:F"2S)-N5[#"0 MS'$4J>P[Y^+.@];*AJ:E1$XX8VF@7?*
*LN;N:'_TD*QP9)C1BTR\;[6$$Y][Q$_YRTZKA8:5] ! M3\'"1WKH$X0[AQ$KFX.=A&(ZJD^;47.*0.,TD!F YTZR0! OLBS[REJA43=**
MFJ'+U6KE732PH7C[>-#I#L2FK-Z>%5) ^N_,MP/+-O'X(-<14>[VHJY%E_H/ MP+7_BO[^*!2% 2EWRO?E?
*EEJ3Z:.]P+]2*S+RB!UO?+'33"?-W7^P,2QOSLH M,AZ2Q'>]7E;9?MF65^E[O(I/]];T+!\&0?+/#7J>,K=3]4*CYT(ICEA;45>E*
M]]^S+T'\[VG7(+DSD/1C?.'/8U#GV0]2$;N3-%4N:14Z_5]W)E0OI5Q:;%? M>_[>WH-*
*%Q6ET!B,O1EJC"7UP,_@")43MF_'\$>!2<^_0T$["D#VC^D5M=!H MH6ZCRUT;$)00S2'SGF% ,K28$YCZ:%3M*7 D^ S-&<[0A^C:*
*&(J2C7I#(MVDO8W&^(V#@@1#_L;S*PD6[Z$"SY/JW0J,G&JNI_3$&HXCP\YV[LN2N$]J(7 M&KI>1>Y5EEEG"N.A?]-*
*$__&WFJI4/P52"'!TXQ7V7W*CS10F9"F>&=4,":*PE MA*Z(II%*>J'X4=L M7_$2<-,,+W?2()M9U?=&[KRD:JU>EC4C-:FJEJNZ2H0*5?*
2R7J\3>916+^O& M^X_BB=P9V$3+0! 8(ZEJ)8G;\S&P >17>]_3(:>\^'8V(6^#G:3-9Q(A##9 M.2DA2_,TMM$G;^:(08J2Q*
1"773;B9U^4=1AA/U7MVW$JZP>;KMG_BQ?Y?+ MJ-&*_6^]@/_B3+GC]BHE.Q2KU.H1XE?3V:U>,TQK:YON9XS7EU6DJUMF5*
M&6H5TPA0ZH+ G]?8Q("6>^PE"ZN6EQL/9 8JBUO12[5FBH2)/_%P5@KNWY M4G0FO&3-($YT>W\9)U\CN%FIZ[%2BY$BH-.J?*
1.;YVYI]DE<^ZI4<>U\ H2 ME(8ODCF&J,L3G,/_-(;1>B>!BVDGWQ0/L9TS!@$TLAVT"P*. ZZ N?3X)+ISXT810W*JH4Y<\&T@?*
*T4"1D*9BAL"H8>S@E9IZZ&XY!N-J5)[#<7MS8 M^.:D-Q\E3!_4!=Z/$1P0=<,_XOZ@^^)+D'8CK($ISA+|-1V-&*
*[PJVF$P4=A^%*FQKW" J,BL8.OAD\5 MAD\8/HH-'S(U0')0[Z $3!,9/A]OMH],@5]$(=7&3R4$Y=+&+X()LICH+?X\ M#D *-*
$&#\%+$421Z'(JX\$@^2 ^^]Q2.YU^743P)H[99<&2[T;;/:.$4+Y.H
MJ)M;6AA]K7R:7[;S@NWMFU^(H\CDXBUMG5]INY%A3\)D=5A2YRL1BP%Q.<6 MQ$Z4,9+CK=;+AKSYJ_0YWE6U1F0U*
*C5*E:M<-TI[?\]P/9[-\;%^RR$4FXZ-Q ML:WD%5X\/R7#>1"=%%D+\SDH@6>02LT;C9;'_I2 $\;(AS6+RC'41>T06NB;&*
(?"7>GHDOQE7K+.!;@81SMVUK6R=]@%\ MW#A]E21!S&1&S 1CZ#ASF$D?$'@B>B3>3+X'^?!Q)_O PL#]0(_*%(2I73D6*
MV]ZFN++3%&2UD/M:5AYW-BE97EA'HCB#!2TH6?)KZI4 M+30,K5HT-*
+585;6Y.LW;FJT^Q>.#$6"^GQM9E+RW$=ANP%>]P$Z].&:X]$3 M57C>6AIK9O+5(F]YNW7=E?*
J=%O[+F50WI].]ZK]._O5=XRR4DV]4:16 M5A0R]>NJM7)%35?'9VLIO']\OY:1[:5\&C;'LECG[+<"K(Y%>4.^95YAD+Y*
M$%9V3W8DK8 C@[5E/$:CDT4P>?]NC MO+Y<:%RUKSO=]I4T:-_?QL78[^Y[5]];@_]G"[#JQ+?C.C'VT21D&DHHF+(M
M:0]0(^2\@1F+Z-GM"B$ D X MKU%T!MU?+VFSIV"C?GS,VCN)E.6E>!2MB6% MX#1DG9OW ZD3;:)6/R$E;G9;G>8-BE)QB?
F(#I#(84&"R6E54F1K)4T.GJP M3+-;X^]$<)(0N67RD>'9);$\^\%@I-[,373@S&V[FS)>$-:&8ND>:6W(1OU"
*M>8F*MUYHM'K=]W;WCX)^]%N_=],Y:KX>'15I,BY^WNFV>K=MH=.\'"%WH-+?B MQ3ML]M)II-*
*%W]^UOZ+K.;VVAX9Q!0!4:SJUXC:T:_J5Y@R+QMM3_UFZ+&)P? M<6M"F[D5;VU/?]T?]%J_?NO=7+7O^TFQ1*G]K^^=P0^AY[P*
*01=ZSJMX-67? MN+S9_R9=W_3^+?PW-X*O"+WF5KQZH='M#=I]?+[@%@47!#G/T]_F9CE.%FWOO?[^%14G-2#+KCYT>]$X<;;;*
*<+&*SXY M%5]SW^Y_OXDCDMY=^SY*(1!&BQN0:')NK)8FK!;E@%1DA,A_X4...R@^PLL1 MV *A#V[F?V,#=M/K?T=626I^Z7T?*
2+?-^U_; ^F^T_]56"5N0 ?R8 P9)9T M89:H1V2<'S&X[]V\9D.WVE?8"@F;PXV$=4/D/%/2EA22PP?MQ4G/\ZSGWN!;*
*M^UYD/'.GHUC2^1$,*D-Q@1**[%LC52Y'D(K*=%*K=#H=[YVFP.1'L&/.B*A5M[_"-UZ2@4U99>S M*ZN(]I>HK*Y-HL SKLG'?*
*X7GM],<3RNHS?6/KY(C) ;0GP31>9=WOF?-S/#M ME 7*NA,]\=(.T>O./9 X[V"(.WA4E^C1KG_#Z*"8)\%#9RX;_@0D.BPZ&O/*
*MGTB*7/H7/HG&=&;1&='#61@=,>/8$SN,#WL.QUYTV P()>##Y, 86,3G#LS/ MI,9PL.P @@"B8<>GE42&#=T/ ND)GT:"_L4E_*-*
*]EYT_IP+KA69UYBNP%KLB?^M#36EG1ZD0*8E?JY\H>97+6#QDJ$]U9=?:%8[L&5 MO:8?A6N']@FA"AJW5K(.:VP)K9E.3*
*C"K;9:W7V 2??HP!,+TDUH[;,F2ST(LV^@Z*QPZUOUK77; MSXL[;T4D=!"=4'P+\?FV/I3^ 2;33\F?:.;0A_ZC;<) 6![:KLJ#KV_?-O/B*
MY]LSWYM"]-Y(]=#7@=1\@[YPH/F<6$NVW>Y\0P0^"YJ:X#/L(_/ON4!A=DW M4-C_E"KW/7?F_[O++4_/H"&\OCHL*
*&&PJ]_+_,)T[7E6M(Q\Y<\>I*8UL=WH M4'ON%X]8DM2U'9KC,QK&TRQ>INFL=(\0B.*1HM1Q32Y8,"Y,QO6@E1?K>_VM M*'=GX*
,+2BUO,K@!A%>@3TM=F\RTNP&+GJ!^AB1#H0$D!=F$997J;)>H8M MI33U;=>TIXY@[NB[@^NX=NWW)*
*ED39>P2GPPPET0YQ;^0T")QQ'@?2W&7H! M5S0Z%R;TF^?;?^WEOGGJKC08(Y\QA3/4L("7% XNC$CG[CY:>,O*B]6TW=+4*
M]Y!)#"0?!A#X9FPO+?@('6^*+2F?X&30>G3N<[,,UW%'R6:>XBWU>#?FF;D MU%595?F$)(/FHW.?F_BR@[,T7.*
*@1#Y"=P;GP20/6,R^@:*SPO%M5;W;JR@H MRXWW0P\ #Q#'7LEI3 '>3VC.(JHS"L_0!7.)2 MIZ6.^PB#T/.#N6?*
D>9F(0:O2A;.)YQ^V2X;=[BYQ+3PCDD'[T6NWZO-WDQE3[$^4F+A)]+0,LG4!FT)/?-^[P8S?GR"=Y6%TKW<.KYPF!2(YS>O_-C
M+H-H/?G)\QUA"&F12C^*('.30MP/D1=&,YADQ_^=Y_FO?/IU5%K2!LYKVJ)T M<[-/IC^#2&70?
*O3;N=EU$:76]J$Y\^W0AG&]V_:S.0;N@]B$0:&\^E_SM5X> M0 =]^%"<;\:(E\@7=DT^N#YOJL-A7;#*A)?50HUS\^=RGNP]X*
*M*R47H,R^@<([',#-!SX$PWAV48@@8!&9B+DE6S\Y6@(.CUKRX M&8>9ZT/3>W#1+984@N?*
*Y*BT/*,Z^@:*SHK.BLZ*SU#90=%9T5G16=);.!HK. MBLZ*SHK.4MM*
*T5G16=%9T5EJ&R@Z*SHK.BLZ2VT#16=%9T5G16>I;.#HK.BL MZ*SH++4-%)T5G16=%9VEMH&BLZ*S>W;V(@1#!Z)_+?*
NQ\1G]F%^=I"WJ;KEJ M3,-/4R^P<16/2Q\ZT9:,3T^V%8Z3M,;%&Y,D3?GM%C ,/&<6;K]E OP'VYVG M=]:6MF8('6!KZ
M$/PL@1%]_R5PGL!+@,=]L>.HURL#?= 8_7<6A/;H9?L@-3X/?2SR]8:G?,7I
M!CUZXJ4=HM>9>XCASO=P:>E@N4_$!NSB/)F_G2-.EE M,?K+@@[2/\%5RN)=I3BZTWHA\!V5^Z03/2=;8$PN2I$;_,E$ 2>:0-
\S$VT MVVYS:+8&G=O;[]WV,1N4R]%9,RH& ^BC:A@O[6S%1M" M.#RT):V\P<8.00#Q PJ-?_Q-J>J?3M+N/0=/^F#C"' $?<^5'L!D
DK\"-[M(_E!^;@2@!UD* [;29NM.;GWJ[<,:-PQ2H_'*?V8$1#0H/?>C.)F!8 IX' MB6@-@X?V-F__K_U;9]"\;-*
Y^C7[)XK3B[/0GZ3VK"B1EJ4$?@(5;-8E5"$GR MXQJ&6!K.FEY3,S9(;^.96Q_N Q<&TWSY\.4^LZ0SV?MP"_A#./5@:+L2<$8@
MMV[\MW[O)F>^>ZG+0FW2S75'COUL1Y{[^?G/O+J;+^U?V[>_Y9):VA M($"#YLRQ_R(6H#'H9{[<=+]M'X->KCS-:J=9TIKL?[
M;^WNCW.>,T"!VJQT6JA-&K4)/,N>3:3I&+HOSG 6OO@@A/E=D[8\WP&N MM\^A6/SXRM5.LP-4&I3>?@1#'R")DUF/8-
*!37GUO_]XYYX'QV:O,%PJ12 MF.%LZGLC&)^*B5[BA?:2^K SG/EUE.WNE_OV8;$QJVZR[0X1.-@#*0TZ#T/@ M0A\?*
9)97)]F^ZWUM=W/E))>[+!0FE<(!:)&^[=VMS/XD2\GL]QGH31HE,;W M)E[@_15GM_SYYT->?4WG]JI]_/C:.>P0.%:]SDJ?65**
*<[+T.WI@X\?"V.+AY08XI=!;]Y(^[^]Y-SA;.5CO-#E!I4'43^"/;^L=JG'+*E+UK9&^C"$C\"TDRGMTU-N_747SAPTN0>Y$%8:%IW-%*
*(D,YLO5+'59*$S*?!%[ZGAY M=C.]$/[E'!:IDEKLL-"95N9NI#]&#D9/}JXNY WX AO9CKIS,;J>%TJ1+ M?H<.:IL)0]O*
[2:QNW:WVV]VKG+E:E8[+?0F5:$HVW3P/C%@2LG.:M1RW%HI M.C8]>FCI/XO>V.:WUUC=_>]UH_^E\-(=&:=YTJGV0$J#4;_?
*E"B:[M0FEH MA\ /\UU3@47/[WN.G:\IYG*7V0$I#0IO0=<+\EROZU_?.SAHO,^5DUSMM-"9 M-*
*#KCP$=OY'C/P+1=X1L9TO7[YF^=5LZV2]STF1V8TJ#I#\Z+"5%T(8J,L>O@ M[YL_>OE*6UWJ,3L0I4'AISZT7#OP\EP?*
B47'#J<@'.=KUKO29W9@2H.>HPC> M\/12.XF,\^HD_]W^ MXZ;9;5Z@?]O= \^19M59)GUG472\/!
*MDJJE[_9W[PVX","0@?//T8]Y(R? ?[#=.88T],+D$]QW'?V9X*B$07.IQ(,1 M8?,]J$EC7QO(GDS M7_KF^?9?GAM_$W=;0O_US-*
,0E^J%"555K7R5G$G+]/5"'70-Z71LINC;J UT=5H"E06,(*M"L*T--AQ]1M,+\IK$_[\,4/,#2T(?@ M9PF,4\O@?,$7H+"Q?)PH;%:$<]!*

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}%Z@/;X-@Q&=T+'%49@<-8WZ,JP,$X. [1JJ90E7!1(4NKR]*".@P#IT= MLTP"V%$CDLM8SZ\Z.W;RM!MR<3IQ>.B5$ZIE1^35]5QOF6TY;-M'-=KN6--$ M:3HN4;0C1'L'16M P>>2UFC9'21@^9#L_A<-V M9V@\DC5=SPV^1.,=7S? HWUKNYYOAR_S"7G3M9:?TOYSAKZ^A>'80]\\PM?M M3ND,/CZJM:C(M!A\$3:<Z| JU'.\#6!BFQF$.1G$,AHYHP6U^@"T?V MAJR'&EZ\/K[RD/#0-()DKPG-/B#!J]34'. N0'+VV<4^&-%0L%\YNDZ,P B- M&-DKU-|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`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

MOK>5KVD>+|"D@6!Y%U<3O:.E0F"%\1=DO/_*3],HHWPOJVG?.3"8S33R N=_MQ <[-HXXPF5IXGA/D?O&?@%4T@-
BFR="5P<7QF08= 40L\&,GW_!Y?(B2K454'B:_=P,] M.+MGPNH!AV SL?;@Q5"+FSW0L[+1MX4G+F.OFCR.FX#7BG)'51,OZOZJ
"C M9WJ*.;DNP@)+3-H1CTTSA/49S;A8.J+-2IP]W7'68?/"!.. V8VP!)V=JLUZ MT7I/7$1SO'W>HQC%
[2G@5TWZ!KN8NAZ>II93+"ZV5@U,!52#_C[58%5*_H!$ M(N6.K6XSLT^6!$FCW_7NK-5
M=Q_<*75,D4N==L.K%D^S*64SCNN(N9W-2'T(IL03%IX[#D>!?X&FJESUH3SN MII*T\U?T-K$*2]=0T_Y)'K"X:&SI52>O'X
M!0^#2WT>Y]QUX\]?#\94.P.E MV]>:TBF'(ZQNNIAZ6?*(X+JZ+2 \6BM*0=73>Z\KB3L$KK
M*N5?/MTR+9!Z3SWRC!P'#SI;SW@B.#Z2?A $<1D)?0TKC[3DMVS%?_/)))S];D](NJO2./2PU\:;;ZE8C77;#*?].!*%[U.R
MCO$:5GPLB80Y":;NF&)H;WDC7DUL/U:,JZ@F=E1AG^9L4IX*M'%JF;5WBLY< M%->-E#IUHT(G0Q(ZD 8V>"_/%
(Q5H"V=>LU):'T7CY4K\2WL_<*X25P_(:35 M1EA1=U"C5JJ*3^#!M&"O/6)RQ*C\,E\1;-QV)+O2B$HM838XU$(M?
G\#"'^FU8XF9;J,.Z6TIX MKI\%>H:#(K:[[H$1@X[6.%C+UMV=/0UUGVOA*7H3*_SP,%D!(H9-IEBAM0+6 M6* ^ZY1DK
M(/.%ZUG>,E&-R%^5](W4]*'K?J<4'27W@O5E?Z78;6+ZR2R"*!*YF4VPKB R M]H
#T1)DF69'(LJ9:+MD4?/"Q:+RM)3_=M)>5#6663F,-[@>(,:AEXS@6CLX MPF0^;[Y:05>.N2N9+?9AM80!4)V
V=YYA6"V*KR]$&_+#T5CYC"[-?2SZF?@ MYQEQ]M(YS9&>$5B>SD#NY9W;WN8'K&&&ORH#M"J>Y-,*,_ M6*J4&JDK!6AG
M$7J@_,=6;7Q?)'43+HBUOK!T"$")),00,Z=I'2%]"F\M,;.DXWY@%P31@B4J M'T-08^*2ME\E_9 M!+M >[6M?-
/J+R3X4F&E]%W)5Z0*KJC]$]N-]$L_K!= M=&?#6[;N/NLG=P4 RN@O6<')$J;+!8(TB#K,(+=?I]IF@MY.
<_%$Y5$L6.6.6&P'E9G_L\#&!2'/.KI(I=0H6A>TK;=(D=CO M]_K,1U"D2I&F]D3)**>VD-I3I.ROCBEX5.Q).P>UNW;2GO3
G1FHZ@CH@;;>-:W-_*_96)I:$[PI+SI?"FD<0?XLR-Z#E34<2.)DT*2YU27_MLB@H!14 ML?2&>GK1MS*/'Q]\FJ?
ISMB]_M;8JYKHMY%L)8L!C(5'%I:WD=20]!>R=(:H M[7?23P"DA&,_M6KLK&8XBGV7W,#=T]OBB7A?
^=B>&Y*A6[N]W],A0LIU>LO-YG$ZYN4);B<8T M4IL,]V:$;9UD HX?D,5-N(C.ZK#^ YN=1XF_:DV:#.VN$LHQR]Z*EA0/)>#T
MV&*0[26.SS;$KTKT_(UZ(T3Y'TXBCVC=C735&SC*,HFC@2M$,N\V"X =NV$I
MON80#%FR.#A0)NT:^A(EQ%M!G,X^QD49;W:AR6XHP7)YUXULT$^^C3_ZQ;J_ M2@X<*;KC/3H-FVRJ5IPZ'-
'3*I,W:QX1Q%8K'O6BZL*3/&'L @CM8 /8%IG0VIAOCSHZ4^^DL1M#!7T&!\HF3;NJH]/7.P'5(NJ/CJF-? M-,)WPC2$14'FO>KL264SR
<7NP5!?GOX?7UNAN7X M1:>,HAPO8YQ,+8I_1Z^F3[UO.S1Y[I !\FT82?4%7,H&4C@\B,C.;Z
M%TMRJPVG!Z4L/]+%R^FE=*X\A>.:*;[$O#*9)F4L8ZB^KV.A\4>VOV(F,+ MS$,J$!XRX:M:M4)93J60>0O7\;?
>8Z]2]+5QT<#FX&M65)9@?EYY*9OM61A. M@9P"ST2!-64&GS4H_]6#';/J[EA[G;5@BTV^1"(6 M_H^'8[,R-TQL77MR]=9"FW1I&
<.7^O847RE)N$F@.V;T.N'DQ2U MIP!W2>2%_2Q%3EZBTDI78&AIA7:/X"CTIR!*T19-2"((T6EN;X:1]^]AS1+@D_.N!',MGCPQ'4 M0
3!'>?W*1K4IRB=K#9RA#428;7$7$63GL_C &HA@*J(*A9C45*?LBBY*4+P M&O*!_OG+YW_<\H[O%=)5%>'$-.F(G8%<6D"C
7Y5#J$$A&J)B4D2<%^MK&)P M'$+-@E M<1])[@Q4):\K 8?094.HEMB&I* @*ZL4+(=0LR!4BR]?PNZ+I>5.
M<0@U"T*U./,E;+HGGNSI* E"UQ!'_4865C]]F *]_ <1CJUQ#$D[%%HG*P# MGM_"(=1("-42D)!,$. :S^=H)X1J.0 E8S3B]/.% M'$*-
A% M7GE9Q!8;'$+MA% M7GE9Z@R4?E-TH6N(B#X$Y,]9Z142N \G03FU M!"-D&2A'ZS?$A\,A5"Z$:@E&R
JH@'T>C&@GA&H)1L@J&J(<0NV$4"W!'"%E# M0596)0X.H69!J!:GO*RC(,,AT59"2*K%*2\,I7A4+S0D>KX^WI^_?O[WOU<9
MNJ4.0<-F"7O'D-&:",|*W\B]C 8"V,@"'] 9O!'?9G<=YSZH$DF_EF"*;((" M8K2HCRB'4)"M013E'YGT!0G)@=0N0"J)92BB,B#^
'K=D*HBE!*\NS9Q/Y! MQC=_$L_-@I;4&=!V6])[#]]6PJN*>,/A\)(YO-H-KRIB$8?#2VD:O*XA2/SY M'Y_O[Y[^O:/$%9)5+?
$91<5OKMX=?[Q[YP=D*::>6"(>*AT5D'N%H)X1J.2RB8@DGY61+E$.HD1"J MY=2$BJT[=,Z%V@FA6DY-J
H*,EX!HIT0JL4KKV())Y%SH79"J!:OO*J!(%.: M4JSZ&F*B]XN9%1 >$JV0*4U\3.P&Q*/(LCJ%P$U>*3U[" M$R\E7",(;CW+(?
Z"1T0K))U:8A&:7$K5 NX%;"2$:HE%:#06P8\NMQ-"M<0B M-
!6L")F7$FXGA&J)16AX0N#TM#@.H49"J!:GO(9M%41>0J&5$%)K<GS[_\Y]75\.)NZ$.(_Y:PBF:"<3/#RFV%$)5]^[> M68%
[Y=6@8##]Y'PJB74HHN<0[470F>M*275^&)PZN1\#IKA2>]O I/"%Z- MA-=9*SSIY55XXE'D@P'RX=>[^X_>GK@8>0*Z;J6
(Z.)9YX *>E$*HE@*-K MG8')S]6V$T&UQ&]T/%0A<2;42@AIM<1O=#Q4H7 (M1-"M40!=+,ST)L2 >0(M*A=!M9RI,/K8TK@IJM
U'*O]!X$5'MH_^,';"FFGE@B'(8(/ST9E?L(&PFA M6DZ3&%CA2>5!LG9"J)93%8:,%<\Y%VHGA&HY56%@7^S3DU$YA!H)H5J<\@96
M>)(YA-H)H5J<\H8&@DQMBB"[HHZT_W[\>O?M\P6F,TN\)6WUM%]+.,7 XS!:
M4ZJ[<0B5"B&]BG#*P>DVAM&TAFH<7N7"JY90BV%R#M5>"-42:S'[8"-IO)!R M.R%41M80C3*E)'.IJCA0_!%/B"0O/'8>CP+]
0USFYXJK MYP"U1)-,N3,PU9,K]7,_:B,A5$LTR50Z ^7T,F\<0HV$4!71I*2:ZX3SF[$;
MW$0OR<(7AIJZLL8[6[838;4$FTRM,]!TSJ3:":%:8A8F/0+2E$K '$*E0LBH M.F9Q@)S#\R'=?K\I/<"O)R+N!M8L-
L<%'[;E$FURI:+@^+Y[AJXW)MX-CA%1 MYKLS>RS$]I[27,30N7?\O1;U>A\^_3>RRBAA<079I=@9JU]3+"M$=O(]G\HYS
M.N1TF*;#JBO'[:5#M8\GRKJB7E:1]J;389$HU6DT>=G8K+JDTP'(%#L#HRNJ M9<6WFHY,+B&XA$A+B*KS% Z@0VRAU-5,3H>
<#J^7#JNNH'D '6(_IJZAEE6" MI.ETR#6UP[!9=77$ Y"I= 9:5U5.SD.H YG74+2"92AY:.?][>4O+?!PP/V)
MK91AL\9N.)R1U%X>^_0+'AT/VM01]5/[V#ZL,:<4KP?>S1X=)SZQCIIY:E]# MZFM*VD9)$5'Z7KVGJPU7
EA<]"0EX!#M_$KO/U'"90C(8G#CVUWMEU6GLKQ]/K>G],9Z+8R6\+I]FBW8]M?S*PE M3I/D,X;CKCKCJ_DT^%5\V_E5?-
OY57S;^55\V_E5?-NO_2J^[5=Y%=_VJ]R* M;_M57L6W_2JOXMM^E5?Q:;_*J_BV7^55?-NO\BJ^[5=Y%=_VJ]R*;_M57L6W
M_2JOXMM^E5?Q:;_*J^BV_QQ8PQE95;1C29;WX9QX]HC]C3FAMA-:-.L22PC&
MSYM;WK/MQ+F4QF9*\!^A']B3993E.OCKT,,WLM_9NQ)/BC)4%8F=V$F7YWNU MQ\$TSF!-
W!B]N[^^Q1KZ[BP,\F_9.>H1<0+BL4]L9PQ_O9,DK I8?[:NA ,7 M^UL5!Q,_IUX\FH7U3&Z&'K& ^WU@3&/\
[:_9J+7W8H!F\L$4S:.^&3=_$O[V/\ MVPY=:'K3^\VI9M1_I--D7T?K99H]0Y5QR2*>&;TX6LT>K.;/Z<]EJ6=H>N97
M_9Y8\'-5E@K=D36_(X(UF^ENK6QE:ZO)Y9W/H>/A'F<-G4%X@S)F/AD2P",A\2 M3Y#[W8UBT34LLZAN+_-
!9:6;O<927U(.:51RR(2O:M7DNN%7<#,N8AU_ZSWV M*D5?&Q?MV\/O?,T*KAGMS'3 JEW=PG *Y:1X)@]\AK:P7SW8,:OL=K#
/]LE% M3:M[_Q2;?(OZ^ACJ^1OI[* 4=T4\X%Q*X\G#-O%,#6$Y^7'R2Y+?^=O!B_W. M0.SV39.3'R>_:R,__?SD)W8&1G
M5D!^:0J3.P-353A]0&///7S[_XI;LO)B2%NO2*>K\ 3%) M1(^*!OEL%*^Y?NVO(H@3'I7I,S8TU:*QRK\^P6)649BUK2R MW\-D^-SD
WTPXE[DFL<&?/?PQ&,JFI)*9M9!YQNFQL5>&E3L%'[G<& M:IU:D2V+: \YC2E5AY"$@?\Y* M/VS-'4>4I,[OAY:I'UK,
<"_P+:]BR\4JW,/I754Z UDL*>>"^PH/V]CSY]G* M*O45]D_.N>!!I89AZ_Q^:)GZH26UI(1?ON7[MKP6-ZFL@Z#HUYA1P@6%))X_
MT58VJ*!0RSI;?VE!I;']5;NE=\-+YO!J-;RDJC.D=\-+:1J\KB&*^/D?G^_OGO[%
M7865$%0M^>>*VAD8_1H/*EWWGM92PD/1.@.9'SZK=V?/7\-#T=E)4AXG;!NV M:LG#5HS.0-5K/(ETW7M:2Y$.!7L-
Z"4Y"KDD.&QG:_$ JWW0VY2FL/IK.#[V MMW]]_?;PZ]TCCYM40C6U9)BK8F>@UQDXN>X]K:74ABIU!HI88WR3._LDZ?PI MSBI+
<9;;& R[;JXAUY)+K2J=@9,1!(A+@DKVM!9?[JIV!G)&Z7TN"2K[MO36ERXJH$U M>7DQJ5!W]OPYOBK-\14S;& >^+EL;-7B2M;Z*
E*4IOYGN[;TUH%:=_:\I30TB34W+JO_%8\+[] MITHM#EY- :VFK*KZW!EXV,Z>OUB&1HME].63*[#SL%##L%5+ZJR&J;.\4U5=
M>UJ+IU/3,=3')4&M.WO^:A@:K8;15ZXU+'2V:AA_^_:OQZ?/__SGU=7#X+ZO M?5RAEJ1GS>P,#+G&R!;W?4E*U:T)=Y[^U/NEG?
YL8 B$PTM2:G&:ZV(VX^_0 M:@.$SEI=0R^ON@:'5R/A==;J&GIYU34XO)H(+_6LU37T\JIK\,#BP0#Y\.O=
M_<=_/3UPWV,E%%5+2KJN=@:JROW)->UI+3$"7>L,)*.D+$ON3SYL9VN)%.C8 M7E_^N21/&TJ)F9!\3_?M:2W>2
,+9!B\+UBM.UN+ M3]+0\+3#R:F.%QJ=.6/CKW_?KW[]OD",QTEWOFK2JJOQ5]M8&:[7N.Y->Z> MDK2J,]MW1N(-
HVE]+CB\RH57+7YMP\QF')!=P'H+$7;=8NO\+1U-G=4PX<4,:MWX\Q>O,;&2
M=U<^/4&51W0+1G3=P)K%QK+@P[9OP*^B17PM:YNGJSF%]W(,SFOCQ[_55-A>TFP MZO)+>TE0Z^.!FJZ:<0"N9 IL
OD5B1V=)A,O&YA51RT/@*4(UCEHTF)98:?6 M2H9K%PZME@\-($1L32%WE8S3M)P0N8K6?A7M[-UAM+[<&:A=32^KP 57T5H
MS ; $F.S9K>OI]M5-5 R7,-1?98QY+&M]\]YXB^QE3)LUM@-AS.2VLM38U<7
M.#H>IA'/GER@]5FS&>E*,Y8X<7+BS"/..DZ]:GVM,S#%D]6&9L5(Z7OUGJXV M7$E@D=*3E(22#_2TZ?X#=5R&@&T&QWT+)R]-
BUCQ^=4DO3.0E*Z9ZP8_XM'/+>_9=N+E-.!1T4+=(#=X)[+')Y;I#P"'/5FRCVQG3)S@ MW0V[K&R*4'O2"0LC]8P]?>P8 -,_*\EF-
Z8"E;+^?KYW_^^%2QG+*R:! JO MQ".-?IO:'MD+$R 7(5@&GW"YBZX$^%_7<_^$W]UA(=1X
Z))VA=0>I+ZR]9IVP9N.TAPW_8#'UG!)HG#![CW('MO%AYP 7NQSM_>L;_7LIM*$W?S?\D8 MB.M9>+9LQZ?L>^:B%M857J?
V:"I8(!$BAHZY@ZA%"'^C 2X4YC&3J"\3!YSR214#F*#CD/I4<"KT01<@63%"70UW3=D(K M.FR3^J1,*
W^.O1^'N1"-5HZ16(^P3007NUQ.(TUZ,2-$?/JKV^QAJ TAD'^ M+6FVEYC)"(9.O(V)2%(5)+'?6J P$L6M?
4O\Q#FAEFX;EF+*$U&1)Z:E2$/- M&LM$'5H:&9GB4.Z3_RA:)[YIZJWW]}G<##UB?;^A2L,[:_9J+7W4E9.K!4NU
MM3M'+6P61#96-@LA!XBL]"LJWRD]4GA"9=O[IP1&&E@ MDGVR_1$PA] C3W#YAYD[^KXVOTQF$P)5DO%M$'V&#R-
@JBW@<8$7 A-D#Q," MZP?ZJ3?&L;6F6V2^?A$^-.-54IF;O+4IA$BZI%1(/D(E$N# ES\!MR:3"?8$ M>*%;(WBHD!W)R2.9D.L^
%,>+D]Y$#8.>,K;&/P<#V\%QF\PQ(\.!<#P'\"L MH##Q5ZX! $2,&;'?&1B]=&SJ)SJIHB.M[6!:> 9*E5/ W%*QESZ!?
=QBJU4.58:AJKUT-GIJN6-*&+D>?N$Z MJ&2L3-G8LH6_/&%)+*^(*7,"5ZJ%,<#J@^CU40FDRGV:46SQB?WLP?)QK6 I M8,3",

(0;77H_K!PPF&JJ%^Y(3 #V)'Q! ^=8CO M"V^8IHJ;0ST+=3. S-&/Q"?|- MX0OJY[M!UP3

%19C!DLXCA1FEZT&K@!>09A2N#1P1+&^D+\8 Y;'*.:S_8# ML7\!._AM#U:&"/D M$@HB\D!YU3A]H0\F3RVX4-*

O[9J;D#&PN!ELA!6$@>LMV0)D3L<&F3%:#?Z/ MT+/]L4TY'CP IPC?V$P_0U9-?BR(Y8@8#4M3"><

*MP"1@[+"D[HJ]=X7U0C_"#VL!KP3"0KL,IH+_?0W!,'>%;_;([<). E5[-EVP M:"X;SBCXQ K0KQ4 U *Z,7!//(_DTE&L_=9[[-*

$Y+T(/##Q)9]&:8 K 7+YG#R<+_ -0-GZ> 4K7?$V[!LF5[A1(IL4B4 M2/7W?O)U($712F#;9V.W$UOT-_AX# MH""W/_\FS!F=)^Z:6O

JXECTP7CC\\P=4NP[]CR,,8]0)TQ]N.Y8SLB-CI&"-R;8N^\0$DJ.-0RG:V("&C61%[FP1< MV1A- >TBS=^0@=A^\DUL

MC'9D]L44C]^ M 6B!9;VP:48W[P/YT,GX/ONR:\,N-F.N5GD!8>%2% $RXP M}3\9?!*Q+SSWQ?9C?FHGO 1T!:T1!3CV;![;'KFN'.=V?*

C&%<3VX,[!]9L M@K>O0U]6QN3IJ-!%FI@U91>1C;'2-M:320R1^D1Q"<8N?0CE8703-J^G?IGH M!J4M#.$!U#?

*8[SG*K@CD6PP94+Y), 2HT/$WZ#_6D9)BNRN\ #-V0Y]=0CGJ MQ@6,UD=*

*4:#G9TK^2,AGO!S!#C(4C%"P'F%S8&D<%AJC%!,&4\!C+$_@#Y]L M/_@QH?,,;7\1HDX"?]%!40C Z'V *Y,*

[J;>^N+,7Y.V[X<$];UGRUN)R\"> MXZ\4KW,D*US:,0KL2)?"BT*?+OD&#>,-L[6ZEJTNXC/AZ?'RX@,VUW5(1E;T M=*;-TH$B]UW*

JZ?C7?.K%I4K@)G(K_J"@+WVZ_1:QL[HY1(HSI1RN+ U9SQ831V>'C8_I4"17? MPZ]2%_DFACE@H9.Z.U-DF$E,N?

7:2&$,=RT+8XQ%(<8)HF](@E<"B(]),N(' M2=4LK<;'TFFG'L#8J^U3U6^\4N6B:>"J)$9.N8(U&VT $M0%H#,$)HWIX,A7

*M3\'ULA8+ OHR.A=0G1B& 1,IH8-I/CAO,#-&T\3]5&S_7PAK_QK/_X'R-UF>MU&_G;0$V1YB[]>IZ8^!6*R=# ;EW, M #>*

*BL>5:1N]&;?O$]B=(YLXHZ7P)OKX[6Y81AI" NRP?G^WEG0#DRM-PYX^ M(=]Q*8&3,&*

*<+#8BTV<>BF1:QO]SN''^/B8R[(!N.%L'/L1;%3OX\5;R2ED?#!% M (WG_K QL J#^TNA$\[&9IE?8V,CT_NVEG5GKK4NG;2S=_M-[*P4*

W'Q\!R'4(#!^0NBGAVII]7%67.5A$AX25>S_P-'GE!,8MNF='("YFX MF>@ M9H0!=TN&N_6TF1D2;2;ZQ3U

*(I@8UHR23*7+$+\EB[\?OR)&9R!E1!LW5N04 MX;B!KXJ$XZYE*U,X)I;-Q&7+JU0T+$[P)/Q]2=@/GH/!)SX=CR+O+0 M..S 8E-*

*CFWJZ :GPG<_B8;E('0$;3D-5*F#,8$XK'N% MU]!"T;JYU@P.*K(M=3A*/#Y'A,%\/H'6J'IE0\PD(XJY:>C*

*M7F!F:7XN9)59CY7OTA?;H64+5@8$"\7[A.:WS*W ^#'S/[. ^HL2,01 M%W5@+@)*

(%I;D0>50G!O>".3@BCTJ0X0):@GG/8SVP(E(K+#?*8=+5"-)O% MBOR_"PLL"W1P>^AR(MT=*

[NHN/H%ZKA)Y(=%W<9X$=5M3+@""[CFRL88H31=N M0&B>A6#%WO)4T."],'5?85)>-

*YG<$:T8YAY%+\T/J=%7ATYLC69M0+3P42P ME.$YC42&01QPQ"@I#BS>H;FU3-@N"VO)IN5OI(X\TVP*Y*PKV\=?Z6;4RJ1:*

*M*PMPK(\46&.8K;1.8'&B(T8(8=RA#?&:$2;?X?QH,GE\8EDNQZ3@KL/:\2I' M+H??GC[X*I.5&@6%#(#---WT0=_?*

G'60$W2;#RP_R+^+7NA_HPB!6=&CP$R@ M?Z4"%:[^&FNG&2XR2>P,E+3M),3.,5B:'8EI[<[?+K:#]6Q@,0>HA$G#N0U6

MYK&S8#,I=SLA#RV^E7T36-^)_QQ14&1]LCR<_,SVBA]6)1Y49:'-01NS_1 ZEQ!S0?=9IYR+Z@/G3B

M448)JAAEVH+U:GDT[^C9L^:^\:/4:\YWFJ\/@%V1I7!MY0/C@EH2JLDD]!? MJ0W(M$-

O&;UR3D")'/=2<#VP5_XY%W\RWM,)9I9RW>V0Z=#;WJ_^;B,(A]TQ=G7:\NW MUV?6;U1D+WIS]'4/OOHY_;FB]@S)S/RJWQ,S^]

*[E"CV-+'8H_(_5^7LE_!! M53DH2=GYJ#TE' O6< [<1=EL8N_Y^CX[0I-5?&@U(?.0"47>M?JGE*V+/:7. M>5%==$-?/J &YV+G2K[[=-*

\SW+4B["JRD65@K($_7I"I2#W[_3]4PY m>[/1'BQKPON^K5IT>13.4-+UX6#Z60PU=0.H@+Y#ZX"@=7?*

Z7T\]'//0F2R7F9MGK1,J%74.RVK45K]\2R "V, MX?

*[J^L4C&BH(J*XAE]7JL@'ELCDEM)82E"HI0RIZ'\:)1C8_-14FR(2(AMH*ZM69*'%ZVF5QD?7I-&59)@W MUQI_9#D4;SX1QZ7Y\D?*

[LQK<8^>J[R_)(7L1OJ7?MQ.1HA2AM:,IP[FT6I0K MZU+)UJ:H0R9>XENVPO$1+L9''M:Y7305*4OM,$'MD)O2HI(W.2T;/GN\&?"*

*M1^XC?-+%F3E\V@&?BM$CK@C19Y"$#>33$FU2FU<5A=*QB=QR,E,Z@1>YY#]-3*

*M%;SC4*1V!F5UH>4H:AJ*CE'TCH.1UAQFQ#UYS).W(U&LB#UT*Y$PWW12_=N@=YR0L CT,;LL&AQZ'7AD.QB+(P_B&*

*MDE=RDR/O>I%WG'.R /24_L4PO5*2?4J*F%>4L,)'=VFC:_W1M0]Y*1 GAXXN M.(4T:XH7*GA"?*

QQ7@MEM[4G["C5M1L#6=785##VI!9%4#GT6P]H1SH2]AE M13K9&_,7,E!W@UZBAPL'/P7\Y MX"\+^SHU59IRIIECGV._;%-*

*E!_@-:JST\SH!GR5?[6=;WSK9>2%9L_]BZXY_ MB5J3%>L)$_7>DV36'&9=)A^[8*Q.-I#Y8N8N"582=T??;UBI?*

5J4WLX$3<3U[OQ+=KG.;%.6^MR^+;C3B>V-7X-$E.'PVUWZX^&M;< M!4G^)^WEY@?=J'=9Z WFM&/GP'H?

L;G@'4_:F@WL6Q/>+%F(>L.'3>5OAD2 MBW:!6I_:B_NZ1!UK?7L,5X<2VUQE[;?6RYHQ[OH_N7.;AX'M^T0+ZAMA]03 M]=W-*

&@[_O+0.$E)/5HL]B@^J88/2:FP Z$+^@A.+L)9R]$\J ?FB;"X*$_]7NBI?0.&A]\"4GB*] M$&*-_M14DK\:_*J\JX[-*

*USVV^T:S(N6_]1Y[PE/<6W (JN\A)%AJFLQI)SHN MV#%=>/Z7Z[7>]E9+QIYSH]OO&\Y9I':L8'T&[P*R;K#[3JM@9F.;);NP+.4/%*

MJ8Q36=E4-AJ%\W!F!61,M;;?5@K;+Z# ?B 3UR-/UH_-DM$3^P<9W_Q)/#>+ M)"5L,&=(HO2>DR4G2TZ6Y9(E%G _BBQE3I:

<+#E9%B3+-4EN$F@6A2D7HXMR M=\,YW0WG'^!E7\6E7ER_OY5[%EYQ9>7+^_E7L67MUEAMDL[<_IWF.A2 MF-

*,L3V$>![$U$R8PG^/B:;R([V$F^YX:D,7#2,7:'ZIJ9Z!WE=.;@33GJ!"' M5VGP*C]^HI7FJ.6 NR; '1T9T#G@..*

*.\GD7%)Q&LP1GZZLV/@13X@G^%#2> MFX!X\UV'*LK. #N(X%K87RR3X/84\"TC\1$DT MT:';K5DSDG"HN7*

*MPKJ0JW@I+%X*BY<=J#W>76EX:;)P66'PLR.%ERLN1D MV;38C DM7D*K G->/^_]EWL#,1^5]*:TG"!&M>BC,J+R(EJX"*

*<^,D!=]& *U!$2S>;)!EY$2U>1*M9N6'\ MA'[F"?USNYE-:BPK?>7"C^ISJN94W1;J+MV0,LI+%.5DSLFM@?$PV5[Y.^>%^,&<.('_8?*

EQ9OF^/8$1X9+=.1]=A\X)&>X':V8Y(_(X M)23PG_)3_"^#S-W]'V]_,!X"&S MX<>"'I[*[OE5R//T(_L"=+]I'MC&% M[R2II](J8#7#7:*

*(>DBD1)K!P JL>@L6(=KA+A.%2@*6@ZP;7"0'<#;L'T_#) M6$BNHQ ML!64GB%1V*QHXD[F[FOOO &*

*[H;IS.!!_MMW[2N6IBD]V=2;5FU+ M[2E2XT[X:#D*RD!=ABQQ"1VK26-'LDBB.JA]6D]-.5*%V)W7;CK+C_TT?*G M@N7*

U/$7\M_0!A&& IX7(>*'NJN/%YJ[57]$YZTSQG\^KZ&Y4E$_V?YHYOJA M1PKK_DI)%71Y205.?

0V:>"'J,_OGHCZU+,N;UU6H^QP773Z]I_.,A=\H=PA M6M+JM(@W[].,*G.*UME:H-*

*U!#D[6G*R+JER5D;5>9ZSC[.&.BPTDY+ICXCB! M-71?B,"<]^3':!:.,9Y@.=\%:S2"?0K8G>Y$^$N9G6QP7%FP,CH#1593F(J#*

*M$G0JQ0:R)QC(!E(0_&9GH"K]'.2OADK#-FFG*9U#RH78%4"S7!!XT N9+7N' MAUX:#;_;V4ZMN? :P2:!>8C8!2-$6,(#!=*

*<39L3WV[)BP*XVZQ$X>V,W+GI"LX).CNB5,^!O /#0PC0.[HC3T!PZ+8?F2K*

M6PO%U8N%XP@=5U<9T"%_88M@_^$WQK0H(EW@&/<4;VPHUX=<0IP.$ M!(6

M.KP1R&H<71#WYAF#MD)?/4\65P%0!E[(IK)]/X3=`R[IIW80TE"=\&H'T\33 M;YXI:PP@\@A,1O

$LZSWZ5/AK\7,VL$[\,A@MAG#T#((->)@(VBU'4P)N4Q M/,$+++2)D).8O\">A$/Q3H-8=7BB3WQG!_"ZT0$(0T\=;%"&JZ/QE%-PIA^(

M_0MQ@#_]&K2&/R YNJ\.\?RIO5C1'S+?:+;"\A@:['PW!\V,O[94LA5KT S M J&3MD'$I(HE;6M8#$!_IVQWG?#S$*

*_J*_&0FJQGLM*T:J25J@7V3;Y!E#<> MJ<+Q8)F?]*&QU <_1:H-P&1:0+_!CX-T[L\6,Z>2NI 6+)GRAAIL9"_*VA[*

M\H_[NWO@7BL+B^92JVSD#L#N9=GX$:SV-3; MN\+KU!Y-J?X#TA2MJ83^XZR&PD2&7RA9JP=J$.'[0$)_S>T/!FA ?#SBL1*

MAN096 S(S]AV@PE3\&2P "1[AUJ$:^Z^9.+20B5R#,P(%AOK0]@.%?5K4';9 M=:.IY3P3.HOU=P?H?3BB0GK?(ZC"]VY

!!$HYWQ,^A52E6"O/ MA^O,KVS4SPY5=M=MS"]MZCQ*YGJ;J,SA=.7>WOSU-BFE!?&*Q92Z>4Y6D^@*

MNCVV?)FS61O9L(8#>8^-O4U\%4 O@;J"AECIH-KCR:AH&]!_+^>!ZFBWC&0:

*M!5EY.22";LN>5(REEX^J3>42!X.K8SNAQ;2)A+H9:7.*Q"*D"]>W\9IW'IE9 M.,!U/NQ/FPG/D8+:7]]B#6%889!_RT[5-*

*DK#:XQF*RI;JYCX.?76>87/Y&8(ML/E^8TU@_.^LV:NU]-'MFYPXS'IKH8].H[WJ?U83:O9S"P,Q8!43E,\+MC\> M0^J42-KTY*

@:A/<8KP:1>V6@3X']<3M_)HXP=6=C MT%K0+V&!!E/8+M@(@(@!9*$_1GV*EC>.N.T.4&R+0>C,U:[*

M:8'V$_%:+KT,)C^'A8F#/P F"J*'N 8('1@X]S1]Z[PYO8M2I:YM11<9X:: MVVQ&^4]LST4:7<)<>+&M=\(;^RW5ZYYM'Q7 L; (AV*

*6P\LG!"40'F2] 3?7<>32VR*OBX32\B'&RT:1'P.RE-Q]6*X+>2[H@ M<]=#+1#P7A DXQB9Z"8:2>4:8L5IW1<*W O[!['@'+!*

D0C7+X5]5C-"N@O)9HE+]G'V5]V6_@^H(ILLW MICQ^2NB.]Y,@MW.,7F1H0R)],:GQMQHUMI.&+Z)/V\P?OKT=D8EU;7CC?G6[*

MW;I@N'BUO#']8.R^.NR/,=)4!-Q8%3Q)]=O%H>Z<$>R!3\"@A]6DO]XY)^#C

M8!XF%M4/=XG4\\VBJ!+9R$D4531W:0[GFT5%ZNB:&BGEK1+RW"%(J!?*L!:> M#8P!%$_'9T\ ]G!_L.9Z#%L\MTI[=_\E0]&I>

*(.+*KAG'W!1;5<^^XA/4G[/ M,N+&J<*-<1U'68XL.3BI#U^.IE]PQK$O^ GT.VM!PL >^5T,4+?%N+DMJ UG*

*MYTE133=>*U8NZY1D2;DO'Q!?.BXY49? .H(E%[.R$6':A8>]5#A4L(0D.2,3*

MXZ=MLZ2JE,BMG2C!52]AUJ.FEV]<%O5$[QTCZ.!:/YV9>1D5%5I%-[.4,0]*

M3[/#69C@.+,GJ.F%:QV.;/!IP$&4Z4@CV!C#LE[@HAE,@&S#1G!IUD%6>N3Z MK3WAMU6P.75K-YGQN'T%"Y$GQA^?@8D2P$#

[D),EEN?@H8/2LHG@B2.,Q>$1 M#S2RHRCO84F3OV/2Z,PF> 8P<[6&F"OJD0DNJ<^V ##]SD%:Q'.FX?G9DAKX M:

*[6^20F9Z"*IHA)I'+>N8#L*5*^M77&MRUY*2!#4-;AWN!2A!B-7)VA@[G3["Y, MRT)J."$SZY#TO6/5T5W)>9'V?*

VK>%=4V+"PC"M]9/M56\.#JL?F,LGA(JMJQ M"T+[S.2M"+ TV]N1I.@?F?49K?0%6: %C>Y?\1PL)E]:7A#M0[Z'H>$T3R.'

MLVA"&X. AXYN[!\W4WL,(WT'<)+[6^/,N 0LPL2R9/I@Z#_%M3]Q3X02#!'B M.32=?DTH&8Q?!@,/-+

(R#3QQ3_3QX&!72>I:A$.SKU M$_;4!.P,.@FPH&9+H#Q@7<+0!@MG-'4]L]+Y$* $!#T73K6R,PCC/4"?PG] M6"';84>R$^[>RE*

:K^]$RVSAN=32886T/H[/QX0 P4[VLZSK]'C9CH*MG@.?+ER,&X-YIJMD)"H-[/5I_B%F M9X]),,1OC3RI)@-E@*;P0CQX"%;W@'G-*

HRV$YY1+]6MZ^DAAL_QB.P!,VYH] MA@O6=8O,R!%0R^R3NS#LH<6,$@FYQ7QJGT

M@1F51Z9VGK([]0P7/@JG8AN68LH349$GIJ5(0\T:RT0=6AH9F>)0[I/_J C: MAL7*\HK=4TU/[\74OZ?;2Y*O.H'K+=?U?
%/-6G399%B#W0!.&D2?X<,V6[C$ M#Z-U1[:*LFWL0*$A/HZF9!QBP'4UV(],AP#>VP2S;99=BKV MB07'5?3QN-
@X5@Q8FQB4UGL:Q5Q*.QBU)TI&RYNX2&4T<6E3^P[>QZ32/B87 MTZKDF_6Z4A92!;QY@P/>X*!H4=.5,@'(^GL,+%"
('R;?".8_8IG=E$&H@+]@ M&^F4]@8V+N!]0SA9G;%?YW%D)74&IID7M6T4697;1^]||O1WUZ,QL(7GCHB? MWQ)#RIQ:)D%?.+
/E1>X# M@D/96XDH4#H#M:LKZ5S$2E'0>HOAB^W8_A3=Z:X[/H3!'33E-F+_^4,X7K^@O MN*"G85[M#*2NE-
$\X#B1WP!EF0,J.!,M$5 : DK7RS+-ZE43Z>/5WD5T54NX M^+.7].C>,"VS&LM;AQ9QAD-%#3"#PBQ
[PSTK]SE%0RM?) ^JU<4Y>7'R*DWP M'D->1F=@=M6,>AX-)J^<;F&;J049_<-V)P_P:K][JOVJ^=5^"R1?&*ODBPLL
M$7P9^2)&T7P1U-1?[=GLUAG?.8'E/-M 6K2Z[LE8T\Y2LE9H:FI_BOEQI!'4K?W'ZO14(_V3"@:ASN4YV]O!NRAA;]G<-
WCQ.XT]C6>"1;(R M5^"N991'_'|&#[W0\P#6Z+^AS>P'OYJSX1KU2.X;<(;A@\;0"Y7$GK77AV'2 M-(.Y&M^&$:
<+0&W']>WP*UB+/LB5L=K7TK3/M63XY;E[Y[M);G;\R2N+&Z'N[,\2#?LLK(14UZL3+P7[K.RE M4'O2"4LA]8P#=?
Q*3\SD%,QB))3^&9_7/N24=G>C;'G2'-LX<)>HTQ97D$G> M1U>-G8O'8]S_ZWKVGZC_4"RD>R->O5G+"^Q_Y)->^ ("<|
M0@6,OF9O[2^>Z_LTZ2:.YM,_6$0__Y!'P:784S>@/@ZZ0#^_M@=]19/3XX/KB+'UQ)X6 .[=%9MGR3(YJ?R N9N0LROEEX
M[C@)HL(T0'5X?:A#TX@:MPB%P[HM#320/-[411\)8^(V84<4IAB],Y#$KI)1B_\M M)Y8& *K-Q%(7K1QQH!;/-
TIZ5]1.3BODQ,&)HWKBV-.^JW1%RXP4K72?%$X> MC8%0F\FCH*)U/'V4I&AI?9I,VE?21[FXHM4$0+696.JBE2,4+4WL#.1^5S6*
M5@9J^)&G2W'8_6J/B$-;"'&9FHEQ^.I M+*U$1H3)6KH[Z>%*"0=7RW@5E>)IJ& EY#YG1:U$B]2O6;*I3++Q$L.7 J=B
MDNT$/)4EV31$F)2!,"[9&@>NNK"5(JGTSD#KIU6@BZX?<"GVY]\M[SO!JB@W M\3',$^S0ZR@\(TM[:FF4+JV-SD#L2OV3>P
UQW_9X,]*8(MBN+@F)G*\L;36EI^S$[PT#++!>T]O<_]
M,PF2D&L6WUB@K:LTQG7#'7TEB^_C\526^%:I^%;3G@_N16X5@ZMEQ"I'LJ%S
M7COY2.W%QD?/W=9WLK.XQRF!TM/*J5\VG>RK&EZV2#?ZG8&J=L72HJAG:'U; MF;.P;4 LI V<@,22E %#I*==)?T4.Y?#LO&PK
F51QP#,B2*0$, ^V9?'8=@N M&-9<0L:0J9B63F^YQX'8>" 6$]-G+]9B*, DY:[13]MB7$RW")8UH?(8,8WG M-L2N(EV$$5-
3V<^S8N7.&9/=#H*3]G^>N]@BOY_??\WU-.|<+*0Y(CZVJ$G)7;XPM7=TG'-/3,EY.+$0OEA6>UH.+RY9AYE)5HY9E-
*74TYN8M6(VB;1@!^#I /PK]C^V403^L^G,,.C@9_ MA0_C2P[2>JIP 1JAY)T8%]C!)1O^_"+ M.XD_BFO:!JXPIX5NX??H 7Y/V.Z]
E\!4CP8_<:S$*B(B]":Q1?"\SPR(O8+ M$29A$'I$@#D3/W =TA4\=VG-@B7-$X.736R8ZA0>""^]96$M,&?/?"R-K80>P
MV"_BB*)/\;'!U/;P$]AC6#W_K)&]/QR#/*-=>#]RS@+2] -_CYR)W#7H]L M^NC57-_3P82+B0=S6;_/\GT7+L5'OMK!=#5R=P@HH)
(R&D)Z[?+J!N>L87H_M@BD1? NC-IA.!}=Y]C"D; (NSWCAM_^QYHOWG](5H80%$(1E._2A\9>X>*%/ MTW'7=TZM0)A:L&
(Y,,'U_L'%?F]%[Y1X+I98[K[&4TYN0?P9+.D?9(2[M/_IO:'MLC2QA& (E8)XC(&AH.W3WV9)9L#R.&^ 7BQGLB@"?X>X%,&9\,'V.
M;],;QB%AZ)S#CB#BUSLRHN3C?_=QQW\&5,V C5)L("4!OZ._1D/*@G=/^)W M%R\VK-)ZBJOI(%#M^<*R/5HYS'(<(-C9LBN\3HD#
[,,3X >B'JX;34&8P(+# MS$>V!SJB#])E1#\8PT!ACG3F.,N1Y7E+G(DU!XX/M\^M)5V.(0YFY,*#K6$$
MXW!!UXP(0+#PH>U/Z5!@8IO+,"&6;P_MF8VTYF5-MBU0_!12OD?A,O4(\$FX M9>H+!,8V%A[)(B#S(6R-
W.*4E]2Z#+"+S)L&UO?9X?R2"NAQJ?XEAMZ>T[I MXQ[\I9_^LEF?R-C61Y+FQ,-D6SLY3!,QUYH(Y]GV\EJP 5)F=-JP-L4FL:<4
MQ;Y)I#4F+-6?81(85#[&*6] +($79AMNP)B>T';G!!NU_KYAN@AO;RZGM$ MFQ_S@PPB)D32):5"
(A9VO+QR#E(<]&]MFV=V!E(OSX 89I-%<@B(S31@[:0B M93MHZ#!!_='UJ4!!U8G*+Z2MCRZR>E1WX#=J5%#]>
S@'Z;IP1UW#@AP_B^G M?Z6)K\NX-$VM ?D%+P^V*0_N.X#84!#CHQ)*P!;KQ||^@=1G[Q?C]^-6XXU+_M8GFYUZGTIT9_ZO2G$;,-
LTMUE6)HT7:C9=>ITL32?/ZQP WX1J<,)M[#Y(N-_M6/D73"6-&J/?S^;WP@HP9YS$/3SXZ97,7LC?Z8YEC5_L#)1>NEAN(\;/:_]T
MZF8-&QLZ]M(GRYLS;"24K('+#1_X%^_+6>-&Q^F.<1^ATI0_=+@V:^@J#GT7_MB6[P]$U]'6_"<=M@@]"[DAI\)-X4B659+EQF.
[VCQC$\[?VK/0ZFL0\M<6.D M_?7MUA#X/9AD'_+3FMA!**!>,TQ%D1M:Q43/W%.N#.V82FF/!$5>6):BC34
MK+%,U*&ED9$1#N4^^0]V-(YNFGKQ%!;6,]D9>L3Z?F--8-+OK-FKM?31;99< M+5BJK=TY:F'WFF&#OPX]]-
BE9UOP%97OE)ZY4V9/^.N&:S&M/V^2Y2NY[FOL$LKIRPHBN@% >5NXLYF]#OA#6BOD=WHOWUW
MN,,#)D:=W&NV2)WJ,,&9M?#)N_B7]V/;7\RLY3O;H<.D-[W??!R2^'9;.ZXD M^WI-
_;T^XP!1@GWTYNCK'G5U<_IS3>V)DI'Y5;\G9GZ>]RA1[2E2]E=YC\K_
M7)6+/6GGH*2=C]IS*.&2"CUD1X2R@JD;0;"]89X,@5S+M(U]C)[..FTF'K_"MAQ8=;--";9NI\L8ZU5T)A?+01H5\G1!7)WV*:R/L>W?
_)4MQ6$OA.]QVX@?? MK(!0[\;X*_$0#*#>K71XD)\K$Q_]V2X/4=SKEH:]-MVB$_L'&=_\23PW
M'2,PQ/[JH&VY:167GA'%J>VJJ,THB]KV)C(9HEAN(Z9F587+/B#=0EW(K%2A
M$+$58B^C&,J6*J0>H0I5/'(Y=^1TO+LT(5XR(6^;BK*D--=1.@/U=)[#RVLT M$2MROURLJ$W"""C?'TXZ^_M5*W8Z
RD;I^W)VTIE/8T@"X52F:SH%2W#766(D_$FPLSUV))Y;<+SYY17LOK M[>Z@B3U=54MR\4GEN?BX]M]
(',U)'"^3MTIB2;R5&P<5&P=JI2JV1),SQ6JL M@X]'+NL2"TK MFMY"05EM1%\6,9RB]M.%\WXZ71!5/'0I?^ATP-S6.Y"QG)2-
4$Q!ES&#I%M" M)K;>DV$DG)2LD)!*"G-@A*W]7+D@%)M1H!,SP=K>]/ICI!@58]E=F-$:MXQ9"N5"J,:$!K)&K3A:[' NAVJP
)7)R94:#1$W. M#P8]#Q>G#G9G, C4C8&B9Y3O*BL85/7*RKDK2\>[0#0#^H@WPT(CW* YD$F>
ME'V11IG2&6@\+-12K)R47I'&B@I8Z3<%*SPLE,?7JPWR*]0SE=$D;N9X['A0ZD*V45J/B #V=.D)T+&G4"#V=FWSE0JG&
@R*V2PH<9,O M3PQ4FQR@]C$1O!H!5O'(Q=R1ER/_KD4OKC&K095*2COF)E83H:36F-6@RLV" M$K? EHE
JSBD9NY(R]'@%V+VEQCUHC6 MI[E4\LE^'VZ!-1)*-6:-:&*SH,0ML#PQ4&UN@T;+8&0>=-T08.81 JSBD.1Z[LC+$4'7HOC6F(:A-
>P\"K>ARH52C6D8FMDL*'$;*D\,5)O,H/>I M&"@I\[[@8'=FWNM@Y>L9 \O.O#]&P%:\LE+NRM+QEIUY?RUJ?+F=.72PQ$U9
M:X@:STV^4K&BE=N90U.1*[LCI>+D%=B#7J;'YB:$V2VWF%EBY4*JQ^8FA-0M*W ++ M$P/5YEX8>FZ'C@T!)ATAP"H>^:[>
(C!>;H$=R'5JS!HQ3'9@56R(VLPML'*A M5&/6B-EO%I2X!98G!JK-;3!I"8R,@G4E"+"*1R[ECKP< 78M:G.-Q3O,AE5<
MX!98J5#2:RS>89;5R91;8-4*,+W:5 A3Q>2\O=6G9+FX *MZY%KNR.EXN05V M(-,8$53IR,W^
MSC2,$D30M2B^]:5AF'VPV)4&A1ZX#54NE.I+PS#[4K.@Q&VH/#%0:3*#V9<[M ZTG9S1'V9)@1Y3PK7KH2O[0Z8"Y%74@WRFU
(?91[-B&HF54@MP ME'VM25CA5E0>)Z\T(<'LZ\C)S;V.O"_*&%8]4P"#F0K]=6D,$5:DT+33O:]<".ID5"JKR:% M*=*:%$;_9
'&;:B*!5BU*04B38;8&THZ2H!5.W*IGSOR<@38M>C%)R5#I!B+ MA"<4]*;HQ=R&*A7EN5&4B.Q4FXR@Z1U!J9B-@0KW
K*8^35I@1(MM">'N=<*.D8$53QR(W?DY8B@:]%LRTUFD,"LUDX_[,BMH$9BI=QD!KG?)*QP
M*RB/D5>;$B"+!W6U/TH$53QR:4=7>VX%' M;@4=R%9JK,V@E-4B@QM)C812C;49E+):9' ;JF(!5FU*@"*C&-A?F^$H"5;Q
MT)7\H9O-BE H>D, M>P_&*NH1,JCBD1NY(Z?CY5;4@6REOC87IH*%&QI4EHQ;4>5"J;XV%Z;:;Q:4
MN!65)P:J32E0L6AF3]721P.V)-@1U86J'KJ4/W0Z8&Y%'D8FM0L M*'$K+$\.5)O3H&%%S_T-W]7B*>V5CUS)'3D=+
[?!#N0ZY29C:&QFUX[F1 MU0:LE)N,H6%M"9.?JFK*EN;DZ#3= IC?RRJ>%)ZY4.7 M\H=.!\SMH ,92XWI%#I-I^B?7M.&FTE-
A))88SJ%KC0+2MR*RI$#8K4Y"?IA MM2F.D6!5CWQ7;8HR!-B5:,.9BCN3*CF/\&H]$'8OTN"O0P]!D1[X%B8B M.!M]#45;]
T9WP;QIW(G_QI]1MPS:/B:0G(-%F],/(3^S%KXY%W\R_NQ[2]F MUO*=[= =H#>]WWPSUV6)&VESTYNCK'GSU<_IS3>V)DI'Y
M5;\G9GZ>]RA1[2E2]E=YC\K_7)6+/6GGH*2=C]JC 1^KZ)Y#:&1SX"Q)R^_8 M 0S9+G N>RS$0]PQZ8A-
U3)M8VO6>N:L'\DB(*@)"W*_"SJHI!RP CM5BI8N MU"@Z8V%L^R/<';\K
M+#PRM\.Y+UCPN>W[H>6,"'*R$CU\Z)#B*B5ZN4I%O2F101C'WW/;R+$^_%50.DE>NXKBDN#=SD]5LFQOE&-
+/I9V[I[NI\6U+]!XM^QXG8' M931W!FD\B;?2>CUO1BOD"!V>T3A\7$;1W=$9[378MI\UTU6>-0O,6LW 2#\N MLO?*K-
L]%;,'$X!/JX+S-V8\,>.+J8U-R_072.G?D=#T_4TP"_A9UZVMNTSS MV$?&_YLE$WB2/$JC46TO$=+XK20KI53OX5D)H0W;:8R\H[/2:
["-*7#PRHS< M,FU^18IENQQY G552"/5Z#0?GH M^)EZ")0(TQ+9P(+.=[-WQE2*IW0]$[$LR M?.F]
Y[*7&5=RFU@"];PTH=%S+1]M]S01!)D!R9O. $F-X?#W\\VJ1S-_G1" M E5;L1QJ5[IS;'U7U8)-GON-86_O9ANE+^;)O HISE*<3^N#
[2/.7?#&.HWV MH*S$F=.*\U;5::55/QV[1.QQRERF:/!_VU%@E>$I8&P8YF0"W]LZO&C,_!?& M;.6?,@56@^EX-J28(M%<<35,9,24'-
T)YL"!_ MGHCA!F.;(?NH,*]\1$^1 M5HM)8-C>-CTF&[N,_<"-66#L_6TZL]#Z[#+\PV*AP/ '6X"A-)27J:E/E:GV MO($%@>/V8ZS.]G/[%
XB;W1#4(7-C+5I[,E(AQCKB(#5,E8"F6<_QCG <-LM M'&XZBP%("X^;\V=8B^9R[!JT\U#R[1\G@7_3.,_M)>/G@B*:@QU;GI("
[R8+K'Y)237 "M*M)W\|*C1VU4VAP<%+X8)#5 V.[J9 MDZ?9"OV=PL,^*%X8#!M;V#:'V8!AW?:.PSYPXVT8]FB;SML[C/O
Y%9;6S2K MVV'8!]YXU/86#8YV\R8/37!U"T"\!@6PEM0J%I\55I\YRO/3TF9V/\&I[53= M#=,"&Z_?6]^+XWG, MN[>S9EQ\KF#-
J1F*==F>?8+WHLF^;#&$&84T9J?@-.!UVK"U.#-&]86-D#(W M#IH'N,?")PHV(XL]Q&FTZ^'S;NG&FEA9MTMA!N]%F]-R(XU7W-
N-H?$JFUL; MT,4Z"%#$2 DH;;6A?(0W/&LB!AGJG%_]4,5JX'E";,P-E%,(H XXQW<4G;D^_M\68B;MY,4U-
9RT_[0JSAHW#*YE#KCCJ3=K7*UV>MT[LAH0K@O\O(,TT %D;2. M-]5 R\".#%Q%"L1;0[^F_XV__CN;@99#S(7 MGSHN%O[&UW
KIYT5JU'!$1QDA.F4,$R#%HIX)!JQ M77\TGTW@<:,NH>=;6[D.GF!4@E&_:K!LL6!$H'A<0G"!/SB::R!3?#3!IO,= MUT-FM4!(#.6/0'-
A4[86BJYY4Y F0:Q<0QZ4LU516([9]JN2<./,0+Q) M'J*%"1_U40P]XOE6@N<'F],[U@VG?:#A#'<;3E?M'68\U $D(]9_X4R!V8A
ME1DZ/R^8!4%G%6"#Q;J1L]O? YO%W!8SW\I)(YC\R?AW-Y\3M76\N#,K=M7^_M1F+'%-86]!.YRHV?EB9SI[6&S#$181O3?.4%-
+$RCJF8E,INLX"7(,&42!S_!<.BD7Y7PM!4R30'([=AB'N;Z_N>7J7?/ M0[$PO@6?AJL[L^."W_-VT3L3CE,GN:M

M+ZH^3M^%>RUN*F2!2V5C4Y?)?]6#@[\!IX$?<$Q@7R-+:XH@/NLAMPK38V=- M=^ZTW0RW4V^^0J-IO\X"NV&-^,
[\1'4T'S2+X$0U,AHWMUDH$T"@WO579U]> M5:@,NZMNB\"6/E_*.M+N8&YJ!1)*872UFI0[2FEZ7=*4:H2PGS1APG,)})=5
M%Z8#>*M2,&LNF,7D,J5W4GUUUJBJ M=>>/8A5NQ"(\XAKP%U_;QF.\(1@7CF>5'\[@$}OB.B1*>9TZ :N&UV1],Y=<' MY2>!
[CGAES#^O,W/5DR&(.2;?JN_RH&KO\\0%(3V<__V:[#,: #?FP>.ZU M-7/:TTS>3FY0%O H_[/EO% 3GK)5=
[=5FNJ6O9\JR7D[&LH[,!F/=OJ,PS<5:U;PM,3B/PUVC.G.7#+"6[!NE3-"58]P] M>#;-FSW$JMT_Z;1*#"F9*#\5H%P>:E>"AUY36BQ?
*,77?FXH%J^G@W6T(WW@ M]F\^B@IWKQ/\7$;+8*@.J-Q\JB$KR$8RE%F9D_HR
M59\\S#D[/BLUAEFVYNM50_,=%5*%#JY/P0G+N"H<.U6 JG3W.%;/*U6LO=!T M.ZE&<7M5C_;Z*!6'A$_5KQ5C+5R%/*6'#7
S@OKVNO5DZV.',I\Q2S: M*X5%L:U960EYY\&AKXVK"FVJ6Y(]" HWW.R0_.6A*.H0)7O::XLX1C M*,/V[U>\4+/?
LV7;AEQUM'%>C)>,,;Y+X5M6NV*]WZYSZ%"&N\ME[A3<9,69 M6QX)GAU#%O-&J@['T.]48Y=_36G $HYA'S.Y(J7&_?*.-
&7Z7"4Y;T=#N;1: MXWX/5'-[4$/NDMG"E;!Z#Z\CRRM=JR 72\[+.V0\O(H<5$E%2C@&"<=P/,OW MN%7(?0D<>7;L5O! (L?
>/4P9'>I7@H=>4%BOA& Y_I%]B3?) MXBJ>'9^5&]$LN2AY@(=1%>AL(T.9U55]>YS4EZGZY&',V?%9J3',LC7?]!J: M[S7",?
P]L)G2:4DTAOW-A5&IE:-#!%7LI'-3*E0Y*HN2C[3O=W,0Z+;D*.S/ MU4LGZ]>YUEVB,1R+17.PZ[9D4?7B2BTK'^\\,/2U<56Q3;5<-
(9A)UL#5EA/ M?4T13PD$4(+>K40'\0Q1ZUY<#=(G"#(\4 >>2^'.5;M,>MBK<[Q*QEC+9>X= M8U\G8VYY#E5OAJR$LLW@NT&%-
OC7E':;*/^W8-UV3!8XWZR9HYC'!Z]M'<5'"%VG%71"[I;0RUR&>K_72(*=GG1(H7%&.RBN8JB 7UY/S M"AZ<5D5/CMH5T9,2"4 B
1S/!CYN >Q(8A:>';OM;_@>HP)VA&=[_?[IL\AD M;+>ZFO (M=D%-*'L:G9V[+:G97L41=BKB")\34%9B06PHQ%ZE&KMD002K#EW
MK=&TQ^&N09VY2\99CV*"EEJ]/1IF56^?/R]*_CF HLM@GU%UV.[WYK(R3]>+UL.U6NT*I53*<65W^/&29=@$]*$]TZLUGIU*#
MG0JIP=<.9# YCZ;C9F; Q"P9;4<)^;[#E#?<)8?26%+A M^M..Y81E$*C:.]?@07*JP_L^U9_M5O?
B2MWK8*3TY3I10$4*K!38@PCLMDVI MMQ38WL75J(1TO+.7US(=*"G[4O8/X8OF@"5N*?%]V*+3$K\7_L?YBKT452FJ
MA]BF2P4J:[<&"%1V]F8U.?B_4%0B\F_YC.Z"&:R*'NI#|><*4=MYR5WW@7_ MN=;U8!98FL^,=
<&21XJ+P(,_6$#]!)F'%PH#ZL_A';X;L.7,_9GF/IEV2+OA MLB#CH9\Y6?"O3-M@MO].59LGR>Y7L[+[/<4)?(PX7-_?W"J:;2RG^#?
@3]T*.M<'D5EQ'U\!MQ5J:PGW,@((/+7IA+L8N)8UG.BZ>\,6T%AF_A*]Z^6PY>T#^T MW!%C)]* >IS7]^_V(:_A1EM=GB M6ZN()
(DWBY^;\-,OZ>\[HR;XKID_M9KM@M_W.MDO67?'ND&UN\U>MR,'E3\H MM==4U&T'1%QEP$'$$NGA(XMCVQ%]N1JL]I2?'L]7;::
M\&LB6J=|&3R+J=|X:$EYH)'@$RTA&B9_';N_7#WX\'$6"IQ(ZP%SCAL[2_3: M]5QI5Q:JG%.'E;O*!,PU98JUN]ZI;61PS^#9?
E3=]>%R<-ONK0?(ZCLICZ> M+M%W1#]9>=),>WVNWXZY"WOC*U2.@-M'?K*F6.W83;$P:VXSXV=F!PPKR6X$
MC_W#]*M66BZ^N8X1P,;JP0*68VF?]=QE9'-Z+-E\Q.Y0W
M'#\P%:B7]3KEJ:=>3NN..\=VYLP%S]!^XH[B)QI.SE1""%"D5J4T1W)*N<=R MO50+C37G)$JZ'8S"^R;^U?27%^5^T; M/MC7$-
JU4*!6C5R*Z;:]-^-MBUY. MS;G=BZM>VB\M#/9S'CQ:,V=5G R-B4$2*2TE>ZX'.1.0%ONVNQK(O+#//S"; M3U8I0_&2AV#
#5SZ[ZYSK/I(8N >B]1 MNQ_0F=G92MC*)JS<"A4^1*E+OGBIN]P=|V/S-5-A#4!A=5J']JXJ8JQ*&7H=_M,G0@?S)?FH875UWU@!Y?
1>2HKDX?++ P!F28=Z\P[^D'*$E2@:LD2=:1)/PY M5# ^\X*L";D:1^Q/;5$9)H!Q=H?NKY&M&]X^VO_\L"@/NX)O]2I8JPQ"5L*LJ
M7.1T7HRY:X73WN5-9TC)*P?/O%#YH&<5-JGIQU4NSS%EG3=8L"TX6-\GBIO-3;L5T M6PXHQXE+1-3.Q97:V1M5N=
RG]KNE_RZB5]S(#-.S;_=BZM^]U6Q:\W<5%G7 M5#7]4-!8WVI#VZI81>V!A9Z.+)VUA2Y99-L]9#L6P7JFM+X_:Q:IF1-7WU(F
MV3SC" 2]MN(K=6O,+=]0L1A]_S!GZ8M4T<-+*:923 _@XN:+Z1#LUI)+%L]7 M2NOJJ,I:+%EE(TDB27)HDFSN*X9_ZSS*2N'51
/P*\JY3G6N"E\FE%E7Y1D; M<|>)?G!-N\^90ZXXZDW:W,QEI777>NH^E3&.:+ MZ4]-^$:9FLS57'VZ@-=HOC+3?
IHS&">]%._&MXUA$L_4N,^TYX%X%$A8(?7IS ,FA(,,,YL!*^&9:0Z*0X;D2EA3+6|+5 &O$<0_,U&)^OP8(8 MRL1U9N :!*X.%$.NF#-
B#9PJSAHKX#1[T51^RYCWZDA=-K&8[B=O_,M_#=7V MX+V'(PMF<]Z841MC:T:\JL1YXH+A@
SVS"QG#G.+9HYO&@.OP4,FCCL3G!*N M 3X:K]!-5P]FG@\LQ]RF\KC,DC$3F9X",F<:3'24]*F=G(6O]9;?&=(5:!E2 M+.HCF>X>>-
S&DZ-ALS-J%^T[V6^VA\5;(*[!7FVV!X-2FBD.1TTUI\/C M[B6MF7XT^.0G2TM MV'>3(X1+5EQ0>BS?\!OTV6 @A^"[\M?
@8,,UYGXJS&&&673_#HPG7.ZF>I[+P9"3BOJ6%OAPG#"T37%]8P)JIT,_VL:H'?&T;7V(6_,K?9MS;WQD6M<'2?=
\TWM$OLF(;75:&4&F3BL=VSIOZ8_7@_B3 M:< ;,^W?P'VZI7G>2N CBE_D"7RXN(8")$,96$$R@T7 !D+V.4%I"01"U#> M
)?"="U4ZV\+1 :.[O3#'M1L\6!S$:^_VVIVU7+<_E:SURGVI'6#;JO-P7 H M!W7&@QKUMXG:K!QLM=4-D(4%@9?
67>:"5.]K.9\2]^E_**[W0(17* CH2C" MP'\280:1P((79 49X* JB1@ MFH!)BW@-W3IET&W=9:=3-)6Z; >(V(*)70?PN[?
CN.SS7+3AP%Y<@N)4$!&Q M >X!3NN /'?,R\Y"*3PZOF95#BOP&)&B;'IPGU#" \K!O3;LPM-%9Z_#I()+ M,
(0O$5%)\=#WIQ#!;J)X#"0&>?_Q[Y=IK=5"/-E0\-E6FVJEUF\NB2 M8;I0QJ9E[8:1NF%_*$*WNE5%94VQ1G5-_=;FNJ9H4_OLN
^PI3U$.J!'-O;C MORX4GEWW_RI,G_Z[B?F3&9?_8:Z350K5:2<:.L"SB9EI+XRTBY+1C)D0:VX
M&HWV;A0OY4#*P>'E(*=OYT'VBH[<*Z2,G(V,J,/. ?>*;I7V"NG#RLK7\[U* MDE>2]WRODN25Y#W?JR1Y)7G/]RI)WFJ=W6PX,:
[\V^_B:M#H=LK";JP2 MCIODJVX_I]W@0<*C_=+"HY*I*LE4.0W[#L)4 \E4=68J=7@03;7-#CBLU@[X
MJA*%>.,L;^JX_B46"6/=+O56N1PSC0H4XW1%V>/P@"H]\?A053ZJ(;']*I M$DR5:H=8WKEC%[OY=CN2<6K).#G]!PZAC;IU3
"43)4P,$OS6C*81ZV2-I+1 MX+.)!E>]?HAW--S7")]%ZT^9[& MI#Q W$ZJRDF5*4-CJQ=772>G'R90VJF.F*A2-Y*
M\%;.H709FJE;'ZN&JKC>ZH+%=_N\6J*)RN%+-7)69YR?CEB5D?"V,; M:J\MI4Q*V6N3LKRF"-M)V6:?M5_Z6:P4L8HPFQ2Q?
>LW2MS'L*2ZTQAT>Y67 MLAW:S%:V+5R"2AT@A>$$8XLMDTD.K:Y#*RG(4H7 2G8+VB^F-C:M/9I?5K6F M1MY?G9JDVA?
F562KDO>7?/^K2J, ^4&&>[+"U]13KXQ7M6F?HA?;(8M^81!VS M,*6\U%=>=JN=S)&7#+GHXIE36:%P*1-
2)BI7$%K>'E)>;JB4%RDO52UR+;Z' M]*NTA[PJ\)3R2UUEVN8A2UW+VXMD7G#-&6RW>M?BRGMX<=7I[ZV\)1-5DHEV
M*WLM3TM)')6:,]ANM:^%M=2@524M]:J. 4JO?Y5EY0>N?XV$:\>:LX'$4]DY M:^U< YO-6ADLA% JK:I %DCVJ4@E[-
Z;J8ZG>)*URJB&W5HS=:NDF61-;+5J M8K,=A.V,<|-|#A\L[K_$B]^UD\6TIFTPVW]W.:+4YY.$C.$*&!N, H7/,PT&
MACT*IC.&R=#'V*Z'.6C^DAWN:\Y?.2[D3OR5P4>#BZMV6Y4\5$,>RJN4*XN%AE5BH5>(
MTF+%)44G@FKAY%^M[L*YKRUY3%6HUC/UJ40"U4.9>,T[EUD$6_#^Q33\:;ALB1O%?%OQ+=H8IA;XZV^9:>Z3:8>4&BY+ MK\
[P0';I:$M5F[U3'&ZI.'"UM7)TE?AW&N$/S;4G=CEVF?;C4IO ^-]IUHNV
M\'!EDA.'6:\0>B<;_3OP?'.R6$^DJ[^.?62*]\!7>""2!75TJ7*)@Y^8<>U' M7W+S\.";8:
MBD(2\)]C6C9;G)XB*B;>+'YNPD^_I+_OMII=-?NG5K-=\/M>I]B3U@VJ#5PR M',I:G?&@1OV-CUJ#8];>@&.V)09)WF6N\
[+NE@RC2JCEHQ@/PZUPI?XG<'QF M\+UZ#ALVW6P25ZT[=!QB .8'!V#[1QO&GS%6<,3SM&36S(/4\6*:=*FF7IEU@Y]*M
M4P;=UEVV1L>HA]/@__O*]Z5>6^OS4?FLJC2W;I0AF;EB5A/LL_,ZKIJ4]WF /1%FUJ MGQWW_;:TAVA'^\C&?OQ7D1RJ81V+
J6,U%=&4D?.1$?4D,E)>79^LH#^'JR1Y)7G/]RD)7DG>\[U*DE>2]WRODN25 MY#W?JUY5%X&O,.F%PG,OE5G@!YJE3&!NLH/ (4-
<.0#ON[GO6_2-'B*F2JNA M]O3)4#B7$0II+= VK-5.K)ML!1JV);X*M* M,;JGZA1OZKC^I<_/9&^!FC-5 M#E[']DR5P3PJJ.U.61
DG&JQ3@Y704.HHWJF#HHF2IA89;F"VSAN*+$6NBS[_?W=XY-F_YZQ?W?'L7 M5]U&K[UW Q094:DD-^747Q3AIAS322+\UYR5?
YI'\549LE7/ZJQE9E!C[5 M7L532J@72]CXZ\A(Y&N[4[P&W,PM)U\?_9*;B\W;X.0ZL/DY:FH;>U\W&X-A
MJ]Q^MCF+55$06ME!^O4UB,Y-5=\@;!GRI%YTV MKQQ;N/0322EKE6(Y*6LE%#24:"=BC7&OT>J?Q=:V0_6RC992Q"J Z0PG&!L
ML?W;)LK1G=OH2@JV5"' DMW<]8NIC4UKC[:25:TYD?=7IV:G]H5K%=FVY/TE MW_^]DHP/5+@F^U-
M/<7Z.$F[UN%YH3VRV#=64<"RNS# M0Q:"EK<7R?36FC/8;M6@A96WVKJXZK;J4L4OF:@*99^E:2E5PHS4G,%VJ_TL
MKJ74*FFI5W4,4'J1IRRK/G"19R1<.];XJ!)II.:LM7.A9S9K9;!0]^^J-VA+ M]JDE^^Q(5:+%1<4G0BPA9,_J]Q+ENN6
M1J#ZZ*5THNF(4J:E3!_'2HBTUM4ZG>P-4;C-5*E M6$NQEF)],B\T3ZPS)+=3AKL@Q5:*K13;73W_LC=CA,UIM(?#6D@UA1!^\35X
M870^]/2*3024#QDZ2@]>1_!YO3A9+!U&JVNQ%1U%7?QV!^(KDX4_B43/- M?3+M<.+#95D5#S\<^]$3WYD^O$[?
S)!J,FWMD$>4/IKLXY0I$Q 5Y1EEQ5.($KC)S;+908"H_F*_,C_0+&4"#.TE MB6':ST"F&L,=
M"V:.JS44C8;TP.8^FXV9JW1:#45MJ5VZZB/3Q;=M^K8#U[M,&6L>O!Y4R1^! MX\,G,8VY:^J,WH1"_,S$]S"Z%].?*K9#-.
GFIJ!*X5#:].#J1/)#7AW&O+ M"KEUDHLWT5#T3?5.Q$WFAG15XBMB$QWT.EPWUUSD;,6?:KXRU9";3-N@BP.W'O-
45JVN\5A[,^L!F>H8\7RL-?M-G_;>&\M5QC 5=-GCOX76? M35^?-I5_,5&!/L3C,A/BRI\Y;'$*.&1OO8#Q0PFXZR.?0T(:B@3
MUYDI&CS'=(U+G-,B(02P,,\@,GR.@<>03"C)SHQ='JR2.8'=":9OVO-$-89XZMP8U(8T!@$VC!=ION@ M2^!V>
(GXJZD\TH3YK:04&=E\@;33$ERFSEP:) M\]4P@6(&.A8F*'04,1\0#Q[QP)AR!U\J;;6AQ'(+EP"I U*7-5%*Q1-*SE=; M 0E5 4##!T
P_%G9P-I'0,<_-^T2-NYS-+\) 5T M5+E$G3$#N0)Z.M8S,_A4X_$J,Z:AP<]-BTA/KDXYLA.2:BFP$]H(Z*AP'*!2
M@;&9390@:YOK!2"'*$>A 8?C#-+BZP#5U2;#CA=;C TE!'AC80I#_V60O@=/F.+X& MS. I #(Y[F)U<"!.\!ZP*(E-7YB%?
1@2K]9L.PCG .HOL1A<;8M=%N8 2A;7 MT44GD'_&02X/?6FL22[;PC%!5P*J#6,(?<\S.0<]
MQ@V2$X=9KQ!Z)QKM%$_@_Z[P0!BK::NCRTX43+H#,PF\O=7HT6JXZ$&?,B.P
MV/TD3!FY3FS%'Q;)O]8DD#S"TS]8COXC$33J78!HZ]H<0RANP,HDR[%Y9T5! MZ)KK+B@B,L/M?GLM\<+0ZO7 ,K?0-%#>P -
AN!;^^/;=OL8LA;1B<:80&E#(MTN8>>Q=^>![F>)LVS9-N>K_\!N3GU208?"'_.6;U9HNSN\C'$6\6/S?AIU_2
MWW>&S7Z_G_E3]]DN^'VOD_V2=7>L&U2[T^RU1W4>5&?8+6=0:K/?5:LV**"4 MNIFG4.OBE"EB.P5^(LL#I2#Z-

#W/HM1V9,8]34[C-A-^343K["N3 M-:6+9*:]F>E(_1E.>M3^@8&Q:Z,!/]8LS=9991IAO]ZDCE>5L]'-@2,KJUH#*

*MX8A;@W/H;R0%30K: 01M<(C"S0Q!&\#NV2TY)4H*6C7X30I:A>H/A^4G%$LY MJP:[23G;!M/G2!O:"#:TP<$[J)"Y'M*

*M32%;84U)L#:&ROP*Y=%T]B:,G"9 ML3CQUDR6C4C,JL.%E$H#=4S*%D_?N{6O*5WO?I+G';G M78F5$/"I2NS7N[AJ=_?*

*9!23O55'A55??]<&%+@M^1S)=M11>RGZMH,(:@,+K MIQL6'5WA'0D"_:3<\XE75>V3#K7!=95,G6KKKT+J*Z=]2DD'*

*M8EWJRKOW%ECN,IXH^B-%6(IPF2(\/$3WA@P11O3SO7.TI 1OG)T4XJ($JH\< M'VDK[K6JL1777I:E(,O=^'!2W**

*[';KP&03(&7#ACJ(/K@D"#",:S-4+*W 46 M @^ M,]?XHQ'@%"[UIO#6J6/!@#S\C>.J!'-$-HQQ?-A<(ZB[!# .S3:!C9. [B'T*

*M._@)4=Y\Q$IT30=>'@(2S5WGR=5F=8$F>PAF,-Y%B**S"I%)&#=<34 DV808E MH-G.!Z^L($5N$-DKAB\\HXD6!4#55V;*,?*

*OFP.$_0\"F$",M0D01=QN(<^80 MRQ!PU*7/W!EL*GZ ,(<3#@Z5R3?[R4V5&>>#X[K."X)AGL\4-TXH!Y23$$FI*

*M>PMI5]OQDP!Z7U#9*JH 9FLJ1?<=?*'V](2*V-_NU02^\Z=BS72'2W;1<-4N M0GA*S-Q!2V 3//XH80.I%U>]83.=9J^,.1 03;C@,$?*

E#[,#PQPUTQY7.R MCD.$/,04LQ81BE]*$]#&88)&8&/_$$OPQ;&?'D&Y?(3G9TZD2_1.Y^ =D-ZY

*M8^I=7/5;&\:T3%R.8!B)VIJM&%@>WZE8#HBT8GHKFMK+7)UBL-+B*1[CJYG0 MV@IBA,?(P; O3& CH])OIW@&C5ZH!^^E_;*

]Q'!0=A#T,'!=?GCHF:L+O1&JL'QH/(F#F,_" MF-.QM$2)?W%,J*3,H=8==2;M;FS+['5J% MX^1N1F?/0.)W3>_'$@:SB?

*MNB*DL@&8YX+$#EQF!SL@J2-W'D7EQ)+#^'&D[MX)B\!"D=X !U@=]N9"YQLI'%NJ8#C?0OSMPGXR:C!T$CZE6P/.F\A@34&H"&*

*M;3#,8>(XV6+PPBR*YT &3P3-30]/[&=3D!+FO4=Z@&'GA(^-;\:],/$:>!:_MA09A./1[X"W?@\#_:,H%?-NAIB $\AVXR*

IUB1/=1$3E)*F)O0?KBD900FSA M@V=BF%E?QH1-AT]VF@RG1S3JR2$H48'UZ$04F4L M%XKDY#1P2X52PXAS=

*MI%=1?)*ZRP2N2(QZ]!^LP!&L7<../T[R&$3!3"=BC&"98QONFQSJ!O_&Y:,!MTH63P*4X M94(GAL,GY4<&&N\4DM]!!7F*

*6!QL7P+L=R(]]/Z-_ALFRFM!'-"20&<.N0^!!C#>T^ZUTV->>0*_90 R3P_,C(CSX)*

=,AK+ M1DQH@ESKV+@$6 &C<=1N!-43R6Q@@T]F46.")}B9A+Q(VO7]*

*MS6U.HX(//%=8>9@R:AX6=3G1+=@30+SPYAGJNF_+TEVX_4%XBP>K%TJ^8O!(M#"<5_AHJ"XRL\,6!>4XFL"0*Z!Q$>ZR-*

NG@,MZ#D5K:%3X&>0'K#7C:6+<=^ MXNJ98GS+]L/J"TSA/B1VT(W]Q9K;T ^ES<.@7=XT5E0DOMAD373((X7?64<*

M:KGG83\84S0B!#YC(&N&\EOSH0G&MV7!MD76-@7G5G4;/ZE"MX7-PSW;GR:X

MGN]H42L<+A.KC^&3#6D:^271R3+&Q_#80=AGSO/]7)=>B58.W(HS6II$/#TR M9=:1H0GBH6 F W>]7K QFV71$?C2X]#:B

*FV@:QD5?$1+O5V$[2;X>E=U%MF M>2:"[IX0TE6ZF&0,O16A5 C*XH0*M",D523HL6'4)J&",IF M+ GU)8)U!TL<0Z+B!*

['&G,EIXNOI F-$G2#KMG=0UKSQ#*IZ+J&% M-7?('%QKF]S+X(^[!AAM?N/0>IL6@NMK;YW"WLI,IAK\N*/)\M:.P;"P*

MK^EWE%&PG&]PT4+3^0&6S'O$@[,P%B_59^6)H^96G(UVA(=+65P]OK3HT:Z MT4G]53MV/CF;-B>#9G2D">';3?*

%OW"@I!_9)R,#UV9E*Y8],PH2\';)0I(L)EGLF"PFL6^KA7V[M][QUKLGN4.5*AZR_3T5D/MG=TK'WLQSDI21><(@?&M^B4*(J^*

*M7ZH)S[M]<:6"'Y:*Q_\9'WX/-U'-O399?G_\E_#3K]I,,SOCB:I"!QR\U]9DQ MRCI-G7^B44Q38\5T?_^ 6UTT=4G-*

A.KG&/5&AW6,!FTP,=<>I8W=HSVB(F> MWTY;T#'*FF>U9;B88S0L;[L=X,E8!M/*=B1GQBCKMMM\K5=PN^V0FJL"PU1A*

*MNY7JNHQ3JCIHZDS';&=-G:@M?P>B?6DX_J5X4J8:[UY_K61FZR&>0$5+S]31*ER M NN3EX]^P 6ZKGFDJ!:Z?@GB(P-*

*G;*GZG4XD8Z /#N_BALCF>$4"OD5 W;[MP6CSN04,A)5]5'+QZ!*&WH*_+<3VH]I@H.!*#76]QE-@:]*ER?)8#L/H$568*

MT51^U4)>R5@^M=.>J(=DO@GI:@H<,XN\$\@+ @! MY3H+J[U%]>LR)Z\JO3P5911#(>78'&'A+2ZV+I#@QDLRE7BL%XP]]D>

A?)M M-7Q^! 4H)V5NBB0G0S[Z-298VAK#'<9>)O"IWM]NW5LUWTX>'3;EQE4ZAD=+R*

MJV;;^.4U1]^1\B1.ADH'QABQ#YJ/S./?P<8\$IW@'U;G:*Q<@Z%I2B^#E$L M)HDYY;['$,#AQ55[_Q;,4@JE%%9HXL6D,*?*

*7^3&D<'1Q-=R[=$0*H13""DV\ MF!!V3RZ$PQ;V0DPWN*V@%!X)1.!TOO+-*

)MS\L@L\7VNA6Z8?/;G6,/DL=="G$T578D8JW3WIXLRD#M^R3F]=:0Y0I;Z,CZ_-D"1LO)/D/L1-

++:5M]7H1Q)UJ^5S7N=5G5YKR]YK]Z\ESJGK0[O#23OG1OO%3-R.ZFC MR1,:N4,P7LTL4;D)2]FRP3N>275,8$?

*G1\S4IV(WW#RT;> M\D*28\/NB0"[J.KH %T-)\ :$;3$^O![K4^0RB1-K;19ZHCWA-IL=''5[NV3*

*M\E3B*I\HGB1E6\IV65;RZ0^.1RV0Z,'>@"12K*582[$.Q?KTY]"C-HAUIRQ M7RG64]RE6'=2Q__%VL5[>^R*

/)/)=;EHWX=CGWHB>],'UZG;X%0\5DS7>59 MLP(F8"2VQXFH-/+&HZ-H^M1DSTS1"#C#988R,W\B2E "KPSQ.":6 XQL/ZT@

MF%&%7PC6M'P2N9PAI_A3S5?^"(2$Q-N0!0/?"[A<2QC=DQ6J=U4'@EM;./S MV62"^$3/S%K@M\BFR3GH3C!W;

\1A9:G$OZ0C9,4HIAQE+7H;4WEFBZ!=9YF MH!G1S#XR77S;IF\[1+"IMGIBNS(/0E?2GIY<]H2_VBMMJO&M?RJFX):33X;E M

F>.$FJL4U3U#H\ULB[BV]?MIC4:=\SQ8!J<9\72 S^!@E?F"$]&_#(A%)H8 MX&\51^MC402L-

*%N$W&"O9X@=^&%T+*KW8%MK=C<3&9&Z C<;8XP+X%Q;(+)/ M*)%%L>K5 [=]'O6QTUQ?36_??^;Z@-*

#IF\HM+")LL#XQUJKFM$&?KUU^^!+A MT!2.NEB8 (.E2&.O[.D/L+G/FMEW.GSV0MN7R<7=UK&X>+@-%X.>@/DM+R',

MZ>'^\W=E;@5>T55;F5]G_?0^:)[I/8!UJAGW]N\$ 6JQM4BU(PSU-M.AWC\W M:V+2?';V0162%I-

*$]4T8("6T$1X;J:G]L2D5@-.+UP3(*FN*XA(&&$*7X MZ1 -05C#VW=\/4N*[YCC@P&E"G8DGNZ;W Y3D! S1+#P9>/2S*

*M8SWCURDY6UI@A)K%[=BDE6S0*Y;H&4W3L>.;PCL(#I"CSKD&9P146P:R.6U" M8M"ZYKH+'R?J2 260 "QW(+$-*

/(XG39#$9(M$)#0CP-1/K9= (/[%E!(WS^ MBISNB$J(#LWO./2_<5K'&X 7,RAA#0;G!3MAAB!NXS!DLOU>8PK<1 O3-\P,75F_;;

M9=5Z4%#$1*/,'/W(O/D'G4+.:I#W3D=C:+ M):Q(B1V90<)TP%""_Q4D82H@+_E,\MG1^:P*B),G/9V_(0@-/SQ)6>Z2A"$.

MB3DIT7T.GO;1S2EEHI0.XTO84&LI8,:]A3LM#!QJ']JC,X!RD>*G!2Y@XA< M#K9DR2*'256-;K>L-*

*IY2Y"K%>5+D#K[+Q5&;6UO'WI,+%OZ;Z;\=2ZNY/XF MA>T5"]L^^UM!8>M>7)W'SG8D7,B3&X-AP28"U6%HJ>S/0@2*03ZD*

*MM?T:R(7GRU[RR\IFA#Z].R]C=EU*3"<+2BI.B?E7XG\%2A.J0YUT MPE 1ZFR?;7;0 ^[L%&B%6U'I?W./=A73U]W @)$4K/99$\?*

*49D"6%97PT?3P M;M,.F+%]1V8H@1$X16D[,RBI(TJK9M*E_*6>,USG)=&N#$=1-*_I]%GF-/U/"*

M8+$%0(;GB9]F$F.ZC\1BZRDIZ_@NN#?XO4:!U8X[/YP]=>QBW[3 MFAU)Z,FNVAS@H]/:/:HW^_-

*RN8088RN^11M[CA7XZV_96+PHM$6'GJJR8G#K%<(O1.-<@L\LQ8[*GY- M2YH2N\%UX =E4.\Z)<6A2">'/Z*R?I>!+%!I?J+""]_J_3-*

6^*Z$N%NJ]GK5ZU>>-#L#XJ^^S6.:=ALMXL]2=*I0F-2-[\()UDH5!RP9;'U9TJ[M776$[GNEQZK)<^+)]:^G.E3AW6T"

[%:G_*H/1ZEA4]\UUC #,_M6@^\B2Q 3U",166)$/B0I6)"'F1A.LH!8"JH4U&I1,%]0C]09-HG' M"3F^3484Y4!!7-@]U+ O-*

<&L8"%EQ(RNM]LLJWGQ\YT],SM@ MGUUG!DQ+0(__,/WI3>#!])C[Z:<(?5UCRSA@[53'R2TRC=O#BZMAH]T[BUH< M*892#*

\@ANV<<]\[QW;FS"7,?;Y%?.);3G%I0_3BQK#3DM(FI:U&TE8H5SI/ MW$(#6 @9XKMGR9+:NK@:9+2(*]S#5@I1I7CIU0I1$1D:G-

YR5#$IM=/HM.5F M)N7PM9:C2FA 67G54MBDL)VOL!6S''ZM-M>KJ MX[/CPI^@/:CX4?&>B^:.\1]]R0JVFL& RE6?7>*

*(<]T,5P4Q%,MJNB[A<:1$ M%)K;7_YKJ+,5]Y+;*K,BDMLDMTEN._YNWS_:;H\H ?NG:4F1D"(A%;#D-LEM MY1VM;*

(BRQQ[ENG>4P:XIUE,,-\E"Q+ +);56: M6S&S.R<%;D/J389QC-+-2NY37;Y+97SVW%-O5AF9OZX.)]*

*MN'>O(,GWDN_/3LN>$(=*7G6Z]\K,VCF#G+\W7QP\,WFK/(7)?^FDX.7L/R&4 M9@BQ 3L)XP$O[9O=?8O*Y6R(65#*

M:F+);9+;)+>]>FXKMN_W6B?8]Q'R3U5/O^^_MI+.1(\G6'1<;$+\U;PH-&S& MK9]D=:=,-Y;)[=59$++EJRA2@_)]I=,PVC3@L,H_[>

M>'92+J1<2"TLN4URF^0VR6T[]/GIH,@!]_PV]/D9F.TG+/3\A=KW+G4!YJ/8 MV$]U;@9>_B>1?-*

*@^*'5JUACU2HVH*WBF*K8%+>*=*KBF&3SX//LC[M-\^". M;!Z\)6UD\V#9DU3V)#T["LKFP5)0I:"> 05E\^#8<)/-@],,7+?*

*87,VZX10) MW!T"=K)@LYR.>G'5;_2ZLBF5%,/7*H;M;HF0%9T."-1P;TSWNHO3]Y:E[%U: W.F#_MK.6G=)61EO@S@_% MK=7KRK;*

)V<.V198WB_OEVV!MV\+_,820(&R/["\7]Y?POVOK9A<]@>6%1?E M55RTC](QL#.\N.]D

:=D#5)EN;.BKWB2W26Z3W%9';BNVVZO'V>U'I;0P MDR(A14(J8,EMDMMD?^!WLC^PA-*

^48^2VRHRMX)@KYTMP5X+96AW6Q=7PS2 MB41QKP*#U)GYI:J5W":Y37);';FMX,:>JA,I96-*

*O7USUTEGK;^\OX(9IK)CK.P8*TV35VR:2&Z3W":Y37)0H*8:CV [VC0)1LQ:*,YEXS%?XU, M9$S-0*[@SS-MA$**

(VS+IFNLNZ")Z1/AL,2V#C7V$Z5(,TT-%9MI!8IS+H'^(M',HGICM/MAF.E&9-DV;NS(PG"A1YF3(Q",=UF3=W;.3L)$F5%\U3YIH)

(W%> M['#,(<@1&50\A+_G;"?'>G:/,<;$=Fl;3"=P5 MO$465PXK+\QEP&]B32>N,R,:81S@2N.C^ W<;A7X!8;?FHJU_3T5*O1;B-B*

MI@WRIW;:$_601,"68CJR"O# ^..*I_Q#?PE=,"< MVVK84-6Q#Z)%MIP%+=YD%?8.!47?5 ^N:+"HJ$AF("VNJ5G-L]P?8B+1$]^9

M/@Q!WX)LR?,$)$/Z3'"'1%S?(E46]D<'>-L(=$:L ESO>(%+&C_%-A,KT/V M*US4A#ILG:!;2=9]KGXM4QN;%JA>.HBQG5#?*

*PE4KCX,K&J \%&J^R&4J_<)5 M>$80,\V/F#/[I >NM#UN:8*2^>IXX9;BL6AZG,&%FH>=0>/2"N;?)7U0P PP M-*

Z@HFNM'IHMOV[Q'7T]2DT.@&%U?=C!JO<'@-!7=ROM%8 MBZ;"+29B3FX&+:GR6)&CD8$B8$1C63#UC-<\BI:N:3BI,<26U-'M-*

DK>MMSGS%QHU!5K?@6;>PY5N"OOV6C MDA,=52NCX]3>"A43_T[=N.[@B5V.P>G]<:E-8/SO-.M%6WCH.R8G#K->(?1. M-,K='"

*[^.G;1;4T/?(4'0LE0>_W+;MX(;K Y?X[\"]*JL;RN;,E+YOAJMXE5 M#?2@@S@'%KN?Q+HH$=VXM:,VL?*

>3S["IP0:F6=^N1AD4=XPP?+T7\DU!6H M/@9;; XO@Z>Q,EGDZ+8"Z+')6NJG/+LU#7<_:!:0CRD/4\9"E:FA_K7 OP O

M%>X6JMQ[^RYE95W]E4(XL>]B/AQ 4N;>^Q=^.$]^(MS2UN\,VV:!]WT?IG< M&:$1(C7_.1;K9HN+MDBH$6\6/S?

AIU_2WW<&S>ZHG_E3J]DN^'VOD_V2=7>L M&U1[V.QTNQ4;U+#9'_4J-J:$FK0VOSNG+2O76OSCAO^:L7AKRTRM386/HZV*

MF7KUVK_'.Y!PK20=$G[E$C'.D>.S)YOV ?9=]<317X%F5=5FB6R3@BSE%;," MK# >J=@FW7,;^KP;&J,UR_4O-_,D'TH^K!P?

[HI/L"MY=@(O&(7/"#WI4?FN-M6]&M=$V"/"=T(I2UXGF=HE]6>(@!W?>@WL-O3"/WY=J[Z*@5@9)5U5=I6A|*
M[T_!MN84]H5?]8O"O[4=>_D'62(DT^FV/=H:;7NT%46)DS%F[>2?HE?JMO;32-M%\%ZBRS-U&M5J4?1L8'J3K'T1^W=L0<1I6FX!*
]G58N3.5,CGKK5R6JKN:DOU-MVA=7W8I_YQ60J4I=>"PEI3B7C^G5>)>MH=Z<=7I[VU|5-MFI=*VQVT:,UM& MI<{(]-*
B&W)N4UK;^X+DKK52?J9),C\[%E8SB2-/C<%$<*<4)*4XUE2G1].B" M$]':VXTX3M@CS'Z%@;+UHBNO6G?5D:)*OC/?*
U/N@E^C%)D$F MU-[)<@@.>O\6SM[:P^[ZZ^(Q56[G2Y/V\T%W&Y]SBC0(QG]S!A] ML]&!I9@9G6JKQNS2'#FE.7+Z*
9[W59*\DKSG>U698-^=0<7#T2DGI HQZ#+O MS[M'[.&BA+4#ZV8X 1;$AK3?PQ"KW&H7SN 2$M6B7F -$M5B2T))*
M5(O7AN8@42U>"ZI%"B-1@@E(,('*@0E(/I1\6 4^E* 6Y8):*!+/0@ZN8H-[M#34#$L^BYI4#14AV*'X:U4+)15\-*
MIK:U;WFRRH\!QFFG^ M_[LP?_KO)N9/9ES^A[E.IB9K1UUG*U(=?UKYE3:6!+DXI'CO!_NWV2A1L=)T*
M;U=)@EQ(D(M*4%>"7%1$:0WV0P4L;I-T2K-)9-SG%=LD4KRW$^_]X/,VVR3=-MBRMX047$6%:45:NB3*)?2/0+"0]PI(OW T%*
<>XS6[Y5RC";1+R2C5X+1$T9'-MT]^P@]FEX?B7XLF9DM-'26BT1M5'@I'6BH07.-^K)'FK96MO<*$D>L.I[\^[*
M1U9B'X,Z]3&OVOOEOJQW(P9E9N-)] :I,Z3,J(G.V,,C&Y;DD9U>K62 .X@Y MW04S()6^&<\A^:9_!YYO3A9+<4Q5;?*
9.$YV)\L#FOJAM;E%M<[=!#]'@+AWXBO[K,J#SI6MZ/RY=-M9E&L&*\!UL33L;GK/)L>/9,_U-DL0QDSQ0?V?((1&(HY4=Z8;[G\O#*
^+-\! M^8>A/SF*INA3#1X&%+VD&3B6HMD&W!/>Y, T8<'J*5-@!9_-9PQ2P\MA2G0T M.WCOB6&^.*X_!3)Y&-KV@3(.9D-*
X#>5E:NI3Q?04S-%/()K8'"--=:7,*S9Z9-UR=6%88& M;!T \733U8.9YV,1K9*/YBSO"9,\W#E;)AU+C\FNOB$D-K 3+K_#L8'M0,I 1'[*
MX"2 N[7 \DENXH5M(+<+QF\L,]EZG5AE#?B(A-6\J3)!V623"4,"P_S7+CZH M-*1B=J&X\N##?^CD"Q]R@T_^#$_F/&/:NA48J-*
%L&+_/7TRB@E^.82'F3.@, M-!J>*6>@H;"?.NA9XG-:OR5I #]D>UBX\/"=GLXOCU38VG&\"3SZYNW2B&"E*
M05Z71[2RTF@4<(4>$(_LO/8YB%%BW;HJ/Q,-]Z)WM*G &L6P3G]>/E(5FW$K MOD4;PXH%_OI;-*
F[CHJ*^,CRL]E<6)/$OS@EM4W.H=4>=2;O;F8RTKCKN:T:' M]<9:G^FC]KC38O\:=*["FZ9N?!H-^\S8A1WIDK:?=YKUHBT\-^3U*
)2K:S.-M3H3=B4-V,L$.OE*I:GU:J7:GJ?QUR89>]5M6'94;9S8SR5KPKFWC)K2;=:!## MCZ:'6S*8I(_P@ ^6H_](^"&C"V%E!*
MOS)E\"]1?D7N$^_&UV2]72W.#(=;*7KB.],'U^E;2-D2H6IB_]_RO0Q<2%#S M[@*M M&1UXB8O]HQGQWKF>\:S!H9QX"D6>X*-!*
[8+G3%T->'J)P?\-M29LV)V[H"@N2LQ8W4<-P U42&FLN;JZSN<5^XJ/!S "&IHO)-'4"'WYEB8L--M46MG&E?=U4OH/C*
FZ@[CNN%R5R\M6O!F.B$Q+"+T_57P9S>]1G*)A%D> MFW_"7(*1>[$A",\L@37?TPC"\;4[!<8G#-6M1_H_ 0@! Y].#-9+CO9_HM':*
MT3\V/#'@KYH+YJ48;9>&_? 9E%DH"XQ$V!4%SC)!3\.TW\UBWN@L!-[<5R# M5D0L P"+5,-0P;@NIH\E=@@FN(3N:D?*
MNJJA4(6/-@RQN\T#[R",2PA2CBZPD93^0>&!\#UA;\:N*2:\D>TTF/-,X%I M#)*
7RYE'[+"U&'(9TS7P(M"/A#'C&"BZ83#Q6;A.R\./)TS/B6:MB>1]4/'/-MN-M8B[IPT'VF>A,;;+2Y:MX\Z8M&&IXB"'050]*
<=O#U+,V>P=!YJ-_B;^WE M-@_9S@9U;RD3V+]0^6@6OCC:D'^!U0EL\X^ B0'!@C@NNG@8"6$:/$>L4KC6 MH8XV8MT)BV<_2*
]?WY=P6R/MD%0.34/S M&/N!(JD1_:"LIX9!@\L%\R]!_(0Y,9":$TM!EX?1[%)>WP^S"&B6&O,%:Y M$BZ#QP9$]Q66F<,L*8*
@XE0!#X;-\\ 06?#@(9+R*8[():3#BX.O=F0H)N5&-MW.(A:P!1@--1"D#EA-&F3'."E?"](3CP[=7'J#EP6X*X.(4(L\I"ID+-MYFZ06!M*
$X]%-PL/'I;7ICU[YK@L=6<81,?W"Z'6XU.$^! C>CJ/IR)S(-7/KZ]\:@G_-I(<%T8K,/11!':U=CCV=H -^)T#$Q)9,(ELPLM1'#1D+S;*
M>D+<,?;T@ 2!#IKVHU1EPBZ@8#38?, O)ROZ2^3,EL<([793/2@G%)RRF.I' MTYL'/HM.'*A FPLJ[1)/11+AT-)0D*
:_@E8"C7D^\]ML\=O*O>X[N%NW!V+K-M@U5]T&QG8EY>H\H&=?^1!,ZG3RT4[U]GX[\I,Y8O>$N"#PN/1]"@&+]--2"2*
M#G=A_@8HSUM;;T8'VF^B"[\]/-6%FX*H5D(3#YP(#_^.S@:C)'34QR7+)6_&21!FPUQVFAEM0,#-9?@*
M:D0PZ!XZE+>1*_@9^%=PP,-BX/(,9+\!G>\KP ?,""PTS)4I&'VT2K 3?F9C M-\!0K=HG/NJ=T8984 7\9G//1*A#3A=AIW*7+*
:8)1PT3EIP8T3OIZ!P**C M0:L>G23CG*_G,%L+#:DXY08M?&XM:]X/GF?"8BKQ.Z(@5"8QW_SV[>8M7D%I*
M!)YI,&$=ZZ0#0F+#5%+NV_AS_?GA'OY]GW>%G47K@L7'LK'TSPQ_2I#8-Y0C_LX?IA M19&'2SYV33:)E#1Z%C_G8X-&-)IL]*
<]]9O<'0S^S ?X0(Q]'.%2^ M8*)X+$I[R%-/,,BDO+F&E02'H:%\8-:3&:YBE).A[M9FF!!77Q*I/ZN3E V1-$A77_5KF?*
1\YHI/]>3,NBG1E,J*> Z^F4 M1;3>F/LD$Y;6)2P-UBBJ$:L,UX+/D:ZB1,L_T:O(9;WHVDD8?1:3!P[>5'+.U#D8*+3',X MSV64?+RL-*
;49#[9SZTZ<#8*U8EG."YEQ<-N,XHJ-3@AN;=MYYO)_#:ORYL.W MF]OKMP>)5U9,^KEH8.Q)03?2;BK/33"$9EX_*
9D8W.PA&Y@)_[B&\V&N.9\ MJ)&G+:Z#)QA5:"!$]H+H@8S!__RJV0$=+E$DYXLY,_$0Y,N7F\CYL[07+S#] M,-K[6_.AB2%@*
(_TT%\/S]6BKT&(<2)_Q\.6A?(F\7GYSK>1S;1N78!A^3?< MS4E<)K@>+FR(%7P3?*
=L0AXJD#,"BP>H55(;B68WP.6\QO01FZ=BB"&<\ R]4 MZ#'\YO/':WXR';_P"TB9#CX'/N22]>;#%Y"IR"7%.H]GS%IPA!-*P_% M-*
Z$S;8+Q!$L.5AT>1@E7=%E;<@FGN[B4PP.-@"I!J# CYN!;AR7TZ7SS]C;'M"U5HK%P[7:%WO7=_2(S%!XX:'3ZW<:@TW\/'X?*
#8:/=:N/'D3IL]*W>>V78 M:/6&C6Y{B!_5[J"AMEOXL=MO-8:C/G[L#UOP"UPP:K2 X=H#^MA1X0)P%N@C M/+?*
3I8^]4:/;Z>"[K#=&.':VBUX:[\Q5$?\=A]=$?^^W^UVKT^?1ZJ:J/?:?'/HVYC-.#/'+4&C?80 MK\&22)C?8$2?*
VQWX;=BBSVH/KN]W^.>1*L;>>-09]?TQEV&QV<*WSNPCB'M7?&YTX7Q=>ES'SYW!_Q=_6&O,: QM!N#+CR_U^*'X_#WJ-*
MOM(8]Y4V2:[EK M<$V+'_7)O+=-(;S(H8:RS:CBQ5N-^H#0.%E734*:1#((HP(W*
M!RX!;>YXP4P;)T57N'[LY]QTHWC21LI,L(HVIG:XAIKE.6(A9T!O'V/H6,QI MF"*:@Q5<%-'11-*
;54F0G4IA<79MPR;7MO6#!E8TE0%1-)=:.CG6]N6/'IM5-MI$F6WA^L& M;:=U,R_"9>X>S[RXPYI3YMI+=L:M!<-*
S@/W>1#]'7ZTS-M:L42/QP\,+& (? M2-[IS+.Q>E/B4+0AKL!IKUPE LGBV'19M4>7%K!"OEQ7V,KH[&ME=!JJ[]B*
M<.1:&2J;%OUM#(XMK8S=+0NP)@;PS%:W@&61L";:HT:OG[8@NC#^WJBW:#7@ MYR',I<\M"V$]\,\]&!N25,0'6V"E]*
(?]LBR+'"GC>WXL!M+BV,B"IG9F34 M)&QR_?N'+[\=.B&DT*!V3A$!3Z-JY5[*&TQ-I>3;ZP_?E%%GJ+S1)I8)1@*6*
MB5]JB\7T[=M#YLN=VB1*G+5'*1 [V33_0)B)WTV6N:,ETQ&BJ^QYD0?J_,I'UU$C%%QBL?QXWW$^. G6]$%-D6802.X3U2^*
MGWS]TB%\F(,+V@X/AQ(9&R(\K8GL=\KWA3'CU#F<@>=KBSAN381+98Z$I/O, M#,J=OT'\#K @WV1]R2V_IK(F%6+M+8K(1M*
PSY>0+ABJ>,TUL73)_K=CVN%> M8FDP<5+)7,-0!5-J9E3'A,GC/(L:><\ M\^=$;D=Z,BZ;8]T8/2?CSC]B6](\ M\-6*
#,T;RZM,%X_MYH&K@\V.R?L$I"4(]2;Z](U\0G,R ;^5;R?P/!,+NQBI M1"%X-L6BA")]6^8'GJV_*
O\65C\XT6AHX6/8"N]8&7!F^C3BJ;5D(I"'V"BF?"5728Z1%.B3O%&600BD?H':%QHBJH7F84*
M3.9GD)2?,7PM^1DU2\3{J0U{J&&N@&&NB?U%A^%1XEL@46Z.SPBIS@U>98^8S MZ*(QYM$NFR_"SB,3R]=^,#2N)PH"?*
MJ&Y@(M,9U6P6*V2'GR,: RQ.J!:3PZ M? =7:NN&1.G749[_K2]?05R4:U-MG%R/D38,D,ARF7* MI_+7$ WE5]<)YLK?'&].5/U/7*
/[%2M.@;\?F/ML$H0COX,.P*)'?K "=C-U M3,S/)IVS$@Z-KGS;B+QD;AL)6%\M6HWPR&(I25:\-./8HQ&=>\ K79?CWV"Z M;,X)"0A^-*
A4'I6>>7 G3N[>\LG?SF:!S7Z",+OHIH65M'FFUB>"B5R.2(3! MB$1N_T2XF'3HX%.9<40A8=?%/Z&
]BUA=&/#T&2X@WP0\&B")25M1??& 5T1B#5MJCNV;29@?WAE M=O@,'#[-T[02A,X:A(@QJ] !N#X(Q->L1V&O7F^B2BY_G3WX?*
NG+SP6CB-F MXP6"I%@(LQ0'D+$X9K'6U8[J[.'N*M^=DW\7&+[1^UG(OPH F0H)'NDT%(I653S9I$.3N-96>C$C*
M(X01W]U6LH9"A"J.!2/L72\N_7 5#-+QD[.):02ZB7$"(_)$@FL8A0H,&%! M$TYYKB,^/PLQC@QL/'VFX?&3-J%4O2BM!*
<\@4T&/2B?&AKX(>@\1E*FV$1 M"_,I1$0Z?\M*%.3Q^'I'>1.[2)KE<6,!5+/%-#I*2Z!6D;\A["VDDR&*6OX>*
MP.C4$3VO%2%&\?)*E>-TJ!Q>493J+"\U6BJ)YNZ-98P^CF3$1(X\G789[(J MTSG99[AVC"X)H_1F; 2*K@Y>D0+Y*FP*
[1[&6*9LYA!')!3XA"L^73[63N 'FP49<5K.,*ST]AE]$,'"TB MCQ';* F$Z$?!,4DIY!>#H^F!C^%-*
>'!THA+%'GFZ8WQS]/3LP&,88<1*J&2E M9O[2:K8SOU_[I%%S,%0W/BJG MW^M*X[*\7GV^,S]^.P=B-*
\2(Y\B5;JQ>UG=Q/9MY?;V^N_[UT]=/=X_"UGE0 M/MX^W/SV\'![?Z=?#[8-R_UGY?'MW?7=S>_U%N;F_^WC[&%[S M_=/#;U\>Z9+*
[;Y^^7^,/#TMDRN@P=[:FP.-2CO[7CQ3WN\;]B.P\@Y]%@.%K M"M@<4'7H(YLV;_&$?;&,-)Y2:%(VEQX9188!=9+:99 AO7! .,5!,K.Q*
E-8%W"W"+*H.LA<*]9.&MT5Q!W3(: M)P&M+V&?DN=4DU_K#+B2E]:#H<#B]VN, ^T'9E)F(PI$?$QE.+K(7$2$:5,4*
M*?!@XJ>;J.7A9"TME*A51510$3:D0U-<]T/\VQ!+F(?(&9CUPG\%D?]W$S". MVM@)$$>;\^*
DH)8IP'Z$64S(6$G$>/$7]L*8>)'(PH4:+SN(SSP],+;G?M2U M+X;V?N&P7D0,+X3SY:&3!K4SF%[#@J FDYMO>*
<+V*"_VN_#;^G(MU,1#Q=5?8.V00JM?$Y+RZI<^] *6>K;@A=6O^4:3NMC2[-7O1&.4U:^Q@NJXN86' MKC^)I2*-*
F]QG3=0DH%CXO>L9DQ2ZQY:"10*2^PGV-'3#>4E1EI")N,XB:MT0 M.N/8ZQ3X*;#%%WX(OYZ0,"6GH=%J/QP\9N!9%*
4>S]&Y>3,@CB+(0<%1TK*W M+AA]9N5#D^?L$E@70CM7.AQ MU+_KU9[0E!FZ-JF.D\L6;0]+"/3/&G"\R$A8?*
B"V4:#4,PPJ4Z!UF9,QV$F# MUC5>(;)P L%Z^C),/(XDY E4ZU#WX%&Y3^ ZT)D>N=P$N!+=P-VVY]XOT] M-8]:WY]8>!-W?0W3?*
[PXAHIY45%0V0VL:/%HVJ'6%,8)-7 S'%)I'*;?7G!5 M&8+KQVU^J:ORG%(;YP%\]UL+NGS#(L1-B0V*98X3=4B1)84=/ APD_LKG/+4*
MO)2]+/?>%F]6-S%NB$;'/,LG(22A*?)B>]R<=;)ZD\O&1:= M&WX#K"F^Y-7'\-W;*,P>]]?R&LEZ:&'CPI: %P&WC-4"A=BJ8@"E'*
M;9YPA& 4649\'H66+98TPOO(R Y=W0FX+QX/F6O8B0MOGR):6V#/F,]? BK& M9J+'F$7=X;E'L=SHIOPG+B_Y)/KO-@\ UQ)]*
%:)FQX MI(B\CI5ZN.\NOT\G5J'&612T<,9XICHWYU1)'#9<]I2Y0XH7)CG!=%-JX4YY M//%"X]9L4=,=T1 IT1ODC-)&"_CY^^??J__X-*
?/OW^Z>[V\9\-Y;__^>W[_9=;V+/OYA:UN+MV M$:]P#C]]_^?#XZ?__5^X_,.7V[N;?S[>-Y3?T9P>FS^)&1X__=_#M]OOGXB[MB#-*
#K(]$5RN1LRJ&FSQ;@VV/=EA+Y!4#0WW]_?H!#-7KKW__]/OMX_4OUU]_ MI0\P/ ;[M(=0U-^O?[^]>;REKJ.>-C:?&\IOW][<_M\=*
J7\]O7ZO[]?/_P" M'_Z)'^!9YLQY-I]@\M>_WWVZAV]@QC?_?/APB\;*_:^?[G@^\M>/G[Y\>?Q^*
MO2V[C*H=8OJJZ:X3*80X*@/6@64Q-!!J(A:_A1X=,%]RRMBARQ0!HICGR/I# M[X?#2%C"A$+%3G%E3.$&)<2#G-Q_*

J83O19%H"31Y&L!5ONLD?3"17.0=,L M?ZKS1KV>[T6(MN2O8CI'O!"A@Q*'K3\'=-;=B #LGV!+<#!C0N>9#A-@@I6'*

*M8KM(S/X4\2>X+O9U:>A/EC,F2)%L*L&^%]V*-0<4,>(6K8BE80X62\SL4D34 M7;Y7\B/\:!,)Q^;)C0*L"H)>Q:$ZGA_&__CI-^Q1T9:>*

*[#4++]6YQLP!TP2L: MPA#F.POLOOP:ZK] Q^O-#8E4C*D#M7O(1*I39G%]A5T;#:9&W)#&BW.$KY>X M%+_K=%L?*

E(]N\$3@K$C0;]@63IN))G%A.V2!KN!BUO\/1*ND%8P9CU_76&5A M, ^2CJ0/.%F+4D(EB&Y=@5N&5"UI82FVQ>0]6$7-Q G?

*9.PT#3EGW\.:I$RM MSSP*Q\0M6I<>1%L.-V&PY(^L+MR!>,59@N\P9Q69'5PPWD!1-),)+.N28B[A M8Q.QK3"7%?@1#*V\BG?*

8WAQ^:41NWVH 9BG^58=&UV='A3<%C$AE=BP)\1OR4V3I)#(V3WMY>E],PNA:DUVW;0TC="[YYRXCD IP %XF7VX!Y$

M;0GYF1C\1!&M,@O(O\+Q=,Q!/3FYOKA+=R]W:&A1 M>X,SBK 4K#.0[\TL*O26..9%WON$YC-)1OM[>/8J#(/@E"KJ(M6N?*

+FX_M$<__@3$9".;HZ!8I>_QY[!B+)G\$[5WBH0UL_VR +_H?]#3FEJ:S ML7,IDODM_,YPP D%&PE&9HBW8RF$YT5YV7@4')8(>-

J^8O^/CQF&_R3!1T M:H7MSP>YT#QXAD@@?T:HWJ>OO[!EY1S\91CMQ9 NV/6TV<)>,0>GW!=$P^#H2_8OE[M1PU+G-

F88(8$(92Y,Q?"7LWH80;# M%;.D>2JZ6C\K.HX3@-^ N<=L97 -\J>;S1(C'R((4[HV#/ U!6?E]B .OKQ M_[/WK/8)#&8Z=OT]'0_+>*

*[QQBY J)"4S*H(/Z!>])[F MKY;03*W0JNQH?T110;+S3H2RY!\6EQ3CX]>??8QJJ_'!>E+*4BI'U35RUP%F M#?*

D>B/>PE/EGC[5KUU=O?S[_9/UT=7WQQ]5E:N'"#&%L"3Z('53]XA32'7?@P<14U')I(627]<3QCGA, M)"$UF 5CRN^4^,)?4%,

<(X[PA),O@"BR#5,8H7X_O$-(Z"XV7KJ*_7'2RO M><"8R(P)RF<@LY&U$*CO&XW"5=X@3%Q?]GE705HY0:7L:(!T*H@LIHLPXJ-*

*^ M*IG1'LIG3+@;'_1*=C=^HT^?:6P\DZ)0'LM9(%N=.E72MH1) ?]DQ3,G#:Z[7ZAD39_WNNL?T<5YG32: Y.#)N3B70R<4[*

*N]/N8VK" MAL[H\VV(J/O'RD9.Z']O#"RJ6C&Y9%YD:NG&,K'31RU5W3(_V(',Q60?9J& M HN5_7BJ I+D0^3 6G8HF-M*B2;204F5,*

<]7BL7>-8H$2-2R(Q(%),2[+# M:I57A3TP8+$65:99>N*%A?-YB+&;?.(1^=DIL;|T5HK,'1/TO!3$>DNAPT.2 MJU"Q_K-*

^FT4L=;H=V&W8S02HDRGEX_9W+.])$6M^`D4S3D]/UQ]5] M!';GU3Y-1(=EK4RRUK7[HZW2REKR?+N8+5\K=^8QIWUR

,X<9JG?//4YBLU0 MF_;=SP'Q+K M-4LNBUC;K9.B-N2GF'((S)FP(+!K;Z-6W M>ZT!ZZV9S.G9_9.BOAPSYZ6,ZB$X8X)1?YXGR'IH[

*M/8[@&\L:#C49RIJCUJO:19E8*K9?N37;'+HWE#FG![ES8];LHC>'<$%,,*EU M"]QO\K&?-*

*PQ0_D3$W==OMO0/[%ZS4\WH!XMP/42X;Y]6582K'L#;DVVE]S+8 MNK%UV_F^TNYT*GK5S#)<#QENG=JGIWO>NYLNPU7?*

HOF.K:IW;!(WV+]-NFH7 M#?;4UCP77K_9@M^WN[W^?O$^(ZSS V%:%N%ZB'#7'@SV#%F;+L(5OVGHU/6F M@:T;6[?

=ST^=PO@Y)3%O+,,UD>&.W>GOF8IAN@Q7?(ONI#$ UQ\% MLQ5<[$<'M$IL?]\XQG$CRK+6M_NMXO>DI@C:Q7?\8[:O=W+?

ZJRW57^BOH2^SX7.YCN&F4I ML>EK8 MW7[1Z@9SS!#+6IEDK6>?]GC+,Y0Y1]UV_8

*I*G]Q^L[U%K$86^WH(V6"E97M:9M;4U9Z2;_UM[P] ?\=NU^^^P?\H>]LR_'OK5!,1"C\D;#BP%KX;FR-!^R0RY"'^%*

*<$_X!7!8M0OR.RAO?65#A>/!V!=X\??W''^/Q1M!A- M+2>RYM/[R!VYL')\"RS!#2U\DSN*7MFP",>#[R-K! 2&YVQK&D1S-W:\R,+Y*

MS>'0,'-&KH@:%E !3&%:]9E>N/0B&G2(M1_X#)N_X7&#P(I]>O+?UZ*KPQ M+NAN&@#E@'HP4Q"#8(8/X6P$_/\B6EJ>GN*

K_.?,N;>&PO(#./TEDLM^2M M::>84'MLM;O?$&W:[6] .(G#\/^A$/2ICR(U@U=,(Z0>_/Y&S&,Q&P)M.TW;

M:C?;?1OX$LW%*':_ "._>AC>Y0"!8AS4.X2,?6?(E\!8SD8CKQ&J?]M>>?+/R MO /VR/'@^6 RB42,SROI)H;[\%$D/ ^5"-

*X%XH/CR>$Z2Z-MYJ$B4;???/GCN.I,DO9!Q77F^DCSC *\(R\\9$'Y45JCCGBTFGE:9;] M_.N8]P/\XN'%:]1.B]:+15I[[QS"$5Z^9*

*M>&G5]H><,F[5P5\:-XU4S6 *':78UU>_Y3Y0#;YI6!]SUF 2:C/+&?VY<$,8 M_:<@=/\,_'2/&,&[0W=(4:"O6XV6-*

*71'^]'"*WIF@S2NZW4)3@D/B3A-0WZ5A M'%.!W0'LCK= I\2Z%G,GGCJV]>G\CYN/%]?GMG7^Z_GEQ:??;>O[]Q>7;W_=*

M=$7SAZEZKE,58ZRYNIMA765J:P-33Q[%U,X.3&T^DJF2CS1[S=^J,34$IPSG M$].1!R\$X2%"%S);\'*L%N8A,3* M!W*

*$.,;_64,'G3DGAF_F01B#M^H&EB=@*ZT*KWX!?S.,@4W@ZXW"0(>!#-W MA/H@?5,0Z(QWB6S-.,CP\^@^ CTEUMR*8*

*X4HM,3#C#Q7.3:U/DBZ,$YN)$^ MLD0ZN#&Q55A?P#MR0-W<^!X_#?*BT;!^6(3(W%D0"GM);%!K77\A%,?=V=P9*

MH08#I^$O.'LI(;?(4G\&;Y=")*4%)Q.#]TL>]"(<6E,@#$QA@BX/JC[Y_Q$- M

Q,2[BX/K/1+YUN\WOK7;BX!46&\X"/_PUN0T=10DHG>F<+M&'T_ #[GM"R+G ^<6/%BCO(\NG#*

*<6<%IH@/T3UD>08.O"MBZ0P]VSAG7M1I^M-M'V!I09B<7_;A[_G#BP),O2K+X3(I*J\@C=:9%I[=AR M:Z'7;7J?*

K5_X[P7\3H2@5_*=4?:E_TY>.@>!#,;:G'}PX,B5>RE8@W\MP.IK M\TY36+7Z55&T?,-%91N!,-K!!G(N?

EIXZ63QY9]L6$MC9V>9B:%MM?T?(M@",&]Z#]JZI"D!@T"D+@N1-+\^JGKY6*!AJ/0+?CQ&9O9I_1S%I![EU#U*+'*

*MPG4'045H!XQ;[/Y-9D>_4A)4[X&T*WLHL. M%Q'NT,VEU.Y-3I]L>]IUQ1_2&*

M3E^,3EO#3E/\WV#P57W.H,_J9.UG+H6T<+Y38KS0'X 8_;C)YO(33B:XPS MNJ,=A#!W,JK(_OI;$'ICD&2QY"+>"?!3G4A%FB/K:*

Q_<I>C::4D55>HUZL_JZ 5]]N_IYI]\XZ??6?M5LM-9^OFFHTT:WW2\TTN;/ M>YWU[ZC"G$X:S<&)87,RD4XFS@EX=]!]

*<*0M"6Z'SV,;[']2SN/X*-5G0Z2X+ M4K[5RR]!9<.6[397#DOD@>1<\1WR4QZ\4'_;GY61RI?+9YT7)?+3:M_SW.T_ MB0)F,C\V03,_E#.*

*[7FA>9KWKY0;/P$^RVBTB4QUR=9Y>CT]Q]+<4!'NZQ5=' M(EB!6('V4Z 7*LLX:+*.EM!MH);5]VQV\U3HU2'}V^6W-VP*

MET_W+>,S6G)KNX.:989,V,%?"&WPH"L^O_S^^OS]7H .Y<4H&;2+GID9/N;E M AH=9HZAS#EJ-^N'[<-BL=T5[#2Y9Y^QS.D/&!

*[44.8H,]$R^8.<^^ MW=74IM8A8*W016H6L>[UR]N.O.*LZ3(6O;FLX>XK+!J;G.L6ZZVQS&FWBN(0 M,W-*

*>*F6M:/O9JAC5.L2MKV+QM[>?XNZ]=_F*5B MA[AHD[LEFV<\G'5 M5-8T.3)K+&MJFO_&HK'=X6QU.#QK*',&76:-*

*H:SIU+5,HPXIQ3___O'ZZOW% M39LU+;=(US7YCR=C%M^9@KK',:?8.D;C*S-F!.8>H M;3+!IM8A<'TYQ[:=-8M;=WM[XB'S2?*

[96<-0&:RYA",,6$;8,G8P;5FM367 M.*)-74IM8A;GT6.KZ(YG4+6W<8"L-4UK0YQ&(H:XK>7U8EQ,*2*

ML8/[5OAVF]7VY9C399MJ'.*5$!7Q9Z^=,CZ8!5[/U__?O/I_#__J5W-7HG/ MNJU#)+YR&.+9:FD,9,_C3)UYC-FW9J^^HCSH<":3:4-*

:PE3&4,8^NV'"MA=/,[M]Q>7;W__=%6W\&R;P[.&LJ;=/@0>+K-FE_#L(?]38@GL&AL]S>Y'Z;AK.FS M0365-*

*0=1&A,,:AURBG\5H]@=NG_5+*NX7;B1IX%'VXJRIL>L,90UK4-PQH2= M@$5C:]T1PPL9RYK";2:8-5RF899G_C."KA*

:%3S]3HEMWI=3$#N>/BY8D>.)J.C9 MRV6\]L#:Q\%BZ D+9Z^_1=XP6WO?8/[?YG_[4B9P4.D MD./_=Q'%[N3^):C3:[0?09UV8[

%^DNJ]^J?SW)9OYM4?SK_>/["'V>6XX^M M!%?-NA.AL)S1GPLW%&-K$@8S*YZJ3^3:K6!B_12$[M_X5]^Z&L7!4(1R.7W;

*M:C?!GZ-!77_D+<8B'VF$3VG .6,XE%N/**L1.+!@O2FDQJ(P5)9J9; M;F0!:SZ+&"1G>&\%BQ#W;<\!Y*)@] ZB^+0^4/X8N3*

EW'D@G @YW_Q77SD M)@:N1\SV=?DQ!K+];>!';A1': _R@X?(._]P#^>AV %W'EZWU"(OUMXV6X_*

M!RNW^S&T_!\6\0),96[%#Z5@;?3A7FK"UK/(RHXOOW,]SQJ+N:!]P9H[88R; M!VK_Q($=)(RLL1N-%E&$MD-

*XP9W:0N1/P(H$=Z#I5H1%YB!X2/%X"@8G%,@ MC%];1^XKZR..>F%;%[&86>V&]<'QG5LQ U$A#+*3-Y'U3KX$]Q@<_\QWO'N0*

M8ASN!]=W0%9!5$&RQW(?PM]BS]8.DA+U]Z2AL9[Z_@#=<$P&0 MF#_

FZQ6_AG>$ANJ??""2T@.4SIG1B)&>S35J+0'2X2NB2K_:!M_DP%K$%WK_@191GR[X0AVNN1/ '"C:::(5V:Q+\6 MOK Z3?*

G)H:1Z9TKL+-(E,OHTXFLWAAF,=C!L0 _/=KT[;6#5 M% E(MDP9E"(?K+YNP%??KG[>Z3=. ^KVU7S4;K;6?;QKJM-%M]PN-

*M/GS7F?] M.ZHPIY-&G78?'&E+ E;!@@PX4AT,ZG9=$#=9T>DN*QK! M+B#"%UC3\BGO9'VRV#04PIK![Z;*;?*

*G',/SVNQLQCY4_V;1WN#K>$5CW*7Y6 M1BI?PB>'(_+3JM^!P:8?U,#,[5.!"Z_M@O,\:]Y-=O"D\%0+WH9[726B=9Y>*

MHTJQ]+=3Q[_=W/N[\.(K)12L2:Q)C]&D.@\!]JOB "@A9OS1N&COG+:CEUC9I MJ?#ZS4[FZ_VK%\V(M_H@5(O%N":"'!A=

(R2"""16L7'";-Y3-VS[_WSL=2$ M3#LVBFP4=\U&M5O[-FTTW2RR"-=#A%OVZ:!HKGQ)1+C._N>L"_5WMGKT+=O M>9P??*

5;W3KX%0:U88#%EV)-ZQ (B\R:7=R 0P#&FK G[!&$;Z\-PI>%T79S M2]N0YU&VZE+TM/ M56LI';C8^82+_%^ 0&;K%.QCW:)-

*,1^<1F;'YEA+:J\EIX/'!8+*JR-%@G\E M=)(8UIFM)UO/YXY7V>WFGNT"2V_64M82W:]!#_M/BZ1I+Q:4G$OH]:]4G<$ MVS*^5'DJ$&*

*H%Z?[%NO6"X$G]YTHD]*X#60<$Y9*6WQBB(5RK^K%PAF@0K MN',B:QS"\GPL$?\2>(N9L$!M[N(IX@:I.)T^S[)_3,*

T5WXKC(4C^YV-"SWKM M>'?.?82V.[MP6/42H?>BT5;-_XY]%==-O. K#D1TQ)Q'<^[!F=1")&>?:" M.Q!VUP?*

*QCH/POD3P%6PT#V(T_>4"WH(VLRH2=B9QG+P <9P4-LXC@8KLYP$I MTG@V3@Q$BVR:*98R67/ZA*9V?*

*7:Y\WL8)W:'P=@%*AU)3$,)Q_3G0O@C$;VB MGZH$)7SG?WX__7,$G_-W5#B'2X@AN'"">]Q.;T&+C^+V4YPV 1T_O!^L0> M0?*

M8=RYLI#&/&C9;S+(!96"TCR%C@!LX)X+3PK:-@-G/CF5Q, M'!!91P&*!+("_D;G#"5H9#*% M?>F!I;J5G"-K!10 ?U521CQK-*

TLP+/=./5(M9+832\O4'L@8]EY M6"REV,OFM40R1R/NCC%U?OG]]?G[\BQO!XPIN23&F&,*7/FQ!A3Y9T38TR5*

M&/V(,:888ZI$M2B,,<7(.(R,PQA3K$FL217&F#J5L_!+B4,<&&MX[OC%<^'?2B?+"Y P8O\A,QA2M5&'&O-A&*

MT=I]HZ@VJ!2+1<8M+%HQR K[4D7/1>/(S)F7,J7=3OU,Z5.B99W(ZBYC/>QL

MQB\C8W$]_IYGE#;C8K&.L(YLN6SLU%5+BH0MR^@E[7'A6'HOB8TG&\\7O-+I M-.L^,-*

:PEJR\\7GH&@GBJIH2=5=C#TN/TOO8E0-$VLL4GB77)%U<7BG>>C" M^F&:&=''2A3]QO@0A55"/*#4]0FP 928$12

?!F,NA@A1$*$B FMSC=4LR]1 M=7P!JBT\#T$TX!4C03]I?U.B^OW'#-,%E=!)?4KP]M6"GF"$W=G

&GH3! MC/Y]<7UF?1!C4.Y0 5^\4UQ54$IO/]Q80P'\\W$(> 4LK5\B7M.(NV,U$/A+ M>5:W U2#A+-AI 9&:C!F3HS44-

*XY,5)#B3$$&*F!D1H8J<'D>F&N+^?Z&@>RR%!^1&JVHHY#\8M:&^U7&=DZ(=L4M2&\<"7!9)_'UNQH4LI(SRT6G^E95#Z?CYPF*

MV,ZZ\,.W!9^2]:,8/;O=AP,-3,^'"%0?/2$X3[,W+0P$<=/&9I%(& _JI#WW MK"Y7ZK&.L(X\]".MHNAQ5=&1BM?

I[7DU67I'B:TG6\\7O"GH]Q^7 U!>^\E: MPEJRJY;T!@PX5$DO8T^VEM[+J!H@@.NGI>BW7C!I>E3>.?: MVO2*%$?P6+=:.0%$5*

*#Z!@L0NO,]Q= RVLQ#\+8"GSKAR"<6:WF\<\)3>^% M$RH2OA,C1<$64;!CRV+Y"]NZ -I:K8;U_2+"*OQ(W7)^<,+/(@92VM8[-XI#*

M=[A 0 5BT8WPQ C1%N2/X"\?PP 1%_3#'YT8B!;9-%/,Q+;F] E-[?KL\N?W M,$[L#H.Q"U0Z2DO
(_'G0O@C$;VBG*PGNO0.Z70B+_F;BBA GX0PW#AA/>X MG%X#EP^?PD,S1\YS&"QB>G\DXM@3,WP](0_!)%,,'M]
(QFUKAHK(O?LU_/WP]\Y2$ M&[NWDFF$& &+!TH3OR5_I*3^JF2+N-5N%N#6;CQZI$*]H1F\O"A%#\E2M%:8 M,.M?"
["QB3&5*KUL8S>+G.)HMRVC_?,@1XIG@%@&F0>5D#;31YPA MK'H1;W[D0?%613C&2'>GFZ=9]LJIF-X8W8KC(6R*GX^="/=.?
<1NG79 MA<.JEPB]%XVVFH#OJ+IWW<1-MC(TXNZP** K3CQU*F)%Y1V66A-#HS TBCES M8FB4\LZ)H5%*#-
K!T"@,C5*BM&J&1F% !P9T8&@4UB36)(9&>9X]5@<(=&]9
MAD2I;^5I>_"XC%5CK\%9@.LAP*U!13%]ZEPXW3,.YL:$%!"VBFP5=^Y*:9P& M\;;. EQ@!SA]7#XBLM2_$ MFOX6Z!YFS>$,ZDE-
#>K+P]D<+HTMEP?,:#9<1;MG#*9?U%A4I8:6=81U9$?0 MDV915ZD2Y[!$B2 @@SXP
(^2;X16+$<(J1/CHX!O;FCL@%H[GW<,'DTC$ M^ XON%N'E8./M)K?-*RJU,@7X=4>F$.KK.KN0?#.-U5&=@G\VP#7NQ[A1;&B
M1!@O=GTP7HP3/AIQ=\"/JUC\[24Q\2>=4Q\7NL>DU@#EH#=VW&FLP< 8@MG" M ;[ZKC(&F2XK)%\8LV0S9LE)H]U\&
(6AS!@3)LZ),4O*,Z=^H]][&.&',4N, M1=-@S!+&+"E1*^,#;_HM,WA)?8M$N_T] MDW1,O_1D ;Z+ ',5<^6JG(VS229<]
[-19*,X<[93ZY'-NXPUBRS"=1'A=J^B MN'IUWMF/>J_,8;<)NWJ%@O@; PR[09644)I;S8l%]9G
M06O;VF1M2V\WZ\;*3NOA2F)6C8+T;#Y<#L+T+$C/YZ.F">;FY;$O#KKX;$8l MHU]PT=V^Z!>/@]
M;\D=ZPCK""/$U+HL=?/9J[H5J6PYV7*^X U!K_FXN__R MVD[6$M:2G;6D]SC,^/)J2=4]C&
[]/(RJ85Z,Q0J.0JZ.MSCDQ3QT@0PPVPRB MP@,X"2<;H!560!AZE<%3*$+W/>_K'B#V)N"0*-
/"?"XGYG)B,PKS2R<1CU*C1^M0ZGP5&.""_M?*Y[RBR\.ZAH/3,+<#T$.&?)JB;$19[?U[DWCZ67WYX=*,V'K4')K4'+[IP8 MU[*>-
S068=[0>$.K8A'VYE-E9;NP'^Y^QH5\3V_N#D#3G;31/&KNYCI75YI:
M#T/0\@LKT5A+6$MX9V7=]Z]ZT+5)\BX[M,7B"WGO:VO#X,U M6/^T_""VG/G< \K"Y*M2^J;*WK RTAG]N7!#,
<9.RU>C.,#\^[[L^FQ-PF!& M?9E_"D+W;_@!_5CV\J7RQUOABY"Z.G\-YTQ=!D=??=UJ=*VA^L#UK7D88)/V
MM86S^/M=2CEM*Q317(RPA;!WW[#.(FO'I=CXME#(6CX_@'%&:!O&&Z8U"F9S
M)Z16Q5@>"I^JEM.;BSL5@;MM&5E:;7F7IUGVSVF81B9OQ?$P%,[G8V<"\W_M>'?.?82&,KMP6/42H?>B MT5:-_(XJ4M9-
W&2EIQ%WK^<]__7\\N+3[U4Q:A0O56OB/MN;RWG[C9/^PP6* M92Z_-'%.7,Y;WCD![TX?+G[G4N4'<;EO%S.R]6(3U/.RQ*S
MAYK5D2ZL2;6JZU4!@N>NZZW1+=6VQ9M]5=$>/'4!E DW2RRWE9?;UN.Z=Y@I MMVORP&O3?+-
C7$]@$R"%V1BR,=RZZD'SX2JS?&^YR;8358.5HZM]_3=6JI&U5V*/3/12N]2 M5*W=N>NOM-W.UU/O!]NPU($[US.[NMVR?
_[]X_75^XN;\BQPA_)ZO2BNK^?Z M>G/FQ/7UY9T3U]>7N/*;Z^NYOKY$*7I<7_5TEP5;$:[[#(*!6L2;Q+7US^\ MQR81
IT"S^VRZ]NU8VS22;LZG4HO%^).-2PZ+[+1?>F MLN8@M=W,FEU84]0+J$J1*(O&-GIU#R(;K+6[1&]Z1=.-F34,8V*8F_WH]OO#
MI;'EX/V-FTTC&6ZK=^[9P\[FZPO&U?64=81W:MK'IQ= 1#=*1()+.$GM*> MIJ_TCA);3[:>+UJ*_[CTC?
+:3]82UI)=M:39>UQ&3'FUI.)>QI[X3:7W,FI0 ME[\1&[L!B /PG-B]XMX@XI^W&FL*:\>PO1Q@*^^LYYE MRCM2\]$P!O/0!?
F!B6T"-+""11RY8T$O^,5W8QPK=F(151?JX'(._!?E6=X. M0 =R20QSP# 'YLR)80[*.R>&.2AQ 3[#'##,08D2(AGF@(NSN3CI.6
.6&+V M4+,ZTH4UJ58P!S(^D&OV__QI' ';JH*3>P<:?[U,V[3;@>8;FMO-RVG[IL MS@2Y+7*M5[4RR,?
U;*EH&23;0K:%VS7GD_1>,EMLZ[^'& M84Z9L(?7 +\2:TZ+'""^;,BT& U+3VED5C:Y#GA-%A M3&5-EPVJH:PY!&-,L*_+K5;><_+383'
-S^FTK%-%XK;HJ;W;:,$Z\"BB00!0A/D'E0"6@S?<09PHZ]B#<_\J!H MJ[H:8R2[T_3+/OG-$P+A6[%\1 X^OG8F<#\7SO>G7,?
H<^073BL>HG0>]%H MJ_I_1P6[ZR9NLH6A$7?'.CD+'1]4M"(65-Y^J#4QV@FCG9@S)T8[*>^<&.VD MQ#@ZP.$.B:I"<%.:G7
M#6WY\>*;3PUU8L@=*PMP7038.(P,+IE^+%./VJ_,8:<)J05L$-D@[KCP]NGC M2AB,-8@LP/40X*='WS-
$@&N]H[>ZO*77#@%E.=)0/_23=J#M*L(ZPCN[9:X"[KE2Q>WA-]N_2N$EM/MIXOB?S0>1S,?7GM
M)VL):\G.6M)E+Z.27L91J_!M:.D]C"K\HWR:B@1^ :NE%3Q#OO2Z&$K)G1-M M1F58Q)$[%A(VPG=C'"%V8A%5!?
L#Z3D6.])S)PR./#D7_L3Y$H14G#ZBK/_(MB@-+ !EF#I)3O@'&6HP0@"(B"(P-3\$\8.Z^-5]$H?!'}Y;X2WYKA<@3VYH[
MH(..Y]U;P602B;B:#*41=X=:^/GZ]YM/Y__YSUEY5K@#V$*RJN>#6V!0A>TC MU;8PGT$52CHG!E4H<;D_@RHPJ$*)TC
95(%+P;D4W Q0A=))Q*/4Z-$Z5#IR ML0(=#$N!SLJ'V%^3($"NUZO\1PY<08)H/FT[ZTI?\I0;X+[3*MJJL0R]O%EN MJRZW.0-
6*=DM\OR^?KUY_+S\]NQ N3YL!$IK! :=QS4N,M, L-Q676YY\ZKV MYO72=?.&G2IS-?
2Y\V3%:]CVTVLN,63V%&//XTR)>8S9U_EG42Z]*#-[C&9/ MU2W- >+_2U7[@=;Z6-KQ;OE/O8RH:2] M(N134O5XHGW5/)X>
]LZ"34F-3)?E7;9HC:[Z!+G6??HC M]G+FX?I"/%B#]4_+#V+++F<\]H"Q,OB(UAFEU(9:S.J,_%VXHQE;@6U>C.!B* M4"ICGVI>.[)U?+
(K9^"T/T;>]GC$[*E.A6TW@I?A%3O^C4<)W71H6QY#SM? M\H'K6_,PP%K8M:7,^/O=VLR'(I]+$39_]^X;UEED;5V1I19CX_M"
(6LG_0!& M&J&%&& ^8V"B8S9V0VLQCFWKX= XD#\85+]C]_OW%Y=O?/UV59X$[U-/J17'W
M^I>SR880Y;;JLMMMU6TUV$9Y+;.FWCG<9T6*KJ)UZ%)^=K(
M0@U;E9\6K2\QL*2NFIPY*6J;F#,O%H2J;6==%HVMHC%@>VHJ;YIM9HV9K"E< M?E,5@UK+5N4K*KN M69E<>M>(K29;S1
B<_7SL3&#^KQWOSKF/ MT#AE%PZK7B+T7C3:*MG?457@NHF;K#PTXNZ@"K\B6L70_;M2H IZ40RJP*_*
MYLR)017*.R<&52AQN3^#*C"H0HGR,QE4@4$5N":<01485($5Z 45] Z@"CHP MP*_*7-
;EM]2LHMT7N'ZM6C]GJTTHM5@U5CJVKT;JD:1>*7)?2,]@U1EMXU8JO)5O,E3AZG>*6E-MJ MLFJP:FQ5C4=BCI=4-2KN4-
05I:D&H I+==2' 54PCI(TXNX5]I_,_[CY>'%] M7IX%[E!AKQ?%%?9<86_.G+C"OKQSX@K[$M=^H,,&V>GN)KO+.]R;(;9'[J:H5[/4?
UU.IH@5[; S9&.Z@.E6$(&&YK;K<=@KW_2Z# MW-9Y$R_<+KP6FWB5\U.6T@^XVX=9W3X&W.W#S%RD*]"2$&0^&"]&
<521C*3< MHEXZ(:G+"4F&))"8."=.2"KOG)XL(:DR^2>_M4'(2S#+=/++>5E]LNWYKN+.M^1,#ED;U%..!2PH!+
MM@U++MZRDQ4I+PIZKVB9%>/3FYJRRIQYL?WU=/?]M2IM U@LMM&KW6*--94U M;6[#8BAKCD[J9TM?
^@KX$"L^^_"O\U\O/IU9:Z\TBSC7Y<6]+6QUG@+XEA&) M=^',GO5@S)GGWZIK"A;-HK&-7MU#X(BSTN[
F5,VIX9RYJA;P+^NBBFM3<3_M[,./Y&1ST)^#_H4R##D<8BIKVGPA8RAKZMHPF"5CZ\&DQ?;44-9T^!K55-84 M;C-:%8-
:A_#_I5AX3A0[=0[_[YM5R5&19X]7'2+(S)S9)5Y5(+6F*N$JEHJM MET+=/4LB66&?
FS6]MM20UESU"M>!U!Z8_K2L7\CG.ML(+L>(>QVT0V!C_4O M%7$YQ+&>.<-YZQR]WC-,<8B+#5;872*D36:-
H;RII2VM#739]=FO%V_7;P_M7IF"M3T,G*'[IW7 M+Q,,Q6*KU]GG"@5367.R)Y0\L^;YC6G],&D=LFI7G.OZ9=4R+H2QG.%\9T,Y
M%:G+YI*FL*5ZTQ;UZ*;V;&M3;9-?^\O']Q1^7ZY&AZY(. M4=[C[PG'C SE#.>]&A*&<:36YV1^+QH;<9(X F\H:1F,VEC5U-;BU"7;#
M\>1W/I[L?3RI:\N_[B&R]C@"M@MGRL^8JL6^_I?#ZP6]C@H(<359PS;.@B_N;9UQ.DZ*6AX.$KR4Y>%XN*&
<.6IUZE=;SF*Q/1N:,8], M94WG$!%79LTNQK2&MK0...W+OG7]8#HXEFLH8QBDPU#&'+5.ZM>NB<5B:^";
M+2ESACE3DHQ]$VQ[*8+7G\Y^O3R_NJEU\)I!+@SE3!7@OZM6>;Y?OD1]9;@U
MX*"AH:P95,#P5]N\U""$N>R!U2_$R9$T0QG#YW)#&=,NZE-4Y4C.HK$]?X"5 MUDS.5&";JW;R?VU@+SY>7[W]_>;
[""T;F+:4A*9SG;^"YM9J<8;Q,0QG#J+R% MXY9]CEL:RAJV,H8RIK:HO"L,)% 7?,?!@6DW&,&"FH8QA5-X:!K^J MR1BV,88RIK:@O.Q
MV!H/:#+FJZFL.6&D9$-9<]09U,^8UB;"??'AW?G[]Y^NS_A<U#<,:$Z R+QM:T% 9_,94UW5.^-S24-9U#@,J;8%!?*-P- M+K
Y)X1RIG(_ZH!0WG!#X6Z=!D8:*LH9;IME*&<.@7)BPF;&DK'U3-\K>G)D MI7TIUA1N&:E$F%[]X->?Z/:
%G[2..GM>D8XQ,H_!;'C60$=$N9A,%Z, MXJCH27 8A&,1'J,KC\N. L\=6WKJ6V7>. R_KY]O_69K0,KNY,@@/%
M<%B$ZR+"S<(MC4LBPE4/0Q[B,M0$;X.M&UNW7<-.=K._)XJ^Z=:-1;@>(MRQ M.X7Q;DLBPA7?H _2RM:$#?I%[PD/%P/
Y,'DGG#/@(!:>493.\#Q<; 8>J(6 MUKHX GLGHNU/@0'%;EN&ZR'#_9,]+0>-EN.)W#]U#H-^;X'&P>6/S
MMKM?;@]XDV8I+KT4MPNC891%BBN^3;*JS-UN#]?;YF=/LLE$UE3F"\$1, M,*I/=!E7_=S<_.%8=%7<# K-?!L[M((L:J ?
^T':.:>&MZV?$-KNT_RZBV)W1U]5(M@F.N/Q9^_/8?O;4RIL!.Z]J-W;4_V7^MR-3\\ND:'4:O;6,SE-'_NRIJ=-K
MM!]!G79C\""R5NN5-%:K?SX+3-ANDGQ]]NO%VT\7MO7+Q_<7?UR>68X_MI*N MU')@*$*K;UOM9KMC
MTUBN/_(68Z&#JE;D>#!YT)MX"A_"G(-Q9#F3&)[#3[)#CIU8-%B05@2I;:(@
MO0W\R(UB,H1Y7I/8'+FOK)_/+O]U<8G"=GUQ]OTE_/=M$'J.'X2V=?;KS=7[M,]NZ//^%NEC:UL6']
[__>/'6MKX___G\PZ^V]=OY'^_/+L^^A?^>7[Z7DGHC MX*US)_SV@SN#_SAOZ-,C%]YV!F+]X<,OE^?PNK/?KVY@H%\^_G1^^?
M[V_KW M+Q>7-V<7U[;U\?P2__:.GGOWR_E_+F[6"^=VN92.R*@-W M[CB>JET_^Z"2]&;ZB#,$AW,1;WYD54?0ANT>#DE0YW0)
M>3#S)Z[)'?_S*W?@=$\[DU:W,SEUNNUAWQEW1&_H],7HM#7L-,7_G;:^T@]-M0[V$N7,KCH>A<#X?$S=?.]Z=GU;\$=FH-.BJB
W2Y"NI<6RM6%J4T1[%K@_M><%=9!V-X2],:#DS.&G$M+?!1#Q0T.C5ZQW)<$H+)'\^57KK!GSU[>KGG7[C MM-5:^U6SL?
[S34.=-KKM?J&1-G_>&72-FU.OL_X=1>=TTF@.3@R;DXET,G%. MP+O3AR5S2YI%:3*8UX=BDA6=
/K(BY9.\2.!EV:\]69\8,@V%L&;PNVED"=B1 MQK1YWXAY+&9XVNDT[1UN@'9L$?04/RLIH2_AD\/1^6F5\,"=LQ[4PTPDN4#P
MVFS9@1-7]ZD6O*V)5Y6(UGEZC2K%TF7T]ND67RFA8$UB37J,)E6^5&\U)O!Z MKQR@(EA;A5M+[I*OSY/CR95^L-
#%RF.2'BJ:TU2NK*36GEE) M!N05L:R52=9:]J#)_:T,9<[@$*UR3,AA8S-4,S-T:I^4N,T>RUJ99*UG=SI% M*^K-
D37>\JJYY3UEMZM6N]$V^K#ZS4HJ8.TPK!K<:(5113:4KIRP<+Q,./%9 MGZ^F<'9;C;IVJF?
AV&JY!HT]N\]JP<#SR^:>\ZRB'_Q@3+E,HO@A_L:<#6=YS M4F?0.,09MDR:5M]#=+O?J&OU\U,*QZ&?*

KZ9PPM'W$)>;51/.:@H'6*X3%HZ# M6)ZG#$":GBQS+2+AA*,IE?:.P8/T@OE,^/%C3BU5N]A9MT2S]:EE=WN'.'Z^
M3.M=EC63UM:RFR<,RVTHSP^;Z:\|:'62>';9XX/U25XV.HW]FPQSL)AT/,5%UOA.K/S7'N7P'Y\@;Z:\YR30M*+]S:MR4N)#]%;AZ''BM(
M7VNP<&P\^G)_;R,3KS4DLQ_X8O/K^%?F_(H96K%?,4,K]JLZX7K=" \^O+6M M6^&+$ [NF++HC&>N[T9Q2&U!&.VKS'
4+;O?/L2U!4.?U%'6.KU# &SP#=$N MM0]\|W6X=(X^ MKWZRUK%/F^5UKRJ^Y15.U*_*EE>_6^2A;,NP@&6BPOVRE_V8GH*
MS54\%2%#>Y49>^+D$$4[#')2/T'K=P\1[^)8Y ZL.1J?V MNR2V,M87FZ%:F*'6J=TY/41R N]Y M-
12VCMWIE[=RJ.*;7K>NE[ET@/^.W2_?_0/^T'.:.>&MZQ_+^;X> MY+GXWT44NY-[^9'KCX4?OVZW&W!V?;Z5T8BO73B
NJ.'U]K&M;X-HA@S\/*5 M&\:O$\.+G"@2<82S ML''VC@4+ J+ #%0V=:#A\&]X\7W--MY&$S M6<%"3S38,E&P+M8=$&7\!?1!T(-
Z)M75AR*(.\:OO9!JW/Q(NG&V03=V4@DP M^$ $F&M&.<#RSD1(!E7'N2V]?X%0KA-D5(HRV=RGH?,^EB>A*+D*,$I"1^TW M#!
<1#!R1EV %F VWCB4EHG9!C@1Q;>"MP,H@ D!G]*_M:?%1[V7IDZH.:1FX#;G.T/7 M47O#%@QS1H(W'<^@3$.AFY GEPCZPI+P8?
%M$HD MP2_(XTZ6Q\ #Q_+!/U_A+[H="X_>EU@2< U@VY,<@B?//OQH=;I-Z9>L,>3(M)Q@E#L%X+T(<"9QW=-
*!3_0;+11N",>O/Q=P9L!U3J2[OI%YBC;=MKS3G0>2 M[Z_IS6 &W]RYXWBJ3N;9!Q6IF^DCSA"_$6\^9$'!64$U!*A.7+2;>9IEOT3
MU^2.__F5.W"ZIYU)J]N9G#K=]K#OC#NB-W3Z8G3:&G::XO].NU_1AZ:A7L(< M_,'C(>Q8GX^="2SZM>/=.?<1!K*RU
)2+7%G+\)NU<#O_C$,,6M]=;4%7V', MGG09^"L*_JTZSCITADC/JQ4Q:T66#,>.4.#Q8Q)X7G 764=C^(M#49(%',?1 ME, 4/5#JZ-
7KW0D$2Z:,Q1UV?%D(/OWJY]U>8] ^7?M5L]%:^_FFH5JM1K]5 M;*C-G_)M41KI<+ONM6\CRM")^T+NC+5*>N5N4>Q/PZ#5>
MBU%\VM+S*\SJYUGS;MS&D^93+7A;"625B-9YK&FH*%U8F!XM3$]4 &RN,W&! M+!!1K$\:-H8]BB;5[RP 57O%R
M(!9>HWA87^%MV]WF@.67Q;>LXMOL=U#>4B26M3+)&IRA.@>JL:Q\G/AC M&'QQ(HC#,+U:3<,&5E">*,V8T8:Q(U*2UJ+
(=O,X4:5):W3+R]D&TM:F22M M93<+=XI^(EFK?'CS?#*19>!4MQPZL=B8SE)-H(A!X8YW54&*8!"1K8:GQ:V.
M6#@VT(O[A;!L;#0EP,E6$)V,?UK0WO+(Y!D(%ZD.@B&L@(- 7A1,9B&%O!(HYBQR?$$BSR M4[^15!'C8_WCB?L7H?S \KQ
E@BZ>J+H(D<(5H+SPU$;5GGX7U#:- ^<^&+_2 M0A@8*^NT'XDVDA/!A0\O\F!Z8^L6-(F$AV!O$,!%W+HC2_RY<.-[F, 7D#!" M>+
(SHWTOW!\%PNVLP[4*Q7@QHFIV)9^ZAC6R'%5%CT7M7G"748:1$TVMH>,A MD,X#4!NFLW L=F+A(XR()-MH$8:(34#
(88A7\&09 RF!, M,]QY6K*V&:;FC]PYR1:\?!Y$"IY!%3B'8A3<^K1@-:9:0F:H!P$5EE?C*&R. M%-
Y!36TFXFD@WST:XYXZD;9USIQ!MA#@H%D<#\R7V46 5\ M+Q&@+$YG2%CQQ0T6D8?
N(R("L1K!5I30)HMHKK@>B_;DT)5'(,="(,+98@8?AS 0\CEA."5G@LS#;#$/@! MTI[B&(3#)?$GTY$;5GHI\2_'!QMQ;
[6T8$3"@Z]H"P<6N.,%2&/R9!:1$E_U MB^_B3W^&?X_!S< 9G?\"+@8)6^;I*;A5((P,#8P/WGH!.%?)ZG!-"2T:UA5(
MN"=N$:X._!.$"=.^3TJ=> I^R1TT2(7#^XPT__J_ T':O5^R8W3Z(]\F:,HK=>:Y6+V5!>\S;ZW<1T MYL69T:>-
FP:B<85N'(2$SY:!SE7$] -TE^/ Y_+V2LAR%,-?@>F3Z#N_'<1NM'8 M'>&/RX1PN,V> _R>MJQ":F5Q-5".4&/Z!2#P+
3ZS8(QE)>85%?X$,%2(E;$RQX,7$0$X[.B]EW M$%8M^"0>$)CV*S)AL(K,W$G8/'B[3[&P+.BSUCS@"C I1(W+
(!CK7\+TLA*%T#?)55$;+UD2=YDYRCJT#XM'CA-R"=8Q>$? &2$:94_81"NP"B MHC'PUCP!8GZ[\!PIF2^$5IN@]%J;H?
2JCXIG#A\N$+N]=4+&#+9C 3)) M+LWUV;4T#>#'CE$/Q_11$LJXN+Y)W%V,&44X3)._=8;^&L;8T$!"B_LLQ$L
M'<88.1C*H#U;'FO(@4A=8(ELF5H@+Q@E+JO$T(^LH8COA ?36Z:VM0L.RE[M[.ID&<=N1-
OL./%:U#*0*IF9$_*JXXVT/9$X_XLP6M E FDJSCP9!>GES.=P MJ..J9()&?+B(961JX1-'"D6 ',+@U\^3L?S7 FB#
<*O$)#"C.!=K+F(WMR.3 M#01C]Q;HD>"08ZPMO@O@=#&'\QI2%TFRH.6#]:-M \CP3L",7.&/[JTC]?&K
MA]DK>9<5&IC'!T0&.!:X>&7Y'WXG^CN^"MBI M"2SY+WBSB%3!#4","4T<-P
,MTU"@6T=B\?"4[_3/=0@4UK"8DX>0G]!I4]VF*I1%G#.< M7!S<9(G/.(/,J<89C<)%&JO4VUT2\JN(ZT7V]=U\&OO423G3P[-)%)3-
2,$L M@9L8>9G5BK-6$!)5:JD!)S1=/9VPM4+@[QR.EAX)XNK@;9W4H09_C"', M$6!G0]ANM',S8$-(AO WNG6:X6%>>*[L"-
R0:N?/B9$%L:>@0B@FDIYEK-I&"QNI:GX[V+LTND)> [? MJ=@JNB@C"CF0S<@=N-:;
.#V.]!;BG*U3NE$WE9CT:D4#1/J2A,H%F&P;^%) MT'3J6X3/7P9?Y/-=E;E1'4DAAB7+EP=E\9>38,NKNXFUFV0_9>% FGC51XNL
M8!1A9X&574B/@F*1\)N$0%[8+ADE%3E9.S'"\A?$%FP7%NLH:_8X7\D8TP\4 MM8YV%S9TZM<&\YH[*I4IQ ,#=4B":8%!CI6W
M@!.7O<5L'(.'?G8./4=4_T+,$XE/0PP#;?* 1FB_9D'V%$-E=F1K";QQ3#U M H0NI%F^L:;!'2PJM+,7*(IB>(NF7CK?6'1*KTZ"L&L9H
@O]U)LV3"C*-@B MUL$NC-#AQ#2'9LY]9F.?._=R61CICAU?71.")X;Q633C?I*$H#NRY*Y-'W:<<3 G99-70EE#@H/Z0%-:'.S9D3R-
R#L5W$!\>=^! MXVXDA5R_5N[$"D1I5\36"7D59R/MEH/7:=VBOP\TEG>\JL%A_PV0'TXPRZ^0 MS%$$1H=4/D3-V^A *']ZKWO-
@5F@]ZO>#$C*0]Z'T[2>*A(NO378.C#:C^*' ML7OPUU" 0+Y&BPC);T(*4:O9W#>'Z-E-X JD<.(A2'HC0Y0GY;E_+MRQEJZ1
M,W=CY48LPE%ETHAN](UX*G,@@\YJTY**=RGIP]F_/7B:-A>]1K==K&/&"_3> MP$FUGZ+WQA:@\5)AB:\F#ST=3'VI"+'BSM4+8?
TM)D1+,P]_P33!+XZ73?EC ME/5Z@:6>VLW6GJ [C/=K%"=K**MIGW:W1-DY9"@OZ79-#X%>""0";X;'%P=
M=2F1X)\V[<'@8<27YS'##UA;%H1#",*)W>H]; $94W*;9ZRJ%S$HK$*'F))[MC/V4J8"9H27+#
([5L7O[^@@E<&59UDQ:6\ON=LT$8BN--7Z_B^FMCM272+A[M?7OPS+X&.YUE$(1^QVZ=/ S?
Q$[G%AK>Q,'H\S3PQD(E#IR\4;7;[&V6V0,X ML7MM!I@VAQ]5EK6^W>ZT#^AM/@K$SAC@E.T78^5.?\!B? 6$A*&-T:;E$]3$
MUZ>-IJ5SYQW*--J$4B>K6NZM@)+*L-175:IDH(%@73N_,)*@X([URF6J0_"=WHLT0'\/C_<
M."UN.!X*)Z1J'3%:A,LP*5@7HE*]XONYK&\@4#Q\]2SPQ;T&8G#]* X7*F4I
MHL(6JI$'QL<+F6Q*:7!IW4_ZGN/;T!F+I*B8L/,B5>H/_8L8 O37RX+]R))Q4R(7%Q0N+VW4N+#;O,M,M+1
MKB*V^"THM!MA9GJ:*)O:3TQJG\=@L_Z6Z$Q4.W#6,R]X%XGXB]F M6&@GQGG .RH)LU)4*)BX+T)M/"(7*R>RI1(9P(9<
G#6/KI84.<'7Y35":A& MB![#A'0<&JBL_WFT?@Q*DB7 F[%,<4WV!UD .5Z,Y)L<+)=3>;:A,Q=@5D>)
M'7]E)Z0A5%2PI$"!%\Q$@FXX@)E0;Y_ M0FF=RBO1ZU5U7C"VPKA5997P,_7LEFG+).\OZ/HD92U979K(:H!<'KV>E$ZP
M)>0LJ1*8Y)PJ*OS%CU3%BBWYH%P=G O]6R&VY$:Q)36R3@7X%%\R(G4;-@+"2/9/T6 MK&LL\"V90BV"R RXY V3"2O
<%9N)TO*#:$V-[%IQ6ITPEO90X?A0 MJ$1_Z3I2,<47@EN2[-8J9*M!)' /#C\$#_$S%3@1:5%(%N332JP$51NG'4A,
M>L8:AF02Y/WBD%(-U+ZP<;)2A(&\'LU"?P>+%E1]%\ B4-11FCPL2(71E,Y M@PR?T(&6KG-
6OJMB<$$:SA:W,"N%P/:\@873WVGE2=ZI+"':(/AC >X[HNDI MR$?$FCB;7K,#03)%.<.4(EF&5*9N]YVT @4)'&C&U,Q:*JK5(RH-
LP<(66QK80: MS1L*=-O@3#MK6&<;P@6V]?5))JJ [J;LP?P[BVF'K)8;EB=V>5U%^':61^A<
ML\GY69N0"+^N"R5&RC)//W<>&!,J3[PQB).W33HG7D92UHVC"H?3PCGR+S/E
M:LK)T0X'N7"T)=A9]BE#!=//FK90NNZI\WD+5BB!MD4JB(!!357 M@27@5D*42LX\Z(>!=PD/K>_3T3-?
MW0_G@3Z(VOQ5XOL@SD>SQ8^'%@Q!BQ1 M3S0?$T[=386?(I2JTC+IFTV<+^ N@CXWK/T7>:<,]]?]WFD>XX@6U>OED8^6
MMS&LP_P+_>&%&TW38&-2,ZV#?+B9#$YZ:]YPTCE]X U5D<+?1!X:1/SERN/B M!&PQ^OJX]=X*7SEY$BTRJ4%5QW_UB"H?
E,7M,FP;T2DA/8&@>#AC.,$H.*0(MQHDFT@#X0HSEN>@N"#]G#I]KC_W;#D8.PH)X'ME!C#AX0"0)*(1(,FF48.G8
MMVJRTF+FY*#C^B#M,FI"<@ICRP.R.LZ1TDCLH^QQD)"3->(*#@L'$.%\BL8 MC2*]$CLE+5,FKN
*TIBX)-0(7@K>S0R];W48=_!XZJH N^)&=@+$3*IG'JL# MB.1D;@)P]@!KD@$@EC6,.G1.WP^#.
SN"&Q:OQF=!A%*.^W,9Q64Y&B9SJB2 _DKB84D M/'*!%F^S@R8=M\[U9.DDZT3D"OL*7V4LHE'H#E.(J=0IR(6*P(C3<7Q=Y EW
MI33ZE,A4BDV,![*L+&Z\D.6;OL(W?1V^Z3-@U'WJ;Q.DKLJG@\1G,*M[[_ZUO
MY7!]VK&ZET$U1IU@U(D]4_,/FG*V/MLL6=1I.:$A+I=#$F1G<_ML$;"("C$T MDT=:H%[:;&[OB(&RTX*W *14BF@U
TRY%/%N@1(&4*DG^D3?/FF=&@@^P0 J M+,([5ZN<=O:L5V7\E")[R-$BHE#1J]QNDB;E;=U-JJ-4)5*/HWZW^XI+76LL M 8-
!C^M9@D]7DXE>6LR>"6AG8[=,#X?H\ MOOKU12\L"M[)7.D81T6N9-[N$L2QI@Y>(PO53""BJ^J1RG+,-T)1X/RR^C6] MNI9Y-
K*.Q!]'#6NW]XZ+)N[]5O)CNE"F'.E,1S8W"&5]BZP/R#8V444*RQVO M9/.$1(M+)IM8W&P97]HRF8*)A.L-
1W>2\W#/M1X29\D#5AT3YKK"#<)EF_Q M*0\BF)TDL**M:%/NZ59X7;%4NY=6O/LL6%&R]'T[)I);SKBOTH8?.D
MW;.2K,Q,>EO@RY))%&\L'8MT.Q#,T),%AI?4Y.RM$P:P+HU,6'M&AU3A9;NJWJK";R3CH=Y8R7)^(
MEK]E&XDA$:GWT63A>=)&4:IO1+.156EZBD#__U)-H#2X2TW^6HU.OLU@>?2I
MH,7X01^/2MEV*6YDNF.HV^E4V#E[E:^N>J;%GEAV=+A]<^ MO)*$OIQ#OV(]'K%L^:(M)H0Z(5*^M&Y>B^
/&NPC64B[TQCL8"*V4+*[-$0F MM[H065N-7IZL#V?QR[Q>ZC)T:EL_K,W3M--.1"V@V&9XK;T:$YGA):!S0A#!I1%:PQY[,%?5!
MYF:4+X;._8]G9Q_3[%^8I"/E7F8!?Q;)[JJRZ<$&S.8R^SN;QDU=TU3E2]+"
M6%?.KYN*MIA^$(OD2+"V,.!UH_H9RIZ>:3]&59^@FL]1?]P_UET6;?V&D#)X ML9(X7L@>5-3I3+9'&
[M89YRT,023I;P=OBE=N\^\@EXYJVYWJK9TF_N4X[OEVE'=_TI!]9YF"&_>H_PGZ]; ;DZ6ECT.L4 M38"$AP9/DVHX.&F<;LE_+-_%Z?
ITHU25,E*ZO5^5\>OZ]R]GEY\N/IU]NOCU MW#J[?&?!!^_UO]]=W+Q]?W7SR_7YC77V_=4OGZP/9]<_GW^RKB]N?EY-OMH8
M@#1Y>[R@?4U%GJA3+QHR53^*=4=H7M'%\H)HC7FU3LX:UK\76!<7.\EF A]X M^M_OY+-TN#VC%WR0@V,%UU-
93EM'"3'HI4!1QA;N8BZAF\!NAEO02!#,1JAJ M0/P@[<2KL5,*GX#4'NQFZ)B<-PREUO/N,USILJ72I9NGV7+9R*[!]&FR3]>B
M/H9=B\J[%MU*N19OKRX_75^]OR&WXN/UU=OS=^A)%/ ;C(N6;D,L2.I?\8C5 M;KX9)[L97=F%@<)-HR#9F# "Z9>M-
QBRDOVXL1S736L[D]I+V'R3&/OY7W*[MID;?UPNP"ZV.<]SJ'8E7ZGB-L'$B CK)"T,XZ>,DZ+OL3JU.\&,5U\[Y.6>S

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}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|_T5F.FBK*>U.0 MD?N1)R0$F[8AZZ6L85U,-LT$?RQ? *Y4>WXJBL6U,:H&,RQ@FK6UE]4S>I&00 MG#*'F)*<0$9S%/-@ -&26TC=YN'-4'$<.KGEQAJ1+"V3 &MM68GE6A!2$?SE* M*6M^LK5Q(V>N8I<@3PC LHB/@\GQ/!C)%M(JP\+.:$/^+3W;^B'=39*=EM1A MJ$^+26';R(D= ["$^!^VQYM30]T@>]=3NX.CHJ=Q9U.%Y(FU78@7NI6XT(W:BW)"G MYZ$L)8=P\E;R.X\ [4;*AEX6I%_'1RD)MJOY3!E#6,&$]QO)7+#2T^^=21 M*$,J36JY?VX:)[UG@"=@B\\F&ZEE4D;,7":;%X])T/@!&DAPTN,HZ2+US9 Z* M2(*-ZG.Y'23D357*5<9&]E(=)PHQ"E)E62,:XB_,E,U*QJ=-,60=@T*MI)9 M:%5?.I;L%HZASC]+=8)&:E>9\)OFN?@9T_@PT2"L& [90X%O#M#DYRW3@E)I'&3C&S)BRX7 MN^[2/I1<;N6$*]D_\AM'WH_2X?\485?!]\#K)> 5N39@#C'T[@9Z6\C<Q3F4E?B2B*.$GW TG3+VX8^"IE"NNR(WU%2?,ASS6)S"]?:X_%C&!&Y?6X M:K_KZGMI2B^337=S BACL:N'AS/XA9?QQ3#OVJ.J6SF!-'&'-C[D^RVZ<3D3 M3SX[4FP>^%E'-'>7_6.R3R6]KW!#J2RH\ M>WQ)RO0=/04TJO25XZ'9L'&GCX5WWB_N'=&6U90? A9GM3HQ!_IO4A\EO)/=0R4E)'P@80]>_V3"S;0 MV)_>IF74^NHWFV>T8]D#>IH_D6GOFAA45MJYG"4WBGH)! 4T"/YF^2BTM%Y MN;2LG&HN7:OI9<+',ZR?R)#UE809T.\A,_'1B;7 ?PK!/*/U4E7$>A+H&\1@ M1S"L).;R"CP&_;NE.M51$."E@I,6<60X >=>3'W!. I:1<%&6@,9@JA/0<99M-E=(9^.88OW4<'R$#[!T7)0)%'F[NISA,Z*3T @DE"=!!+)YLI'RWMQ>KJ(#W*)N!S MR[?'C95\ (BDSZ6M55%S64(1"8*JX[4^1I.S!0?W< 8K6<@$^[QHXE4S';<2 MZP"6Y(L;+'"*PE:!UF$N!6=BP-!F@H1[M^N/I/-]]*;[Z!.^CR['?? 12+F'V M\D = L"R$MXWS+5]K+0ZCG]'6U M7>L(=<% WH; M2K9-G>S&,9CD>#_JPC+4A98>@:0USA8I'^? MWCW+ /X86*EB8$OS.^C$Y?>_ML+_080"<;)7XGWI2.3^_*M[Q3+AXI$/C4I];D2KV-DS%]\5DZS>]EW.RCHO-'*1I+P]\B91_I:$ _SN=L8C#IE\OCQ'@QC7-3Q9:$A*C+Q]43"2=R0(F72*V2 MMZQ48)&"B*#N9 V9I$B:/PT?2L2,K()FTR. <],1+6:4EUZP.06QFV@S[4M"Y OH^D"#]AX,W>.X!>]14BZ20EE(HDDAK1"%)U%],*]7FD>9"XR'['RB^6@*.X/ M>)2ML#SIV#-*0I!)M&\!9_00']%!2VD_B'6J6 5HAQ9,!6LHJ7?U%I.>!QN@ MS$_"6E4JE3DAA/*,DL#73<2=KA9IG:3S2[)R5J4([Z9EC4Y]/TD[]'(LH# M7>+!T 4P'9<265'[*SVOF9L$)&B@H4A0\>A6!/-YO(!N^W-)*@H;48TAGUV7 MKC+!6*QBGKI=OZ6 ?9Z!4G9QT%"0E:"S8G;;T#DL)#MP*APJJS$6L+*Q1L5= M^'I<3R3PM_K&*W_CBBJ. M!9^EN4 YY$8L+]&]HJB<_NQ[,];2:S\+_405 M8U]6\TBH71%T^%ZF#VC+E>702JQ<'DU]A-!*OF)4KEB!FX"RF[E#>$B48S]IBT%0CE7LJ!_(<=Q;) MV@Q76\+E\#2%SMYB9)[74'W''W?!]\.GH5]???'MO)O390C#N:OCSN--]096:"P8;F]@Z3QG#;UBZ- MU/!DJLX=)59F3?_$599'P/4XFQ$EQ)7W&D0C%4B MF,PYE)8?[\/CI)859;*#!R:%^EJ6F3WL"8_M NP)C^@R224*8S@;I*)_L.R M8":..!H:J9VXD;SO1+T:[D96XY)?)=K)V8[C7K@0.DO2W>W!>.471?HK2$D?I MB;XA7:L+'&I,WGB8->>62 *ACA_1,!T-[)^ MDE>=;^F6_<(?-:PO#>M[4>6T#FD"*M"@4)2038U;;&<)!)*^R.;,']5*&C M00C^BRE_,H-#$N-:R#;UD8+A#+_0\7_I-IQV.7E=I9LS4#Y4LO%]47E:((I M;?(=W8I'69_.T:? S(4VB5;B+.N@7Y(RH$'^8N &9W*O>W;&_&&6BSK08\;;#S W=^S(6O\O0D/BR2,/ M\G5-/#.)1C:L78(='\1?[@A^\4G\Y4BQ^E6$V,8L$Q;2QRT9&H91P=?V HB;P\"Q/QTD=LJNJG*LB6[\DM>RRJ3-*1ZYL:]WM@]#A_B ! M/5PN9]L"\I 49^QV\SW/%HW8+UZ];> U'O$HD]V3AP38^68MN9';7!9:%9R_MCRO079E=AK*BZ.N/WW^@'\7B5D/<);]*SG=Z4SK2OK)W?YQY) AO'5]A<6%2 MF>NIFM(4%5KG0:V9 [$"IR%#V[=AL)BC[0(S%4FERXQNYZ&S*.$2K](W6"WK M-S+_R2,P+0E/<9\&:T-U3R9+).6>3!EQN>SI%> AW#J26EN*CR4E-#H@K"!+ M9O!N B#3T1QR,338=^Z5"@+))LO7^!=*)#7\H?U!?DSA:>EKC)C3%(ABY\F MNF4+7$@7 BJ)2O(JY:LU3_QDNCH^H* GP.B @.12E9N9,JU @_KD*W1: MDHF833MR%A(A/F]+H@0EZ Y<.KS#I_U5+U9W_DK0PU2>EUZX3@'8B:PFB[.MIQY3'J7%*5N&4K$&=4[(.1'0PQ_^_O6]M;AO)SOXK*&^R924415QXLY.ITLCR MC+,>6RMY-LG[90HD01$Q27 TA+WU[_GUHT&2$HD15F0W*G*[_Q%XM*7I_E M. <_I.]YL46!215K,&B'"PX2CM4N1]90(4L*&LNCQ%4 "DVK:@$-M L4J*-5P MM1*WOH',^I*'Z<4TSBO#%INRX\WFO$$^0IZ2ON4)84K4_I<.0W$8Y]]2[S$;+#$LAIUFY MNBS)Q>-SG--OS7<'R+V,X+-1F(M@2&D"JI)/HF@N*K<)?R7G1$;^LP*L7 M:YPT3P=:BG.M49H:^$UF><[7?50>]3KD]O_CV1>54A*!>Z M*SXV+!1UY=Y2$O0D:2LF70[+[&M1KF7?,L/9RI+*P\ KY MU_G4I)$R)4)9'G5(=))/2LA=BN0&JN+X:Z3OENNID1PF:X=B(; CBNE:TZV8 M[B\7!)/ISF5M.""5";R_6MG@8JTVOB$AYW%S%C*>-'@%?(GX_4A_H2Y MK93B+D%.SILKWEG]O59>N>K+Y)1HE;IU9SW"'XXDT^5TG$$!EQ:449"YS 64 M<.?*!-1X!?9-TE7%QNK7<7#5:7OJH[NVL$UWJ\P?534G0$@K1!>\9'5XJ"' M>"E1(IVR3"^]X-P6JR:-JB--VQR1/@2+.8OH!CS<&"O75UUAG9K%8S4SG,Z< MFFH*M_)!:'")+)+)U#Y^R5JJV,_QDM6P-*"R"/.\H6";$"%G="/1(JR7+\U49 MY%#7)QFJ,$,CTCM/9LPD6HE2&"H5A,A22$5)26I5TO7^E0IYP+#7J9T"2.+> M)=+W.UKX1\5IS:$4_6Z%#(QV:XK[L"6T12Q% [A8%MM4PU?)F9\ KAYSOJ/$ MP=_O@>D(\#A3B6P2Y"MQ-TD&.0R*[M:!7>]_%@KNF&=>NL+LTYS'B*"+ID_75"/'7'7/A0O5]1I R%=BD-*%L\GGY# M.81K&:A$J(:(7X+61FOR8GP6!B7GU_!/Z!0"ZXB/'K%.UW$.\(5Z)#"B,AY. M>(T:&/,-5T/HC3A=7R[1QT-B.@QC,8N862BC4"KLTX1PM6!XPYQ1(T+J",4! M93TF;*(;HYK7WZ!SJFBXG:<&MNO$(]5RS(_ZWGN"H)/1M\>.9E-H3\MV,6R:0?I MMU-JY%-W+K'GSWLV/*M%GE#U8=A,#K&=<"C).$E\ =QG^_'\D* >X M[2VX+E\B?8;!P%7&1FN3W+3/K0AMM) \U&J-V7K+?.6+116AEV)PK^UU9NIP M:M58LQ*"O'H>=\/NTC8/!WZD^$%[U]BACU ?\%/\[%HV'QWD\ M(N(Z$D6$US8!:W6AXAW87DHJ:IM'*YQ&X >0/HU^.!7!C]/RK6KJV-1620V% M%3)4>Y/8LQF34?^J9[;%)0L*H"Q_8Q#C-S[^6B"H8B,Z\]41$D_I,:DF*93 MTFQC&ULQ=,:2LR]]]10-& S.O/BDN]G#8KJ:,LLY#XLY\J!6G;LUB?D5@=WM M,_,O!MLVC%;-D#PE1T"6]U@Z@IBC1N$C-?[EW#?%&O%"*&!*F6>)K,NWT'@@ M3<6%-*&)]-=7"@N_+T;[TVDS7^A^7131%D-L]96XZR-VGL(*,3A##6WIE>%1 M6CZJZ1?B6RQF,/G^6LVE5KP+Q_MFR52+B9Q]_L>'=\=NUR%K7,F^W43AU_7] M,LVP@'.^P-$V:)&1:(] (!.0256F9=NN^_?TK/21>;3C&K#$7DJAJ-TGJ\CTC M<8C(8;HN"MOAU\Y_)*BE@"66BSFT1JU@_BQJHB#]'6+T8"RO4QQ*FRHL8!% M6BPTP_MA EBK%$KN!!6:.6@Q%IF-HH96(=]

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l."46)D]2D];-J!4- M=V-Y&38,Z0MH(I']@'8MA<71$J1!XQC03:1JA(W@C2:3[.8BW.'F?BA%1FK. M&6N!_*IK;HDC0*+(I.R9!_9(ITWPB&7"D1HDN2?*^ #@X':"X<=:]6+T9F5] M*I-:-X0QC3@A;"CUH#45P4Y!C==\1UYG*^\%YT64B:6-_9C'RY7MF0]IZ?[F M"TO4JF:,3"_6_!=1*8NU9K,Q/B*W,\92\KSTJ;2_#.$D?O/QS*AK%@"G0X7(M)B8U)=$OI)>QJNO&;$,A+JW3D@9*:!BBY4:DWC1*DX5*6?!6-"CRNEJCM/ZT M6$Y>D%'3IZ4YM'BD)OW^(BVYV@@"$YTLE-H$H\!'16+F2G_65!OL)XPB M>B M_FV6<['>')"L@2X]L8YK,PU05'=5RWUT>L?P:A]RBN6H,50P(FZI4]KY.RQN3 MLQ,NLE',7%:$+?&K;-K ^H=)-J!EV;"7H :ZAJ M5-.9-';3"P**5*46&\EC+2WB,*EK+J?*_47D8MN92=^7$@K2 *2L;O/DD+VL MB_%PP1KQS#MJ_85. (2HR/5AID8K6;+I:,=C-<.'[^C_CE9%%XWZGV]P&#,# M$]7O,QT]-!\LD1"K,LI*S-GS;R0!10:Q6$R*85GU@YS;5S-%W 3=85O2$ZGR M&AA,5=Y[DJQ0#FA!*NOQOO"*22NFP>!D.#X%QYFILR>'I"GB9/I,=#OFC>!6 M,R9O4T%F/G3XX*9#9EJ9AN#TV@+Q@@Q'D0AZHJ=;#>TXR3+M!DGUJ1K!FDEV MJBFR8:WH)RF;DC1+RBPK*;\H";+JM:E3LC4J=AJ7EJ6J\:HT M"A.9$K#/I(>,-MLGJ!9#M@-5]JJ[5FOZ)75_%*P%+!F78F>JL_AKNJY M"B(M9P[*T#A?@X6KR5MY)$%QOK1:0XX=YH&Y]NHIQ+H8Z;2/6Y5[-%M0B_ MZXS]+T*!>()$_X&7>U_/U+^\N+H\43/2B? CB)BL;&;R%Z?&XG-][/8 D# M($_C$$6FLP4F^2]D/$[A05Z?G5V*3(Q](I8@@3(@KO8-Z]$O<#1F]0?Y=["1* ME#.C@8[29%,59JOA*7W,T5EK\@!'*HX>1*J19U#8] MLC&GIW2ANG.EF"-J9M1*[3UVPYE9M",8M3$CB6(TPDH1->/**W,5RY*97* <75[XNLY(X8GR*Z6H.%ZCI*%7'/F^^K'25K"]>9" I4U@C5QQV@Q8I'-&_4O:\$^G(W#Y9N8 M)-B.Z4=OBW? U\6Z!33WY2YT0_ZSC$2W6^\T?1R,>0K_/U WEG&JPSB=K'X. M/^JL_TNC[JH]?-.5.NUZU[O[4B?T9/QT\/XXQO_YRG^5+X4!&K)OO-FMXQ8' M=1P-5X<@F3WZ?FB7]P,M-^QA\->_N*W&6R]'D_G@V;_7[Y\NSW_Y;YA%;RLW="WRUT;V8./T_@)Z-,6D[D25._49-S6C1YB'4,)B0X"TQ! MIT $GG"LU:-BMC4I/]&Y,_SQ-#&_J21<5H^N[PTRL$[]#8;<75#&]^O-H+L3 MS&S^O.D?!K#< ! [*MP^UU4/YW7;U'JH9=+[C><,;X=_PU-D*F2]0.WNPPUG3 MP#>2L3G@JQLPOF*O/LW(?$E0 XJ%V39:]A5Y5HS, ((5W<_.IBCRHUI,K&<*/ MN>[$Z:G0ICME17KR"+A;S2R,!_R?&%C"J?PN6])Z0U/8=3@@>FGG6H3T>QF_A>"%)_TFXI(\PNMF+ M2L/*}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|^N'GS]\N:,,\?G9,-4Y^P'WHS02 M%23JWRX*!A_@X6[Q/\YO1W$O)C$OZMX]<%_-(Y[:8OO=B^W]@Q3;^XT#%=L' MG37%]CL4R\,X] (^E!=B;;#&!R5B^W6)&OC^2<#CFT[OS_W&^?';*D/+=J_F# M3G/W:OZ6WSQ(G:97;S1VN[)&78!FO=LZ9,R P^#UAG?_B? N4U3T"B7S8F^?_ &=48JN\6@^GV5O M3DYN;F[J\)SUZ^3;R6G:'X$YDYU$@^LP/4$9J1/?[;C-X 2?E__5<_'?@^9) M.+F>PNMY[3^PNTW7AW_<_NG71W.8V5.45-4"31?CD-3;?HO2:U3$&I_"%]6^_M>>V:-,?*

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

GEM0I'DUTO*AJI("&)"LA1+F%MTP9JHG8%5:5%_"KHA>BE%^?%]:FFHA+_MOMJD_$HIL1"1W'*]J3#R*"E
JW;2<7(3)N]R:O;B*U414"HM2"K!4T0MQ_MR:W'BTM;3<1%KO1Q37QLV2]93(DY"K'+K==5:BF1E"8!FBYGI/ZF]T^0]?Y.
MG04D5'A'_M\RO)UMJ"!;D[40XEQY(%,2R7QDJ$?24%H<_GF-AYM=]6_&-J&K_MR\"S'.*E4?*63ZE/=6&OQ(4((?ZXZ<0!_+)-A'TO-
M/D!+9\R0=+X0_AVN_#2_M"&S/7,INCL!1PH[ML<,N"<'/B@)%_L(0R!5(#D,@)1"!1,1%HKU,E!+:2/3C
M@NJ$K<987J,";2FQ$+=P>NU2]8XG"JC[Y=/$,5F8/C8_M,9=/'PE=PU2VL8RA2W_=Z)XA1@ARKD*3_CDKEXW0T8]L2(YD\T(.?
S(R:_MD6&1.FVK_G,!F1"V7,DF?5:WD#3L'0![B_GG'BT0BD-E(T%-;+4GR.KP'-["U/N01_MW%MD-=F_K.
[2V^0A["P4MP75HF#5(XP\(>!XU'9\IVX_=\?8==WV/K"VM4$L)R1$+S"HS0)>!%GE&+=6-2B_T:J
M&!V0"1')U64RAYL:Z'O1D:0D8X]:JD!4G[L0R5RI1NH,5'99L"=Y0[X*F[$)
M5L)RB27AXWVK(6_U.M$@(U$8(;DJ4(T(22N"$DW0,#I2]Q8W.11K;:;(3O!;UA&[NH_M5F^5XR1$,5?X*46QV9TR?^"U%FH2;
(20YJESQ^J^D'"'OV?ZW6E[W"G*%@92_\:7X>8%V:M./;P'NS[U%_M:S>V#$@IA*B#]BKQLP_-S1(+0-U?H\#^\BSHLES)Z=*VPD-
,SPX;>0G",F5_M^$H#)!&*,E)12NQ;#$3^JK=0D&$D1%3RHIO&IYV%S_O4PDV.DQ_XR>MQWH_K_M==16\AFS_@G=)P6YNY"-
Z37(FM%-YT%88+;,<2$1?YAOH>F/A)_ML)\=EV#;^IV8'S'\SK(G\!OQ($>A:X=],SG#Z=7X^:%05Z(P/F0?(_.P5D/\<=H\ZG3EQ+.I.J
^8!*3;Z9Y])MLE_M<5L(+\&[V/_O6N!DTN+OD;UH"8@BWCE+QS-F<8K_JQ_M4Z8NMJ,>'XX!_(>A^:]@?]-Y8N0*V]
[>2@4.*A:'ORVQS5Y@#*3^0I>5+_^B'_M9DL="&7W2=8)!858EB&%YK&D*FTZ,VM!PY<%5;OJ_M)>4\PZ&&"ZGG]WD4[(*,TX-5;?
C_L3.A3OC.9Q^,BI..IU)7R3/0-:CR%K!C_M]NR<*CO]_F/MT#&'MDT?PC>[2_NADHNNSIA@'Z:DZ6JZB\J!X26F3PORZ%_:_MU/BMU
$2E*\YD/JQ&_DC>7U[NIJE)D-9*V5(=3$S>7!(TACA]6#_MP2B3;3==AF$WWY#XBC:QDUY?L"XNCDL[T]7A03U)5\DST,]DR)6
/[;#Y2<;_MX,_&_CW#OP,_/0_\7UY3=LM+"-'%=06WWE0GIA4$6B2E|>4]D"HM+2<<#?%3_M>-,6Y3=RN"1N\P4@(R;@-
PU\CUTO8#GKX0-VS?*,]:78:YM]%1B8V8M;N-CQ_M5@1"VPR?4XICWQM[7L#-97\PV_AX"\-MZ!7WCNQL;'!QZDY^/1W^2D@L
M>A_M]\2=<>W8_!T^+/$4V6>]N%2"V8OWZ/";F*B>$Y*B<_HP>#A#Q:IGSS;_;\$V
M.C,3MDO]J.*R%QS(6$$>>GT8P/LHVTF#1'SM(EMD#O;",M]/ZZ)O?
*O6^Z"1%@[_Z6G'QCW!&N.PE1;J3W;LK&NUXMDV6J@]A%R9>#O!\'C0_M2@O-?[K[-E^,OGX5=,]
<,QTZZ.7M>'+U;3&M5OVPE0Z:?R&&;RVMQVK-#UOI_MH/EB].M\-KX;B4;S;"L=-.>K@^BB0<'06-A4B^ZZP(_?"';];N>D_]V!3"4
MM-8!CI1N/?BW+VU)IK4.EDP"IDM8L32(-W4@^QNODS&V5/G[$!1^9:H$A-M-UKB_M$%\XE(@)M1T^XGVJ.^+!
M=&QL>/^^)S;=\=>N$6/C4)NNG^ZL]48X\=7BI07T55>$?72KL)>@U'2GKTKS_MU/T(,!BYOO5[A$_-
+Y3RTG6I,NP=G77[\%34$P,8C6-#B/&#:3-'_?V!_/\C+CL(8\9+(+,.636MN6L_MY:.V-CL]
((YB,@K"2/>"T&0O^9(+;R56>CAAXQ*2UCT%U[G_:!E2+8P<]D_2_MT]X[T5ADJB;Z\C-R%(,-#"X.S*361=_M66LM3-G/Q6QZ*IB-
0>$3R=E<@H-6)J=T!1VJJ:%$SF_QO1;F#GN]_H%^Y5-#_M05,]C#B%4;_3ZTE-#05-]3_B.Q#TE(:-GE:F0$Z4='J>IQ>/VX*D6)F-5L9/
M+*=DP!/DS_H,M#*8S<_%^@I2&@4&6AB<+-9@$5_8DJ>BE$:!@Q8F[ZL3Y=U0_M9+,2"RV,CJ?
R$=OXR\SGIR<24XTTN1;&\G5%/.P4HR-(]50XZ&%R')&EG5!D_ML3P#O0S.%BU2^@I.D"LPT,+@8?
\LM;UQ*LRIBEMK8]8)L2&2D.A\]S(\'_MEY(D(2]:QC4"R0%*C9EFC@#-H!N&J42I_GSRD?6&.D@(_P9JIZ.QL;79:.(-5L%-
(=7E!NR]7X!!3ZF$B+V+(V5345!,C_MWIW\W036YJDU16SW,Z)^E"C%]<8I1V%H+4_8'"]BXQ_]3WNOYH"!Y3D&5G1;.
M&)Z>0LL,V8N:F-F"P4A,_MIP7TR1WFX6GK_4,DR87HHF<1E5C\V0\D)LKNW\$V3]YX3]VU]2Q'/(?WG^VA
MX@L(BUZ(=D=M^X:Z["[!TL?_ZC'[Z_A@F'HW<'P9IN+=CO)L=7V@*\(M?1.L_MY"@I0ZG%.'E+G34["WM-EGXX]ON?
V0W;$H\O2Y%J863VC3I/;'3BX1D0_YCLUX.T#FU[\EQPG.W8FUG0U?(+$=[T>J1W61]DI_M_Z]O1Y,G7W#>C6?3WYZ*7_C3)SA-
LSR>'O[V],^/+YE_^E__^-O?_OX?C/WW_M_>OG[R8I>,CG"Z>[,\1%IB??!TO/CU9?,(G?\WF_QY_@2?O)K_HL_D18_]8
M_MG^[//)?'SX:?%$KP06[_-+)>/KO7^L_$3I\0L,;=LM??WOZ_M:;'X_.NS9U^_?OWE6YQ/?IG-#Y]}SM6SLT_77W\VY7/?
U7+3XL0PK/EN^?TB?_C8>-HM8)KJ_[KQK]WRQ=>S!(OEK-^)Z\F-GZB_ML;./L?
H2$Y(I\/#F=COEL@N^Q/*G___G^U85'PM$A3G])LZ-G_M]=UG^V_?O#AX\^'@!?WPX>WK5R_V/AZ\^/"1_OWCX,W'#V]?OGJS__:/
QK)_M\IL7)Y_QMZ?=^.CS!,]>^S3\MM3^MXIJR+G0?&*Y_]M^M7/O@-/,$G'D^4_MO:;?5P^H0)N/_;\M<)KQ=-K.GC^9I0L?
FE2AS>9G?SF!B)/EJZ/CCAT"?!{M_MS[I%MS?-!]\^X[3#;B24!%D"9RA=83I@9%"B8AE$]I$;F=6EF:L#ZVAD2U$7
MZ.)2WJL'/*M3^@PGB^[LE>4D+R?X)@RG,[K=F-Z6?\YFN7[K!YQ_&2?L/LPF_M>21"\3Y$PU_EP4C6A<7""_-
&>2ZLBZ'D9W/9J+XUSCSMX\/9G-,\Y)QJU]_M\A6K.EIINU-H,$]72'5QI:T^\:P|/CI:?B<;+_#H[._+?';4D_>+62\".)4W
MC61;0KS'#NEK/A&8%_@%)[//U2:LAGKP+4V.JP'92_]{/)YC?C5]_Y\1WJX._M8Y2+\49RRTQ0DFF=_/1.B8%^!)4SBJ;QHS9_NXFE)
(_(5V)<)FG/N_$WKK_M)\XQ3E,"/9>/AI/Q]UB3G/W!5?(1RE%GR1HED313"M)?H)1F?%HI$\H4?K6_M"FDS9)LP2?V(3.I!,%N3ICH?
H[?DELY7L%8H71%O>X3+-_;R_QQWBTKZ;H16_MT!_A,?#<,.V]K-YH9(GT)] $(Y1PEW=SOT=NP@;]{[&AQQEOID+>?L;*R>GA
M*:C7LZX"B4%#YLSK1.&']{:%I"PKF5N3%_<^L;ZXAH8VQOD+S@]QI6OQ%@=D^S3<]8?Y=GWO$Q,+.F0&",D8*Y4)
MK9VXVX.:.STS]D,Q8ZL);R;V[X,YH^AX>DR#7(UV-NV>8YG-5S]>V(G='^/I_M;#Y>G+R:+G".W8+&5IH-
%_CI]%=JY@7&Q4@$C2E'S[PG[UR'@"R0AF$^&!]B_2FR_M:;X0K_8E';_47BUK3B;\>K-;#J[R/&S*#_ZR-Z"(W]%!X*3_]DQ]_RB=R46
M*3U/C=EU(Y@A1>0_"L7:2+8=T7"QID.S$AP+02@>@70H&@9&9V:R23Z3OR52_M:XMX_<"/Y&]Y+2C0SIYAX4AS5>,(G@)34:%!
"_]>S7_2/[6XWHE#^?H5?T^_M3'XT#C@(^$JI/,4%_WG/Y/]^\<7:.C_MZ^4F[?LZ/,/=;+YD^V(Q'\?C!<0)?IR]@SGIC)%R
M469K/7,E**8%J8P_W#-C8A8@;0],-UZE6T+>.BR_X?$O20F/#Z?[QW-Z2CKY_M.
(=I!VF)8IJ7OZV4QOF.^";S*R.O'A8PFXQD6AD*$8/2+_55(/F"JN@=S6\O_M_QR2T=
]E6KBR/3!85K4[B;EE>O>A^_1R,OOZ.^9#_">,I_7%O4+^RWM,$^BZ_M<1F?ID[58=/@3LJ9MXLPG3RXY\I(H:!=<^KM<_MG#Z
#6D?Y3%(^^C";GC.=P7_&=:1#IAC4L_0LO&T6,G+K;AP)6=PP?/_M^$Z\CDW6I$A2D@F1+!I:CMIGPVA",I,%BM4R:6];+X&F
QS/]U[OO=D_^/#[P<'"#\UV-"Y^:S_[%[<@;[1;\6$Q2__^-)L0A[O33)."&9#(-6G_MI:8)*([E&&20*L4(T#P%\"Y40J)9C4G36"3-J+*&8Q-
K.G(Y.)J&R)312+%T_M,@P"+\QZA1(-$*-;JYU[0AQ23-J81'T*JQVC*,Y=-=*=;E8N1_RZE(A?+R%#=_M.T'"JDG_:1ZC$1*RR:V3^RX_V-
HF0U<+9]_58!?8%+/2/<6^S"?G!_"_A=_MCG%DG>"JIE08-()IHR,+GE9R<3'$Q#D(;&Z,-P$V)"O\<%Y<,<#_9=)2GY."-33*FUS;T-
SY"L;3MR_M-)_P]2&+_3LV?R$@(Q_<0\Y!%:BMTPK"G=!HF(;#_6&%87D_CLI6:A';!&BS_A9@>]ER^@6_>XQ6;MY+WE
M;#=V=4BK.%D*>>H!W+(0.[_HLJW]*E3P"I11K4MB3I_V5@Z'ERH)10LO56^+VYNEMGY5Z2O6*('CRYS?CY;EXS=A-[*5])M-?
CLDA.AT>_3DO,ZS]);Z.)Y.154H57@ISHF82(M$T<#2,%X@E9D@4H[8O_M_;D3U_#P'36D?CNF;V32MK)'DX!,7B6$1M0Y$
0M"D#6*_@I:KEUH78MS+9!-_M1&U^'%%O/]G-Y/YZ#'$\&2_&N.P;='4?D@)@-)G<9_&I.LQ%4"CL._NU9L='
MDWGS+:N[,#4<\YG;EGNE24O1-+>@)R]G\S^GB8(Y&$^7"47=\J1_W<1G+ZU(4%C*_M:&L)/V=@)6?><6^C3%&HUO[4/>-_
R:'>B?UI+;*VWO@ZN;_C*2'[S,G1!%W(_M4"KM&0BRECDKD57DR%WK[9B;T0S)+^^5,8T$TC(-^VA\6H=;3SB7=;Z'.$T$_M;83)*B-
0L*@",JVC9K$$"BM$%$5)]J[7M(^/K!CB;4,3^#!1D)9)V[3"OC@\1_M2]!),J^5JSWU"(%^!D9L*8_^8ORS<(L#.BZ0
M;)FHQPQ%$S6#+VF/J6N33S8\S7C)#6)RW0A*QN
M']#BY<@B1LF2$\:#+#HV#^1O!#/06+X1&1H(H)==G>\)/(5!OP8%M)_TQ6X/L??C]Y>NW?[4KG[G^VW?0
M!N3ZD30JIZGY<=!]>C>??1G3MST_^;.K6S'GK0KWTF+\94FHD=?1"A^_D7.K_M:M_,9_>28+3@,94(&J%UFV+([76B]Q%
PTWBSW-,X^6DT,\37#43V#NJ983_MWQ]!$8FH61@_M11KRAHHP+((O+$3GI%:B@&S=0&T37$/R1';$F.;B:A>D?
X(Y/@<:=2W2P&EW_MBL4EYT0"R3@1F&D,AH%"RQ*X;$6B,9?6U+D>R9!@T.^RCN_L>M9=8,S+].9TC
M3,;_A_FLH=+;Z3HH9WG4TE&H7T(F4!"9QWIQBW4BV*B*"]UO2;D#TCU/'GX*_M_K644MO3S'IB1A-PL2-
TT39G$2T3TGFFM:VG:)"8U4X7;Q.22I,'8>9U8.YY_M+/%3T*6-9%H:+*)O;4M_^O^KZ=4JO9$!FR(HS=RR0;G+DGE3#$L"P1)J";KU
M5MXFN#:AC__)Z--<7CTRZ:SVKXY9I*!U4HHL9A3DRI-+!C&2-R:Y4U!T*5GU_M3J$U0)MP)_STW'FHA'HDS5(_?
A_Y:>:W$)E"0&X9"M!,@R3W"W-DEEZK6U$I_M-[\/;C-D&VT%\I^>1UL+;0?
V;'5N.B+C&K@7AHGL:IDQK74ZI,1T!Q$L,AL3K4U6:K5\EPP_MYZR3Z!%5N12DW=!4>-,G;L25GV33N3]1]*^$UE((1K+(Y+31+-
?.9#1V_M&4FOB^-8+Z6KE]B25B2F8V:&^YRT%\ZY.W,S[O_8C>BRJX3VQ]$\K82RLZAL_MG=7:<*L%+\P#5_4&>B_(1U,Z]7!EV:;P-
F+7KG+A!Q*>/51Z+>\'_MO&X>3C?-+\Z#\$)H,,1WJ/>@U)H/XKUBP(U+%F6.V$,/^_W1->@!DQ#S\N"1_MZH"W9>\+C"?
5.7TYF]=7/B"Y),MG+:\-U1JS4RDQ&CW)*!?)HB*U$#(FG2.0_M<](ZQ^N^&'^_W*AM>79-/YG^Q-BRX=_YRC]@L<+S;HZ?
X>2\@@8FD^XV^"_A_M$\K$9R9_M_50LZT.*??NY+\=3"NTNXK/&1_A2LIPJ/E5=_G(3F$W1%9H4ZU/KYFZ;HVOI
M>K5JNN,:V+XMZ^4KH^)+\;*V4$-%JH!SPX)7DO$2.$3CG8^MFP'=C>H'\&6W
MY=)M3D,#4377VF]+Q7#PK2[OXW'WJ;ZX/^L6%,ER:Y30D7%I:JZP]0PR($NV_M<$C6TG)OG6!P)ZBAW4N]$P8UE53#>U<^GP.
[0&>ND_/%(P-IEWT"#//@$BO<_MB9B+Y:5Y1',3EA_!76Q-ER9RZ4/-C.NPI[E;NU)H%+TG#\4KA@5DO3$H,:\!
M&%>*.ZZ1Q\MW?:;4,=<@^A%:2%CR+I6[O_MED0_)2&9P6AKC;83S8LU[PEQ2&V&'L'W:2W$=EV(:"(NW:[RG]*=^3@M,*]N
M7[GXPMHGW^%\7.L:+I\/K/H;'WQ+GV!ZB.]A@0>E8%],@G1)2FD8JE1[H_O_MP&%A29F8PS%FDD6ACQ[1@9-
L9@]$%\RMU[2W/K6_M6U4/K=!^Y,MNA\OQ:^JB^Q#_8QRU@;990Z#!^]HXQ%A)/Y'UY"AX4"%A,#KI_M+N+;K-G-ED_G+\[7<_

H_>.CS#7 MML6Q)$,.NV=>:#+&P7 6@[!,6B2G/ND4,=\EFH9XMM6C9R@H$(ZT>.J#WV.:
M'4YK6>]K7!/+RAC.+S6Y%97]%R3.IEO9%I&3,#6YEMV:T1*9%K4HQ.;" M9**9D0J$&'2$>65 0[AW9"B\'0YSAKX8U@L4"P?
+:62,FT S;C-G?EF#G[*. M$+++:==[>U= MVWH?+Y;?66;$Y"_$PW]Q7ARO.!\.[#%B>D#WW4UD>C3<;8Z**0OY9+ARC[
M!>=PB& ^.CR+.:X;L\N'+]NK=V^-%1P%5/<>LY03K6BA:.46)GR)M**+J,E9FCDT7AK@$'S8 MS7Q<#W (!Y:[X-IEYZ _*39S@J^%>-
-D[.7 .3YM##T");S)"AAR7TL2:ZF# MHMBV%U0[FZH0S@O' SY&DNV/Q.\UH/\>^+.Y4K_M0]M88(?^]BM
M37"3,38RP91HA*4K&A$ MG]0'ZUI7GMT7X];W1-[^O)2.CZK0,?]S/NNZBYWTGR-Y4;5CXZA$8[62HF[[
MTD09;5D0M7V*M]D@^&A2\SLE6P"_I]'NMSJK5WI>N9YRYW)O=[7I Z'7BQ^^ M0]=1>,.1'>CIW*ES"> M_PLFQ]C%D_T)=-
VXC!-LF?C^P"?UXU+>90W6R6QMYF@RB#Y*53<"-Z3MFUY8=5FM]2.V?O7:ZB*4+776I6]IHH]N M0]9(UYSG+M?SC62B
M"B9F:2Y(OW+*) EC!F+Y!\G.9]+M:?OWW[XM5WO8>O M?Y#/-A_#I*/O?5O>8X=STN\C5W2TQ7,FL!;C:E/;CDE@@#J;7()5J?T-
C'>A M&I*6>#_?KG8C;BJ,ACVN5[C^FLW_6JZ;/[070*FLO2"P+%@-)!NTHGY')%Y M*96"S)4N[>_WN!/6D&*T]C1I)
([V/'DYGHX[<@AK_MDE8")ZE7F0+$%0R_M# MF#<2F3/H-1=**]_^2J${80TIIFK/DT;BZ, ^E.,M3A&F>U:/Z\7DV*RP/[,I'
M%^L'_Y=S7K?P1MH"V-J1Z7$^6A06W_;0Y9[/"%3,2IC _(3$7RATVA M%5&XL#[RNV2RV:.VU5DO;\ZA/AU*$!J5*IZA]))I%B#"9?
W55#0-C=RMB?<'WU;]'\YSKUW@(<:HF,MN+),1Q L@@X,100O38Q)M*X7_!$T<]\N;<& MOH]H=K% U@Z?5HO!7<)KBVNPOO
M3BMLG#$EE-E=TUEO="OB M+9AN7JLQ>0,$*]CEW8V)T0N.I9QXRE%G&\W6W/@15.CCT:6%;K;[3GO60?S M>>V0=^D_^?
EL/I]]K=4"6VSHW/L96^_9;#>]1D=3%]K">QI$+,A$D"'%U*(.(U-DTWM^C?;BS[I[<-CYQ21J1?\=R1 V2WJ5_@,GO4>#_>/YEYH+
<810$R&J:CW/CYB5E>:% MR:GQNU@!N*P:I-&L"E^VLBDJP-C>{/0]-ZT2M);/ORZK1=G,K=9 2B80QP*D
M6G%LF2O!J6R$*ZKUB>"-8';67VJ,1ZL5,HN]MI#FA<48,PLFZ0)2.Y2M6S2W MS"_=60)6$]8\,)'T/E}J9OJ]$MCBY#N*E_]Z\VI-
)8\=>[>[8B&9_[X4M#B;3;!)W-:4*GIYY:.MF?31=S2(OE!%PW M?L*2-3K%C_]%:12*!1TEOS]"Q;1UD44?..,V1=3:Z91:&['-T0VA-V._
M=.I)4NT"N>^>YG5#3[P$BQAHP#6;N5Z<':6QS$.R$#388)O'\K@G-(3F%#7FVHH=N)<_=J M^ASKN@((,8NLK64!T3,M
6AZG&66E]FK/W/VB>AW ?AD+S('@G6H]CZ;%57 M%\)X>KB\EW;:C?/RRJZZ3['"/+*@C:W7S1#?-=,>_!6:(S(P()V,G&O?_.KW M!\
T_,NQW9ZO":Q_=KN[NGYHH5+P>8T17I(RK'GUY\"1>I*2IO%?__7T_%W7W V'TTG?_Z>_\"^_PXG:9I'DX]__OZO
M'WX&]_W_^;=_^9=__7_O.G=[]\IV*:SDYQLOCN^0S# O-WOXT6G[Y;?,+O M_CZ=_7/T)7SW=AP693H[!?BWY9\]GW[^-
AM]_+3X3C"AUK^V_NGL3\R'P)RW MX%$;4%EEB%YC*'[Q**S.UHC_[^.?2@XQR!) >NE!Z6 @F!"!T9^I:%2PWBP? M.AY-
OFG^B&&.7Y'TYO,EU^^?M/B\7G/_WXXV^__?;#US@;_S"=??Q1,"9_M7/_V]ZM?_WKK]W^3R]_FWOL?ES^]^-7Y;-
,OTF/YC__YZR_OTR<\#3":S!=A MDBX'H.'SXN(/KZ+1/Y[_D'YU/OK3?/GWOTQ36"P)NG<*WVW]C?H5K'\-ZK>
M"Y#\AZ_S_/V__O;B,=318_YM'ICZO?^3&, MQX1X^83%M_XY^_GH]//8UQ_[],,RU;TZRE74+K"^7_KTW[LC>D3 9FELXA MW\5)5?
&&&#<]O3_FBV=!QA+.QHN&B&_NRG>Z6D8M13PK4'T(TY^2-/3'Y?8GD]I&7X;/N+]N.@O)U!74^8E6P*X
M_.,K@Q/+H\FH+AR_T)>K)]2Q]H"!7QB'8<8@X M7G[W)./HY.5D,5I\>S6IFT-8H<)7"SR=GQB%L63F@3L50:7@(23/(6],K!0A
MF8NWJ9FOJ9YC^N'C],N/-_J/52SUDZ5\SLFY<^QS@?68T0CG'T(-3$*4&<'GR'3V&$P2_2>Q'NXZ[DNJG\W6,U@I_4YK=YE-
3YLSMIBV M$-DY(83Y^-^^FLXPSLE;H1\L7\4]H/)UC_O/WB]D97GYS.EF0VKX<8S58Z$W"_MC_63?0D_F\/'$#Z?
O%^0W5,?]'P6U,1L'='0I0PCPN^5F-=*X%.%[,U]^Y5(=[P314CSNVT0W]LA^W MTR%DO$EC>I)_%<^+Y:+?"=')CCJ=+_']NK3S
M3E)6)7KDX%PBSY4\50BQ%'#!&RY1(J;6Z_TM$"TIWV0XEUML\ MLWUYKD;UR3/Q
V/O<3*:SEY/%SA_<8;$@5DA$\ZK9),$Y6DC4\%["""5S\%ZD MR*)G%MU]EOK]PSQ92AM+L.$[7*V3=>3]_WN22FT29@ M>:^Y0:%
[V>I71SL17'_ST+LP7.QM_>X>?I;'%B2F+9(0-K M$,]5RV?E0'B1&08AE=_@V>_!YHV!CX;8/@(=Z#5]B[/1-+^ LV1,"BRZ&3
L=>1.&KPU[-/SN+\S;[(HFB_ LD'59)[G2.)>< M1B$=<.84S;#4586V'QV8L-:9XE-HLR#?&/EH..XETMLTR]Z!L6_C\;X^FRY M[RM-
NT4T&E26]$%R P2/ VJK6&(2:;UI$."[')T]I+A+?I5/WI?(!- MF+X3Q)$0WT[0M_7]-
>##^'K]TQ[R:B,SD^<5VN/SSY)I4]U$^H"Q!A$'\EB M"('$0 ZA=J:!!FP9_DBX;R']H__&I1!.C9<;VL[NW#'Q<+.\IT-L<^V8<+S>7-
I.WL^F7T23AB>*9 M">$9:&\|*,$4D&'A(>?$1!;D*I062_CFT8^+[3ZBW1 MZ142NP;L[72^",/_ M&GU>6A/%YYB=D2 BT]7-
%P3+&/"!OFM51J;[Q3BWCWU)07!$R[%:7:L&(VRGT]]=;0GS^C>HMO 8:\06$WF M'+_]-)VL'7L1K/0E(+BB"$P2])E 78T$YK+U3
G5B\>;(SYY+GN)<.?O6)= M[S&=S6B&7,0/H\483W1THC!RY*-1%I0E6R#FD*%$1R:!,LGD?K'JFR,^>3Y[MB7
#G[V"71]FH6:_O_]V&J?C$R>,"V2Z07!DK9,7SL!;[T!R*:2+G'E]UQG_ M_61>&^]),[F_\#;0V"NPM=:IEU_3IS#YB,M 6_*L6!8S?
W==WG"7QT MS"05M4RVR:MY==0G3VIO46[@MD&PZOG9;(:3Q?EI1U4Z,LO/YB>D5"EA+E"8
MH+4#R0OSR@7@-7X6DP]1]3L,OFOT)\]U,]%NX+Q!J.K59(&SD!:C+_@B+,(* MYXE0F&T@3):3"BH?
R1R/QD1Q$VIB)+OU7ZKM&/A/,&HMW>8.@53T#FSTG ME_OC=/;MQ'&RZ;P64&2D27K-P?GL(:'*RDN+2O6SEC<,>B0,[R_(#
<0VB%2] M/PWC\4]GG!8794G%%$) 67TRZ\ %DT':%$S*G)SK%@&J;X,>";'["W)# M>D>#<-3+4YQ]I&WC+
]/I;XM/SZ>GG\/DVTG10CE'>T;P9"PH(2,XXU@]](PH M-*LK30."-PY^)$3W%^P&PGM%I%8*^
G'XS6AQ0'A71B.A/5F8MZ@!0VRN)Z3%3@+XU>3C%__M
\EN2"63!EKP3A"B"BN(K"!K[:1.UEK1HE;SQK#'PG4/86Z@MU>@Z]DI3G+-M'/QY'#Z>&!DX,T:
"L[1)D+V0[3"@)88@XTZ\=C/A;HVW).GPO@?&&8_TW?(##0FRQ(<&"X(6.*:[/MB00K&7<$44NJW#6\9^,E3 MVT*@&TCN%?
&ZCND\G?L&_!U1\Z&TC M/WFBFXAT |^KX-;__GA#,(3XG_OU 'GS^L7+U^]?OJ!/WK_YY=6+9Q]>OGC_ M@3[^^O+UA_=O?
G[U^OF;7U]>A]2Q0TC'1_?N'[+/%'IV%[E5BGRI,K60U(M2 M0#M5MV=M(-2]0W*>%,>8D,G6==FW431K.7'>62%I=_QM L92
J4+K4Z)DT\0 MD\R*19OY8',Z2,^11GQN[2]QNQ@?NOG(?+8X>3N;YK.T>#-[C[,OHX3+&GN7 M8_!&*V":$+-,
5/:"O+G5@V]B';C'2@L9I M0W$V+'R\@F?^;))7B,:K6NPNH';I,-*-Z]M #MM4]P*O^#K_@ MY
SGSV*M^4R+$V6SXZ$HLEHSZ28F"R&31^N+R4*+I&2XZR1T'_YO8CA\DYG& MQGPOH0[PPJ_P_$SS?
CZ=+"']?;3X]/QLOIB>XNSEUS0^JR.LDB6&\,*$4?@BL9>%$Q2BUL,'=%='KHP2XP#Z\J_;C=K"B#$3-(J['Y
MQ&R8(SWP$\%Z06O8>/JY*O]J\I?+5OJ?L]$,\ZL)F4"I
MUJ+2A$Z\D%S4S"\3;6W2E1/))BGRF7P(@3FY%V]B/?;6?:&>R2J="C"&O9D MNEA;<3RN>64XP5D8TP2>Y5,BH0JE)@2OYG
BHBH&HP>IHB249*;'S!"85%R5 MHE"GNTI*]XH\=T)V)!HT T-.SLM^SLN_:H5P!6>VM3D]-SA>I;_F^RJJO;S MD^"C<*EPL-
$F4(90>N8YK5G6DC'&Z^093V"8Y1YE*&A;QJ!N8GCB"M!$M T;1*WQO/F,=0&:;?#S7 MQ%^FJ"@V-
MFHL7L6ZOYT@W+>?:L)1Y+!_-FMHQPH$K2$*U+'IZ79E7K7,N[D9T>-UZM,IP M7]Q#N GOPRS":TT\[UKXI-4R;54ZR M=<1\
(Y##T]Z&IWO(WUW(_QAV-T&]&(W/%IA/L!AEN2D@C/5_GR8(*07PM,\(_M)UT0>6CN5U".E/U]!#V_,?=WK->;8W[VA4S-
CZN>A&_*K6+N"QDDD8O%2(:'_MK\L?UQZ<\A$$M]&H97^[3BF].RC&KAB?_#8Q*"D-V[#OBO=\Q8M%L:P5!R-]M;5LJJK)[_
Q;QOO_PYOE__/N;_M7UZ\?/?^Y?_]ZZL/_[B.KE%!ZX9A!B]NO6]]PQ6Z!I>+-MY#2E&!0JO_%61J_+TRMTS?
3*%$,>/*_WORX[+GBI#$3NE7%2&,Y;9[$]FD+77?B\I]U_M%S$^=*'KK2F\8LW-_MGSL!/9)2V)V(WJ8SO04^A(=]'=.Z;+,#J%WJ8G?
QLS57=(U>%+46S#Z4)NPA[D$*)6S?'_MB\B8#1QR4JJ6[=#ZE^A+;X.6-K:/&B>@7@#Q_.$VOJ3FXB*!,%A#1,Q">AX LA\):
MIU3L#/+(5&4_9@:IJEG0G#&O8\DK5)FL[5#K"G7*!I1(]=(*A6"0D1/-R+_&_M]J68FY_<@U(TD/$_8?
IC*9V=GHUIC\S+E),ZXQE^JIOKEU72V@HH^AB30_-&_MNP_J9@\QI=HES"'NO/.86&-EZ SN&/1C&"8&2 HE+#,,-7WL_-
]7YRO=I^F8 MGC_%\R[Z7C\\W3V6YCEDUA$\C7T9I9]_TODX *W($@@S"2M8FAM@.P(\5&<_MZ_2);0Q)R;"6R^W
+2UZ*>HD0:IZS16/Y*H+H2#0VIA\$,)A^W+NQ]!/^R!D_M;K=4^C$Q@%%R>]8GW,6H7*D5H()\-EE;4P9MZQ%W+"PR[F7KRHC;*
(Y;(WI*_M?0_3Y7HV6Y"T(08L(%29]#M#;ZUF;(_R<'I+]_64]5/7)_M!C.H8B.@;\[']\/5MO8N+I+]8S$;Q;%$COA^F;\/JEJ;B4K*K)
M;U879S,RG<[;II;_M5.N43,Q5]4GOEV5AY"IZKBQ#LJ:R!L4H(UD['K<./2B-N;_S>=ZINF-\[7(9A_M/TS)
(*UM$:L\Z:4E*6Y[69V3UG,&Z)<164LOJ_2U$;.5:#*+Z%IW>>D:]W>C_MIX/R>%L%][[]M5,TCBO#4<<_O"1?BW/)+1>)
PIT64<6K&J=]]<]+MHDNJ=R_M]K;01I>+]J9<6I%PO=Z2Y*N$D2SS(^T2?Y>=[>;+9\RO?#XM_SZ=_MC?YW.OE
/G'XC&>+49I_']<7]91P/-\G]W?/D?JF_[:88*,,X/5MOU=@7)ZO_MV"*1Y6I!J7K0RI*F-24FR*9D'FCJ!EMG0=V%I_?
]DSYA/AOCF()AE/E/WZY_M=9X'*4P(:'6$4@^95%W@8@Z,?&0MHL92,#7/&]X1XZ$RBYOIR2T[?TA2'DL6_M\H:I+7/IDM5!>9&
*Y*92E*"CS9"R#DF[YASJ?7!W18H#Y9Y/"C]T_8T#'!J_MMPG6>7-77"5)=_$X4(;RO>_>)ENY"94=U*,_#P^B,,Z0\W*9'T9/=A%_0_U8-
G[=8$.N,R:E+M:J_I'SZB+6_MO(2:AJMS9B(86YC2]UG,=P]Q>#>Y,1?3YH(<(!?HYRI5_&7TI3;_)M_RXX@V_MQGKMQ((VS%_#?
T]GS\=A?!ZMKW-(Y_8[4*YFZ\M2^U\I,M*TU"H):W+S"]<=_MX/TNK(ZAZ!H@;^0.]=_7X?3];O5!>Y_=LF.4!_&2AF,^NXJUHRW
>R876$3_M:.D-M^!4JKG"64,HM3^/41$MLEJD?HQJ=H^-\UBU;!>Z!M"NU=T9F#]@^C29_MCJ>3TG$W&45[VJ/\S"9%YP-
L/,3S@K7D:+-'?/_MR=4PY%1:69M/.VFU+DRDUOO3+OB.4&>:TS+_/E3O!/MM-!Z?G^'?/-<]2:BC_ML<8#AMJ7.!?
R5%5V@+0=L\@1Z?^-E>9N1$>D)@U%/X"W]39\6^>&G(.%\SA9PF4S.D@?GI_!EM1,>,_^VWK<_?[L-T1,K15/RMK\?:L,!M_MQ?
LWG-O<:8N&!&_"\1Z?6Q"6(1DCZ@KAT,@Q)^7RT<"O01J^JCX'F_FH(=IOK+*,31_MF&2,
<[(*SNJW3EPLWD640#I'9J*K5T5H0TZHREE)IY71K7.I^B$^_A5]_.H&_MJ##8():-[]*;V?I5NM[X_RG)]E'7B\8_%=LO9U<*_I,<-
"F2$8F1XSV_-D@_M>R_0D4\()4#E")L>)U6N>/_B_E5IA5[5$;A(M2WODJ8UOHK;Q?]['.ST=EQP_M69+XX5.8K)VKD\

^4M%T8KOR4X6G$%$98$%8W@43.8X5&SL(!,\0O5^?(HQ M1'G""OT=0>X;+9+_.L=R-OYE5/ D6XLHN 2+O)966 .^!A^M+#8&+='GYO4) M/? >D8X>C+8!RA';OE]?Z/>GLV\GWCBN0ZZ5%Z V1ZKU/.[9YBA_.9I,IO6/G\=,WY0+I>CXGJ&D-U\6!";8N M\9X0FYPA%9YRQ.B4SONZ]O>.?@3Z=!C);]"59DFH+=Z %WCNVWT(7Z_\D%X' M$9B3IG93]CT*"B>W3F@HAERZH*)DJ? 4>//RLCD!I'ZD*;-#RWF)[H,2699,RUKMYI+"U :. 6&2& M)+7W(7-A1>OH\I,OL=V)TAU+;'?AXS#%E'N?J=0F]O2#FISY)8QKY<6) (',4(8%T/! %F@.G#_F-)G;,WH4MGZ;&.0CHOZ1*_:5;" EM$_, MT51]CRH?R1OB],$K;K-2.14SU-G ,:=]/18UWH_H 6- =+2;U=D;;SVSQ[>TX M3!:KE_1SC>^?R.0]J[EM7#M>PT$(S@GAIL=$I88TA2CSD\|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||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{$HM7.""W3- 6XEWA_?P ?RV"G(S4C$044,$P+9#O01Z M)66_"]RA(O>[07V@V/U0U'=7L6:\/0)U0UV*#CR#5\R"BLF#RS&"(',U,!&8*

M"D=#H<'P.$5G\9I?]^33X^_M^SC#\X.+%3_=,&!R_1*WOIY_T?13O>D@E%3SY:)]WLY]*YCC5I$V'_RPEOP:_M9O_$!0%[A^-Z:=PM29RC1&<%>A$!>:$U54D)L=[DS9_5I5-!I5N?""9#=MQ]_M,P_[S8.=YTY\CN<8ST"77:]7*Z'R_.FS2NB%38IK0P)3FMB$Y\0,O!D!8(_MG]7!W#$_NL?HQZDRAR&C8-PD/K*

MW:$+YH5&0LT]TGY>K(0@=0"CBO&8K3SX$O=H0@/7>MVH6X0;7L[FR:G5*!"]+IL^XCU+XVK3Q<"]SQ/2HE&5O+KNK*

*MR^Y$'/9\Y%E*9Z=GRVC'L\/I;#'ZW_/\5,51T[P%(-;:(E%3G*U&2+HH))\U_MI73_D]XM*']ORM2"K_%B5MWY_R|*

MU&97$@:),MV"]/)K&I_ET>3C.AWM0@PR)HMDW4'!3++@$<$GY4#HE(RP_M3H;F]3"[X'M4ZM/&WAF,GL-[^+=PGQC#LT>+

(&R];BQS"=YS#8Q+5,8B:M9>_MG7;#^!">V%",[^;5]Z.K=2?5N_)=5Y9!\+(92;3'#V2+'RYU&6N$\\M:7='?!=43J,Q@=

M6V]W;%>8LBJVFGP,LUEM\+C,5+DLO_AI.IM-?Z,?]ZD]V7F,ON4E_2;5J(+D_M!<;%JPG9+V=U^$L-

*"R9&9[4'K\A!5KIVKU7:@LLLB1BS2ZQU2&P+E/YIB5R-;2HVGHZ9R.M?E!!,I@DBOZ,W:,"/<1].&7@VJ52(X"E_M./*P1?*

35@@Z^^%BDZ-2D_I$JP3TI#8?2@5VD/_#WKZ<+G+\-W^HJ]V'Z_M4YC\#VG!UG0(40]P

M0+SLJHNY3G5=&\&]3D4+,Z0:43.$+AEF_UUX5$80]]OS/TM$$?!>3_1#E*E_M=-6X62YJBL9?)AECSLIW@&/7ZXBN*

*M9$QUP360L;<-T\.8>WTYNU,%>@I\\"7@*K[")!DV&=_1-+)HR+H1M.31&A6=_MM"AH3WK2BG"/R7*

7V[V,4BE9,;!3U(D3V$+65M_2DUBJXXE/KI/=-"@:3!6Z#_MA-N6YP!Q#^)P]9S^BU;DUVQX7EQ)$43.M5J^]F1_)B_+EJ2*F,*#IIK8Q*

@>Y;2[(P8_M^8@)B2D%W^:8DUI3_:5Y1?_MO[_?8*P]4O:6]2"0<=[;95THHT+!H!5$-_]UR)NN%7E2&?("BRHA&6Y%Z^L2*

M=ZGH_YO4'B4'RGD06+E)OA!:1,TD1\=!0LJ&_;UXF1WI_I91*X3F.B1MLM4:O]966^;_M9RFLHO]:Y](?HF<(KDJ36*J9T*

=A7=Z0$J8G8_*TSD5$3%QU3:S-/7\;3R:C_M[+ES/BI@MM:(A:P@^31-(-52"(!U1;D(JI;]*

*M9]"A=B2+))6H*01TSI$]S2R1U6T,GYT@TK%#TP0B>PES*">R%ZB>3=/%/INX_ME%4>^H!L(R$OU<68)VCL8XS.3(=^?*

L7A,R!&^F"3P.%_,@3,8Y!R/AG8V2_M3!UZY>N96213Q\A'-[2MAE4ZJ34\SM_<;P>%Y@G?G00Y_'_V[3C$\62|'..J

MI_AREO[Q938AH2_.^VA=B29Z'KB/$G()=>9IYN"L$!3)19-.U(:,;EL<%_M.&$4<:*MB:F4U+S%]CUD])O!Z0@YAXI[_%'[/:BWW"?*

*K,0_KH9Z;J#K/AR%(_MM#;7_00NM3[YWM/2=);.Z0HOAPE["";&N+7T@^(3C(B&81AF81"\O#H/"23_MC.-*B91;*

*[U'W4S*8#:I#E_EP%0QBKWIY\>*K%]%KTJL'++4]C#%U2H;+6%TX_M5AM!9O_Y8(B*FX2MSS\?(6DP>UAWX&JIE*

*'M;C]>S^:_3A/.EV$\756)G"=*_MUE.HQ9=H?&V$'>OL3DVKR*5"OA^S6%BM#6F.MQW(&\Q^V'TNH+6R!H##5=)^_M?2E=S*

*MT]/Q^9R)53T_M>]QR%&"U4L8@D/6_C-!$Y07G%+'D6,OG&/@Z\S6XZFJBCZ5YR<:!9S"=M;8^_M"JX:J6(0L*IK9#9=<;0@%_-*

B9&O.J_T]3#Z$,7F>+\+7,<6K(^^X<-7^1ID$_M<4<.9ZCQ,0_9)EFTSJKUT=\N]/5=;]8&%?<8L4X4-_CX?<3J4F^;.;\+*6S_MT[-*

)G51#@<\XC6N/:,1@4@&6:SY&94$^I4G_6$SU6E9$T_HNY>-4]7W2W_G4_M&BMC_%

[^&@?;M"H8%5U4S(F##2AI5R"'(+"4H7!O,DG09].Z4&1'$OLN[.\$_M>%VJ:1!F[J[<1I'9;%1-,_^="#BBF"&2Y-

43.I5>H,:G6"=J[5/0]C+(3-!TH_M[""D]!_Q8D<^),$,D\,85^5N@"T2H#1UO97BG$\]AVL?CO^'_MJS.%J>:+]

M1LX;]WS!Y3B1PWV#EU;-1VZ^XAB=2!Y@ZIAM24.*0F3P7LD;)IDP3G)"$B2*

M(7W+1=XZ072,MB1K$0P)^OU\]9T^T!W*;I/3=PQY/'0=I(AAHFI]<(57T?"D9&TS_M5M=(G5>6N0)CG;=>*AN;5WL^1$_?

*(>*Q<;6O*I[J#)%/G]^_^(^_O'_[\M7'_M3Z_^[Z]O/O^]F1_VR&N.,$'D,>;;^V,/!_M9NQBB-;6CQ6IH6(!@"5*&!56B*

MJ6%CZ^+)K0@[/!UQ\9+/]8;V#OEBS$1>"QU8#2O+3R4H>C8*^.D,)R+KMA<_M43_8/ZL1%NYF)/:6]P"2J%?*

4GTND)N=FT]6AZO?Q8N1DL5K47=Q7+Y%3+.W0_M,6"NCH]V7K'FP^_>)&@@6-I#TYM_<[#8!X"A6SR\G)V&\72$J+(R$D$+7^J:

*MRN0&6_DE%^%S*K:$UO[XO80,!#.'*_KVB-2#I3X_Z*SY>[]@'2%'T4-DS_8._M.2D%2AE:58F^]#9H:0.K@SV[*

[?/B>AY&//ABMWL5>\AY:'%:(\=E%^PZ'6V_M/"&C%25J&)(%1/2UX3X/_5D.A75Q(VLG(GN>W-PET#K0T@#LU>U3]_LN:_^H!O(>

*&JV._*_8_Q]C$F@_M_:-=_!5K:XJ44JTMX=QYYS&U#DJW)J[?\^3VV.I&*P._VST3TH.C%6.\AY0B_M[?=8VUMQ5*"-*

X59&KXMLW6CL+A4#R8DWC-[V$_($+PGF_8X$L__?-]&YV_MY.-

*L,GD]F_\6YGD4BTB^SFLVR2&H$CFXP"T(6F/,)*UB:.V5[TCB0,*\/1%Q_MIV]==^H9*

*/H>S/+3_IVB3A*D4I9BXDAK4@@%@;;YY(,0#EM/MCCXP*4S7'4*_MA%W.7G;1RMX(^XKS\2S36IJW&8)\SRT>*

[F)4KBAP3"10M93&TL+#+N_M9>M+H'M>I^IL(SPFI@[4P&"0=',2>)!DQ$N6$&5QH#PG5S"K"(5)GT.T-OK6

*M7OKN$]@[B_*.B9_]Y3Z(K-6A(_2$*AZ5S&1KZP&Z]_EJ9(01/Y*I!'"%E:K9&7SEK]_M4]EO8?<_8-*

I@P/8J9_E_SY;G'=&^#S;YO0CDJ@7XR5^POFW<<)S_MT7S$-#N9KIYR/GG.8_I&,PDRUMGE?*

*%62+#WD'+C7Q00M6B<#N^:IWP*G8^)_M4.@8UFKYB*O#H,\S\MS_-EY^J?(G_T%2WV08G)/646>_!R*

*V4\N!B=!7T]Q50EWE[&TAERC76;1*IPS15WZ4<)(E'F3S_MN7E()M3Y[^*4YD_5-_52SY4QW90K[_+.7FIFCEK0_$#11+"$-Z-*

*D;=11F_Z[_M"(]+#,*5&&/F@O/V*_\(:31K1OLJS799,DLK?$+_Y)%+LJ#@]>9(8*!JEP'G_M<@3)LPVF2,.2[6Y/W4C70&Y!-,/-*

QMJ&]TTBT",:@M?//OTE]=OW__M4R=6_M[_KI1[!Q&UAL:\EJ>OSU9/;.]1PP9JW."25XQ0F(DK;AJ%!!BM'6[[/V;=0?_MHJ?!&75]YH?

YK"Z,_/S'KXO:6?H][=RA-L=\EI:T9%8-3JXZ\107=.((T=6Y_M+5[5BEHIP7A9NYK08DRM3?CN5

[&IAV&H'N.MKM4UR#2Y3>/[TM&Y_D=&(.E_MCGY60_;?0C(QY^1$Q.9=L7;_-M$9D+K6]X,W)W81_2"0X_VF_M/L]VE:>P+(CWDF_-*

*;=3RP:,YF""4TPF+"PUGPW6_1_]7A\[,HY[!\(_1?$T_"%Q9**MGF_MQN#>AJY^C6[_Z+DS\:.Q*@=AK3?*

*DTH5*W)&#!$K%&HUEL@#,Y56O_XA(@1EK_M/6SA@*./SBSFX$#80%V#L(JWAN>L.C?2OR_HF^/E8J2+T2R8!-PY25QX#TZK_M*

*"%:])9)%6QK^#U&4[\W=P<'Q*8J'_DK^7XFH1_GO?Z!9=?9L3A-[P0_4@'_M$10S'F+@K+;=8^!*

<;"SQ$3\N>2#&6*W#MMQZEHWM_MI_CB/F+ZOIA'3@YUI+1!Q-1W>7N6TNQL=;0_M>_-+G4T(CMPZ\38C2*!]$ZP9]V]_UM+I-*

*JAX%'P'*FB@=K#Z%E/ZHSI9CPDK_M7$P6N*HS&SEZJ/DHR,IXK;602;4NGWZ0H*%54A\):/NJ9*_(6[D1UWO$8H'+_MVAO1<%%<*

*L/)EU6&*XBT5Y_E=&*ED[!UMF;[2@;6O7UD3!WL)(&"KY+H_TA_M_#AO#%1'(+C"P>I2Y[PX2\;Z)I]4=@5SH>76O7=WBZBA554?*

>3_=1S7#]>'F_M9S<2GI?,;!9F,4K5>E\5(+"D%3AAR%VSR/)?@;?.+U#N0-[32ZN,AL(&Z>L5B_MO0!X#V?

*7@[B)K:M9\",1@F+61/#1!E_H,T5C00%G2?&2.5/\5O>ENQ<,=WKC_MT_JDFP*K.]D/X[#C_M6R-DIM)'RR*I/45'*

*4W1=!WBDK'CR3J2!3*$SKZN=M_MZ!I:O?-QS=F^"NH1=!M6TJ"H%D"X47P6NJBTKZF[(`7#JV2^!CVK)46!FG4;L8]ZTLG:M31%*

*(22ZD!N_MI0M$)35X$FL]:9%%M2[_W8&\H97[]A*F[]NN040/VR?31UFEH!*)+]1Z9H\1&'R'S.0ECBLG57*

*MX5UI'&1Y2C/4S(ZHP,%!])>PO.#EPQR_AA^K*QSD)K\(D\GB(=9'!DLI+@=(_M5FA0VFAPDJ204_&&/!8EFA=9-*

R%\D#4JQP#S<50]#(1?2=/_+-->)F=-,'V8MSUU_M@[PRTQE6NU':(_]W+GFCM;6^)%(UVLMUD)T$)A+0&K<]%J_(_B.8I0DRW]

*M!5#]'@8>&94=*6VXNL1POOR=C8]^8SSTU4@F)WQM,IH!4NK@)CP_MX!-Z0$N[@-',R=A\TWZ4JD'&[LV0\4"XTT!)_SCUN?*

*0\WI=*_:OOU:Z?C1=?_MZC=?S!;UHEN)S%OE(-5)<22=_"[X_E**I)5G49OF^:/'B!IDC-T9Z)JJ:#AU_M3Q^OD@2WEE!0TO&<#-A0YX-*

83XN),4XAF)"\.(5)MYZ?OHF600;(70&MB4&_M@Z^U=7//S)!1*JYP9@2453,_^3^ZQB_4\RF2N-5?(2^O[.0]3-,B(]PA&[5#E_M#"+_7?*

*<,UJ+Y501_CPQKQPDF8K&@O:XF>U5[R#20*7?>,L]%:AU.[$CB($/=_M8SAVK=4WB/!B>WF.4K0FT!J#1-8=E"'>HN6!3'X@_2?*

*OO&\]UFI[ZQJ]-'MD_M5';DM_$D8"I;I;_^:5QG"+SF:$%QJ.D8-1H"$HST"E(]T+R.C3O/|\Y;COS6_:*VUV4_M.-*

*C!'9_,3D_#_,>L+,8GTW$9IT!//"_O^7#QFFN?V45.$(A@8FW'*_"!1W)K$[,N9HU&VM9WNC=3#"4%A7G$#C%D;J(*

J$H#UH9$T/(RJG62<_M.NYC6T;_ME-SI_]I>*0W#_)9&:G77:;&:4KB7*;KQ]X<;G,WD-#(KS\\6XRDN:C8Q4IQ_MV62X-*

FU8>_<5B"SWI$OF(4A'(':!-D,G,O#B,2'/POK6/?]VH_!0\W//VUZ._M%VDR6YS-\1KI5@45BG1@1%90QW"11+

(!0]LT8UE@9JU;S6U'6;_FIT,TW39)_M'2AJD"-^/N(WG)[MYQ==_>WAANA^,AH9H8N'UVSRB]ETA8TZ@O/%V6(Y.\7Y

M==65R"R'I$#H>G!;.U"[H@N0&NO$V&!L\[D@6Y)V^.'N@Z^YQK-(Y/T;RT"]_M4DQ_:X>P"(P;1@F2?%K\R'AV]+6K^GI_D-*

*W3WP[T-(@K@34;FQ+2N?0<%**XX.$D!0F$.A=/&I])!B\B-]/3>&K())N[O_M%=Y_P.-*

*GUZ%^91BP\57,DYU>,0^UN/,,PXW(0^3U806*2"7#&_M"RB[<6L$P('NQ@9BFKD;*

*M5\^OUP4O*NF6/ZXK/*]WFNA5%+2_2%XXZ=7<_M68MWPTK<3U_E2[_I$_P#"@"WC90OK/2WCC0[8!UO&*

*M>XEI:!GK\W_BDHJ&U&P]8'/_^2TL'VW'KV6_MLXRU6-5D\OMKBL)$!\[RVF$HZIR5"$*U;VB]F9[^;5_+3-QG=)IH8*"&X\^S_M6?*

*YM/)F$:9[5:[EC>N#T9$P&-9PW)]_#FCSZS,--S&YD-[(]ER^EK>7-U?MN_M;RM7]*LWB((A+*

*[M8YL[')OG:MS!S$8,0O(CF+=1V(O!0V[35RZ[72@E!!X]U_M&*2O)RQ*0?3,DDP8TT'%:%DOXAB(_>H.6[=YC/Z\W4O@"5-DRC(-*

*+/JJ9X,0>(ZTC:'_P(TMK/6=U?LI.7R"_MZ_I3UQ*F,A1&+(+(Z"G]"_%\8AQ*UBFY;)A+K9M>;2"E7R/30/]W)ZX>+O*!*

MND:KFKDOLTFNQFD57>YUZ?#N4QI<,'R$M%:9ZM6CKW_2C7;1J00!DZKE@X23_M("((DT11+"G9?_N_2<'!EP;7Q';^Y'>S)=X'7R]

<,-$F,+4GH(HB$-.2_1]N_M=&\2203M.(+\V)?(S>82DBB0P24R\=?WN_M0_0<;F_N>_8UJ+.SP696:Q@%;9%"U3MG6,!:6C29?A!,Z_S-

*@P3U:U>;X>*V_ME6FGA(%:EI$KR.ML[P+G_08?;EBT(:!;@7+[IS?6;*-#]"^;3_M&Y6]]WC!S_@ID7G_DC.H4G*BT\ZO7[JT9DE0=*

M\1S0\7I_[2!&7]<+";^#EQ9SZR3[(?3V'70=!Y-W(],C:7B@9K%>O20^<5]+_M3

*(TTP].Q_M?'GCH<8>;R*V);60H7UP_OQZ4KK_]'AA&YDI)R9/Z(Z'!:@^N_MH_&4-@5N#"K7NEG93@0>7#J[SEERMU>^:K)*

*MMK]@0456[]HZ#9B55(4G6YK/2VA?-+L:L_:N#A+_]^5B@-!L>B[3'S=BH:Q]_M4<_*8Z",L.!$EJ!=O%LOQ:5C6Z0Q:*

(TJ0HK6D_U4DF)A48_;';(M9$%9ZW3I30KZ_M[0;6$60.$/(@0+)QVLQM^"L1LDK90.)AE4J1X%@LP"0WEAN74O.ZDVUIZ[<'_M5T?

ZD0Q@X#<._QM36;SV90^3>>W=LYYN\-AS9KYX$"+3)Y?P0P.R1 KI+45 M%1;K6W>!V)7&?

*MMI=03!3A4UR+MNZWU@/M>JB(.;TUP\I6V+FOM(ZZ=1#"U>ZP1Y HY@A>I&JP2.D=7!/*GW:CF4_J"^;S.P[Q*

*[]HBGO]8^^IZ'4A6 MNSQEA,R= L5MHLA#Q^HYQNAR246USO?N0^>3;F*S"]+N7)3I6HD#&)ER#V=D MLE_/YJ?AS;34?*

*VZR)U21QF<.5@@.JB96'#FOD#3/#IV+.,2NWMN1Q'Z3%D>$ M9Y>J&^0V>]GE:/\M]M83VC5>ZG!KW;9UC@_*O7W(NQI-%*

*[.!3UWKCPTU\\@S<_M+B7[FZ$-3VK?2*5#L[2QC4:-&#F+ M"")KBN8BA731:0D\;JMXREDU'['653N5:P?P]AOJ.4*BC?*

WE>')6YSS=A+K5 M+LA:D9J30U")W+] 83,($4@4*%FVW3GR.Y$ZT%8LNV!HL]?>G=(&>DUAK57# M_L;I[D.:-

*FWIT"3MT:"#%)K1< &6)4-^-\^T+1'4?/*Q6'+#=6D]0^5XK5OJ MX]>>^BV,)U7H%!E\"I/;V()RQ+/.N?:"KD,7C(00"P/#L^?*

>9Q^;MZSH64E7MF^GUD2KF MYV%21]_^^H)X83[6NVNAYLYR$*XZE5&;VLI3@]T#]DI!KVX7 -^J)%SV$;],V'-.T=U/$&O:E;3/

*J1.M)NZ:0^Z5R@F@Q@&0^ M<9F"B*SU07&''82NG="KE[PXF]>E>@O4/!2; UHHD8)OI1.QI;RE30S)OJ MDW86*CQ,6_]:;PNL;*

X/&FIFH.;FL78]^]N@+9_A#JW5;KUABG-6&.F@ M9.5H=Y(:0@@6$N,4N1JMK&P=41RU[]#UNKE\[5J=N'62RV+ YCK& 2VY"]RD

M.AN4G C:GZ5M?4?L 7>4D>A75"SV9(=II&^@X1UBWQ38+IZKN*^F!4;-ZVFBABH*[WW591^QN: MC<_JHJ-5ET>&-*

WL820PQ.%O;N-9ZB)0MQ+J!$7:<04Y.2VC=^:%Q7ZLK)#}]+ MZ>ST;%(S6.]KE/)B=DH*^8+3Q:H/0!T]\G:VN+VAALQI$5%

*(R;!NJ$87VK*5 M(I@C-^B+I_VV,WNS%\F#ZH&U"WXV&Z'N53> 6WX?,=U(NKX_6V[%^2VNF8P\ M:!-*

*!%)')Q^060F(>C"#I.VM]S*TWR#:4]^O(-\1M#XH(S)J.Q!4LP&*D0R6{7),);LA+8Q$BP:+^ N&[U=6_&KMYQ'*

MKA0ROQV'.)ZLSK9^.1=\?C_]6,^[YA14K>J ;RT+3"F0*N1Y[Q*^"H(Q@9@ MS#M,PH8@6W?!:\K @!O)[8**

[S5OUL94\@(U[AQ$]SXLRWJ@.LX7#1'6?)8Z M\CLY"3&[5&=K"MIR,@CH7[;^L/*

M/;ZC]HJ=)NCV;VAGHXC,"@7&>T[^7@H0I"U@F2H6'8J(K;>V'IHLWDIGOYM5 MC8;)L]-

*:B]HX3Z,C*7OYL1;=OY[-7\PILCL__4T_/OT6OM[>+:QT*=1)Q-S5 M/)?("'"Z0*1E& P+M*SD8RAL3E7?&<'CP'##&*

<61E3HH%^!%6'QY/9G]5D6- M"PKL)F=D5MY,]TMA>$*I<]H 3R&"#VH>N M%;3H1C(*6?9>6"AH%*BL*$@7D8-!SU

4SD1H7B6:=K$AH@D<>1>N"GL8L]-N8 M:T@KY%@X&.HEBJUZ%+_$91A/.NRZ?/F"8S5=OI>A[GLNQRB\3L(#2E_O]Z4Z

*MCZX4X#*8DDS4,K;.#[?ON7SYY'=GIQ'G5XV!IR>?|&2UCD;&Y4CL. BU&8'R M3M)G40!7B?NBK9#-^V1L)&:P#9EWP<*=_F]-1#^*

*G7DM?GZ)1 09W*H:^GR" MEXU]3F?SY?B?X:+YSQVM%T?12Y(F6F"NWA91@OA600-3OB!*G8SM8&4UH7VP M+:*

*/06@OBAWH'KM^W+3V^;S\938?_Y.V! MN"^+_?1)=-)*C3X!#Z66<3 &+A'(/%=%,,UB<:V+(H?;)[%&>2-A0D"K(Q1R*

ML>L6$B#FP(#D)*+&4C"U[ARY*XU/JC_B+@@[I#_BSLH;P/Y_#U?/OH\7HV1U M4%ZDZK=H4$F2N&)M9Y5S3-

XQYU+K]CX;2.D7:MWJ__%NASLK8Z"8JI_.$5_. M3L-X.G)&HF$D%<]J-V03(GA+WHW)S ?CK!2J]:WP1XD:ADD[2/5;P&E_/?1=

*M0GF/(_,+UBALY*4NU]H"D7,$LND*0E(*=,Y,A#IC7NG''+>'7S$\;!R@QUES MH0[YKP>3\=+?*

*#O^AG<*29__^"7\]VR^:LFR6E,ZA\05A>C*>5VGWQ"31E%L MHZ5625B3FR>!=B"OWVCTJ/M=5TH;-*

AZO&7L73B]7,#%',3ZWX%0JH$+6$$HM MF# JHD660F@=!>U(8L]7K[N"RO:0/%AO X#E2_R&D]E7S)\Q?9G.)K.3'Q_'

M)U^6EU8_JVQXMA9R4IGDIPTX258_BN0Q.O)%0NO0\Q&2!@N[P^%PIT->.]T, M &KW[!]OZ1MOEGBZ&-DBD>5H@5A9938UN!

*39%,R#QF+P=8CVQZBI]_+0'W' MF/NI99@06S7!_3 ?)QQIM#FRD$!&[LXO:,DZHM<4DTU$##*UOF'S($&#"R+V MU/OC@-I3"0-*

"U%IF\68ARCQ,%^>4\1%GQA/"&(K-K510N)-6Z\)$ M.D+F>B-]PQ@2TAG>FJMH /"[;(?T >?C&7D<:8YA@2_Q_-]10AV--1XP((DM

*MUP&N*CM \FI9Y(CT7V/ /4Q1O_MF9Q!KJ(8!@.I#^'%>MS6[R!I=R@T7?ZYU M)"/CA:O-'*

!E<554'IR3=52/=L)C)K>UM3/V&$W]7B#M#%A-5=%W0O8>0[R1 MO[_B8HGYV32_/ULN([*]9;A;V&>B>6"+""+D#3YL2]P*

+X$"U9QP752-L9' MC]T;TM/OQ+-8G&V$D#]I(9;]SNGM0/)2D[S MC_AU$LYG?5[()<;$!3,">(E(2]4FB$5(^H#:1Z^"$MOU;#PBT?

*U.93T:S >A M\P'X #N(9JW?!'D^M<8TCUPLWD640'@E-YJ^A*B- :=R5M)I9;3J+]*YA^*M MX&V?#+Q[4.. 0+LFQGO7[?OYY;*]O):*

[2D!<_'24?>3!B 2N6 :K\6RN" [- M%,G(K8JQ^:2J-I1O!6+W9$%\1+4.",QK2_4^C\+@5DO#/]FE,3R0#& %77+[P)GF)% OM&&>

*(*_+K"<3=Z."XZR MM8B"2[#(>1U9;<#79+25Q<:@)?KL&R^(0^C=[JR /3F 'TV' \!KV\5\,<=E MY(WC.F0%029+VYZP]2Y@@,*

T$UX9Y^41#AT.9V0[A#_=X[#^M#[U,OGL_ET M1NOY/&^-I;HDOT1:MIL='%@@JU[D2<&3M7T.Y=&W;X?% MIW-4=APU_,Y,*

*],L+%CZ'[VL_I)4G G/2@%2JCO0NG&)FH:$8BI>#BI*EUHY# M]UQM!_BG=W W,#S\?E?*

(^6^/;/0!C6&T&=5!FB)8B%%R$XDF:5/H?E-ZDX9 MVFY=/+USQ^&@8 !+XBK^U9BX"9ER_H-FH=GR/-*

[:M(3^4Y7YJR;TSSEFE('G/ M0'"'P-3P+W,*7)T(K8>4#GP6G)9LEV=3G(3ZSKD$H+/#DA2T1D3R%"W=E]_*

MU[7DNR#LX%KR790W@(UU]<2[Z+'OI.46XN>Y:()4M,0 (A^YZ-IJA&(M0+OR5E7K+9[C;BDZTEWTF/ MV]62[R+4 =B<76I-

HQ4INR)!,UT[4'H+7C$+TA?,6B7%??-I4[_;6O)#]KNN ME#9L/-Y;A!H5T\[2^BH]D!BC#;3P"@?BCF+P&M7_;RUY)U YL)9\%[T-):/

MU2NS;%+&J.C3$!948@)BD1F2U-Z'S(45K=-KOZM:!W@L&,M^2ZZ&0#4'LQ7 MHA F)%%SBZ6

8HH<"YT#R$!N2PF*OV_M>3'BC'W4\N (-;BB*0.J[GHH?HM M3%9M@9WSR42A(0;&:1\)Y%4S+("&!W*H<^!\R-*

*=V[G(TN#!F3^1U>%)V(Q^ M9XMB[3*3$MHGYHCUVM/.1PH,.7WPBMNL5$[%=&6PCW^%K9];0T-9 OLI_7>&*

M_,V]M64]1:C7^KAVO&;D$)P/ D1+'G:>:7H*C/>*6,#[@LPE)71!A2_LY5R M'1=DY.4;>.#LEQ'?#:6&-EP,T,AK(:]E7\[PI_*

M&B829):@5)J0@JKCHH%@59H'\&!U#ZP+SG:[B]=,)X1#4[27:-4"BVZNJ M2159HM6UB7]NZP-KYT0--CHEK#$DV2&G8?:[L-

Q/GX.AF,S#0/#[71'K10U- MQL@S>5NU_11)I APD<22K./.&IU""G(<>D"12S_M$P:X-O:%P^X+Q)\OD"F>

*MU.%DGSLK.MQ&*N$^J:PJY<|_[X94,/N@LX-@ZID9+P&B14%A2K"Z\,(4V[O- M4V-:!]P>81_H#U'#?*

5]ANR'DNKYOWUA^?/6_P^5(D_OGT!9L?7-2ZF.839?BIII)%,.I5!:RM .>' >Q_!&?>-7TI MCY%I&E(E32E,\!2E]!2*!"4,6!4S-*

*JJ'&1LC<'?1R7-3OK?MI)F!V4,%%,W M;_[G)!-:'R#8VM_7U=8&61]PABN*_#S3DAT!74^ADF87U>]<2;.+'OH.0QXH*

*M^J"U9:R2P(*E8,JB]JW,/M*A"W(&ISYVA,#CX/K((4, M'&/O:V+E[TFP+V835>IA;^- MEU]>G"V6I/?Y5;HAEV*

CLP]215O()3U:S74;!)L-BS.!=/36WK/GC;^.,;V0E&/@(3%IP6ACQ3;J-M'91VPLC3,+>[H'/S&4!?^N\Q,EG,EZ,+'MI/

M+SA892:YBM)$IP"#X:"\+E#[;P)&#(K\:.)NJWXD](U[-)7U[C=],ZA' GT M!H=90]T, UOK KE(:HH2DN "@6F6H1;U@PN ?V@

MK(U.[P+D0 $/(#=RP>M/[3=?V4B_>XNI;_W^YPE^N\0EDKD*];A;)E]JRR #C@L!0NE@HT% M%0M%L8$\#'36&6^\YTIOI>

;C^VW<+:.1AO<75-\J?O775^_>?/[!%3B-BK$X MR#H%4"99<*$$8$:G+3U0I7M/+#UQ_9;7MK*!=M;4'VK^#]^?*WAP>7E+QZB*

M]T990%];"65((@DP:-%(JF\MQ_LZ"4N\(%S$ MK!5Z$@#)H8MI;O]P'FNA-51\N(R:"]J]UX7P5F9P1%RA3(AF2UCYEL/[GEN;BMS*

M?8"T^M;T\[=OWKWX^^?WEZ;(ER0S;3#$./F,.G)B7]'%)J%2SG8BM%WWQN-MSS-I&^GY*

%GUK>:_8EJ.X_C[!>F%2<$TMV"E*K6-#M8[/ 901UTP:>YNWR'> MH.:;S^UY$FLC-1\@JJ[5_/G5?

WWZ\.;CJPO2JX.HLT90&N0[PF<7BJ@K4@S ME9$"ANW,]LWG]CQ8M%FPO+>L^E;SJN/#Y1G=!?W*:B]ES!"XJ^GX+.FS@I!H*

MT^$,>69Q.UW?_">!WPVRW\=)K7AG$]?'\NN>+K7Q==9N+@_PEP, MQL@$AK9;4+7PTPE#WE1)PF8C5,"MAJP_!K5-

*!/1WIZ:18F>MI=PC5-+L;+J< M_QC]^FF4,M*RD*)V1\ZUPZL!K[4"2Q&5-4CQ](.CYQ:8_G@R^_;SQ1//H7'Q*

MQ34RKM_7(PS:&UVD-0'X,J\FTU_O?3"C,Q&YWISNI91*EF;J4D?@&49)8_! M%]NZ8^/;Z_O9?=ICX5#)#@-4NV[*

;Z^*+G.RD3E,Y(=EBM=KJ/%4H#DDA=. M*6Y"ZP;[>Q,]E*%%:?;L[Q]7Z .#]2"7)]^]I)$FL\?9'*]*P(PH2DL=P%JG0/E4,PST 3VZ*

*MK!BIU[5.P3Q S]'FZNK1K[Z'TXLF>.?6'EWTUBM&_H@C:Q_(X8RQ#L$JB1%2//SI9?9G.RTZN85SA1+Q0[B*K>*

M>3"Z0'26@Y2896;%<,_^[0M -2@8"G\/4O D\^\M\D,BY"(Y\S(;"(P072SUX M%0DBUPA2\9A40:Y#]]@90D>_%GI^%#I["'T

*X"&J<;$U&P3T>RS2S=:TOX2'!(_+8MA@ M;(A>01**#&UV%#TZ5%!*]$5+IV5LG72Z14*_AN0 96Z"Q1Z2[?LV!M'^=PSS*

*MA6")T[5&A;16+&&;089'!NNR*6^Y_?[^;0A?[W M%=X -H;[]LKK)*,WE@JB!!](1\H26XS-SYTEQ6ZCZ!^SQ\Z#GD/ MU1*

X/2JE'H'1M>Y3['+NM35U PES#H?$[0.K;O33]T9VV?/QW6Q9#_;>3^M8 M]]D"\[.<5ZUHPZ2>8:C,D2N=_)FO#2 -L62+

*]\9B:4PM':[_AC;O6]X4=!A M(.I*U'YCYRX'5(;*.PCO4H"IG6]0Y\81"D"!.U=D@ZCD'DKR#SPDN'M;@UP MTDJH?8-*

*CU69B/K[8[+]OQ#LW+%N'H(.KUW3)XXM%*W+[D\S>9G]G)-!#+3L> M?5^_'3PZ@DP'HNX,/1^0B*X#!.]CYGI!\!28-*

IX$96K/$@HA2%J.@=4I]\"] M8'F[-GEM[+;EIB]EDG.N\WI$2R<0@.%!\6OFH(]M4 MK?IATAE:'EZ[0KA'GA)OZU%CN/_[''W4*

*41;OT[G5Z-W24[/<8IEO%R0X.88 M%KCXB(NS26V!OKKI]#O+*UJLPGQ*7"PI*%U](0R]FIU_/SI]99O/G M83%.89I?CB=GM'A???*

ATP+VN?5]U^.6O)DPVNB%V20N!Z5.E9>U"4/+16 3& MR=,B,!?

P01M@KD1IBN""M[[+N8F6PYH&5'$^NQ;G^3ONL"M33F3J$WF7G!:O MXY[D MZA&/"=[6";H!HA >;(Z%)9$E-K^:<2\A_:"H,X7?

K@TY6/;#@]"(W$UOC,W M8D90K':B%26"L8D^]\&7YG/=I]%UIGA::#2AT"RDW0'X,W_#<P-Q=<4-%Y<4JORO._-*

*]GBV6M51WE(D6=*D=!,(F1!%K %NYZGN2VN_!8?](;:S,03A^&Z2ZB=51R1EYL@IX$1&45AIB3@JDMTG* M;((5>!QKNHG$?*

H\M^T=I(^7M;U%GRS!I#L6#[DX;(?P)9\FXD+>9&5YDY;Z2 P7J] :@N1 M10TE,VZU2E'FUQ'M!E+Z.3#O"T3[R'^0)P!OIM_P?,=?

*7'9_F)5GW\)X4N]= MOI[-/X4)KOW2097=^[VJ1?EW R:;U8BOO2;6UG&O_N=LO/SQ"=/9?%R/UZ\! M*SEW7ED(7-*

*29>YF#CP+!V'*MD=Q;VWIQ;T_=H1;MES#_!XF9Y'_]/.[OID[MP8K,("53%"V1'Q$Q&0@F._21:X.MPXB-Q/1]3;43K-*

PV;FU4,8!=\O5X&J9I M7&^CD%C.JN!6Y4>,L6BS(1^QU)!56N-8'6]>%N MM9?Z ,#S>1ZF'WKS=0.C>EV[W,/=XC,],*

*O&**82<45KO;6S=R\E/1=-#@5T M#=34_QRB51?N3U]F\^5GG)^^F1**R8]^CF%.4KVSD'0T7(C:?,DJ46L+/7BF*

M/"2C>7$\Y+CE2+F=7MMO4'BKL"08D(W NO(F:3>>OLT:XT#B\:WA,>LR/J:@#'68_P ME]+9Z5D=8IC_/)\M%O6R?

9A4AO],N\5S++/YJE#((#&M90*IL@-ER9V(,F?(MEI?LHM"86A_ -B%\>*;R**CM0*O#-ZL;F:[W'Z^9YK0Y*45B+Q8]J*P=[5): M XM&\$0+6S1O.]B$\'Z=T.%!>7^M[@YE?P[E*9Y40CYWANAKOF]*852,X[6"
M"3!'!)4L@QB#!.UC$#G$8I/O&+2;:.NW^OIXN&RBFZ=SKOPZC.=_#9,S7,0? M+R9AL1B7<5]J]I_6Q\N-OZNA4>4<6>SA4-
M*9DB48C;61IT3PV4CPB97D2]') MMDZX#>%067*?;1 ,BI"^#M+FX)E.P$-(D6,FWEM'0[^#0^4=L++]H?(NJAB MA[CI-
,H'K;3C"6QVH8[WLQ",]22A8%,I4EK=>OM\8H?*.REZRT/E7:0^ / T MS;-RSIS0Y J46,<-
XYU(@D'Z54D#T200]HZROC]'RKO!@N#Y5WT6[?25-N M^[&+M4WEOQ=OZ/SXIU ,,M.
M(X.HZ'@X#K,ZNE4C4*E,%55=N)K5&V\4GQ='/\S_>X)RX"[<3@,#V(M?A,47 M6J/UG^KQ?J-50HOC*F"[GM(S\G'5<)]V R'I
R:D$+\.Z^$VU;'?3-G6,XRV M)FYXSMZ>@)@=0SL#@-WV.1_GF4#FB"6L%WI"!N]R!%F8C#P4ZVQIC+JF^;B> MCCP. 5TGNFEV0-
=1/NYN76]\N/EU.K%GFDN,Q9)0FS6WD23IHG_EVGWWGM@7L_LBJ:KFR$PER21UC]WS0HO%0\(T!>B M9%5I?OWQ &N()D
(I&!GIF':6W%].4+#WD#R#K9(S1+OAYM*NML7HF M=,_OEI=W-YJOI/4[7GY;Y%M9/OY3Q/?A.ZY2@QB,1AX3H!:N,DO6.6L#**QA
M,6)<="\'2+D#@3I=[?P.Y3&:3'9'"R+"30W,4*?XF.=$)0FU/:F".AU'3%K M$@3%.#AT
HW)+J=!S[4O8/!Y*J9!V7%1L!A%)5,GZM>^S3H#["(RICP#4;!. MW]82 L\%LG8VD^>:@O,O^66/?
^QTZ&BIJ$43J760;WI]=3&;X\7%JT32N9Y4 MO3H-.C*OZIQ'+6OZWZD 6T 7\,327_AL+57^00ITV:3QKJT6LJ_4QC57RYQ
M<[R$PN1CUL!L'< >>>)U>3#8VV^19<<)21'L$0-TC:EI_J(GJ!\!I?SWT=1_Y M6*R27-(%3?0J%T/MZRGTJY1D<9HY.>R-
N(/[:"1]//7TM[2*\B7W<3V'^]=HE M\SD+IH,%GFP$9>ICI/)A!=<9B^5#X-Z/EYP9V\^.&V!^YCQT7XR[0$(F_YU M:
[/4Z"#93&Y5X0*BLP6,(-.8C)?DO;>"PM2.ZI[*>]CN/20WL<)_#W_-OE|] M7Q,>%*HHW*'\W@LJO_?1B96^C\H6+>37@PL9
MSL,\X>=OB)?O%M=5*M#(*UGF3,B?-7)+23=@$0Z<%0F&:.MUZTWTSY%R[2= M)J/'(BTTT"F2-MY4M(4Q[L%C=8.8SQ3?DZM-
7E&2R7JE_#&PU$7XT43; R"T MA^@[-%]VL3[Q3Q=[_-Z=7&!-[61V3$K9 IUK 1=R5Y*"'SQ.LQ"1*E8RKYU
M=9[D3@M,M*Q[X"Q]-5!T#<_BCRX<]Y774W^_$1EZG]\BN>!1-#+BK4 M+6-T!2@Z7#&'")Q.+E?1DQ/:>MC"8.*F-7N; H;
JSS=GF7P2@R364ERLCS:ESH\HD"0%.,C(DRFM=Z4V M)'_:IXUC0_GX&N\&[+<"_>T?[]_>NC5G3N6
QF&]IDBJB0ZQ$UJ#TSZBXSDR MT[]_^GF*IDV!'AN23?32(\K^>#^[/W)GM8'/6(KK4F)@)6-T4=01):EXR(4) MGNC.L]?4-
JC;2MET^95)D3=X7KJO;QW%<@]Y+M-I>^S/[IIT>]P)HY?_ZN, MUT9D#;I(BK)#G;A@ZX*:HKCF5I>D3G?OPTU'U^N?=Q,-
_[Y<7/T@M^$ZX%-6 MIFBQGDA+Q\6Q^F NZ$3J0II(10G5>AOV$+I.I@)X%P0]FKS06D$=W*9/9D8C M4X8S%D$:LL9*HX>0T8
O13);.+?-]R<=]!(QWGB$YEH?^A2QBPHZA=(Z.\I4 M0:RS.PUWMH07&>;*SQT/TK=N 3_$I8B>-
[_(4L8/X.T#2K=W>8K5O!HU\)I5A M]1S>A!]5AG>"'VED5+8V38MB07F7(,8ZY#)([X.,#%GK?,6A-$^;9!O]ICRJ M2CN|
N)&Q[H/\G1@P@6*73.Q%=P'"%*:7,MJD@RMG\|:)-2.X*@= QV[Y=AV M456/P-N>N]',,66U@3IKDF,[@AWL 8B'JV]Z
MM34U/[EI=+M_QK:P9D-BK-:..U4W\HB4(!X M_3B#S&M;NJ:MU9K. $^HW:F! M?7WW],-EY%X[Y0SP6*LUA:<@5/
.>0L,Y>"E;R#BS 67,V_'ER/H[/>'XK? MX]7WQ3)\^8;+\ .O+F?I@LYQFY?BYW]VTZ?B'=@X_EMQSH9%;QTPKK#N1*8K MNI
EJW7]GALL.K4NESO>6_%+TS_6$VZY(XYU78*KZX1;0],!AE)_ ->O N*GBZP;J:D#J*BIUKYG;724X 'J?83E-8.7$0)CJ?B4!KG
M8NN8YY I&D>HFFZG]8&#_'910:=(NC\0(#+C-)<6.%WUY(WJNC+/DIOA8\D\ MD /B6Q?QG>@@C9U4O_,@C5WT,'54L-
TI6;JA\JQTJCNZ6; 4MWNC(>C" ;-* MVG,>)3>#'/_GOM(?0@I0YF(,T9[R[$/O7?%9;E 4!(%RVH#WY!N@CTDB9J[%
M0;4L4|\^/$*O1?,+|*C*ZWO\(3,&Y6KGN\8$"NM<96_F[)UFH< M?#WN(M,>9A&M#@KYE,EF[L"S.C]+&B*??@_<9?I?
43S7@W(HIS&4:N2+:S^Q M]H"%C8>7N"D2%1T,CJ"L,! 5@=DY+I4RY#J60F(NU2Z2ZVHN
ME9+:>98BR$2NO.)&@50WM>)G\SN$ M!TUT\N)!6F[HNJIEFC%&8$DSR2*/@K=P+^]]=)JPI9GB]Y9?!ZFX%Z^^.T]_
MSLE:"@XN.06*85U]S.HSL54NJ6RC&33[O^6;PKN="J"/T%P[6NIW)$5U ,'A M,T",5URAR,"MKD-O@H>8F
)3A$.MDH_8NC7MY":VM$7'WN-:=E%5-QA\LHI; M&D='5@CPUN4ZG[C6RS+R!Z7CE@7E2AH'>
<5W$^7Z&N)MB9*Z1%BV^NS7;&Y M;NF K.1 4R;HCG 4A& *BKD0O&!C5Y >4%H_78@^$N0.5U+#(OJ1BI+>S;[/
M+C%_#,O+M2%O4Y#T],]M6HPTD/SC%R+5IU>G-0.C@JL33@0$U X2P2/&NMLP MM5['/44ATNTW\W\Y)/P3 'XLE*>2Z?,_B]
<\WX1*_+I8_KYU@XV3Q)7K(HH99 M,BIP7!O@10A1GR&C:&W@]J7U9(J5=D':TX'%B(KLX/Z]TZ1Z\|O_-<,E$?7M MYSO\
\|763_#=)2BN3C[B B$Z)8"5)%42RF;>>F+!,,IZ"3#&1,G373,X1K_6CJ;<#*-]R^(7^BU]K#'HQ(P'^.K_Z3N:@ MZOE,6*%%%
FH^!,YMB'F^Y^9-DG9R_N2=&%N,JK ,,OCJG MGS4GTO_ 6^[.BLS,U_*&:(L@GRA)<,8P8-[8Y(MUP;:.P[<23$)
[.11U/[U&6S6X\KN=RW(TZR M5X)\=G!,9KH3Z&((20:PF64M?18I#%LD_M*7>JET.!+FVDN_VQ[Q.>'O\+GA
M#WY*FZ>6YTAK^+!2/_/SE]E%.E_4J/:V&3<**SF/P)/PH(I9U5!K(*5GIS.+ MNOF;P3/DM+@U5S_Z4_CS=SHD2S*
<%X3F#^43*6A)^#ZS-6,56!W015&[2K: MPR2 H&R53@F5:EUK(3)5TS^'M,#'MLNLH38FG9GVB*?_6"S_^7;^<;E(>/&
M*:]Y83ER"*;NF*D+>+V1!I@6*I7$*;QO/>5T %G31@.C8ZR1/OH"&7E_LPMR M"_Y]L<@/F)+>A5R%AL0]^BPV57"^_O1B\MP
M/I(?73'_Y^S\/,S5HHXTG]$/G'^M";RP&FF^B5\69?,O#W"W]__8X5YY(T8; M.>^;;[R:Y[9XQ@9$)0HD2(=>=]YBCHLA0,.T+
M/QY*'AJU0S7006YUP\(9&J5"C@%*R(E"$"'7 ^20A:Z3PP\; 9>M97IMO]P&7 MO97X!"AVDNC>2/A!-
GF1/U^&Y653/'R\6J9O=>YG2C71-IM_?97_\VI=*'AF M>%%""JSU\)PN<*
JHO)!\BHTQLY29:;YK#L33GD9181@1$VO%0G1TKW/Z\!7[9&KTKIB9Z<+;K20;K0+;A>) M'GC!_3K/DX=R;S-];%9FM3+ID6-
YC/!N" ''#/EV%L@D86#0,BL?/%B-$I1' M6Q_M&#BT'%7.GI?6R<&CAH&W;Z4U(W>)[V9_X*//KCO#.2^V< ;9U%K06E$4 M=_Y
00ZBDU[8T#HZ'$Y='U% >TP]79?85%\=7+7/\//ZY^_A/Q?+-^=D0ZX' MBL9HLD&$4K(!I7-MJZU=CBBUJQ+8(>5C=/9*Z^D;B+6-
W M9K*A+D4'GL$K1IY,3!YC<2)VXY& LJPR%YL-XZ@.4O MM55H\0/S%TS?YHOSQ=>?GV9?O]VL0*7(J02K&7"%=)I-
%N!*J9M6@PDB">F; M+[Q[@:1N87+K=([IHK=%:@ M%ZL2 ++]2DJ(&ATP9$7I5%#IUCU\PRB;>)/B$2$W@J8FKX^^GC2?:Z5);7)
<-M;25;V>U5*\UVRVV%34HK0T)#7G>L* @4IX$A! F>I<$\L&9ZCZ]/O/[P"' [MCF(ZL'QOYQG+#HYPPFBUDN0(J[K$#&/-L;
(,=06NH&/FO&L=5.Q(8B]-4:.& MN6.JK7]4;CWF@GFAD;CC'LGD%RLA2!W J&(\9BN/CLS^0MY18;,;1_681L825X>O?
E[6&!YDUC!4/D4M3BUXC>%DR_8K[*(6O2]J.![@53=U" M;6\D# ?;[DKI'6:O4KKZ?K5*.[WZOEA>SO[K>J:)XJA)4@(0ZT ?
4:=#68V0 M=%%HG$HI'?'9]PDJN\U*P&*+12W.SC]-3CG^+5^^ A7[YDHUA>+ CC)"93D M";PC/Y8'C#EY)8)M_=3V/$7=YJ6/
+I=%=*L)^R0>/81"[_^E/%D%844!E+L%[KH%QBI;E+_*GNKU;#S-P(\AYPIOU
M16Z>0U9,NU9,)F8/1A'AX0*4SSOCHRL%KKH(DP8 M8N[/% M>!^**RTS!#WHDZ?D(R9N,9(T]:.DYRE,3[L%RN M1M*-
V&+TZ!OC=Q$]S]8TC4(J&R4)G-+63;Q128@E6,B,)T?&AW/?.BEZU$:A MNX:Z#E:_[TS(6T4FCQ8@WTTD/%$^EQN\0ZCO_[U
^<79"3K:S5ILCXN7J1P_O]C6)Y%IG*T(H&,:(CE MZ,'1'T&VFON2A,WBB.]A0\GN8_C ^'@]MH9/#M3OZ?KZ\B>>_X&_+^:7W\@+
M$D*76@SDLB O*"<'WJ4(Q4K,S(0H9//M.@=1W,=P@]Z@?)!>3P[%]9Q^^7-Q M9C(OR-""U9+7K6^E9@XT,4G..X\:L?
F0V+T([6/(0F^8W4>+!PE5PAZ>%1]* MU.0=):T$L4EGTT=CP9'?Y$MP6>?6D?J>I$X;O'<-UYTU>9*_6UQ59MO3&19 M)
[H\Z@."D0(\XPBI&(N)6!1R6D]W0^D@N)K_CG#=68^GB5;ZMV=%^V3K%@VK M_D[TF4(0K':*N9<:19Q_O>ZG MO1U,]'JQ7"
[^I+\^9"[3SM\X/&EZ&%N-DJ9U"_06F*+16ENZ@'UA@2)V)L!) M@V"9DMP%+J5VC<_^=DH.'\(0+]_.Z6==K5H3K_<,EABD=0Y"X;
[.\U'T*Y00 M5,DI&*5*\WK8+61,F_!LH/?',Q4.$W4'-^6[Q?PK_;3OE96ZJF_5ZY4-<9ZM M 2=L[?
6R$4+0"HI1KNB":%WKD'@;'=/CY2#E/IR0<*BD.T3+NAF+.Y=*K6@L MQ=$5+V*&R*.O[^/!%Q^+%*UMYW9*ID7,X1I^ 3)
JB+L#T+Q?7.+%Q_"SG] O MB]=A_L]-@[Q"EEUP"7BJ/:76:0@*["6CEET+"-OO;'P26+Z@LX^FEZ,(?8. M\/,94]W-
746SF57$O4Y%"RC.U+G07H-;U0RB+CP*8^C/&^/F$1'3OH:-@)?# MQ-P!3NY?V"OC]XC>U? -K)WKR@H&WJS*
[T5FUI&#%]L/'"M(Q;1(:>W&'"CE M[G!RIZ=<%2;IELZ KCYWN4)7M:!S1,"/3EH49"1'14LOLR$.U?&SD-E3X)./ M9I)_,T*O+M5?
KO#MO*1R8R=]EDD$!2Z;2+)ABH))_E/::.+&2"[X_,W]0%_M3WZC)SSL]\!%>VE.#@K^-||V7! />LU#(C)BD-
88$X5U]W.$0$AE8*8J).J,) M)@U#Q/8/]'2E-(%# SE.C@5]"^@[+(@D<[&!XC];*X&2=>!U=H"!6ZDU:LY> M3-4^_.GK609
0F'2W%J('PAQ_S=(LR)@U<_EK/S.VQ(Q2)'X\'H6/?@.@Z, M6 9E TYY&22'@2&I[\Q;9E(>T TDN;4H*
+CV]%MC:QFC$!@DORQ:T*$+U< M;=$R*?,4=61#G8>M7YBV$&,4U^%P24X.!_$W=O?",YN1D8X":Y%H5+:!-%E0NM;<(M-=BD4
>TUO XT'/8^H%IBPC&GCXF]>/]-'Z+_ZNL6&)DE6M!0$SVL1EZPV MM%@-J4B3,3]*PX=YJ7L2,"S_Q4X'4<=0Q-1@VYC7M3U=
<[C%RN(?.%_SY\EI M$]%[_>/#0'9"6=:Q%3 YP&HE_5T.[QP8 M>Q,5&FT<+^!S/3 LDMQ8R2!3<,HXR6P:W\T<
MN$U!A)9%&8SN5M, M^\0'@6CP)X=AZ 33O&V%/36$[E=*W+"@K)*IOH)SE14H)2PXK@LP63)#*Q4S
M:MAEM/7G#P/"":5V&XAQ:B3O< M <5M&4E2)<;=K,G+WQQ6]W9"J=N1Q-T+BNYP1)R(.W[:YIY5 A%Y !;*$DJV'"G!R
"C2&Y/R+OU"8";F$;S/%-G1 MC0J^+IE/*#-%^T%G/[T_O$/'P: 4TJK'BC R0%PWY62FP7]RU>4/R
MW'.NA03+*7Y7OAAPDN(NSI5AB>1E]#"(I/CA8=@YH?3JF(+O!53O9_,GW.[- M0Y0)3JE0&$COZ:CP[.ML-?*]N'
>F$TK3C"+L7"-5,T':N M_(WCI3$CB4LF1_=N"4@Q7$B A_'LXEL8,'3X$\.@])I6['$?;4$+HMB?@P
MQZW&5=WDD.C"+D%H<)5=^Q]*3E[XY#$2GE+L=1]Q3 MH^BF_._I._J&KZ(X>H<,M*JC;2-GX*)AP()55A:TC@VK8-KAH\-
P=$)IWK$$ M/C60-JFD7V=?O]W/)RE^-X[D1CN/=8>]KU,\,7.(VB%($5AA2EK-=ZNK?.&# MP_I23S#KVU+04X-G];BZ\?*VGXE-
)ENDR)#K3-8T$5M6:XA\M;Q99HLJ!VGE M,",T^)O#/('1":=^1Q#TYBC:F]L-5\,7%F"20S(@7[SAX4S2(D(TR)9%=_M'?8V.?

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|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|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

*#27>)E_51*B)+QIV%P*PEM+L,7DD#NJCHN46I M?>NB]Z=HF?:^;J'G%Z&SA] [, ^& M"X40]:*)D M4()[|*
(4E0.:U8%C'7+=V@[:0,>TU-@I^#A5V!WC96@BBT!;.G 1&;C\9:O+_ MHTN,U&R]%*
M@56%%\>#QMRZC_\Q%=,.VFS[*&0A+O#R/OP_:8D4>B<,'A(*E2LZT"H)QO, M6=$E>95B\WC*5JFSA\?IN-*
G(:.GP*>>H/]*_LT(O3*4O}1ML%65FY!/68KP M! ,NA0$5R.A2I">@%J&D3/+2XL6BC1>^T1,>]E7@HKTT)P>%OF5",+E9#$P7*
M)$H1 EC',2A7RS_I_R"[+)'[Z$0:MBIP^\^?.L';' R'2[&+:V5SR;Z[J78S MG$?&70!4=0$Y0P4AI *9>Q,M-*
X7;\1ZVW^U45:U/P_DX3,8=P.3W\-?L^]7W M=TA._+ ST1'RA_D_ MPG)6_8C*XID*1ME@-=C:.JC0DO$-3(%6T:./1>CFTQL&D-*
5+LJ>U_6JCA]-I MQOB;2^_) YK'M_:Z26C9W9[*"+PV0KBM4)0C(,%*>H,Q2?07/'M*?STW)GV2=UNNCC(/T!;AQU+KBV%4,;7*
78%7/1.>6F4*.-5W)]X%\@E9I0Z@!#1@,HR M0+#* ".AJJ!9L0\SZJTJ(Q\3TPNJQD/"]M+)]72 ;[N)FJ(H75:&4/4 7D"*
M%**&0;GNJ_01,)N=!'=SL>+1:_]97WEY2[PI!6QIHDK J^{H3)=7-.(6% MNB\W@GN[-#ONHH*IGY@?Q>0/F^^4$=P[S2%@J/N7*
MJW7EV4-40I$;8 09[D&/S2]]J1>D'*K0Q5C2G1 J%\O+LPT;UZ6D=9Y]#A** M\8["W+J3H0B$E"0)Q;B"..B>HA]\Q\+0[VZMR\-*
O]I)8W_\N.DB*$VH_K6D^ M>W5^OJ:_)C^NST8V0AME%3AO.:B4&02/ AP7*,F*%HG/W3<7F/[V=?''OVV^ M<8V&S>]NT?*
<#=-8CL.TN6@LVA[@\>O?/YUA]$('1IY]78&JI'"WW@@+SC I M@HY&XG.9TYWA0-^<1OWM-/<0"KN*L0?5__OKCV>Z1%DHA*
,IZ_(3)Q-X[3*4 MHE$F6;+PS]T).ZN>OCE-?#*>ZG<58P^J__OG7\ZLQ& C\U5+2'"%X)(>&<0[%*
M)H-.\&2U:*EZ^N8T[L!X]M]5C%W$H8_JN .W27N=0;A ,95A%CS3HH[-T\(H M[ABJ(7[AOU WQ&%9BX,DW!U&[I3S9B6LCC:!#*
(6PSA)"4(J!1:8YW6Y!FN=, MQK]T-\1..A[:#;&+P*?.2KP2?V/LMF9;F,TD(/*$L!(M ME5)4R$&+@') N9 M?#!*^0?FY:G*]^T?Z*
D)^ZINT5B.DTY46G'Q&]G2CXO9_++^XG_C0(M>Q(P=?:\ M-9J.H8<.T+:X6K[F-]TK\I8K'6A+WRX2[PHY*
MO\W^PGRW>^S,!>YS]@Q23 D4SQ0PY.B!BURBY$H8;+UIZ1ERIH[4Q\+/87+O*
M(HC:H0,Q9UV440X*L[7CM0YT]72_6[KDD7&+);5OUSO=QM##(#:*5DZH>>_J M^_>P_+DH?Y\O,9S/_@MS+9N_"/-<2^?*
QXA.FQ==Y_?/9_-6'-V^;=_3M2\!8 M;7Y-!-)![Y]%PX/5'HRLV4JK"WGQ19.M3,4Y73#:H_0C';OW;V@##R.N?;^<$*
MA>N#7O_YN_H1^LO7/Y\]M[WVHYDV,7*A(->5]2I&!=Z2,QTE15S2Q"+$459C MC<)=+Q[HN'@_O)'L*.CIRO?*
=K;'*T%W)$X)4BM?I170G1Z%!!$V.OR0WG[=_M%3_E9LB^<->HSW('$'0]:=[O9**CIQ(58.-*KM@P4?O0!>/EB6O4;;N9OH7*
MZ[/]6>2S]8)#C9E!2HK1=%+#E"XC-J@LIFW]B9.JL]R M)R4/ZK/<1>(=P.;9WT\H=3:N4%":*1Y5SK%:.(,0@HGGB6H%T =*
MJO?'VRL;*6'Z(K@!C:M&QN0R,)XR*&L0HF;DHX;:Z! 2)R$.*GUKTA8\T:[*
M/<#27KK3@V6]MO7N*\!#A@2J8(NQP(35H&2M_JP+KB1G*EK&9?!B$%Q>_E8O M#RTM*
=-8PAW<6,_ZG+=O5"$R;GA==Y[Z._B]]DD-_-0IR=K]Z;PCR_N?I^=;[ZA]=53*T?PG?YYDAOWWNS MW<%SM](L,)DG9=16\L:&*
M]#$5TV;"^\1@(YUU@+IM%?I29$V>$E&?(AV>RI[BT5=6UDWSN0;1-7;^=I258>?*
\'K_SVK^QVW@A^MS_3%+X[=6+H;RQT\K;'5RW+DP.M,7Z4MUA=G6><4*9Y5DM&W=I6Z M>%H;O2;%\&BM=@SH?-*
<=4M6GD3F!\4)CSC9K-]Z.F__I)&V!]PD[27=!S\0[M5SXN%_DJ77Y8?L;E'[-T/?F,>2:\585<^*!K\8@#'WD"5EP4&:7/;M#SX@N[*
M5[9]NT-L=H"114.%]0&X>N+7'&RRLTP7:PUCH*PG?TI3%!"9HK#22TH M6B/&0)D2P:&+$)PK*
BEV=*EU/=HA]/:29.SR1CPZ($X8_)M!\VCHGX^F)R_) M:$3KP0NE +&DS UZIULW/!Q&\;0NX?&0U0C2>ZCYA$&]OK\8B\5G7<*
:2==A M,.0LA90 D_0B"<3,6WBNX UC>7X*__YZH6HQ!?B_DJ MX5'-@TZ*%Q0"RLH\<*'!\9@@&?+";/0BQ-*
;INV<)ZN4%JFM7HYU*.\#G QI6 MYUM'NJ4XG2]>%#'AZL[@[2@DU$8*RCR;#TC;"LATQK)AHI>M)9Z!]"Y8[,W MA_0]7M[K5?*
NXDQ/:)X&NIDS[N^ M6YLIM /[^.R.5$!S#MI/5=!C#M MHH(.X/3\[!^?F,GH-4@M*
T5D7H"3GH.,1OFD7&*I>1_6B0Y@VDGO.PU@VD4) MT_4>7%$4.$A44"O(2F925!<@=/$4THQ)C0:9?R7\"T#UC:2[<#\W-O 0.Q*
ML^8B*Q-*'1Z5G:IC)E2&X"*'4E0H60J59>MD\G9*>DE=-#8X#<2^.WC\-7CF M>'G,04R"R\(%IQ.@90+%N =OI +NF?36*FW3>*
(O!#A[$=(1%EB?GN1^HY ZL MWB?\ ^=7^!MI97.P_V-V^>W-U<4E"7A)?L#Y5:Y%:W7]R 7F.GE'%V,UQMJ@*
M8U1]\PD412<.2N>44^%6<=,8QWN0V8N#U@XMC]X9QE5=%PF0]XOYX@'?EVY?";1"YY#J*
.?"MT048,+/D!=8LQBD9'9UDT&3Q+3BW\W&M:,]*$# M>[=Q-];DUU[G,U^$<$PQT)&H5W5-@)UYHA_M)NF\(J-*
GX[O[^FJTKJP_RZ[Z9*Z^W\?J,-/PM!R)A-W3TAZG(@ MZ/)W?;*86K\Z[4EJQ[G<-F \A@H[,'?/L7F/M95=OY$U/_,\,@+ M*
]=R%!Q:DFU"L,(J9,6FH%NG;_>EM>/H97RL-E/BZ?3OW;"*+=_W[QG[_FO MC-2GMP-K'?3F:>NR#(SPY!)%TUI%<"D0Q',]N6-*
PV;5>335A;]Z-;B[NJ.9U M._SA)^_(6Y-0MQ-EMVD,G[!B]G7^>K?KN>QN))=3!(2KTU?K#@(DFQ8=';@ALX?*
0.P#/A@',KRX>.=/K5REK5 IH$8KBNB9- M%45_NKKR)*'D)-T4[0=]OTA6;Y#:1_^/'EO:*J.+7/:S54 \Q:S12!#.!E E M1O#"*
<8@AV:3J>BN?>BOF&W]09E^W9#,%=F'NGGG0USQ96Q_>12YT=(FO.GB(M'&/K._D#@<]WFK/DRK>VTGKNQ3O[:*'"#N#T?-*
V8T';+0@8Z&\GO>]4O+>+$DZ@>$\FZ6S)92W=5*.8^ 1+23K G*% M/.*#PJQ_O>*]?*
<#27KI=.%=/U)&AL6]J;QA+NP.'9%HVL/$(E95W&8" I2]"Q%<\^>HHRM!;&U;I6V=K7>8J6 M;6U.IT%*
<$\5U"L#U,27^7?!,D[DEPZNREQ +0RA.NFQXA#%]<*9]XMYNOY5+1>], 'R*J7EU;T5G2L&B;,UC_>VVESWB^5D0RP2 M;-*
%TIYO:VXV^EM\;G6NWM7ZXZ.)^.S^[6FCMC'@-++\.[C2[O@)=U8EW2P? MEB$)+2Q()@PHIP0X+3QDPW2,WGBGQVN?*
V4+0M'YZI]Y5.Q5VA<<;7C[<*#2):C72S2LXS=I=&,Q"ECA%1.M4R040E, ^*OLYQ) M.)DJD"A?@=[1[Y0+(D+](7[L[8.-@ W0*,?*
&O(2S M)@PTBJRD$!!K_*H[>Q7EG)DU$,_R M+7_2E"@7QW.OUON_&45K\[.B,_L>96R41ME#5#Z8 ZMY+R:B[K_4.T/UG8<>*
ME2'@>+?S12K6G(^57J0-%Z9OK:'W;&\/=+V51!C68JW#=:E&=0OLYOFHV2BA(=OM3QB.9*
M6"\^=M1I#^4D#H$=R9/.4U#DBYX!U$VD]O4.X=+48#II& ?LID.9+&.1_;Z MSV^]<*7KUVPVBL/"7@NTDW2X6Y-NY%*
MP[F5Q7Y!3R4XI^@@Y3]I0-9G9U_6I>L\R6%]FQI!T8I!]?>C?0@]S=6WT8R'LI)+F]SE%MG$-Z@_N?!-U*
]_C[,DJ3:1)OK9]$/Z]XQJ>)"BZ6\&H0;ZL>TAU<>:7E M$C],I5&V-?A^OC WP^@.;,.XS@%F[^;6(5QL Y!3=F*7S!0:YQ+/ XA40 'R$*
MT5SKU1@(_!U=A742D52NJYTC0KL"@N?ZN_"1?U\FLHPK,$&Y0S-.(I-*?77G MD&H5T&C55P70,3)(]8_%6(#*GU&T?*
LI'7.JOK;FYX ZZ\,<%/V!<:W+":WU* M$+0-UPXJ'(I(:N^Q-X1^\GA97(:HP\1,R'5PZ4@](IY,5;Z%8^>Q$\EI6C5O M?YMK4 +9!HQ7?*
6650G3C!5FZ$1< .NU1,&M*VKD6EH[C%_EHDQY Y*ABX9V% M[BA* PEOM8J_SN>;O%6NLLE+>B?D8)&^I,\2*
M0K/.K6&NU)H4$P#T$9#=V*R[F(]7\76N@-2M!<5U'OR0+#K6'-XAS8Z: M=V806?IG>9NQ.W/=Q7!:=N*+S(SAURO)GJ792V?*
9;)"QO()5KAB W@W2F/H M=]-7P)&-["OF\^H^V]I?M;3;'[W8>)80\[E_JS2"AK>W!-.-['Y/NH.S&U7K M[!H?^M>EVP.X2??6T!:%,.*
[A32^=*#+(A]-M-X;3PH/+;@![AW>C:,<\P6.(M%]G89/"CS\Q_YXS2-3;K;4PM=*G:'C5%F'EE]2.G5R+,4]Y MK#C;^E#PB9-Z1+S]?*
S^]K+Q@EY=I4UA9BS6<3I-8X]YE,&.M'1TO!/IIZ<(.Z*^FKO[66DHE(HV7+05IV]T;><(M?2R*B5!1"G%\KXJ%=DN*]YBKY0)?*
H4&LEE&:KD=1PH"$JH-$NP_%7R\+,]@U-M56;+75M8?#4"A<8F3+1K3CR%:^$&>]FY*^@?K&9@L;$1%. ^&$M]59@L]A-0K*
M+#N($) BUF'C72\"H*6%+ JAM#05/* V(N-=#!(25]N(0]_S629J;9XVV5"I M/V_FQ1-N-\E4&\-U;Z'4[=@4WCTAGG+*
[48G]V5@),T]Y,8D4C[^]BE2S_*B@ MOB2[-85WQ8AW]LZ'2G+Z/W!UG\5B#I1#=VH [Z81,*V;:2.G\$F2N2^E+0TY M*4XJ=^1!*
(]+R->"]'R;_((1W;4-)[TI99\ZDD=ND_5*Y<]C^_Z-IRDII2X MZD@>]JB.7I9D)+\FN0+]-5. M9>4=.OQJ 9WDHI2 LM&"?*
4.M65"9'@$)5H?GI!>EA)&%% HI?I!7S0Z!G 2B ME.6IHP%]$2*"2R5W&$YZ4,K!5#I/H\P[6(ZN]:KO**5)"):IBNR+7KAL#;OA*
M>2R38AL&J$ZU'=Y)1$H)$'?*T.5"G G# MGM:R/+O*ILH<(0*K/V[=#H30"DKTD(.>@7!_O077*E /:.3=)32("WD4'U] MX#*
[+$TWF1$;%RY-2FKII\ZI")0,0^!2!I1F0=PEQQM#;+>QOM[!WRV@IF4ZXG.?#Z40R[5\P MJWD++-H8ZK9&:"<&?:5@K()XN?*
$8">W\?-)A@U\D-#J]N#CYKI83NXN1O@V\&'39WX","^ M<#U^T*;)%IX=0D-]>[>C$]DZMNIVO-/BR!?Z9EB=G0]";4V%R?>*
[MT(D_1^H MLX6__B/Z]A?FGY57EE#F\C;C@@ "Y-_; M 86UG;BUE>#,Q7S(P,C0P.3,P>#$P>'$N:'1M[5QM<]NX$?]>7X$ZTYPS*
M(\F2+,>VK'C&2>R>OEQRKJ>9?NJ !"BB)@D>0$I6?WV?!:@W2W;EYLY67&8F M3DB\]2Z>?78!*
]G@0%VER/H@E%^=_&ORYV62?=5BF,BM8:"0OI&"E5=F(?1/2*
MWK)FL^KU2>=3HT9QP;KM;H]]T^96C;EO+U21R//9/(,#_SPX<(L,_BVFYP.A*
MQDR)#WOJY.BPW3D4I\=MV>V%4>^TQSMMT7X?'AUWV\>]DW]V]C 4W?T86TP3*
M^6$O55DSEK1^O]=M'1_EQ=E$B2+N=]KMO^RM="WD7='DB1IE?2V:;51D6^HU7_EE@1 MB[O'B1?H&/,D*I,S*
3M=$NGR+E:!*MAA9W! O6=*K:O&S0C:!;HH=-H_P>1+ M&H0PJ#0OI,*GR^N;X=7PT\7-\,LO?UM58UL%_E7:0D73/UR#WD8-*
A@W,$DA3 ML(L6^VBXF/!I@WV*N3*8F^F(%;%D'S4W@EXK&;'+.QF6A1I+]B6*5"@-XYE@ M7XVT2I"78,Q%.I(9&V9AJ\'0@?*
3#/+QX^^;HY.P)9LJY$'"U9B(C"+S9KNW'9]Y!:;A.U(I^PVTY-$BI%L^%W[M;;YKQN^:T!*
FTPA*6(NK#$XX9656F%)"%X2IM/)%SE(\&<43%O$0KPS3*6BW MT+[?6H=,AM):;J;4)>6WTE' ?*
$Z+=P)B8SL'S)N5O7O[YJ3;.3ZS%?2J7(2H M1OO<9=^^3-SM&^]%)TCH1_ M\H^*4MO,8YCF9\2!2]#V "-9MEXH6EDHPD*DYWW*
HP=E#M^5KAV^WVWH[O-W MNX+=]ZW3#MGA,U+H$6VABYC_'5\-"N8A+^WV0RBJ!A)8J5;R<5J7!A. T\;*
M.J9$+YFY>2AM7W#L,F,;F7 'OBI0+P#4J-B<&A7X%K)8G2CA#L^V#'!04-PH M4D#Y=,+%D(QF*BV%>.>NUN4#CE>UE1*
(QV8W* ?#JK!,.+$LU')"+%(%C/") MQ^;,.">\"24/ W9A)BN]BZ)V'>;!#,#_LK<-\;Y);0_OV]+@UZ.$H8YQB,91; MG7&**
]S"#RBI)8#C&#P#&^"O>* 254PI9]BT++F>PZ4#FO>:E:Y+2;$+-W>5 M0GEINAPG#+413@"7'N-PAM0E 9[1(G-R*>J"U-*
]C&JZG9)Z1B.MEQ&$7)1-<9FV0TYY3POV8*Q_>/]-+,B,P(Q!H)MK4]F UT6 M#TNP34SA\]Z2+2+%#B&RXEF_V8^<3=RE*

M094]NCX;,?H$GJ5D08=A:0@D2Y%YPZRIM@7>T_TMYK(A)JK$8_L/#(F =C#@ MO=Z5X#C"27??05=.%>%/6:)N95)=?MSK MW_AN$WVW'^SZB?#H]9P(W>6IF#E18\%M1+K+\%W0' 'P"0G-6N8\EXXC>RZT ML?,Y'+*BQ2"ENF V, MY)2I8L_&>\#7GR? LWGGL DE 9$ P#6!!.EH$FMS5? 6]AH^A*AOK9"PID&9\ M5'UA,!63RC1/]%2B=1)KSYU\!=0
X>^29;2VA(;SK$'A#G%5AP"PE*8)8R<| MM[(_^||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end XML 85
amgn-20240930_htm.xml IDEA: XBRL DOCUMENT 0000318154 2024-01-012024-09-30 0000318154 us-gaap:CommonStockMember 2024-01-012024-09-30 0000318154 amgn:A2.00SeniorNotesDue2026Member 2024-01-012024-09-30 0000318154 2024-10-25 0000318154 us-gaap:ProductMember 2024-07-012024-09-30 0000318154 us-gaap:ProductMember 2023-07-012023-09-30 0000318154 us-gaap:ProductMember 2024-01-012024-09-30 0000318154 us-gaap:ProductMember 2023-01-012023-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2024-07-012024-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2023-07-012023-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2024-01-012024-09-30 0000318154 us-gaap:ProductAndServiceOtherMember 2023-01-012023-09-30 0000318154 2024-07-012024-09-30 0000318154 2023-07-012023-09-30 0000318154 2023-01-012023-09-30 0000318154 2024-09-30 0000318154 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000318154 2024-01-012024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0000318154 us-gaap:CommonStockMember 2024-01-012024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-01-012024-03-31 0000318154 us-gaap:CommonStockMember 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000318154 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000318154 2024-04-012024-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0000318154 us-gaap:CommonStockMember 2024-04-012024-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-04-012024-06-30 0000318154 us-gaap:CommonStockMember 2024-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-06-30 0000318154 us-gaap:RetainedEarningsMember 2024-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000318154 2024-06-30 0000318154 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000318154 us-gaap:CommonStockMember 2024-07-012024-09-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-07-012024-09-30 0000318154 us-gaap:CommonStockMember 2024-09-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-09-30 0000318154 us-gaap:RetainedEarningsMember 2024-09-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000318154 us-gaap:CommonStockMember 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000318154 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000318154 2023-01-012023-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0000318154 us-gaap:CommonStockMember 2023-01-012023-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-01-012023-03-31 0000318154 us-gaap:CommonStockMember 2023-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-03-31 0000318154 us-gaap:RetainedEarningsMember 2023-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000318154 2023-03-31 0000318154 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000318154 2023-04-012023-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0000318154 us-gaap:CommonStockMember 2023-04-012023-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-04-012023-06-30 0000318154 us-gaap:CommonStockMember 2023-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-06-30 0000318154 us-gaap:RetainedEarningsMember 2023-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000318154 2023-06-30 0000318154 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000318154 us-gaap:CommonStockMember 2023-07-012023-09-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-07-012023-09-30 0000318154 us-gaap:CommonStockMember 2023-09-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-09-30 0000318154 us-gaap:RetainedEarningsMember 2023-09-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000318154 2023-09-30 0000318154 amgn:HorizonTherapeuticsMember 2023-10-06 0000318154 amgn:HorizonTherapeuticsMember 2023-10-062023-10-06 0000318154 amgn:HorizonTherapeuticsMember 2024-01-012024-09-30 0000318154 amgn:HorizonTherapeuticsMemberus-gaap:DevelopedTechnologyRightsMember 2023-10-06 0000318154 amgn:HorizonTherapeuticsMemberus-gaap:DevelopedTechnologyRightsMember 2023-10-062023-10-06 0000318154 amgn:HorizonTherapeuticsMember 2023-07-012023-09-30 0000318154 amgn:HorizonTherapeuticsMember 2023-01-012023-09-30 0000318154 amgn:ProliaMembercountry:US 2024-07-012024-09-30 0000318154 amgn:ProliaMemberus-

gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:ProliaMember 2024-07-012024-09-30 0000318154 amgn:ProliaMembercountry:US 2023-07-012023-09-30 0000318154 amgn:ProliaMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:ProliaMember 2023-07-012023-09-30 0000318154 amgn:EnbrelMembercountry:US 2024-07-012024-09-30 0000318154 amgn:EnbrelMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:EnbrelMember 2024-07-012024-09-30 0000318154 amgn:EnbrelMembercountry:US 2023-07-012023-09-30 0000318154 amgn:EnbrelMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:EnbrelMember 2023-07-012023-09-30 0000318154 amgn:XgevaMembercountry:US 2024-07-012024-09-30 0000318154 amgn:XgevaMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:XgevaMember 2024-07-012024-09-30 0000318154 amgn:XgevaMembercountry:US 2023-07-012023-09-30 0000318154 amgn:XgevaMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:XgevaMember 2023-07-012023-09-30 0000318154 amgn:RepathaevolocumabMembercountry:US 2024-07-012024-09-30 0000318154 amgn:RepathaevolocumabMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:RepathaevolocumabMember 2024-07-012024-09-30 0000318154 amgn:RepathaevolocumabMembercountry:US 2023-07-012023-09-30 0000318154 amgn:RepathaevolocumabMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:RepathaevolocumabMember 2023-07-012023-09-30 0000318154 amgn:OtezlaMembercountry:US 2024-07-012024-09-30 0000318154 amgn:OtezlaMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:OtezlaMember 2024-07-012024-09-30 0000318154 amgn:OtezlaMembercountry:US 2023-07-012023-09-30 0000318154 amgn:OtezlaMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:OtezlaMember 2023-07-012023-09-30 0000318154 amgn:TEPEZZAMembercountry:US 2024-07-012024-09-30 0000318154 amgn:TEPEZZAMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:TEPEZZAMember 2024-07-012024-09-30 0000318154 amgn:TEPEZZAMembercountry:US 2023-07-012023-09-30 0000318154 amgn:TEPEZZAMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:TEPEZZAMember 2023-07-012023-09-30 0000318154 amgn:EVENITYMembercountry:US 2024-07-012024-09-30 0000318154 amgn:EVENITYMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:EVENITYMember 2024-07-012024-09-30 0000318154 amgn:EVENITYMembercountry:US 2023-07-012023-09-30 0000318154 amgn:EVENITYMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:EVENITYMember 2023-07-012023-09-30 0000318154 amgn:KyprolisMembercountry:US 2024-07-012024-09-30 0000318154 amgn:KyprolisMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:KyprolisMember 2024-07-012024-09-30 0000318154 amgn:KyprolisMembercountry:US 2023-07-012023-09-30 0000318154 amgn:KyprolisMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:KyprolisMember 2023-07-012023-09-30 0000318154 amgn:NplateMembercountry:US 2024-07-012024-09-30 0000318154 amgn:NplateMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:NplateMember 2024-07-012024-09-30 0000318154 amgn:NplateMembercountry:US 2023-07-012023-09-30 0000318154 amgn:NplateMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:NplateMember 2023-07-012023-09-30 0000318154 amgn:AranespMembercountry:US 2024-07-012024-09-30 0000318154 amgn:AranespMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:AranespMember 2024-07-012024-09-30 0000318154 amgn:AranespMembercountry:US 2023-07-012023-09-30 0000318154 amgn:AranespMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:AranespMember 2023-07-012023-09-30 0000318154 amgn:KRYSTEXXAMembercountry:US 2024-07-012024-09-30 0000318154 amgn:KRYSTEXXAMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:KRYSTEXXAMember 2024-07-012024-09-30 0000318154 amgn:KRYSTEXXAMembercountry:US 2023-07-012023-09-30 0000318154 amgn:KRYSTEXXAMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:KRYSTEXXAMember 2023-07-012023-09-30 0000318154 amgn:BLINCYTOMembercountry:US 2024-07-012024-09-30 0000318154 amgn:BLINCYTOMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:BLINCYTOMember 2024-07-012024-09-30 0000318154 amgn:BLINCYTOMembercountry:US 2023-07-012023-09-30 0000318154 amgn:BLINCYTOMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:BLINCYTOMember 2023-07-012023-09-30 0000318154 amgn:VectibixMembercountry:US 2024-07-012024-09-30 0000318154 amgn:VectibixMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:VectibixMember 2024-07-012024-09-30 0000318154 amgn:VectibixMembercountry:US 2023-07-012023-09-30 0000318154 amgn:VectibixMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:VectibixMember 2023-07-012023-09-30 0000318154 amgn:TEZSPIREMembercountry:US 2024-07-012024-09-30 0000318154 amgn:TEZSPIREMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:TEZSPIREMember 2024-07-012024-09-30 0000318154 amgn:TEZSPIREMembercountry:US 2023-07-012023-09-30 0000318154 amgn:TEZSPIREMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:TEZSPIREMember 2023-07-012023-09-30 0000318154 amgn:OtherProductsMembercountry:US 2024-07-012024-09-30 0000318154 amgn:OtherProductsMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 amgn:OtherProductsMember 2024-07-012024-09-30 0000318154 amgn:OtherProductsMembercountry:US 2023-07-012023-09-30 0000318154 amgn:OtherProductsMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:OtherProductsMember 2023-07-012023-09-30 0000318154 us-gaap:ProductMembercountry:US 2024-07-012024-09-30 0000318154 us-gaap:ProductMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000318154 us-gaap:ProductMembercountry:US 2023-07-012023-09-30 0000318154 us-gaap:ProductMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000318154 amgn:ProliaMembercountry:US 2024-01-012024-09-30 0000318154 amgn:ProliaMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:ProliaMember 2024-01-012024-09-30 0000318154 amgn:ProliaMembercountry:US 2023-01-012023-09-30 0000318154 amgn:ProliaMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:ProliaMember 2023-01-012023-09-30 0000318154 amgn:EnbrelMembercountry:US 2024-01-012024-09-30 0000318154 amgn:EnbrelMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:EnbrelMember 2024-01-012024-09-30 0000318154 amgn:EnbrelMembercountry:US 2023-01-012023-09-30 0000318154 amgn:EnbrelMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:EnbrelMember 2023-01-012023-09-30 0000318154 amgn:XgevaMembercountry:US 2024-01-012024-09-30 0000318154 amgn:XgevaMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:XgevaMember 2024-01-012024-09-30 0000318154 amgn:XgevaMembercountry:US 2023-01-012023-09-30 0000318154 amgn:XgevaMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:XgevaMember 2023-01-012023-09-30 0000318154 amgn:RepathaevolocumabMembercountry:US 2024-01-012024-09-30 0000318154 amgn:RepathaevolocumabMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:RepathaevolocumabMember 2024-01-012024-09-30 0000318154 amgn:RepathaevolocumabMembercountry:US 2023-01-012023-09-30 0000318154 amgn:RepathaevolocumabMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:RepathaevolocumabMember 2023-01-012023-09-30 0000318154 amgn:OtezlaMembercountry:US 2024-01-012024-09-30 0000318154 amgn:OtezlaMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:OtezlaMember 2024-01-012024-09-30 0000318154 amgn:OtezlaMembercountry:US 2023-01-012023-09-30 0000318154 amgn:OtezlaMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:OtezlaMember 2023-01-012023-09-30 0000318154 amgn:TEPEZZAMembercountry:US 2024-01-012024-09-30 0000318154 amgn:TEPEZZAMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:TEPEZZAMember 2024-01-012024-09-30 0000318154 amgn:TEPEZZAMembercountry:US 2023-01-012023-09-30 0000318154 amgn:TEPEZZAMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:TEPEZZAMember 2023-01-012023-09-30 0000318154 amgn:EVENITYMembercountry:US 2024-01-012024-09-30 0000318154 amgn:EVENITYMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:EVENITYMember 2024-01-012024-09-30 0000318154 amgn:EVENITYMembercountry:US 2023-01-012023-09-30 0000318154 amgn:EVENITYMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:EVENITYMember 2023-01-012023-09-30 0000318154 amgn:KyprolisMembercountry:US 2024-01-012024-09-30 0000318154 amgn:KyprolisMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:KyprolisMember 2024-01-012024-09-30 0000318154 amgn:KyprolisMembercountry:US 2023-01-012023-09-30 0000318154 amgn:KyprolisMemberus-gaap:NonUsMember 2023-01-

012023-09-30 0000318154 amgn:KyprolisMember 2023-01-012023-09-30 0000318154 amgn:NplateMembercountry:US 2024-01-012024-09-30 0000318154 amgn:NplateMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:NplateMember 2024-01-012024-09-30 0000318154 amgn:NplateMembercountry:US 2023-01-012023-09-30 0000318154 amgn:NplateMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:NplateMember 2023-01-012023-09-30 0000318154 amgn:AranespMembercountry:US 2024-01-012024-09-30 0000318154 amgn:AranespMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:AranespMember 2024-01-012024-09-30 0000318154 amgn:AranespMembercountry:US 2023-01-012023-09-30 0000318154 amgn:AranespMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:AranespMember 2023-01-012023-09-30 0000318154 amgn:KRYSTEXXAMembercountry:US 2024-01-012024-09-30 0000318154 amgn:KRYSTEXXAMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:KRYSTEXXAMember 2024-01-012024-09-30 0000318154 amgn:KRYSTEXXAMembercountry:US 2023-01-012023-09-30 0000318154 amgn:KRYSTEXXAMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:KRYSTEXXAMember 2023-01-012023-09-30 0000318154 amgn:BLINCYTOMembercountry:US 2024-01-012024-09-30 0000318154 amgn:BLINCYTOMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:BLINCYTOMember 2024-01-012024-09-30 0000318154 amgn:BLINCYTOMembercountry:US 2023-01-012023-09-30 0000318154 amgn:BLINCYTOMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:BLINCYTOMember 2023-01-012023-09-30 0000318154 amgn:VectibixMembercountry:US 2024-01-012024-09-30 0000318154 amgn:VectibixMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:VectibixMember 2024-01-012024-09-30 0000318154 amgn:VectibixMembercountry:US 2023-01-012023-09-30 0000318154 amgn:VectibixMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:VectibixMember 2023-01-012023-09-30 0000318154 amgn:TEZSPIREMembercountry:US 2024-01-012024-09-30 0000318154 amgn:TEZSPIREMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:TEZSPIREMember 2024-01-012024-09-30 0000318154 amgn:TEZSPIREMembercountry:US 2023-01-012023-09-30 0000318154 amgn:TEZSPIREMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:TEZSPIREMember 2023-01-012023-09-30 0000318154 amgn:OtherProductsMembercountry:US 2024-01-012024-09-30 0000318154 amgn:OtherProductsMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 amgn:OtherProductsMember 2024-01-012024-09-30 0000318154 amgn:OtherProductsMembercountry:US 2023-01-012023-09-30 0000318154 amgn:OtherProductsMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 amgn:OtherProductsMember 2023-01-012023-09-30 0000318154 us-gaap:ProductMembercountry:US 2024-01-012024-09-30 0000318154 us-gaap:ProductMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000318154 us-gaap:ProductMembercountry:US 2023-01-012023-09-30 0000318154 us-gaap:ProductMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000318154 us-gaap:DomesticCountryMember 2021-05-31 0000318154 us-gaap:DomesticCountryMemberamgn:TaxYears20102012Member 2021-05-31 0000318154 us-gaap:DomesticCountryMemberamgn:TaxYears20132015Member 2022-04-28 0000318154 us-gaap:DomesticCountryMember 2022-12-19 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0000318154 us-gaap:MoneyMarketFundsMember 2024-09-30 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2024-09-30 0000318154 us-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000318154 us-gaap:MoneyMarketFundsMember 2023-12-31 0000318154 amgn:OtherShortTermInterestBearingSecuritiesMember 2023-12-31 0000318154 amgn:AvailableForSalesInvestmentsMember 2024-09-30 0000318154 amgn:AvailableForSalesInvestmentsMember 2023-12-31 0000318154 amgn:BeiGeneMember 2024-09-30 0000318154 amgn:BeiGeneMember 2023-12-31 0000318154 us-gaap:OtherNoncurrentAssetsMemberamgn:BeiGeneMember 2024-09-30 0000318154 us-gaap:OtherNoncurrentAssetsMemberamgn:BeiGeneMember 2023-12-31 0000318154 amgn:BeiGeneMember 2024-07-012024-09-30 0000318154 amgn:BeiGeneMember 2023-07-012023-09-30 0000318154 amgn:BeiGeneMember 2024-01-012024-09-30 0000318154 amgn:BeiGeneMember 2023-01-012023-09-30 0000318154 srt:MaximumMemberamgn:BeiGeneMember 2023-09-30 0000318154 srt:MaximumMemberamgn:BeiGeneMember 2024-09-30 0000318154 us-gaap:OtherNoncurrentAssetsMember 2024-09-30 0000318154 us-gaap:OtherNoncurrentAssetsMember 2023-12-31 0000318154 amgn:NeumoraTherapeuticsIncMember 2024-09-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2023-12-31 0000318154 amgn:NeumoraTherapeuticsIncMember 2024-07-012024-09-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2023-07-012023-09-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2024-01-012024-09-30 0000318154 amgn:NeumoraTherapeuticsIncMember 2023-01-012023-09-30 0000318154 srt:MaximumMemberamgn:NeumoraTherapeuticsIncMember 2023-09-30 0000318154 srt:MinimumMemberamgn:NeumoraTherapeuticsIncMember 2023-09-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-09-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-12-31 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-01-012024-09-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-01-012023-09-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2023-07-012023-09-30 0000318154 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember 2024-07-012024-09-30 0000318154 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000318154 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000318154 us-gaap:LicensingAgreementsMember 2024-09-30 0000318154 us-gaap:LicensingAgreementsMember 2023-12-31 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2024-09-30 0000318154 us-gaap:MarketingRelatedIntangibleAssetsMember 2023-12-31 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2024-09-30 0000318154 amgn:AcquiredResearchAndDevelopmentTechnologyRightsMember 2023-12-31 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000318154 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000318154 amgn:A3.625NotesDueIn2024Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A3.625NotesDueIn2024Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A1.90NotesDue2025Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A1.90NotesDue2025Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A525NotesDue2025Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A525NotesDue2025Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TermLoanDueApril2025Memberus-gaap:SecuredDebtMember 2024-09-30 0000318154 amgn:TermLoanDueApril2025Memberus-gaap:SecuredDebtMember 2023-12-31 0000318154 amgn:A3.125NotesDue2025Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A3.125NotesDue2025Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A2.00NotesDue2026Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A2.00NotesDue2026Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A5507NotesDue2026Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A5507NotesDue2026Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointSixZeroNotesDueTwoZeroTwoSixMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TermLoanDueOctober2026Memberus-gaap:SecuredDebtMember 2024-09-30 0000318154 amgn:TermLoanDueOctober2026Memberus-gaap:SecuredDebtMember 2023-12-31 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointTwoZeroPercentNotesDueTwoZeroTwoSevenMemberus-

gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:ThreePointTwoZeroNotesDue2027Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:ThreePointTwoZeroNotesDue2027Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A515NotesDue2028Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A515NotesDue2028Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:OnePointSixFivePercent2028NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:OnePointSixFivePercent2028NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A3002029NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A3002029NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A4052029NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointFourFivePercentNotesDue2030Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A525NotesDue2030Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A525NotesDue2030Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointThreeZeroPercentNotesDue2031Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointZeroPercent2032NotesMemberMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointZeroPercent2032NotesMemberMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A3352032NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A3352032NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A4202033NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A525NotesDue2033Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A525NotesDue2033Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:SixPointThreeSevenFivePercentNotesDue2037Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:SixPointNineZeroPercentNotesDue2038Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:SixPointFourZeroPercentNotesDue2039Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:ThreePointOneFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FivePointSevenFivePercentNotesDue2040Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointEightZeroPercent2041NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointEightZeroPercent2041NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FourPointNineFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FivePointOneFivePercentNotesDue2041Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FivePointSixFivePercentNotesDue2042Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FivePointSixFivePercentNotesDue2042Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A560NotesDue2043Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A560NotesDue2043Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FivePointThreeSevenFivePercentNotesDue2043Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FourPointFourZeroPercentNotesDueTwoZeroFourFiveMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FourPointFiveSixThreePercentNotesDueTwoZeroFourEightMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:ThreePointThreeSevenFivePercentNotesDue2050Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:FourPointSixSixThreePercentNotesDueTwoZeroFiveOneMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A300NotesDue20523002052NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A300NotesDue20523002052NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A4202052NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A48752053NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A48752053NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A565NotesDue2053Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A565NotesDue2053Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:TwoPointSevenSevenPercentNotesDueTwoZeroFiveThreeMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A4402062NotesMemberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A4402062NotesMemberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:A575NotesDue2063Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:A575NotesDue2063Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 amgn:OtherNotesDue2097Memberus-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 amgn:OtherNotesDue2097Memberus-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 us-gaap:NotesPayableToBanksMember 2024-01-012024-09-30 0000318154 amgn:TermLoanDueApril2025Memberus-gaap:NotesPayableToBanksMember 2024-01-012024-09-30 0000318154 amgn:TermLoanDueOctober2026Memberus-gaap:NotesPayableToBanksMember 2024-01-012024-09-30 0000318154 amgn:A3.625NotesDueIn2024Memberus-gaap:NotesPayableToBanksMember 2024-01-012024-09-30 0000318154 2023-10-012023-12-31 0000318154 us-gaap:SubsequentEventMember 2024-10-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2023-12-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-03-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-03-31 0000318154

amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2024-01-012024-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2024-03-31 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-012024-06-30 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-012024-06-30 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2024-04-012024-06-30 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-30 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2024-06-30 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-012024-09-30 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2024-07-012024-09-30 0000318154 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000318154 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000318154 amgn:AccumulatedOtherAdjustmentAttributabletoParentMember 2024-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000318154 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000318154 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel3Memberamgn:OtherShortTermInterestBearingSecuritiesMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel1Member 2024-09-30 0000318154 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000318154 us-gaap:FairValueInputsLevel3Member 2024-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000318154 us-gaap:ForeignExchangeContractMember 2024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000318154 amgn:CrossCurrencySwapContractsMember 2024-09-30 0000318154 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0000318154 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0000318154 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0000318154 us-gaap:InterestRateSwapMember 2024-09-30 0000318154 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryBillSecuritiesMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel1Memberamgn:OtherShortTermInterestBearingSecuritiesMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel2Memberamgn:OtherShortTermInterestBearingSecuritiesMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel3Memberamgn:OtherShortTermInterestBearingSecuritiesMember 2023-12-31 0000318154 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000318154 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000318154 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000318154 us-gaap:ForeignExchangeContractMember 2023-12-31 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000318154

amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000318154 amgn:CrossCurrencySwapContractsMember 2023-12-31 0000318154 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000318154 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000318154 us-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000318154 us-gaap:InterestRateSwapMember 2023-12-31 0000318154 us-gaap:NotesPayableToBanksMember 2024-09-30 0000318154 us-gaap:NotesPayableToBanksMember 2023-12-31 0000318154 us-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 us-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:A2.00NotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 currency:EURamgn:A2.00NotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 currency:USDamgn:A2.00NotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 amgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 currency:GBPamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 currency:USDamgn:FivePointFiveZeroPercentPoundSterlingNotesDue2026Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 amgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 currency:GBPamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 currency:USDamgn:FourPercentPoundSterlingNotesDue2029Memberamgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2024-07-012024-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2023-07-012023-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2024-01-012024-09-30 0000318154 us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember 2023-01-012023-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-07-012024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2023-07-012023-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2024-01-012024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:CashFlowHedgingMember 2023-01-012023-09-30 0000318154 amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember 2024-07-012024-09-30 0000318154 amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember 2023-07-012023-09-30 0000318154 amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember 2024-01-012024-09-30 0000318154 amgn:ForwardInterestRateContractsMemberus-gaap:CashFlowHedgingMember 2023-01-012023-09-30 0000318154 us-gaap:CashFlowHedgingMember 2024-07-012024-09-30 0000318154 us-gaap:CashFlowHedgingMember 2023-07-012023-09-30 0000318154 us-gaap:CashFlowHedgingMember 2024-01-012024-09-30 0000318154 us-gaap:CashFlowHedgingMember 2023-01-012023-09-30 0000318154 us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 us-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:A3.625NotesDueIn2024Memberus-gaap:InterestRateSwapMember 2024-09-30 0000318154 amgn:A525NotesDue2033Memberus-gaap:InterestRateSwapMember 2024-09-30 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2024-09-30 0000318154 amgn:LongTermDebtCurrentMaturitiesMember 2023-12-31 0000318154 us-gaap:LongTermDebtMember 2024-09-30 0000318154 us-gaap:LongTermDebtMember 2023-12-31 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-012024-09-30 0000318154 us-gaap:InterestRateSwapMember 2024-07-012024-09-30 0000318154 us-gaap:InterestRateSwapMember 2024-01-012024-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000318154 us-gaap:ProductMemberus-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000318154 amgn:CrossCurrencySwapContractsMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-012023-09-30 0000318154 us-gaap:InterestRateSwapMember 2023-07-012023-09-30 0000318154 us-gaap:InterestRateSwapMember 2023-01-012023-09-30 0000318154 us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember 2024-09-30 0000318154 us-gaap:ForwardContractsMemberus-gaap:NondesignatedMember 2023-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 amgn:OtherCurrentNoncurrentAssetsMemberamgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberamgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 amgn:OtherCurrentNoncurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000318154 amgn:OtherCurrentNoncurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMemberamgn:CrossCurrencySwapContractsMemberus-

gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberamgn:CrossCurrencySwapContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:OtherCurrentNoncurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 amgn:AccruedLiabilitiesOtherNonCurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000318154 us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 shares iso4217:USD iso4217:USD shares amgn:segment amgn:Segment pure amgn:notice amgn:case iso4217:EUR iso4217:GBP0000318154false2024Q3--12-31http://fasb.org/srt/2024#PartnershipInterestMemberhttp://fasb.org/srt/2024#PartnershipInterestMember10-Qtrue2024-09-30false001-37702Amgen Inc.DE95-3540776One Amgen Center Drive91320-1799Thousand OaksCA805447-1000Common stock, $0.0001 par valueAMGNNASDAQ2.00% Senior Notes due 2026AMGN26NASDAQYesYesLarge Accelerated Filerfalsefalsefalse53753272381510000006548000000233100000001907700000035200000035500000010280000009170000008440000032000000-5000000-25300000018100000-76000000730000001000000170000000-300000037000000-181000000154000000-470000001050000002649000000188400000034160000006055000000901100000010944000000731700000072680000007362000000.00010.000127500000002750000005354000033393000000330700000000-25530000000-26549000000-336000000-289000000752700000062320000009088300000097154000000535400000330700000000-26549000000-289000000623200000-113000000-113000000990000009900000002.25120800000012080000001000000.03400000034000000103000000103000000125000000125627870000000-190000000502200000074600000074600000035000000350000008000000650000006500000015700000015700000010000000016271240000000-155000000592500000028300000002830000000-181000000-1810000002.25123600000012360000003000006700000067000000136000000136000000140000001400000053750000033393000025530000000-33600000075270000005340000000.032514000000-28622000000-231000000366100000028410000002841000000-37000000-370000002.13113800000011380000003000001100000011000000470000004700000037000000370000005343000003253500000026919000000-26800000053480000001379000000137900000-12000000-120000006000001600000016000000119000000119000000690000006900000053490000032601000000-25540000000-28000000067810000001730000000173000000015400000015400000002.13116100000011610000002000003300000033000000124971000000-12600000076560000003463000005950000000419500000026910000003960000002700000000-894000000-650000000110000001700000071700000013040000000-1000000-57900000032000000582000000-220900000008200000063800000033200000054400000000-215000000-106400000009980000000-561000000293000000-636000000690000005360000004150000000-72000000-150000000671900000079330000000112500000000550000000072500000008630000000-81000000-73000000-64400000088500000000237810000006590000000550000000360000000001454000000362700000003416000000-122000000-67000000-800800000001829400000000-193300000002711200000001094400000007629000000090110000003474100000000Summary of significant accounting policies Business Amgen Inc. (including its consolidated subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. Basis of presentation The interim unaudited financial information for the three and nine months ended September 30, 2024 and 2023, has been prepared in accordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) that Amgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with the current presentation. Use of estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $10.3 billion and $9.8 billion as of September 30, 2024 and December 31, 2023, respectively. Recent accounting pronouncements In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure

requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or may elect retrospective application. We are currently evaluating the impact of adopting this new standard on our related disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted, and the standard requires retrospective application to all prior periods presented. We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements. Business Amgen Inc. (including its consolidated subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) is a global biotechnology pioneer that discovers, develops, manufactures and delivers innovative human therapeutics. We operate in one business segment: human therapeutics. 1 Basis of presentation The interim unaudited financial information for the three and nine months ended September 30, 2024 and 2023, has been prepared in accordance with GAAP and includes all adjustments (consisting of only normal, recurring adjustments unless otherwise indicated) that Amgen considers necessary for a fair presentation, in all material respects, of its condensed consolidated results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year. The condensed consolidated financial statements should be read in conjunction with our consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2023, and with our condensed consolidated financial statements and the notes thereto contained in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024. Principles of consolidation The condensed consolidated financial statements include the accounts of Amgen as well as its majority-owned subsidiaries. In determining whether we are the primary beneficiary of a variable interest entity, we consider whether we have both the power to direct activities of the entity that most significantly impact the entity’s economic performance and the obligation to absorb losses of or the right to receive benefits from the entity that could potentially be significant to that entity. We do not have any significant interests in any variable interest entities of which we are the primary beneficiary. All material intercompany transactions and balances have been eliminated in consolidation. Certain reclassifications have been made to prior periods in the condensed consolidated financial statements and accompanying notes to conform with the current presentation. Use of estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may differ from those estimates. Property, plant and equipment, net Property, plant and equipment is recorded at historical cost, net of accumulated depreciation and amortization, of $10.3 billion and $9.8 billion as of September 30, 2024 and December 31, 2023, respectively. 10300000000098000000000 Recent accounting pronouncements In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve income tax disclosure requirements by requiring more detailed information on several income tax disclosures, such as enhancing disclosure of income taxes paid and requiring disaggregation of the effective income tax rate reconciliation. The standard is effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted, and entities may apply the standard prospectively or may elect retrospective application. We are currently evaluating the impact of adopting this new standard on our related disclosures. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improving Reportable Segment Disclosures, to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses and additional interim segment reporting disclosures, including for companies with a single reportable segment. The standard is effective for public business entities for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. Early adoption is permitted, and the standard requires retrospective application to all prior periods presented. We expect the adoption of this new standard to result in incremental disclosures to the notes to our financial statements. Acquisitions Acquisition of Horizon Therapeutics plc On October 6, 2023, Amgen completed its acquisition of Horizon by acquiring all of the outstanding shares of Horizon for $116.50 per share in cash, representing a total consideration of approximately $27.8 billion. Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs of patients impacted by rare, autoimmune and severe inflammatory

diseases. The acquisition, which was accounted for as a business combination, aligns with Amgen's core strategy of delivering innovative medicines that make a significant difference for patients suffering from serious diseases and strengthens Amgen's leading rare disease portfolio by adding first-in-class, early-in-lifecycle medicines, including TEPEZZA for thyroid eye disease, KRYSTEXXA for chronic refractory gout and UPLIZNA for neuromyelitis optica spectrum disorder. Upon its acquisition, Horizon became a wholly owned subsidiary of Amgen, and its operations have been included in our consolidated financial statements commencing on the acquisition date. During the nine months ended September 30, 2024, the purchase price allocation of the acquisition was completed and measurement period adjustments were finalized, which included changes to the purchase price allocation that resulted in a net increase of approximately $25 million to goodwill. The measurement period adjustments resulted primarily from adjustments to acquired assets and liabilities, including deferred tax attributes, based on facts and circumstances that existed as of the acquisition date and did not result from events subsequent to the acquisition date. The adjustments did not have a significant impact on Amgen's results of operations during the nine months ended September 30, 2024, and would not have had a significant impact on prior period results if the adjustments had been made as of the acquisition date.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions):</div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Inventories</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,014 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Finite-lived intangible assets – developed-product-technology rights</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">IPR&D</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,060 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Goodwill</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,136 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Deferred tax asset</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">795 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Deferred tax liability</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,488) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other assets and liabilities, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(273) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Total assets acquired, net of liabilities assumed </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27,833 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The $27.8 billion total consideration for this transaction consisted of (i) cash consideration transferred to common shareholders of $26.7 billion; (ii) cash consideration transferred to vested and outstanding stock options, outstanding restricted stock unit (RSU) awards and outstanding performance stock unit (PSU) awards of $523 million; (iii) the fair value of Amgen replacement awards (based on conversion of outstanding employee RSU awards) of $180 million representing noncash consideration; and (iv) a portion of Horizon's debt, settled by Amgen on the acquisition closing date, of $382 million. Amgen issued 1.7 million replacement equity awards with the original vesting conditions, the fair value of which was determined based on the acquisition date fair value based on the conversion calculation. The estimated fair values of $20.7 billion for the developed-product-technology rights and IPR&D intangible assets were determined using a multi-period excess earnings income approach that discounts expected future cash flows to present value by applying a discount rate that represents the estimated rate that market participants would use to value the intangible assets. The projected cash flows were based on certain assumptions attributable to the respective intangible asset, including estimates of future revenues and expenses, the time and resources needed to complete development and the probabilities of obtaining marketing approval from the FDA and other regulatory agencies. The developed-product-technology rights are being amortized on a straight-line basis over a weighted-average period of approximately 10 years from the acquisition date using the straight-line methodology. The estimated fair value of the acquired inventory of $5.0 billion was determined using the comparative sales method, which uses actual or expected selling prices of inventory as the base amount to which adjustments for selling effort and a profit on the buyer's effort are applied. The inventory fair value adjustment is being amortized using a weighted-average inventory turnover, which we estimate to approximate 27 months from the acquisition date. A deferred tax liability of $2.5 billion was recognized on the temporary differences related to the book bases and tax bases of the acquired identifiable assets and assumed liabilities, primarily driven by the intangible assets acquired, as well as an associated deferred tax asset for anticipatory foreign tax credits of $795 million. The excess of the acquisition date consideration over the fair values assigned to the assets acquired and the liabilities assumed of $3.1 billion was recorded as goodwill, which is not deductible for tax purposes. The goodwill value represents expected synergies from the marketed products acquired and other benefits.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">Supplemental Pro Forma Financial Information</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the three and nine months ended September 30, 2023, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions):</div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Total revenues</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,854 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,728 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">902 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,518 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The unaudited supplemental pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical

financial information of Amgen and Horizon. In order to reflect the occurrence of the acquisition on January 1, 2022, the unaudited supplemental pro forma financial information includes adjustments to reflect the following: (i) incremental amortization expense based on the fair values of the identifiable intangible assets and inventory step-up; (ii) the additional interest expense associated with the issuance of debt to finance the acquisition; and (iii) the income tax impact using an estimated effective tax rate applied to the combined entity. The unaudited supplemental pro forma financial information is not necessarily indicative of what the condensed consolidated results of operations would have been had the acquisition been completed on January 1, 2022. In addition, the unaudited supplemental pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition. 116.50278000000002500000 The following table summarizes the final total consideration and allocated acquisition date fair values of assets acquired and liabilities assumed, inclusive of measurement period adjustments (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">681 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom">Inventories</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,014 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">318 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Finite-lived intangible assets – developed-product-technology rights</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">IPR&D</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,060 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Goodwill</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,136 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Deferred tax asset</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">795 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Deferred tax liability</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2,488) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other assets and liabilities, net</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(273) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt">Total assets acquired, net of liabilities assumed</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27,833 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6810000000501400000003180000001959000000001060000000031360000007950000002488000000-

273000000278330000002780000000026700000000523000000180000000382000000170000020700000000P10Y5000000000P2
style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The following table presents the unaudited supplemental pro forma results of a hypothetical combined Amgen and Horizon entity for the three and nine months ended September 30, 2023, as if the acquisition of Horizon had occurred on January 1, 2022 (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Total revenues </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,854 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">22,728 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">902 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,518 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 7854000000227280000009020000003518000000Revenues We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers' locations, are presented below. The majority of ROW revenues relates to products sold in Europe. Revenues were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt

*solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prolia</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">683 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">362 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,045 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">313 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">986 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ENBREL</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">817 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">825 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,026 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">XGEVA</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">168 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">541 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">374 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 *

</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">519 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Repatha</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">281 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">567 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">183 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Otezla</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">460 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">564 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">462 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">567 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEPEZZA(1) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">482 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">EVENITY</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">289 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">214 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">307 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">KYPROLIS</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">378 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">231 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">349 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Nplate</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">345 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">456 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">322 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">419 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Aranesp</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">337 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> KRYSTEXXA(1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLINCYTO</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">327 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">220 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vectibix</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">282 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">252 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEZSPIRE(2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other products(3) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">958 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,363 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">675 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">329 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,004 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total product sales(4) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,979 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,172 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,151 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,691 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,857 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,548 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other

revenues</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">352 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">355 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,503 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,903 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td>

<td colspan="3" style="display:none"></td>

<td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prolia</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,110 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,099 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,209 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,987 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">954 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,941 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ENBREL</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2,280</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">21</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,301 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2,645</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">37</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,682 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px

1pt;text-align:left;vertical-align:bottom">XGEVA</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,138</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">526</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,664 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,145</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">440</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,585 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Repatha</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">824</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">792</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,616 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">592</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">626</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Otezla</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,185</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">317</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,502 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,251</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">308</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,559 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEPEZZA(1) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,379</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">12</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,391 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">806</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">326</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,132 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">570</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">272</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">842 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">KYPROLIS</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">712</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">419</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,131 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">699</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">354</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,053 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Nplate</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">749</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">370</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,119 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">744</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">347</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,091 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Aranesp</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">296</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">738</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,034 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">345</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">698</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> KRYSTEXXA(1) </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-

color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">839</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">839 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLINCYTO</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">555</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">280</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">835 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">418</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">202</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">620 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vectibix</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">385</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">414</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">799 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">345</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">388</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEZSPIRE(2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">676</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">676 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">390</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">390 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">Other products(3) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,858 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,204</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,062 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,271 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,049</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,320 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total product sales(4) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,792 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,518 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,310 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,402 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,675 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,077 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,028 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">917 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">24,338 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,994 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>_____ </div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.</div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(2) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.</div><div style="margin-bottom:8pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(3) Consists of product sales of our non-principal products.</div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt">(4) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2024 and 2023.</div>1<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">Revenues were as follows (in millions):</div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.154%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prolia</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">683 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">362 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">

$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,045 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">673 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">313 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">986 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ENBREL</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">817 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">825 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,026 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,035 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">XGEVA</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">168 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">374 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">519 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Repatha</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">281 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">286 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">567 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">183 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">223 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">406 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Otezla</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">460 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">564 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">462 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">567 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEPEZZA(1) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">482 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">488 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">EVENITY</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">289 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">214 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">93 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">307 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-

align:left;vertical-align:bottom">KYPROLIS</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">378 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">231 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">349 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Nplate</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">345 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">456 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">322 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">419 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Aranesp</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">105 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">232 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">337 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">216 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">323 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> KRYSTEXXA(1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">310 </td><td style="background-

color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLINCYTO</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">237 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">327 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">220 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vectibix</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">282 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">136 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">252 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEZSPIRE(2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">269 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">161

</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other products(3) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">958 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,363 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">675 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">329 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,004 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total product sales(4) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5,979 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,172 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,151 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4,691 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,857 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,548 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">352 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">355 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td>

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,503 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,903 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

*colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td>

***style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">ROW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prolia</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,110 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,099 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,209 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,987 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">954 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,941 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">ENBREL</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2,280</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">21</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,301 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2,645</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">37</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,682 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">XGEVA</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,138</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">526</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,664 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,145</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">440</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">1,585 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Repatha</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">824</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">792</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,616 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">592</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">626</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Otezla</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,185</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">317</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,502 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,251</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">308</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,559 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEPEZZA(1) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,379</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">12</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,391 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">EVENITY</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">806</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">326</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,132 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">570</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">272</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">842

</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">KYPROLIS</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">712</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">419</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,131 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">699</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">354</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,053 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Nplate</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">749</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">370</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,119 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">744</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">347</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,091 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Aranesp</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">296</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">738</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,034 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">345</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">698</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,043 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> KRYSTEXXA(1) </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:right;vertical-align:bottom">839</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">839 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">BLINCYTO</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">555</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">280</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">835 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">418</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">202</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">620 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vectibix</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">385</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">414</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">799 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">345</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">388</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">733 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> TEZSPIRE(2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">676</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">676 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">390</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">390 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other products(3) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,858 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1,204</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,062 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,271 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,320 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total product sales(4) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,792 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,518 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,310 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13,402 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,675 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19,077 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other revenues</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,028 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">917 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total revenues</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,338 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,994 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>_____ (1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.

(2) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States. (3) Consists of product sales of our non-principal products. (4) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2024 and 2023. 6830000003620000001045000000673000000313000000986000000817000000800000008250000001026000000900000001

taxes The effective tax rates for the three and nine months ended September 30, 2024, were 8.7% and 9.5%, respectively, compared with 11.1% and 15.0%, respectively, for the corresponding periods in the prior year. The decrease in our effective tax rate for the three months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets), partially offset by the quarter-to-date unrealized gains on our strategic equity investments (primarily BeiGene). See Note 6, Investments—BeiGene, Ltd. The decrease in our effective tax rate for the nine months ended September 30, 2024, was primarily due to the earnings mix as a result of the inclusion of the Horizon business (including the amortization of Horizon acquired assets). The effective tax rates differ from the federal statutory rate primarily due to the impact of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from locations where the Company has significant manufacturing operations, including Singapore, Ireland and Puerto Rico, a territory of the United States that is treated as a foreign jurisdiction for U.S. tax purposes. Our operations in Puerto Rico are subject to a tax incentive grant through 2050. Additionally, the Company's operations conducted in Singapore are subject to a tax incentive grant through 2036. Our foreign earnings are also subject to U.S. tax at a reduced rate of 10.5%. Additionally, effective January 1, 2024, selected individual countries, including the United Kingdom and EU member countries, have enacted the global minimum tax agreement. Our legal entities in such countries, along with their direct and indirect subsidiaries, are now subject to a 15% minimum tax rate on adjusted financial statement income. Beginning on January 1, 2023, we were no longer subject to a 4% excise tax in the U.S. territory of Puerto Rico on the gross intercompany purchase price of goods and services from our manufacturer in Puerto Rico. We qualify for and are subject to the alternative income tax rate on industrial development income of our Puerto Rico affiliate. In the United States, this income tax qualifies for foreign tax credits. Both this income tax and the associated foreign tax credits are generally recognized in our provision for income taxes. We accounted for the 2022 excise tax that was capitalized in Inventories as an expense in Cost of sales when the related products were sold in the first half of 2023, and a foreign tax credit was not recognized with respect to the excise tax expense in 2023. We do not have this excise tax exposure in 2024. One or more of our legal entities file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. Our income tax returns are routinely examined by tax authorities in those jurisdictions. Significant disputes can and have arisen with tax authorities involving issues regarding the timing and amount of deductions, the use of tax credits and allocations of income and expenses among various tax jurisdictions because of differing interpretations of tax laws, regulations and relevant facts. Tax authorities, including the IRS, are becoming more aggressive and are particularly focused on such matters. In 2017, we received an RAR and a modified RAR from the IRS for the years 2010–2012, proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2021, we filed a petition in the U.S. Tax Court to contest two duplicate Statutory Notices of Deficiency (Notices) for the years 2010-2012 that we received in May and July 2021, which seek to increase our U.S. taxable income for the years 2010-2012 by an amount that would result in additional federal tax of approximately $3.6 billion, plus interest. Any additional tax that could be imposed for the years 2010-2012 would be reduced by up to approximately $900 million of repatriation tax previously accrued on our foreign earnings. In 2020, we received an RAR and a modified RAR from the IRS for the years 2013-2015, also proposing significant adjustments that primarily relate to the allocation of profits between certain of our entities in the United States and the U.S. territory of Puerto Rico similar to those proposed for the years 2010–2012. We disagreed with the proposed adjustments and calculations and pursued resolution with the IRS appeals office but were unable to reach resolution. In July 2022, we filed a petition in the U.S. Tax Court to contest a Notice for the years 2013–2015 that we previously reported receiving in April 2022 that seeks to increase our U.S. taxable income for the years 2013–2015 by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest. In addition, the Notice asserts penalties of approximately $2.0 billion. Any additional tax that could be imposed for the years 2013–2015 would be reduced by up to approximately $2.2 billion of repatriation tax previously accrued on our foreign earnings. We firmly believe that the IRS positions set forth in the 2010–2012 and 2013–2015 Notices are without merit. We are contesting the 2010–2012 and 2013–2015 Notices through the judicial process. The two cases were consolidated in the U.S. Tax Court on December 19, 2022. The trial is currently scheduled to begin on November 4, 2024. We are currently under examination by the IRS for the years 2016–2018 with respect to issues similar to those for the 2010 through 2015 period. In addition, we are under examination by a number of state and foreign tax jurisdictions. Final resolution of these complex matters is not likely within the next 12 months. We continue to believe our accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, application of the tax law to our facts and judgments about potential actions by tax authorities; however, due to the complexity of the provision for income taxes and uncertain resolution of these matters, the ultimate outcome of any tax matters may result in payments substantially greater than amounts accrued and could have a material adverse impact on our condensed

consolidated financial statements. During the three and nine months ended September 30, 2024, the gross amounts of our UTBs increased by $40 million and $120 million, respectively, as a result of tax positions taken during the current year. Substantially all of the UTBs as of September 30, 2024, if recognized, would affect our effective tax rate.</div>0.0870.0950.1110.150236000000000900000000510000000020000000002200000000024000000012000000Earnings per share<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The computation of basic EPS is based on the weighted-average number of our common shares outstanding. The computation of diluted EPS is based on the weighted-average number of our common shares outstanding and dilutive potential common shares, which primarily include shares that may be issued under our stock option, restricted stock and performance unit award programs (collectively, dilutive securities), as determined by using the treasury stock method.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The computations for basic and diluted EPS were as follows (in millions, except per-share data):</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Income (Numerator):</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Net income for basic and diluted EPS</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,830 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,730 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,463 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,950 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Shares (Denominator):</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td>

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Weighted-average shares for basic EPS</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">535 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">535 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Effect of dilutive securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Weighted-average shares for diluted EPS</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">542 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">538 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">541 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">538 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Basic EPS</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">5.27 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">3.23 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6.45 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Diluted EPS</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-

align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5.22 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.22 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6.40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.06 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the three and nine months ended September 30, 2024 and 2023, the number of antidilutive employee stock-based awards excluded from the computation of diluted EPS was not significant. The computations for basic and diluted EPS were as follows (in millions, except per-share data): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Income (Numerator):</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Net income for basic and diluted EPS</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,830 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,730 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3,463 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,950 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Shares (Denominator):</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Weighted-average shares for basic EPS</td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">535 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">537 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">535 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Effect of dilutive securities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Weighted-average shares for diluted EPS</td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">542 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">538 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">541 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">538 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Basic EPS</td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">5.27 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">3.23 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">6.45 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.12 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Diluted EPS</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5.22 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.22 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">6.40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.06 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
2830000000017300000003463000000595000000053700000053500000005370000005350000005000000300000004000000360000003

style="margin-bottom:8pt;text-align:justify">Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Types of securities as of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair
values</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid

#000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total interest-bearing securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">

— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Types of securities as of December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair
values</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total interest-bearing securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td

style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Condensed Consolidated Balance Sheets locations</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total interest-bearing securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Cash and cash equivalents in the above table excludes bank account cash of $435 million and $540 million as of September 30, 2024 and December 31, 2023, respectively. All interest-bearing securities as of September 30, 2024 and December 31, 2023, mature in one year or less. For the three and nine months ended September 30, 2024 and 2023, realized gains and losses on interest-bearing securities were not material. Realized gains and losses on interest-bearing securities are recorded in Other income, net, in the Condensed Consolidated Statements of Income. The cost of securities sold is based on the specific-identification method. The primary objective of our investment portfolio is to maintain safety of principal, prudent levels of liquidity and acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. Equity securities BeiGene, Ltd. Our ownership interest in BeiGene was approximately 18% as of both September 30, 2024 and December 31, 2023, and the fair values of our investment were $4.3 billion and $3.4 billion, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. In the first quarter of 2023, we began to account for our ownership interest as an equity security with a readily determinable fair value, with changes in fair value recorded in Other income, net, in our Condensed Consolidated Statements of Income. See Note 11, Fair value measurement. During the three months ended September 30, 2024 and 2023, we recognized unrealized gains of $1.6 billion and $30 million, respectively, recorded in Other income, net, in our Condensed Consolidated Statements of Income. During the nine months ended September 30, 2024 and 2023, we recognized unrealized gains of $836 million and $1.2 billion, respectively, recorded in Other income, net, in our Condensed Consolidated Statements of Income. Subject to certain exceptions or otherwise agreed to by BeiGene, while Amgen holds at least 5.0% of BeiGene's outstanding common stock, (A) we may only sell our BeiGene equity investment via: (i) a registered public offering, (ii) a sale under Rule 144 of the Securities Act of 1933 (the "Securities Act") or (iii) a private sale exempt from registration requirements under the Securities Act, and (B) we may not sell more than 5.0% of BeiGene's outstanding common stock in any rolling 12-month period. Other equity securities Excluding our equity investments in BeiGene (discussed above) and Neumora (discussed below), we held investments in other equity securities with readily determinable fair values (publicly traded securities) of $336 million and $494 million as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in

*the Condensed Consolidated Balance Sheets. During the three and nine months ended September 30, 2024 and 2023, net unrealized gains and losses on these publicly traded securities were not material. Additionally, net realized gains and losses on sales of publicly traded securities for the three and nine months ended September 30, 2024 and 2023, were not material. We held investments of $318 million and $309 million in equity securities without readily determinable fair values as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. During the three and nine months ended September 30, 2024 and 2023, upward and downward adjustments on these securities were not material. Adjustments were based on observable price transactions. Net realized gains and losses on sales of securities without readily determinable fair values for the three and nine months ended September 30, 2024 and 2023, were not material. Equity method investments Neumora Therapeutics, Inc. As of September 30, 2024 and December 31, 2023, our ownership interests in Neumora were approximately 22.1% and 23.2%, respectively, and the fair values of our investment were $467 million and $603 million, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. Although our equity investment qualifies us for the equity method of accounting, we have elected the fair value option to account for our investment. Under the fair value option, changes in the fair value of the investment are recognized through earnings in Other income, net, in our Condensed Consolidated Statements of Income each reporting period. See Note 11, Fair value measurement. We believe the fair value option best reflects the economics of the underlying transaction. During the three months ended September 30, 2024 and 2023, we recognized unrealized gains of $119 million and $153 million, respectively, and during the nine months ended September 30, 2024 and 2023, we recognized $136 million of unrealized losses and $134 million of unrealized gains, respectively. We are contractually restricted from selling more than 5.0% of Neumora's outstanding common stock in any rolling 12-month period for as long as we hold at least 10.0% of their outstanding common stock, subject to certain exceptions or otherwise agreed to by Neumora. Limited partnerships We held limited partnership investments of $272 million and $251 million as of September 30, 2024 and December 31, 2023, respectively, which are included in Other noncurrent assets in the Condensed Consolidated Balance Sheets. These investments, primarily investment funds of early-stage biotechnology companies, are accounted for by using the equity method of accounting and are measured by using our proportionate share of the net asset values of the underlying investments held by the limited partnerships as a practical expedient. These investments are typically redeemable only through distributions upon liquidation of the underlying assets. As of September 30, 2024, unfunded additional commitments to be made for these investments during the next several years amounted to $139 million. For the three and nine months ended September 30, 2024 and 2023, net unrealized gains and losses from our limited partnership investments were not material.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The amortized cost, gross unrealized gains, gross unrealized losses and fair values of interest-bearing securities, which are considered available-for-sale, by type of security were as follows (in millions):</div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Types of securities as of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair
values</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— *

</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total interest-bearing securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Types of securities as of December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair
values</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total interest-bearing securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">10,404 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
9960000000099600000074370000000074370000001430000000014300000085760000000008576000000000010266000000
style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The fair values of interest-bearing securities by location in the Condensed Consolidated Balance Sheets were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Condensed Consolidated Balance Sheets locations</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total interest-bearing securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8,576 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,404 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
85760000001040400000085760000001040400000043500000054000000000.180.184300000000340000000016000000003(
1360000001340000000.0500.100272000000251000000139000000000000Inventories Inventories consisted of the following (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">788 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">993 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Work in process</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,339 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2"

style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,747 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,235 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,778 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top">Total inventories</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,362 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,518 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Inventories consisted of the following (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Raw materials</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">788 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">993 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Work in process</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,339 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,747 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finished goods</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,235 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,778 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top">Total inventories</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,362 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">9,518 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
* 788000000099300000043390000005747000000223500000002778000000736200000009518000000Goodwill and other intangible assets <span style="color:#000000;font-family:'Times New*

Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill The change in the carrying amount of goodwill was as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance at January 1, 2024 </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">18,629 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt">Adjustments to goodwill resulting from acquisitions (1)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt">Foreign currency translation adjustments</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance at September 30, 2024</div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,658 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) For the nine months ended September 30, 2024, adjustments to goodwill consisted of measurement period adjustments related to our Horizon acquisition. See Note 2, Acquisitions. Other intangible assets Other intangible assets consisted of the following (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
carrying
amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other intangible
assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
carrying
amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other intangible
assets, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed-product-technology rights</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48,636 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(21,472) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27,164 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48,631 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(18,049) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">30,582 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Licensing rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,864 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,360)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">504 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,865 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,265)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Marketing-related rights</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,203 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,188) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,339 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td

colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,264)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Research and development technology rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,400 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,253)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,394 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,228)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total finite-lived intangible assets</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,103 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,273)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,830 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,229 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23,806)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,423 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived intangible assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">In-process research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,090 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,090 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total other intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,193 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(27,273)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28,920 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,447 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(23,806)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,641 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Developed-product-technology rights consists of rights related to marketed products. Licensing rights primarily consists of contractual rights to receive future milestone, royalty and profit-sharing payments; capitalized payments to third parties for milestones related to regulatory approvals to commercialize products; and upfront payments associated with royalty obligations for marketed products. Marketing-related rights primarily consists of rights related to the sale and distribution of marketed products. R&D technology rights pertain to technologies used in R&D that have alternative future uses. IPR&D consists of R&D projects acquired in a business combination that are not complete at the time of acquisition due to remaining technological risks and/or lack of receipt of required regulatory approvals. We review IPR&D projects for impairment annually, whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable and upon the establishment of technological feasibility or regulatory approval. During the three months ended September 30, 2024 and 2023, we recognized amortization associated with our finite-lived intangible assets of $1.2 billion and $693 million, respectively. During the nine months ended September 30, 2024 and 2023, we recognized amortization associated with our finite-lived intangible assets of $3.6 billion and $2.1 billion, respectively. Amortization of intangible assets is primarily included in Cost of sales in the Condensed Consolidated Statements of Income. As of September 30, 2024, the total estimated amortization of our finite-lived intangible assets for the remaining three months ending December 31, 2024, and the years ending December 31, 2025, 2026, 2027, 2028 and 2029, are $1.2 billion, $4.5 billion, $3.9 billion, $3.9 billion, $2.9 billion and $2.2 billion, respectively.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The change in the carrying amount of goodwill was as follows (in millions):</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.331%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Balance at January 1, 2024</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">18,629 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Adjustments to goodwill resulting from acquisitions (1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Foreign currency translation adjustments </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance at September 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18,658 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt">_____ </div><div style="margin-bottom:8pt;padding-left:13.5pt;text-indent:-13.5pt">(1) For the nine months ended September 30, 2024, adjustments to goodwill consisted of measurement period adjustments related to our Horizon acquisition. See Note 2, Acquisitions.</div>18629000000250000004000000018658000000<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">Other intangible assets consisted of the following (in millions):</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
carrying
amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other intangible
assets, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
carrying
amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other intangible
assets, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Finite-lived intangible assets:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Developed-product-technology rights</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,636 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(21,472)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27,164 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">48,631 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(18,049) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">30,582 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Licensing rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,864 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,360)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">504 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,865 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,265)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Marketing-related rights</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,203 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,188) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,339 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,264) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">75 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Research and development technology rights</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,400 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,253) </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,394 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,228) </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total finite-lived intangible assets</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,103 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(27,273)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27,830 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">55,229 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23,806)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31,423 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived intangible assets:</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">In-process research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,090 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,090 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,218 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Total other intangible assets</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,193 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(27,273)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28,920 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,447 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(23,806)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32,641 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
4863600000021472000000271640000004863100000018049000000305820000000386400000033600000005040000003865
arrangements Our borrowings consisted of the following (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.625% notes due 2024 (3.625% 2024 Notes) </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,400 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.90% notes due 2025 (1.90% 2025 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% notes due 2025 (5.25% 2025 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-

align:bottom">Term loan due April 2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.125% notes due 2025 (3.125% 2025 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">835 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">828 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.507% notes due 2026 (5.507% 2026 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.60% notes due 2026 (2.60% 2026 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Term loan due October 2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">635 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">605 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.20% notes due 2027 (2.20% 2027 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.20% notes due 2027 (3.20% 2027 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.15% notes due 2028 (5.15% 2028 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.65% notes due 2028 (1.65% 2028 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.00% notes due 2029 (3.00% 2029 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.05% notes due 2029 (4.05% 2029 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">936 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">892 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.45% notes due 2030 (2.45% 2030 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% notes due 2030 (5.25% 2030 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.30% notes due 2031 (2.30% 2031 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.00% notes due 2032 (2.00% 2032 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">1,001 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.35% notes due 2032 (3.35% 2032 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.20% notes due 2033 (4.20% 2033 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% notes due 2033 (5.25% 2033 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.375% notes due 2037 (6.375% 2037 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">478 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">478 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.90% notes due 2038 (6.90% 2038 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.40% notes due 2039 (6.40% 2039 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.15% notes due 2040 (3.15% 2040 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,803 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.75% notes due 2040 (5.75% 2040 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.80% notes due 2041 (2.80% 2041 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">776 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">949 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.95% notes due 2041 (4.95% 2041 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.15% notes due 2041 (5.15% 2041 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">729 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">729 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.65% notes due 2042 (5.65% 2042 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">415 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">415 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.60% notes due 2043 (5.60% 2043 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.375% notes due 2043 (5.375% 2043 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.40% notes due 2045 (4.40% 2045 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.563% notes due 2048 (4.563% 2048 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,415 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,415 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.375% notes due 2050 (3.375% 2050 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,764 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,132 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.663% notes due 2051 (4.663% 2051 Notes) </td><td colspan="2"

style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.00% notes due 2052 (3.00% 2052 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">890 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">999 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.20% notes due 2052 (4.20% 2052 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">895 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.875% notes due 2053 (4.875% 2053 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.65% notes due 2053 (5.65% 2053 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.77% notes due 2053 (2.77% 2053 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.40% notes due 2062 (4.40% 2062 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,165 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,200 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.75% notes due 2063 (5.75% 2063 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other notes due 2097</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized bond discounts, premiums and issuance costs, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,373) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,420)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(192) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(314)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total carrying value of debt</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,398 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less current portion</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,544)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,443)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,854 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">63,170 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> There are no material differences between the effective interest rates and coupon rates of our notes except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively. The Term loans have an interest rate of three-month SOFR plus 1.225%. Debt repayments During the nine months ended September 30, 2024, we repaid the $2.0 billion aggregate principal amount on the Term loan due April 2025, $200 million aggregate principal amount of the Term loan due October 2026 and the $1.4 billion aggregate principal

amount of the 3.625% 2024 Notes. Debt extinguishment During the nine months ended September 30, 2024, we repurchased an aggregate principal amount of our debt of $875 million, including portions of the 3.15% 2040 Notes, 2.80% 2041 Notes, 3.375% 2050 Notes, 3.00% 2052 Notes, 4.20% 2052 Notes and 4.40% 2062 Notes, for an aggregate cost of $659 million, which resulted in the recognition of a $215 million gain on extinguishment of debt recorded in Other income, net, in the Condensed Consolidated Statements of Income.</div><div style="margin-bottom:8pt;text-align:justify">Interest rate swap contracts</div>See Note 12, Derivative instruments, for a discussion of interest rate swap contracts related to certain of our notes.<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">Our borrowings consisted of the following (in millions):</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>3.625% notes due 2024 (3.625% 2024 Notes)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,400 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.90% notes due 2025 (1.90% 2025 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% notes due 2025 (5.25% 2025 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Term loan due April 2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.125% notes due 2025 (3.125% 2025 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.00% €750 million notes due 2026 (2.00% 2026 euro Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">835 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">828 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.507% notes due 2026 (5.507% 2026 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.60% notes due 2026 (2.60% 2026 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Term loan due October 2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,800 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.50% £475 million notes due 2026 (5.50% 2026 pound sterling Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">635 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">605 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.20% notes due 2027 (2.20% 2027 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,724 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.20% notes due 2027 (3.20% 2027 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.15% notes due 2028 (5.15% 2028 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.65% notes due 2028 (1.65% 2028 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,234 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.00% notes due 2029 (3.00% 2029 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750

</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.05% notes due 2029 (4.05% 2029 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.00% £700 million notes due 2029 (4.00% 2029 pound sterling Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">936 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">892 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.45% notes due 2030 (2.45% 2030 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% notes due 2030 (5.25% 2030 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.30% notes due 2031 (2.30% 2031 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.00% notes due 2032 (2.00% 2032 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,001 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.35% notes due 2032 (3.35% 2032 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.20% notes due 2033 (4.20% 2033 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> <span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% notes due 2033 (5.25% 2033 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.375% notes due 2037 (6.375% 2037 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">478 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">478 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.90% notes due 2038 (6.90% 2038 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.40% notes due 2039 (6.40% 2039 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">333 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.15% notes due 2040 (3.15% 2040 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,803 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.75% notes due 2040 (5.75% 2040 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">373 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.80% notes due 2041 (2.80% 2041 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">776 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">949 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.95% notes due 2041 (4.95% 2041 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.15% notes due 2041 (5.15% 2041 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">729 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">729 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.65% notes

due 2042 (5.65% 2042 Notes) </td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">415 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">415 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.60% notes due 2043 (5.60% 2043 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.375% notes due 2043 (5.375% 2043 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">185 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.40% notes due 2045 (4.40% 2045 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,250 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.563% notes due 2048 (4.563% 2048 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,415 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,415 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.375% notes due 2050 (3.375% 2050 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,764 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,132 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.663% notes due 2051 (4.663% 2051 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,541 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.00% notes due 2052 (3.00% 2052 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">890 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">999 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.20% notes due 2052 (4.20% 2052 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">895 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3"

style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.875% notes due 2053 (4.875% 2053 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.65% notes due 2053 (5.65% 2053 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.77% notes due 2053 (2.77% 2053 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.40% notes due 2062 (4.40% 2062 Notes) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,165 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,200 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.75% notes due 2063 (5.75% 2063 Notes) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,750 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other notes due 2097</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unamortized bond discounts, premiums and issuance costs, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,373) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,420)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Fair value adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(192) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(314)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total carrying value of debt</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">60,398 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,613 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less current portion</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3,544)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1,443)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">56,854 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">63,170 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
0.036250.036250140000000000.01900.01905000000005000000000.05250.0525200000000020000000000200000000000.03192000000-
3140000002700000017000000603980000006461300000035440000001443000000056854000000063170000000000.045630.046630.
equity Stock repurchase program During the nine months ended September 30, 2024 and 2023, we did not repurchase shares under our stock repurchase program. As of September 30, 2024, $7.0 billion of authorization remained available under our stock repurchase program. Dividends In August 2024, March 2024 and December 2023, our Board of Directors declared quarterly cash dividends of $2.25 per share, which were paid in September 2024, June 2024 and March 2024, respectively. In October 2024, our Board of Directors declared a quarterly cash dividend of $2.25 per share that will be paid in December 2024. Accumulated other comprehensive income (loss) The components of AOCI were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign currency translation adjustments </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Cash flow
hedges</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-

align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">AOCI</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(298)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">31 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(289)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Unrealized gains</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Reclassification adjustments into earnings </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Income taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(32)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(32)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of March 31, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(322)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Unrealized gains</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117

</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Reclassification adjustments into earnings </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Income taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of June 30, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(337) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(155) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Unrealized losses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(158)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(158)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Reclassification adjustments into earnings </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(166)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(166)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Income taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of September 30, 2024 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-

*align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(266)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(98)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(336)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Components of AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Statements of Income locations</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Foreign currency contract gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Product sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Cross-currency swap contract gains (losses)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(86)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New*

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision for income taxes</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">130 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(42)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none">

color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Product sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Cross-currency swap contract gains (losses)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income, net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision for income taxes</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">187 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 7000000000.02.252.252.252.25 The components of AOCI were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign currency translation adjustments </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Cash flow
hedges</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Other</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">AOCI</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Balance as of December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(298)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">31 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(289)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Unrealized gains</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">178 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> <span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments into earnings </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Income taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(32)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(32)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of March 31, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(322)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(190)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Unrealized gains</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">117 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Reclassification adjustments into earnings </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(52)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Income taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of June 30, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(337) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">155 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(155)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Foreign currency translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Unrealized losses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(158)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(158)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Reclassification adjustments into earnings </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(166)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(166)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Income taxes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:400;line-height:100%">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">71 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Balance as of September 30, 2024 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(266)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(98)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(336)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -298000000-2200000031000000-289000000-2400000000-2400000001780000000178000000020000000020000000000-3000000-300000003200000003200000000-3220000001040000002800000-190000000-1500000000-150000000117000000011700000005200000005200000000-1000000-1000000014000000014000000-337000000155000000270000000-155000000071000000007100000000-158000000-158000000001660000000166000000000100000010000000-710000000-71000000-266000000-98000000028000000-336000000 Reclassifications out of AOCI and into earnings, including related income tax expenses, were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Components of AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Statements of Income locations</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Foreign currency contract gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Product sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Cross-currency swap contract gains (losses)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(86)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income, net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">166 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(53)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision for income taxes</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">130 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(42)</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Components of AOCI</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

*Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Statements of Income locations</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash flow hedges:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Foreign currency contract gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Product sales</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Cross-currency swap contract gains (losses)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(57)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other income, net</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(51)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Provision for income taxes</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">187 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td></tr><tr><td colspan="3" style="display:none"></td><td*

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 450000003300000012100000-860000001660000005300000036000000-110000001300000004200000015100000012100000087000000-570000002380000006400000051000000140000001870000005000000Fair value measurement To estimate the fair value of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing an asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three levels based on the sources of inputs as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:6.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.243%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top">Level 1</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top">—</td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top">Level 2</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top">—</td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top">Valuations for which all significant inputs are observable either directly or indirectly—other than Level 1 inputs</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top">Level 3</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top">—</td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top">Valuations based on inputs that are unobservable and significant to the overall fair value measurement</td></tr></table> The availability of observable inputs can vary among different types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, inputs used for measuring fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level of input used that is significant to the overall fair value measurement. The fair values of each major class of the Company's financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices
in active markets
for identical assets
(Level 1)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
other observable
inputs
(Level 2)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable
inputs
(Level 3)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Fair value measurement as of September 30, 2024, using:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-

color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Available-for-sale securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Equity securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,057 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,057 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span

*style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12,494 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,251 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,745 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— *

</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Interest rate swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt">Contingent consideration obligations</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">998 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices
in active markets
for identical assets
(Level 1)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
other observable
inputs
(Level 2)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable
inputs
(Level 3)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Fair value measurement as of December 31, 2023, using:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Available-for-sale securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Equity securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,514 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,514 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt">

</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,780 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">283 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,063 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0

1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Interest rate swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Contingent consideration obligations </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px

1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,092 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,188 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 Interest-bearing and equity securities The fair values of our money market mutual funds and equity investments in publicly traded securities, including our equity investments in BeiGene and Neumora, as of September 30, 2024 and December 31, 2023, are based on quoted market prices in active markets, with no valuation adjustment. Derivatives All of our foreign currency forward contracts, cross-currency swap contracts and interest rate swap contracts are with counterparties that have minimum credit ratings of A- or equivalent by S&P, Moody’s or Fitch. We estimate the fair values of these contracts by taking into consideration valuations obtained from a third-party valuation service that uses an income-based industry-standard valuation model for which all significant inputs are observable either directly or indirectly. These inputs, as applicable, include foreign currency exchange rates, SOFR, swap rates, obligor credit default swap rates and cross-currency basis swap spreads. Certain inputs, when applicable, are at commonly quoted intervals. See Note 12, Derivative instruments. Contingent consideration obligations As a result of our business acquisitions, we have incurred contingent consideration obligations as discussed below. The contingent consideration obligations are recorded at their fair values by using probability-adjusted discounted cash flows, and we revalue these obligations each reporting period until the related contingencies have been resolved. The fair value measurements of these obligations are based on significant unobservable inputs related to licensing rights and product candidates acquired in business combinations, and they are reviewed quarterly by management in our R&D and commercial sales organizations. The inputs include, as applicable, estimated probabilities and the timing of achieving specified development, regulatory and commercial milestones as well as estimated annual sales. Significant changes that increase or decrease the probabilities of achieving the related development, regulatory and commercial events or that shorten or lengthen the time required to achieve such events or that increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of the obligations, as applicable. Changes in the fair values of contingent consideration obligations are recognized in Other operating expenses in the Condensed Consolidated Statements of Income. Changes in the carrying amounts of contingent consideration obligations were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-

weight:700;line-height:100%">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">107 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">248 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">270 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Payments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net changes in valuations</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(147)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(165)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid

#000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024 and December 31, 2023, our contingent consideration obligations are primarily the result of our acquisition of Teneobio, Inc. in October 2021, which obligates us to pay the former shareholders payments upon achieving separate development and regulatory milestones with regard to various R&D programs. Summary of the fair values of other financial instruments Cash equivalents The fair values of cash equivalents are approximated at their carrying values due to the short-term nature of such financial instruments. Borrowings We estimate the fair values of our fixed-rate notes by using Level 2 inputs. As of September 30, 2024 and December 31, 2023, the aggregate fair values of our fixed-rate notes were $58.0 billion and $59.2 billion, respectively, and the carrying values of this debt were $58.6 billion and $60.6 billion, respectively. The estimate of the fair values of our Term loans is approximated as the carrying values as of September 30, 2024 and December 31, 2023 as these debt instruments bear interest at floating rates. During the nine months ended September 30, 2024 and 2023, there were no transfers of assets or liabilities between fair value measurement levels, and there were no material remeasurements to the fair values of assets and liabilities that are not measured at fair value on a recurring basis. The fair values of each major class of the Company's financial assets and liabilities measured at fair value on a recurring basis were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices
in active markets
for identical assets
(Level 1)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
other observable
inputs
(Level 2)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable
inputs
(Level 3)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Fair value measurement as of September 30, 2024, using:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Assets:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Available-for-sale securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,437 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">143 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Equity securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,057 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,057 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">—

</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12,494 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,251 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">13,745 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-

~~align:right;vertical-align:bottom">121 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">361 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Interest rate swap contracts</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Contingent consideration obligations </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total liabilities</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-~~

align:bottom">998 </td><td style="background-color:#ccceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Quoted prices
in active markets
for identical assets
(Level 1)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
other observable
inputs
(Level 2)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Significant
unobservable
inputs
(Level 3) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">Fair value measurement as of December 31, 2023, using:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Assets:</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Available-for-sale securities:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">U.S. Treasury bills</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Money market mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,266 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Other short-term interest-bearing securities</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Equity securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,514 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,514 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total assets</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">14,780 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">283 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,063 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:top">Liabilities:</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-

~~color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top">Derivatives:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Interest rate swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Contingent consideration obligations </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span~~

*style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top">Total liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,092 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,188 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
0996000000009960000007437000000007437000000014300000001430000000505700000000505700000000990000000099000*
*style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">Changes in the carrying amounts of contingent consideration obligations were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">107 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">248 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">96 </td><td style="background-color:#cceeff;border-top:1pt solid*

#000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">270 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Payments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Net changes in valuations</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(147)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(165)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">98 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 10700000024800000096000000270000000200000030000006000000700000070000000-147000000220000000-165000000112000000980000001120000009800000058000000000.059200000000586000000000606000000000Derivative instruments The Company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. To reduce our risks related to such exposures, we use or have used certain derivative instruments, including foreign currency forward, foreign currency option, cross-currency swap, forward interest rate and interest rate swap contracts. We have designated certain of our derivatives as cash flow and fair value hedges; we also have derivatives not designated as hedges. We do not use derivatives for speculative trading purposes. Cash flow

hedges We are exposed to possible changes in the values of certain anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates primarily associated with our euro-denominated international product sales. The foreign currency exchange rate fluctuation exposure associated with cash inflows from our international product sales is partially offset by corresponding cash outflows from our international operating expenses. To further reduce our exposure, we enter into foreign currency forward contracts to hedge a portion of our projected international product sales up to a maximum of three years into the future; and at any given point in time, a higher percentage of nearer-term projected product sales is being hedged than in successive periods. As of September 30, 2024 and December 31, 2023, we had outstanding foreign currency forward contracts with aggregate notional amounts of $7.1 billion and $6.6 billion, respectively. We have designated these foreign currency forward contracts, which are primarily euro based, as cash flow hedges. Accordingly, we report the unrealized gains and losses on these contracts in AOCI in the Condensed Consolidated Balance Sheets, and we reclassify them to Product sales in the Condensed Consolidated Statements of Income in the same periods during which the hedged transactions affect earnings.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">To hedge our exposure to foreign currency exchange rate risk associated with certain of our long-term debt denominated in foreign currencies, we enter into cross-currency swap contracts. Under the terms of such contracts, we paid euros and pounds sterling and received U.S. dollars for the notional amounts at the inception of the contracts; and based on these notional amounts, we exchange interest payments at fixed rates over the terms of the contracts by paying U.S. dollars and receiving euros and pounds sterling. In addition, we will pay U.S. dollars to and receive euros and pounds sterling from the counterparties at the maturities of the contracts for these same notional amounts. The terms of these contracts correspond to the related hedged debt, thereby effectively converting the interest payments and principal repayment on the debt from euros and pounds sterling to U.S. dollars. We have designated these cross-currency swap contracts as cash flow hedges. Accordingly, the unrealized gains and losses on these contracts are reported in AOCI in the Condensed Consolidated Balance Sheets and reclassified to Other income, net, in the Condensed Consolidated Statements of Income in the same periods during which the hedged debt affects earnings.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The notional amounts and interest rates of our cross-currency swaps as of September 30, 2024, were as follows (notional amounts in millions):</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign currency</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. dollars</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Hedged notes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest rates</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest rates</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>2.00% 2026 euro Notes</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">€</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">% </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">833 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.50% 2026 pound sterling Notes </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">475 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">747 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>4.00% 2029 pound sterling Notes</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally enter into forward interest rate contracts in order to hedge the variability in cash flows due to changes in the applicable U.S. Treasury rate between the time we enter into these contracts and the time the related debt is issued. Gains and losses on forward interest rate contracts, which are designated as cash flow hedges, are recognized in AOCI in the Condensed Consolidated Balance Sheets and are amortized into Interest expense, net, in the Condensed Consolidated Statements of Income over the terms of the associated debt issuances. Amounts recognized in connection with forward interest rate contracts during the nine months ended September 30, 2024, and amounts expected to be recognized during the subsequent 12 months are not material. Unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives in cash flow hedging relationships</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid

#000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(238)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">198 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">222 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Forward interest rate contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">(31)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top">Total unrealized (losses) gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(158)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">176 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td

colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">137 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">155 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Fair value hedges To achieve a desired mix of fixed-rate and floating-rate debt, we entered into interest rate swap contracts that qualified for and were designated as fair value hedges. These interest rate swap contracts effectively convert fixed-rate coupons to floating-rate coupons over the terms of the related hedge contracts. As of both September 30, 2024 and December 31, 2023, we had interest rate swap contracts with aggregate notional amounts of $6.7 billion, that hedge certain portions of our long-term debt issuances. During the nine months ended September 30, 2024, interest rate swaps with an aggregate notional amount of $1.4 billion matured in connection with the repayment of the 3.625% 2024 Notes. In addition, we entered into new interest rate swaps with respect to the 5.25% 2033 Notes for an aggregate notional amount of $1.4 billion at an interest rate of SOFR plus 1.8%.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">For interest rate swap contracts that qualify for and are designated as fair value hedges, we recognize in Interest expense, net, in the Condensed Consolidated Statements of Income the unrealized gain or loss on the derivative resulting from the change in fair value during the period, as well as the offsetting unrealized loss or gain of the hedged item resulting from the change in fair value during the period attributable to the hedged risk. If a hedging relationship involving an interest rate swap contract is terminated, the gain or loss realized on contract termination is recorded as an adjustment to the carrying value of the debt and amortized into Interest expense, net, over the remaining term of the previously hedged debt.</div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions):</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Carrying amounts of hedged liabilities(1)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2)</div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Condensed Consolidated Balance Sheets locations</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Current portion of long-term debt</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,039 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,441 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,307 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">4,788 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(231)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(355)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) Current portion of long-term debt includes $58 million and $69 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $245 million and $288 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. (2) Current portion of long-term debt includes $58 million and $69 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $145 million and $188 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Impact of hedging transactions The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td

colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,151 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(776)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,310 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,408)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">The effects of cash flow and fair value hedging:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Gains on cash flow hedging relationships reclassified out of AOCI:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—

</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">(Losses) gains on fair value hedging relationships—interest rate swap agreements:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt">Hedged items(1)</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

*style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(153)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(122)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">168 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">176 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New*

*Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,548 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">685 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(759)</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">19,077 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,431 </td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,054)</td><td style="background-color:#ccceff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">The effects of cash flow and fair value hedging:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— *

</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(86)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(57)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Gains (losses) on fair value hedging relationships—interest rate swap agreements:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt">Hedged items(1)</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">58 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px

1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(37)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) Gains (losses) on hedged items do not exactly offset losses (gains) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. No portions of our cash flow hedge contracts were excluded from the assessment of hedge effectiveness. As of September 30, 2024, amounts expected to be recognized into earnings during the subsequent 12 months on our foreign currency and cross-currency swap contracts are not material. Derivatives not designated as hedges To reduce our exposure to foreign currency fluctuations in certain assets and liabilities denominated in foreign currencies, we enter into foreign currency forward contracts that are not designated as hedging transactions. Most of these exposures are hedged on a month-to-month basis. As of September 30, 2024 and December 31, 2023, the total notional amounts of these foreign currency forward contracts were $82 million and $457 million, respectively. Gains and losses recognized in earnings for our derivative instruments not designated as hedging instruments were not material for the three and nine months ended September 30, 2024 and 2023. Fair values of derivatives The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td

***style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative liabilities</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as hedging instruments: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt">Accrued liabilities/ Other noncurrent liabilities</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">361 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td***

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Total derivatives designated as hedging instruments </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative liabilities</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as hedging instruments: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid

#000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt">Accrued liabilities/ Other noncurrent liabilities</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">405 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Total derivatives designated as hedging instruments </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,092 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total

derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,092 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For additional information, see Note 11, Fair value measurement. Our derivative contracts that were in liability positions as of September 30, 2024, contain certain credit-risk-related contingent provisions that would be triggered if (i) we were to undergo a change-in-control and (ii) our or the surviving entity's creditworthiness deteriorates, which is generally defined as having either a credit rating that is below investment grade or a materially weaker creditworthiness after the change-in-control. If these events were to occur, the counterparties would have the right, but not the obligation, to close the contracts under early-termination provisions. In such circumstances, the counterparties could request immediate settlement of these contracts for amounts that approximate the then current fair values of the contracts. In addition, our derivative contracts are not subject to any type of master netting arrangement, and amounts due either to or from a counterparty under the contracts may be offset against other amounts due either to or from the same counterparty only if an event of default or termination, as defined, were to occur. The cash flow effects of our derivative contracts in the Condensed Consolidated Statements of Cash Flows are included in Net cash provided by operating activities, except for the settlement of notional amounts of cross-currency swaps, which are included in Net cash (used in) provided by financing activities. P3Y7100000000066000000000 The notional amounts and interest rates of our cross-currency swaps as of September 30, 2024, were as follows (notional amounts in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign currency</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. dollars</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Hedged notes</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest rates</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional amounts</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest rates</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2.00% 2026 euro Notes </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">€</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.50% 2026 pound sterling Notes </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">475 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">747 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>4.00% 2029 pound sterling Notes</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">700 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,111 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
0.02007500000000.0208330000000.0390.05504750000000.0557470000000.0600.04007000000000.04011110000000.046
style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">Unrealized gains and losses recognized in AOCI for our derivative instruments designated as cash flow hedges were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives in cash flow hedging relationships</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">Foreign currency forward contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(238)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">198 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">222 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Cross-currency swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(36)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Forward interest rate contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(31)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top">Total unrealized (losses) gains</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(158)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">176 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">137 </td><td style="background-color:#ffffff;border-

bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">155 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
-2380000001980000008700000022200000080000000-22000000500000000-360000000000-310000000-158000000176000000137000000155000000067000000006700000000140000000000.036250.052514000000000.018 The hedged liabilities and related cumulative-basis adjustments for fair value hedges of those liabilities were recorded in the Condensed Consolidated Balance Sheets as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Carrying amounts of hedged liabilities(1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Cumulative amounts of fair value hedging adjustments related to the carrying amounts of the hedged liabilities(2) </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Condensed Consolidated Balance Sheets locations</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">Current portion of long-term debt</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,039 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,441 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">41 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5,307 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">4,788 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(231)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(355)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) Current portion of long-term debt includes $58 million and $69 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $245 million and $288 million of carrying value with discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. (2)   Current portion of long-term debt includes $58 million and $69 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively. Long-term debt includes $145 million and $188 million of hedging adjustments on discontinued hedging relationships as of September 30, 2024 and December 31, 2023, respectively.</div>1039000000144100000039000000410000005307000000478800000-231000000-355000000580000006900000024500000028800000058000000690000001450000001880000000<div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt">The following tables summarize the amounts recorded in income and expense line items and the effects thereon from fair value and cash flow hedging, including discontinued hedging relationships (in millions):</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,151 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">

$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(776)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">23,310 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,288 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,408)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">The effects of cash flow and fair value hedging:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Gains on cash flow hedging relationships reclassified out of AOCI:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">45 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">87 </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">(Losses) gains on fair value hedging relationships—interest rate swap agreements:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Hedged items(1) </td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(153) </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;padding:2px 0;text-align:right;vertical-align:bottom">(122)</td><td style="background-color:#ccceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments</td><td colspan="3"

*style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">168 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">176 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Product sales</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other income, net</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Interest expense, net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total amounts recorded in income and (expense) line items presented in the Condensed Consolidated Statements of Income </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,548 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">685 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-*

color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(759)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">19,077</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2,431</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(2,054)</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">The effects of cash flow and fair value hedging:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Gains (losses) on cash flow hedging relationships reclassified out of AOCI:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">33</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">121</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(86)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(57)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Gains (losses) on fair value hedging relationships—interest rate swap agreements:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Hedged items(1) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">58 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(37)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> _____ (1) Gains (losses) on hedged items do not exactly offset losses (gains) on the related designated hedging instruments due to amortization of the cumulative amounts of fair value hedging adjustments included in the carrying amount of the hedged debt for discontinued hedging relationships and the recognition of gains on terminated hedges when the corresponding hedged item was paid down in the period. 8151000000183000000077600000023310000000128800000002408000000450000000151000000121000000087000000-153000000-122000000016800000001760000006548000000685000000759000000190770000002431000000205400000033000000121000000-86000000-57000000058000000063000000-37000000050000008200000045700000000 The fair values of derivatives included in the Condensed Consolidated Balance Sheets were as follows (in millions): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative liabilities</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as hedging instruments: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">99 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt">Accrued liabilities/ Other noncurrent liabilities</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">121 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">361 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">404 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Total derivatives designated as hedging instruments </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-

*color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">112 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">886 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>
</div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Derivative liabilities</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Condensed Consolidated
Balance Sheets locations</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair values</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt">Derivatives designated as hedging instruments:</div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forward contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swap contracts</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span*

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest rate swap contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other current assets/ Other noncurrent assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Accrued liabilities/ Other noncurrent liabilities </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">571 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Total derivatives designated as hedging instruments </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,092 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">Total derivatives</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">145 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,092 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
99000000121000000400000036100000090000004040000001120000008860000001120000008860000001450000001160
and commitments Contingencies In the ordinary course of business, we are involved in various legal proceedings, government investigations and other matters that are complex in nature and have outcomes that are difficult to predict. See our Annual Report on Form 10-K for the year ended December 31, 2023, Part I, Item 1A. Risk Factors—Our business may be affected by litigation and government investigations. We describe our legal proceedings and other matters that are significant or that we believe could become significant in this footnote; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of the liability that has been accrued previously. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:120%">Our legal proceedings involve various aspects of our business and a variety of claims, some of which present novel factual allegations and/or unique legal theories. In each of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024, in which we could incur a liability, our opponents seek an award of a not-yet-quantified amount of damages or an amount that is not material. In addition, a number of the matters pending against us are at very early stages of the legal process, which in complex proceedings of the sort we face often extend for several years. As a result, none of the matters described in this filing; in Note 20, Contingencies and commitments, to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2023; and in Note 13, Contingencies and commitments, to the condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2024 and June 30, 2024, in which we could incur a liability, have progressed sufficiently through discovery and/or the development of important factual information and legal issues to enable us to estimate a range of possible loss, if any, or such amounts are not material. While it is not possible to accurately predict or determine the eventual outcomes of these matters, an adverse determination in one or more of these matters currently pending could have a material adverse effect on our consolidated results of operations, financial position or cash flows. Certain recent developments concerning our legal proceedings and other matters are discussed below. Repatha Patent Litigation Patent Disputes in the International Region Germany On October 17, 2024 in Sanofi-Aventis Deutschland GmbH (Sanofi-Aventis) and Regeneron Pharmaceuticals, Inc.’s (Regeneron) actions seeking damages arising from the provisional enforcement of an injunction against PRALUENT®, the Munich Regional Court scheduled a hearing for February 26, 2025. Unified Patent Court of the European Union Amgen filed a Statement of Appeal on September 13, 2024, asking the Court of Appeals to the Unified Patent Court (UPC) to set aside the decision of the UPC Central Division revoking Amgen’s European Patent No. 3,666,797 (EP ‘797). On September 25, 2024, Sanofi Biotechnologies SAS and Regeneron filed a brief seeking to expand the ongoing UPC action, alleging that Amgen’s Repatha infringes a newly-issued patent, European Patent No. 4,252,857, seeking an injunction against the marketing, use, or importation of Repatha in 18 countries (Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Sweden) and damages for past infringement. European Patent Office The European Patent Office (EPO) Opposition Division will hear argument on Sanofi-Aventis and Regeneron’s opposition against Amgen’s EP ‘797 from March 31 to April 4, 2025. In Amgen’s opposition before the EPO against Regeneron’s European Patent No. 3,536,712, the Opposition Division will hear argument on March 11 and 12, 2025. Japan On September 16, 2024, Amgen filed an appeal brief with the Japanese Intellectual Property High Court, seeking to overturn the Japanese Patent Office’s decision to reject Amgen’s amended patent claims following a remand of the case to the Japanese Patent Office from the Japanese Intellectual Property High Court. Prolia/XGEVA Biologics Price Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al. On August 12, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the District of New Jersey (New Jersey District Court) against Samsung Bioepis Co. Ltd. (Bioepis) and Samsung Biologics Co., Ltd., (Biologics, and collectively with Bioepis, Samsung) based on the submission to the FDA of a Biologics License Application (BLA) seeking approval to market and sell a biosimilar version of Amgen’s Prolia and XGEVA products. The complaint asserts infringement of the following 34 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,058,418; 8,247,210; 8,460,896; 8,680,248; 9,012,178; 9,320,816; 9,328,134; 9,359,435; 9,481,901; 10,106,829; 10,167,492; 10,227,627; 10,421,987; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 10,907,186; 11,098,079; 11,130,980; 11,254,963; 11,292,829; 11,299,760; 11,384,378; 11,427,848; 11,434,514; 11,634,476; 11,685,772; 11,744,950; and 11,946,085 (collectively, the Asserted Patents). Amgen seeks a judgment from the New Jersey District Court that Samsung has infringed or will infringe one or more claims of each of the Asserted Patents and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Samsung’s proposed denosumab biosimilar before expiration of each of the Asserted Patents found infringed. Amgen also seeks monetary remedies for any past acts of infringement. Bioepis filed its Answer and Counterclaims in response to the Complaint on October 1, 2024. Biologic’s response to the Complaint is due on October 28, 2024. Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al. On October 4, 2024, Amgen Inc. and Amgen Manufacturing Limited LLC filed a lawsuit in the U.S. District Court for the Northern District of Illinois (Northern Illinois District Court) against Fresenius Kabi USA, LLC, Fresenius SwissBiosim GmbH, Fresenius Kabi Deutschland, GmbH, and Fresenius Kabi Austria GmbH (collectively, Fresenius) based on the submission to the FDA of a BLA seeking approval to market and sell a biosimilar version of Amgen’s

Prolia and XGEVA products. The complaint asserts infringement of the following 33 patents: U.S. Patent Nos. 7,364,736; 7,888,101; 7,928,205; 8,053,236; 8,058,418; 8,460,896; 8,680,248; 9,012,178; 9,228,168; 9,320,816; 9,328,134; 9,359,435; 10,106,829; 10,167,492; 10,227,627; 10,513,723; 10,583,397; 10,655,156; 10,822,630; 10,894,972; 11,077,404; 11,098,079; 11,130,980; 11,254,963; 11,299,760; 11,319,568; 11,434,514; 11,459,595; 11,744,950; 11,786,866; 11,946,085; 11,952,605; and 12,084,686 (collectively, the Asserted Patents). Amgen seeks a judgment from the Northern Illinois District Court that Fresenius has infringed or will infringe one or more claims of each of the Asserted Patents and, based on that judgment, a permanent injunction prohibiting the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of Fresenius's proposed denosumab biosimilar before expiration of each of the Asserted Patents found infringed. Amgen also seeks monetary remedies for any past acts of infringement. PAVBLU™ (formerly ABP 938 (aflibercept-ayyh)) Patent Litigation On September 23, 2024, the U.S. District Court for the Northern District of West Virginia denied Regeneron's motion for a preliminary injunction, and Regeneron filed a notice of appeal, a motion to expedite the appeal, and an emergency motion for an injunction pending resolution of the appeal and for an administrative stay with the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit Court). On September 25, 2024, the Federal Circuit Court issued an order temporarily enjoining the launch of PAVBLU on an administrative basis while it considered Regeneron's motion for an injunction pending appeal. On October 22, 2024, the Federal Circuit Court denied Regeneron's motion for an injunction pending appeal and lifted the temporary injunction that was entered on September 25, 2024. Amgen's response brief to the appeal is due on November 4, 2024, Regeneron's reply brief is due on November 13, 2024 and oral arguments for the appeal will be scheduled for January 2025. Antitrust Class Actions Sensipar Antitrust Class Actions On September 13, 2024, the putative class of direct purchasers of Sensipar (Sensipar Plaintiffs) filed their opening brief in its appeal of the dismissal of its claims by the U.S. District Court for the District of Delaware (Delaware District Court). Amgen has obtained an extension until November 14, 2024 to file its opposing brief. The Sensipar Plaintiffs' reply is due December 5, 2024. Regeneron Pharmaceuticals, Inc. Antitrust Action The trial before the Delaware District Court that had been set to begin on November 12, 2024 was taken off calendar. A new date for the trial has not yet been set. The Delaware District Court set a hearing on November 20, 2024 to hear Amgen's motion for summary judgment and the parties' motions to exclude expert testimony. CareFirst of Maryland Antitrust Class Action On August 6, 2024, CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., and CareFirst BlueChoice, Inc. (collectively, CareFirst), filed a class action antitrust lawsuit against Amgen Inc., Amgen Manufacturing, Limited (corrected to Amgen Manufacturing Limited LLC in CareFirst's amended complaint on October 11, 2024), and Immunex Corporation in the U.S. District Court for the Eastern District of Virginia, alleging federal and state antitrust claims and state consumer protection claims. The plaintiffs allege that, in 2004, Amgen entered into an anticompetitive agreement with certain F. Hoffman-La Roche AG entities (Roche) and other parties that provided Amgen with rights to Roche's patents in a manner that enabled Amgen to allegedly unlawfully extend the life of patents applicable to ENBREL and, thereby, delay biosimilar entry. Amgen's response to the complaint is due on November 4, 2024. U.S. Tax Litigation and Related Matters Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue See Note 4, Income taxes, for discussion of the IRS tax dispute and the Company's petitions in the U.S. Tax Court. Securities Class Action Litigation (Roofers Local No. 149 Pension Fund) On September 30, 2024, the U.S. District Court for the Southern District of New York denied Amgen's motion to dismiss. Amgen's response to the complaint is due on November 20, 2024. Shareholder Derivative Litigation (Hamilton) On October 16, 2024, David Hamilton filed a derivative action captioned David Hamilton v. Robert A. Bradway, et al., No. 2024-1063 (Del. Chan. Ct. Oct. 16, 2024), purportedly on behalf of Amgen, against Amgen, Robert Bradway, Peter Griffith and Amgen's Board members during the relevant time period. The action was filed in the Delaware Chancery Court. The complaint in this matter alleges claims for breach of fiduciary duty and unjust enrichment. The factual allegations that form the basis for these claims are fundamentally the same as those asserted by the Roofers Local No. 149 Pension Fund on March 13, 2023 (alleging false and misleading statements and omissions made from July 29, 2020 through April 27, 2022 relating to Amgen's tax liabilities, business and finances, and the adequacy and maintenance of its internal controls). ChemoCentryx, Inc. Securities Matters On September 10, 2024, the U.S. District Court for the Northern District of California granted an administrative motion to extend certain case schedule deadlines, including setting the expert discovery cutoff to December 20, 2024 and setting the deadlines for summary judgment motions on April 4, 2025, summary judgment oppositions on April 25, 2025, and summary judgment replies on May 9, 2025. Trial is set for September 2025. falsefalsefalsefalse

"D+D8;C(8:^A&$-Q"C#*2+R*X5D(@CM"!,8"PKJ%X.#P>P;&U MKCH X#-WS+N;UK$Z033'((E6KBL10 GHH5 $3[+D@>%N3'^AM#52P/H5.GH M_134-^CJ()7-

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|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

*(DL::Q&FLGE[VA)HA]=)=KV9(?00_M?#,D2:,UW -EQ1N+OGA-*D+,U,J8$_/T7A;[\VB&=(BZZTNT277/\I+BDYNG M F^%BF=C!4L!G!8$28@QE%,>@^Q(@G,B>_Q)]6J%;4B> 0\JBKI!(++TK6]< M[=]&LY+.B)[UA9\M5G\IK/(\9P:F7'2*1 180@U(Y:@N;3)(JIU:^"BH$T:M M)T^_K:NQ!J=<Z*K$76CH/KNKM+GY_"WY^>:.[2]S?-!44(WI6&L$MDHH2 M[GV:1$VE<-2&VI6G7;$-3[#*:KU/FA8Z:=9,:X/GS3_?O\7W*"R'-U\F0W&; M%0*B\!Z$\@&\2!)8E-9+%[7@M4=<[$?TW'A24? X5C=7"E=H8YL=%P"///* 3 M'8E!.YU\ FNU!4,)Y4$12V2WIIT]'OI)HAJ'1IOKB=(V M;H'X8H/Y$B,X::(M_;(E&DW%,CC&-5#E-$">2[FJZ[4&{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{X#$IKW!&C3%G4SQOKBNXY,*2) M)AKD$FQ6OBC1^/SW-+GX8?Q/-QV5R+A OA1.">VT!%TJPD32N*DY(D *;Y/U MF>$7S3:/G;"> TOJRG[G+4+C I?/X6N*UU=IDA],9YG5KGGI\JPF93"]%]FP M,B:8Y!G7#*).$80U&@SC#HS.-"+ {F.*ULSP'J(Q!&YET:?'#J=2X*F6A%'&! M\=8(RQ7&XNW*'TY>&=-'IX]5QO21Y#E7QLS^${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{GH63P'DHW5]X "M-A)QEXH'GR.P^^]I;??C,YZ"^OJ)K\?;]]?FW M2\V3TY[8(ND$PGETV BED'50R3 :M-PW6;BW^O"9ST%]?477Y#3D06*UHSI(M*R,PXS!V4T2#)9*55IV2*4$-2;5'S9]OPU;\N1><-.%!'SE7+SAA M_R!DDU[/U+IA&OJ J8!@#BV98,J#=]1"0IL4K%-"V'L&8%=APO8'G%%E0B_Q M3RK+KG:=R1NT6A\G**+RQ?]-T\DJ>_7CY'H/@+3KLNBN<_:&@>: M"H3I @5O+0-MG./&)Q)Y[D:1SL]\%JQH(^$&<<#6'@N!1*%3N;;)&D-+91 3 M!C7@%0E..ZE0'I6=@'/N/'-,+'"T?!_J7#9J-M(%U4OM/--+8]VZCAPB[N$Z MSPC&G6,B01;2E$PP1!=PEQ),6DJR8S5S12$&9 MQ$$(CS&/=!I41$>7H>&SZN5UGNFEKLB*5$LR(]Q%R#Z9T@M1@Z&$ ME!-.1I(K'E#M(=OG79%:IP#D""DWU? Z;T8\4;Q="7AJ,7V.T!((/ 02-Z/U& M;X&RF#VG&..FVL/7]L!Y3APX3M:G+4R.46:AA(%,="FA+FUY+6Z'&O?$1*A. M.=2O-7U:A JS0 M3M&0@ M!2_-&M(>>26!.HNO+T=&E]>\4GV8)\'G1KE)U<0_U#UM=W '8K^KB M6IKM7EU\@%H&Y4T0WJ ++TJP5MXA[\%Z:T!FFS0)5B9>NW#P>507-Z%+'VT, M5EVL@HW:, HZ1(&>B! 8 D8'F7(O51(ZTMH.W]E7%_=25*?]XCY2'KJZV',9 ME:I%:6/9[O3L'*N+GYQK)0QONPQQ,W8T4?R#5BQ:H;[M^X_PU8V_W !<-U2F(GLB)63/V;*&Q'CG(3L;HA6"!VTKTV(OH#.K;^ZENX=# MB2L)OG:Z:(? B:\5],!$(#1&$5@F\).BQNU+8X@)%D71*^GMBY>R'J+N^1.MG M>RZF8]^^2KH/CR7A=%8:"-,2!"]YJ&6N'J=$>$TH=Y9U4OCCSWHN*J\LU09N MXX?YUS1]/?GV\S1]++1:RF+WB5Q?'^TY/]+4W?I%Q+9]2N'*SV2B/5DYWRKB1 M_>E^7":T@YPI 2Q:M)")HF=-DX;(B5&>N.BKIP157L(IN=?LRN*4:MYIF1K? M*B_6$_\8.3^ZPH]/Y?[T]?6WZZO%'RXS:VI?)/=Y9I. [XX,7W;#/,6=18HR- MNUOPR-Y@&#AA)$3JLR3<4T)}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

M1I&'@HA2CT2+)U'2U2PX=;HY)&@.4>48(ST'S(7<9C9I5V!%$RJBX/V8Z,:. MSRFY'#DO1\G,ZH"<$G;?
B3AYO9UMNZE7[&]R;/G@[TDEI =R5Y*'KT)--2"XYELN';%6"2O$KEWX],Q58R]5Y"0B@*U)R0![5JD^N'_8O M!(]R<#.;
<<:#TK,J\X!OZ<74!-GR!+6,7H&7(G44Z'Q-'-NL, M1F:U:N<#MF_W'(QH9QDO>U7_N"IOR%
(H8WLCV+ILUV&,K1_62^5C_5+*!=QO M12G(4O&AEG,_"VD>Q"WYOB TBB+NA3 5!$.<< 235/H_)!)Q& H_C)EGX2(Z M86X>?
[+A0!K&G@6PE'^+RG"[R\G#T-S?F@U;*YNHV %;?]31Z_F%DC94',OO MMER"]@%L^02*T0M &U:!Y-7AUI5+Z%SM53GA:=[-
*9!)"3+T()C&6%A/AA'I^1 7V=#:BCE*8 M>$L*OY4D_Q$4BB#@:P$4>?"F^[KYHV'F1SV[=QRH<1OF1'PS>_1"1/![2U)S
M&^ZX]+P+WV@B#Z85>8>4O>CG6]*3TK1645W6F#HO#;S&W!V_<1;3=9+OW@R=_MOM#.77LOROQ)/KXG47TD>?
D7LER+3WDAKFKQ4"U$FGD)QA[,O)!!S)#TP#(_M@CQ)N,\PHV&4F!Q^*/F@8T-0\/>CTG"9G@)@Z0QNR M%\9@&+LW6D(Z]FZ-
UDINM5\RRIS!116R!MI3O* M_$%JP1[>[=Z^DG>T^J6_+!5J97X!99[N>Q>\/52?,DV&O=O M@M_EQ=U5(0DT#DZECA=%MX_\,2]
(P7*RO!:EBH)549^7!=]^O:IRY1#UT9^W M:MEP*[I7/TOY_K8($A0$// AC4@,L0@Y1(P0Z(LHS(C'0S^,32;5F?F?6,45
MZVJQG1.:+]MH$5)P*Y=7DF[>&JW\@_QC#7WCO^X3\YPP[D31!US#=R)3A@P
MD.8";.5IKNY9!P.1FB<^^*63Z@+TU="V7BJ.O0K*9LUIP]8/D9/>+P95MV/-5 MP4I!*O%>M/^7?
R_7*G_DPW=VKP)&ODI9/V29D+X5ISC#&?L10ONE9^%$%NS:?Y(:# MV/)O-LO-_*3U)KD_[O,S=-4E9Q=MI.N
076DVO,.VDO4<]S[.5BC02P6V M+\4%V(@&>MF $@ZTTKF;Y%[GJ3B:XV9F?
M8I[G4>S/X,]TI;=B[KUX$LO5HYI_^Z.25&U9>@C&$?7DO"122#P10R^.8Y8**O\G3)9= M6E0G7BQ=%?"Q90*4'1>-
^>%;/LQF$#TH]0R_M!VF:)5F6>!(_HPT=A[Q-;'\V/(+'#9-F!L?E<] S2Z^$KIGQ:JF!#9<78,,= M&+
('6OX:PJ;=T[((>AX;=_/4HS$VD!GHN-J)\R2BWFWM,Z#ZL7>U)G#F02/W)9$.4C#RQ;>IH@9:8?NC,KO2G M0V>L93*S!IKB&
7.'&3=*G!F=Z39 F<."C ,G#E\P3E[*,-U@=J>.,"\6&0! M#I&'*8RB*(4XCB.8(#^%#
<\I3A@"%OLD&A0_A^R_Z&#HU,VG&_$DBH_YD^@L;9/T M\WXMD!=ZW0L<^@CY-$ PC<*@C;4BB'L0>UD!M\"(W MT -
ONJ^;/XQS \TAUK">DP)GN"A2#("&%]!^;K@!BIW>Z>K2#=_WB%H85W,8 M#4SMI'#:&=Y)8#6SQ-:HC-
IE\U'GL]+6$N_8;/M1S"RX8'QQN5QVZ^O+LE2; M5$WX;ZH;A) #CEM2E[&8V\YC8#C585[B1K28Y M1+
<897R[!CTY\"SJJBM>KYC:UYNKX+O5P^,EJ]=DN7R^)CG_2[4I&+K-SM%4
M19VQIEXK2A9$4;5)+STO0#$#GJJW@V*\^CJJA=!I774-CN%1D"XNX'>G.4*F MDELIM!:!V13;1-
RA@AO==V[Q@LU9SY=L^^5E58EZD<78BY*(04]P 7&296H? M29T^IP)[+$(!-=I[UB$ZL5784@-$D3,\-M:"36^[V3489E9@@$-
#Z0+GT7!>[V"$Y"N5/3@-PO'J!QKW MVM10"MY&*.Q]_JM'P=FG!WAIED4!A9''$,0T(Y &+(6<,B8"&B#"D'XEI:-T
M)M\SD71W]TP05GLFS=?-'^;UE(Z#IK$YX@8*,[O0B;M=D%\5K>PV)9:.2V]2 M:,D)"N=O7MSDW\'MM]7QC0L=D
RK,IT4?;PVT_';9ZS0=%*&W3I-IR\W7]E\ M7A6?QVX\3D_;2JK:T66.MV+FC*:C?8S\-N./)_*NDYGLT].6R])*O'N78'Y?D3G=:/W+
[Q!.\H@H46>@/E].@ MXT!_WC\F_6D/P('@9B;BA,S@=T7>D8-P0C@K5^'8F+,Y#2>$&KH/IRZU?0 @5FGR.,"
[L]^(U=:IHBM'AY61=.!XGVN.O,5 M?#.AOA=L*?_'%TD2HBB).>0A5_7*6:+RY4/Y'Y2D*/!('&NUT#,A.OUAG62A M[5IS
7C/A=31EKP*$@=5TYOE35Z =37X1G-#S@AB%0D2S"" 2(IQ$F*()+>9W&L1H?2-E+QZMY1*=[OZM7C,W^<5:U8UVO%)
M1T>8.CJI(0P:RBJU\S9O6T7_^OGZ"B@FY_K4K=#S@DP3J]$W.!@IM.Z$'3; M%*X"ETY*:A>V='S8^8*63HJV$[)T^NISXQ@^;?
H',$*2((H)Q*DO_2.J.F!% M6$ _C4,O]D7$A5&^_ $:\T4IN&BR\,FZM8*5P&:::2KK&:$%+Z1Q'DGPZ;7[
M);P0\7B_NJQ^8X.#LYHX1L1GKI1C \S+^CE6HUA$)7VI M[T7YBRA$298?
OJNX5M'&238_7/*_KMO4VVJ1>%$6"-46,T8"8D2Q*J*30$)9 M&@7$HURNZ'6#E+3)3FQN&G(&$3GZ<(W;D^E ,+,C#270\0
Z)L";EHT?+T#[M^X"52; R"&::!#.[V"9WV)D%-1E#,!KCI#_:?"%/QA+N1$"9WVWGMOVR6O%O M^7)YW?
CULHEX5@\4$/;W==XVES!SW?20U?/8G.-E9F![\A?@ M5T'4!DES@MM5X=]RX,XS,Y+7D4.F1W-
6/\P(AGWWR^QF\YW0:_+\EVK0CF6[M?:.[T: YRG3OM20.GJJ=QDE;^H[W(0R%M=H1U!E_MJU! V&'>X0FMUDL%=KZ
M=IL%B!IJI91B+?CN&F41,QZD69A!A-27T/^("9PR4V#?QE?7PUUA:3H&9F(O:ZZ3U?@"$7^N4Q
MST'*8&4Q"6)V*PM7R)FM*XP!&%U7Z(\VW[K"6,*==87YW1:>@9!+EW*U?KQ5 M_;V:D]?[U5+>^[4N+A]JW8/2$\-
,;"D5=="0!PU],& ?!7UNBR,&FGJ */A M+KG#Q-!5.A\.,U=)3U [-^G$V/.Y2'T"[KA'FK>-P=]Z\R3$ MF8>)1#,2]NDU3F 212',HC#F61
0@@W/;$:H37Y$LZFQ/Z!^QCGK.'2Z!S.. M #$]A["PK[EP)B,KOL.'*3U.LT'QL0^VH%@]"9;5>\+DJHT*%(\;WJIWJP? M567-VU7?
JN1==W;95*+XJIIKEH*WQGZ! ARG!'DP]7$,<>IE,!&,0L_S0AI3 M/V:Q8;L1%VQ-;#Q^*[)UP:432SAO=@;E?"B?U$-
NTT0Y@FC$#"$I2$:2 $SQ:%N%.=I+3] MJ9-DM50W;55W2%Q;@U5-,@'*#<'J A0C)6+L\=-VJ=Q@8NM9[7&5&II^+!SXM(G3$L
M_(1HQR-1SPD$[XIGG)D5?GR$B35(%4QQEAP^@L/1#48W$)@IF(;T3M/$3\MH M6U3FU9/%3XNV5VYFFI3Q?VM/$;\.#A&
[GIM>3/T Y*)$/(L0!)4BD$;4M*>6$0Q--L4JY'IQVKS*PY=EP MK]#U@]$S,*\(MIE9&I:C&GCM
U[5ZGO#K;ILN[G8,WPQ#$V8IUR54UB=E[%R MP]TKE;=R"NWQLE=NR=A9[;#S9GYR'4T]*IE] M1847(\Y;3.&80"_J*!R]T"
(J^HI+VYEGN7)VKHI:/M!_E*NJ6O@A MC85/8HCD))O)I?L"<\X]"E#@D248"06M8I)&I\\],@9+=XW1/6/90;TI4?8
M,V#4"T(3MW$%=8^&X?G4$(@M[;891 4:ZD[A, AE=@J++70CS^'L"[A07;QT% M+FN+.QJP?'J4^0*5M27:"5#6O\O,SE5E?: ALQ"?
R8/H]R8I19AE&60$$VGC M$@H)(2'T4.:E/"$A]C*=OG!RV#%=$#3 'R[^V/H@&@5G45U_07G4-[C!W?9N49Y42UF6?
&N00'+AU8MUK M$^:'*84=Z9,A:5IRGW;XSQ393-OLI35R]4=DLG+T#XTWFYL_(LS0R1^[S'*# M*"_R6GS*GP3?
GUGEPRKK_+\;]Z@K-_"?@I1-YYL%1CQ)&4IADOAR7DR2 ":I M[T$6>MCGGJH_JS4OGLG'Q(K;IK5(JY4_J*@W0
:LJ)WBK.$:+A7;!YQ!U4!" MOF.QX0Z4Y2/1W)N:'FC#7:L6PX:C%^N-BZ;\"%/8#[F[(JQMFNTPRVM\Z!Q MM=EER<6\VV#G0?
5B@^S,X6O*0'=?FU?^_DER GQ$?4QA1%.)<@$!S -*(4QQV' >92%:;!X;&J*W-2D MK.<%>I^P-M@_B[N\4"U/ "7+Q@.:!C[.0BPR$L
HXA'$(8]A$H<$!C0*?2]. M(I:&'7P?"LV <;?@]62UH?O0OF[3XJ8W4[I"PFPZW"TQWA*^ /2D]05/RJ@ M^WKB+TF]5AWQHT*/U_?
H_%%KMJ&-FTD+S)OS>?V]Z1?8]#Y&'4-1,)N<]1 M'&>0DBR5FI[X,,$!ASAB&?7"C/M"OY&J-MF)O>OP;;375A4C*;]MOELW%55
M'U"-/?A)8#+UC9^&34:/-AB56%ET8=5'RV"+?A+4[+;J7:)GMG%O#,+H!K[^ M:/-MY!M+N+.A;WZWC765[T5#Y'->B,-4_.
[]#JB0[KR(8("0RK6A(20H(E"(MQ&,\DIYHI%\"5I_NQ/85OTWW[:L/WK3?I_[:L^I#H&=A*@#"VL_*&S$8J+ M$2/A6YE8?
V6>RFDNO^X M7'WKPL^[=¥JPD @>>S!!OLKL8 P2+CR8$89XG*01989!W@?I3+]](JF"3))M M:N&91F@?QD:$(K6=BXQ5Z<
=7%S MHKDV/U=8PT6YDE/1 WV6B_OFB:,BN5J&'Z0Q[_I[3,P7"^_1B^TLU76YXFM6 M7Q,\1I1/.6NK9W=O'\69H$3X$
7*$91+:YBDQ(-!ZA'"0Y](C]!$*<>(S7+H M7(HG4:Q-+=8H1GH:ZDIR,T7MJ#8[W!W=OEZ]>XW5$=&1XHZ2FE5_=83>5V.M
M>RQ6>+!Q6AP2IN=^RI MSYD[8@8KBSW9-99;]A*9Z6!/QV:]M">5P9K(7CJ[=<_)1V:VECG,_NAZ9>^6 M^=8DAWG=67<\&*:9
MZR*K-^5/@)>9Y7$$E;$C8"BX(Y]E^JL[H$A%/N>@NGM9@:EJ=A4/B]^NUE$
M.$"Q'T4P#DFH:E2J7H,>ABB)448\&D9Z3;^V0TYL!GY[>W,\K>"8E.-Z:\>[MF4K^]OGJ]L-[<'-[>?OAYGR->\GR2*QG=W&K2]T?
6S4:##6+AKQDO7_Y#_QB MXPR3[RHPJD*>[\E_^Z.[U/?#6# "J3K0P+&(Y/28,)CZ@?"#@#(>Q/I.\4$:
M4SO'Y'L3[EY6%8=/SELX4U])M?RFGE0A\6V,25/EMP2Y?:X$$;
M>M>C$HU[V8=OG=';'N5]U^L>O]3.^_YWD=_=UX)?/HF2W(G/:S7F^WRYEM^] MB(;9MI%:>
(QFYZ*R#V&S!5[/69\!3#/SUS,$.HY RY*"M>5G&_2G&LEZ52)"KM%691 M EF42KN5H Q2/Z,0"_BPU!HYSV<8CT;,W98IM9
MDJX_;4/O FPINK,/HP(YTO[#-&;5[5$Q]S5W_&(SO>0B7WPHZKQ^EBY-G_W- M&F^RM0@+Y@G.N)=
DG$$<1AZ,$49AXF/@XBR*(Q1JK.L.4EIXL5-2[OIL[)+ MO9O^])3T-%[CBNH4!3-EM09 6VFUA1O92I!CM#HK/VQ5]?
3(LZBKMH"]RNK? MX#RIM"WY$:99%#/BPSA."<21__!1,B9520!(RR.A3 L/':"Y.23;$,%L+Z7
M)FDRG0WGV).XZ4VW+K$P4^;17$XY%X\7CW&9L'F@/,J4F9DSUE$Q%=X@U_*<
M6BHOZQ^.$&IK^F@<]YFP5QFYU543Q)^I0*INH &,)00%,.$BAI@G/DPQ\R&-*>8IHP0'F7U]Z<-$)WM%'L#,U&B[P,#,60R
^K8H[>"O*!Z#XV*GL/%>IYG'Q)ZB^ M?(3@JQ54'@=@K$;RB3O/R:I5'_Y+E*LNY^%:>N3\1D[G\L:[,0($BOKPP301 MOD<"F-
(00ZQ(#&F:)) G@@4H9#C1:UMY#A,3.R;AV]#[1_!/_^!'P9]Q'(*'M?+E42^UACAB*5 ZNNJ[Y_*@8!E7'\1DIN89/(T4BCA,:04]9;
>AQ8S\7>*;KS$UF;_-1\;1).FNX C<[.'8Y M:!+E<_*D#9&UR9J>#N&S'8KY!O;2?]X>QKR[$LYN2;M_/LF#7%
<4LD2'J[S[,LB2,!$Y6/C<,DA GU!"19A$28I3[+ NU96)OLQ/-N M]#;U=C.Q@P2\:,]M/AM/J_J :MCW26 R=.CS[\,LXATS,
[0K$BL+"ZZ/EH'- MG@0U.ROM$CTSJVP,PJ@=UA]M/LMK+.&.K36_VVY'Y-=5(9Y_)>7?1/U16O&J M>YTS2D(6TAAZA'&
(8\JABLJ"C&6<>2S- LS-=D$.$YK<3V[(@H>&+GA8JP;= M(%/TS38_CL"DM^%QONAF-
K&5N24(&HH3)#&."^5HZ^((D5FW*\8%W=^B.'&U MA0OT'W?BB?1JF6&YBD4AY")0:<:"0LI\ AD2** (RX5NI.WD# :>V(WYCU\^
M_.728-H=BJSAAE@*8J94C0PV/L10& ,OP5(H.S^@$ M#W"Y,P$?^MUNBOTL:E6/X+I5<\)^??ZO4Z<:71U'*IU3<7;(Z?VIB?
A1HUXVG=M' !'4[T!X5FG?W-_]ET"BQ&F-C2;!-TT2$2,> Q9Q@3$3-4'I2K5RV->8W)\ ME)KY^>9,3+X&V%0;JMH,WT-
VYT]3&1[#7.AIX9O<$$V2)FV/R>RVZ762I^T! MLK=59Z94OSS2O632KAL13WHJB:3KAL]2^K:HV#&0;OG)G]3CLM>_J*\ZZ[E]]
(R6\?[MJ& MOMO5HF;GW2.W3SPK-E3!;?Z@MKA:TOK]=H])/*Y2CH0UTZD#NM1.)) T MY=?-
_"Y.'T&DG[^E/,U6>JKUT'93^O6N6*;*9:&Q.[2$T^)9Z5@!P><3;O& MQ!FJUNAU=F[BY1/)EVJ;O].I"B2B'$$$Q1+YU&U $B# M-

((^)V&:>1D6C)HL W4)3ZRL'TE>@B>R-.X H T<(CX+PHA#0K,,8KEDAM0/ M,4P]XL<|9 E/0Y 0ATF
,P]T:#M_YX7$7%0UI(*4R@1LZ[I-!*>7H13'C$(4 M> QB%0A/,@]#CI$O(N(E"3>L.34%H%9+FPTC,%N5L)*L#. T/+?5QE OZ3,%
M1F9S3+.GN"5T 7;14DRY6QZ9BNMHT:1-=M:EE"D8^PLLX_OM9K*?UU5>B*JZ M9'|?YU73NKNZ+E>2Z /Y+.KM"
<5"3EXDPH$'LUBHSN4A@2DF"4S2F,81XE0D M6GFLQI0GGLM4&$-N<12JCYR>L9@$#S-KT;, !CQQ M](Z,AS[=6:V',1S[YL-|-
M2>J,MT<,8T2B1CD:",@%QB -E-!#,HB3#+$@"
M3+7\7SUR4Y^#M#7E#K52U^JD;@/@N.UP#XN9P3@7$8MB>Y;=Y74K[KU^1WDS M45_6WIN@JWQO5 9#5]*"+-
=MM5S>F!>RO"8YORK>D<=<+G(6E-*$1WZL"JZ' M$$=RR4$IPC 0%,<|C2(<&<:.FI"?? G1O?.5XJ;I"T=YOORA6S;_&:"+.)3?=C6|
5G7]ZLR_V_!_PQ6VP?V3_^0(!_].0SB MMV%_J1Q8O;@-T3 (W^+='P+#=IDFSU3/DYGJ.9G9IJ%1D@N?#2-@RPE0K"C8
M.F8<=MVT@,!5,TX3TO/VZ+0 Y47K3ILQS#?/KXHJEU=V6X?7JV7.Y%I+.E#L MDW2KKFKQ<,JMUQQENO>_(P[Z;>:>?&,W%
^"KY75^%WQ AIF'.TS&XAMM>VL M,_YLN] &P@XWI4UNLYNL?ZO$E^Q#5>_?
2<*&#TOG:!;;&WS6>>:P8/LSR9&K;#WCJJXN"[A^Z,H*G5^$7@)3K)0 M!?RIJF|\>@JGP"$Q]02+! QR&R.3\8I_ +.
<4VTPHT9$U]2WW4-'U'^UE-?41 M):5F0OQP2D +%_"P%,[KF8RG$^]4#R8L%2FF< MB(A"Y@>1U+M42)7#"/HBXK'|2:Y
C3JMGZ0X\9[3X2W9G@7P>|N$82CN:1BM MMZSMP7&Q5:V/BXL-ZL.R3KD#XNOL1%]Y$;;+LYL2:IJTVE"]7B]
M7+&\BTJ\%F6^XC^+;%6*6_+]LJ[+G*[K)MUF=4V:.-8D\I(,80:1'Q.(,4IA M@GP/XHRG.!,9C7U_48@[E<1S:]+G^5S.M-
0G;=7G!7_:JK3/)R";_E=J3ZE> M 4'*PKPBM(,GHV>&9@+:LG?T'KA-BOGEEW=7F_ADT#)X 6C#HNI9(RW9@$L@
M'T'+I\O>TJXP<]9V^FR&9NY({0K E\VJG8UL$8K-_WJ[4BD5EP^U=OSUX)Z) MW:%M:SZE%(JF="M)-
_DWO7$,8K"'HI[>S+.5TLQ>'!?PE'QFX=8'A+&+L1X. M-
%]@]0'V=Z*I#_UNK@R#DS.IE*LG43X;JL;Q$296%),WQT3NTWKB1F0SK1G0 M!#W1Z93GM(16JC0R[&R*=5JTH9II7&TQ
]W=U>_NB[OKHBK^0I97QV?Z_ MJ$/B_2H3/XM"9'D-Y,P/+I=+Z3<6E7JWK^6PE7SO'U=EW13? 4HRL]\"3>"[MP?1H_!PTYM
I'X'A1/L:Z#M,[S\+3KNIWIC:?/Z +1 [3H/U(+:A_$DEJM'M0G& M[HO5_+<2UX2,2HRX<=+4_3];2W=V\Q7#.]6-V(IF/2^?
A6D6I?"8(%^Z-X9EN:DD!-)1QAT ME(V7Z0?E/NV$GRNRF5K:2FOD"(^)9.7K'AQP-G=V3)RAQSIZG9D>566]+:SS
MBUC=E>3Q/F=DV51GBED8QQE*81QX$<21JCD>!?(_A,<)3D4*7.?7XE=9?G>5V*1_+<',I>%OR=])JK+]GQ)-$%1EADL4<@2D,!
M<1QCF#"!H<](& 0\Q5X:FL5[.N'+Y)VW"A/MN6P/6A\V?*KMG+;/3[,18YMQ M[^;AZ+G2LP-N9F1VD=XRJ#)&-RPVP74-D^H!S)J.
[A0^1XZ\&YYF=?>=PKB_ M*' [N$61)$+72U)^RJMZKU*U;J6D8P-,[,UT=($B?&&ZM7]%BGQ4)90#_H)E=Y-*@)(4\0@Q2CUA&">
[R4613G=<3BY MG]-&Z*^+4I"E2AL%;Y:2*5']".XD@S;%/1T^'CW_YA4A-S-)\O[7[2-4!3# MH.'X BB>-
[\2Q3C8YWP8|>>X2*E[5%U6.'7(W?SE4=U#>["VZ@1D[$RWJO76 M'(A?
%8_KNOJDMG&#ON%D*OPXC&+H$YI"S.5_")7_X<2/8Y'QA*:&?6!'J$UN M4F_RNZ*!KZBE85W12I1/C;.1-[Q(;5;
<@$"SH;8.@'J&TA$H9D:OJ?''74%7) M\XKN!>@ F. \14-$1Q9HC-
LUD1#Y'W+H'.+^2+HP]_KY\MO):_/V6,)].)4)R=781/A:V8AIH76<:R4!6)6 M*SX3.K.M 2V$'ZX*;6ZW=#:DRR)GX3;5@4DZ1=-
%KBDTOS%^[_.*R<7.NA2+ M("0D%LR'E$<,XB3&0,8LD/X(R6A"XH1SPR)#AAQ,[I2\V7^)-5"+CELVC:8 M
JKID$P'DJ&3TC(">DY S\!%VP7B8FB/M@PY]%OLD'#ERQA2G]>_L8/FA<]C M.8R9 6J:>K\KU0JK(W3SC3SVQ/H0J%":%!RR!
(99&D&L2E.G?D)@&*0B"2+& M RH6A:C'38T6+2V=V>1^UF9&I2$.6:\TE20/6$>_W3_:,"<9M+(_"1_Q1!C[
M'H.QX*HH!L]@$F8'I3G'/8[KGS07<^%3F' RSB:NAO)VV%.W-W*41
MKV@!!U^QM3I2:USL^6#9(6L(SY&7Y.WYT[>1F.UDK6YI9F O#;QF%M8;9)8Y MUTB>?H8UN^GL!LY'SV_;4KJL2!3-
<9#&/FIM'5Q$$'*8@%YT[V IY@'9GU* M3:A//&&)S@+.>ES\9>F:F4B-HQ'$1P[, <-]&68/V:S5-UH=E MI$6RP2"6[7H8*]>"?\H)S9?-
R'T+0S_"WN#U&F]@](YL$DC A,.2,TC@E# M8638%^48KZ+7B4G,[!8C%^BMYYW(XI\57Y>U:)ZOQ82L*CW9B,A.*,8(LH\B".Y
MGB3&?T5T#.X+!;_IP%B]DB2$O2T170^ CS+7^T)-E9^^C= M85D1EE3WZE]U O8DO9JBKKZ*JBYSE:ZC?
K@L^.X7@RL7*4EB/T*QVAICJF]* M!). <9CQS*>^1TC"T\5C4PGJIB;EB0U')SR9O/7[G.FO^U48E0H99^J#V%(' MI
94W.6%*D2G3A9;$H;U:,]Z)ESX),%!"B,28X@3$L#$"QB,LXS@A'H1"Y+N MF7PH^!_RB?1\N7D>0G[_*D]"SQV=#5O#G3])J(L7'-"[
%M60'N)@GWOR^$= M#BL5NP#*55GCLWB9MP:R"]A>%$QV,JCE,GG8SOV25LTVX") 7L"#C$*42'<; M,\YADA
,18@(BA/L(Q\9+I$/T9G^W*&KMMF>HILV!CT(C>:R^%QQ#9?$#;EM M==''?>Y(,-
\9&17*U&#Y(8]Z%\)B8+Q;!HQ?;:>0OJQ7_EB^7BXPF412& 8QB M&D$<(23+,(PP,+S0C\CB0A--L;
[@2=>W/9DS)1M(W6,H\CS,A]&"?$A]@B' MJ1 ,TI 3$<@5/N/"W NVD=W:H?V9R#^94.[2_R7%6H6Z^1=-_RY+3 @+4>;%
M$@35Q!E[*($DB#F,6)1@@GWDM#4"[5'Q-BA'.!Q(S6PG6F!P#L+$CTS;".D MF>4]^;8;V]E]GAV9ULVPLUK3?
6'V#>B+W^ULYE7!1987>2T^Y4^"7Q6U?$8Y M78K60/]*_KHJWZE,B<_DH6]WD*&0>9E4)3^(8H@C@2$E2%J;5&I5Q'@8>(&)
M>;7@86)+O.4(+A5+8,L3Z#V&ABW0\ 448Y;=)6P>@)X*3PRKF;8/$/WD#E%C
MW&)HZLB0T'LQ]>,R#:MU'G#&5S!H(EVEZ(FMW);A?;3\,D0;Z D5!5[&(L
M70%!0TB2F/LA9AX+L/()QTL"$QLB_!9Y_PB*P4%'B,";]MOF<|.*2=CA(9!T M3CS.$]W,6.S+9W6X<4!.DR.-
|^2U.|C8E]O5H<5Q6<:/*@[<-^,!Q7&N=X\E M1JZS]8F>Y*-;E<_;..EMS8,X]A,849] G'(/IE*J,_2T L\RL/,L#/D
M&+G)]WEZXL;A#Z,@Z3HH;@0W]40ZJH,,!_#()#TC=01TYE:,D)K9?S@M]$M' M0>,>"X_@]MOJ>I47]7^)AS92!B[)%
(C9^2FZR#GR7TP%'W5]M >;S],QE6_' M_3&^VUN&=UOX75_%(ZGOB7A:+=4$0VCW<@>"I6&"4TA5'BBFA, D)0RB
MF")!2(88US(/8T0F-@8=50-?X!@8&DZ2 Q'-]+HC"-YL2?YHX_\!F4MS0KA1#^;8O?,Y+">XW_%/3EUK&2_:=*&Z*G[;5/3K]WM]*39I
M[JKJE[1R5T55E\U[4/D+CH+48TD@C8^?08P3+BU0PB#!Q$L]/_80U4JJ/I>1 MJ4,)=K+2@>]DJRH[/#65'>Y;=D#CS4C-J.
[SQ^H";&MGR/6BJ/*[HIG82;6Y M(=*8!C :/NX]+RA.1Z"F1W==DG;\C0LR*#61L<;N-(V#Q@\4QT7,4J MVK(Q;YCBF6"]B% |=SSS
F4?I>RK0O0])M^OQ>WJ?5[]?2WI]^4.OV2WY'O7 MHZ\R: !C,_;$IJYC:=O)5.UUU2NPSY8*OI:,@9XS\Q;(5L".6[Y,#6S7)/!
M:51_[!Q,K J161&$ M!(3"!*N3-.YYD%(20!ZR@*0B$RC2:I-SDM+$!DB1!DM)NU&5CKII2N(H4CK; MZ8[D-
JQ"5Z(KLDW"W5!TJTWS,0Q,-LH=86&Y.7X4$U?;X1KBC6^!CPTXF412-W MAAR[6]TZ-]A8*?+]/P4I*^3Y@?PW[!M@)H&?
T"2"),OD4C%B"*;8I9!$01J& M&<*IB7TZ2&-JRR3G9T45**I0D371QL.HZ-BBLV4UM$*=F-563BOS%F]_M7%LEE/X^U&LF/
M4IEX)NKH-GK6$3;,]QG':'Q&<2:YV>Q@);11@]R30IW1(/?XV+,UR#TIWK!! M[NF+S922BWSQH:CS^OFJD'/!0S/;?-H4M &I<-
=V);Z.;MI)KJZ>>8"-[[7* 5CWE MAZUFGAAV%M74$ZW73(8/CP\+E?/0MS4E +^3"K!P77;=Q=[^6?OI&^R45)54WI;9W2_
VWC0BQ2GE!(:0Q][!&*1"4@X M8C!"-/#2, Q0K#6=&M"<6+NU*G WC!AFO.O J:?]CD$RLP-:A;9/X&-L @PD M=F0,="C.:A8,(-
@W$":WGI%M=BNA%X-|C&VUS,#OS[YI*OP@E.YVG,80LSB! M:4Q"&(5(\"R+(Z2W)C:D.[')0&^#_8PS7V6?2*8)H./\,WWIM3+0-(:;
M/P=-7\:#66@&MY]7X^WK:JFZ*:I.F0LO2DE,LP1F2+6W#QB"E*8A9"E2GI^*)NB(&OI5AZ#1\Z/.%-C,)K*:ET&[(TCBN"#2F|
M2G&P R(>JQ-VZ-(S6YQOD_6K;?U3'U&,1""70 F'6&HFI"A $(6Q%R*6A"3@ M)KHX1FQBI3S8"
[/2J1!J#IN>GKH"PTQA[7&P[VL^(J#KQN:'2+U.9_,1H8^V M-A^[QTZ]K\L5$X)7'R6CW?Z6.CK\4M^+\F->D(+EQ=TE]_.G9A6U4&
<%U \" M&/!4:GR013#): Y)2@,,A;SP+"IL"$')F^^58VVPY3ZK.;$$IH]"V,[C&4^Y^KA ML13WHJCR)W%5L-
6#^"SJ)A5A02/L>0@RN6J F*0JW#[Q(4/"CV,41+[>>N$8@8G7"#U)T--L M"M?JQQT>_E]
[PR\=EV;IS8\#:T@")FV$5N1S@]5\M:+C.SL!4)_*XHN6P6=T@"5TWB M=L:>MSG<(;%>-(4[>-%Y@0(?
5Z7([XH^Z>FV)$75ECWK"S$M1"AHR#WIS8^8$%??L=Q#!J$7R6\01^08U$/!B/8F9FO M@JD&1MOJ2>OZ2W;)I)^U;FKK-
N1#SE5_PKCI3)2&,/(Y M)P$-8Q8:=:H\CYV)S=$^'S@O,C-29ST7/<,V'MIDQ.P_H M"3)7W #ER.J=R?Z,YN__?NJ_-
M5T83!5%5S_/U55*)\$G+!2)# (>"STXY2H=5N80HR1VCSR*10>DMY+C'TO28S#7X^2F]P(],0OP*,B MW]1^$3T#%Z
0FO6RM;#3,PBN\#"S!%L@KC=_?-@"\7D$")MHUI,2N@M=/4YJ M[CC5DT(?"$H]?8_%LN3G=947TFK(-0_-
B\;+4RY%+F]O_FCVC3)1EJ(AJ4J! MM(6UJJNJ6@NN2FW)#^H(OHG*5ZLI>5TIR]]"ZA%K*D,TN]O5@C(2QIAAB%E" M(4Z22"YS2
Q1YGE^$HM(NA/:RYP9&9]XV;3#=KM1W?+=%+(KM]P TK!CL):8 M\^EJ+,S^H,_,S#SV0H"!%!=@]R$.!+D K2B;(H45:
(4!EZIR82?.19=F]$5M M5;4B@8%,X/*/_.0-5J5_T#? ;I7[1WP3S);0K_X1I?D<_(SWQ+_%5#>V3)X M#?J6";:
[AU:2RR:OK_J4$YHO)6<'LO\6+,@RE$4!Y &/(49^ &E$!8P0IH*& M)"%YA#FJDP&YPPF$1R'80B)OQ$A;\B0PNE075R@]3R
JF!+;)""< MYUUU[D>2I*["X9\"3%N9,"=2$XD!RH?>O9S0L_ M?%?;D%U?LJN'1V7'K M"&(C?/6\F*E0,S-%^C5AM5KE3%$>5L?
Z3%0G=F8S= XH%I5C71F?;E>)?\R+ MO!:?\B>AVKC(MRR71"ZK2M35O\OEW;UTNBZE121WXK=*9.OEISR3:RR4",2C
M"'H)BN4:"Q.88BX76HF?44HQ1[Y1*L,YS$QLG'JZ@+2$U5(J7W%EJ\C#JJSS M_R;F]>C/
E_/4LT%J9GEZKD"+5NPX0ML&0,M9Q=@ WO''&BY XH]AUE0#D!R ME31U#BOSYE@Y .U%2I:+,>TC\5KW0J6$??A>JU!D2?
5#L7[H]NP7@I(X1*$' MO8@F$(<1@8GG9S"*D<=BZ7FEB9&]TZ YL5G;_ M'$-D9J;.1\:@\W5O-=XMN2WY9EG)-F+=#O2>U-MT-
T;.G3OQ+J])0;>:Q>E.2KGZ8V:.9C5=0ZR53@+H=4X$0^ M >P+)@3-A&&0OSD3TY]D2WY
MEQ]Z\HZYSTO@&R8^9/9JL,":KU%R+3PF=E1 ME1?48-=S_^@S>*,8DA#^"#8\#0IA3U(\WQX31^L6"P9F7<;8 [2_JCEC) M'
M[:I@I2"5>"_:_U\5GZ7 371/?4N^;\)Z%EAD08@%ASP,"<0>5S5L*(5ID@64 MQ3'+4J]=6J!+=>(UTZ=5<0?E?0^@)M_-8_[,_-3PV*:

Q70/I*4,WO0*",# MMFRH4MK;^+XI<#)PXJ; R\Z5GJE\.[Z>\Y'Z$A(48!^B)(@@CAB!28BX7 G+;Z,,,R[0'#5ZYFCZ>F[E&)M^L.
<]'3U_ M<3;,S4SYQ'#/5J=GBL:SY_'R/Z)*SVBS6C>#GE<\4>6\[)WV;4/&-TNV,,,B M#;B 'O6EV\F9@*G@!/(L96G*LB0*?)OZB5K4)S:
(FVZ%*K3{Q7'X(%_"NB^< M&=9ZY6FXR!,W,FU/PK,LJ&H'@N+*B'NU7*;YH!,NQ^HIF@]@9HV.&3E5OE${B
MM8KU617#SD&WJ[9OD+_ +&*"APD,0I[(%;''8*+:R_A>PGR2>6'"DD4A[I1!
MO=6W4&>PI*5M::MM+Q@S6>LH!T$NF4V3X\Y!6||X30V>E:D:\;+Z/E5-@ZJ. MN\D;53D R9$I.X>360V;\CVS9R+
(2VB&E1GN2:1YGZUE+=\K8O+AUH[KN'@ MW1.[20U1,* *OHIZ74H]>5BM1_1"5_9QR^)&;#.#82NQ6:3#J%!VL0Z'AYPO
MVF%4I)UXA_$K;:J/$OF$Q)?LRV,7>E1=KY8Y&R0_Q0QEA%("(Z26,G[*(1%J MK\<+(Y1ETIU(J4'
PTF"DQ_J]54/3$IOGD1)8YO2&YW$-:54Z9$L<_-Z2 MUTJ[L('$I":I2VCLML+?BXK)*4M40$YPH&@!4X'S!9!CY?7S_ZX
[=ZFJ&E>R_+9?/E8WLB5C4KOEQ>^%CF!'_E6W"5-9>T+(%5@U<3?P$>5I+A
M^E[RJS+_=EGEVV4E658K>3E76RB=L*58MN4C\H='.7T3;; 49<7K:ONZ2!*" ML/O-R(T\ZG;:-$Y3L2 -*:%.IKJ(N"-^EI\)P^/JH -
Z0+F2_$DBK5*!E*_MDK*0DE<_OMWII4ZHVOC;?18#;@HAN*HF#*@ ?U\3"4>6"_[G@[*PU7K)U872
M%C^)Y_8T>ETU0RIF*U"MI6"D C](KX:O&N[%\OF'"_!#RX:0));-%Y+A'}H' MK\1?*6?HA[?@]EXB()9M@)_\V(LIZ*V6I?TA=78FZI
[:OVV+R>K]}EM#5H MO/+MR5%FK'^K*]%N%5SMNVPC\/>/9RX9*]?JJ+O=:92KRVORW.S#9U'FXS!) M)="JK%U(*4RH2" 7D?
S#"WV?^*8U<;6I3Q\VV%+N>C:WZVJ+:I@F@.HMIB<" MZ?P3:6E!N_5SPP/HF' 9EV\LN;/X?'W*,\?I&T/R,E[?? CS%>Z'O]?/E]]*
M7EWROWXLC.LX'+E]XC5N5[>N+?$%+K?MDU3/H%6MVDCJKW./(7!ZH>M >#/M MUI!
{@HH*)\2T6OL>&W.VQ>\)H8:KWU.7FBO=55OL[K;DC9>02T4N5^R2KQYK MP3\NR9VN^IT<;&)%
[.B#/N&DYZ+Q4IOZW[SQJCN.])7R-$*GU=,I.*;3L!$N MX'?%CB-UU1;;2G%/CSZ;"FL+.E1F_9LLRZ^1ZG[!,B](PC2#A(4!Q"G.I <>
M8(@CS_=\=42?:$5_#@>>=6),5"<.Z9TI2/=?8E'\S91MEW;PDV8!75S7'U)#S M%A4;"/&B:MCP-]O"&)O8E_?BL10L;]/@Q.-2-
,608I\R.8!B'B6'5R\6.SI:HKUN98QVX"R_B T[9RX8!%L&H:P1SO M!6%:5\/1L]-3_==X'F;F8_@@ABQ>@ V3#=Y#-B_ 7E.*B]VN%"[+;
[C%SUDI M#D=LS5R6PRV8+TMT.![??9B.LOX?EZMO_R;XG>@[K_XLLE4I]L,<)4>WY/LB
M3BFE7L!A@.,08I0%,$W2%"8^92**B;33D8DSXY2[B;VBWXI2D&7^W](TW$EN M*O!F*1D2(RV'9W@@>H;WU6 VL[X:T3Y-
1]B%S3\7@Q;/U\ VK -7L1O*WLL M.9\G#L@:T!DB@\QY^\/$"EG#:A(}9$_$OJ2E7(7697-;_"DOQ%4M'JI%R#DG M64PA%X)#'/(
)HGTBA.<(#\)49(PH^26(W0FMIA-W<4M6?"[(@P:RH;1V,=P MTC-_#J0W,V16@EN5E1P1RV$%R4-49B\6.2+JH;J08Y>;[|)^)@^"?
_@NV%J=M[`_)!60^F!Q2')RH(EULJ$/-@R G@.;TY+3H)S>F'6*AYF6GH9B@@,4;7FM M=F1/CS[;CJRVH,,=6?V;SFZ(T80P5I?
K^GY5*J=^D89!BC'Q8(!4R]# 2R E M)($\E@L;%$4X3I%U(XQ]:I-O*1DUP&A:752 ;-AK&F&TW]IWP'B!L.8&L1O4 M#/>-
=SI>M'3!EO D72Z.2>>^N\4+2J_5U>*8R"/=+([>8FUU)F\N%OX.,E\U3DX$AZ%6 @?IIZT"ICX 8L1\46H&7ILR<'D
MEJ(C;*_RII"&O@1/B!3&H0(R2U)(619!A&@4131F <\6M0HS?W5 MUQHP]ES M_L"V)UQ55&HO(/ZP_7-
?'#K6=T)032SQ"\J6;>LJ$#9SBP/V+@ '8/N#+0E M$(Z,MBGU60VY)33[QMUV&)O4DF[LSZM:!<5_:;;9I87DEQMO2.VBBIBD.*(8
M1B1$TK3C")+$"R$*$)+F"7DT)MH5FO1H3KW,VRA-T;+1GQPJ1H:^8#VR+6J- MY{C)F0@EP\7?JP)DDI?
B'"B[Y!0G@!DF%!B)/IY5H#?4C*D%1K+MYA>8W>K^ MW/"SJ+]DXXFVQJ=/$!1+/V\D(:>7%5'&4R%GT!&B4]I&F2,&X4_.>)K8O/;
MGF2QG9.LYKCPQRY7HFAS?#F1Q&_%H^YRE*\S1\$_[AJ MF/D+69J$BH\,,;%A_/7S]=6PPE##0;,V5CQ(0%LCV/0MU3^(&
(/D]!&$(S3, M;)()$$Y#PC6DM3IZ&!MWMD,'#>&&QPTZE]NY3R.-F8917Q^^JT)>MF'I2+YZ?G M/VWE?I6_?I1\MAW
M0/%H%HHDA0(S'V(4)I!X.((>Y3Q*8Y^2.-/> [1B86+CBM]B[Q_5YHVH)=. M!?)P"-ZTWS:?&^8T#R/. %ICBS?7OT-
Q!$CF59KPC$B M$]OM;:L-1;1OL*D(&P;1'@1(STD]5VPS>]M(?&LFL;$+.2:2(Y_P((E9G;PQ M(?>]MM%K[52R">!IRP16;;V*18"*
A9 &D8QQ#[,8>I\#)(!,;.$L<2/.#<) M_GA)8N+XCG:-6@W(_M,_),B/_]PD8>HV=AE!*.)9&B4XAG&@3!;S4D@I%1(K MS#)!?#^A=-
%V5;^I25G/@=,^.6VT?A9W>:%JJP%*EJH2VMGP)"E.4C;TKHXBI:>8 M+N0W4T\KT8V5\Y1O)Z.Z7]N9U2;NZ%J#]UA5P;9U^@
M+/!#JDIL>-*UR B%-/,]Z&44XQ!%,:*AB=(>(S2QTG9D04,7](2MUD1'H=+3 M6A< F&FM],']ML9KL[=>2/*Y]$>O5U43^K-
!XP+T*+E>.)V2V9%&'R4SJT:? M$G9?HT]>;[F08O>"KY?B2]:W>-GFV"'A!5&,5:$C2+10A]%0R&(R%@BI)
6B8BUQF,>4P$9JF1>H1- M%,HJ(|)CXP+$;Y MP6?R,_%YDNM4D5DS11:4,A(R)B!5FTF8QAY,4SDE1'Z81+&/F9=H94Z^QK-R
MD];3]1YI']GF6;W"H]";/68$V&Q:<9JD\X?)S'$\(YW+S?^D3)QCX'JXX%*IJ^)VW36VD4+SV3Y0H#,WO44P5;LA> 9'+6)?+Y>I;L[?>
MY.N4@N?J&$)UNNO8%<"1NNV./:M^'11K7Z$.7^2J96$SBW<=$HN[3SFA^3*O
MCDX$CID&'VE5V(*U805\TH#-0B"F#'DD"B!,>0AI@!I, 9?)?%F,O,-D[&@X^\490&UC,2%D^JW?] MJE# MM8_%N"Q7?F=
9B>V;2%P8=+#9NC9 MDQWVA3J4Y/#B&HL"H$EHVF20QC3-,(6A2*5^15$"$^:',$QBQ!%F M*!-:A_3'"$RL;?
@MVLL/#0*5'XJ:_%#YV3@_J!!(X]KE0G0S#=N7SR9E\^#+ MH)^0>::\=NF6^W({2IX2&?ZZ(J+OE?J^NR MO'EB[ZI^;:U9Q.?
([5/O(*@M5[7O/CA[NB[S50EN1/F4,P'>K2I-?V4,A'$[MX4A^PVT&+=$=[D)H2&E5]N?
8F+.5Z3DAU+!$SZE+S=2.BWSQOK.7;;&)ZR9Y MZZ/\KEH$',=^2%/H\R!2.P\93 EB,$@(E^8J%(GGZ6CG*)6)];.GV]==:2F#
MAK2>5HYC-*Z7SB0WTTPKH;754NH464][>**#]L%7%\U%E444NP7AGU+C:?
M!2^7RTW#CW>D%G>K,M]X49I3X=@8$^N;)#UH(;,EKC\#C@)P>AIT);N9QAT3 MV_'LIR.,/)4.MZ=SEC70)C'#
D.$YAA*C*N,X\F*A/:8R% M_">*4F[4]/,XJ8EU]5C>F%6^YPA@>CM(;F P4UN+[#'G&:&GY9XP@^PULD)/
M"ZR31>8F,_1E''G3;T$N8YA8,)_QC"<8\C21BHZ]#*J.+#):1 $C..0:?F_ M6M2FGI>W-,&CH@<>1=DV7&E:K_#56<20U+8
K?,R,P.&TD88R M:$A/FAGR4L+I\D &M%X[Z^.EV!HY'@=NFJ,/MMM:!!)H4G#%*<^A"3 MA*I&30(F42PRS!,?
(Z.L,RLN)K83#DK.RC_L!58?=@.J\.[/Y@YEL)[^XE#*<&OA2A_*5?K1XOV MO"-#3'W8W5(&BC1H:-NTY!V#X/1>@B/IS2S$F.
3-.#5D-%J1V%LW-DV%#2$ M&^XGZ%QN&2;?:GG?2"844>*'20I3G%$5,ZMJVODD#81VY3CKD)S73S8 X85;;'*O_?FVJN&{2#
.@@0%$$>]JT'@46DD.()> MD(HL1((BI%7_>G_@N4ZQ%2WS8^M&]'$5/D<@,S75D\7J-'K(^%D'T,U LY\Y M#]D_=,R||
{O=_/E>E/E34]O@W:IH)F0U:'=.DW 11 'U8(Q5IHF7,$A]E,+0 M3*0>%X:AT;)ZV/$1E:8#6G0T[8\UQI%3&]:=(6#H9[90&
|^^G(YFC6&R4U MZVRG(_3^+*=UCZU2T_JJD/YU8R6N"]DOHJJ_DEI\R#+!%,VNWP2Y$PN4!2C. M*
((D$E++$S^&Q*.^5/HX2H74\H09)4 849]8[3<4U=9TPPY^D1V M%4^B#?UM:TY\%2K?2/#+AR;W_.?
G+BKGN5U%^E0NP3,1PB#B$<0<>Y!01]'/ MXDAX*/(\&MN59C5C9&(KM&6FK]ABM3"WAEG/),T:GIEU,L?MC$*O=D([KP)K
MR,8KE8BU_^MX_5C+|>QR2GXNLKJZY'^U./XZJ)/< QV0E+KO))#8\Z:5S(BU'Y>R=BE-CFA01 B+T## M-,
L2D@<)!%D0A6+04D&:1HIAR!(* N1GP9:Q=F/$9A8,X.W0;B7$XK F_;; MYK-
Y3N@!D,;UTH7H9DJY+Y]53N@!.4UR0L^3URXG=%]N5SFAQV49SPD]<-^, M.:''N=[-
"1VYSGS^;L+1FK"_MHO3U[KX2[4YGS>>SS6'F]B*M#%V S; 5U&O MRP+\I1I$?>C/{[H@G9[O)\#'S-3H03/!_&\HN94_H$MC-O_
4.BAOV!ZJX7_ M<)-_'^N9*XU,VDTD:1#3E*0AS()4>A6>P##)6 9Y3'*6^2@1OGZE"6VR$UN) MZ$5_\B %;Z*N/[G\;.QKZ -JX8%,
I.9L9 L:'3(;K"R\%CTT3+P8R9!SF0-D#,*H6Z0_VGS.DK&$.RZ4^=UC%*9O-V N"]Z%'6\#]#R6A3Z7BS/D M^URNU?Q
=99%*HS*"S!.L@";US(_2FYB;]J6SNN+DXN6^(]_LBA)?APPO7U7 M=S"86+>)^^RS+X^(GD2[61 M^G%5WT"E4&=%-X*MRZ;
<8)=Z(+BJUO(SJ51?3"_S \(93&+J0ZGS#*8^]V'" M>"Q2W^,I3DRJ!IHR8&0+S"L+;@@"IEV;QQI+/:,P)4)F9J(Y(MZ2O@ ;UF"V
M*J%B[@)L$1RM;F0>*FT)@ZM@:E/R\X9;6X+S(B#;=AS+Z)3*>>BX-4U>594 MVS,>Z=,TJ\>%2$,
<"6EAO%AU3"$HD%8G$"J}$@D>>8$P:YP]3F[JL+.>.'AL MJ>]E6:\K;IUA?0)'/3OC#AU#J[(!IB/AW$F6D*Z"BP9)S9O M)
(F6X"]"1_3NLJUTSD5V/._QP_>N8&W?4701>3%%B<]@% 0,8AH@2+R(0S]D MA/,(97'LFY8[-V/!1
NLDJ>V#!W+HS8M@FZ(L9ZMF!(W,^LQ .QPXG0%WFS8 MV70,/FY?+6JBVT'AK#"Z(?F9JZ/;@?.R1+KE.&:6J2KKQ:_D>_ZP?
NCV[R*$ MXR!*.$Q"AN1R)U698ZE0%HAB0!@@598VEV.-6X"QAS-2[M(^-
PF_$H\V,**6\:**/\:ZN(+\>;1<..BM&KSO$++'<*!F4(5)36K@8NPB#U MTH!)S4@B.3
B])"Z$H=1E/HFOOHXN8FU9T@<,.GJW(E*3;\KEC>5 M3[[E]?V)&6P?CX&IN%#B#S$Q'+_?JP+R8@1UN FB)Z&K)/TYLW@6^EN
O MEO-Z=YG'7GSX^SJOGU5F9C.V'&_]\-B47LNS3)1"RF014FDVZL0VH&4&;+@! M6W; EA^;F$M#\,:5?UK&$*@U@(B$.
<0:I)5SQ!Z/_G[MV;&\>1?-&OPHB),Z[>,[?_<(!XV)R1I5I)=I7WTU\ )"7J12%!D*Z]L3O5LD0B M,W]D)A) /N(D8DF6IAGDO*&?
W,BG"^U)XYZOX-_K] QJ=@Z#/RQ@=J*WT-G* M-"^>I)I91\CQRY9I8C]+?;*.X(!"9-V[AF:'':G@N'K[TOE+9*J!;V8K]6G M5<5-+
{1%9UHL9%;&@I:HP 0CS&B.:"$B1'!4I!DAE$;,+6%L,&\C>R9;\L$. M_>"ZG%7WYB-
P^>'SN=B9GE="&V:G6B;UHN98)=B5KB6S4QGVY*.IL]4"K_[. MB%AZSV4;SMDKI;=Y@_1TQIL_$FY6^?-
B_EN;=X$CG"AO"R,>1CG"A&:H8$PY M7D7,E+-59C($';EVQA[9*GZY_D^8T>N*;6>T'(6!&1U%1/UWA ;-1[CWI.;=
MD2=5TR,B[:O9L4L<-T";KNG-46C3+_TN+!C'(>:H)#I((4DX(C%.$8MCGBBW MI,AC#*S7>)30Z$>/+=DV/@&X@WD<'M
%)QT%@J J^+VR.97>8\1>@T% M[A'XA!+WW>&0TV4VQ]XM'K\MQ8-.]7\6==#SI\5J97[[&ZWF*_V7T%L1U_*6 M_KBI6UA?KM?
+JGQ::Y-RN[BA9NK)25;F:9KK#8(8X5@21+(P1TF<));:,QPHOB^"AO.@RWJP7@0U\Z_XI #Y::_XQ-RRV%
[SR<&RWD:"MC+#YHJ4TBG-Z2@Q/+NG!\),ZHJ>$VW<_ M3U[GX'3>?E^8?-JO>DSSSUY&K;I
Y]E^5!;@5J$LVKC0G#*>IB&*3/_Y5 B M0L,2Q5FSI_+&!TN_X74/'=F[93JK<9S7'6-PXA*7>1-IG'9JI(2M%Y?@"-.D0%&.)<(BIXB&

M.8TZA,HHPEF?T6X7$:(^M\^DN\7W4R#-[4WYK^*J3QZ&R,_W# 8"9B%K* MG7I$H5/]R>,20TI0#I;D?J+41Z_=<)ZE+V\
[Y:D[+_4;;NF M#>AYMW@LJWG=DKY:L=EB];04VT@YR7$LPRA%!WG+N^%]YYJPAX]J4#K3S9P_S/E[NA9W85$6A OE@1!,='O*
I$R M92A/&8[2E"9I8MV#[A21D0W IH=;35BOPZL%#SZJKRT-0B]"_>KO2VZ8LC<4 M6XE-1W9%-'C?UU\(U,7NG$Q.'>U.#CI9=
[MS8G4[W9V]%I[J_T6W=+[\4:WN M2)+R/"YRE!4QTU5BF;>G_[J+0KUO.LL&4R5$L4/[_@1@#^TH >RM/LL\K"/)+KMN'4B:,;;K
M.+++]$Z'D;V?X&_LY\7\R]-,1&&91I?+Y>WR<;[F'V?TWO8=/CG R&^U#O?7 MA --
&46!HJT5N.Z"*Y:/VO\4W/Z=/PW$>2WP@@%,+^S$#_[07'A*$3\KI9,Z MG1YU,@4[*UA7YO7\"%33V6?WO\EDL
MZ;T(ZF83FKZ8KYIB!J;V'4@3CZ-AI8B#@8#KX7 ,H'K8*Z2K&AX?=$HM[!5K
M3PG[KW5,L];%&=_2E2[4NGUX'=.Z>ONRO>:&ONCO+K_3)3?_Z.;#EW-^HUX0 M/2LW_:PAJ=0CT!]
[VW(V"PQQTWH>FCX]!MYV^YRO#37,RFP1'J'=^)A0^,J' M'H/%:1.C1P3Y($-
Z3%IP[^;Z;;U:T[DN,_E%L(6:)%^NYARR3CX]PM@>#FC9 MW"/H>=?%CXPPL]*A&;1$=?]RKJL7/RD?
QM_*^[QX3FY+S["3.2[G1>NZ+A97 M>SL\U03NY[KP_!57*E[)BFZ*TICSQJ7@2M,_J:^K65VI7I>L4G:#KAYTSPQU
MR3.=:8MQETB1$ZY+225IA+# I>X'EJ,L+:*8%B4)"S[PT-4CNR/;!4W0]'MA M^H/8TAU\JH^#YA' 'N^_VB>SKWVP/0+P%@?
B8U!UFS_^54QG:,WO+^^7HO8+V_ ^ MGF:"F91?&2-<1!11'G%$&>,DQ$E$: :Q]2 MI(;9Q*W 6YHC5,0Y*YDG
W2:SJ2VXZRX^VI__@;'_:GU@OWK2ID#P=_+749 M 1,C8M9RJ^.KOKN"LI*0C"CE56],\[+4P7(E"B.1,Z7H:<* O3\A>Q9U$5"I#'?P
M<;&4HEH_^6Q)- >7]M2#AQ,N^OD#M'!IM* H1P2#S[_N'SU>T_F@DW9GE: M)$6(TH*'RHAAK(P8P2C&22%"R3-
26H49'0X]L@?2T ($U>*WF\HAHD#T_^& MC$N>P*Y(@/0 9]'UT_X!H MF69"@0;)3#+Q=^)"")?
K&;_@4+!E+0;Y^)O0Z%'A&%1+%/.H3U"'(U9\;(5 M\%YW_*9.KZ2JOUTG@[*UU;29=6>OOR=\'OS0G3K"YK_U!],Y'J94&*+,Y3
M%.91@7 A4D0RSE%(99:FJ92R2$&=@9W8&%GW&J!:ERPHNG\@R':K^_&A@VFX M"VKP-L*#A/;57MB-B6G;#@\"ZJ =\;#1'-
;O5W.V5%.^>"_J_U[-=5OTE?I: M'WH\B]7EG%_.9HOO>M?NCHB$%C1,E$4J4X1%*!#):8@H%YR+/,ZCU+XJ%(CT MV.%QC"V?
E,^ZTAP$U88%<\)(6R8 :VD8KA;;!Z.A!;,^+1O!FY:1OP17\\#P M$FR9"10WP>7HN
'V*$;#SVT/PR^.L!T/)RAZ=T1@(TZW8^(DZ4Y+O3YU=1@>6$V M[[2H7O-V>J5R6F8='W&RQ5:O0-TE5_^%CF>P3^5*_-
>3TM(/S^H?'2S;!)Y' M5$9%B)G"*F$()X2A@E..TB(+PTB$M,16AQ1G*8VL@5NZ@2%L&7<.1,MND>0% M
YA6.HH//[X\)YJO0\J3=*8]BCPG[L&!X]D;W!2X.:5>7RW]<<=$F15Q6J(HDV8-H6 U8PVNPWK(74/[/I]7Z$1XM/\G3M#-1/]LS@AE&
MB_X>[1-L)0DZHIB]JXXPI@W(YL[2B!3LRU3?1'_X,[13/@-/YGH2EBUL+]:B\?5'4M3Q@J>
(TJHFC'R]$241@6*!PB.S,\6'"8W721&6S6>F7R M9(>.TYC4 MAC*B%,DTUYE^&44TCV*4YV'.BCS#14)?
*ZO[.,LCF[V6:+"F/X)90_;E]=*Z M3SPWSADALHA0GDJ!<):4B(@X07E(6%E$:2*WNY2W_^,>W^YVY^W_;Y^BG9?[MDSR4GRE)?_-
\E1S=*W[.1/U^T'_"9/T3#/^/3=CO?P!C)NV?H>SF%WP6WSN=_MQ)>+N?K(ZC1CTU?\I?
YWFPF2\Z*,XC)&I90$X9P2_2E!.$X(9[&@82$ALSR4 M@9'G;/5T]#DMW3:Z_[;#$\SN@]&UL^)C8@:SR8J38,M*L,N+;MRL^0C^:/X[
M2K\-5S |V4HP^4DMGRLX^W;,>1PWJ_2!+N>*T.I&+$TZ\/MJ]J2\M[N$RY+S M!".)=5_ DA:HS*(4Q07E>2QS'"8AK
#!"4H0C7$J,M#0,:4"GE8\^":6=#DLH)J4/IP\W4T MI.Q,K@?Y89:U):A[M]25$92K6A/U9SO/2.7)1)ZB,JDE/"JOL$[=[EKT16U
M"-56L[L+,38I$QQC*7*I%#13B_!(I(BF18P*B0OHBS/(U"9I).4)C[+<S$GFK07**SL251LZ(>UA/Y-P-;NKZM\6"?Z]FL[H\
MR7Z8_5W$HX3B2"))2N6-%%3IK!02%8*22"1Y27$!T=E^C"E M/0.5G>;Z P"FOBW=B[91VI',%W_:;">E)Y4^0VQ2O;83?
%^Y+>\:FOK\EJZJ MU==O:E!^/?^=+LVNS!?=[4XD,8^5WZS6&TQG%48%(C$K4*+\:!F20D8)2,TM M:(Y^,-%R(8(9@VZZ!CRP=
<-.BT' MP1MWR:XBLE*9^%X'1&\OE;WK<4G14$9H+5Z6:K-ENW; MEU_1/Q=+XWD8)Q5+GB8\C5'*XZP_6B-$F1S%,1LEPFH0
=@P)HCQV*:SA! MAI5@RTM[U%*^!(:=H/:&75Q_",YVEF0D]& 6Q2MP8./B ($G(P.A/*FQ<8!D MW^BX#.'=^%PR]O3X--
,GVY>/B^6Z^N\ZRUSF(LY2SA$M="$$%D:HB+C>32AD M(4-=Z#"")1[!F7 XG8>9HP[=@'8(>S,YI] =;'F&(#:" ;H(NE!>VD#ITPB=
M06-\6W2*@9_%))T!"&"9SHT$KPG0U&*#=.#IW#*RPP)KN=,5I5_%!T@!T]NV
M/*&_WCE'V'9*V^^.,UFR_A'FNRGZQWZ&O=&ZQ_F'^;I:ORC-$4N=Z?$LWM,U M;1J?W]&29F$8ARA*8XRP3#)$!2V12 FC"2&
<9U9Z<([0R(I1DPXZM --O$G1 MLNRO>1:L?B7R"0'P:,U1>FM%LQ6M1_/4$+7FJ0];S3L[\"2J:"M>]YO6U\.G MGR]BU>[]OU^(U>?
%^HLP(51M/RQP"6#[$4>/1-HP$G#%23!?K(-ES5*ZEI?/M)KIO<"/BZ7^YJM@3TL3/OE>E.N[2!:"4YF@,&0"
MX;+@J(PBBL(*4+3MEL]C(@@S-+O0:T@NEDA?YK$0B",8ODJ#0,E/ M6RS$$9R#\B&NXSA&7C_ITLW7\OJ;8E**?
[)*6QE]^&KE:614M969E[ESCJDUC9&1,O","LQE;X M#='@ZSGAX<'/YP3S%>5\DLZTX;)BM3^>!P85>'YR=]7FU
MQP&S6"V;YCELGLK%J2?1LGODD:A5EW$I1\GW& 5-7P&47GF;-NAR#%@/ C5' M(3(P%ELQTUJ=F\6J,@5[RM5:
[U/=Q452Q,04;XR59>:91 7/"6*4,]/!-I:@ M3N4V1$5M-9MMUX)-@R6F+_(F<:*<.&TO<)BC,BP* ME%-
&2)R%81C'$%/13VYD(_';+U]_"5KZ@;++,Z"?=08L.SO@#P*8!?CMZU9V M3;FSSS-"!VP[*3UI_1EBD^J[G>#[FFYYEZ-
3<+S')\@#"C"$LBA@1 M)A@B$4V2I!0XST!U68X,!IL&-J(9D\+Y%P*&:!]$FQ_7V:?(COUI+I* R>
M6BZ=DZJWN]+)FZ=KI'2._YV>26>S5TC7@6*HWE)L?MO4 M-P#&;<.0MO-+QL,/9NV@T(VP*G&#PE>P-HSXM(':3L
+@&'V8ETLQ M:]2 4EF*/ N1H#1"F,4A*D))4)I1]3E-<)%;;5(V7#Y\ T_R. MU!8>C:LL,+VNQ7!Q6W;D ;@JKG*YN2>U?+]X*_Q?
[D@A*4U3@O)$>1\XRXDR"RQ'0E"!I8@293=>JW3OALN1 M34Q+!QP -\XCL7-87AUHF/T;J83KAO.?LV;K ;_89G6+8__8RNS'L
\9C'6 M0V(.KMG'ZEG<+*KY^GHNS&>QU-5'MZM2'#4S?HYYPC.U1B0DE@@GC"#*1(:4 M;8XCFF F);/VVZS)CFQQTU^BO4TM'
5OZF_-9_">ECV@%B[A*# !UX$Z-\GP M$"@F@OK/FHV=/2"%E8-/;8\6P.$C#/%0Q"KUMK/]IT/B]8PAV' M&'ZWF[=<-
_&ZI3^:1W/U4J?XLG%4M=NTYWWUO0'U(D]A52H5@ D3B6211&JB27)]3U&9U'D](^J^^WGNF%9Z M+^["HM!-Y
LD2EV9BF49(E)0%(HHHXQ'L0A#6"$[6]*C+]UKTJ9FW45@T@Q-_MH>B&/+2,G36B=IH^#DXPY3?
I:ELF+H(-9E\,9C4GP7C[H+P%T:ECG!4H=#E[F.=BQ1F6&,)"FB M/,6,%0)H2XX3&MERM,1T :DG<%K:271L[<)PF:%68%O:
MP7*/S"N5K3PN[.E:E2>N=]/3+^)9S)^$3EU]MYB;:.?_K-8/[YY6:^5S+#_| M8+,G7LWO]?+;TWX (IXL MM L'DQKO
1#MV_4A0SG6#UC,-VGU]=*R65?>E9B%)5>&/2Z*".$RDLH,I0R5 M@DCU7QJEH561LK.41C;?U^L'T>[/7 1S85F7[#Q
=B;%B]@PP]$E&33[-6\: MJA[W:,Y*YJMJP$DZTU8-."?N0=6 LS>X>FE,UP2N9,7,2<;UT_I:=FIRFA=>
M!\0OQ8,BIYS$FOK[Q2.MYG=Q'$D2YPQEI-19**ER+_(0HT3$(DIE0C$&);,. M8V=DY=]G+E@\F83,;JG:VD#L<-AJS1\UD\
-.BOIQ;1R>Q6^%LYW)&Q$]F(WS MR0['Z(^/X3 M_:VHOU;./P2:GO1_T#!NQLA8ND^+^?VM6#Z:FH:R8)AF"4&12N0R%-.Q*?
%:F5^N^3_?%]MM:J_%7*QU.?I=WF>8%:& M!FI_L)PXB4:L8/0UQJT:.26BV,G#GX>;33'<1^[9T$&A?M/CJ)O]$<_>6B
M6:YLN;H(:KYZ=UH]X0F(F1P;5[?PR;'PA852#L&F-ZK2:>#I BR'R+T3:SEH M(#?_Z(.4PA3YWX0\Z=_$O2]>S9^J^7U3C7,Q7]WA*,
(94YY2(A*!L,QC5+ L M193EI AI4F(.ZGMM3WIDF[UAI!-@Z-!3$P"EG?LU#D PR[W%IA.3J-DPJ4!S M5LVJ)C6H"63QV/$>++XG;PY
>%(W#P[(OO_G,,+KYSZ^%U(LE^8,)QJ"JVZ-R.[+Q:ND9HT4UQ==+B3Q\4G:&
M[J?!'V8;CZ5(#L^0W#Q0;6GKNW[.7,F32/^$.9.'O/Z/S9T\"?N8.92GB3I& M1(CU.[IZ,.D=7/"W+[^M=**F3M5[-
DXXHJN9_";XU3.D^ MPU7+4$ W' &C*NQ!MK/3XT ',[H:-3P?.''V-KQ." M(Q2F/2,X+>+!*4'/I0.3>R^?U@^+9;5^TL MJ;C?*
[A[CNI1N7RGJ.X2>9T,U:."GDQ0/7[UL$T;LQ*HZ_%_4E](8!&C.(W+F# LI"Q<]ER.$1M98S?K]@[MX]-/3#D@7K; M"QML V0H&
([[%V 27430]J@?]> M/(O9XIL^2&K"I;=9#\TVP-7<-%G4VP>KM6X*&Y9Y2E$B18BPY+H89:F, 1%1 M$4TJ98WLTG'M]Q!
(Y3=\;8S&Q-A"+,J.^!UV-I6LNBD M4[6[H=4\:)@+-'<>77L/&'D+2W;G9.*8Y,&0'08D#Q_2S>IU]S+GW#36>%C,
MU/VK#XK8^N6.2RY)+%)$6,'4(B1GJ%0F#64%#X5(1222'+('<([@R!L"=2+M
MK'.RH/5PU6'CSW]2XN5_#81A!V;3SJ)I9[A\8@2S3I_V@/G0#P+8W-A*YLFF
MG"4WJ>&P%7[?.EC?!S,!II/]TTQ$89E&E\OE(?)QON8?9_3>9J%R^NZ1ER>:.M:*"IHJC;^2;0,9OZ'$=P.YWM$;]?
2_U(#O0:S@H=_*$Y\+ F.2_>$>5<"?;+ M_>+Y_ZB;&[UD?*N./4-.HH#G16I5SN)*N))=SF:7_)^W"QVZUI2AM%2PPSM'
M5BY%L!,$N0K6"Q,VV;8ULM>L(S*?UZIAXL(TZHRD'NMH]DOFI$Q'AIM,D4Z+ MTE6BGJL&]J-
Y^[+Y^/=*++7;_/)).\UF.QB7I)19F"*<91AA2ADB.%/>*X_C M DM1" ;*EK,C.[)6=IJH;&@;]^SSY>].>^F68-IYJ_XA@FGR$'3N[
MB4P_T==I'F,%Q,FF,79WNYF,OPM^KY;-[\6JNJ\#?,Q;S648D5*M:+.RC/2* M-D>TP +E4A(F8_5K"@K4/DYF9)/0$_TZ5)TLP0F,
[#1_N.0P37<0&JS@_3)Y M4N@31"95X'Y!]Q7VS-5#:S)N2T#J)6Y#;!O;\KY:L=E"=Y>Z%3_6;Y48_[HK M2"0)CCG"42(13G.A*U\G")=
<%G%9AGF)87ON0]@9?=-]RUQ0;;ESK?+H@+>= M29@*0YCAZ(#78:T\ZL/)*]2G=03M= MPW+ F!YMW]]H-=?Q1&]?
&@Z^B%F=OAP;[$NU M^M>MCE^^PV&1YKH]@ A+'9M *"(R#%'(<88S$K-(.E:X'9OUD9VHXV;A(M"R M-
$%TR@)H1H!>U80/=X!9?O5'YL.(PYZ6'U,]*G!C&O9Q&'_]:6#4!V(U:8S+ M@9\B?=OM3MN"5Y\V@5H\22)1<()H:(Z!U?
*YX&6(:"X3+C,:,V'5;G4$WL8^ M;QI83.Z3:.^'"*I;EA8E#DJ2UFBB&>%R*,HXD4" ML58@ZB.;J@XO9F]QAYN=;47'FJ8PJ.T,U&@
PJR33^S 9LD) T\V"49[4H/D M!,N^-7(;Q/W$5VSJ,W2.EO7W=Y1(QGA6HCC5.5JB)*C_+$;*$&')RRS.(E". M5B^UL4T-72Y?
3/6#NMV77O8\&'ZZP?%9L8\=&Y^_R3$BK)I7:[7L>M89$6OU-E2;8BV_ MTG\NEN_T@NXSW?0TD$F629QG*$I$J0OT241(6*
X*K(L3"@6G()"PV#TQXX1 M,]P@PTZPY:8>:&A:]0,R#U M:6/.W* Y"#YS',:A"/2M>BQU?_C;[XO_5RP7V\;P<=[$1:=8$IS%:AT4)01A
MG):H2-,<82YY),LX(SFSKOEL07!D0Y3\$H?_*YAKL@%7LZ\F'+RIOS6?#4>G M4QC=0.RW,V-_S,LAGA@J >*?

#IUT@$[UN0SH:H(*5 M9@;(W5N)V6:YOVF=,N?.##U9%IV=B-V,.LL['";D+^(;72_K0O6W],>U M+B_Q;;$2_)+SJF[MKMN E$F,RSRF* VS4DW7-$%4UX20-.,LYG$::]G8CG4="X+3+8=7P9X*]S)N9KSZKGB3[1. ME+5T:G;O&MFX;8G]F[VCLB? 7>O65+@3)"=* M/(Y(ENE(-1PB0F*"9,3R2+D6RB31N!FX-Z," M;<6;)Z84G]PAXP9K^C1::" MZO$;9>M@63.HRTV(QV^SQ8L0=? 4I5&K> M:M02'J F# .+8!#\CNM&9LO-WZ MX6IZR! ,;NB+"0?N5,K1C4/84]B? [E8FLFYPV]P71UQBDB*6ZAX>C$]DK*%$$2E)$K%2IB6H MYZXUY9%=D&[$Z<)$G+*=B-/98@4,4;"M$PRRL)0((%3@7 I,:(28\2R-!:X MR!(< M/#1T'5*1?\|OK=U5BX64X!8V !,_@:A.!RK=S\|FEM>DBI.?5&Z;$R M_/ZV>9T%GBYB>T9"&*XI)&> <)P&%G98E<&1C;)\|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{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

M^KJ:U6?)JY5R=;DI9%A?U_GQ+A5)GF8B0GE1$H19HER-$)>(9U'"BPP7DEI-M21/Q._(T5%?*;%I6Z+([LRUI0&3W5
_/8MGYSG^HINRVN?YZG#>R8-AGV M_1W7QF=CPHYMDV&ZV_%M.K)N6P\ZJ%9LB+ULPG3-]^_JD+'J6;25P-HR8'=Y
MA(LPD0*5),L0)A(C&A41*K.L#.,TPJ2,8)EKCIR,OOW[<5,Z,J#;\SO8(M(5 MY30KX[B@'!59$B&<$7V&D5
4)QD/649Y$5N5$)@08PUS1/SFXI/\'S@#E(-4.; M>>_EHE/KT:3PB(N@\[@V!27?M*QYS,,;"(ZG1;,K%Y,N@-="M;^8'3JK1&@Q?
C3]06T%W:G32#@-L>\1;,0W$S-1^JC%C3D89PQ ME,98(!P*K+L#4A3B,HT$2?,R9; EVEF:HR_&:@[^#9AD>!8J.U_"J_A I6^J
M7W2\|9$+RUH+ZRN=[RR]:5/U;,4_2,.SOA$^QW_48UZNKN7-9\]7ZI/CPO^3^6L!KJ?JB-["G<
M+*O%LFY9K3CLZL>V'4\S8_YM2>=KTTH\N)R_!)T[UP]TK6^=F7E4%T*X_/9M M5C$S?_ZN.Y3/[_7Q-
*_J,^GW3\OZ&V7#U(!Z#'L7Q--#/.^E3/_\8#;M9WET MGHO@^X7=R8/RQ,)D3I9?R+I^F.>1W5RU=W3UH!9]^C_ZM7ZF,
[V#>62*N$NS M+*5IF*)0%!1AQI3+QEF"\E1DI,2D%"R:I[/=:4QY[AU+$[Z>/P[J0.'QB.?<28EPD44(AJ7$1(<)P5)BI2$$2!;]QB-
D2U$^DN\5RXA3G6V M;FRJ):C/#MFZ1Z']MPR> (#9@%K*G7#_U"U;]ZC$H&S=H9*[9NL>(N M6[=/
MI#/9ND=OG3);MX_WO6S=WDL=]I/O[]+)'*]\$_-5?5X":25X1&:+C6!G<8';/P,EA>WO'A7*;2MW=ZCI
M=FV/BK"S07O\"I>\U$UENVNY7X.I${7[]N7=C*Y6E:SJ.G=7<[746"UF%=+A M#-U*>*N]\PB1XI@1$JLI7>? %[10BX)"H
3G,LZ%R'.!(9F5(_,[^A[P5_8@ M^%/=<+E;U[)\"799AF0:COT0+=R.G^G!P,Q3]RFHA[)AWA0Y,+VQ._SK8K"[M$]A?
@ZX,NT5)00=9K_!D(9FG/]$3=G/4%+VG&5T&?'OXL!.J99X_W2EJ^_V7S#JR,G+[:G$SU!/IS9<=F8L(,VXGPW,W+G8HH
MO"6@KF([NWE0+MKG)[/X$C(G84(2E(9IC' :443#0JJ5>2Q%&E(ILL*V*^#^_MX".[UX9<8.@%-4'[UH './3/?T.E@TU7 ,%
+0)/2>#4)?!@L,D:!9X2H]LK M\.0U\OYOWW91!T:Y;W\4:WNE,()P0B@H6,Y2G-$MY+F@L0$G. MO=3&5JJ68.T#!7]HFJX5\(^B9;?
U[0T#H.K!Q'>O)-\GEN]B\$=IO4X]]SZQ M3Y9D[[UIT,[1Y\7Z'V+=]H07'!Z*;#'6:^\R*
<8"Q5FP9=Z=.D1(K>F\AR4",!BZF76:P&ML<9T5]\3&U_G[W&;S]T**Y5+P3:Y()UWM MLUC?)7E,XD1-Y9F,.
<(RS!&)9*'0IGE4T+R0N95/;$EO=#=Y?H\TA_%O^-!E M1MPSCLZA9S>_>\0$9@Q:PIVR'-TT6M/ R]]\;RFFIQG_'+5)YWQ+T?=G?
=O; M'%NF-GNS.LSF:/&*IL>6C(NPS"0J12P05D C$K(0I9Q*3C(I20KJL65'=F1# MT-
V7/EFNQJWGE26L=J;!/U@P"W$*&_]]I6"2^FJ6:D=TVFZI(" .VJ7"[G:S M'+L-270)G.MYMS96$6-6A@E!HL APHDN2,]"@7(L<$@)3_-
,MC6A;^TMQQFR M5EJP6Q+Z%FXY-.E5H!SEIB#T:M.V!68FSF%H9Q]\0.)D&/9:&;7%PPM)*;J<#?@+8V#-TE3:UA]A@>\G8>P
MWP", S, %ABXA0;=QX<2)R<5Y#J:MP-3>E?YI2@O/[.L7LKDQCQG,2HZR4>A$E."(D3%"+J^A(B1J=#1=-(3*O]4T!
M8OLK36I#=.JJH@ @CA0$A=SMS5*TX[^CWZHUG6U2G E6]H+G$6*2EPB74:S; MFLP;'![XJ.'!+Y[4'^I>5"IQV*C&#U%-
TV4TK;\!C2A' "[MLZGQ *4?<[/!L^%DE&QS. #C&9Y3A%_;^)P!Q,(G1O!S0C]2G]4CT^/G\3\ M?
OUP+74]DH^+I:CNY^^>EDLQ9R\Z)^KC;/'=U(^ZPX3&L7)2D-2;.#C)."I2
MGB,AB!",I21E&63S%TA_[.,@PX8I/Z<+LS3UYY0BR9JG@#5,!:SI;KX*WBR6 MP4RL;%=[KL#;V:
(1X809I(:18(NHYN4B:+@)6G;JU$G-4%VASI]5!1Z7W+VJ_X\6$ M*;6;A*! D!.R.,5\[(\U67C'"2&ZD1RG+O%6?
=&F4O'EL4K%5_.U>N:5NGAU MEQ@G-$21BCDM$LS2G)([LF[R/S.;)B?ZSFU5J@6?5LG(&6;+M& M^?.?BCB*_AIP\2QF:@7#T;?
E@C^Q-5H+]C!?S!;W+\&RNG^ ;RB,]53M7(F? MX%G!K--(%>.;I__)//V.(*-6\?2)!'CE/KUP^=IU07U";5% U"LY/TUD;NA+
M'0FP:!AHK]$EF PWUT_KE:+.]=:7*>IT)R,'TH/LPYRV+R@]M;7?07GD1U'P&BM&@PVE3B&SZIS"L943D.,KT_E/P5;FWJ35+
<"UQ'M]4GL]'VK;R6]"3P2E*0YD1%2QH4AK+LJ M%4SD*(S"+"G#*,V%U8&();V134D=G]#0;38X_D\3M3#?, 0*[[%TL)E]0L/ MS)
[4$@RWU=B/!(:S-_A2 !^D7'#?O\.CKLVC?'K3[@Z^R(/:"]IU%L-, MY[+9R[3CC@%N&
[;1W&E_4J<5M'UP5U>KU9/@UTO]7[VS49<8N)9?'ZCZO?[U MCN<\"Y4SAJ*XY,H1BU)$8Y(B3&D1TBB-$@%JC>:'K9%MZQ?
Q;4:9\3#:7(%Z M>R"H#/G@334/5H8?X%FRIZ<"VQ>>#FO'?8.=SDQ-WE++8U!SH=[]H.7RHBDG MHL^J:T[]I_#ZPV:SV-
[N!P_L>7?WR]_?!__^]E,_\3 MGG'.6(A"4D;*/.81(EA*%%&9%$*DC%#[M(F]P4XW7&S3EWCV&%@\?A8
MU4E8N@3Y8J[W(\2<56*UK3N^+2B21B)C(0Y1)A*A?*>,HD)@@?(DY7F>Y]GD M$A8+#&,_\@*ZQ0-W&:@;#VP9!/8<@$%KYP"-
!Q?,('7XJ)L0[.#6[3#EM5S+ M,!A\]2& $9^V&8$3, <="=Q&<=U!+]='.JM%<5PJYP.C/_5XBQ/=?A/4J*,
MT5+9')+ED=4A;S^9T7?'RS6PWQH$(]O]*&20W>_P4([I&;WR>1M[_HHD8EW
MJOL$/=R7[KW:W4=8S+^NE:JW^\X,AY3E&9)I3'4 !D&T8 P584KR/_J3I "= M91U0&#V<0M,+#$'XI+Z+191C&C&9(660",
(X25$1A02)I$@D+SAA601WB9S1 M!-G^R&JV5#[3LO1QG!.".3/LJ>.SG=E82C[[({OB3 MNQM'Q3OF41R_$!Z0_ZN@QKKIFJ66P?
B=6T8V+0TER[S ?7'ZU6.)#"E:(AX M*[)Z@G&GP/KN.),%U1]AOAM0?^QGQS)H6D/JK;RZX>2-6%8+;DZ8S3[?6[H2 MO)L!<9=EJ2
B4XOPD*C),.)J'N9$H"B+HE!W_HLSD*,,9V%DE3+[G;JB_T(& MW;E(Y\:I9S<7S$1%?]_6#SMG&\&WY>)^21^!ZW:'1V
WJXT++$S#ZSWCYB3B MHF[!<5$?/2##1AM6MQN;0J4.6_FX6$I1K;TV%70'QU?U-3@#TU9B"5XCP\2SN+.?T3@EG1+G^F
M7FW+X46P>6Y?=A]-&\13LVENVC#JMT*=/^ \%K+SP-3D]>[\ 7FL+)['T>%+ M*363WR_F0N<%/8OER_LG<;OX\$/;?
5VSD:V<.%W^E6 M[W#[T#K=1P)65F]?.G_5I:63J.!Q(2A*YCT5_*%2A?NE\,K>-M";OEDG1$,($+4N\X#BCZ#0/#>_EO2_*O M5 @
M]3[,U]7ZY<.C6-XK%^IOR\7W]8-->U=+YRUU"4E8R3E!2 MYC'">5ZJ920-4<[S/"ZDS(24MMWU>NB,;'QJRD%+.JA!PUQ^Z9[?
4CU&Q*/ M\L/LA:/HH+9\%H(Y=>CK&W>R9GT6PG7[]ME<[E]*DJM5CZYS8ZL^":,^<0E*)V@. MZU"Z#>-FACI%3S8YG=M0FCM1
1F9#U%I=ZC]JSOG:9Z"RLQW^ ("9BIV68MO^\YV -7\VPDY&3R;A
M#+%)+8"=X/L*;WF7<\7KNFW9AQ_TL2D742^5(\IQG%*"PK@4"$M=X)HG%&%< M\@SC/,8,5&CN)*7QCXK:OGD=RF[[#:?
1LO4,/&]0%:\2] \KN4G.Z7S5^% MZ1-TIBXHW2_ND?K19VYP7AN M@!GB-"$,8TJC-(6MXO5*> Z)8\V#6V!@^ZZ/^\/$/=]^0T/%YLP
MAGIR#49)\H(*[WT?_@S95]I_MP/C]+Z[Y?WP8(+/B_G?%*DF&/:]6+%E]#?8OC)SOOM1>T>\P/NGR:F6ZTNLCLS#COE_R?
3W6GSC;GB:K_ MT[WC>)E&NHTF1B4I,*)EGF6<%8DD'+)BMB,[?KC0;IN5]9:5@&YX 3H$EHC:
MN0/^<8+9@P[]PV8J6S:"R_5Z695/:^,;K!?!#:V=!>_I53! /#D(ED0G=0]@ M0.P[!\"[7;KTSI1&SDUQQ&W?
W\]BW;8#OHM)D82,%XCAG"(L2(%HRK2%B1.> M105)4ON:WN>HC>T]B'5P;SISOYDI:KKQK(G]G56/E5:=;W2YGJMA'ZIO0671
MH-H!SGY[XATDH!G94NXTZ+[0Y5"[_;M]X@%IT>L1%['Z:&G4#S PZE/H>1U3+)%SSP-9(_9*#K)1N971=+O6-/
MN5*R$?)OF61U"'TR7VW7!W6]?W]\)W?NVB$H4BH3IZC04%9&@**)J^9,31BFW MBA_L#CJR"O\V-\['5S49F>
(.ZE44RXK1B^#]8C:C2TO_8P>&?KUT%0ZF@.YR M62O;,4%ZM*JJO%:MJ^M?NT,-XDB'1.@U9BCOPW(7G]8S-0=J[IXI>YM?ZS:
MF4ADB6,=29/IZDYQ*!#)U)\TQ#QF69B%/ 6>'=C2'OWPH,O)_VXRTAU2T*UP MM#Q&& ,;F)8V-
7#'*0<'EL]GSK@5W>E3Q2%P',T0!PT =XM-]Y7;Q_N_+[[_ M.O]6O9NON/H;>E+0/\K(,ZHAKGL+5_/[BT"Q$/SZ^>8J:)MU"6E#-
/BC)@N,_MESL.D-WL/%ALIYD8(#%X/NZ5R-/<>YS&I/-LKYC[R-,22AS&:%8YLJ()K1 9<&H#E9/<,F2DDA0BLP).F,?R+54@RU9
MI^274S#9J:<'X6$*ZB(W6$7/2.5)24]1F51-SXBZKZCG+G=,+UG,[V_%\E%7 M:&T";^Y*0GB,XP0Q6N1(+7PC1
B.451D/,=)$68QZ!C]"(V15;0-_NV6)J] MSH4,9HH)I(9Z#+AB YA8<@0D&BJ$2BP1BTN&<"F)\B\P4^]:QHHH2[%"\&XN
M[O7AY;@PD1JF+BUKH#[I=':VB]9P;.P,V,#7 F:\-#&DJ06:W#90\%>Z?EKV MYQK!TVM."^8KI^8(A6D3:4Z+>)
]TW.I:\I,W7GFBWK?-PDY?Q?\OL[NUQO MOKQ+"E*F92%0DM(,X31)$17*[](C6[A-TZ:EXB18?:?? M=,U)4U8;& D$0-
-.K\?!"*;N&W@T$]UT.L-'G7L;T'7G%Y]Y.%#YO27F6!.> M.%,'"LAAZ@YXA*%)!MNNJ:NMP[4RISGFT[7<.&0W8BD7RT==" 9RSK=?
-X70 M/NDWILTUVNZ=E27.B"PR%&59I+PL(A%5C@,*PU!*P>.LR$&F:3K61S9M7Y\> M'^GRI8[L-[ESNI-
+6^KK4S47P962Q#D#8O0G:WGX\5,^+YB9[69A=*3H+!!7 MP58.?=5V$=D1Q3S@SB^+MD-
A*\]$^1Q3/0CO&2&C,_Y*.253/9#362F3<> 0 MO-I6JGJW>"R;?-9-3Z1U>])AOOZRF,T^+I9Z*_XNYB47!8N13"*!L.YB1'F4
MH(RE+&=AS!FQ;Y_HQ,+(\|>F3%N'J8MM)[!UL,-7\(?F+&A8@_0O=(._?W*8 M!E28D?^Y\01$T(Z.JUM8[3CXPH)M!T'3&X'K-
O)T8;F#)-^)U1TVDD.D N=F M8J$S',;/QZ)P;(,5S@TT=KS"AGZ@&'CS_!>;HC<.&89@6,N0BKT,#[$Y;HF B\ ^*&TQ%U[6JX=
<',9NUY?9Y(F6) M"X(XXUSO&F>H2-7"(L[3,N1Y**3_ZI[U]W&D61=]/]^"@(+:YUJP-F'E^3M M+& #
[BI73V%5E[VKW#V8Z1]&7FW.R)2'E-WE>?J325(2)5%41BI)]QY@NF2)
MS(CXR(B,S(R+4;N4X>&G#J9NR_PU%&V[$.R@,6X>SY<19LQ XEE4,!R2XHSR MA3O#S5R[<$B4P*%@U?
9JI$^PZZ>EJW_UAPY@2J?^,PFBJD M,W"L-/0L7"P4UTC:,S1Y?/R95=M(V$-=-[O-.E!QIS7 %[&Z^LX6SURW*EDN
M^1_%8G%)ZR9J[XY)DG,:Y<@7(4;8#R2BF< HPYS&+$\C8+]L"/')@Q7WFH<4
MVS88I&'.L"^]%;!F:YFIX((9BH/^(&UUG7<;5KPU+S]XOZ_9<5I#'(Z"N^A% M<])SQR^"01F(8(2/ 3\3O*VX6L
J?;LM5@NC[@""=TUL#!H:YL=Z>Q*=/L.S M%P:FJK<5:11R;\. %R\%?R8+;UQ.T&'=L$A6)W-[0\UV##$GWSKLB%FVZ-R%
MPFPVM!<0ID3FLED4WQ@2P5F%C9W!9RZC,2388:V,P:LLP@P_JH=WLU0NVT?E MNWTKOM\J#/6>$U.#Z_H;M6[K^\?
R[Z):ZDNOBON'=?G8G'$9"88125BJ?%KL MHRP)0R3R*)1YAJ5DJ7&LH3T?$RLH_C%.HO_T2LU#TYDZ]''FO>N^;OYH^(-4
MCCP#]'$-GQ%*F"G0A+R&*4]SY2FVO(8OKV.L!=%3K'F*-T\SYS4W->R=KN+K M%&1 V.$\8-
O%'DX..BP,\7RH1F,1SQA^OH#$\S'8B4IT,-QY69I=XHY._[S# M3 K,?8%H(BG"*1&
(J.]0$D8T$GGJ4^6'=8G,M_"LS!XI(]79S9R^/2,+LSO% MO?!* ,?"2NKS$BJOU!)^&$NCMTZ:'!#&<79DG*;I$$.B'@LWW'H
M4LL%47%?%K)@I%Q=,J9W.-7:]6:Y*%@AZFV(;,2PX$0FB'.U1E*J21!)<8HR MJ2QIF/MQ&@I@_4,CPI 7UZ[XX3:IL-YRY)$-2]Y3QQ-

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|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|G>!^QQ:=NM;"\'P05?&BGN6+:*M*;)+(ML'^ ME[1N#H?NF/23.*,2Q5R&32U*1",ND(@C2K(@S-- F)V 04E/?B:VY:4VW% % MHV=@FR9"!&:OMDRL2\[T$D?[>3EK5B V# (8P*Y-!)R=K>L!V):S^M&1H;.0 M#0<3^WK7YCU&[$$THTU#A#Q \%8EB$5"_ 4QP" M0SI-Z$[N[C8=777F&M,?Q)818&2G$8CC]GHR8& V>H-(\Z''P85'5MZ:"5?% M=ZV$=A7W:41SW@!0" P'D:"@FZWVYM)XN^A.HF[FI"QC,<\Y(D&F*Z D%!%. M0B1HP+@?$;I^!FS-#=&8?&]]WJ4BE'XN$B1DGJ@E)18H M(TF*TM

7/J.$IR*X*W56K^!F+@J0 Z,W=1-MO.5CBD6E+8AF+LH4P)S7CEXN M*^_=FA=/O\D_=
(N@#3_>EB'W#>]'!2#CN5V]*_4W:UP.A.=;-'CJ,G='1CM/J MM8MN4_]_.W+IR]*WJ9=R>HNY&DBL9\@*66
L!_D*,^%^I1(J77N)U2"$CK& MR4WL];3$O7I#'69:3D!E9DG< 0 S')WL6\(7WL??T)=/%]Z6NCLK82:E(Z-P M@MBL-L!,|'V5-
[SKC/YUV]':K?'UKG3,?3\6N=[,T$7 [N-C=,.X[]Y]Z[W)U@6;2".P*5F7H[@"FVT=DGR!+R4 \E^W*CE":O[G8
MN,B#KL8!)A)&F3(CP*=DQK])M0X4O\A$<,,5-7?JO5L9)BR:$U@8BOP-TJIN,(OW)>_^@NS)X1=D/ M.-"%8ENGM:D36[?M\
37E]U4A5K_ZGMK[_:!K#Q2"4_+MR(E;QH]E-S[M5DL MF;8+.^]YC!NFV1X%S(C-^A0MI3G2T?]&Q@^EFCYP]FV>BBT$W/
M/Q4+,ECFN88#;+!4+PAA8 D5WUL3 A.6_[M"@ (!UTK(/?"3,:Z&?S=Y6+1-5DN1-VU8X@#BD-
=3911*A'V,XGR!,EB2P6<4H../J[DIDF'I#I35691-Q1ER"]>VMZJ[_ MVJKMZ/"SJ*F)@&NU-+K6;N;^60U1?
UXJU:ZORZOO^JSBN:@?] KT6NHZY7=^ MFF$BLA2E@JI._()RDGJHUB&F.=^&DL<0*;MDQ0G5E!-WUN6GM@AK1UGKHC#
MING3Z)G-T4XQ@6EP |<[3?L'CNF M/_2KUW!P;D^\R9ZBX9KCS_1L@ N6\QZ+??.]J:%RW;!O,G[?ILG?U/ ?;0PX M.6&[">&+6.E
W9MJ^5)PP7]Z_;76B\%-;]YM1,LF#3!B?AZQ+$=9K&LA25\7 M/0]T9R@12Z$L/,L-LT[MF8 8!ON ?+E8_M%&
<7ERVZQXPXQA8NH94)N9X6GA M@]E5Q4L;L;_F1IO7=YHAKRA_\+8]G[=,F22N@NVM/2:.#*@% [-:1'N]DW< M&2/!S^;^5EV5O-
OYWM_I?O]2\;]5^_OAL*,YV_'G.)D3)3<] WJOSX_4Q^8$ M:>7N*,X:_M,G<7,@;W$0-QGHCD_>SH7/ZN#-
FNALYV[GPM(_=CM[K+/*@73V M5%>36[<4K'M.Y5CA!BPE)T&4H2!1"W,<1@&B$E-$8BJB(-,E+&.K.B'V/$WN MP)U=0.0,O,>-
W9M@"+-|O8H9&_9ZS41KK\?@--5(SD#?JDS)/$_A[/HEAM1/XZ5Y&GS#]_N") ^?C95@)Y0Q";U$BY7Q$8S]*$F)>'MF(YL0.]X8)?5KR
MY*QLLAFY!@,|06GVL=<>:JLK(9/I BR|YQLJRW[O8/%ED.3C=9C- MA[JQ)#-(MMWJS+!;+8_9EI5>';Y?
=W%:5RB@*9>4*>_;5]XWED&(,IZ%B$9! M2BC):(HQ;.=TF-#DSK4B*XK[TEM'+.B\5\V';=^J(W@9GD*=C0'PZ*B3=4-P M@HR>
<9E(@B*D)EST*,B @#%,B$9EB$C H?E(9\+D(6CEZ+S]7-MXDP,K-A M9TL.,V%KD_;>K8G_H(\@-KCHC=S?
T1#\0],)9K>:+$]T_E#_7:,^SYT%D9!'-,<)\A)F0B*1ABJ(P M%R2,9>('Y@T+3M.;.IJN\[V+G::GP%6'*70&VS!N ;%;A^PV0@6L2JQ
>R]-MN 7';M_E!$B.]EK,)1W=9S$89KX]%G.9=O97 +?!HS\N^3]NES=B^7[Y^/2Q MW#:M-PSN.'+
[Q#:K5_[X=NG=7%U[FKXHZZZ-_.(B).R&H5\'!LS-GB&4X(U0]7.'6IA?IIS;Y]O/^E?"KT M.1-< 8\-,+4*-G/ ;?&H@W!^^7+SJ7=2#5"
[H^(;*)X+R8&J-R+T%.IV2D([MA3LZZGPJ=TJP':4[>;&%VMW?KV[*NE0*77]]8>_K%2RF\=C]4RO=_7W5E!?U M;I2]URW#MY-!
[7T3U4O!M"M6&V;CC4)AH($.4]H#$ CF,!3XE]IXG'!IU/ M$4^(M:.'IZZUVVW[(.KBOM0E0I]0.)0DHCA(DN
M_T5YH);=1"V_\XSZ6$)VQ0UH3JS)6PX\4GL=#[UX,-CNFPF&)!19FL<"<3^- M$8YBC$@*8#6PAA3,Y,Q!4XPN[$%Z&8#T-
46H)8/[_?N7Z=+'UL07)5>-R4[M;\UU(!@'Q=:A]UL4>5P^/EVRU3-9+%YO2,%_]YOZL%UN+GAGPW"XB1VU_MZ:
MMV;'T_QX+_6/72>"CB=_45#J$ZOP29 "68H(!-L$<"E-^N&*(AC?E*'|*$ MWBET"+S5SL7XQI3[_;P0U_+;2HWV4YM>?]L$
N14,,RC 5A0A!.1(*(GT0H M)$GL\RR-<&I4T-F UL2V84U9IS VM'5F=E?NHJ$/+$(RA]J9W^ ("Y@%:$A= M=()OH#B% -@=,)#-
D0$F!$MA'AR9<,74'.15.0L]@6Y&P;8 ,K5QB":;;U M[@&"&8#Q4J47GJY@,45%"IC%2A\4-CTOB2&L'",RJH<<%W-?&D2OA M2_+?
ZE5Y_V$U6&'ALE3._[;0 NP %#SPQ*[X;UTGP _Z;-"DN(C>S_]MK1JR M5V?$?!4/1_?T>GY28&$J[Q!3QZ>QUB!9+?_AU&;;"+
&HK\E8#^(G2OP5U'< M/^CS#?5^D'OQY5F/]=8K.G^C[M7VV9;'2Y0G$*B%1."S&&$N,T1%S! 7$2%1
MDDE*@(EC4!8F7URL&4*DY:A-EZJ]Y[,,F\?(@CTOVDTVI7]BG6VTR:P"KC_ MSX#&)"8R%(BRF"(,"08)0S'J8R):#^F%,^
9NMG!;N=Q]$N7PL2FU[M?I@:4C,G;TJ@8//!FA.O8\5K>6FV?%KX>NQ<>!^*Q7-3E&N"E9\M*(Z\23#Y M67U-
6W#V/5'K<>RFA7;%J0R-3&0<$$03W:D31S[*9"!0%N8XH3@DD<\@J\)V MV%E6@L2B$V.BH1Y0!.Q//UJVZZ>7)8QO9U.-
(3T=R=*NV:2FO7JO8V9:MR0,Z M>RO7,>P.MW@O/,T/:UR#'I,7[=+ONG28,^L&G^FW@DV8^;-L$0. VP=0T:U
MLY@ZS/M:_KQ<\EHM4[O@[_K;^.HODF28W95-2@@W4V5SXD9O>=Z^Y7T6C%_V&_7] ZE%$S7Q-!:1 M"@Q&-QJ.:$YXU&!0-R
M$(*'\&BFD4 MYRBGD:XI&#.4!PE%)..."<,%HZF/C^AXV'$SL4ZQ9:;2%;YGQ5AMNO*IA!U#G MP@KI<>LS"W[
#9*.&V^#H>+'ZS'D;3GR6I9LBH;8O;,F942F!M6NL,@&W,KX M!755A?L<0$;KCU@-/%]%DG/DWJE1-]E,[@#']'T4?&_+
(7NRZ>TX_7#L[A= M_E8LVZ/N:_F7Y:-XKVN[5:^?R1^7CRO3 "7HN!/[7!T[WIH?CS\+O9+9L*27
M@)HIK^/*4VQ=Z.W49]/5GQ6:XWH_-9# />A), 0%'MF"815W!"8V6]B1+0S] MJ"/K,6PWBQ\?B[9.B/)-=/VTHKQOV\'?I2G+
Y]$*&:Q0#ACH5KKX101F7#& M$DQ]!BR-,$)M MH[%#UN6&\DG9G.TH'Z1HC)K.F@ %%A N_;; MYG/#D:$BCT%ELA5S-@
PQ6VE;"AZ']:RV^RF#$L,V2\Y6W*['9$A!%SM>(R* M-+ZG,7SKC+L6H[SO[DN,7PI?K]Q6_+*J;D751(FJAZFCXTT7)8,W3QTKLZ76
M1/*;+R:&13V]8CA;2IB9N*U(TPE6T51?BVX7UE!HD/<_*IB5BS\\XFQ^_*A M?6=]_$++@+=U?[TN7J3DO;V%KAX!OR[5
N&YJHJF!>R795FM_]2='NK/12D^ MK<1C?2\S1M]-P6L!\%XDQ"Q,^Z-SJ6UX[A=_D3*?ZZ/*;%D:93)$$F2 M"H2C)$ T"1C*TU3D1
2IS$"U/(]2FMCH-G1AUO$X*%&8DXS(&&7"3Q#.(HXR MPAB*6*#[?F&.20#;@7("BV6=C.^"HZ:+2.D2([/9P(G<,,O>KL\ZFGI#NJ$Z
M06'-D{Y,K3'Z+SE7C[U^KSY>5[?+/\]{A! 2LI"AA%"& MU*)0*6OD!\H%H3Q.!4M)EIHH[B-
B36VI>IU9"||35C!XFG29MHYAL^X=CJ2 M&J:=5@(;*Z.!2",;.NKN5@_5AZWZC8TYB_H9"+56/Y-+K2M,,R%X_5&Q]:FN
MGXEB^5I^7I;W>@OI@Z"ZI@.F,O$)PCQ7_V$I0YF/U:?AY>T;&APQ*X8@!<4?H4AF;SJ5MD8 I\LP/(IQX@FC[2#'@?
MQJ"Q*1IM**V[I8[.L!\)[HF MOM-QF$VH\MGP4GY=U?9?Y:1ID!*,PH:G6N0#E@5]J1SY+,D']B#$?4@=H M9W20NL'+ >FU0-$0
VZ:[2" "<,A3S/$(IXC3/_921B2&(?BSSW!2;BKA2K MJ>3?I#:OWD+ZA(@HCO($^3C5RT+=\RU4TBOHG[JF](-
WN5I5!7U>K0^';HC; MQ*5!P5QM(N^,/>_V\9!8!QO'@Q?9!/4U(6275=6X-<;1?/V[)M:B@2@WP_J4 M
P*.J\QYLL'T92AXSY7/=EP.RUB]G:%F#-(;FW.F_P"CLO[%/Y(K]&NMK# MZRHQK%Z_Z3B1)I1D4|
T4Y.R'V5J+DI%B+">K&D6Q4@($:J54<1"R2"SDCGI MB96MQ\A%LS^Y*2RR>O6VW)B4-CT78[/9;1KD8*KL$#3P) B7W]$,"2 \Z_0)
M!V1_;K48 3[QWKP\-:V)P,T!#VZ._7,E M+KR&%_/I^%#LTS/R61+#-'E V+:;E]L^GZ-264W1AZ/--DL?%:0_41^_R&ZN
M_NFY+DI1UTWUC;K0>]._?^?[/(\BGR&:Q+I?.LL0I2Q&-.9I*&@8I#YHO_((MG8EU;DW5ZY&UVKD\!I/9W.I >)CZV<@-
GC%/2.5H>CQ&9=:Y\(2H^Q/?JZK\>WY\;%ZU5TYZU5Y2Q>P-CSPD2?6V=W& M,(JKYXU+J-E[;A9[;1N9K^)I66UZQ?2:R
(G4PMT3\^VTP(+LP>6F*X>Q "N MCCOQV.-D-<%;D)O-_["'HN\BG#$*W#!]>.&\OJZN5P_5557>US?\NMPP\&6E
MO_^C_BH73%._72TTZ8_+RJ9AF-24Y^1%B\%%Z52L675M:V^6K?9:=I9*Q7:.M544=-
=U<^$=1:]V3B[8(NE*^MD+]COKIS6^[/F,N'M-IDS?S$X+9P+D?CF,S MZ1!,*[OI@OYLAM0A6'W+ZG)8N^6:3BT0FZ2\5[V!T!1
>19\D[O77//^^;%I M]O4B/I6L$J06'T3[[UVF>Z#Y0D?+$H9PQB.419@C)G$N19XGU$\@2SL'/$UL ME]<)&63K^&AMYSU.-
]DJE6CK1]4/Q1,P\+6!4>S+H0=0KB_:'8YM&W* MS\=BT34INXM%R'QE#%&6!AQA'\>(,NRCC(5^+ 7- PG,]=D./O4*NLUYT?2Z
M!GO0U)X>#N,&Z5SI@,M8<\$L4G@.)3@C=Z+[ZQ&3 TB!B1$I8))89XL,; #'2+]{D;CM+\56\"#67
MZ\P@7;-1C_C78O7P7CGDRT=1;<\Q99SD,HX2%/M,I\6G0I]!I2B7/N6$"9H% MH) 04\(33\H=&\|
EA3%J9G9B"BQ@EJ+CH,WF6_/@_:&8\-9<>+\[/2.VE=V1 MN3 F.ZO!@(*Q;S+]\,J\@]=OM1'98G(0N^H?53?
U'>9\%,_Y@P%&%.=^ZM\ M"1Q%*!.13%@4I[XP*ILQ0F/J;>*.JM>2;7<+&\+F?OHQ=$Z[ZPYD!FZ\PL4% M>>\G!+)RXH^-.9LO?
T*HODM_ZE*[^?H;>Q#\>2&N9;MD^&O!U7J[B>;1VV,] M W#U7>E 219KY:]_>KVIEOR9K?I-
_YJCPSOHS*@:81DG,8Z9S]OLW2%R&(_M2!E+L@_RN4_"Y3R>0#L%KMG:S'ZU1U^]-6>[[2O;""I@Y,HTS]',W7CSIP,S M5-_$?
6.GVB/PHKR_\,:?U<7Z0?6?T\G'!/9<)H71D9LS#8^S^D23PKSO0$U+_MS#9N7R?"?%N159-%L=F#"*1:DT4D06D6"833($$TI 0%?
1H3II9C40"JMWB$ MSL1FM\NIVI](_1^&"8SF^A_>)A5LY';(GI^5"IGH?+#5&:.BQ\5]3 (?OSR M,ZN3=?]\+DH1W
5"\"C&#,5I$BE%%1CE-!-(!GE 2$QPBHU.=D>IS'-XL2G8 MU7WP-&WONC2,ZAO'R?1,XTSIK0XWX(+;5RL;$NS\>F4[H[Y-Q;
(AP8[6+!N\ MV&X&57.UFN9A=W&4X"2-* H#7;28B! IC0ST=!I3+B3/ MU3B 2?0XJ:D5=
(>P766R$9S,9E$WT@,5]$!P3=5==SASV1Q-IR.$9IU13PN\ M/ZD:W&&IP$!G_/.V>T0@DHA2IESCD"",HQCEV]1PL)TZ>T
71>JSC(8Q#W+[TF1;0E.?JNS6[;KP-&7O M]Y;V687*>EB9F1H7" #/6.R$/[-XV:%DDY0PZY%YPT)FA*.ES,;N-ZBYFF3 M?
_#M85FM=_753Z52#%&O?A)$]UO9)M)W*1H)$U&8!@'R<:_6&2SF*.FA.O8V6GF@:\MBH,-T"QUO2U\PY?.U<%6:T@&*W0
M"AMQOI*M5I+NU'"U&\'.?VI;8@T$R-TE6498(@(44U^'B@>-_R50GC&>DSSS MF0X5-
Z\S>902R,C":TZV26VDH0[SEXYC8^8P.9$89B);DD>B5=TY3"M!CS=-T['OO6N_;3XW'!F6XX5" M:K#*F 8HF&HW/'@-$_ITTM-
L>!T?._WF%5P6*PP 8(#EQ33 V:TMG ((6V+ M81A=7P"&FV]Q 9=Q9V5A<;ME#_.B+%;BLZ+ U?I%O2 %7:S;[S[],,1_-Z_5
MU7==:4(TT;WJVKM(AD2&$4%1P'1E=UV:C24^XE$4LXSF2@)_K\539,HX7F6B_-.[:]4Q3D4.]K3FP ;G=_S%;Z$P/,]!!
M:Q%L&/*V'+7MQ75Q]*>VY$F?N8LN@E_=X[!K^%G N&H/;L?$O'W SP+JH.'W
M>:/99_4H)@O/Y]G%9=RH.)$6>,X$%=0]DV=0F+/R>'9'G#V+9U"@ MH1R>X0OMR["'7"NQ7K>3U@^
_+Y>_B)6U_*KJ$7U(NH[@9,X]F,?I3Q(]=EO MA*AND8)%I-OC9,0/!2PQWX JY/6T[!_?DO;N-6UX8?53J)G-]8Z1@"GJAOB%
MMT&CH7_AZ08CRGE:\^"VA+JAP YKIY^B.'O1=$,(AJJEF]YJTSSS::%,2K=D M%CY1*S@JD0SS!&&?
1XA@DB(2AD%*U0(B3PWK<1R,/;ERM\0@C2#[DAOLKMA* M U/0EHI58\N^/)!&EI9R63:N"],P":5 ZR/-
Z7LWS!C$\H!/G>;3@Y=8#>] M-V>?7Q13I'YHDTPZ+_TNX(&?I3Q!G.KF]#S#B' 9(Y8SD6:Y#!+E39?B7J^I MS2;UH[2,WJ--%
[@M1>)?*'CWRZ\4@#CS(]C9#:%GR?W&:$;'"=%G!Y/#= M$Z]L&Z+>;?

&H@UU^^7+S21=MJ0NNR]R:'U@>$7Q<"=W(#-.^,7&]WS5M1^5\ MQP6S.K(\,N1L1Y;C(O6/+$]<:>'=KCLNO%\^TJ)L/)7W3?
*7(>^6XK!JA\W6O M35Q]0UZ;?^\H\W6&_NE,LI3%&(B2Q93*RW M<.U>4P-XGV!_SP#<>4U5>HQ=>%O6O!W>^OT(E>LR/]*
*E<%\B-NM);9% M'K84<8/5Z.+E3!+S+7?<8+&S0'(T)-PW^]0.O6V$^=DPOVS\YBEW^!J:WD#_
*MT]IQZIB9B%9.R\BPLSDNIT7K.R\&5Y^Y7S]0!C:/DP2'6" 4&PH XO#@B$#;M+/62[7%@/['?G)J^*.47J;'7CS M^KG.B^ $ E=.SK!-
*@+MQ#K$ 3;U*P_EQ[^F++ MH+MUOL%/9*&;TWY[$&+U<[5\?E*4/BJ_LV0%66R*-KTG3TU+F*U+F"1QE#+" M41(G*
*<*9KK04)A&BOI^PB"8XB(SBGETQ-+%)V";)7'@=AU[#HK?FL3EF;KGL ME1I;\WE&68BS'Y69'S#G X"9H'FPAP?
*L.0+,5>C>N>S,&\3G"+R#<#Y7XUKT M81?+2[9Z)HO%J^ZF!_1UAN^>V*K=7%U[:ZIM"\"S7)LC")SV:\X7'F91SI,;
*MUIQ]5#2[#NW#0\[7IGU4I)U>[>-7GEN7>Z#+=/W3:^^O;7>(W.SJ77N3-.TX!QOGE:T!++Q1X6HX2,?K4EN,91$1P?]QNVP,X_>B
*M-@Z$Z-\T=?S#IF6HMUKNS).&_;X.I3SM$%@+"%/UXI)YOVO*KD(=AJ2QBW#8 M&6F^P(8A 7;B&08OL
ACN&2L>MXVP2Q$O0Y#>O]<5>I!]7[I D #RG"682X MH)AP03*\XR@+&2AS"6726Q45]:2_M3JUS+D+;9T_]^V)_=__4>0^/]=JJ?7
*MR2]39"AU_&S\ZM%3+(%C(#XA&GAM(M)&'HS MEPVLZIU$ R^EJ_I0]F",!AU8##M?H(&]S#O!!6<,8[G/O*Q$<5]>?6O
*M'EOW]KLG10G,P1J'+0MX%-*0(2ZIKCD2*=BHH(CX"DV?9+Z?1K"<-6? V66K M[4,GEU43AK]&T"EZAMOAKA !
*[G5W4*SI;CM$NJN 1+1U>[T**UYMYY-Q#[8 M5S:ZR3X;_+8B9;NH;'MOW?$PRAE.?%W40NCSM0QE?IRBE% 689*&<'[
M1":VB)M4Z2W=KK,8/"O\ )]Q+78E-4QY+02VR@X_)M%9">('@\Z>(WY,K$T
*M\;/7VJO@_WDFE7K+%Z_=&Y9F:D%)"$%!Q@+EH401HH3Z*$@2I9D1S1-FU*EQ
MA,9<"K@A:ZU_^^"8J]\9(EMJG[&T5LIW1)ZS=&]_S-E5[XA00YIW[%+S9Z_M+*OBW\OR5JU R)-X7A5LO326L0BS)):
*(X4#I'HU\M3 (T,W1 T&3U'A/ MYRB9B=6OH^OU"0-V%(ZC8[#_XD1FF/X-B6NSDW)<;L"&B1/Y[?9%0(\=MO-Q
*M4JK1#8[C=\^WCW%2@IWMBM-7GQG]UA5Z*OG.O@?1 ;#\6KD6>D6J0^]*_F59 M5NL_?R)UT;4!CGD:X82'*,I%I
P5S5$N.%=>.TU$CKGZ+[$@SN7LZEW.WHQ M61MFFB; ?7;L&C:[>SJ&2_VWP!RX+> &;OL8-U?0N
*YV.YNOMXEZ#E7@0:LWV(MIB I^7=5O;YY9\OQ-^*OPPYH@Q MX2/,&4$DC2/$\RRFJ1!9$%#8CB:0@\GW.'O\>.TI">MSY"T4,\"6
*T",S8SA MA+B!3^TV@+6G=3NL;J#:&Y^V-3T4BPY;%U@AX6KA@9 ZO.V.;"#YJ#Y@>4P MMCVCNU.N=NFJ.Z0HW_ZYODM"
*(E,2^B"48X]B.4^2)'OO2YB/V,I]0H.O 4 MH8F=LI;TYD1[0]QKJ4,;1Q\!Z_36CRL(8 ;#5GJ+[M'CHIW10/K(P#/WD!X7 M[["-]
*(GK[5R(KV)%BE+P*U*5:LSU'D J*8LRCA&).$-88HSR-,L1]FDF>,HP MY] %US"9Z8-Z-G,;%
I)@!;"LUQ%PS;X\T6&*>::GKV%O:_7)^JF*2X#]TZL:#?:D] 9'9M S]K[M)JJ7@NF3]1J2VS(D^+B^N9
9IFFGQ'6H>>$L\ML&1IPOKR6$7%VLEK&KK,X M!OE-L%5!B^_K&8Z%$8UXA*(P5/,:"]5[P3Y2%^RRY!^*Q?-J,Q_?Z-Z=I%>R1;+
*#V(>(L9CW0:")8CZ MF",I_23,8^D3/P>4I3:C.OG>EU[5/Z\V36NHYJK9O.8M7YY8.X9/3;-9,M)_ MTAI:
*]/B'BZ8R6GH>Y>ZHT0'3,>";C;A-4R "P5!(((4S',.E65AO&/OTO95 MG?%67[M@IOV8;0#D\1&PKGE!I&6F MP[/IF];.4E"TOYKM-
*1N"]B@>ZS\]I^(=4_Q4J'DWS3$29-$,KG35FR7/G$ MH<04\4"Y:CA)*2(YBU"0BB!)PS1,.*B"W"BUB;5_2]O;$C^CYMLX@C,|
*M8%I_!A1@/\!(1$?S_CBM6>=Y([']WYW6SF^P4?:!F^5?!EO=E\6_!/W&UJB]D M0;:-574)E4JY&#OA:>JWYT?=A56?
*B!YMRGH74$J2("=(8F4Q,(L(HC)($(_] MA 8^21,>0LS&C+Q/;(0^W7S]+_+X]-\?8+9FSH=G9KG^I(\$N)DWV+)A*X?7 M%Z1M-
]V5F===O2.5K\B12?-A;>5YTC/:H?M+-_@.3@RUG-R/JOI?X-'LC^1 MO 4+;AHBW3Y7Y5(M:]L>P]=R4_9\S>-
*=E!#"TUPYH3[G"*O_(4(2@0(JLI1P MBB-F7DO(AH.)IXB-46)]H[3JN-)[YKJG]5)ZQ:9 /^DX.Z]OSVGH3=)SK\:N.DX]ARA7':>*VOC
*M/G-/.RMH#OO_)2MSK)0Z@O/O@S1-;[U-;TT44-Y] M6-K3\0EG"PI3\D,9G99Y'Y7&*M)@>,390@M&!>K'$HQ?:-$406M?_7ZA9K_;
MY2_E4Z'[4GXJ^1?R(Q[)(R,,;$N:1* W@ACPI[6(5=RPE2II>HU9/5$>5L\ M"MU#X9"GX,UEXH[C .BH8"&W78&%LX/GZ+1B(M]-
^P>1Z MVYH)'XN%J-:?9?*!/LQCI#$N8]P(!)$9)*@!$N?1,(/*0&62M@9?^I9KJT1 MT)#<3 +0N@B[@(QKJ ,Q@7,<2$*+V@>#*X"
*[U?1T MX#I:<$_ X*QK\ND WE^V3T@)OC9YO_PF%H*M!._JZ4$6)8,W3VT<%7"D?/76 ME+V.]+@[,BCWZ?7)V2+#
I)2=M#%QZA$5JN.X1%G6VZ,"M1?9XQ?"-.ENEK= M*65J-?BB>/I7JU1:&E55&[YWNW>J1]-8T'994,9)J;/)1 _0F'O77]BT; M'WN6-
*\U(O/7;9G;QL3>N_RP^JT__^W^MOU'_H:06__M__?]02P,$% @ M9Y5>6=^9KKZWJ0 -=(' !4
*!A;6=N+3(P,C0P.3,P7W!R92YX;6SLO6F3 M6\F--OI]?D5?
*WZ\7[MP7Q\R\H=56C%K2*ZGM\7QAY((L</GEI^47_.EOL_D_QM_"3Q\F85EF\U. ?U_]V8O9UQ_S\O-ZJ&3\?0??ZH?
*8EC@3\3>=+'Z\M_^\&6Y_/JGGW_^[;??_O@]SB=_ MG,U/?A:,R9\O?_L/%[_^_<[O_R97O\V]]S^O?GKUJXOQ?;}(C^4__^-
*OU*_@\M>@?@NX ,G_^'V1 M__#O__+33^?BF,\F^!'+3_7??S^^N?'*<'J"TS^FV>G/]:<_OY@1&CZ$DTKK
MZF^7/{[BO_UA,3[].KGZWILOO'_O?[CGZ]?_G6."T+, MBMFW](V+9]2W[4$(?E_B-,Y=Y>OF,S2C5^:5-G.YI=_.0D1)ZOOCC.1ZLG
*M/XN+Y3RDY8@'$5FQ"HS@#)0K#B(7"]}BQ1FOK>;B)M^5Y@41O5+% M,?3V;?M?]8'_UQE43]9"64ED#NO.Q?,?
*G2_FB[*RS$N/H<4[FX_)]89[NJ/O84X/ M@O1E/,F7?UWFL],6VEK.6LCN7#-$[Q]^(K8+SN>8WYXK9B-W*]:69%5Q]9O[M*OUL
*2%\^+6?I'\^^CQ65-9#P$ML]/3 MV73%P"]X&G$^2EF5Z)&#F;1/>8Z/OZ:K> @!@Z'QM+L$1=7&^^/-],:[UWZ]_B&3.QB9!3&DID'
M[E0DX00/(7E.5A7)@2M",O?0;K.E>WKON_L!2AM'I%4>\;&9:;@,_WNJ!0L MP>0(I7!+\L $L80"-
*GOGO>8&A3X(#>MOZ]D1;:"Y60,Q#D3]__MLOAR9DEAVR,:Q',3Y[-R(+S(#(.0RF,3)-QZ<<]&H1M0'"'+<@>#C \['
ML_QJFE^2:SZR5O <@P.=4O%8L%9\L4%%ET,N>4Z\B;HN/':K; AGQ@V]A?L M0)#Q>1ZFBW$5R@6Z77(:A73
*F5,DD5*M'[E?.C!AK3/%I]!F$[GUYJWPH9X8 M/@X2[R#\SM?C";X[6_G,2M..&(TF+TO2!\D-$#L<4%O%$I-(=K&!MWG]QJT@_MH9\
() X2YR"@\!%/QC5#/%V^"Z=D[3A;0< (E0"5"A'E2D#A K(. Q9MIFLW)N*V$LDK^O9B=39?S'R]F&4?2RJ0H1(/" MD8)X3=NA,SZ
*<$JQ@E[P)BAYD(BM0&.?%&C:"7T0&/HD<--"T(- S+.<21^+ MBW^J>/A(.9W)B1(0+2?19%V9\.2.(D3V ME.Z0
*++:0=_//\QGW\;3A"/%,Q/",]#>>%"""*2#/RT/.B8DL*(8K+?:=^]^^ M'52>2FZUF9R'A)2J7(ANP@JX>8+BD(GMA0G(3!BM$H
*M#TN:K+]M.S0\E23KWG+L6?_UTNGDPY?9]#+3(X*5O@0$5Q31G@1])E!7+XJY M;#U30AV$@=MOW X'3R69>I
*|>\;")TQG#G!D8Y.%*821*,L*$N^ M4LPA0XF.7"9EDLF";[-UV*'@JB=/])3D0<_#J>_H2IB>X MRO@FSXIEP0'YPN3:<%^W-I[
*1\=,4E'+9)N8A/6W;@>(IY(4/5BN@P@N7IS- MJ^S.CPHKODDA9XL1X35I) MT 9R'@1>WDSI:2$MQ]_P95B&"[9&0F&V@5BPG-
*"N?*0H*1H']4!1V)B*+(?M M+_^]?3N\/*U4: ,Y#P(O]?!Y_B(L\60V_5G-QEJP44&4DF7G-P/GM(J++R MTJ)2AT4E]
*[QTNPMB3RL+NK]4!P&*3Z=A,GE^MB!I+,@&*DMH5@@!90VSK0,7 M3 9I4S I_<7ZJ# ,6K4YR?T,[XY_GLM^67%[/3KV'Z
*M8U2T4,[1MA@L^5)*R C..%9O*D04FE6#V <]['Y\.Y \K43GX5(>!%@^?<') MY)+ZY(H1%'=#(EQ3/&XU1)\<:)Y%UJYX+U,+
[+VSNV@\52RG@?=!"(6*O# M^O2%A+AX?[:LQ?DU:!])FY/R+)R0]S4*V\1B9MH2$C%!N]#BU/ZAVC8#C%/ M)3_:6.;#0!")
*<1XF;Z89O_\'DEN52B:P6_!.$ .5BR"R@JRUDSI9:T6+2J=; MK]T.)T\E=WJX9'N&QK-3G.9ZK?KU))R,C R<&2-
*!>=HGR3W*EIA0$N,P4:= M>#PLS+WQNNV@\%02J/M+2\/N><"<>"LR9,G52F(7R*_6
*MG@)U&3"CXDG)AA!9>_5V('DJ.=0V$N[[CL9Y#N\:Z)?/[U__>;=B_>_O+K)PY:=O;9\=(.^ M7_LP<6!7L,LF#
*[5TX12ONL1<=9TJ&*5//H&Q3M<;/@DB1P\F*ZZC=&@>].?V MZ8:R@91FK:3.6Q0DC8ZA3< 8\:1T(;.8. 5?, ?N#11J=W 7*@@ ?
*01.R" MD6A5.H^.\L- GI'QZ$*G;62[G"@ M<2V1]\LO.+_@Q44BUT4-%B6%9E%S\";2ZD&'FDF1K7OHCMD!2+F7GGX:Q70. MG,-E/P
*<7>W)UU%@[:#G12F@G:I90FT@U)9I7I+=Y9B0R^ITUE# >P/D&\[CK"U$7I.D7LRF*R;^-EY^>7&V6%(T.'_U/4W.ZM'D ML\4"Z?
*_Y<_@^$MY+)UD$ZXT!I>A#<"4#+RI&J84-YJ'W/04M7[V0)E8)-\<'6 M$OLUW[V?
EH'L;&U,5Q.!#$54[>ES_/9GG=6_PTF^214#$;3>AD5IS@/$V+Y63X=3U>MR6KEPP77
*M(Q%5,1@]2!4E\46QL>!6E/738+13_'6@DEZAMFK,MODJ-7+!TP<'Y$='J!_R?Y/W69?98A1\%"X5#C92I*T,\>6=SR!T[?H>F.'N
MUK'(AI;W6[^RGR:DG6"H0UD/8%N]+:I1;8&0&1?K267E5=A,9[,,L]RE#0 MMDZ%WZ:AGW:EG?MA>XMY?
YC,EF'2!";OOV(UE=.3<]2_G2THN$G9.4(T"&4Y M&9413JC0*=D79S37#[4D7(2I-Q#1K^[5>.8[U Q#P IUY1?9D/&TS/BZ(*U
*MV73Q',ML?F$^/X?ON/AE/)W-+\M#<5&S_S>?]HK\PN6/7W#Y948_^8:7MK9$ MRTLJ"@KGI3:!%N!-EL"5MI)
*[IF7NYJ;+4=CK=P]MC.RAPF(*V;E0IQS=M^V MHPU+F<<"T:"IUWLVT.@ W\5)T M%WR\Q$B!N0F9UR:# @V"DDQ
*$#*!U#ZQJ#DKKO4IPSUD](O&EE]^8S$/$_GN MJ/"G])GB21V6_+D9>-[-IK.;CLUEP$U^KT^2,;#:U@7&:$=1@9QBPTELVAI3
*M6MNVC<3TFW;K$$AMQ#\((W1ATB_H?T[Q>!DO1XRKZ)VVX+V-0+:YGMPE 4S'-M&+3.SNO6@<@&4OJ-7#MQV0X3]R
*2LN]PN19/B:Q$H?\!%X;(C[5!0*G#A8(1 M*?!<,F]]7GF#@'XF;W2$D?U%.P#'^U683\DF+C[@?%7I?65M;;$A2DR 63C:
*M9FOO&>09),KDN/?,8^M+?IMHZ6?D1D=H:2+P09B4VYP\#XMQ&N5 AE%F#ED4 M#JH(!L'+VOVLGAUDE9-
L?:1S+R']^L1MM/P(='87^"!Q\W(\.2-?>X3%,M-M 6&L!_HT04@I@*<=53CI@LA=(^>"E'[=X*-@9Q^A#P(J?\/QR1>B_!D]-)Q<
M='%^7^ZT;F26A*Y6(SDH/EJK+GVX)2/(+B-1JVZ^FY5];(#K':EL9_90!UM M<)TJZ$E!\-
P^QZ)8UHJ#D;ZVF!=U<7D,*54%',&66)?^!O 1MDM6O:$YNZ* M&S(N+TS]W49.M10)4RR@G* /3 :
*(3#)@1:L4Z/GVP<$T#9&YB<1^-^(A8+.) M\AJB\ZC=#UZ_^7#QU=_H=]Y\]=7';9"N.\]1^B+!"A[C9HD7&WP[\M5=K6V M
*YSC%YPNQM\NSHFN8,PE*Y8'"P6Y!B6L@A"YA,PD]_:+NQ(8MML6!2V M=B9SH$UMB<@%.3HV,="'"&Z$ M^AZY5$Z(K??
*E<_C^H;:)ZTME_-Q/%O6XK[/LP\K+5R)SQFC?>T)C[$.$JB= M<$*AW7LSDY}]/S-DSI MQVH.?>U@3]Q/\^JKR3D,KJZ
*;B&D$=/).LD18N0!E"$O)I@80%H5&#3V9_?87S"?XYS">UF\^*_3RCY@F M8;&XFKA

$U((@1ZTK@,P=/:N"XSV,#^>0D"L;VH7^$V*AD5Q[VHP[R$C[S6^&ER!)@"X[476